Heidelberg	B-Diagnostic_tool
retina	I-Diagnostic_tool
tomography	I-Diagnostic_tool
and	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
in	O
normal	O
,	O
ocular	B-Disease
-	I-Disease
hypertensive	I-Disease
,	O
and	O
glaucomatous	B-Disease
eyes	B-Anatomy
.	O
	
To	O
evaluate	O
optic	B-Anatomy
disc	I-Anatomy
and	O
retinal	B-Anatomy
nerve	I-Anatomy
fiber	I-Anatomy
layer	I-Anatomy
(	O
RNFL	B-Anatomy
)	O
appearance	O
in	O
normal	O
,	O
ocular	B-Disease
-	I-Disease
hypertensive	I-Disease
,	O
and	O
glaucomatous	B-Disease
eyes	B-Anatomy
undergoing	O
confocal	B-Diagnostic_tool
scanning	I-Diagnostic_tool
laser	I-Diagnostic_tool
ophthalmoscopy	I-Diagnostic_tool
and	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
.	O
	
Prospective	O
,	O
cross	O
-	O
sectional	O
study	O
.	O
	
Seventy	O
-	O
eight	O
eyes	O
of	O
78	O
consecutive	O
normal	O
(	O
n	O
=	O
17	O
)	O
,	O
ocular	B-Disease
-	I-Disease
hypertensive	I-Disease
(	O
n	O
=	O
23	O
)	O
,	O
and	O
glaucomatous	B-Disease
subjects	O
(	O
n	O
=	O
38	O
)	O
were	O
enrolled	O
.	O
	
Each	O
patient	O
underwent	O
complete	O
ophthalmic	B-Diagnostic_tool
examination	I-Diagnostic_tool
,	O
achromatic	B-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
,	O
confocal	B-Diagnostic_tool
scanning	I-Diagnostic_tool
laser	I-Diagnostic_tool
ophthalmoscopy	I-Diagnostic_tool
(	O
Heidelberg	B-Diagnostic_tool
Retinal	I-Diagnostic_tool
Tomography	I-Diagnostic_tool
[	O
HRT	B-Diagnostic_tool
]	O
)	O
,	O
and	O
OCT	B-Diagnostic_tool
.	O
	
Topographic	B-Characteristic
HRT	I-Characteristic
parameters	I-Characteristic
(	O
disc	B-Characteristic
area	I-Characteristic
,	O
cup	B-Characteristic
-	I-Characteristic
disc	I-Characteristic
ratio	I-Characteristic
,	O
rim	B-Characteristic
area	I-Characteristic
,	O
rim	B-Characteristic
volume	I-Characteristic
,	O
cup	B-Characteristic
shape	I-Characteristic
measure	I-Characteristic
,	O
mean	B-Characteristic
RNFL	I-Characteristic
thickness	I-Characteristic
,	O
and	O
cross	B-Characteristic
-	I-Characteristic
sectional	I-Characteristic
area	I-Characteristic
)	O
and	O
mean	B-Characteristic
OCT	I-Characteristic
-	I-Characteristic
generated	I-Characteristic
RNFL	I-Characteristic
thickness	I-Characteristic
were	O
evaluated	O
in	O
each	O
group	O
.	O
	
OCT	B-Diagnostic_tool
and	O
HRT	B-Diagnostic_tool
assessment	O
of	O
optic	B-Anatomy
disc	I-Anatomy
and	O
RNFL	B-Anatomy
anatomy	O
.	O
	
OCT	B-Characteristic
RNFL	I-Characteristic
thickness	I-Characteristic
showed	O
no	O
difference	O
between	O
normal	O
and	O
ocular	B-Disease
-	I-Disease
hypertensive	I-Disease
eyes	B-Anatomy
(	O
P	O
=	O
0	O
.	O
15	O
)	O
but	O
was	O
significantly	O
less	O
in	O
glaucomatous	B-Disease
eyes	B-Anatomy
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
HRT	B-Diagnostic_tool
measurements	O
of	O
rim	B-Characteristic
area	I-Characteristic
,	O
cup	B-Characteristic
-	I-Characteristic
disc	I-Characteristic
ratio	I-Characteristic
,	O
cup	B-Characteristic
shape	I-Characteristic
measure	I-Characteristic
,	O
RNFL	B-Characteristic
thickness	I-Characteristic
,	O
and	O
RNFL	B-Characteristic
cross	I-Characteristic
-	I-Characteristic
sectional	I-Characteristic
area	I-Characteristic
were	O
significantly	O
less	O
in	O
glaucomatous	B-Disease
eyes	B-Anatomy
(	O
all	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
were	O
correlated	O
with	O
mean	B-Characteristic
OCT	I-Characteristic
RNFL	I-Characteristic
thickness	I-Characteristic
(	O
all	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O
	
RNFL	B-Characteristic
thickness	I-Characteristic
using	O
OCT	B-Diagnostic_tool
or	O
HRT	B-Diagnostic_tool
was	O
highly	O
correlated	O
with	O
visual	B-Symptom
field	I-Symptom
mean	I-Symptom
defect	I-Symptom
during	O
achromatic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
	
Both	O
HRT	B-Diagnostic_tool
and	O
OCT	B-Diagnostic_tool
can	O
differentiate	O
glaucomatous	B-Disease
from	O
nonglaucomatous	O
eyes	B-Anatomy
.	O
	
RNFL	B-Characteristic
thickness	I-Characteristic
measurements	O
using	O
OCT	B-Diagnostic_tool
correspond	O
to	O
disc	B-Characteristic
topographic	I-Characteristic
parameters	I-Characteristic
using	O
HRT	B-Diagnostic_tool
.	O
	
Methods	O
for	O
evaluation	O
of	O
retinal	B-Symptom
microvascular	I-Symptom
abnormalities	I-Symptom
associated	O
with	O
hypertension	B-Disease
/	I-Disease
sclerosis	I-Disease
in	O
the	O
Atherosclerosis	B-Disease
Risk	O
in	O
Communities	O
Study	O
.	O
	
To	O
develop	O
protocols	O
to	O
photograph	O
and	O
evaluate	O
retinal	B-Symptom
vascular	I-Symptom
abnormalities	I-Symptom
in	O
the	O
Atherosclerosis	B-Disease
Risk	O
in	O
Communities	O
(	O
ARIC	O
)	O
Study	O
;	O
to	O
test	O
reproducibility	O
of	O
the	O
grading	O
system	O
;	O
and	O
to	O
explore	O
the	O
relationship	O
of	O
these	O
microvascular	B-Symptom
changes	I-Symptom
with	O
blood	B-Characteristic
pressure	I-Characteristic
.	O
	
Population	O
-	O
based	O
,	O
cross	O
-	O
sectional	O
study	O
.	O
	
Among	O
4	O
examination	O
centers	O
,	O
11	O
,	O
114	O
participants	O
(	O
48	B-Characteristic
-	I-Characteristic
73	I-Characteristic
years	I-Characteristic
of	I-Characteristic
age	I-Characteristic
)	O
at	O
their	O
third	O
triennial	O
examination	O
,	O
after	O
excluding	O
persons	O
with	O
diabetes	B-Disease
from	O
this	O
analysis	O
.	O
	
One	O
eye	B-Anatomy
of	O
each	O
participant	O
was	O
photographed	O
by	O
technicians	O
with	O
nonmydriatic	B-Diagnostic_tool
fundus	I-Diagnostic_tool
cameras	I-Diagnostic_tool
.	O
	
Reading	O
center	O
graders	O
evaluated	O
focal	B-Symptom
arteriolar	I-Symptom
narrowing	I-Symptom
,	O
arteriovenous	B-Symptom
(	I-Symptom
AV	I-Symptom
)	I-Symptom
nicking	I-Symptom
,	O
and	O
retinopathy	B-Disease
by	O
examining	O
slides	O
on	O
a	O
light	O
box	O
and	O
measured	O
diameters	B-Characteristic
of	I-Characteristic
all	I-Characteristic
vessels	I-Characteristic
in	O
a	O
zone	B-Anatomy
surrounding	I-Anatomy
the	I-Anatomy
optic	I-Anatomy
disc	I-Anatomy
on	O
enhanced	O
digitized	O
images	O
.	O
	
To	O
gauge	O
generalized	O
narrowing	O
,	O
vessel	B-Characteristic
diameters	I-Characteristic
were	O
combined	O
into	O
central	B-Anatomy
arteriolar	I-Anatomy
and	O
venular	B-Anatomy
equivalents	O
with	O
formulas	O
adjusting	O
for	O
branching	O
,	O
and	O
the	O
ratio	B-Characteristic
of	I-Characteristic
equivalents	I-Characteristic
(	O
A	B-Characteristic
/	I-Characteristic
V	I-Characteristic
ratio	I-Characteristic
)	O
was	O
calculated	O
.	O
	
Retinal	B-Symptom
vascular	I-Symptom
abnormalities	I-Symptom
,	O
mean	B-Characteristic
arteriolar	I-Characteristic
blood	I-Characteristic
pressure	I-Characteristic
(	O
MABP	B-Characteristic
)	O
.	O
	
Among	O
11	O
,	O
114	O
participants	O
,	O
photographs	O
were	O
obtained	O
of	O
99	O
%	O
,	O
with	O
quality	O
sufficient	O
to	O
perform	O
retinal	B-Anatomy
evaluations	O
in	O
81	O
%	O
.	O
	
In	O
the	O
9040	O
subjects	O
with	O
usable	O
photographs	O
,	O
A	B-Characteristic
/	I-Characteristic
V	I-Characteristic
ratio	I-Characteristic
(	O
lower	O
values	O
indicate	O
generalized	B-Symptom
arteriolar	I-Symptom
narrowing	I-Symptom
)	O
ranged	O
from	O
0	O
.	O
57	O
to	O
1	O
.	O
22	O
(	O
median	O
=	O
0	O
.	O
84	O
,	O
interquartile	O
range	O
=	O
0	O
.	O
10	O
)	O
,	O
focal	B-Symptom
arteriolar	I-Symptom
narrowing	I-Symptom
was	O
found	O
in	O
7	O
%	O
,	O
AV	B-Symptom
nicking	I-Symptom
in	O
6	O
%	O
,	O
and	O
retinopathy	B-Disease
in	O
4	O
%	O
.	O
	
Because	O
of	O
attrition	O
of	O
subjects	O
and	O
limitation	O
of	O
methods	O
,	O
prevalence	O
of	O
abnormality	O
was	O
likely	O
underestimated	O
.	O
	
Controlling	O
for	O
gender	B-Characteristic
,	O
race	B-Characteristic
,	O
age	B-Characteristic
,	O
and	O
smoking	B-Characteristic
status	I-Characteristic
,	O
these	O
retinal	B-Symptom
changes	I-Symptom
were	O
associated	O
with	O
higher	B-Characteristic
blood	I-Characteristic
pressure	I-Characteristic
.	O
	
For	O
every	O
10	O
-	O
mmHg	O
increase	O
in	O
MABP	B-Characteristic
,	O
A	B-Characteristic
/	I-Characteristic
V	I-Characteristic
ratio	I-Characteristic
decreased	O
by	O
0	O
.	O
02	O
unit	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
focal	B-Symptom
arteriolar	I-Symptom
narrowing	I-Symptom
had	O
an	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
2	O
.	O
00	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
1	O
.	O
87	O
-	O
2	O
.	O
14	O
)	O
,	O
AV	B-Symptom
nicking	I-Symptom
had	O
an	O
OR	O
of	O
1	O
.	O
25	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
16	O
-	O
1	O
.	O
34	O
)	O
,	O
and	O
retinopathy	B-Disease
had	O
an	O
OR	O
of	O
1	O
.	O
25	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
15	O
-	O
1	O
.	O
37	O
)	O
.	O
	
For	O
any	O
degree	O
of	O
generalized	B-Symptom
narrowing	I-Symptom
,	O
individuals	O
with	O
focal	B-Symptom
narrowing	I-Symptom
had	O
MABP	B-Characteristic
approximately	O
8	O
mmHg	O
higher	O
than	O
those	O
without	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
	
Masked	O
replicate	O
assessment	O
of	O
a	O
sample	O
found	O
the	O
following	O
reproducibility	O
:	O
for	O
A	B-Characteristic
/	I-Characteristic
V	I-Characteristic
ratio	I-Characteristic
,	O
correlation	O
coefficient	O
=	O
0	O
.	O
79	O
and	O
median	O
absolute	O
difference	O
=	O
0	O
.	O
03	O
;	O
for	O
focal	B-Symptom
arteriolar	I-Symptom
narrowing	I-Symptom
,	O
kappa	O
=	O
0	O
.	O
45	O
;	O
for	O
AV	B-Symptom
nicking	I-Symptom
,	O
kappa	O
=	O
0	O
.	O
61	O
;	O
and	O
for	O
retinopathy	B-Disease
,	O
kappa	O
=	O
0	O
.	O
89	O
.	O
	
Protocols	O
have	O
been	O
developed	O
for	O
nonmydriatic	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photography	I-Diagnostic_tool
and	O
for	O
evaluation	O
of	O
retinal	B-Symptom
vascular	I-Symptom
abnormalities	I-Symptom
.	O
	
Several	O
microvascular	B-Symptom
changes	I-Symptom
were	O
significantly	O
associated	O
with	O
higher	B-Characteristic
blood	I-Characteristic
pressure	I-Characteristic
;	O
follow	O
-	O
up	O
will	O
show	O
whether	O
these	O
are	O
predictive	O
of	O
later	B-Disease
cerebrovascular	I-Disease
or	I-Disease
cardiovascular	I-Disease
disease	I-Disease
independently	O
of	O
other	O
known	O
risk	O
factors	O
.	O
	
Circumscribed	B-Disease
choroidal	I-Disease
hemangioma	I-Disease
:	O
characteristic	O
features	O
with	O
indocyanine	B-Diagnostic_tool
green	I-Diagnostic_tool
videoangiography	I-Diagnostic_tool
.	O
	
To	O
determine	O
the	O
characteristic	O
features	O
of	O
indocyanine	B-Diagnostic_tool
green	I-Diagnostic_tool
videoangiography	I-Diagnostic_tool
(	O
ICG	B-Diagnostic_tool
-	I-Diagnostic_tool
V	I-Diagnostic_tool
)	O
of	O
circumscribed	B-Disease
choroidal	I-Disease
hemangioma	I-Disease
.	O
	
Prospective	O
,	O
observational	O
case	O
series	O
.	O
	
Twenty	O
-	O
five	O
eyes	B-Anatomy
of	O
25	O
consecutive	O
patients	O
with	O
circumscribed	B-Disease
choroidal	I-Disease
hemangioma	I-Disease
.	O
	
Indocyanine	B-Diagnostic_tool
green	I-Diagnostic_tool
videoangiography	I-Diagnostic_tool
and	O
intravenous	B-Diagnostic_tool
fluorescein	I-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
IVFA	B-Diagnostic_tool
)	O
were	O
prospectively	O
performed	O
and	O
reviewed	O
.	O
	
The	O
specific	O
features	O
on	O
ICG	B-Diagnostic_tool
-	I-Diagnostic_tool
V	I-Diagnostic_tool
were	O
compared	O
with	O
features	O
of	O
IVFA	B-Diagnostic_tool
.	O
	
The	O
behavior	O
of	O
circumscribed	B-Disease
choroidal	I-Disease
hemangioma	I-Disease
cases	O
was	O
observed	O
with	O
ICG	B-Diagnostic_tool
-	I-Diagnostic_tool
V	I-Diagnostic_tool
and	O
IVFA	B-Diagnostic_tool
.	O
	
On	O
ICG	B-Diagnostic_tool
-	I-Diagnostic_tool
V	I-Diagnostic_tool
,	O
earliest	O
hyperfluorescence	B-Characteristic
of	O
circumscribed	B-Disease
choroidal	I-Disease
hemangioma	I-Disease
was	O
achieved	O
at	O
a	O
mean	O
of	O
27	O
.	O
6	O
seconds	O
(	O
range	O
,	O
13	O
-	O
62	O
seconds	O
)	O
,	O
whereas	O
maximum	O
hyperfluorescence	O
occurred	O
at	O
222	O
seconds	O
(	O
range	O
,	O
33	O
-	O
707	O
seconds	O
)	O
.	O
	
In	O
the	O
late	O
frames	O
,	O
all	O
eyes	B-Anatomy
demonstrated	O
a	O
relative	O
decrease	O
in	O
fluorescence	O
,	O
including	O
18	O
eyes	B-Anatomy
(	O
72	O
%	O
)	O
that	O
demonstrated	O
"	O
washout	O
"	O
of	O
the	O
dye	O
.	O
	
Other	O
findings	O
on	O
ICG	B-Diagnostic_tool
-	I-Diagnostic_tool
V	I-Diagnostic_tool
included	O
intrinsic	B-Characteristic
vessels	I-Characteristic
in	O
19	O
eyes	B-Anatomy
(	O
76	O
%	O
)	O
,	O
a	O
late	B-Characteristic
hyperfluorescent	I-Characteristic
rim	I-Characteristic
in	O
19	O
eyes	B-Anatomy
(	O
76	O
%	O
)	O
,	O
and	O
late	B-Characteristic
frame	I-Characteristic
hot	I-Characteristic
spots	I-Characteristic
in	O
14	O
eyes	B-Anatomy
(	O
56	O
%	O
)	O
.	O
	
On	O
IVFA	B-Diagnostic_tool
,	O
the	O
earliest	O
hyperfluorescence	B-Characteristic
was	O
achieved	O
at	O
a	O
mean	O
of	O
24	O
seconds	O
(	O
range	O
,	O
10	O
-	O
66	O
seconds	O
)	O
,	O
whereas	O
maximum	O
hyperfluorescence	B-Characteristic
occurred	O
at	O
a	O
mean	O
of	O
76	O
.	O
3	O
seconds	O
(	O
range	O
,	O
21	O
-	O
720	O
seconds	O
)	O
.	O
	
Increasing	O
hyperfluorescence	B-Characteristic
in	O
the	O
late	O
frames	O
was	O
found	O
in	O
all	O
cases	O
.	O
	
Other	O
findings	O
included	O
intrinsic	B-Characteristic
vessels	I-Characteristic
in	O
12	O
eyes	B-Anatomy
(	O
48	O
%	O
)	O
and	O
hot	B-Characteristic
spots	I-Characteristic
in	O
the	O
late	O
frames	O
in	O
9	O
eyes	B-Anatomy
(	O
36	O
%	O
)	O
.	O
	
Circumscribed	B-Disease
choroidal	I-Disease
hemangioma	I-Disease
have	O
specific	O
characteristics	O
on	O
ICG	B-Diagnostic_tool
-	I-Diagnostic_tool
V	I-Diagnostic_tool
that	O
are	O
not	O
visualized	O
with	O
IVFA	B-Diagnostic_tool
.	O
	
We	O
believe	O
that	O
ICG	B-Diagnostic_tool
-	I-Diagnostic_tool
V	I-Diagnostic_tool
may	O
become	O
an	O
important	O
noninvasive	O
tool	O
for	O
the	O
diagnosis	O
of	O
choroidal	B-Disease
hemangioma	I-Disease
.	O
	
Comparison	O
between	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
and	O
fundus	B-Diagnostic_tool
fluorescein	I-Diagnostic_tool
angiography	I-Diagnostic_tool
for	O
the	O
detection	O
of	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
in	O
patients	O
with	O
uveitis	B-Disease
.	O
	
To	O
compare	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
with	O
fundus	B-Diagnostic_tool
fluorescein	I-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
FFA	B-Diagnostic_tool
)	O
for	O
the	O
detection	O
of	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
(	O
CME	B-Disease
)	O
in	O
patients	O
with	O
uveitis	B-Disease
.	O
	
Prospective	O
comparative	O
observational	O
series	O
.	O
	
One	O
hundred	O
twenty	O
-	O
one	O
eyes	B-Anatomy
of	O
58	O
patients	O
with	O
uveitis	B-Disease
of	O
varied	O
causes	O
(	O
seven	O
patients	O
were	O
studied	O
twice	O
)	O
.	O
	
Patients	O
with	O
suspected	O
CME	B-Disease
underwent	O
OCT	B-Diagnostic_tool
scanning	I-Diagnostic_tool
followed	O
by	O
FFA	B-Diagnostic_tool
at	O
the	O
same	O
visit	O
.	O
	
Detection	O
and	O
distribution	O
of	O
macular	B-Disease
edema	I-Disease
.	O
	
One	O
hundred	O
eight	O
eyes	B-Anatomy
had	O
similar	O
results	O
on	O
both	O
OCT	B-Diagnostic_tool
and	O
FFA	B-Diagnostic_tool
in	O
that	O
67	O
eyes	B-Anatomy
had	O
CME	B-Disease
and	O
41	O
eyes	B-Anatomy
had	O
no	O
CME	B-Disease
.	O
	
In	O
10	O
eyes	B-Anatomy
subretinal	B-Symptom
fluid	I-Symptom
was	O
detected	O
on	O
OCT	B-Diagnostic_tool
but	O
not	O
FFA	B-Diagnostic_tool
.	O
	
Five	O
of	O
these	O
eyes	B-Anatomy
had	O
CME	B-Disease
on	O
FFA	B-Diagnostic_tool
but	O
not	O
OCT	B-Diagnostic_tool
.	O
	
Three	O
other	O
eyes	B-Anatomy
had	O
CME	B-Disease
that	O
was	O
detected	O
by	O
FFA	B-Diagnostic_tool
but	O
not	O
by	O
OCT	B-Diagnostic_tool
.	O
	
Compared	O
with	O
FFA	B-Diagnostic_tool
,	O
the	O
OCT	B-Diagnostic_tool
sensitivity	O
for	O
detecting	O
CME	B-Disease
was	O
96	O
%	O
(	O
including	O
the	O
eyes	B-Anatomy
with	O
subretinal	B-Symptom
fluid	I-Symptom
)	O
,	O
and	O
the	O
OCT	B-Diagnostic_tool
specificity	O
was	O
100	O
%	O
.	O
	
OCT	B-Diagnostic_tool
is	O
as	O
effective	O
at	O
detecting	O
CME	B-Disease
as	O
is	O
FFA	B-Diagnostic_tool
but	O
is	O
superior	O
in	O
demonstrating	O
axial	O
distribution	O
of	O
fluid	O
.	O
	
Entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
screening	O
for	O
central	B-Symptom
diabetic	I-Symptom
scotomas	I-Symptom
and	O
macular	B-Disease
edema	I-Disease
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
,	O
using	O
conventional	B-Diagnostic_tool
television	I-Diagnostic_tool
,	O
to	O
Amsler	B-Diagnostic_tool
grid	I-Diagnostic_tool
and	O
patient	B-Symptom
-	I-Symptom
reported	I-Symptom
visual	I-Symptom
loss	I-Symptom
for	O
the	O
detection	O
of	O
functional	B-Disease
diabetic	I-Disease
maculopathy	I-Disease
and	O
macular	B-Disease
edema	I-Disease
.	O
	
Observational	O
case	O
series	O
.	O
	
A	O
single	O
eye	B-Anatomy
from	O
each	O
of	O
104	O
consecutive	O
patients	O
with	O
diabetes	B-Disease
in	O
an	O
academic	O
retina	B-Anatomy
clinic	O
.	O
	
Each	O
eye	B-Anatomy
was	O
screened	O
by	O
Amsler	B-Diagnostic_tool
grid	I-Diagnostic_tool
,	O
entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
,	O
and	O
Humphrey	B-Diagnostic_tool
10	I-Diagnostic_tool
-	I-Diagnostic_tool
2	I-Diagnostic_tool
threshold	I-Diagnostic_tool
visual	I-Diagnostic_tool
field	I-Diagnostic_tool
testing	I-Diagnostic_tool
(	O
HVF	B-Diagnostic_tool
10	I-Diagnostic_tool
-	I-Diagnostic_tool
2	I-Diagnostic_tool
;	O
Humphrey	O
Instruments	O
Inc	O
.	O
,	O
San	O
Leandro	O
,	O
CA	O
)	O
in	O
random	O
order	O
.	O
	
Eyes	B-Anatomy
were	O
then	O
examined	O
clinically	O
.	O
	
The	O
presence	O
or	O
absence	O
of	O
new	O
visual	B-Symptom
decline	I-Symptom
since	O
the	O
patient	O
'	O
s	O
last	O
clinical	O
examination	O
,	O
the	O
presence	O
or	O
absence	O
of	O
central	B-Symptom
visual	I-Symptom
field	I-Symptom
abnormalities	I-Symptom
using	O
an	O
Amsler	B-Diagnostic_tool
grid	I-Diagnostic_tool
,	O
entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
,	O
HVF	B-Diagnostic_tool
10	I-Diagnostic_tool
-	I-Diagnostic_tool
2	I-Diagnostic_tool
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
clinically	B-Disease
significant	I-Disease
macular	I-Disease
edema	I-Disease
(	O
CSME	B-Disease
)	O
.	O
	
The	O
sensitivities	O
and	O
specificities	O
for	O
the	O
detection	O
of	O
central	B-Symptom
diabetic	I-Symptom
scotomas	I-Symptom
as	O
evidenced	O
by	O
HVF	B-Diagnostic_tool
10	I-Diagnostic_tool
-	I-Diagnostic_tool
2	I-Diagnostic_tool
abnormalities	O
were	O
:	O
subjective	O
impression	O
,	O
31	O
of	O
90	O
eyes	B-Anatomy
(	O
34	O
.	O
4	O
%	O
)	O
and	O
11	O
of	O
14	O
eyes	B-Anatomy
(	O
78	O
.	O
6	O
%	O
)	O
;	O
Amsler	B-Diagnostic_tool
grid	I-Diagnostic_tool
,	O
29	O
of	O
90	O
eyes	B-Anatomy
(	O
32	O
.	O
2	O
%	O
)	O
and	O
13	O
of	O
14	O
eyes	B-Anatomy
(	O
92	O
.	O
9	O
%	O
)	O
;	O
and	O
entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
,	O
58	O
of	O
90	O
eyes	B-Anatomy
(	O
64	O
.	O
4	O
%	O
)	O
and	O
11	O
of	O
14	O
eyes	B-Anatomy
(	O
78	O
.	O
6	O
%	O
)	O
.	O
	
Entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
was	O
statistically	O
more	O
sensitive	O
than	O
both	O
subjective	O
impression	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
Amsler	B-Diagnostic_tool
grid	I-Diagnostic_tool
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
the	O
specificities	O
were	O
statistically	O
indistinguishable	O
.	O
	
The	O
sensitivities	O
and	O
specificities	O
for	O
the	O
detection	O
of	O
CSME	B-Disease
were	O
:	O
subjective	O
impression	O
,	O
6	O
of	O
24	O
eyes	B-Anatomy
(	O
25	O
.	O
0	O
%	O
)	O
and	O
52	O
of	O
80	O
eyes	B-Anatomy
(	O
65	O
.	O
0	O
%	O
)	O
;	O
Amsler	B-Diagnostic_tool
grid	I-Diagnostic_tool
,	O
9	O
of	O
24	O
eyes	B-Anatomy
(	O
37	O
.	O
5	O
%	O
)	O
and	O
59	O
of	O
80	O
eyes	B-Anatomy
(	O
73	O
.	O
8	O
%	O
)	O
;	O
and	O
entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
,	O
17	O
of	O
24	O
eyes	B-Anatomy
(	O
70	O
.	O
8	O
%	O
)	O
and	O
44	O
of	O
80	O
(	O
55	O
.	O
0	O
%	O
)	O
eyes	B-Anatomy
.	O
	
These	O
results	O
are	O
also	O
statistically	O
significant	O
,	O
with	O
entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
being	O
more	O
sensitive	O
and	O
less	O
specific	O
than	O
both	O
subjective	O
impression	O
(	O
P	O
=	O
0	O
.	O
007	O
and	O
P	O
=	O
0	O
.	O
011	O
,	O
respectively	O
)	O
and	O
Amsler	B-Diagnostic_tool
grid	I-Diagnostic_tool
(	O
P	O
=	O
0	O
.	O
008	O
and	O
P	O
<	O
0	O
.	O
001	O
,	O
respectively	O
)	O
in	O
this	O
subset	O
of	O
patients	O
.	O
	
Entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
is	O
87	O
%	O
more	O
sensitive	O
than	O
the	O
subjective	O
impression	O
of	O
visual	B-Symptom
decline	I-Symptom
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
100	O
%	O
more	O
sensitive	O
than	O
Amsler	B-Diagnostic_tool
grid	I-Diagnostic_tool
(	O
P	O
<	O
0	O
.	O
001	O
)	O
for	O
the	O
detection	O
of	O
central	B-Symptom
scotomas	I-Symptom
in	O
diabetic	B-Disease
patients	O
.	O
	
For	O
the	O
detection	O
of	O
CSME	B-Disease
,	O
entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
is	O
183	O
%	O
more	O
sensitive	O
than	O
subjective	O
impression	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
89	O
%	O
more	O
sensitive	O
than	O
Amsler	B-Diagnostic_tool
grid	I-Diagnostic_tool
(	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O
	
Hence	O
,	O
entoptic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
,	O
performed	O
using	O
conventional	B-Diagnostic_tool
television	I-Diagnostic_tool
,	O
has	O
the	O
potential	O
to	O
be	O
an	O
effective	O
,	O
inexpensive	O
,	O
and	O
widespread	O
adjunct	O
to	O
surveillance	O
examinations	O
for	O
the	O
early	O
detection	O
of	O
diabetic	B-Disease
maculopathy	I-Disease
.	O
	
Computerized	B-Diagnostic_tool
stereochronoscopy	I-Diagnostic_tool
and	I-Diagnostic_tool
alternation	I-Diagnostic_tool
flicker	I-Diagnostic_tool
to	O
detect	O
optic	B-Symptom
nerve	I-Symptom
head	I-Symptom
contour	I-Symptom
change	I-Symptom
.	O
	
Stereochronoscopy	B-Diagnostic_tool
,	O
a	O
technique	O
previously	O
explored	O
but	O
abandoned	O
for	O
glaucoma	B-Disease
diagnosis	O
,	O
viewed	O
optic	B-Diagnostic_tool
nerve	I-Diagnostic_tool
images	I-Diagnostic_tool
acquired	O
at	O
separate	O
points	O
in	O
time	O
as	O
if	O
a	O
stereo	O
pair	O
.	O
	
Prior	O
efforts	O
to	O
exploit	O
this	O
technique	O
were	O
impaired	O
by	O
a	O
lack	O
of	O
superimposability	O
for	O
sequential	O
optic	B-Diagnostic_tool
nerve	I-Diagnostic_tool
images	I-Diagnostic_tool
.	O
	
We	O
investigated	O
computerized	B-Diagnostic_tool
registration	I-Diagnostic_tool
techniques	I-Diagnostic_tool
for	O
aligning	O
sequential	B-Diagnostic_tool
,	I-Diagnostic_tool
monoscopic	I-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
images	I-Diagnostic_tool
to	O
facilitate	O
sensitive	O
detection	O
of	O
optic	B-Symptom
nerve	I-Symptom
head	I-Symptom
contour	I-Symptom
changes	I-Symptom
in	O
glaucoma	B-Disease
.	O
	
Algorithm	O
and	O
software	O
development	O
.	O
	
Comparisons	O
with	O
standard	O
techniques	O
.	O
	
Existing	O
patient	O
records	O
from	O
the	O
Glaucoma	B-Disease
Service	O
,	O
Scheie	O
Eye	O
Institute	O
,	O
University	O
of	O
Pennsylvania	O
.	O
	
Two	O
sets	O
of	O
optic	B-Diagnostic_tool
disc	I-Diagnostic_tool
photographs	I-Diagnostic_tool
,	O
separated	O
in	O
time	O
by	O
1	O
to	O
18	O
years	O
,	O
of	O
25	O
eyes	B-Anatomy
with	O
and	O
without	O
glaucomatous	B-Symptom
optic	I-Symptom
disc	I-Symptom
progression	I-Symptom
were	O
digitized	O
.	O
	
We	O
developed	O
custom	O
software	O
for	O
accurate	O
image	O
alignment	O
.	O
	
Change	B-Symptom
in	I-Symptom
disc	I-Symptom
morphology	I-Symptom
was	O
then	O
judged	O
by	O
digital	B-Diagnostic_tool
stereochronoscopy	I-Diagnostic_tool
and	O
user	B-Diagnostic_tool
-	I-Diagnostic_tool
controlled	I-Diagnostic_tool
alternation	I-Diagnostic_tool
flicker	I-Diagnostic_tool
of	I-Diagnostic_tool
superimposed	I-Diagnostic_tool
,	I-Diagnostic_tool
time	I-Diagnostic_tool
-	I-Diagnostic_tool
separated	I-Diagnostic_tool
images	I-Diagnostic_tool
on	O
a	O
computer	O
monitor	O
.	O
	
Comparisons	O
were	O
made	O
with	O
standard	O
stereoscopic	O
comparison	O
.	O
	
Identification	O
of	O
change	O
or	O
no	O
change	B-Symptom
in	I-Symptom
optic	I-Symptom
nerve	I-Symptom
head	I-Symptom
contour	I-Symptom
for	O
images	O
acquired	O
at	O
separate	O
points	O
in	O
time	O
.	O
	
Image	O
processing	O
and	O
registration	O
permits	O
accurate	O
alignment	O
of	O
optic	B-Diagnostic_tool
disc	I-Diagnostic_tool
photographs	I-Diagnostic_tool
.	O
	
Alternation	B-Diagnostic_tool
flicker	I-Diagnostic_tool
of	I-Diagnostic_tool
superimposed	I-Diagnostic_tool
,	I-Diagnostic_tool
sequential	I-Diagnostic_tool
images	I-Diagnostic_tool
facilitates	O
image	O
comparison	O
and	O
detection	O
of	O
change	O
as	O
indicated	O
by	O
change	B-Characteristic
in	I-Characteristic
vessel	I-Characteristic
position	I-Characteristic
,	I-Characteristic
color	I-Characteristic
,	I-Characteristic
and	I-Characteristic
other	I-Characteristic
cues	I-Characteristic
for	I-Characteristic
contour	I-Characteristic
change	I-Characteristic
.	O
	
A	O
high	O
concordance	O
was	O
found	O
between	O
standard	B-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
comparison	I-Diagnostic_tool
and	O
alternation	B-Diagnostic_tool
flicker	I-Diagnostic_tool
.	O
	
In	O
several	O
cases	O
,	O
reinspection	O
of	O
stereo	O
comparison	O
led	O
to	O
a	O
revised	O
judgment	O
on	O
the	O
basis	O
of	O
disc	B-Symptom
changes	I-Symptom
rendered	O
more	O
obvious	O
with	O
alternation	B-Diagnostic_tool
flicker	I-Diagnostic_tool
.	O
	
Digital	B-Diagnostic_tool
stereochronoscopy	I-Diagnostic_tool
was	O
less	O
concordant	O
with	O
standard	O
techniques	O
.	O
	
Digital	B-Diagnostic_tool
image	I-Diagnostic_tool
processing	I-Diagnostic_tool
techniques	I-Diagnostic_tool
and	I-Diagnostic_tool
alternation	I-Diagnostic_tool
flicker	I-Diagnostic_tool
provide	O
a	O
simple	O
,	O
sensitive	O
,	O
software	O
-	O
based	O
method	O
for	O
detecting	O
glaucomatous	B-Symptom
optic	I-Symptom
disc	I-Symptom
change	I-Symptom
.	O
	
A	O
comparison	O
of	O
stereoscopic	B-Diagnostic_tool
fluorescein	I-Diagnostic_tool
angiography	I-Diagnostic_tool
with	O
indocyanine	B-Diagnostic_tool
green	I-Diagnostic_tool
videoangiography	I-Diagnostic_tool
in	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
.	O
	
To	O
correlate	O
features	O
of	O
indocyanine	B-Diagnostic_tool
green	I-Diagnostic_tool
(	I-Diagnostic_tool
ICG	I-Diagnostic_tool
)	I-Diagnostic_tool
videoangiography	I-Diagnostic_tool
with	O
stereo	B-Diagnostic_tool
film	I-Diagnostic_tool
fluorescein	I-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
FA	B-Diagnostic_tool
)	O
in	O
the	O
analysis	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
A	O
retrospective	O
study	O
with	O
concurrent	O
comparison	O
of	O
two	O
methods	O
of	O
assessment	O
on	O
one	O
set	O
of	O
patients	O
with	O
AMD	B-Disease
undergoing	O
sequential	O
FA	B-Diagnostic_tool
-	O
ICG	B-Diagnostic_tool
videoangiography	I-Diagnostic_tool
.	O
	
One	O
hundred	O
four	O
patients	O
with	O
AMD	B-Disease
who	O
had	O
undergone	O
immediately	O
sequential	O
FA	B-Diagnostic_tool
-	O
ICG	B-Diagnostic_tool
videoangiography	I-Diagnostic_tool
were	O
selected	O
in	O
a	O
consecutive	O
fashion	O
from	O
the	O
photographic	O
files	O
of	O
the	O
Casey	O
Eye	O
Institute	O
.	O
	
Three	O
interpreters	O
independently	O
graded	O
in	O
an	O
unbiased	O
fashion	O
the	O
FA	B-Characteristic
features	I-Characteristic
of	O
AMD	B-Disease
.	O
	
These	O
were	O
compared	O
with	O
ICG	B-Characteristic
videoangiography	I-Characteristic
features	I-Characteristic
of	O
hypocyanescence	B-Characteristic
(	O
ICG	B-Characteristic
videoangiography	I-Characteristic
hypofluorescence	I-Characteristic
)	O
,	O
moderate	B-Characteristic
or	I-Characteristic
intense	I-Characteristic
hypercyanescence	I-Characteristic
(	O
ICG	B-Characteristic
videoangiography	I-Characteristic
hyperfluorescence	I-Characteristic
)	O
,	O
or	O
absence	B-Characteristic
of	I-Characteristic
fluorescence	I-Characteristic
over	I-Characteristic
background	I-Characteristic
(	O
ICG	B-Characteristic
videoangiography	I-Characteristic
isocyanescence	I-Characteristic
)	O
.	O
	
We	O
also	O
assessed	O
ICG	B-Characteristic
videoangiography	I-Characteristic
features	I-Characteristic
in	O
the	O
opposite	O
eye	B-Anatomy
of	O
those	O
with	O
choroidal	B-Symptom
neovascularization	I-Symptom
(	O
CNV	B-Symptom
)	O
by	O
FA	B-Diagnostic_tool
in	O
one	O
eye	B-Anatomy
by	O
examining	O
an	O
additional	O
96	O
FA	B-Diagnostic_tool
-	O
ICG	B-Diagnostic_tool
videoangiography	I-Diagnostic_tool
scans	O
.	O
	
Outcomes	O
were	O
the	O
ICG	B-Diagnostic_tool
videoangiography	I-Diagnostic_tool
characteristics	O
of	O
classic	B-Symptom
and	I-Symptom
occult	I-Symptom
CNV	I-Symptom
,	O
serous	B-Symptom
pigment	I-Symptom
epithelial	I-Symptom
detachments	I-Symptom
(	I-Symptom
SPEDs	I-Symptom
)	I-Symptom
both	I-Symptom
with	I-Symptom
and	I-Symptom
without	I-Symptom
CNV	I-Symptom
,	O
macular	B-Symptom
hemorrhage	I-Symptom
,	O
and	O
the	O
comparative	O
size	O
of	O
these	O
features	O
.	O
	
There	O
were	O
25	O
eyes	B-Anatomy
that	O
had	O
significant	O
macular	B-Symptom
hemorrhage	I-Symptom
by	O
FA	B-Diagnostic_tool
.	O
	
Of	O
these	O
,	O
the	O
FA	B-Diagnostic_tool
revealed	O
CNV	B-Symptom
in	O
its	O
entirety	O
under	O
or	O
near	O
the	O
hemorrhage	B-Symptom
in	O
11	O
.	O
	
The	O
ICG	B-Diagnostic_tool
examination	O
revealed	O
all	O
11	O
plus	O
an	O
additional	O
12	O
hypercyanescent	B-Characteristic
features	I-Characteristic
that	O
were	O
not	O
visible	O
by	O
FA	B-Diagnostic_tool
.	O
	
Although	O
26	O
of	O
32	O
SPEDs	B-Symptom
had	O
CNV	B-Symptom
by	O
FA	B-Diagnostic_tool
analysis	O
,	O
31	O
of	O
32	O
had	O
well	O
-	O
defined	O
hypercyanescence	B-Characteristic
under	O
or	O
at	O
the	O
SPED	B-Symptom
edge	O
by	O
ICG	B-Diagnostic_tool
videoangiography	I-Diagnostic_tool
.	O
	
Eighty	O
-	O
seven	O
percent	O
of	O
eyes	B-Anatomy
with	O
classic	B-Symptom
choroidal	I-Symptom
neovascular	I-Symptom
membranes	I-Symptom
(	O
CCNV	B-Symptom
;	O
20	O
of	O
23	O
)	O
and	O
93	O
%	O
of	O
eyes	B-Anatomy
with	O
fibrovascular	B-Symptom
pigment	I-Symptom
epithelial	I-Symptom
detachments	I-Symptom
(	O
FVPED	B-Symptom
;	O
66	O
of	O
71	O
)	O
were	O
hypercyanescent	B-Characteristic
with	O
distinct	O
edges	O
.	O
	
Fifty	O
percent	O
of	O
eyes	B-Anatomy
with	O
only	O
late	B-Symptom
leakage	I-Symptom
of	I-Symptom
undetermined	I-Symptom
source	I-Symptom
(	O
LLUS	B-Symptom
)	O
were	O
hypercyanescent	B-Characteristic
,	O
whereas	O
50	O
%	O
were	O
isocyanescent	B-Characteristic
on	O
ICG	B-Diagnostic_tool
videoangiography	I-Diagnostic_tool
.	O
	
There	O
were	O
four	O
of	O
104	O
eyes	B-Anatomy
in	O
which	O
ICG	B-Diagnostic_tool
videoangiography	I-Diagnostic_tool
revealed	O
poorly	O
defined	O
hypercyanescent	B-Characteristic
areas	O
when	O
,	O
by	O
FA	B-Diagnostic_tool
,	O
there	O
were	O
only	O
drusen	B-Symptom
or	O
elevated	B-Symptom
blocked	I-Symptom
fluorescence	I-Symptom
.	O
	
Indocyanine	B-Diagnostic_tool
green	I-Diagnostic_tool
videoangiography	I-Diagnostic_tool
revealed	O
only	O
three	O
eyes	B-Anatomy
with	O
poorly	O
defined	O
hypercyanescence	B-Characteristic
of	O
200	O
fellow	O
eyes	B-Anatomy
in	O
patients	O
with	O
unilateral	O
AMD	B-Disease
.	O
	
Indocyanine	B-Diagnostic_tool
green	I-Diagnostic_tool
videoangiography	I-Diagnostic_tool
correlated	O
fairly	O
well	O
with	O
stereoscopic	B-Diagnostic_tool
FA	I-Diagnostic_tool
for	O
the	O
presence	O
of	O
CCNV	B-Symptom
or	O
FVPED	B-Symptom
,	O
but	O
correlated	O
poorly	O
when	O
LLUS	B-Symptom
was	O
present	O
.	O
	
In	O
certain	O
cases	O
where	O
CNV	B-Symptom
was	O
associated	O
with	O
SPED	B-Symptom
or	O
macular	B-Symptom
hemorrhage	I-Symptom
,	O
ICG	B-Diagnostic_tool
videoangiography	I-Diagnostic_tool
demonstrated	O
features	O
not	O
apparent	O
on	O
FA	B-Diagnostic_tool
.	O
	
Patterns	O
of	O
adherence	O
to	O
diabetes	B-Disease
vision	O
care	O
guidelines	O
:	O
baseline	O
findings	O
from	O
the	O
Diabetic	B-Disease
Retinopathy	I-Disease
Awareness	O
Program	O
.	O
	
(	O
1	O
)	O
To	O
describe	O
baseline	O
patterns	O
of	O
adherence	O
to	O
American	O
Diabetes	B-Disease
Association	O
and	O
American	B-Classification_system
Academy	I-Classification_system
of	I-Classification_system
Ophthalmology	I-Classification_system
vision	I-Classification_system
care	I-Classification_system
guidelines	I-Classification_system
for	O
diabetes	B-Disease
in	O
the	O
Diabetic	B-Disease
Retinopathy	I-Disease
Awareness	O
Program	O
,	O
and	O
(	O
2	O
)	O
to	O
evaluate	O
factors	O
associated	O
with	O
nonadherence	O
.	O
	
This	O
paper	O
describes	O
the	O
baseline	O
characteristics	O
of	O
a	O
population	O
enrolled	O
in	O
a	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
.	O
	
Cross	O
-	O
sectional	O
study	O
.	O
	
Between	O
October	O
1993	O
and	O
May	O
1994	O
,	O
the	O
study	O
identified	O
2308	O
persons	O
with	O
diabetes	B-Disease
,	O
18	B-Characteristic
years	I-Characteristic
of	I-Characteristic
age	I-Characteristic
or	I-Characteristic
older	I-Characteristic
,	O
who	O
were	O
residents	B-Characteristic
of	I-Characteristic
Suffolk	I-Characteristic
County	I-Characteristic
,	I-Characteristic
New	I-Characteristic
York	I-Characteristic
,	O
via	O
a	O
multimedia	O
community	O
-	O
wide	O
recruitment	O
campaign	O
.	O
	
Eligibility	O
for	O
the	O
trial	O
was	O
determined	O
during	O
a	O
20	O
-	O
minute	O
phone	O
interview	O
,	O
which	O
included	O
questions	O
about	O
vision	O
care	O
practices	O
;	O
diabetes	B-Disease
management	O
;	O
and	O
knowledge	O
,	O
attitudes	O
,	O
and	O
beliefs	O
about	O
diabetes	B-Disease
,	O
vision	O
,	O
and	O
diabetic	B-Disease
retinopathy	I-Disease
.	O
	
This	O
paper	O
describes	O
these	O
patient	O
characteristics	O
at	O
baseline	O
.	O
	
Eligible	O
patients	O
would	O
be	O
randomized	O
subsequently	O
to	O
a	O
2	O
-	O
year	O
diabetes	B-Disease
educational	O
intervention	O
arm	O
,	O
which	O
included	O
mailed	O
packets	O
and	O
newsletters	O
focused	O
on	O
vision	O
care	O
,	O
or	O
to	O
a	O
control	O
nonintervention	O
arm	O
.	O
	
Nonadherence	O
to	O
guidelines	O
at	O
baseline	O
was	O
defined	O
as	O
the	O
absence	O
of	O
a	O
dilated	O
eye	B-Anatomy
examination	O
during	O
the	O
year	O
before	O
recruitment	O
into	O
the	O
study	O
.	O
	
Of	O
the	O
2308	O
persons	O
interviewed	O
,	O
813	O
(	O
35	O
%	O
)	O
did	O
not	O
follow	O
the	O
vision	O
care	O
guidelines	O
;	O
two	O
thirds	O
of	O
this	O
group	O
reported	O
no	O
eye	B-Anatomy
examination	O
in	O
the	O
year	O
before	O
the	O
interview	O
,	O
and	O
one	O
third	O
had	O
an	O
undilated	O
examination	O
.	O
	
Ophthalmologists	O
performed	O
49	O
%	O
of	O
the	O
examinations	O
in	O
the	O
nonadherent	O
group	O
,	O
versus	O
86	O
%	O
in	O
the	O
adherent	O
group	O
.	O
	
In	O
logistic	O
regression	O
analyses	O
,	O
factors	O
related	O
to	O
nonadherence	O
were	O
:	O
younger	B-Characteristic
age	I-Characteristic
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
0	O
.	O
97	O
)	O
,	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
with	O
or	O
without	O
insulin	O
use	O
(	O
OR	O
=	O
1	O
.	O
62	O
and	O
1	O
.	O
99	O
,	O
respectively	O
)	O
,	O
shorter	O
diabetes	B-Characteristic
duration	I-Characteristic
(	O
OR	O
=	O
0	O
.	O
97	O
)	O
,	O
last	O
eye	B-Characteristic
examination	I-Characteristic
performed	I-Characteristic
by	I-Characteristic
an	I-Characteristic
optometrist	I-Characteristic
(	O
OR	O
=	O
5	O
.	O
32	O
)	O
or	O
other	O
nonophthalmologist	O
(	O
OR	O
=	O
4	O
.	O
29	O
)	O
,	O
less	O
practical	B-Characteristic
knowledge	I-Characteristic
about	I-Characteristic
diabetes	I-Characteristic
(	O
OR	O
=	O
1	O
.	O
57	O
)	O
,	O
and	O
no	O
prior	B-Characteristic
formal	I-Characteristic
diabetes	I-Characteristic
education	I-Characteristic
(	O
OR	O
=	O
1	O
.	O
30	O
)	O
.	O
	
Within	O
this	O
population	O
,	O
more	O
than	O
one	O
third	O
of	O
participants	O
had	O
not	O
been	O
following	O
vision	O
care	O
guidelines	O
.	O
	
Nonadherence	O
was	O
linked	O
to	O
several	O
potentially	O
modifiable	O
factors	O
;	O
changes	O
in	O
these	O
factors	O
could	O
enhance	O
the	O
early	O
detection	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
.	O
	
Stereo	B-Diagnostic_tool
nonmydriatic	I-Diagnostic_tool
digital	I-Diagnostic_tool
-	I-Diagnostic_tool
video	I-Diagnostic_tool
color	I-Diagnostic_tool
retinal	I-Diagnostic_tool
imaging	I-Diagnostic_tool
compared	O
with	O
Early	B-Classification_system
Treatment	I-Classification_system
Diabetic	I-Classification_system
Retinopathy	I-Classification_system
Study	I-Classification_system
seven	O
standard	B-Diagnostic_tool
field	I-Diagnostic_tool
35	I-Diagnostic_tool
-	I-Diagnostic_tool
mm	I-Diagnostic_tool
stereo	I-Diagnostic_tool
color	I-Diagnostic_tool
photos	I-Diagnostic_tool
for	O
determining	O
level	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
.	O
	
To	O
evaluate	O
the	O
ability	O
to	O
determine	O
clinical	O
levels	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
,	O
timing	O
of	O
next	O
appropriate	O
retinal	O
evaluation	O
,	O
and	O
necessity	O
of	O
referral	O
to	O
ophthalmology	O
specialists	O
using	O
stereoscopic	B-Diagnostic_tool
nonmydriatic	I-Diagnostic_tool
digital	I-Diagnostic_tool
-	I-Diagnostic_tool
video	I-Diagnostic_tool
color	I-Diagnostic_tool
retinal	I-Diagnostic_tool
images	I-Diagnostic_tool
as	O
compared	O
with	O
Early	B-Classification_system
Treatment	I-Classification_system
Diabetic	I-Classification_system
Retinopathy	I-Classification_system
Study	I-Classification_system
(	O
ETDRS	B-Classification_system
)	O
seven	O
standard	B-Diagnostic_tool
field	I-Diagnostic_tool
35	I-Diagnostic_tool
-	I-Diagnostic_tool
mm	I-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
color	I-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
.	O
	
Prospective	O
,	O
clinic	O
-	O
based	O
,	O
comparative	O
instrument	O
validation	O
study	O
.	O
	
Fifty	O
-	O
four	O
patients	O
(	O
108	O
eyes	B-Anatomy
)	O
with	O
type	B-Disease
1	I-Disease
or	I-Disease
type	I-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
selected	O
after	O
chart	O
review	O
from	O
a	O
single	O
center	O
to	O
include	O
the	O
full	O
spectrum	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
.	O
	
Nonsimultaneous	B-Diagnostic_tool
45	I-Diagnostic_tool
degrees	I-Diagnostic_tool
-	I-Diagnostic_tool
field	I-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
digital	I-Diagnostic_tool
-	I-Diagnostic_tool
video	I-Diagnostic_tool
color	I-Diagnostic_tool
images	I-Diagnostic_tool
(	O
JVN	B-Diagnostic_tool
images	I-Diagnostic_tool
)	O
were	O
obtained	O
from	O
three	O
fields	O
with	O
the	O
Joslin	B-Diagnostic_tool
Vision	I-Diagnostic_tool
Network	I-Diagnostic_tool
(	O
JVN	B-Diagnostic_tool
)	O
system	O
before	O
pupil	B-Anatomy
dilation	O
.	O
	
Following	O
pupil	B-Anatomy
dilation	O
,	O
ETDRS	B-Classification_system
seven	O
standard	B-Diagnostic_tool
field	I-Diagnostic_tool
35	I-Diagnostic_tool
-	I-Diagnostic_tool
mm	I-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
color	I-Diagnostic_tool
30	I-Diagnostic_tool
degrees	I-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
(	O
ETDRS	B-Diagnostic_tool
photos	I-Diagnostic_tool
)	O
were	O
obtained	O
.	O
	
Joslin	B-Diagnostic_tool
Vision	I-Diagnostic_tool
Network	I-Diagnostic_tool
images	I-Diagnostic_tool
and	O
ETDRS	B-Diagnostic_tool
photos	I-Diagnostic_tool
were	O
graded	O
on	O
a	O
lesion	O
-	O
by	O
-	O
lesion	O
basis	O
by	O
two	O
independent	O
,	O
masked	O
readers	O
to	O
assess	O
ETDRS	B-Classification_system
clinical	O
level	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
.	O
	
An	O
independent	O
ophthalmology	O
retina	O
specialist	O
adjudicated	O
interreader	O
disagreements	O
in	O
a	O
masked	O
fashion	O
.	O
	
Determination	O
of	O
ETDRS	B-Classification_system
clinical	O
level	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
,	O
timing	O
of	O
next	O
ophthalmic	O
evaluation	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
,	O
and	O
need	O
for	O
prompt	O
referral	O
to	O
ophthalmology	O
specialist	O
.	O
	
There	O
was	O
substantial	O
agreement	O
(	O
kappa	O
=	O
0	O
.	O
65	O
)	O
between	O
the	O
clinical	O
level	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
assessed	O
from	O
the	O
undilated	B-Diagnostic_tool
JVN	I-Diagnostic_tool
images	I-Diagnostic_tool
and	O
the	O
dilated	B-Diagnostic_tool
ETDRS	I-Diagnostic_tool
photos	I-Diagnostic_tool
.	O
	
Agreement	O
was	O
excellent	O
(	O
kappa	O
=	O
0	O
.	O
87	O
)	O
for	O
suggested	O
referral	O
to	O
ophthalmology	O
specialists	O
for	O
eye	B-Anatomy
examinations	O
.	O
	
Comparison	O
of	O
individual	O
lesions	O
between	O
the	O
JVN	B-Diagnostic_tool
images	I-Diagnostic_tool
and	O
the	O
ETDRS	B-Diagnostic_tool
photos	I-Diagnostic_tool
and	O
for	O
interreader	O
comparisons	O
were	O
comparable	O
to	O
the	O
prior	O
ETDRS	B-Classification_system
study	O
.	O
	
Undilated	B-Diagnostic_tool
digital	I-Diagnostic_tool
-	I-Diagnostic_tool
video	I-Diagnostic_tool
images	I-Diagnostic_tool
using	O
the	O
JVN	B-Diagnostic_tool
system	O
were	O
comparable	O
photographs	O
for	O
the	O
determination	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
level	O
.	O
	
The	O
results	O
validate	O
the	O
agreement	O
between	O
nonmydriatic	B-Diagnostic_tool
JVN	I-Diagnostic_tool
images	I-Diagnostic_tool
and	O
dilated	B-Diagnostic_tool
ETDRS	I-Diagnostic_tool
photographs	I-Diagnostic_tool
and	O
suggest	O
that	O
this	O
digital	O
technique	O
may	O
be	O
an	O
effective	O
telemedicine	O
tool	O
for	O
remotely	O
determining	O
the	O
level	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
,	O
suggesting	O
timing	O
of	O
next	O
retinal	O
evaluation	O
and	O
identifying	O
the	O
need	O
for	O
prompt	O
referral	O
to	O
ophthalmology	O
specialists	O
.	O
	
Thus	O
,	O
the	O
JVN	B-Diagnostic_tool
system	O
would	O
be	O
an	O
appropriate	O
tool	O
for	O
facilitating	O
increased	O
access	O
of	O
diabetic	B-Disease
patients	O
into	O
recommended	O
eye	B-Anatomy
evaluations	O
,	O
but	O
should	O
not	O
be	O
construed	O
as	O
a	O
paradigm	O
that	O
would	O
replace	O
the	O
need	O
for	O
comprehensive	O
eye	B-Anatomy
examinations	O
.	O
	
Quality	O
of	O
life	O
in	O
newly	O
diagnosed	O
glaucoma	B-Disease
patients	O
:	O
The	O
Collaborative	O
Initial	O
Glaucoma	B-Disease
Treatment	O
Study	O
.	O
	
The	O
Collaborative	O
Initial	O
Glaucoma	B-Disease
Treatment	O
Study	O
(	O
CIGTS	O
)	O
was	O
designed	O
to	O
determine	O
whether	O
patients	O
with	O
newly	O
diagnosed	O
open	B-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
are	O
better	O
treated	O
initially	O
by	O
medicine	O
or	O
immediate	O
filtering	O
surgery	O
.	O
	
This	O
paper	O
describes	O
the	O
quality	O
-	O
of	O
-	O
life	O
(	O
QOL	O
)	O
measurement	O
approach	O
,	O
instruments	O
included	O
,	O
and	O
the	O
CIGTS	O
participants	O
'	O
QOL	O
findings	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O
	
Baseline	O
results	O
from	O
a	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O
	
Six	O
hundred	O
seven	O
patients	O
from	O
14	O
clinical	O
centers	O
were	O
enrolled	O
.	O
	
Patients	O
randomized	O
to	O
initial	O
medication	O
received	O
a	O
stepped	O
medical	O
regimen	O
(	O
n	O
=	O
307	O
)	O
.	O
	
Those	O
randomized	O
to	O
initial	O
surgery	O
underwent	O
a	O
trabeculectomy	O
(	O
n	O
=	O
300	O
)	O
.	O
	
The	O
baseline	O
interview	O
was	O
conducted	O
before	O
treatment	O
initiation	O
.	O
	
All	O
baseline	O
and	O
posttreatment	O
QOL	O
assessments	O
were	O
conducted	O
by	O
telephone	O
from	O
a	O
centralized	O
interviewing	O
center	O
.	O
	
The	O
primary	O
outcome	O
measure	O
described	O
in	O
this	O
paper	O
was	O
QOL	O
.	O
	
The	O
QOL	B-Diagnostic_tool
instrument	I-Diagnostic_tool
is	O
multidimensional	O
and	O
incorporates	O
both	O
disease	O
-	O
specific	O
and	O
generic	O
measures	O
,	O
including	O
the	O
Visual	B-Diagnostic_tool
Activities	I-Diagnostic_tool
Questionnaire	I-Diagnostic_tool
,	O
Sickness	O
Impact	O
Profile	O
,	O
and	O
a	O
Symptom	O
and	O
Health	O
Problem	O
CHECKLIST	O
:	O
The	O
correlations	O
between	O
QOL	O
measures	O
and	O
clinical	O
outcomes	O
were	O
in	O
the	O
expected	O
direction	O
,	O
but	O
relatively	O
weak	O
.	O
	
At	O
initial	O
diagnosis	O
,	O
difficulty	O
with	O
bright	O
lights	O
and	O
with	O
light	O
and	O
dark	O
adaptation	O
were	O
the	O
most	O
frequently	O
reported	O
symptoms	O
related	O
to	O
visual	B-Characteristic
function	I-Characteristic
,	O
whereas	O
visual	B-Symptom
distortion	I-Symptom
was	O
the	O
most	O
bothersome	O
.	O
	
Approximately	O
half	O
of	O
the	O
patients	O
reported	O
at	O
least	O
some	O
worry	O
or	O
concern	O
about	O
the	O
possibility	O
of	O
blindness	B-Symptom
.	O
	
Within	O
the	O
Visual	B-Diagnostic_tool
Activities	I-Diagnostic_tool
Questionnaire	I-Diagnostic_tool
,	O
higher	O
scores	O
on	O
the	O
Peripheral	B-Diagnostic_tool
Vision	I-Diagnostic_tool
subscale	I-Diagnostic_tool
were	O
associated	O
with	O
more	O
field	B-Symptom
loss	I-Symptom
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
	
In	O
regression	O
analyses	O
controlling	O
for	O
sociodemographics	B-Characteristic
and	O
nonocular	B-Symptom
comorbidities	I-Symptom
,	O
increased	O
visual	B-Symptom
field	I-Symptom
loss	I-Symptom
was	O
significantly	O
associated	O
with	O
higher	O
dysfunction	O
among	O
five	O
disease	O
-	O
specific	O
QOL	O
measures	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
Newly	O
diagnosed	O
glaucoma	B-Disease
patients	O
reported	O
experiencing	O
some	O
visual	B-Symptom
function	I-Symptom
symptoms	I-Symptom
at	O
the	O
time	O
of	O
diagnosis	O
that	O
would	O
not	O
be	O
intuitively	O
expected	O
based	O
on	O
clinical	O
testing	O
.	O
	
Some	O
discussion	O
about	O
the	O
association	O
between	O
clinical	O
presentation	O
and	O
worry	O
about	O
blindness	B-Symptom
may	O
reduce	O
unnecessary	O
concern	O
.	O
	
These	O
results	O
provide	O
the	O
basis	O
for	O
long	O
-	O
term	O
comparisons	O
of	O
the	O
QOL	O
effects	O
of	O
initial	O
medical	O
and	O
surgical	O
treatment	O
for	O
open	B-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
.	O
	
Vitreous	B-Diagnostic_tool
fluorophotometry	I-Diagnostic_tool
in	O
diabetes	B-Disease
mellitus	I-Disease
.	O
	
Vitreous	B-Diagnostic_tool
fluorophotometry	I-Diagnostic_tool
has	O
proved	O
to	O
be	O
a	O
useful	O
method	O
to	O
evaluate	O
the	O
integrity	B-Characteristic
of	I-Characteristic
the	I-Characteristic
blood	I-Characteristic
-	I-Characteristic
ocular	I-Characteristic
barrier	I-Characteristic
to	I-Characteristic
fluorescein	I-Characteristic
in	O
clinical	O
and	O
experimental	O
diabetes	B-Disease
mellitus	I-Disease
.	O
	
Diabetic	B-Disease
patients	O
with	O
or	O
without	O
background	B-Disease
retinopathy	I-Disease
had	O
increased	B-Symptom
vitreous	I-Symptom
accumulation	I-Symptom
of	I-Symptom
fluorescein	I-Symptom
after	O
intravenous	O
injection	O
when	O
compared	O
with	O
age	B-Characteristic
-	O
matched	O
controls	O
.	O
	
Streptozotocin	B-Disease
-	I-Disease
induced	I-Disease
diabetes	I-Disease
in	O
rats	O
increase	O
vitreous	B-Characteristic
fluorescein	I-Characteristic
levels	O
.	O
	
In	O
the	O
rat	O
,	O
this	O
abnormality	O
was	O
reversed	O
with	O
insulin	O
therapy	O
and	O
with	O
pancreatic	B-Anatomy
islet	I-Anatomy
transplantation	O
.	O
	
The	O
breakdown	B-Symptom
of	I-Symptom
the	I-Symptom
blood	I-Symptom
-	I-Symptom
ocular	I-Symptom
barrier	I-Symptom
to	I-Symptom
fluorescein	I-Symptom
appears	O
to	O
be	O
the	O
earliest	O
detectable	O
ocular	O
abnormality	O
of	O
diabetes	B-Disease
.	O
	
A	O
new	O
optotype	B-Diagnostic_tool
chart	I-Diagnostic_tool
for	O
detection	O
of	O
nonorganic	B-Symptom
visual	I-Symptom
loss	I-Symptom
.	O
	
To	O
develop	O
a	O
new	O
optotype	B-Diagnostic_tool
chart	I-Diagnostic_tool
for	O
detection	O
of	O
nonorganic	B-Symptom
decreased	I-Symptom
vision	I-Symptom
.	O
	
Comparative	O
observational	O
case	O
series	O
.	O
	
Optotype	B-Characteristic
thresholds	I-Characteristic
determination	O
in	O
three	O
normal	B-Characteristic
subjects	I-Characteristic
and	O
testing	O
on	O
30	O
consecutive	O
patients	O
with	O
unclear	O
visual	B-Symptom
acuity	I-Symptom
loss	I-Symptom
.	O
	
A	O
new	O
optotype	B-Diagnostic_tool
chart	I-Diagnostic_tool
was	O
developed	O
,	O
with	O
an	O
optotype	B-Diagnostic_tool
minimum	O
angle	O
of	O
resolution	O
that	O
is	O
independent	O
of	O
size	O
.	O
	
In	O
three	O
normal	B-Characteristic
subjects	I-Characteristic
rank	O
correlation	O
was	O
calculated	O
between	O
the	O
optotype	B-Diagnostic_tool
thresholds	O
and	O
the	O
optotype	B-Diagnostic_tool
sizes	O
.	O
	
A	O
pocket	B-Diagnostic_tool
chart	I-Diagnostic_tool
was	O
tested	O
in	O
a	O
masked	O
manner	O
on	O
30	O
consecutive	O
patients	O
referred	O
because	O
of	O
unclear	O
visual	B-Symptom
acuity	I-Symptom
loss	I-Symptom
.	O
	
Optotype	B-Characteristic
thresholds	I-Characteristic
and	O
usefulness	O
in	O
clinical	O
routine	O
(	O
positive	O
and	O
negative	O
predictive	O
values	O
including	O
95	O
%	O
confidence	O
intervals	O
[	O
CI	O
]	O
)	O
.	O
	
The	O
optotype	B-Characteristic
thresholds	I-Characteristic
did	O
not	O
correlate	O
with	O
the	O
optotype	B-Diagnostic_tool
sizes	O
.	O
	
Ten	O
percent	O
(	O
3	O
of	O
30	O
)	O
of	O
the	O
patients	O
referred	O
because	O
of	O
unclear	O
visual	B-Symptom
acuity	I-Symptom
loss	I-Symptom
had	O
to	O
be	O
excluded	O
,	O
because	O
their	O
diagnosis	O
remained	O
unclear	O
.	O
	
All	O
patients	O
(	O
16	O
of	O
16	O
)	O
with	O
organic	B-Symptom
visual	I-Symptom
loss	I-Symptom
saw	O
all	O
optotypes	B-Diagnostic_tool
sizes	O
.	O
	
Eighty	O
-	O
nine	O
percent	O
(	O
10	O
of	O
11	O
)	O
of	O
patients	O
with	O
nonorganic	B-Symptom
visual	I-Symptom
loss	I-Symptom
claimed	O
to	O
see	O
only	O
the	O
larger	O
optotypes	B-Diagnostic_tool
.	O
	
The	O
positive	O
predictive	O
value	O
for	O
nonorganic	B-Symptom
visual	I-Symptom
loss	I-Symptom
of	O
the	O
new	O
pocket	B-Diagnostic_tool
chart	I-Diagnostic_tool
was	O
100	O
%	O
(	O
CI	O
,	O
74	O
%	O
-	O
100	O
%	O
)	O
;	O
the	O
negative	O
predictive	O
value	O
was	O
94	O
%	O
(	O
CI	O
,	O
75	O
%	O
-	O
100	O
%	O
)	O
.	O
	
The	O
new	O
pocket	B-Diagnostic_tool
chart	I-Diagnostic_tool
seems	O
to	O
be	O
useful	O
for	O
detection	O
of	O
visual	B-Symptom
loss	I-Symptom
caused	O
by	O
nonorganic	O
disease	O
.	O
	
Detection	O
of	O
optic	B-Disease
neuropathy	I-Disease
in	O
glaucomatous	B-Disease
eyes	B-Anatomy
with	O
normal	B-Characteristic
standard	I-Characteristic
visual	I-Characteristic
fields	I-Characteristic
using	O
a	O
test	O
battery	O
of	O
short	B-Diagnostic_tool
-	I-Diagnostic_tool
wavelength	I-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
and	O
pattern	B-Diagnostic_tool
electroretinography	I-Diagnostic_tool
.	O
	
To	O
evaluate	O
the	O
clinical	O
use	O
of	O
a	O
test	O
battery	O
of	O
short	B-Diagnostic_tool
-	I-Diagnostic_tool
wavelength	I-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
(	O
SWAP	B-Diagnostic_tool
)	O
,	O
frequency	B-Diagnostic_tool
-	I-Diagnostic_tool
doubling	I-Diagnostic_tool
technology	I-Diagnostic_tool
(	I-Diagnostic_tool
FDT	I-Diagnostic_tool
)	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
,	O
and	O
pattern	B-Diagnostic_tool
-	I-Diagnostic_tool
electroretinography	I-Diagnostic_tool
(	O
PERG	B-Diagnostic_tool
)	O
in	O
patients	O
with	O
definite	O
primary	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
(	O
POAG	B-Disease
)	O
but	O
normal	O
results	O
on	O
standard	B-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
(	O
SAP	B-Diagnostic_tool
)	O
.	O
	
Prospective	O
,	O
comparative	O
,	O
observational	O
case	O
series	O
.	O
	
Thirty	O
-	O
six	O
patients	O
with	O
POAG	B-Disease
with	O
standard	O
visual	B-Symptom
field	I-Symptom
defects	I-Symptom
in	O
one	O
eye	B-Anatomy
and	O
normal	B-Characteristic
standard	I-Characteristic
visual	I-Characteristic
fields	I-Characteristic
in	O
the	O
contralateral	O
eye	B-Anatomy
and	O
36	O
normal	O
controls	O
were	O
enrolled	O
.	O
	
SWAP	B-Diagnostic_tool
,	O
PERG	B-Diagnostic_tool
,	O
FDT	B-Diagnostic_tool
,	O
and	O
SAP	B-Diagnostic_tool
were	O
performed	O
in	O
all	O
eyes	B-Anatomy
,	O
and	O
global	O
indices	O
and	O
amplitudes	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O
	
When	O
contralateral	O
POAG	B-Disease
eyes	B-Anatomy
with	O
asymmetric	B-Symptom
glaucomatous	I-Symptom
damage	I-Symptom
was	O
compared	O
,	O
a	O
paired	O
t	O
test	O
showed	O
significant	O
differences	O
in	O
SAP	B-Characteristic
mean	I-Characteristic
deviation	I-Characteristic
(	O
MD	O
)	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
SWAP	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
(	O
P	O
=	O
0	O
.	O
0003	O
)	O
,	O
FDT	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
(	O
P	O
=	O
0	O
.	O
0008	O
)	O
,	O
and	O
PERG	B-Characteristic
amplitudes	I-Characteristic
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
	
When	O
comparing	O
between	O
POAG	B-Disease
eyes	B-Anatomy
with	O
normal	O
results	O
on	O
SAP	B-Diagnostic_tool
and	O
normal	O
controls	O
,	O
Student	O
'	O
s	O
t	O
test	O
showed	O
significant	O
differences	O
for	O
SWAP	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
FDT	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
(	O
P	O
=	O
0	O
.	O
0006	O
)	O
,	O
PERG	B-Characteristic
N1P1	I-Characteristic
-	I-Characteristic
amplitude	I-Characteristic
(	O
P	O
=	O
0	O
.	O
0486	O
)	O
and	O
P1N2	B-Characteristic
-	I-Characteristic
amplitude	I-Characteristic
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
;	O
receiver	O
operating	O
characteristic	O
analysis	O
revealed	O
promising	O
accuracy	O
for	O
SWAP	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
of	O
73	O
.	O
6	O
%	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
	
SWAP	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
FDT	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
correlated	O
significantly	O
with	O
SAP	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
and	O
with	O
each	O
other	O
(	O
range	O
,	O
P	O
<	O
0	O
.	O
0001	O
to	O
P	O
=	O
0	O
.	O
0020	O
)	O
.	O
	
Regression	O
analysis	O
revealed	O
that	O
PERG	B-Characteristic
P1N2	I-Characteristic
-	I-Characteristic
amplitude	I-Characteristic
could	O
improve	O
the	O
power	O
of	O
SWAP	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
from	O
73	O
.	O
6	O
%	O
to	O
detect	O
early	B-Disease
POAG	I-Disease
in	O
eyes	B-Anatomy
with	O
normal	O
results	O
on	O
SAP	B-Diagnostic_tool
to	O
an	O
accuracy	O
of	O
81	O
.	O
9	O
%	O
.	O
	
A	O
test	O
battery	O
of	O
SWAP	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
and	O
PERG	B-Characteristic
P1N2	I-Characteristic
-	I-Characteristic
amplitude	I-Characteristic
could	O
detect	O
glaucomatous	B-Disease
optic	I-Disease
neuropathy	I-Disease
in	O
POAG	B-Disease
eyes	B-Anatomy
with	O
normal	B-Characteristic
standard	I-Characteristic
visual	I-Characteristic
fields	I-Characteristic
,	O
whereas	O
FDT	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
and	O
SWAP	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
significantly	O
correlated	O
with	O
each	O
other	O
and	O
with	O
SAP	B-Characteristic
-	I-Characteristic
MD	I-Characteristic
.	O
	
All	O
tests	O
were	O
able	O
to	O
detect	O
the	O
eye	B-Anatomy
with	O
the	O
more	O
severe	O
glaucomatous	B-Disease
optic	I-Disease
neuropathy	I-Disease
in	O
patients	O
with	O
asymmetric	B-Disease
POAG	I-Disease
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
measurement	O
of	O
macular	B-Characteristic
and	I-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
in	O
normal	O
and	O
glaucomatous	B-Disease
human	O
eyes	B-Anatomy
.	O
	
To	O
evaluate	O
the	O
hypothesis	O
that	O
macular	B-Characteristic
thickness	I-Characteristic
correlates	O
with	O
the	O
diagnosis	O
of	O
glaucoma	B-Disease
.	O
	
Cross	O
-	O
sectional	O
study	O
.	O
	
We	O
studied	O
367	O
subjects	O
(	O
534	O
eyes	B-Anatomy
)	O
,	O
including	O
166	O
eyes	B-Anatomy
of	O
109	O
normal	O
subjects	O
,	O
83	O
eyes	B-Anatomy
of	O
58	O
glaucoma	B-Disease
suspects	O
,	O
196	O
eyes	B-Anatomy
of	O
132	O
early	B-Disease
glaucoma	I-Disease
patients	O
,	O
and	O
89	O
eyes	B-Anatomy
of	O
68	O
advanced	B-Disease
glaucoma	I-Disease
patients	O
.	O
	
We	O
used	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
to	O
measure	O
macular	B-Characteristic
and	I-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
(	I-Characteristic
NFL	I-Characteristic
)	I-Characteristic
thickness	I-Characteristic
and	O
to	O
analyze	O
their	O
correlation	O
with	O
each	O
other	O
and	O
with	O
glaucoma	B-Disease
status	O
.	O
	
We	O
used	O
both	O
the	O
commercial	O
and	O
prototype	O
OCT	B-Diagnostic_tool
units	O
and	O
evaluated	O
correspondence	O
between	O
measurements	O
performed	O
on	O
the	O
same	O
eyes	B-Anatomy
on	O
the	O
same	O
days	O
.	O
	
Macular	B-Characteristic
and	I-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
as	O
measured	O
by	O
OCT	B-Diagnostic_tool
.	O
	
All	O
NFL	B-Characteristic
parameters	I-Characteristic
both	O
in	O
prototype	O
and	O
commercial	O
OCT	B-Diagnostic_tool
units	O
were	O
statistically	O
significantly	O
different	O
comparing	O
normal	O
subjects	O
and	O
either	O
early	B-Disease
or	I-Disease
advanced	I-Disease
glaucoma	I-Disease
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
Inner	B-Characteristic
ring	I-Characteristic
,	I-Characteristic
outer	I-Characteristic
ring	I-Characteristic
,	I-Characteristic
and	I-Characteristic
mean	I-Characteristic
macular	I-Characteristic
thickness	I-Characteristic
both	O
in	O
prototype	O
and	O
commercial	O
OCT	B-Diagnostic_tool
devices	O
were	O
found	O
to	O
be	O
significantly	O
different	O
between	O
normal	O
subjects	O
and	O
advanced	B-Disease
glaucomatous	I-Disease
eyes	B-Anatomy
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
The	O
outer	B-Characteristic
ring	I-Characteristic
was	O
the	O
only	O
macular	B-Characteristic
parameter	I-Characteristic
that	O
could	O
significantly	O
differentiate	O
between	O
normal	O
and	O
early	B-Disease
glaucoma	I-Disease
with	O
either	O
the	O
prototype	O
or	O
commercial	O
OCT	B-Diagnostic_tool
unit	O
(	O
P	O
=	O
0	O
.	O
003	O
,	O
P	O
=	O
0	O
.	O
008	O
,	O
respectively	O
)	O
.	O
	
The	O
area	O
under	O
the	O
receiver	O
operator	O
characteristic	O
(	O
AROC	O
)	O
curves	O
comparing	O
mean	B-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
between	O
normal	O
and	O
advanced	B-Disease
glaucomatous	I-Disease
eyes	B-Anatomy
was	O
1	O
.	O
00	O
for	O
both	O
the	O
prototype	O
and	O
commercial	O
OCT	B-Diagnostic_tool
devices	O
for	O
eyes	B-Anatomy
scanned	O
on	O
both	O
machines	O
on	O
the	O
same	O
day	O
.	O
	
The	O
AROC	O
comparing	O
mean	B-Characteristic
macular	I-Characteristic
thickness	I-Characteristic
in	O
normal	O
and	O
advanced	B-Disease
glaucomatous	I-Disease
eyes	B-Anatomy
scanned	O
on	O
both	O
machines	O
on	O
the	O
same	O
day	O
was	O
0	O
.	O
88	O
for	O
the	O
prototype	O
OCT	B-Diagnostic_tool
device	O
and	O
0	O
.	O
80	O
for	O
the	O
commercial	O
OCT	B-Diagnostic_tool
.	O
	
Both	O
macular	B-Characteristic
and	I-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
as	O
measured	O
by	O
OCT	B-Diagnostic_tool
showed	O
statistically	O
significant	O
correlations	O
with	O
glaucoma	B-Disease
,	O
although	O
NFL	B-Characteristic
thickness	I-Characteristic
showed	O
a	O
stronger	O
association	O
than	O
macular	B-Characteristic
thickness	I-Characteristic
.	O
	
There	O
was	O
good	O
correspondence	O
between	O
findings	O
using	O
both	O
the	O
prototype	O
and	O
commercial	O
OCT	B-Diagnostic_tool
units	O
.	O
	
Macular	B-Characteristic
and	I-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
measurements	O
made	O
with	O
OCT	B-Diagnostic_tool
may	O
have	O
usefulness	O
in	O
the	O
clinical	O
assessment	O
of	O
glaucoma	B-Disease
.	O
	
Misleading	O
statistical	O
calculations	O
in	O
far	B-Disease
-	I-Disease
advanced	I-Disease
glaucomatous	I-Disease
visual	B-Symptom
field	I-Symptom
loss	I-Symptom
.	O
	
In	O
this	O
study	O
,	O
the	O
capability	O
of	O
statistical	B-Characteristic
analysis	I-Characteristic
indices	I-Characteristic
to	O
characterize	O
static	B-Diagnostic_tool
automated	I-Diagnostic_tool
visual	I-Diagnostic_tool
fields	I-Diagnostic_tool
(	O
VFs	B-Diagnostic_tool
)	O
accurately	O
in	O
cases	O
of	O
far	B-Disease
-	I-Disease
advanced	I-Disease
glaucoma	I-Disease
was	O
assessed	O
.	O
	
Retrospective	O
observational	O
case	O
series	O
.	O
	
Sixteen	O
eyes	B-Anatomy
of	O
15	O
patients	O
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
glaucoma	I-Disease
and	O
evidence	O
of	O
collapse	B-Characteristic
of	I-Characteristic
VF	I-Characteristic
statistical	I-Characteristic
analysis	I-Characteristic
indices	I-Characteristic
were	O
included	O
in	O
the	O
study	O
.	O
	
End	B-Disease
-	I-Disease
stage	I-Disease
glaucoma	I-Disease
was	O
defined	O
as	O
vertical	B-Symptom
cup	I-Symptom
-	I-Symptom
to	I-Symptom
-	I-Symptom
disc	I-Symptom
ratio	I-Symptom
of	I-Symptom
0	I-Symptom
.	I-Symptom
9	I-Symptom
or	I-Symptom
more	I-Symptom
,	O
mean	B-Symptom
deviation	I-Symptom
less	I-Symptom
than	I-Symptom
-	I-Symptom
24	I-Symptom
dB	I-Symptom
and	O
with	O
only	O
a	O
central	B-Symptom
or	I-Symptom
temporal	I-Symptom
island	I-Symptom
remaining	I-Symptom
in	I-Symptom
the	I-Symptom
VF	I-Symptom
gray	I-Symptom
scale	I-Symptom
.	O
	
Collapse	B-Characteristic
of	I-Characteristic
statistical	I-Characteristic
indices	I-Characteristic
was	O
defined	O
as	O
any	O
of	O
the	O
following	O
:	O
pattern	B-Characteristic
deviation	I-Characteristic
probability	I-Characteristic
plot	I-Characteristic
without	I-Characteristic
a	I-Characteristic
single	I-Characteristic
VF	I-Characteristic
location	I-Characteristic
showing	I-Characteristic
P	I-Characteristic
<	I-Characteristic
0	I-Characteristic
.	I-Characteristic
5	I-Characteristic
%	I-Characteristic
;	O
corrected	B-Characteristic
pattern	I-Characteristic
standard	I-Characteristic
deviation	I-Characteristic
(	O
CPSD	B-Characteristic
)	O
and	O
pattern	B-Characteristic
standard	I-Characteristic
deviation	I-Characteristic
(	I-Characteristic
PSD	I-Characteristic
)	I-Characteristic
probability	I-Characteristic
less	I-Characteristic
than	I-Characteristic
5	I-Characteristic
%	I-Characteristic
or	I-Characteristic
within	I-Characteristic
normal	I-Characteristic
limits	I-Characteristic
(	I-Characteristic
WNL	I-Characteristic
)	I-Characteristic
;	O
short	B-Characteristic
-	I-Characteristic
term	I-Characteristic
fluctuation	I-Characteristic
(	I-Characteristic
SF	I-Characteristic
)	I-Characteristic
probability	I-Characteristic
WNL	I-Characteristic
;	O
glaucoma	B-Characteristic
hemifield	I-Characteristic
test	I-Characteristic
(	I-Characteristic
GHT	I-Characteristic
)	I-Characteristic
not	I-Characteristic
outside	I-Characteristic
normal	I-Characteristic
limits	I-Characteristic
(	I-Characteristic
ONL	I-Characteristic
)	I-Characteristic
;	O
or	O
presence	B-Characteristic
of	I-Characteristic
a	I-Characteristic
low	I-Characteristic
patient	I-Characteristic
reliability	I-Characteristic
comment	I-Characteristic
triggered	I-Characteristic
by	I-Characteristic
40	I-Characteristic
%	I-Characteristic
or	I-Characteristic
more	I-Characteristic
false	I-Characteristic
-	I-Characteristic
negative	I-Characteristic
(	I-Characteristic
FN	I-Characteristic
)	I-Characteristic
responses	I-Characteristic
.	O
	
Visual	O
field	O
statistical	O
indices	O
.	O
	
Of	O
the	O
16	O
VFs	B-Characteristic
showing	O
misleading	O
statistical	O
calculations	O
,	O
9	O
of	O
16	O
eyes	B-Anatomy
had	O
a	O
normal	O
pattern	B-Characteristic
deviation	I-Characteristic
probability	I-Characteristic
plot	I-Characteristic
.	O
	
The	O
PSD	B-Characteristic
,	O
SF	B-Characteristic
,	I-Characteristic
and	O
CPSD	B-Characteristic
parameters	O
were	O
normal	O
or	O
barely	O
outside	O
the	O
normal	O
range	O
in	O
4	O
of	O
16	O
,	O
10	O
of	O
16	O
,	O
and	O
5	O
of	O
16	O
eyes	B-Anatomy
,	O
respectively	O
.	O
	
The	O
GHT	B-Diagnostic_tool
was	O
ONL	B-Characteristic
in	O
7	O
of	O
13	O
eyes	B-Anatomy
,	O
borderline	O
with	O
generalized	B-Characteristic
reduction	I-Characteristic
of	I-Characteristic
sensitivity	I-Characteristic
(	O
GRS	B-Characteristic
)	O
in	O
three	O
eyes	B-Anatomy
,	O
and	O
only	O
GRS	B-Characteristic
in	O
two	O
additional	O
eyes	B-Anatomy
.	O
	
Low	B-Characteristic
patient	I-Characteristic
reliability	I-Characteristic
was	O
triggered	O
because	O
of	O
an	O
FN	B-Characteristic
score	I-Characteristic
of	I-Characteristic
40	I-Characteristic
%	I-Characteristic
or	I-Characteristic
more	I-Characteristic
in	O
10	O
of	O
16	O
eyes	B-Anatomy
.	O
	
Statistical	B-Characteristic
indices	I-Characteristic
are	O
crucial	O
for	O
the	O
interpretation	O
of	O
automated	B-Diagnostic_tool
static	I-Diagnostic_tool
VFs	I-Diagnostic_tool
.	O
	
However	O
,	O
in	O
end	B-Disease
-	I-Disease
stage	I-Disease
glaucomatous	I-Disease
VF	B-Symptom
loss	I-Symptom
,	O
both	O
summary	O
statistical	B-Characteristic
indices	I-Characteristic
and	O
reliability	B-Characteristic
indices	I-Characteristic
may	O
not	O
detect	O
abnormality	O
,	O
thus	O
misleading	O
the	O
casual	O
observer	O
.	O
	
Reproducibility	O
of	O
evaluation	O
of	O
optic	B-Anatomy
disc	I-Anatomy
change	O
for	O
glaucoma	B-Disease
with	O
stereo	B-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
photographs	I-Diagnostic_tool
.	O
	
To	O
determine	O
the	O
reproducibility	O
of	O
the	O
assessment	O
for	O
glaucomatous	B-Symptom
change	I-Symptom
in	O
serial	B-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
stereo	I-Diagnostic_tool
-	I-Diagnostic_tool
slides	I-Diagnostic_tool
.	O
	
Masked	O
interobserver	O
variability	O
study	O
.	O
	
Serial	B-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
stereo	I-Diagnostic_tool
-	I-Diagnostic_tool
slides	I-Diagnostic_tool
from	O
40	O
patients	O
.	O
	
Three	O
independent	O
ophthalmologists	O
evaluated	O
for	O
change	O
a	O
set	O
of	O
two	O
serial	B-Diagnostic_tool
20	I-Diagnostic_tool
degrees	I-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
color	I-Diagnostic_tool
stereo	I-Diagnostic_tool
-	I-Diagnostic_tool
slides	I-Diagnostic_tool
of	O
40	O
patients	O
.	O
	
This	O
test	O
set	O
was	O
not	O
from	O
European	O
Glaucoma	B-Disease
Prevention	O
Study	O
(	O
EGPS	O
)	O
patients	O
.	O
	
Each	O
observer	O
performed	O
two	O
evaluations	O
at	O
least	O
30	O
days	O
apart	O
and	O
was	O
masked	O
from	O
the	O
temporal	O
sequence	O
of	O
the	O
slides	O
and	O
his	O
or	O
her	O
previous	O
evaluation	O
.	O
	
Each	O
patient	O
was	O
graded	O
as	O
changed	O
or	O
stable	O
by	O
two	O
-	O
out	O
-	O
of	O
-	O
three	O
agreement	O
.	O
	
A	O
kappa	O
statistic	O
was	O
used	O
to	O
calculate	O
the	O
intra	O
-	O
and	O
interobserver	O
reproducibility	O
as	O
well	O
as	O
the	O
assignment	O
reproducibility	O
(	O
first	O
consensus	O
versus	O
second	O
consensus	O
)	O
.	O
	
The	O
same	O
procedure	O
was	O
followed	O
to	O
test	O
the	O
reproducibility	O
when	O
another	O
experienced	O
ophthalmologist	O
was	O
added	O
to	O
one	O
of	O
the	O
three	O
reading	O
centers	O
.	O
	
Reproducibility	O
in	O
evaluating	O
glaucomatous	B-Symptom
optic	I-Symptom
disc	I-Symptom
change	I-Symptom
.	O
	
The	O
intraobserver	O
reproducibility	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
)	O
in	O
the	O
evaluation	O
of	O
change	O
ranged	O
between	O
0	O
.	O
79	O
(	O
0	O
.	O
45	O
-	O
1	O
.	O
14	O
)	O
and	O
1	O
.	O
00	O
(	O
0	O
.	O
69	O
-	O
1	O
.	O
31	O
)	O
.	O
	
The	O
interobserver	O
reproducibility	O
(	O
95	O
%	O
CI	O
)	O
in	O
the	O
evaluation	O
of	O
change	O
ranged	O
between	O
0	O
.	O
45	O
(	O
0	O
.	O
15	O
-	O
0	O
.	O
75	O
)	O
and	O
0	O
.	O
75	O
(	O
0	O
.	O
44	O
-	O
1	O
.	O
06	O
)	O
.	O
	
The	O
assignment	O
reproducibility	O
(	O
first	O
consensus	O
versus	O
second	O
consensus	O
in	O
the	O
evaluation	O
of	O
change	O
)	O
between	O
the	O
senior	O
EGPS	O
readers	O
was	O
0	O
.	O
94	O
(	O
0	O
.	O
63	O
-	O
1	O
.	O
25	O
)	O
.	O
	
The	O
assignment	O
reproducibility	O
when	O
another	O
experienced	O
ophthalmologist	O
replaced	O
one	O
of	O
the	O
readers	O
was	O
0	O
.	O
94	O
(	O
0	O
.	O
63	O
-	O
1	O
.	O
25	O
)	O
.	O
	
The	O
assignment	O
reproducibility	O
of	O
three	O
expert	O
readers	O
looking	O
for	O
glaucomatous	B-Symptom
change	I-Symptom
in	O
serial	B-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
stereo	I-Diagnostic_tool
-	I-Diagnostic_tool
slides	I-Diagnostic_tool
was	O
excellent	O
.	O
	
It	O
remained	O
so	O
when	O
one	O
of	O
the	O
three	O
experts	O
was	O
replaced	O
by	O
another	O
experienced	O
reader	O
.	O
	
The	O
risk	O
and	O
natural	O
course	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
:	O
follow	O
-	O
up	O
at	O
6	O
1	O
/	O
2	O
years	O
in	O
the	O
Rotterdam	O
study	O
	
Objectives	O
:	O
To	O
evaluate	O
the	O
natural	O
course	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
(	O
ARM	B-Disease
)	O
and	O
to	O
assess	O
the	O
incidence	O
and	O
absolute	O
risk	O
of	O
its	O
final	O
stage	O
,	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Methods	O
:	O
In	O
a	O
population	O
-	O
based	O
prospective	O
cohort	O
study	O
of	O
6418	O
persons	O
55	B-Characteristic
years	I-Characteristic
and	I-Characteristic
older	I-Characteristic
,	O
we	O
studied	O
the	O
incidence	O
and	O
natural	O
course	O
of	O
ARM	B-Disease
.	O
	
Subjects	O
underwent	O
identical	O
examinations	O
,	O
including	O
stereoscopic	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photography	I-Diagnostic_tool
,	O
at	O
baseline	O
and	O
at	O
2	O
.	O
0	O
and	O
6	O
(	O
1	O
/	O
2	O
)	O
years	O
'	O
follow	O
-	O
up	O
.	O
	
Age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
was	O
graded	O
according	O
to	O
the	O
International	B-Classification_system
Classification	I-Classification_system
and	I-Classification_system
Grading	I-Classification_system
System	I-Classification_system
for	O
ARM	B-Disease
and	O
AMD	B-Disease
,	O
and	O
stratified	O
into	O
5	O
exclusive	O
stages	O
.	O
	
Incidence	O
was	O
expressed	O
in	O
rates	O
and	O
5	O
-	O
year	O
absolute	O
risks	O
.	O
	
Results	O
:	O
At	O
follow	O
-	O
up	O
,	O
47	O
new	O
cases	O
of	O
AMD	B-Disease
were	O
identified	O
,	O
with	O
a	O
ratio	O
of	O
neovascular	B-Disease
-	I-Disease
atrophic	I-Disease
AMD	I-Disease
of	O
1	O
.	O
4	O
:	O
1	O
.	O
	
The	O
5	O
-	O
year	O
risk	O
of	O
AMD	B-Disease
increased	O
with	O
more	O
severe	O
stages	O
to	O
28	O
.	O
0	O
%	O
for	O
subjects	O
55	B-Characteristic
years	I-Characteristic
and	I-Characteristic
older	I-Characteristic
with	O
indistinct	B-Symptom
drusen	I-Symptom
and	O
pigmentary	B-Symptom
irregularities	I-Symptom
(	O
stage	B-Disease
3	I-Disease
)	O
.	O
	
Age	B-Characteristic
,	O
but	O
not	O
sex	B-Characteristic
,	O
independently	O
increased	O
this	O
risk	O
to	O
a	O
maximum	O
of	O
42	O
.	O
0	O
%	O
for	O
subjects	O
with	O
stage	B-Disease
3	I-Disease
ARM	I-Disease
who	O
were	O
80	B-Characteristic
years	I-Characteristic
and	I-Characteristic
older	I-Characteristic
.	O
	
Individual	O
ARM	B-Disease
fundus	B-Symptom
signs	I-Symptom
that	O
predicted	O
best	O
the	O
development	O
of	O
AMD	B-Disease
were	O
10	B-Symptom
or	I-Symptom
more	I-Symptom
large	I-Symptom
drusen	I-Symptom
(	O
>	B-Dimension
or	I-Dimension
=	I-Dimension
125	I-Dimension
microm	I-Dimension
)	O
and	O
10	B-Symptom
%	I-Symptom
or	I-Symptom
more	I-Symptom
of	I-Symptom
the	I-Symptom
grid	I-Symptom
area	I-Symptom
covered	I-Symptom
by	I-Symptom
drusen	I-Symptom
.	O
	
Subjects	O
who	O
developed	O
atrophic	B-Disease
AMD	I-Disease
showed	O
no	O
significant	O
(	O
P	O
=	O
.	O
25	O
)	O
differences	O
in	O
baseline	O
fundus	B-Symptom
signs	I-Symptom
and	O
natural	O
course	O
compared	O
with	O
subjects	O
who	O
developed	O
neovascular	B-Disease
AMD	I-Disease
.	O
	
Conclusions	O
:	O
We	O
provided	O
the	O
absolute	O
risk	O
of	O
AMD	B-Disease
as	O
a	O
function	O
of	O
age	B-Characteristic
and	O
early	B-Symptom
ARM	I-Symptom
fundus	I-Symptom
signs	I-Symptom
,	O
and	O
showed	O
that	O
both	O
are	O
prominent	O
independent	O
risk	O
factors	O
.	O
	
The	O
progression	O
of	O
ARM	B-Disease
stages	O
follows	O
,	O
after	O
the	O
appearance	O
of	O
the	O
first	B-Symptom
soft	I-Symptom
drusen	I-Symptom
,	O
a	O
distinct	O
course	O
at	O
a	O
gradual	O
pace	O
that	O
accelerates	O
with	O
increasing	O
age	B-Characteristic
.	O
	
Optic	B-Disease
neuritis	I-Disease
:	O
correlation	O
of	O
pain	B-Symptom
and	O
magnetic	B-Diagnostic_tool
resonance	I-Diagnostic_tool
imaging	I-Diagnostic_tool
.	O
	
To	O
demonstrate	O
whether	O
the	O
magnetic	B-Diagnostic_tool
resonance	I-Diagnostic_tool
imaging	I-Diagnostic_tool
(	O
MRI	B-Diagnostic_tool
)	O
localization	O
of	O
the	O
abnormal	B-Symptom
enhancement	I-Symptom
of	I-Symptom
the	I-Symptom
optic	I-Symptom
nerve	I-Symptom
can	O
be	O
related	O
to	O
the	O
pain	B-Symptom
or	O
pattern	O
of	O
visual	B-Symptom
field	I-Symptom
loss	I-Symptom
associated	O
with	O
acute	B-Disease
optic	I-Disease
neuritis	I-Disease
.	O
	
Retrospective	O
observational	O
series	O
and	O
MRI	B-Diagnostic_tool
review	O
from	O
a	O
referral	O
neuro	O
-	O
ophthalmology	O
service	O
.	O
	
Seventy	O
-	O
three	O
women	B-Characteristic
and	O
23	O
men	B-Characteristic
with	O
acute	B-Disease
optic	I-Disease
neuritis	I-Disease
who	O
had	O
high	B-Diagnostic_tool
resolution	I-Diagnostic_tool
gadolinium	I-Diagnostic_tool
-	I-Diagnostic_tool
enhanced	I-Diagnostic_tool
fat	I-Diagnostic_tool
-	I-Diagnostic_tool
suppressed	I-Diagnostic_tool
MRI	I-Diagnostic_tool
within	O
twenty	O
days	O
of	O
the	O
onset	O
of	O
visual	B-Symptom
loss	I-Symptom
.	O
	
The	O
presence	O
of	O
eye	B-Symptom
or	I-Symptom
other	I-Symptom
fifth	I-Symptom
cranial	I-Symptom
nerve	I-Symptom
(	I-Symptom
V	I-Symptom
(	I-Symptom
1	I-Symptom
)	I-Symptom
)	I-Symptom
pain	I-Symptom
,	O
and	O
pain	B-Symptom
with	I-Symptom
eye	I-Symptom
movement	I-Symptom
ipsilateral	I-Symptom
to	I-Symptom
the	I-Symptom
affected	I-Symptom
optic	I-Symptom
nerve	I-Symptom
or	O
no	B-Characteristic
eye	I-Characteristic
pain	I-Characteristic
was	O
recorded	O
.	O
	
The	O
neuroradiologist	O
reviewed	O
the	O
MRI	B-Diagnostic_tool
,	O
masked	O
to	O
the	O
affected	O
eye	B-Anatomy
,	O
and	O
recorded	O
the	O
length	B-Characteristic
and	I-Characteristic
segment	I-Characteristic
(	I-Characteristic
orbital	I-Characteristic
,	I-Characteristic
canalicular	I-Characteristic
,	I-Characteristic
intracranial	I-Characteristic
,	I-Characteristic
or	I-Characteristic
combination	I-Characteristic
of	I-Characteristic
segments	I-Characteristic
)	I-Characteristic
of	I-Characteristic
abnormal	I-Characteristic
optic	I-Characteristic
nerve	I-Characteristic
enhancement	I-Characteristic
.	O
	
The	O
presenting	O
visual	B-Symptom
field	I-Symptom
defects	I-Symptom
were	O
characterized	O
as	O
diffuse	B-Characteristic
,	I-Characteristic
central	I-Characteristic
,	I-Characteristic
arcuate	I-Characteristic
,	I-Characteristic
nasal	I-Characteristic
or	I-Characteristic
temporal	I-Characteristic
.	O
	
The	O
types	O
of	O
pain	B-Symptom
and	O
patterns	O
of	O
field	B-Symptom
loss	I-Symptom
were	O
correlated	O
with	O
the	O
segments	B-Characteristic
of	I-Characteristic
optic	I-Characteristic
nerve	I-Characteristic
enhancement	I-Characteristic
in	O
the	O
affected	O
eye	B-Anatomy
.	O
	
Five	O
patients	O
had	O
nerves	B-Characteristic
that	I-Characteristic
did	I-Characteristic
not	I-Characteristic
enhance	I-Characteristic
and	O
were	O
excluded	O
from	O
the	O
outcome	O
analysis	O
.	O
	
In	O
the	O
91	O
patients	O
with	O
abnormal	B-Symptom
enhancement	I-Symptom
,	O
70	O
experienced	O
eye	B-Symptom
/	I-Symptom
V	I-Symptom
(	I-Symptom
1	I-Symptom
)	I-Symptom
pain	I-Symptom
,	O
67	O
had	O
pain	B-Symptom
with	I-Symptom
eye	I-Symptom
movement	I-Symptom
and	O
17	O
patients	O
had	O
no	B-Characteristic
pain	I-Characteristic
.	O
	
Enhancement	B-Symptom
of	I-Symptom
the	I-Symptom
orbital	I-Symptom
optic	I-Symptom
nerve	I-Symptom
occurred	O
in	O
66	O
patients	O
,	O
93	O
.	O
9	O
%	O
who	O
had	O
eye	B-Symptom
/	I-Symptom
V	I-Symptom
(	I-Symptom
1	I-Symptom
)	I-Symptom
pain	I-Symptom
and	O
92	O
.	O
4	O
%	O
who	O
had	O
pain	B-Symptom
with	I-Symptom
eye	I-Symptom
movement	I-Symptom
.	O
	
In	O
the	O
25	O
patients	O
with	O
enhancement	B-Symptom
of	I-Symptom
the	I-Symptom
canalicular	I-Symptom
,	I-Symptom
intracranial	I-Symptom
or	I-Symptom
both	I-Symptom
segments	I-Symptom
,	O
without	O
orbital	O
involvement	O
,	O
32	O
%	O
had	O
eye	B-Symptom
/	I-Symptom
V	I-Symptom
(	I-Symptom
1	I-Symptom
)	I-Symptom
pain	I-Symptom
and	O
24	O
%	O
had	O
pain	B-Symptom
with	I-Symptom
eye	I-Symptom
movement	I-Symptom
.	O
	
No	B-Characteristic
pain	I-Characteristic
occurred	O
in	O
3	O
%	O
with	O
enhancement	B-Symptom
of	I-Symptom
the	I-Symptom
orbital	I-Symptom
segment	I-Symptom
and	O
in	O
60	O
%	O
with	O
enhancement	B-Symptom
of	I-Symptom
the	I-Symptom
other	I-Symptom
optic	I-Symptom
nerve	I-Symptom
segments	I-Symptom
.	O
	
The	O
length	B-Characteristic
of	I-Characteristic
enhancement	I-Characteristic
moderately	O
correlated	O
with	O
eye	B-Symptom
/	I-Symptom
V	I-Symptom
(	I-Symptom
1	I-Symptom
)	I-Symptom
pain	I-Symptom
(	O
r	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
pain	B-Symptom
with	I-Symptom
eye	I-Symptom
movement	I-Symptom
(	O
r	O
=	O
0	O
.	O
37	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O
	
Patients	O
with	O
enhancement	B-Characteristic
longer	I-Characteristic
than	I-Characteristic
10	I-Characteristic
mm	I-Characteristic
had	O
pain	B-Symptom
five	O
times	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
more	O
frequent	O
than	O
did	O
those	O
with	O
enhancement	B-Characteristic
<	I-Characteristic
or	I-Characteristic
=	I-Characteristic
10	I-Characteristic
mm	I-Characteristic
.	O
	
There	O
was	O
no	O
significant	O
specific	O
pattern	O
of	O
field	B-Symptom
loss	I-Symptom
associated	O
with	O
a	O
particular	O
location	B-Characteristic
of	I-Characteristic
enhancement	I-Characteristic
,	O
except	O
temporal	B-Symptom
field	I-Symptom
loss	I-Symptom
occurred	O
in	O
25	O
%	O
of	O
intracranial	B-Symptom
lesions	I-Symptom
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O
	
When	O
optic	B-Disease
neuritis	I-Disease
involved	O
the	O
orbital	B-Characteristic
segment	I-Characteristic
of	I-Characteristic
the	I-Characteristic
optic	I-Characteristic
nerve	I-Characteristic
,	O
eye	B-Symptom
or	I-Symptom
other	I-Symptom
V	I-Symptom
(	I-Symptom
1	I-Symptom
)	I-Symptom
distribution	I-Symptom
pain	I-Symptom
(	O
94	O
.	O
3	O
%	O
vs	O
.	O
32	O
%	O
)	O
and	O
pain	B-Symptom
with	I-Symptom
eye	I-Symptom
movement	I-Symptom
(	O
91	O
.	O
4	O
%	O
vs	O
.	O
24	O
%	O
)	O
were	O
significantly	O
more	O
frequent	O
.	O
	
In	O
contrast	O
,	O
pain	B-Symptom
was	O
absent	O
20	O
times	O
more	O
often	O
when	O
the	O
orbital	B-Characteristic
segment	I-Characteristic
was	I-Characteristic
not	I-Characteristic
involved	I-Characteristic
(	O
60	O
%	O
vs	O
.	O
3	O
%	O
)	O
.	O
	
Except	O
for	O
temporal	B-Symptom
field	I-Symptom
loss	I-Symptom
in	I-Symptom
eyes	I-Symptom
with	I-Symptom
intracranial	I-Symptom
nerve	I-Symptom
lesions	I-Symptom
,	O
no	O
pattern	O
of	O
visual	B-Symptom
field	I-Symptom
loss	I-Symptom
appeared	O
to	O
correlate	O
with	O
the	O
location	B-Characteristic
or	I-Characteristic
length	I-Characteristic
of	I-Characteristic
abnormal	I-Characteristic
optic	I-Characteristic
nerve	I-Characteristic
enhancement	I-Characteristic
.	O
	
Proposed	O
international	O
clinical	O
diabetic	B-Disease
retinopathy	I-Disease
and	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
disease	O
severity	O
scales	O
.	O
	
To	O
develop	O
consensus	O
regarding	O
clinical	O
disease	O
severity	O
classification	O
systems	O
for	O
diabetic	B-Disease
retinopathy	I-Disease
and	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
that	O
can	O
be	O
used	O
around	O
the	O
world	O
,	O
and	O
to	O
improve	O
communication	O
and	O
coordination	O
of	O
care	O
among	O
physicians	O
who	O
care	O
for	O
patients	O
with	O
diabetes	B-Disease
.	O
	
Report	O
regarding	O
the	O
development	O
of	O
clinical	O
diabetic	B-Disease
retinopathy	I-Disease
disease	O
severity	O
scales	O
.	O
	
A	O
group	O
of	O
31	O
individuals	O
from	O
16	O
countries	O
,	O
representing	O
comprehensive	O
ophthalmology	O
,	O
retina	B-Anatomy
subspecialties	O
,	O
endocrinology	O
,	O
and	O
epidemiology	O
.	O
	
An	O
initial	O
clinical	O
classification	O
system	O
,	O
based	O
on	O
the	O
Early	O
Treatment	O
Diabetic	B-Disease
Retinopathy	I-Disease
Study	O
and	O
the	O
Wisconsin	B-Characteristic
Epidemiologic	O
Study	O
of	O
Diabetic	B-Disease
Retinopathy	I-Disease
publications	O
,	O
was	O
circulated	O
to	O
the	O
group	O
in	O
advance	O
of	O
a	O
workshop	O
.	O
	
Each	O
member	O
reviewed	O
this	O
using	O
e	O
-	O
mail	O
,	O
and	O
a	O
modified	O
Delphi	O
system	O
was	O
used	O
to	O
stratify	O
responses	O
.	O
	
At	O
a	O
later	O
workshop	O
,	O
separate	O
systems	O
for	O
diabetic	B-Disease
retinopathy	I-Disease
and	O
macular	B-Disease
edema	I-Disease
were	O
developed	O
.	O
	
These	O
were	O
then	O
reevaluated	O
by	O
group	O
members	O
,	O
and	O
the	O
modified	O
Delphi	O
system	O
was	O
again	O
used	O
to	O
measure	O
degrees	O
of	O
agreement	O
.	O
	
Consensus	O
regarding	O
specific	O
classification	O
systems	O
was	O
achieved	O
.	O
	
A	O
five	O
-	O
stage	O
disease	O
severity	O
classification	O
for	O
diabetic	B-Disease
retinopathy	I-Disease
includes	O
three	B-Characteristic
stages	I-Characteristic
of	I-Characteristic
low	I-Characteristic
risk	I-Characteristic
,	O
a	O
fourth	O
stage	O
of	O
severe	B-Disease
nonproliferative	I-Disease
retinopathy	I-Disease
,	O
and	O
a	O
fifth	O
stage	O
of	O
proliferative	B-Disease
retinopathy	I-Disease
.	O
	
Diabetic	B-Disease
macular	I-Disease
edema	I-Disease
is	O
classified	O
as	O
apparently	O
present	O
or	O
apparently	O
absent	O
.	O
	
If	O
training	O
and	O
equipment	O
allow	O
the	O
screener	O
to	O
make	O
a	O
valid	O
decision	O
,	O
macular	B-Disease
edema	I-Disease
is	O
further	O
categorized	O
as	O
a	O
function	O
of	O
its	O
distance	B-Anatomy
from	I-Anatomy
the	I-Anatomy
central	I-Anatomy
macula	I-Anatomy
.	O
	
There	O
seems	O
to	O
be	O
a	O
genuine	O
need	O
for	O
consistent	O
international	O
clinical	O
classification	O
systems	O
for	O
diabetic	B-Disease
retinopathy	I-Disease
and	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
that	O
are	O
supported	O
with	O
solid	O
evidence	O
.	O
	
The	O
proposed	O
clinical	O
classification	O
systems	O
provide	O
a	O
means	O
of	O
appropriately	O
categorizing	O
diabetic	B-Disease
retinopathy	I-Disease
and	O
macular	B-Disease
edema	I-Disease
.	O
	
It	O
is	O
hoped	O
that	O
these	O
systems	O
will	O
be	O
valuable	O
in	O
improving	O
both	O
screening	O
of	O
individuals	O
with	O
diabetes	B-Disease
and	O
communication	O
and	O
discussion	O
among	O
individuals	O
caring	O
for	O
these	O
patients	O
.	O
	
Telemedicine	O
approach	O
to	O
screening	O
for	O
severe	B-Disease
retinopathy	I-Disease
of	I-Disease
prematurity	I-Disease
:	O
a	O
pilot	O
study	O
.	O
	
To	O
evaluate	O
the	O
use	O
of	O
remote	O
reading	O
of	O
digital	B-Diagnostic_tool
retinal	I-Diagnostic_tool
photographs	I-Diagnostic_tool
in	O
the	O
diagnosis	O
of	O
severe	B-Disease
(	I-Disease
referral	I-Disease
-	I-Disease
warranted	I-Disease
)	I-Disease
retinopathy	I-Disease
of	I-Disease
prematurity	I-Disease
(	O
ROP	B-Disease
)	O
during	O
longitudinal	O
screening	O
for	O
ROP	B-Disease
.	O
	
Prospective	O
,	O
longitudinal	O
cohort	O
study	O
.	O
	
Forty	O
-	O
four	O
consecutive	O
premature	B-Characteristic
infants	I-Characteristic
at	O
risk	O
for	O
ROP	B-Disease
.	O
	
All	O
infants	B-Characteristic
were	O
examined	O
longitudinally	O
,	O
over	O
a	O
series	O
of	O
examinations	O
,	O
by	O
indirect	B-Diagnostic_tool
ophthalmoscopy	I-Diagnostic_tool
(	O
gold	O
standard	O
)	O
and	O
digital	B-Diagnostic_tool
photography	I-Diagnostic_tool
using	O
the	O
RetCam	B-Diagnostic_tool
-	I-Diagnostic_tool
120	I-Diagnostic_tool
Digital	I-Diagnostic_tool
Retinal	I-Diagnostic_tool
Camera	I-Diagnostic_tool
(	I-Diagnostic_tool
Massie	I-Diagnostic_tool
Research	I-Diagnostic_tool
Laboratories	I-Diagnostic_tool
Inc	I-Diagnostic_tool
.	I-Diagnostic_tool
,	I-Diagnostic_tool
Dublin	I-Diagnostic_tool
,	I-Diagnostic_tool
CA	I-Diagnostic_tool
)	I-Diagnostic_tool
equipped	I-Diagnostic_tool
with	I-Diagnostic_tool
an	I-Diagnostic_tool
ROP	I-Diagnostic_tool
lens	I-Diagnostic_tool
.	O
	
Images	O
were	O
stored	O
and	O
read	O
remotely	O
by	O
a	O
masked	O
reader	O
.	O
	
Referral	B-Disease
-	I-Disease
warranted	I-Disease
ROP	I-Disease
was	O
defined	O
as	O
ROP	B-Disease
in	O
zone	O
1	O
,	O
the	O
presence	O
of	O
plus	O
disease	O
or	O
the	O
presence	O
of	O
any	O
stage	B-Disease
3	I-Disease
ROP	I-Disease
.	O
	
We	O
determined	O
whether	O
and	O
when	O
referral	B-Disease
-	I-Disease
warranted	I-Disease
ROP	I-Disease
was	O
diagnosed	O
for	O
each	O
eye	B-Anatomy
,	O
of	O
each	O
infant	B-Characteristic
,	O
on	O
each	O
examination	O
,	O
during	O
the	O
course	O
of	O
each	O
of	O
the	O
infant	B-Characteristic
'	I-Characteristic
s	I-Characteristic
screening	O
.	O
	
Severe	B-Disease
(	I-Disease
referral	I-Disease
-	I-Disease
warranted	I-Disease
)	I-Disease
ROP	I-Disease
was	O
diagnosed	O
in	O
23	O
eyes	B-Anatomy
by	O
indirect	B-Diagnostic_tool
ophthalmoscopy	I-Diagnostic_tool
during	O
their	O
series	O
of	O
examinations	O
.	O
	
Digital	B-Diagnostic_tool
photography	I-Diagnostic_tool
had	O
a	O
sensitivity	O
of	O
100	O
%	O
and	O
a	O
specificity	O
of	O
96	O
%	O
in	O
detecting	O
referral	B-Disease
-	I-Disease
warranted	I-Disease
ROP	I-Disease
.	O
	
The	O
positive	O
predictive	O
value	O
of	O
digital	B-Diagnostic_tool
photography	I-Diagnostic_tool
was	O
92	O
%	O
,	O
and	O
the	O
negative	O
predictive	O
value	O
was	O
100	O
%	O
.	O
	
In	O
87	O
%	O
of	O
eyes	B-Anatomy
,	O
referral	B-Disease
-	I-Disease
warranted	I-Disease
ROP	I-Disease
was	O
diagnosed	O
by	O
digital	B-Diagnostic_tool
photography	I-Diagnostic_tool
before	O
or	O
at	O
the	O
same	O
time	O
as	O
indirect	B-Diagnostic_tool
ophthalmoscopy	I-Diagnostic_tool
.	O
	
Longitudinal	O
remote	O
reading	O
of	O
digital	B-Diagnostic_tool
photographs	I-Diagnostic_tool
using	O
the	O
RetCam	B-Diagnostic_tool
-	I-Diagnostic_tool
120	I-Diagnostic_tool
system	O
has	O
excellent	O
specificity	O
and	O
sensitivity	O
in	O
detecting	O
referral	B-Disease
-	I-Disease
warranted	I-Disease
ROP	I-Disease
.	O
	
This	O
pilot	O
study	O
has	O
shown	O
that	O
remote	O
reading	O
of	O
digital	B-Diagnostic_tool
photographs	I-Diagnostic_tool
has	O
promise	O
for	O
telemedicine	O
strategies	O
in	O
ROP	B-Disease
screening	O
.	O
	
Trypan	O
blue	O
staining	O
in	O
vitreoretinal	O
surgery	O
.	O
	
To	O
evaluate	O
the	O
efficacy	O
of	O
trypan	O
blue	O
for	O
staining	O
the	O
internal	B-Anatomy
limiting	I-Anatomy
membrane	I-Anatomy
(	O
ILM	B-Anatomy
)	O
and	O
epiretinal	B-Symptom
membranes	I-Symptom
(	O
ERM	B-Symptom
)	O
in	O
vitreoretinal	O
surgery	O
.	O
	
Prospective	O
noncomparative	O
case	O
series	O
.	O
	
Fifty	O
eyes	B-Anatomy
of	O
50	O
patients	O
with	O
macular	B-Symptom
pucker	I-Symptom
(	O
n	O
=	O
22	O
)	O
,	O
macular	B-Symptom
hole	I-Symptom
(	O
n	O
=	O
18	O
)	O
,	O
or	O
a	O
combination	O
(	O
n	O
=	O
2	O
)	O
,	O
proliferative	B-Disease
vitreoretinopathy	I-Disease
(	O
n	O
=	O
5	O
)	O
,	O
or	O
diabetic	B-Disease
retinopathy	I-Disease
(	O
n	O
=	O
3	O
)	O
.	O
	
Trypan	O
blue	O
0	O
.	O
2	O
%	O
was	O
used	O
to	O
stain	O
the	O
ILM	B-Anatomy
or	O
ERM	B-Symptom
during	O
vitreoretinal	O
surgery	O
.	O
	
The	O
intraoperative	O
visibility	O
of	O
the	O
membranes	O
was	O
scored	O
as	O
poor	O
,	O
moderate	O
,	O
good	O
,	O
or	O
excellent	O
.	O
	
The	O
application	O
of	O
trypan	O
blue	O
onto	O
the	O
ILM	B-Anatomy
or	O
the	O
ERM	B-Symptom
resulted	O
in	O
a	O
useful	O
bluish	O
staining	O
,	O
facilitating	O
the	O
identification	O
,	O
delineation	O
,	O
and	O
removal	O
of	O
the	O
membranes	O
in	O
all	O
surgeries	O
.	O
	
No	O
residual	O
staining	O
or	O
adverse	O
effects	O
related	O
to	O
the	O
dye	O
were	O
observed	O
.	O
	
Trypan	O
blue	O
stains	O
both	O
ILM	B-Anatomy
and	O
ERM	B-Symptom
and	O
might	O
be	O
an	O
useful	O
tool	O
in	O
vitreoretinal	O
surgery	O
.	O
	
What	O
is	O
lost	O
by	O
digitizing	B-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
fundus	I-Diagnostic_tool
color	I-Diagnostic_tool
slides	I-Diagnostic_tool
for	O
macular	B-Anatomy
grading	O
in	O
age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
and	I-Disease
degeneration	I-Disease
?	O
	
To	O
compare	O
35	B-Diagnostic_tool
-	I-Diagnostic_tool
mm	I-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
slide	I-Diagnostic_tool
transparencies	I-Diagnostic_tool
with	O
digitized	B-Diagnostic_tool
nonstereoscopic	I-Diagnostic_tool
images	I-Diagnostic_tool
(	O
resolution	O
1024x768	O
pixels	O
)	O
for	O
grading	O
abnormalities	O
in	O
age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
(	O
ARM	B-Disease
)	O
and	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Comparative	O
observational	O
case	O
series	O
.	O
	
Twenty	O
-	O
five	O
patients	O
(	O
50	O
eyes	B-Anatomy
)	O
with	O
ARM	B-Disease
and	O
/	O
or	O
AMD	B-Disease
.	O
	
Twenty	O
-	O
five	O
patients	O
with	O
ARM	B-Disease
/	O
AMD	B-Disease
in	O
at	O
least	O
1	O
eye	B-Anatomy
were	O
randomly	O
selected	O
from	O
a	O
large	O
ongoing	O
collection	O
of	O
clinical	O
data	O
and	O
DNA	O
in	O
a	O
tertiary	O
referral	O
United	B-Characteristic
Kingdom	I-Characteristic
population	O
.	O
	
Retinal	B-Diagnostic_tool
photography	I-Diagnostic_tool
was	O
performed	O
with	O
mydriasis	B-Symptom
using	O
the	O
Zeiss	B-Diagnostic_tool
FF	I-Diagnostic_tool
-	I-Diagnostic_tool
series	I-Diagnostic_tool
30	I-Diagnostic_tool
degrees	I-Diagnostic_tool
fundus	I-Diagnostic_tool
camera	I-Diagnostic_tool
on	O
Ektachrome	B-Diagnostic_tool
slide	I-Diagnostic_tool
transparency	I-Diagnostic_tool
film	I-Diagnostic_tool
.	O
	
The	O
images	O
were	O
centered	O
on	O
the	O
macula	B-Anatomy
.	O
	
The	O
color	B-Diagnostic_tool
transparencies	I-Diagnostic_tool
were	O
then	O
digitized	O
.	O
	
The	O
grading	O
process	O
has	O
been	O
set	O
up	O
based	O
on	O
the	O
International	B-Classification_system
ARM	I-Classification_system
Epidemiology	I-Classification_system
Study	I-Classification_system
Group	I-Classification_system
.	O
	
All	O
images	O
were	O
independently	O
graded	O
by	O
3	O
retinal	B-Anatomy
specialists	O
.	O
	
Both	O
kappa	O
statistics	O
and	O
exact	O
agreement	O
were	O
calculated	O
to	O
assess	O
agreement	O
between	O
and	O
within	O
observers	O
and	O
between	O
the	O
2	O
master	O
copies	O
derived	O
from	O
the	O
gradings	O
of	O
the	O
color	B-Diagnostic_tool
slides	I-Diagnostic_tool
and	O
digitized	B-Diagnostic_tool
images	I-Diagnostic_tool
.	O
	
Agreement	O
between	O
the	O
2	O
master	O
copies	O
derived	O
from	O
the	O
gradings	O
obtained	O
from	O
stereoscopic	B-Diagnostic_tool
slide	I-Diagnostic_tool
transparencies	I-Diagnostic_tool
and	O
digitized	B-Diagnostic_tool
nonstereoscopic	I-Diagnostic_tool
images	I-Diagnostic_tool
.	O
	
For	O
small	B-Symptom
hard	I-Symptom
and	I-Symptom
intermediate	I-Symptom
soft	I-Symptom
drusen	I-Symptom
,	O
agreement	O
ranged	O
between	O
77	O
%	O
and	O
91	O
%	O
(	O
kappa	O
,	O
0	O
.	O
56	O
-	O
0	O
.	O
72	O
)	O
and	O
83	O
%	O
and	O
93	O
%	O
(	O
kappa	O
,	O
0	O
.	O
31	O
-	O
0	O
.	O
64	O
)	O
,	O
respectively	O
,	O
for	O
the	O
3	B-Anatomy
macular	I-Anatomy
subfields	I-Anatomy
.	O
	
Agreement	O
for	O
the	O
presence	O
of	O
hyperpigmentation	B-Symptom
was	O
12	O
%	O
to	O
56	O
%	O
(	O
kappa	O
,	O
0	O
.	O
00	O
-	O
0	O
.	O
27	O
)	O
.	O
	
Agreement	O
was	O
94	O
%	O
to	O
96	O
%	O
(	O
kappa	O
,	O
0	O
.	O
80	O
-	O
0	O
.	O
82	O
)	O
for	O
the	O
presence	O
of	O
geographic	B-Symptom
atrophy	I-Symptom
and	O
93	O
%	O
(	O
kappa	O
,	O
0	O
.	O
78	O
)	O
for	O
the	O
area	O
covered	O
.	O
	
For	O
the	O
presence	O
of	O
choroidal	B-Symptom
neovascularization	I-Symptom
(	O
CNV	B-Symptom
)	O
,	O
agreement	O
was	O
94	O
%	O
to	O
98	O
%	O
(	O
kappa	O
,	O
0	O
.	O
81	O
-	O
0	O
.	O
88	O
)	O
,	O
and	O
it	O
was	O
95	O
%	O
(	O
kappa	O
,	O
0	O
.	O
83	O
)	O
for	O
the	O
area	O
covered	O
.	O
	
For	O
individual	O
features	O
of	O
CNV	B-Symptom
,	O
exact	O
agreement	O
was	O
88	O
%	O
to	O
96	O
%	O
(	O
kappa	O
,	O
0	O
.	O
22	O
-	O
0	O
.	O
49	O
)	O
.	O
	
In	O
3	O
cases	O
of	O
geographic	B-Symptom
atrophy	I-Symptom
and	O
2	O
cases	O
of	O
CNV	B-Symptom
,	O
the	O
lesion	O
was	O
missed	O
on	O
digitized	B-Diagnostic_tool
images	I-Diagnostic_tool
.	O
	
Because	O
of	O
the	O
close	O
agreement	O
for	O
most	O
categories	O
between	O
the	O
grading	O
of	O
stereoscopic	B-Diagnostic_tool
color	I-Diagnostic_tool
slides	I-Diagnostic_tool
and	O
digitized	B-Diagnostic_tool
images	I-Diagnostic_tool
,	O
digitized	B-Diagnostic_tool
nonstereoscopic	I-Diagnostic_tool
color	I-Diagnostic_tool
images	I-Diagnostic_tool
prove	O
to	O
be	O
useful	O
for	O
grading	O
ARM	B-Disease
and	O
AMD	B-Disease
.	O
	
Variable	O
corneal	B-Anatomy
compensation	O
improves	O
discrimination	O
between	O
normal	O
and	O
glaucomatous	B-Disease
eyes	B-Anatomy
with	O
the	O
scanning	B-Diagnostic_tool
laser	I-Diagnostic_tool
polarimeter	I-Diagnostic_tool
.	O
	
The	O
presently	O
available	O
scanning	B-Diagnostic_tool
laser	I-Diagnostic_tool
polarimeter	I-Diagnostic_tool
(	O
SLP	B-Diagnostic_tool
)	O
has	O
a	O
fixed	O
corneal	B-Anatomy
compensator	O
(	O
FCC	O
)	O
that	O
neutralizes	O
corneal	B-Characteristic
birefringence	I-Characteristic
only	O
in	O
eyes	B-Anatomy
with	O
birefringence	B-Characteristic
that	O
matches	O
the	O
population	O
mode	O
.	O
	
A	O
prototype	O
variable	O
corneal	B-Anatomy
compensator	O
(	O
VCC	O
)	O
provides	O
neutralization	O
of	O
individual	O
corneal	B-Characteristic
birefringence	I-Characteristic
based	O
on	O
individual	O
macular	B-Anatomy
retardation	O
patterns	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relative	O
ability	O
of	O
the	O
SLP	B-Diagnostic_tool
with	O
the	O
FCC	O
and	O
with	O
the	O
VCC	O
to	O
discriminate	O
between	O
normal	O
and	O
glaucomatous	B-Disease
eyes	B-Anatomy
.	O
	
Prospective	O
,	O
nonrandomized	O
,	O
comparative	O
case	O
series	O
.	O
	
Algorithm	O
-	O
generating	O
set	O
consisting	O
of	O
56	O
normal	O
eyes	B-Anatomy
and	O
55	O
glaucomatous	B-Disease
eyes	B-Anatomy
and	O
an	O
independent	O
data	O
set	O
consisting	O
of	O
83	O
normal	O
eyes	B-Anatomy
and	O
56	O
glaucomatous	B-Disease
eyes	B-Anatomy
.	O
	
Sixteen	O
retardation	O
measurements	O
were	O
obtained	O
with	O
the	O
SLP	B-Diagnostic_tool
with	O
the	O
FCC	O
and	O
the	O
VCC	O
from	O
all	O
subjects	O
.	O
	
Dependency	O
of	O
parameters	O
on	O
age	B-Characteristic
,	O
gender	B-Characteristic
,	O
ethnic	B-Characteristic
origin	I-Characteristic
,	O
and	O
eye	B-Characteristic
side	I-Characteristic
was	O
sought	O
.	O
	
Logistic	O
regression	O
was	O
used	O
to	O
evaluate	O
how	O
well	O
the	O
various	O
parameters	O
could	O
detect	O
glaucoma	B-Disease
.	O
	
Discriminant	O
functions	O
were	O
generated	O
,	O
and	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
was	O
determined	O
.	O
	
Discrimination	O
between	O
normal	O
and	O
glaucomatous	B-Disease
eyes	B-Anatomy
on	O
the	O
basis	O
of	O
single	O
parameters	O
was	O
significantly	O
better	O
with	O
the	O
VCC	O
than	O
with	O
the	O
FCC	O
for	O
6	O
retardation	O
parameters	O
:	O
nasal	O
average	O
(	O
P	O
=	O
0	O
.	O
0003	O
)	O
,	O
superior	O
maximum	O
(	O
P	O
=	O
0	O
.	O
0003	O
)	O
,	O
ellipse	O
average	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
,	O
average	O
thickness	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
superior	O
average	O
(	O
P	O
=	O
0	O
.	O
010	O
)	O
,	O
and	O
inferior	O
average	O
(	O
P	O
=	O
0	O
.	O
010	O
)	O
.	O
	
Discriminant	O
analysis	O
identified	O
the	O
optimal	O
combination	O
of	O
parameters	O
for	O
the	O
FCC	O
and	O
for	O
the	O
VCC	O
.	O
	
When	O
the	O
discriminant	O
functions	O
were	O
applied	O
to	O
the	O
independent	O
data	O
set	O
,	O
areas	O
under	O
the	O
ROC	O
curve	O
were	O
0	O
.	O
84	O
for	O
the	O
FCC	O
and	O
0	O
.	O
90	O
for	O
the	O
VCC	O
(	O
P	O
<	O
0	O
.	O
021	O
)	O
.	O
	
When	O
the	O
discriminant	O
functions	O
were	O
applied	O
to	O
a	O
subset	O
of	O
patients	O
with	O
early	O
visual	B-Symptom
field	I-Symptom
loss	I-Symptom
,	O
areas	O
under	O
the	O
ROC	O
curve	O
were	O
0	O
.	O
82	O
for	O
the	O
FCC	O
and	O
0	O
.	O
90	O
for	O
the	O
VCC	O
(	O
P	O
<	O
0	O
.	O
016	O
)	O
.	O
	
Individual	O
correction	O
for	O
corneal	B-Characteristic
birefringence	I-Characteristic
with	O
the	O
VCC	O
significantly	O
improved	O
the	O
ability	O
of	O
the	O
SLP	B-Diagnostic_tool
to	O
distinguish	O
between	O
normal	O
and	O
glaucomatous	B-Disease
eyes	B-Anatomy
and	O
enabled	O
detection	O
of	O
patients	O
with	O
early	B-Disease
glaucoma	I-Disease
.	O
	
Comparison	O
of	O
the	O
clinical	O
diagnosis	O
of	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
with	O
diagnosis	O
by	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
.	O
	
To	O
compare	O
the	O
diagnosis	O
of	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
by	O
stereoscopic	B-Diagnostic_tool
slit	I-Diagnostic_tool
-	I-Diagnostic_tool
lamp	I-Diagnostic_tool
biomicroscopic	I-Diagnostic_tool
examination	I-Diagnostic_tool
of	O
the	O
fundus	O
with	O
a	O
78	O
-	O
diopter	O
noncontact	O
lens	O
with	O
diagnosis	O
by	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
.	O
	
Prospective	O
,	O
double	O
-	O
masked	O
,	O
noninterventional	O
diagnostic	O
study	O
.	O
	
Analysis	O
of	O
slit	B-Diagnostic_tool
-	I-Diagnostic_tool
lamp	I-Diagnostic_tool
biomicroscopic	I-Diagnostic_tool
findings	O
compared	O
with	O
OCT	B-Diagnostic_tool
measurements	O
.	O
	
Patients	O
with	O
DME	B-Disease
from	O
a	O
private	O
retina	B-Anatomy
practice	O
.	O
	
Presence	O
or	O
absence	O
of	O
macular	B-Symptom
thickening	I-Symptom
.	O
	
The	O
reference	O
range	O
for	O
this	O
clinic	O
was	O
comparable	O
to	O
reference	O
ranges	O
published	O
from	O
other	O
clinics	O
.	O
	
The	O
clinical	O
detection	O
of	O
DME	B-Disease
was	O
less	O
than	O
detection	O
by	O
OCT	B-Diagnostic_tool
.	O
	
Chance	O
-	O
corrected	O
agreements	O
(	O
kappa	O
statistic	O
)	O
of	O
the	O
2	O
methods	O
were	O
0	O
.	O
63	O
for	O
the	O
foveal	B-Anatomy
zone	O
and	O
0	O
.	O
36	O
to	O
0	O
.	O
42	O
for	O
the	O
4	O
parafoveal	B-Anatomy
zones	O
.	O
	
The	O
errors	O
committed	O
in	O
clinical	O
examination	O
were	O
primarily	O
of	O
the	O
type	O
in	O
which	O
clinical	O
examination	O
did	O
not	O
detect	O
DME	B-Disease
but	O
OCT	B-Diagnostic_tool
did	O
(	O
58	O
%	O
-	O
90	O
%	O
)	O
for	O
the	O
5	O
zones	O
analyzed	O
.	O
	
Reference	O
ranges	O
for	O
OCT	B-Diagnostic_tool
seem	O
to	O
be	O
similar	O
for	O
different	O
clinical	O
settings	O
,	O
suggesting	O
the	O
usefulness	O
of	O
OCT	B-Diagnostic_tool
in	O
multicenter	O
studies	O
.	O
	
The	O
current	O
standard	O
of	O
care	O
for	O
DME	B-Disease
detection	O
,	O
stereoscopic	B-Diagnostic_tool
slit	I-Diagnostic_tool
-	I-Diagnostic_tool
lamp	I-Diagnostic_tool
examination	I-Diagnostic_tool
of	O
the	O
fundus	B-Anatomy
,	O
is	O
less	O
sensitive	O
than	O
OCT	B-Diagnostic_tool
for	O
detection	O
of	O
DME	B-Disease
.	O
	
Because	O
the	O
principal	O
therapy	O
for	O
DME	B-Disease
,	O
focal	O
laser	O
photocoagulation	O
,	O
is	O
mainly	O
sight	O
preserving	O
and	O
not	O
sight	O
restoring	O
,	O
the	O
wider	O
use	O
of	O
OCT	B-Diagnostic_tool
may	O
beneficially	O
impact	O
visual	B-Symptom
disability	I-Symptom
from	O
DME	B-Disease
.	O
	
Birdshot	B-Disease
chorioretinopathy	I-Disease
:	O
long	O
-	O
term	O
manifestations	O
and	O
visual	O
prognosis	O
.	O
	
To	O
ascertain	O
the	O
clinical	O
features	O
and	O
long	O
-	O
term	O
visual	O
prognosis	O
of	O
birdshot	B-Disease
chorioretinopathy	I-Disease
(	O
BCR	B-Disease
)	O
,	O
and	O
to	O
identify	O
patients	O
at	O
risk	O
of	O
visual	B-Symptom
loss	I-Symptom
.	O
	
Retrospective	O
noncomparative	O
case	O
series	O
.	O
	
Fifty	O
-	O
five	O
consecutive	O
patients	O
with	O
HLA	B-Characteristic
-	I-Characteristic
A29	I-Characteristic
-	I-Characteristic
positive	I-Characteristic
BCR	B-Disease
who	O
were	O
identified	O
in	O
ophthalmology	O
departments	O
of	O
the	O
University	O
Medical	O
Center	O
of	O
Utrecht	O
and	O
The	O
Eye	B-Anatomy
Hospital	O
Rotterdam	O
,	O
of	O
whom	O
37	O
were	O
observed	O
for	O
at	O
least	O
5	O
years	O
.	O
	
A	O
review	O
of	O
the	O
medical	O
and	O
photographic	B-Diagnostic_tool
and	I-Diagnostic_tool
/	I-Diagnostic_tool
or	I-Diagnostic_tool
angiographic	I-Diagnostic_tool
records	I-Diagnostic_tool
of	O
55	O
patients	O
with	O
HLA	B-Characteristic
-	I-Characteristic
A29	I-Characteristic
-	I-Characteristic
positive	I-Characteristic
BCR	B-Disease
.	O
	
Numerous	O
variables	O
were	O
compared	O
,	O
including	O
age	O
and	O
gender	O
distribution	O
,	O
onset	O
and	O
course	O
of	O
BCR	B-Disease
,	O
ocular	O
manifestations	O
,	O
therapeutic	O
strategies	O
and	O
their	O
outcomes	O
,	O
complications	O
,	O
systemic	O
diseases	O
,	O
visual	B-Characteristic
acuity	I-Characteristic
(	O
VA	B-Characteristic
)	O
,	O
and	O
features	O
associated	O
with	O
poor	O
visual	O
outcome	O
.	O
	
Loss	B-Symptom
of	I-Symptom
VA	I-Symptom
was	O
gradual	O
;	O
the	O
number	O
of	O
affected	O
eyes	B-Anatomy
with	O
VA	B-Symptom
less	I-Symptom
than	I-Symptom
20	I-Symptom
/	I-Symptom
200	I-Symptom
increased	O
from	O
9	O
of	O
108	O
(	O
8	O
%	O
)	O
at	O
onset	O
to	O
22	O
of	O
73	O
(	O
30	O
%	O
)	O
at	O
5	O
years	O
and	O
19	O
of	O
49	O
(	O
39	O
%	O
)	O
at	O
10	O
years	O
of	O
follow	O
-	O
up	O
.	O
	
The	O
cause	O
of	O
compromised	B-Symptom
VA	I-Symptom
was	O
predominantly	O
macular	B-Symptom
edema	I-Symptom
and	O
macular	B-Symptom
atrophy	I-Symptom
(	O
42	O
of	O
55	O
[	O
76	O
%	O
of	O
cases	O
]	O
)	O
.	O
	
We	O
found	O
strong	O
associations	O
between	O
the	O
VA	B-Characteristic
at	O
onset	B-Disease
and	O
visual	B-Symptom
outcome	I-Symptom
after	I-Symptom
5	I-Symptom
and	I-Symptom
10	I-Symptom
years	I-Symptom
(	O
P	O
=	O
0	O
.	O
005	O
and	O
P	O
=	O
0	O
.	O
006	O
,	O
respectively	O
)	O
.	O
	
Mean	B-Characteristic
VA	I-Characteristic
at	I-Characteristic
the	I-Characteristic
5	I-Characteristic
-	I-Characteristic
year	I-Characteristic
follow	I-Characteristic
-	I-Characteristic
up	I-Characteristic
was	I-Characteristic
significantly	I-Characteristic
lower	I-Characteristic
if	O
macular	B-Symptom
leakage	I-Symptom
was	O
observed	O
on	O
angiography	B-Diagnostic_tool
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
No	O
differences	O
in	O
annual	O
loss	B-Symptom
of	I-Symptom
VA	I-Symptom
were	O
observed	O
between	O
patients	O
treated	O
by	O
standard	O
therapeutic	O
modalities	O
and	O
untreated	O
patients	O
.	O
	
The	O
visual	O
prognosis	O
of	O
BCR	B-Disease
in	O
a	O
spectrum	O
of	O
uveitis	B-Disease
is	O
poor	O
,	O
and	O
the	O
recommended	O
therapeutic	O
regimens	O
have	O
had	O
no	O
effect	O
on	O
long	O
-	O
term	O
visual	O
prognosis	O
.	O
	
New	O
treatment	O
strategies	O
are	O
needed	O
for	O
this	O
blinding	B-Disease
disorder	I-Disease
.	O
	
Retinotopic	B-Diagnostic_tool
mapping	I-Diagnostic_tool
of	I-Diagnostic_tool
the	I-Diagnostic_tool
visual	I-Diagnostic_tool
cortex	I-Diagnostic_tool
using	I-Diagnostic_tool
functional	I-Diagnostic_tool
magnetic	I-Diagnostic_tool
resonance	I-Diagnostic_tool
imaging	I-Diagnostic_tool
in	O
a	O
patient	O
with	O
central	B-Symptom
scotomas	I-Symptom
from	O
atrophic	B-Disease
macular	I-Disease
degeneration	I-Disease
.	O
	
To	O
describe	O
retinotopic	B-Diagnostic_tool
mapping	I-Diagnostic_tool
of	I-Diagnostic_tool
the	I-Diagnostic_tool
visual	I-Diagnostic_tool
cortex	I-Diagnostic_tool
when	O
a	O
central	B-Symptom
scotoma	I-Symptom
is	O
present	O
.	O
	
Single	O
observational	O
case	O
report	O
.	O
	
Scanning	B-Diagnostic_tool
laser	I-Diagnostic_tool
ophthalmoscope	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
was	O
used	O
to	O
define	O
the	O
site	O
and	O
stability	O
of	O
fixation	O
and	O
the	O
area	O
of	O
dense	O
scotoma	B-Symptom
.	O
	
Functional	B-Diagnostic_tool
magnetic	I-Diagnostic_tool
resonance	I-Diagnostic_tool
imaging	I-Diagnostic_tool
of	I-Diagnostic_tool
the	I-Diagnostic_tool
visual	I-Diagnostic_tool
cortex	I-Diagnostic_tool
was	O
performed	O
while	O
the	O
patient	O
viewed	O
an	O
expanding	O
annular	O
stimulus	O
.	O
	
Retinotopic	B-Diagnostic_tool
mapping	I-Diagnostic_tool
of	I-Diagnostic_tool
the	I-Diagnostic_tool
visual	I-Diagnostic_tool
cortex	I-Diagnostic_tool
for	O
a	O
patient	O
with	O
a	O
horseshoe	B-Symptom
scotoma	I-Symptom
from	I-Symptom
geographic	I-Symptom
atrophy	I-Symptom
involving	I-Symptom
the	I-Symptom
macular	I-Symptom
region	I-Symptom
showed	O
a	O
loss	B-Symptom
of	I-Symptom
stimulation	I-Symptom
to	I-Symptom
the	I-Symptom
cortical	I-Symptom
areas	I-Symptom
representing	O
the	O
site	O
of	O
the	O
atrophic	B-Symptom
lesion	I-Symptom
.	O
	
Cortical	B-Diagnostic_tool
retinotopic	I-Diagnostic_tool
mapping	I-Diagnostic_tool
can	O
be	O
performed	O
successfully	O
in	O
patients	O
with	O
central	B-Symptom
scotomas	I-Symptom
from	O
macular	B-Disease
disease	I-Disease
.	O
	
This	O
study	O
can	O
serve	O
as	O
a	O
basis	O
for	O
the	O
future	O
investigation	O
of	O
cortical	B-Anatomy
plasticity	O
in	O
visual	B-Anatomy
cortex	I-Anatomy
.	O
	
Diagnostic	O
accuracy	O
of	O
the	O
GDx	B-Diagnostic_tool
VCC	I-Diagnostic_tool
for	O
glaucoma	B-Disease
.	O
	
To	O
determine	O
the	O
diagnostic	O
accuracy	O
of	O
the	O
GDx	B-Diagnostic_tool
VCC	I-Diagnostic_tool
in	O
the	O
diagnosis	O
of	O
glaucoma	B-Disease
.	O
	
Prospective	O
,	O
comparative	O
,	O
observational	O
,	O
clinic	O
-	O
based	O
case	O
series	O
.	O
	
One	O
eye	O
each	O
of	O
77	O
healthy	O
subjects	O
and	O
162	O
patients	O
with	O
primary	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
of	O
Caucasian	B-Characteristic
racial	I-Characteristic
origin	I-Characteristic
.	O
	
Healthy	O
subjects	O
had	O
normal	B-Characteristic
visual	I-Characteristic
fields	I-Characteristic
(	O
VFs	B-Characteristic
)	O
,	O
healthy	B-Characteristic
-	I-Characteristic
looking	I-Characteristic
optic	I-Characteristic
discs	I-Characteristic
,	O
and	O
intraocular	B-Characteristic
pressures	I-Characteristic
of	I-Characteristic
<	I-Characteristic
or	I-Characteristic
=	I-Characteristic
21	I-Characteristic
mmHg	I-Characteristic
in	I-Characteristic
both	I-Characteristic
eyes	I-Characteristic
.	O
	
Glaucoma	B-Disease
patients	O
had	O
a	O
reproducible	B-Symptom
glaucomatous	I-Symptom
VF	I-Symptom
defect	I-Symptom
and	O
a	O
glaucomatous	B-Symptom
appearance	I-Symptom
of	I-Symptom
the	I-Symptom
optic	I-Symptom
disc	I-Symptom
in	I-Symptom
at	I-Symptom
least	I-Symptom
one	I-Symptom
eye	I-Symptom
.	O
	
All	O
subjects	O
were	O
measured	O
with	O
the	O
GDx	B-Diagnostic_tool
VCC	I-Diagnostic_tool
with	I-Diagnostic_tool
an	I-Diagnostic_tool
automated	I-Diagnostic_tool
variable	I-Diagnostic_tool
corneal	I-Diagnostic_tool
compensator	I-Diagnostic_tool
.	O
	
We	O
constructed	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
for	O
all	O
available	O
parameters	O
.	O
	
Subsequently	O
,	O
we	O
calculated	O
sensitivity	O
,	O
specificity	O
,	O
and	O
multilevel	O
likelihood	O
ratios	O
for	O
the	O
best	O
discriminating	O
parameter	O
in	O
the	O
entire	O
group	O
.	O
	
In	O
addition	O
,	O
we	O
calculated	O
sensitivity	O
and	O
specificity	O
in	O
patients	O
with	O
mild	B-Symptom
,	I-Symptom
moderate	I-Symptom
,	I-Symptom
and	I-Symptom
severe	I-Symptom
glaucomatous	I-Symptom
damage	I-Symptom
separately	O
.	O
	
Software	O
-	O
derived	O
parameters	O
TSNIT	O
(	O
temporal	O
,	O
superior	O
,	O
nasal	O
,	O
inferior	O
,	O
temporal	O
)	O
Average	O
,	O
Superior	O
Average	O
,	O
Inferior	O
Average	O
,	O
TSNIT	O
Std	O
.	O
	
Dev	O
.	O
	
(	O
standard	O
deviation	O
)	O
,	O
and	O
Nerve	O
Fiber	O
Indicator	O
(	O
NFI	O
)	O
.	O
	
The	O
areas	O
under	O
the	O
ROC	O
curve	O
for	O
TSNIT	O
Average	O
,	O
Superior	O
Average	O
,	O
Inferior	O
Average	O
,	O
TSNIT	O
Std	O
.	O
	
Dev	O
.	O
,	O
and	O
NFI	O
were	O
0	O
.	O
93	O
,	O
0	O
.	O
94	O
,	O
0	O
.	O
90	O
,	O
0	O
.	O
92	O
,	O
and	O
0	O
.	O
98	O
,	O
respectively	O
.	O
	
For	O
the	O
best	O
discriminating	O
parameter	O
NFI	O
,	O
the	O
sensitivity	O
and	O
specificity	O
with	O
a	O
cutoff	O
point	O
of	O
>	O
or	O
=	O
40	O
were	O
89	O
.	O
0	O
%	O
and	O
95	O
.	O
9	O
%	O
,	O
respectively	O
.	O
	
The	O
multilevel	O
likelihood	O
ratios	O
for	O
glaucoma	B-Disease
were	O
0	O
.	O
07	O
at	O
NFI	O
values	O
of	O
<	O
35	O
,	O
1	O
.	O
30	O
at	O
values	O
between	O
35	O
and	O
44	O
,	O
and	O
61	O
.	O
50	O
at	O
values	O
of	O
>	O
or	O
=	O
44	O
.	O
	
At	O
the	O
cutoff	O
level	O
of	O
>	O
or	O
=	O
40	O
,	O
the	O
sensitivities	O
of	O
the	O
NFI	O
for	O
correctly	O
identifying	O
glaucoma	B-Disease
patients	O
with	O
mild	B-Symptom
,	I-Symptom
moderate	I-Symptom
,	I-Symptom
and	I-Symptom
severe	I-Symptom
damage	I-Symptom
were	O
83	O
.	O
8	O
%	O
,	O
92	O
.	O
9	O
%	O
,	O
and	O
90	O
.	O
1	O
%	O
,	O
respectively	O
.	O
	
The	O
GDx	B-Diagnostic_tool
VCC	I-Diagnostic_tool
allowed	O
easy	O
,	O
rapid	O
,	O
and	O
accurate	O
discrimination	O
between	O
healthy	O
and	O
glaucomatous	B-Disease
eyes	B-Anatomy
.	O
	
The	O
NFI	O
was	O
the	O
best	O
discriminating	O
parameter	O
.	O
	
The	O
GDx	B-Diagnostic_tool
VCC	I-Diagnostic_tool
seems	O
to	O
fulfill	O
criteria	O
for	O
a	O
glaucoma	B-Diagnostic_tool
screening	I-Diagnostic_tool
device	I-Diagnostic_tool
.	O
	
Short	B-Diagnostic_tool
-	I-Diagnostic_tool
wavelength	I-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
results	O
are	O
correlated	O
with	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
measurements	I-Characteristic
in	O
glaucomatous	B-Disease
eyes	B-Anatomy
.	O
	
To	O
determine	O
the	O
relationship	O
between	O
retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
(	I-Characteristic
RNFL	I-Characteristic
)	I-Characteristic
thickness	I-Characteristic
measured	O
using	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
and	O
short	B-Characteristic
wavelength	I-Characteristic
-	I-Characteristic
sensitive	I-Characteristic
visual	I-Characteristic
function	I-Characteristic
measured	O
using	O
short	B-Diagnostic_tool
-	I-Diagnostic_tool
wavelength	I-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
(	O
SWAP	B-Diagnostic_tool
)	O
.	O
	
Retrospective	O
observational	O
case	O
series	O
.	O
	
Subjects	O
were	O
recruited	O
from	O
the	O
longitudinal	O
University	O
of	O
California	O
,	O
San	O
Diego	O
,	O
Diagnostic	O
Innovations	O
in	O
Glaucoma	B-Disease
Study	O
and	O
included	O
29	O
glaucoma	B-Disease
patients	O
with	O
OCT	B-Diagnostic_tool
imaging	I-Diagnostic_tool
and	O
reliable	O
SWAP	B-Diagnostic_tool
visual	I-Diagnostic_tool
field	I-Diagnostic_tool
(	I-Diagnostic_tool
VF	I-Diagnostic_tool
)	I-Diagnostic_tool
testing	O
within	O
a	O
6	O
-	O
month	O
window	O
.	O
	
Correlations	O
between	O
deviation	B-Characteristic
from	I-Characteristic
normal	I-Characteristic
(	I-Characteristic
thinner	I-Characteristic
than	I-Characteristic
97	I-Characteristic
.	I-Characteristic
5	I-Characteristic
%	I-Characteristic
of	I-Characteristic
normal	I-Characteristic
)	I-Characteristic
RNFL	I-Characteristic
measurements	I-Characteristic
taken	O
at	O
30	O
degrees	O
sectors	O
(	O
12	O
sectors	O
described	O
as	O
clock	O
hours	O
)	O
and	O
SWAP	B-Characteristic
average	I-Characteristic
pattern	I-Characteristic
deviation	I-Characteristic
within	I-Characteristic
21	I-Characteristic
VF	I-Characteristic
zones	I-Characteristic
were	O
determined	O
.	O
	
The	O
number	O
of	O
OCT	B-Characteristic
-	I-Characteristic
measured	I-Characteristic
RNFL	I-Characteristic
sectors	I-Characteristic
outside	O
of	O
normal	O
limits	O
and	O
the	O
number	O
of	O
VF	B-Characteristic
zones	I-Characteristic
outside	O
of	O
normal	O
limits	O
also	O
were	O
compared	O
.	O
	
The	O
OCT	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
was	O
outside	O
of	O
the	O
normal	O
limits	O
in	O
at	O
least	O
1	O
sector	O
in	O
26	O
(	O
89	O
.	O
6	O
%	O
)	O
patients	O
.	O
	
Twenty	O
-	O
eight	O
(	O
96	O
.	O
5	O
%	O
)	O
patients	O
had	O
at	O
least	O
1	O
SWAP	B-Characteristic
VF	I-Characteristic
zone	I-Characteristic
outside	O
of	O
normal	O
limits	O
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
sectors	O
6	O
-	O
o	O
'	O
clock	O
,	O
7	O
-	O
o	O
'	O
clock	O
,	O
and	O
8	O
-	O
o	O
'	O
clock	O
(	O
inferior	O
and	O
inferotemporal	O
)	O
and	O
SWAP	B-Characteristic
VF	I-Characteristic
zones	I-Characteristic
13	O
,	O
14	O
,	O
and	O
16	O
(	O
superior	B-Anatomy
hemifield	I-Anatomy
central	I-Anatomy
and	I-Anatomy
arcuate	I-Anatomy
areas	I-Anatomy
)	O
were	O
the	O
most	O
frequently	O
damaged	O
.	O
	
In	O
general	O
,	O
the	O
strongest	O
R2	O
associations	O
were	O
between	O
inferior	O
and	O
inferior	B-Characteristic
temporal	I-Characteristic
RNFL	I-Characteristic
sectors	I-Characteristic
(	O
e	O
.	O
g	O
.	O
,	O
6	O
-	O
o	O
'	O
clock	O
,	O
7	O
-	O
o	O
'	O
clock	O
)	O
and	O
superior	B-Characteristic
nasal	I-Characteristic
/	I-Characteristic
arcuate	I-Characteristic
VF	I-Characteristic
zones	I-Characteristic
(	O
e	O
.	O
g	O
.	O
,	O
zones	O
13	O
,	O
14	O
,	O
15	O
)	O
and	O
between	O
superior	B-Characteristic
and	I-Characteristic
superior	I-Characteristic
temporal	I-Characteristic
RNFL	I-Characteristic
sectors	I-Characteristic
(	O
e	O
.	O
g	O
.	O
,	O
12	O
-	O
o	O
'	O
clock	O
,	O
11	O
-	O
o	O
'	O
clock	O
)	O
and	O
inferior	B-Characteristic
central	I-Characteristic
and	I-Characteristic
arcuate	I-Characteristic
VF	I-Characteristic
zones	I-Characteristic
(	O
e	O
.	O
g	O
.	O
,	O
zones	O
5	O
,	O
6	O
,	O
7	O
)	O
(	O
R2	O
range	O
=	O
24	O
.	O
3	O
%	O
-	O
37	O
.	O
3	O
%	O
,	O
all	O
Ps	O
<	O
or	O
=	O
0	O
.	O
005	O
)	O
.	O
	
Most	O
nonsignificant	O
associations	O
were	O
found	O
between	O
superior	B-Characteristic
RNFL	I-Characteristic
sectors	I-Characteristic
and	O
superior	B-Characteristic
VF	I-Characteristic
zones	I-Characteristic
.	O
	
Retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
measured	O
with	O
OCT	B-Diagnostic_tool
is	O
topographically	O
correlated	O
with	O
glaucomatous	B-Symptom
VF	I-Symptom
defects	I-Symptom
measured	O
with	O
SWAP	B-Diagnostic_tool
.	O
	
Digital	B-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
analysis	I-Diagnostic_tool
of	I-Diagnostic_tool
the	I-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
:	O
evaluation	O
of	O
a	O
teaching	O
program	O
.	O
	
To	O
determine	O
if	O
a	O
computer	O
-	O
based	O
stereoscopic	O
teaching	O
program	O
could	O
improve	O
optic	B-Characteristic
cup	I-Characteristic
/	I-Characteristic
disc	I-Characteristic
ratio	I-Characteristic
(	O
CDR	B-Characteristic
)	O
agreement	O
between	O
student	O
observers	O
and	O
an	O
expert	O
.	O
	
Experimental	O
study	O
.	O
	
Six	O
student	O
observers	O
(	O
A	O
-	O
F	O
)	O
assessed	O
at	O
least	O
30	O
digital	B-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
images	I-Diagnostic_tool
using	O
a	O
digital	O
stereoscopic	O
analysis	O
program	O
.	O
	
All	O
observers	O
made	O
36	O
CDR	B-Characteristic
measurements	O
(	O
every	O
10	O
degrees	O
)	O
for	O
each	O
disc	B-Diagnostic_tool
image	I-Diagnostic_tool
that	O
they	O
assessed	O
.	O
	
Disc	B-Diagnostic_tool
images	I-Diagnostic_tool
were	O
divided	O
into	O
3	O
sets	O
of	O
10	O
images	B-Diagnostic_tool
(	O
image	B-Diagnostic_tool
sets	I-Diagnostic_tool
1	O
,	O
2	O
,	O
and	O
3	O
)	O
.	O
	
Observers	O
A	O
,	O
B	O
,	O
and	O
C	O
determined	O
CDRs	B-Characteristic
for	O
all	O
3	O
image	B-Diagnostic_tool
sets	I-Diagnostic_tool
.	O
	
Set	O
1	O
was	O
examined	O
without	O
access	O
to	O
a	O
teaching	O
program	O
,	O
set	O
2	O
using	O
a	O
teaching	O
program	O
that	O
allowed	O
the	O
observer	O
to	O
view	O
an	O
expert	O
assessment	O
of	O
the	O
optic	B-Anatomy
disc	I-Anatomy
,	O
and	O
set	O
3	O
after	O
using	O
the	O
teaching	O
program	O
.	O
	
Observers	O
D	O
,	O
E	O
,	O
and	O
F	O
evaluated	O
image	O
sets	O
1	O
and	O
3	O
only	O
and	O
did	O
not	O
have	O
access	O
to	O
the	O
teaching	O
program	O
.	O
	
Ten	O
months	O
later	O
,	O
these	O
same	O
observers	O
(	O
D	O
-	O
F	O
)	O
viewed	O
image	O
set	O
2	O
using	O
the	O
teaching	O
program	O
and	O
then	O
reassessed	O
image	O
set	O
3	O
.	O
	
Standard	O
deviation	O
(	O
SD	O
)	O
of	O
CDR	B-Characteristic
differences	O
between	O
observers	O
and	O
an	O
expert	O
,	O
the	O
percentage	O
of	O
CDR	B-Characteristic
observations	O
differing	O
>	O
or	O
=	O
0	O
.	O
20	O
from	O
those	O
of	O
the	O
expert	O
,	O
and	O
intraclass	O
correlation	O
coefficients	O
(	O
ICCs	O
)	O
between	O
observers	O
.	O
	
Before	O
teaching	O
,	O
the	O
average	O
SD	O
of	O
differences	O
between	O
all	O
observers	O
and	O
the	O
expert	O
was	O
0	O
.	O
10	O
.	O
	
After	O
teaching	O
,	O
the	O
average	O
SD	O
of	O
differences	O
between	O
all	O
observers	O
and	O
the	O
expert	O
was	O
0	O
.	O
057	O
.	O
	
For	O
observers	O
D	O
,	O
E	O
,	O
and	O
F	O
,	O
the	O
average	O
SD	O
of	O
differences	O
for	O
image	O
set	O
3	O
without	O
teaching	O
was	O
0	O
.	O
074	O
.	O
	
The	O
percentage	O
of	O
all	O
observer	O
measurements	O
that	O
differed	O
>	O
or	O
=	O
0	O
.	O
20	O
from	O
those	O
of	O
the	O
expert	O
for	O
image	O
set	O
1	O
was	O
16	O
.	O
7	O
%	O
;	O
for	O
set	O
3	O
after	O
teaching	O
,	O
1	O
.	O
7	O
%	O
;	O
and	O
for	O
set	O
3	O
for	O
observers	O
D	O
,	O
E	O
,	O
and	O
F	O
without	O
teaching	O
,	O
10	O
%	O
.	O
	
Interobserver	O
ICC	O
values	O
for	O
all	O
observers	O
were	O
0	O
.	O
37	O
before	O
teaching	O
and	O
0	O
.	O
76	O
after	O
.	O
	
For	O
observers	O
D	O
,	O
E	O
,	O
and	O
F	O
,	O
the	O
ICC	O
value	O
for	O
set	O
3	O
without	O
access	O
to	O
teaching	O
was	O
0	O
.	O
69	O
.	O
	
This	O
study	O
suggests	O
that	O
an	O
interactive	O
digital	B-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
teaching	O
program	O
improves	O
agreement	O
between	O
observers	O
and	O
an	O
expert	O
when	O
assessing	O
CDRs	B-Characteristic
.	O
	
Central	B-Characteristic
corneal	I-Characteristic
thickness	I-Characteristic
:	O
will	O
one	O
measurement	O
suffice	O
?	O
	
To	O
evaluate	O
the	O
measurement	O
of	O
central	B-Characteristic
corneal	I-Characteristic
thickness	I-Characteristic
(	O
CCT	B-Characteristic
)	O
in	O
a	O
cohort	O
of	O
glaucoma	B-Disease
patients	O
over	O
a	O
3	O
-	O
month	O
period	O
.	O
	
Measurements	O
were	O
then	O
applied	O
to	O
the	O
criteria	O
described	O
in	O
the	O
Ocular	B-Disease
Hypertension	I-Disease
Treatment	O
Study	O
(	O
OHTS	O
)	O
.	O
	
Cohort	O
study	O
.	O
	
Fifty	O
-	O
one	O
patients	O
were	O
recruited	O
from	O
a	O
glaucoma	B-Disease
clinic	O
at	O
Moorfields	O
Eye	B-Anatomy
Hospital	O
.	O
	
Central	B-Characteristic
corneal	I-Characteristic
thickness	I-Characteristic
was	O
measured	O
using	O
an	O
ultrasonic	B-Diagnostic_tool
handheld	I-Diagnostic_tool
pachymeter	I-Diagnostic_tool
by	O
a	O
trained	O
observer	O
.	O
	
Patients	O
'	O
CCTs	B-Characteristic
were	O
measured	O
at	O
2	O
consecutive	O
clinic	O
visits	O
.	O
	
Mean	B-Characteristic
central	I-Characteristic
corneal	I-Characteristic
thickness	I-Characteristic
.	O
	
The	O
readings	O
showed	O
clear	O
fluctuation	O
over	O
the	O
3	O
-	O
month	O
period	O
,	O
with	O
a	O
mean	O
difference	O
in	O
corneal	B-Characteristic
thickness	I-Characteristic
of	O
9	O
.	O
6	O
+	O
/	O
-	O
26	O
.	O
9	O
microm	O
in	O
the	O
right	O
eye	B-Anatomy
and	O
19	O
.	O
0	O
+	O
/	O
-	O
29	O
.	O
2	O
microm	O
in	O
the	O
left	O
eye	B-Anatomy
.	O
	
In	O
addition	O
,	O
there	O
was	O
a	O
systematic	O
bias	O
towards	O
increased	O
corneal	B-Characteristic
thickness	I-Characteristic
being	O
recorded	O
at	O
the	O
second	O
reading	O
in	O
both	O
eyes	B-Anatomy
.	O
	
This	O
reached	O
statistical	O
significance	O
in	O
both	O
the	O
right	O
eye	B-Anatomy
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
the	O
left	O
eye	B-Anatomy
(	O
P	O
=	O
0	O
.	O
0003	O
)	O
.	O
	
The	O
criteria	O
used	O
to	O
categorize	O
the	O
risk	O
of	O
patients	O
developing	O
glaucoma	B-Disease
in	O
the	O
OHTS	O
were	O
then	O
applied	O
to	O
these	O
results	O
.	O
	
On	O
the	O
basis	O
of	O
the	O
second	O
reading	O
,	O
32	O
%	O
of	O
eyes	B-Anatomy
required	O
recategorization	O
in	O
both	O
the	O
right	O
and	O
left	O
eyes	B-Anatomy
.	O
	
Measurements	O
of	O
CCT	B-Characteristic
taken	O
within	O
a	O
clinical	O
setting	O
by	O
a	O
trained	O
observer	O
may	O
show	O
significant	O
variability	O
.	O
	
For	O
CCT	B-Characteristic
to	O
become	O
a	O
valuable	O
addition	O
to	O
the	O
assessment	O
of	O
glaucoma	B-Disease
suspects	O
,	O
more	O
than	O
one	O
reading	O
may	O
be	O
required	O
.	O
	
Failure	O
to	O
do	O
so	O
may	O
result	O
in	O
misclassification	O
and	O
,	O
thus	O
,	O
an	O
inaccurate	O
assignment	O
of	O
risk	O
.	O
	
Severe	B-Disease
strabismus	I-Disease
after	O
scleral	O
buckling	O
:	O
multiple	O
mechanisms	O
revealed	O
by	O
high	B-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
magnetic	I-Diagnostic_tool
resonance	I-Diagnostic_tool
imaging	I-Diagnostic_tool
.	O
	
Strabismus	B-Disease
occurring	O
after	O
scleral	O
buckling	O
for	O
retinal	B-Symptom
detachment	I-Symptom
typically	O
is	O
attributed	O
to	O
scarring	B-Symptom
,	O
but	O
this	O
is	O
not	O
the	O
only	O
mechanism	O
.	O
	
We	O
investigated	O
use	O
of	O
magnetic	B-Diagnostic_tool
resonance	I-Diagnostic_tool
imaging	I-Diagnostic_tool
(	O
MRI	B-Diagnostic_tool
)	O
to	O
identify	O
a	O
spectrum	O
of	O
mechanisms	O
of	O
strabismus	B-Disease
occurring	O
after	O
scleral	O
buckling	O
.	O
	
Prospective	O
,	O
noncomparative	O
,	O
observational	O
case	O
series	O
in	O
an	O
academic	O
referral	O
setting	O
.	O
	
Six	O
patients	O
with	O
long	O
-	O
standing	O
,	O
large	B-Disease
-	I-Disease
angle	I-Disease
strabismus	I-Disease
after	O
monocular	O
or	O
binocular	O
scleral	O
buckling	O
.	O
	
Horizontal	B-Symptom
and	I-Symptom
vertical	I-Symptom
preoperative	I-Symptom
deviations	I-Symptom
,	O
present	O
from	O
8	O
to	O
120	O
months	O
,	O
ranged	O
from	O
25	O
prism	O
diopters	O
to	O
more	O
than	O
90	O
prism	O
diopters	O
.	O
	
Multipositional	B-Diagnostic_tool
high	I-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
MRI	I-Diagnostic_tool
of	O
both	O
orbits	B-Anatomy
was	O
performed	O
using	O
surface	B-Diagnostic_tool
coils	I-Diagnostic_tool
in	O
multiple	O
,	O
controlled	O
gaze	O
positions	O
.	O
	
Coronal	B-Diagnostic_tool
,	I-Diagnostic_tool
sagittal	I-Diagnostic_tool
,	I-Diagnostic_tool
and	I-Diagnostic_tool
axial	I-Diagnostic_tool
images	I-Diagnostic_tool
were	O
obtained	O
as	O
clinically	O
appropriate	O
.	O
	
Different	O
mechanisms	O
of	O
pathologic	O
characteristics	O
of	O
the	O
extraocular	B-Anatomy
muscles	I-Anatomy
(	O
EOMs	B-Anatomy
)	O
in	O
complicated	O
strabismus	B-Disease
after	O
scleral	O
buckling	O
.	O
	
Magnetic	B-Diagnostic_tool
resonance	I-Diagnostic_tool
imaging	I-Diagnostic_tool
readily	O
demonstrated	O
EOM	B-Characteristic
size	I-Characteristic
and	I-Characteristic
contractility	I-Characteristic
,	O
as	O
well	O
as	O
features	O
of	O
scleral	O
buckle	O
hardware	O
such	O
as	O
grooves	O
and	O
junctions	O
and	O
relationships	O
of	O
EOMs	B-Anatomy
to	O
the	O
buckle	O
and	O
sclera	B-Anatomy
.	O
	
Imaging	B-Diagnostic_tool
demonstrated	O
that	O
5	O
rectus	B-Anatomy
EOMs	I-Anatomy
were	O
disinserted	O
from	O
the	O
globe	B-Anatomy
at	O
the	O
buckle	O
:	O
2	O
superior	B-Anatomy
rectus	I-Anatomy
,	O
2	O
medial	B-Anatomy
rectus	I-Anatomy
,	O
and	O
1	O
lateral	B-Anatomy
rectus	I-Anatomy
.	O
	
One	O
patient	O
with	O
suspected	B-Symptom
inferior	I-Symptom
rectus	I-Symptom
muscle	I-Symptom
disinsertion	I-Symptom
had	O
restrictive	B-Disease
strabismus	I-Disease
as	O
a	O
result	O
of	O
interference	O
by	O
a	O
meridional	O
explant	O
and	O
myopic	B-Disease
staphyloma	I-Disease
.	O
	
Magnetic	B-Diagnostic_tool
resonance	I-Diagnostic_tool
imaging	I-Diagnostic_tool
demonstrated	O
anterior	B-Symptom
migration	I-Symptom
and	O
transection	O
by	O
the	O
silicone	O
element	O
through	O
rectus	B-Anatomy
EOMs	I-Anatomy
in	O
3	O
patients	O
.	O
	
Disinserted	B-Symptom
EOMs	I-Symptom
were	O
retrieved	O
successfully	O
by	O
transconjunctival	O
surgery	O
in	O
4	O
patients	O
and	O
by	O
orbitotomy	O
in	O
1	O
patient	O
,	O
markedly	O
improving	O
alignment	O
even	O
as	O
long	O
as	O
5	O
years	O
after	O
EOM	B-Symptom
disinsertion	I-Symptom
.	O
	
Multipositional	B-Diagnostic_tool
high	I-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
MRI	I-Diagnostic_tool
provides	O
valuable	O
information	O
such	O
as	O
location	O
and	O
contractile	O
potential	O
of	O
disinserted	B-Symptom
EOMs	I-Symptom
,	O
as	O
well	O
as	O
mass	O
effect	O
from	O
the	O
scleral	O
buckle	O
.	O
	
Preoperative	B-Diagnostic_tool
orbital	I-Diagnostic_tool
MRI	I-Diagnostic_tool
may	O
be	O
a	O
useful	O
tool	O
to	O
distinguish	O
multiple	O
mechanisms	O
of	O
persistent	O
severe	B-Disease
strabismus	I-Disease
after	O
scleral	O
buckling	O
and	O
is	O
helpful	O
in	O
surgical	O
planning	O
.	O
	
Comparison	O
of	O
macular	B-Characteristic
and	I-Characteristic
peripapillary	I-Characteristic
measurements	I-Characteristic
for	O
the	O
detection	O
of	O
glaucoma	B-Disease
:	O
an	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
study	O
.	O
	
To	O
evaluate	O
macular	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
(	I-Characteristic
NFL	I-Characteristic
)	I-Characteristic
thickness	I-Characteristic
in	O
glaucomatous	B-Symptom
damage	I-Symptom
by	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
and	O
to	O
compare	O
its	O
discriminating	O
power	O
for	O
glaucoma	B-Disease
and	O
glaucoma	B-Disease
suspects	I-Disease
with	O
that	O
of	O
total	B-Characteristic
macular	I-Characteristic
thickness	I-Characteristic
and	O
peripapillary	B-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
.	O
	
Cross	O
-	O
sectional	O
,	O
case	O
-	O
control	O
,	O
comparative	O
study	O
.	O
	
A	O
total	O
of	O
133	O
eyes	B-Anatomy
from	O
133	O
subjects	O
including	O
46	O
normal	O
eyes	B-Anatomy
,	O
48	O
glaucoma	B-Disease
-	I-Disease
suspect	I-Disease
eyes	B-Anatomy
,	O
and	O
39	O
glaucoma	B-Disease
eyes	B-Anatomy
were	O
enrolled	O
.	O
	
Macular	B-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
,	O
total	B-Characteristic
macular	I-Characteristic
thickness	I-Characteristic
,	O
and	O
peripapillary	B-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
were	O
measured	O
by	O
Stratus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
in	O
each	O
diagnostic	O
group	O
.	O
	
The	O
patterns	O
and	O
measurements	O
of	O
macular	B-Characteristic
NFL	I-Characteristic
,	I-Characteristic
total	I-Characteristic
macular	I-Characteristic
,	I-Characteristic
and	I-Characteristic
peripapillary	I-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
in	O
total	O
mean	O
,	O
4	O
quadrants	O
,	O
and	O
12	O
clock	O
hours	O
.	O
	
The	O
discriminating	O
power	O
of	O
each	O
parameter	O
for	O
detection	O
of	O
glaucoma	B-Disease
suspects	I-Disease
and	O
glaucoma	B-Disease
was	O
evaluated	O
by	O
areas	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
AROC	O
)	O
.	O
	
Correspondence	O
with	O
visual	B-Characteristic
field	I-Characteristic
function	I-Characteristic
was	O
studied	O
by	O
linear	O
regression	O
analysis	O
.	O
	
The	O
macular	B-Characteristic
NFL	I-Characteristic
profile	I-Characteristic
exhibited	O
a	O
double	O
-	O
hump	O
pattern	O
with	O
peaks	O
over	O
superonasal	B-Anatomy
and	I-Anatomy
inferonasal	I-Anatomy
sectors	I-Anatomy
.	O
	
A	O
significant	O
difference	O
in	O
macular	B-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
between	O
normal	O
and	O
glaucoma	B-Disease
-	I-Disease
suspect	I-Disease
groups	O
was	O
found	O
at	O
the	O
6	O
-	O
o	O
'	O
clock	O
position	O
,	O
whereas	O
a	O
difference	O
was	O
found	O
in	O
all	O
except	O
the	O
temporal	O
clock	O
hours	O
between	O
normal	O
and	O
glaucoma	B-Disease
subjects	O
.	O
	
No	O
significant	O
difference	O
in	O
AROCs	O
for	O
detection	O
of	O
glaucoma	B-Disease
suspects	I-Disease
or	O
glaucoma	B-Disease
was	O
found	O
when	O
macular	B-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
and	O
total	B-Characteristic
macular	I-Characteristic
thickness	I-Characteristic
measurements	O
were	O
compared	O
.	O
	
However	O
,	O
mean	B-Characteristic
macular	I-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
demonstrated	O
a	O
stronger	O
correlation	O
with	O
visual	B-Characteristic
function	I-Characteristic
than	O
mean	B-Characteristic
macular	I-Characteristic
thickness	I-Characteristic
(	O
r	O
=	O
0	O
.	O
39	O
/	O
R2	O
=	O
0	O
.	O
15	O
vs	O
.	O
r	O
=	O
0	O
.	O
23	O
/	O
R2	O
=	O
0	O
.	O
05	O
,	O
P	O
=	O
0	O
.	O
042	O
)	O
.	O
	
Among	O
all	O
the	O
findings	O
,	O
inferior	B-Characteristic
peripapillary	I-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
had	O
the	O
best	O
performance	O
in	O
discriminating	O
glaucoma	B-Disease
(	O
AROC	O
,	O
0	O
.	O
91	O
)	O
and	O
glaucoma	B-Disease
suspects	I-Disease
(	O
AROC	O
,	O
0	O
.	O
67	O
)	O
.	O
	
It	O
also	O
had	O
the	O
strongest	O
correlation	O
with	O
visual	B-Characteristic
function	I-Characteristic
(	O
r	O
=	O
0	O
.	O
60	O
/	O
R2	O
=	O
0	O
.	O
36	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
Macular	B-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
was	O
significantly	O
reduced	O
in	O
glaucoma	B-Disease
.	O
	
It	O
had	O
a	O
similar	O
discriminating	O
power	O
for	O
glaucoma	B-Disease
detection	O
but	O
a	O
stronger	O
correlation	O
with	O
visual	B-Characteristic
function	I-Characteristic
than	O
total	B-Characteristic
macular	I-Characteristic
thickness	I-Characteristic
.	O
	
Peripapillary	B-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
,	O
however	O
,	O
outperformed	O
both	O
total	B-Characteristic
macular	I-Characteristic
and	I-Characteristic
macular	I-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
in	O
terms	O
of	O
glaucoma	B-Disease
detection	O
and	O
visual	B-Characteristic
function	I-Characteristic
correlation	O
.	O
	
Peripapillary	B-Characteristic
NFL	I-Characteristic
thickness	I-Characteristic
,	O
as	O
a	O
total	B-Characteristic
measurement	I-Characteristic
of	I-Characteristic
both	I-Characteristic
macular	I-Characteristic
and	I-Characteristic
peripheral	I-Characteristic
NFL	I-Characteristic
,	O
is	O
still	O
the	O
best	O
surrogate	O
marker	O
in	O
glaucoma	B-Disease
assessment	O
.	O
	
Coats	B-Disease
'	I-Disease
disease	I-Disease
diagnosed	O
in	O
adulthood	B-Characteristic
.	O
	
To	O
investigate	O
the	O
manifestations	O
and	O
clinical	O
course	O
of	O
Coats	B-Disease
'	I-Disease
disease	I-Disease
diagnosed	O
in	O
adulthood	B-Characteristic
and	O
to	O
describe	O
the	O
characteristics	O
of	O
patients	O
who	O
develop	O
it	O
.	O
	
Retrospective	O
observational	O
case	O
series	O
.	O
	
Thirteen	O
eyes	B-Anatomy
of	O
13	O
patients	O
with	O
Coats	B-Disease
'	I-Disease
disease	I-Disease
diagnosed	O
after	B-Characteristic
age	I-Characteristic
35	I-Characteristic
years	I-Characteristic
.	O
	
All	O
patients	O
examined	O
in	O
the	O
authors	O
'	O
referral	O
practices	O
for	O
Coats	B-Disease
'	I-Disease
disease	I-Disease
diagnosed	O
after	B-Characteristic
the	I-Characteristic
age	I-Characteristic
of	I-Characteristic
35	I-Characteristic
years	I-Characteristic
were	O
identified	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
radiation	B-Characteristic
exposure	I-Characteristic
,	O
intraocular	B-Characteristic
inflammation	I-Characteristic
,	O
retinal	B-Characteristic
vascular	I-Characteristic
occlusion	I-Characteristic
,	O
or	O
Coats	B-Characteristic
'	I-Characteristic
response	I-Characteristic
were	O
excluded	O
.	O
	
A	O
review	O
of	O
their	O
historical	O
,	O
clinical	O
,	O
and	O
fluorescein	B-Diagnostic_tool
angiographic	I-Diagnostic_tool
features	O
and	O
demographics	B-Characteristic
was	O
performed	O
.	O
	
There	O
were	O
13	O
patients	O
with	O
a	O
mean	O
age	B-Characteristic
at	I-Characteristic
diagnosis	I-Characteristic
of	I-Characteristic
50	I-Characteristic
years	I-Characteristic
(	I-Characteristic
range	I-Characteristic
,	I-Characteristic
36	I-Characteristic
-	I-Characteristic
79	I-Characteristic
)	I-Characteristic
and	O
a	O
mean	O
follow	B-Characteristic
-	I-Characteristic
up	I-Characteristic
of	I-Characteristic
5	I-Characteristic
.	I-Characteristic
8	I-Characteristic
years	I-Characteristic
(	I-Characteristic
range	I-Characteristic
,	I-Characteristic
0	I-Characteristic
-	I-Characteristic
17	I-Characteristic
)	I-Characteristic
.	O
	
These	O
patients	O
manifested	O
many	O
findings	O
typical	O
of	O
Coats	B-Disease
'	I-Disease
disease	I-Disease
,	O
including	O
the	O
unilateral	O
nature	O
of	O
the	O
disease	O
(	O
13	O
/	O
13	O
patients	O
)	O
,	O
male	B-Characteristic
predominance	O
(	O
12	O
/	O
13	O
)	O
,	O
vascular	B-Symptom
telangiectasis	I-Symptom
,	O
lipid	B-Symptom
exudation	I-Symptom
,	O
macular	B-Symptom
edema	I-Symptom
,	O
and	O
areas	B-Symptom
of	I-Symptom
capillary	I-Symptom
nonperfusion	I-Symptom
with	I-Symptom
adjacent	I-Symptom
webs	I-Symptom
of	I-Symptom
filigreelike	I-Symptom
capillaries	I-Symptom
.	O
	
Disease	O
was	O
limited	O
to	O
<	O
or	O
=	O
6	O
clock	O
hours	O
in	O
10	O
of	O
13	O
patients	O
(	O
76	O
.	O
9	O
%	O
)	O
,	O
did	O
not	O
generally	O
involve	O
the	O
retinal	B-Anatomy
vasculature	I-Anatomy
anterior	I-Anatomy
to	I-Anatomy
the	I-Anatomy
equator	I-Anatomy
,	O
and	O
showed	O
limited	O
potential	O
to	O
expand	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O
	
A	O
localized	B-Symptom
hemorrhage	I-Symptom
was	O
noted	O
in	O
10	O
of	O
13	O
patients	O
(	O
76	O
.	O
9	O
%	O
)	O
,	O
almost	O
always	O
near	O
larger	B-Symptom
aneurysmal	I-Symptom
dilatations	I-Symptom
.	O
	
Limited	B-Symptom
exudative	I-Symptom
detachment	I-Symptom
of	I-Symptom
the	I-Symptom
retina	I-Symptom
was	O
seen	O
in	O
4	O
eyes	B-Anatomy
,	O
3	O
of	O
which	O
responded	O
to	O
localized	O
laser	O
photocoagulation	O
.	O
	
One	O
patient	O
had	O
subretinal	B-Symptom
fluid	I-Symptom
seen	O
on	O
ocular	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
that	O
did	O
not	O
require	O
treatment	O
.	O
	
On	O
average	O
,	O
patients	O
lost	O
2	O
.	O
1	O
lines	O
of	O
visual	B-Characteristic
acuity	I-Characteristic
during	O
the	O
follow	O
-	O
up	O
period	O
;	O
6	O
patients	O
had	O
a	O
decline	B-Symptom
in	I-Symptom
vision	I-Symptom
,	O
2	O
patients	O
had	O
improved	B-Symptom
vision	I-Symptom
,	O
and	O
3	O
patients	O
had	O
stable	B-Characteristic
vision	I-Characteristic
.	O
	
No	O
patient	O
had	O
end	O
-	O
stage	O
findings	O
of	O
Coats	B-Disease
'	I-Disease
disease	I-Disease
,	O
such	O
as	O
iris	B-Symptom
neovascularization	I-Symptom
or	O
total	B-Symptom
exudative	I-Symptom
detachment	I-Symptom
.	O
	
Coats	B-Disease
'	I-Disease
disease	I-Disease
can	O
first	O
be	O
diagnosed	O
in	O
adulthood	B-Characteristic
with	O
retinal	B-Symptom
vascular	I-Symptom
abnormalities	I-Symptom
similar	O
to	O
those	O
seen	O
in	O
younger	B-Characteristic
patients	I-Characteristic
.	O
	
There	O
are	O
a	O
number	O
of	O
important	O
differences	O
in	O
disease	O
manifestation	O
in	O
adults	B-Characteristic
,	O
including	O
limited	O
area	O
of	O
involvement	O
,	O
slower	O
apparent	O
progression	O
of	O
disease	O
,	O
and	O
hemorrhage	B-Symptom
near	I-Symptom
larger	I-Symptom
vascular	I-Symptom
dilatations	I-Symptom
.	O
	
The	O
dragged	B-Disease
-	I-Disease
fovea	I-Disease
diplopia	I-Disease
syndrome	I-Disease
:	O
clinical	O
characteristics	O
,	O
diagnosis	O
,	O
and	O
treatment	O
.	O
	
To	O
identify	O
the	O
clinical	O
characteristics	O
of	O
the	O
dragged	B-Disease
-	I-Disease
fovea	I-Disease
diplopia	I-Disease
syndrome	I-Disease
,	O
to	O
introduce	O
a	O
simple	O
diagnostic	O
test	O
that	O
aids	O
in	O
the	O
evaluation	O
of	O
such	O
patients	O
,	O
and	O
to	O
provide	O
a	O
simple	O
treatment	O
option	O
to	O
improve	O
the	O
diplopia	B-Disease
in	O
some	O
of	O
these	O
patients	O
.	O
	
Retrospective	O
,	O
observational	O
case	O
series	O
.	O
	
Ninety	O
-	O
five	O
affected	O
eyes	B-Anatomy
in	O
83	O
consecutive	O
patients	O
seen	O
between	O
January	O
1	O
,	O
1993	O
,	O
and	O
August	O
9	O
,	O
2004	O
,	O
who	O
were	O
diagnosed	O
with	O
the	O
dragged	B-Disease
-	I-Disease
fovea	I-Disease
diplopia	I-Disease
syndrome	I-Disease
at	O
one	O
institution	O
.	O
	
We	O
reviewed	O
the	O
records	O
of	O
222	O
patients	O
who	O
have	O
been	O
seen	O
in	O
the	O
Krieger	O
Children	O
'	O
s	O
Eye	O
Center	O
at	O
The	O
Wilmer	O
Institute	O
since	O
1993	O
with	O
a	O
diagnosis	O
of	O
maculopathy	B-Disease
,	O
internal	B-Disease
limiting	I-Disease
membrane	I-Disease
,	O
or	O
dragged	B-Disease
fovea	I-Disease
.	O
	
We	O
collected	O
ocular	O
findings	O
and	O
history	O
for	O
those	O
patients	O
who	O
reported	O
binocular	B-Disease
diplopia	I-Disease
that	O
was	O
not	O
amenable	O
to	O
prism	O
therapy	O
and	O
not	O
secondary	O
to	O
acquired	B-Disease
strabismus	I-Disease
.	O
	
We	O
recorded	O
the	O
presence	O
of	O
metamorphopsia	B-Symptom
on	O
Amsler	B-Diagnostic_tool
grid	I-Diagnostic_tool
testing	O
or	O
other	O
clinical	O
evidence	O
of	O
macular	B-Symptom
wrinkling	I-Symptom
,	O
response	O
to	O
prism	O
trial	O
,	O
response	O
to	O
the	O
small	B-Diagnostic_tool
-	I-Diagnostic_tool
field	I-Diagnostic_tool
central	I-Diagnostic_tool
fusion	I-Diagnostic_tool
test	I-Diagnostic_tool
(	O
lights	B-Diagnostic_tool
on	I-Diagnostic_tool
-	I-Diagnostic_tool
off	I-Diagnostic_tool
test	I-Diagnostic_tool
)	O
,	O
and	O
response	O
to	O
partial	B-Diagnostic_tool
occlusion	I-Diagnostic_tool
with	I-Diagnostic_tool
Scotch	I-Diagnostic_tool
Satin	I-Diagnostic_tool
tape	I-Diagnostic_tool
(	O
3M	O
Co	O
.	O
,	O
St	O
.	O
Paul	O
,	O
MN	O
)	O
.	O
	
Ninety	O
-	O
five	O
affected	O
eyes	B-Anatomy
in	O
83	O
patients	O
met	O
the	O
criteria	O
for	O
inclusion	O
in	O
the	O
study	O
.	O
	
All	O
patients	O
who	O
were	O
tested	O
with	O
the	O
lights	B-Diagnostic_tool
on	I-Diagnostic_tool
-	I-Diagnostic_tool
off	I-Diagnostic_tool
test	I-Diagnostic_tool
(	O
n	O
=	O
69	O
)	O
responded	O
positively	O
,	O
demonstrating	O
rapid	O
central	B-Characteristic
fusion	I-Characteristic
with	O
room	O
lights	O
off	O
,	O
and	O
recurrence	O
of	O
central	B-Disease
diplopia	I-Disease
with	O
peripheral	B-Symptom
fusion	I-Symptom
with	O
room	O
lights	O
on	O
.	O
	
Forty	O
-	O
six	O
patients	O
(	O
of	O
64	O
tested	O
)	O
were	O
receptive	O
to	O
monocular	B-Diagnostic_tool
occlusion	I-Diagnostic_tool
with	I-Diagnostic_tool
Scotch	I-Diagnostic_tool
Satin	I-Diagnostic_tool
tape	I-Diagnostic_tool
.	O
	
The	O
dragged	B-Disease
-	I-Disease
fovea	I-Disease
diplopia	I-Disease
syndrome	I-Disease
consists	O
of	O
central	B-Disease
diplopia	I-Disease
in	O
the	O
presence	O
of	O
peripheral	B-Symptom
fusion	I-Symptom
,	O
secondary	O
to	O
dragging	B-Symptom
of	I-Symptom
the	I-Symptom
fovea	I-Symptom
in	I-Symptom
one	I-Symptom
or	I-Symptom
both	I-Symptom
eyes	I-Symptom
by	O
retinal	B-Anatomy
disease	O
.	O
	
The	O
central	B-Symptom
diplopia	I-Symptom
cannot	O
be	O
eliminated	O
by	O
prism	O
therapy	O
or	O
eye	B-Anatomy
muscle	I-Anatomy
surgery	O
.	O
	
The	O
lights	B-Diagnostic_tool
on	I-Diagnostic_tool
-	I-Diagnostic_tool
off	I-Diagnostic_tool
test	I-Diagnostic_tool
has	O
proved	O
pathognomonic	O
for	O
this	O
syndrome	O
,	O
and	O
many	O
patients	O
have	O
benefited	O
from	O
partial	B-Diagnostic_tool
monocular	I-Diagnostic_tool
occlusion	I-Diagnostic_tool
with	I-Diagnostic_tool
Scotch	I-Diagnostic_tool
Satin	I-Diagnostic_tool
tape	I-Diagnostic_tool
.	O
	
The	O
Age	B-Classification_system
-	I-Classification_system
Related	I-Classification_system
Eye	I-Classification_system
Disease	I-Classification_system
Study	I-Classification_system
severity	O
scale	O
for	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
:	O
AREDS	B-Classification_system
Report	O
No	O
.	O
17	O
	
Objective	O
:	O
To	O
develop	O
a	O
fundus	B-Diagnostic_tool
photographic	I-Diagnostic_tool
severity	O
scale	O
for	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Methods	O
:	O
In	O
the	O
Age	B-Classification_system
-	I-Classification_system
Related	I-Classification_system
Eye	I-Classification_system
Disease	I-Classification_system
Study	I-Classification_system
,	O
stereoscopic	B-Diagnostic_tool
color	I-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
were	O
taken	O
at	O
baseline	O
,	O
at	O
the	O
2	O
-	O
year	O
follow	O
-	O
up	O
visit	O
,	O
and	O
annually	O
thereafter	O
.	O
	
Photographs	B-Diagnostic_tool
were	O
graded	O
for	O
drusen	B-Symptom
characteristics	O
(	O
size	O
,	O
type	O
,	O
area	O
)	O
,	O
pigmentary	B-Symptom
abnormalities	I-Symptom
(	O
increased	B-Symptom
pigment	I-Symptom
,	O
depigmentation	B-Symptom
,	O
geographic	B-Symptom
atrophy	I-Symptom
)	O
,	O
and	O
presence	O
of	O
abnormalities	B-Symptom
characteristic	O
of	O
neovascular	B-Disease
AMD	I-Disease
(	O
retinal	B-Symptom
pigment	I-Symptom
epithelial	I-Symptom
detachment	I-Symptom
,	O
serous	B-Symptom
or	I-Symptom
hemorrhagic	I-Symptom
sensory	I-Symptom
retinal	I-Symptom
detachment	I-Symptom
,	O
subretinal	B-Symptom
or	I-Symptom
sub	I-Symptom
-	I-Symptom
retinal	I-Symptom
pigment	I-Symptom
epithelial	I-Symptom
hemorrhage	I-Symptom
,	O
subretinal	B-Symptom
fibrous	I-Symptom
tissue	I-Symptom
)	O
.	O
	
Advanced	B-Disease
AMD	I-Disease
was	O
defined	O
as	O
presence	O
of	O
1	B-Symptom
or	I-Symptom
more	I-Symptom
neovascular	I-Symptom
AMD	I-Symptom
abnormalities	I-Symptom
,	O
photocoagulation	B-Symptom
for	I-Symptom
AMD	I-Symptom
,	O
or	O
geographic	B-Symptom
atrophy	I-Symptom
involving	I-Symptom
the	I-Symptom
center	I-Symptom
of	I-Symptom
the	I-Symptom
macula	I-Symptom
.	O
	
We	O
explored	O
associations	O
among	O
right	B-Anatomy
eyes	I-Anatomy
of	O
3212	O
participants	O
between	O
severity	O
of	O
drusen	B-Symptom
characteristics	O
and	O
pigmentary	B-Symptom
abnormalities	I-Symptom
at	O
baseline	O
and	O
development	O
of	O
advanced	B-Disease
AMD	I-Disease
within	O
5	O
years	O
of	O
follow	O
-	O
up	O
.	O
	
Results	O
:	O
A	O
9	O
-	O
step	O
severity	O
scale	O
that	O
combines	O
a	O
6	O
-	O
step	O
drusen	B-Symptom
area	O
scale	O
with	O
a	O
5	O
-	O
step	O
pigmentary	B-Symptom
abnormality	I-Symptom
scale	O
was	O
developed	O
,	O
on	O
which	O
the	O
5	O
-	O
year	O
risk	O
of	O
advanced	B-Disease
AMD	I-Disease
increased	O
progressively	O
from	O
less	O
than	O
1	O
%	O
in	O
step	O
1	O
to	O
about	O
50	O
%	O
in	O
step	O
9	O
.	O
	
Among	O
the	O
334	O
eyes	B-Anatomy
that	O
had	O
at	O
least	O
a	O
3	O
-	O
step	O
progression	O
on	O
the	O
scale	O
between	O
the	O
baseline	O
and	O
5	O
-	O
year	O
visits	O
,	O
almost	O
half	O
showed	O
stepwise	O
progression	O
through	O
intervening	O
severity	O
levels	O
at	O
intervening	O
visits	O
.	O
	
Replicate	O
gradings	O
showed	O
agreement	O
within	O
1	O
step	O
on	O
the	O
scale	O
in	O
87	O
%	O
of	O
eyes	B-Anatomy
.	O
	
Conclusions	O
:	O
The	O
scale	O
provides	O
convenient	O
risk	O
categories	O
and	O
has	O
acceptable	O
reproducibility	O
.	O
	
Progression	O
along	O
it	O
may	O
prove	O
to	O
be	O
useful	O
as	O
a	O
surrogate	O
for	O
progression	O
to	O
advanced	B-Disease
AMD	I-Disease
.	O
	
A	O
simplified	O
severity	O
scale	O
for	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
:	O
AREDS	B-Classification_system
Report	O
No	O
.	O
18	O
	
Objective	O
:	O
To	O
develop	O
a	O
simplified	O
clinical	O
scale	O
defining	O
risk	O
categories	O
for	O
development	O
of	O
advanced	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Methods	O
:	O
Following	O
development	O
of	O
a	O
detailed	O
scale	O
for	O
individual	O
eyes	B-Anatomy
based	O
on	O
gradings	O
of	O
fundus	B-Diagnostic_tool
photographs	I-Diagnostic_tool
in	O
the	O
Age	B-Classification_system
-	I-Classification_system
Related	I-Classification_system
Eye	I-Classification_system
Disease	I-Classification_system
Study	I-Classification_system
,	O
rates	O
of	O
progression	O
to	O
advanced	B-Disease
AMD	I-Disease
were	O
assessed	O
in	O
cross	O
-	O
tabulations	O
of	O
presence	O
or	O
absence	O
in	O
each	O
eye	B-Anatomy
of	O
2	O
easily	O
identified	O
retinal	B-Symptom
abnormalities	I-Symptom
,	O
drusen	B-Symptom
and	O
pigment	B-Symptom
abnormalities	I-Symptom
.	O
	
Large	B-Symptom
drusen	I-Symptom
and	O
any	O
pigment	B-Symptom
changes	I-Symptom
were	O
particularly	O
predictive	O
of	O
developing	O
advanced	B-Disease
AMD	I-Disease
.	O
	
Results	O
:	O
The	O
scoring	O
system	O
developed	O
for	O
patients	O
assigns	O
to	O
each	O
eye	B-Anatomy
1	O
risk	O
factor	O
for	O
the	O
presence	O
of	O
1	B-Symptom
or	I-Symptom
more	I-Symptom
large	I-Symptom
(	I-Symptom
>	I-Symptom
or	I-Symptom
=	I-Symptom
125	I-Symptom
microm	I-Symptom
,	I-Symptom
width	I-Symptom
of	I-Symptom
a	I-Symptom
large	I-Symptom
vein	I-Symptom
at	I-Symptom
disc	I-Symptom
margin	I-Symptom
)	I-Symptom
drusen	I-Symptom
and	O
1	O
risk	O
factor	O
for	O
the	O
presence	O
of	O
any	O
pigment	B-Symptom
abnormality	I-Symptom
.	O
	
Risk	O
factors	O
are	O
summed	O
across	O
both	O
eyes	B-Anatomy
,	O
yielding	O
a	O
5	O
-	O
step	O
scale	O
(	O
0	O
-	O
4	O
)	O
on	O
which	O
the	O
approximate	O
5	O
-	O
year	O
risk	O
of	O
developing	O
advanced	B-Disease
AMD	I-Disease
in	O
at	O
least	O
one	O
eye	B-Anatomy
increases	O
in	O
this	O
easily	O
remembered	O
sequence	O
:	O
0	O
factors	O
,	O
0	O
.	O
5	O
%	O
;	O
1	O
factor	O
,	O
3	O
%	O
;	O
2	O
factors	O
,	O
12	O
%	O
;	O
3	O
factors	O
,	O
25	O
%	O
;	O
and	O
4	O
factors	O
,	O
50	O
%	O
.	O
	
For	O
persons	O
with	O
no	O
large	B-Symptom
drusen	I-Symptom
,	O
presence	O
of	O
intermediate	B-Symptom
drusen	I-Symptom
in	O
both	O
eyes	B-Anatomy
is	O
counted	O
as	O
1	O
risk	O
factor	O
.	O
	
Conclusion	O
:	O
This	O
simplified	O
scale	O
provides	O
convenient	O
risk	O
categories	O
for	O
development	O
of	O
advanced	B-Disease
AMD	I-Disease
that	O
can	O
be	O
determined	O
by	O
clinical	O
examination	O
or	O
by	O
less	O
demanding	O
photographic	B-Diagnostic_tool
procedures	I-Diagnostic_tool
than	O
used	O
in	O
the	O
Age	B-Classification_system
-	I-Classification_system
Related	I-Classification_system
Eye	I-Classification_system
Disease	I-Classification_system
Study	I-Classification_system
.	O
	
Evaluation	O
of	O
the	O
clinical	B-Classification_system
age	I-Classification_system
-	I-Classification_system
related	I-Classification_system
maculopathy	I-Classification_system
staging	I-Classification_system
system	O
.	O
	
To	O
evaluate	O
a	O
clinical	O
classification	O
system	O
,	O
the	O
Clinical	B-Classification_system
Age	I-Classification_system
-	I-Classification_system
Related	I-Classification_system
Maculopathy	I-Classification_system
Staging	I-Classification_system
(	O
CARMS	B-Classification_system
)	O
system	O
,	O
for	O
age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
(	O
ARM	B-Disease
)	O
using	O
a	O
simple	O
grading	O
scale	O
designed	O
for	O
clinical	O
practice	O
and	O
clinical	O
research	O
protocols	O
.	O
	
Two	O
hundred	O
forty	O
-	O
six	O
male	O
and	O
female	O
participants	O
with	O
various	O
stages	O
of	O
ARM	B-Disease
who	O
were	O
enrolled	O
during	O
the	O
first	O
4	O
years	O
of	O
a	O
longitudinal	O
study	O
were	O
selected	O
for	O
the	O
evaluation	O
of	O
the	O
CARMS	B-Classification_system
system	O
.	O
	
Cross	O
-	O
sectional	O
comparison	O
study	O
.	O
	
The	O
CARMS	B-Classification_system
system	O
divides	O
patients	O
into	O
5	O
mutually	O
exclusive	O
categories	O
based	O
on	O
slit	B-Diagnostic_tool
-	I-Diagnostic_tool
lamp	I-Diagnostic_tool
assessment	I-Diagnostic_tool
of	O
drusen	B-Symptom
,	O
retinal	B-Symptom
pigment	I-Symptom
epithelial	I-Symptom
irregularities	I-Symptom
,	O
geographic	B-Symptom
atrophy	I-Symptom
,	O
retinal	B-Symptom
pigment	I-Symptom
epithelial	I-Symptom
detachment	I-Symptom
,	O
and	O
choroidal	B-Symptom
neovascularization	I-Symptom
.	O
	
Fundus	B-Diagnostic_tool
photographs	I-Diagnostic_tool
and	O
clinical	B-Diagnostic_tool
data	I-Diagnostic_tool
of	O
the	O
subjects	O
were	O
used	O
to	O
evaluate	O
this	O
scale	O
.	O
	
Clinical	O
grades	O
assigned	O
for	O
492	O
eyes	B-Anatomy
of	O
246	O
patients	O
with	O
varying	O
stages	O
of	O
ARM	B-Disease
were	O
compared	O
with	O
grades	O
obtained	O
from	O
photographs	B-Diagnostic_tool
evaluated	O
by	O
a	O
reading	O
center	O
.	O
	
To	O
compare	O
grades	O
obtained	O
from	O
an	O
inexperienced	O
grader	O
with	O
those	O
of	O
an	O
experienced	O
grader	O
,	O
observations	O
based	O
on	O
photographs	B-Diagnostic_tool
from	O
50	O
randomly	O
selected	O
patients	O
were	O
reviewed	O
.	O
	
To	O
quantify	O
intraobserver	O
agreement	O
for	O
photographic	B-Characteristic
grades	I-Characteristic
,	O
observations	O
from	O
one	O
observer	O
were	O
compared	O
with	O
those	O
made	O
at	O
a	O
later	O
date	O
by	O
the	O
same	O
observer	O
.	O
	
Reliability	O
and	O
validity	O
of	O
the	O
CARMS	B-Classification_system
system	O
in	O
grading	O
various	O
stages	O
of	O
ARM	B-Disease
based	O
on	O
clinical	B-Diagnostic_tool
examination	I-Diagnostic_tool
and	O
photography	B-Diagnostic_tool
.	O
	
The	O
degree	O
of	O
overall	O
agreement	O
between	O
the	O
clinically	O
assigned	O
grade	O
and	O
photographic	O
assessment	O
for	O
492	O
eyes	B-Anatomy
was	O
substantial	O
(	O
exact	O
overall	O
agreement	O
,	O
75	O
%	O
;	O
unweighted	O
kappa	O
,	O
0	O
.	O
63	O
;	O
weighted	O
kappa	O
,	O
0	O
.	O
78	O
)	O
.	O
	
For	O
advanced	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
,	O
the	O
sensitivity	O
was	O
0	O
.	O
83	O
,	O
and	O
specificity	O
was	O
0	O
.	O
97	O
.	O
	
When	O
assessing	O
photographic	O
grades	O
,	O
the	O
degree	O
of	O
agreement	O
between	O
an	O
inexperienced	O
and	O
an	O
experienced	O
grader	O
was	O
very	O
high	O
(	O
unweighted	O
kappa	O
,	O
0	O
.	O
79	O
;	O
weighted	O
kappa	O
,	O
0	O
.	O
86	O
)	O
,	O
and	O
the	O
degree	O
of	O
intraobserver	O
agreement	O
was	O
excellent	O
(	O
unweighted	O
kappa	O
,	O
0	O
.	O
92	O
;	O
weighted	O
kappa	O
,	O
0	O
.	O
97	O
)	O
.	O
	
The	O
CARMS	B-Classification_system
system	O
,	O
a	O
5	O
-	O
level	O
clinical	O
scale	O
,	O
is	O
a	O
valid	O
and	O
reliable	O
staging	O
system	O
that	O
can	O
be	O
used	O
in	O
both	O
clinical	O
practice	O
and	O
in	O
clinical	O
research	O
protocols	O
involving	O
patients	O
with	O
all	O
stages	O
of	O
ARM	B-Disease
.	O
	
Long	B-Disease
-	I-Disease
standing	I-Disease
bullous	I-Disease
keratopathy	I-Disease
is	O
associated	O
with	O
peripheral	B-Symptom
conjunctivalization	I-Symptom
and	O
limbal	B-Symptom
deficiency	I-Symptom
.	O
	
To	O
investigate	O
whether	O
peripheral	B-Symptom
corneal	I-Symptom
neovascularization	I-Symptom
in	O
bullous	B-Disease
keratopathy	I-Disease
(	O
BK	B-Disease
)	O
is	O
due	O
to	O
conjunctivalization	B-Symptom
,	O
a	O
sign	O
of	O
limbal	B-Symptom
stem	I-Symptom
cell	I-Symptom
deficiency	I-Symptom
.	O
	
Observational	O
case	O
-	O
control	O
study	O
.	O
	
Sixteen	O
BK	B-Disease
patients	O
.	O
	
Patients	O
were	O
divided	O
into	O
2	O
groups	O
:	O
BK	B-Disease
without	O
peripheral	B-Symptom
neovascularization	I-Symptom
[	O
NV	O
(	O
-	O
)	O
group	O
;	O
5	O
patients	O
,	O
5	O
eyes	O
]	O
and	O
BK	B-Disease
with	O
neovascularization	B-Symptom
[	O
NV	O
(	O
+	O
)	O
group	O
;	O
11	O
patients	O
,	O
13	O
eyes	O
]	O
.	O
	
Evidence	O
of	O
conjunctivalization	B-Symptom
was	O
evaluated	O
by	O
periodic	O
acid	B-Diagnostic_tool
-	I-Diagnostic_tool
Schiff	I-Diagnostic_tool
staining	I-Diagnostic_tool
of	I-Diagnostic_tool
impression	I-Diagnostic_tool
cytology	I-Diagnostic_tool
samples	O
from	O
the	O
peripheral	B-Symptom
vascularized	I-Symptom
cornea	I-Symptom
.	O
	
The	O
2	O
groups	O
'	O
durations	O
of	O
disease	O
also	O
were	O
compared	O
.	O
	
Penetrating	O
keratoplasty	O
(	O
PK	O
)	O
was	O
performed	O
in	O
all	O
16	O
cases	O
,	O
and	O
the	O
2	O
groups	O
'	O
durations	O
of	O
reepithelialization	O
after	O
PK	O
were	O
compared	O
.	O
	
Presence	O
of	O
goblet	B-Anatomy
cells	I-Anatomy
using	O
impression	B-Diagnostic_tool
cytology	I-Diagnostic_tool
,	O
duration	O
of	O
BK	B-Disease
,	O
and	O
duration	O
of	O
postoperative	O
reepithelialization	O
.	O
	
Goblet	B-Anatomy
cells	I-Anatomy
were	O
found	O
on	O
the	O
peripheral	B-Anatomy
corneal	I-Anatomy
surface	I-Anatomy
in	O
all	O
eyes	B-Anatomy
in	O
the	O
NV	O
(	O
+	O
)	O
group	O
.	O
	
However	O
,	O
all	O
eyes	B-Anatomy
in	O
the	O
NV	O
(	O
-	O
)	O
group	O
were	O
negative	O
for	O
goblet	B-Anatomy
cells	I-Anatomy
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
	
Duration	O
of	O
disease	O
was	O
14	O
.	O
4	O
+	O
/	O
-	O
5	O
.	O
4	O
months	O
in	O
the	O
NV	O
(	O
-	O
)	O
group	O
and	O
66	O
.	O
2	O
+	O
/	O
-	O
65	O
.	O
5	O
months	O
in	O
the	O
NV	O
(	O
+	O
)	O
group	O
(	O
P	O
=	O
0	O
.	O
030	O
)	O
.	O
	
Duration	O
of	O
postoperative	O
epithelialization	O
was	O
6	O
.	O
2	O
+	O
/	O
-	O
2	O
.	O
2	O
days	O
in	O
the	O
NV	O
(	O
-	O
)	O
group	O
and	O
28	O
.	O
8	O
+	O
/	O
-	O
36	O
.	O
5	O
days	O
in	O
the	O
NV	O
(	O
+	O
)	O
group	O
(	O
P	O
=	O
0	O
.	O
046	O
)	O
.	O
	
Conjunctivalization	O
of	O
the	O
peripheral	B-Anatomy
cornea	I-Anatomy
and	O
delayed	O
postoperative	O
epithelialization	O
in	O
BK	B-Disease
patients	O
with	O
NV	B-Symptom
suggest	O
the	O
presence	O
of	O
limbal	B-Symptom
stem	I-Symptom
cell	I-Symptom
deficiency	I-Symptom
in	O
such	O
patients	O
.	O
	
Patients	O
with	O
long	O
-	O
standing	O
disease	O
were	O
found	O
to	O
be	O
more	O
prone	O
to	O
neovascularization	B-Symptom
.	O
	
For	O
this	O
reason	O
,	O
early	O
surgery	O
may	O
lead	O
to	O
a	O
better	O
surgical	O
outcome	O
.	O
	
Clinical	O
application	O
of	O
rapid	B-Diagnostic_tool
serial	I-Diagnostic_tool
fourier	I-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
for	O
macular	B-Diagnostic_tool
imaging	I-Diagnostic_tool
.	O
	
To	O
introduce	O
and	O
examine	O
the	O
utility	O
of	O
a	O
retinal	B-Diagnostic_tool
imaging	I-Diagnostic_tool
technique	O
using	O
high	B-Diagnostic_tool
-	I-Diagnostic_tool
speed	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
for	O
creating	O
a	O
more	O
complete	O
retinal	B-Anatomy
structural	O
map	O
to	O
aid	O
in	O
the	O
evaluation	O
of	O
patients	O
with	O
macular	B-Disease
pathology	I-Disease
.	O
	
Prospective	O
observational	O
case	O
series	O
.	O
	
Five	O
patients	O
with	O
a	O
variety	O
of	O
macular	B-Disease
pathologies	I-Disease
.	O
	
Patients	O
were	O
imaged	O
with	O
a	O
Fourier	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
high	I-Diagnostic_tool
-	I-Diagnostic_tool
speed	I-Diagnostic_tool
high	I-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
OCT	I-Diagnostic_tool
system	O
built	O
at	O
our	O
institution	O
.	O
	
A	O
sweeping	B-Diagnostic_tool
serial	I-Diagnostic_tool
OCT	I-Diagnostic_tool
B	I-Diagnostic_tool
-	I-Diagnostic_tool
scan	I-Diagnostic_tool
of	I-Diagnostic_tool
the	I-Diagnostic_tool
macula	I-Diagnostic_tool
was	O
acquired	O
to	O
create	O
a	O
detailed	O
retinal	B-Anatomy
structural	O
map	O
.	O
	
The	O
data	O
were	O
then	O
used	O
to	O
make	O
individual	O
clinical	O
observations	O
.	O
	
Rapid	B-Diagnostic_tool
serial	I-Diagnostic_tool
OCT	I-Diagnostic_tool
B	I-Diagnostic_tool
-	I-Diagnostic_tool
scans	I-Diagnostic_tool
produced	O
detailed	O
macular	O
maps	O
for	O
all	O
5	O
patients	O
.	O
	
Diagnoses	O
of	O
imaged	O
patients	O
included	O
macular	B-Symptom
hole	I-Symptom
,	O
lamellar	B-Symptom
macular	I-Symptom
hole	I-Symptom
,	O
regressed	B-Symptom
macular	I-Symptom
hole	I-Symptom
or	O
macular	B-Symptom
microhole	I-Symptom
,	O
choroidal	B-Symptom
neovascular	I-Symptom
membrane	I-Symptom
(	O
CNV	B-Symptom
)	O
from	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
,	O
and	O
CNV	B-Symptom
from	O
presumed	O
ocular	B-Disease
histoplasmosis	I-Disease
syndrome	I-Disease
.	O
	
Reconstructed	O
B	B-Diagnostic_tool
-	I-Diagnostic_tool
scans	I-Diagnostic_tool
and	O
C	B-Diagnostic_tool
-	I-Diagnostic_tool
scans	I-Diagnostic_tool
are	O
shown	O
for	O
selected	O
patients	O
to	O
illustrate	O
the	O
additional	O
perspectives	O
gained	O
by	O
obtaining	O
a	O
detailed	O
retinal	B-Anatomy
map	O
.	O
	
Rapid	B-Diagnostic_tool
serial	I-Diagnostic_tool
Fourier	I-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
OCT	I-Diagnostic_tool
B	I-Diagnostic_tool
-	I-Diagnostic_tool
scanning	I-Diagnostic_tool
can	O
be	O
used	O
to	O
create	O
a	O
detailed	O
retinal	B-Anatomy
structural	O
map	O
.	O
	
This	O
technique	O
provides	O
additional	O
information	O
that	O
can	O
be	O
missed	O
on	O
single	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
and	O
provides	O
an	O
accurate	O
way	O
to	O
image	O
large	O
or	O
complex	O
lesions	O
,	O
and	O
allows	O
B	B-Diagnostic_tool
-	I-Diagnostic_tool
scan	I-Diagnostic_tool
and	O
C	B-Diagnostic_tool
-	I-Diagnostic_tool
scan	I-Diagnostic_tool
reconstructions	O
to	O
be	O
made	O
that	O
provide	O
additional	O
perspectives	O
into	O
retinal	B-Anatomy
structures	O
that	O
may	O
be	O
missed	O
using	O
traditional	O
imaging	O
methods	O
.	O
	
Diagnostic	O
sensitivity	O
of	O
fast	B-Diagnostic_tool
blue	I-Diagnostic_tool
-	I-Diagnostic_tool
yellow	I-Diagnostic_tool
and	I-Diagnostic_tool
standard	I-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
in	O
early	B-Disease
glaucoma	I-Disease
:	O
a	O
comparison	O
between	O
different	O
test	O
programs	O
.	O
	
To	O
compare	O
the	O
ability	O
of	O
Fast	B-Diagnostic_tool
Swedish	I-Diagnostic_tool
interactive	I-Diagnostic_tool
threshold	I-Diagnostic_tool
algorithm	I-Diagnostic_tool
(	I-Diagnostic_tool
SITA	I-Diagnostic_tool
)	I-Diagnostic_tool
short	I-Diagnostic_tool
-	I-Diagnostic_tool
wavelength	I-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
(	O
SWAP	B-Diagnostic_tool
)	O
,	O
lengthier	O
full	B-Diagnostic_tool
-	I-Diagnostic_tool
threshold	I-Diagnostic_tool
SWAP	I-Diagnostic_tool
,	O
and	O
standard	B-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
(	I-Diagnostic_tool
SAP	I-Diagnostic_tool
)	I-Diagnostic_tool
using	I-Diagnostic_tool
the	I-Diagnostic_tool
SITA	I-Diagnostic_tool
Fast	I-Diagnostic_tool
program	I-Diagnostic_tool
to	O
detect	O
early	B-Symptom
glaucomatous	I-Symptom
visual	I-Symptom
field	I-Symptom
loss	I-Symptom
.	O
	
Cross	O
-	O
sectional	O
prospective	O
study	O
of	O
perimetric	B-Characteristic
diagnostic	I-Characteristic
sensitivity	I-Characteristic
as	O
defined	O
by	O
reference	O
limits	O
determined	O
in	O
the	O
same	O
healthy	B-Characteristic
participants	I-Characteristic
for	O
all	O
3	O
test	O
programs	O
.	O
	
One	O
hundred	O
one	O
patients	O
with	O
ocular	B-Disease
hypertension	I-Disease
,	O
or	O
suspect	O
or	O
early	B-Disease
manifest	I-Disease
glaucoma	I-Disease
.	O
	
One	O
eye	B-Anatomy
of	O
each	O
patient	O
was	O
tested	O
with	O
2	O
blue	B-Diagnostic_tool
-	I-Diagnostic_tool
yellow	I-Diagnostic_tool
perimetric	I-Diagnostic_tool
programs	I-Diagnostic_tool
:	O
the	O
SITA	B-Diagnostic_tool
and	I-Diagnostic_tool
full	I-Diagnostic_tool
-	I-Diagnostic_tool
threshold	I-Diagnostic_tool
SWAP	I-Diagnostic_tool
and	O
the	O
SAP	B-Diagnostic_tool
SITA	I-Diagnostic_tool
Fast	I-Diagnostic_tool
program	I-Diagnostic_tool
.	O
	
Glaucomatous	B-Symptom
visual	I-Symptom
field	I-Symptom
loss	I-Symptom
,	O
defined	O
as	O
number	O
of	O
significantly	O
depressed	O
test	O
point	O
locations	O
or	O
the	O
number	O
of	O
clusters	O
of	O
such	O
test	O
points	O
.	O
	
No	O
significant	O
difference	O
in	O
number	O
of	O
significantly	O
depressed	O
test	O
point	O
locations	O
between	O
the	O
3	O
programs	O
could	O
be	O
detected	O
,	O
neither	O
at	O
the	O
P	O
<	O
5	O
%	O
limit	O
nor	O
at	O
the	O
P	O
<	O
2	O
%	O
limit	O
.	O
	
The	O
difference	O
in	O
number	O
of	O
points	O
depressed	O
below	O
the	O
fifth	O
percentile	O
was	O
0	O
.	O
5	O
between	O
full	B-Diagnostic_tool
-	I-Diagnostic_tool
threshold	I-Diagnostic_tool
SWAP	I-Diagnostic_tool
and	O
SITA	B-Diagnostic_tool
SWAP	I-Diagnostic_tool
,	O
1	O
.	O
09	O
between	O
full	B-Diagnostic_tool
-	I-Diagnostic_tool
threshold	I-Diagnostic_tool
SWAP	I-Diagnostic_tool
and	O
SAP	B-Diagnostic_tool
,	O
and	O
1	O
.	O
04	O
between	O
SITA	B-Diagnostic_tool
SWAP	I-Diagnostic_tool
and	O
SAP	B-Diagnostic_tool
.	O
	
The	O
number	O
of	O
eyes	B-Anatomy
showing	O
clusters	O
of	O
significantly	O
depressed	O
points	O
also	O
was	O
similar	O
with	O
the	O
3	O
test	O
programs	O
:	O
full	B-Diagnostic_tool
-	I-Diagnostic_tool
threshold	I-Diagnostic_tool
SWAP	I-Diagnostic_tool
identified	O
clusters	O
in	O
66	O
eyes	B-Anatomy
,	O
SITA	B-Diagnostic_tool
SWAP	I-Diagnostic_tool
identified	O
clusters	O
in	O
67	O
eyes	B-Anatomy
,	O
and	O
SITA	B-Diagnostic_tool
Fast	I-Diagnostic_tool
SAP	I-Diagnostic_tool
identified	O
clusters	O
in	O
65	O
eyes	B-Anatomy
.	O
	
Average	O
test	O
time	O
was	O
12	O
.	O
0	O
minutes	O
using	O
full	B-Diagnostic_tool
-	I-Diagnostic_tool
threshold	I-Diagnostic_tool
SWAP	I-Diagnostic_tool
,	O
4	O
.	O
1	O
minutes	O
with	O
SITA	B-Diagnostic_tool
SWAP	I-Diagnostic_tool
,	O
and	O
3	O
.	O
5	O
with	O
SITA	B-Diagnostic_tool
Fast	I-Diagnostic_tool
.	O
	
The	O
SITA	B-Diagnostic_tool
SWAP	I-Diagnostic_tool
identified	O
at	O
least	O
as	O
much	O
glaucomatous	B-Symptom
visual	I-Symptom
field	I-Symptom
loss	I-Symptom
as	O
the	O
older	O
full	B-Diagnostic_tool
-	I-Diagnostic_tool
threshold	I-Diagnostic_tool
SWAP	I-Diagnostic_tool
,	O
although	O
test	O
time	O
was	O
considerably	O
reduced	O
.	O
	
Conventional	O
SAP	B-Diagnostic_tool
using	I-Diagnostic_tool
SITA	I-Diagnostic_tool
Fast	I-Diagnostic_tool
was	O
not	O
significantly	O
less	O
sensitive	O
than	O
either	O
of	O
the	O
2	O
SWAP	B-Diagnostic_tool
programs	O
.	O
	
Comparison	O
of	O
visual	B-Symptom
acuity	I-Symptom
loss	I-Symptom
in	O
patients	O
with	O
different	O
stages	O
of	O
Stargardt	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
To	O
investigate	O
a	O
previously	O
reported	O
observation	O
that	O
the	O
presence	O
of	O
diffuse	O
,	O
as	O
compared	O
with	O
localized	O
,	O
fundus	B-Symptom
flecks	I-Symptom
is	O
an	O
indicator	O
of	O
a	O
more	O
severe	O
course	O
for	O
visual	B-Symptom
acuity	I-Symptom
(	I-Symptom
VA	I-Symptom
)	I-Symptom
loss	I-Symptom
beyond	I-Symptom
20	I-Symptom
/	I-Symptom
200	I-Symptom
in	O
patients	O
with	O
Stargardt	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
Retrospective	O
clinic	O
-	O
based	O
cross	O
-	O
sectional	O
study	O
.	O
	
Four	O
hundred	O
five	O
patients	O
with	O
Stargardt	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
Visual	B-Characteristic
acuity	I-Characteristic
in	O
405	O
patients	O
with	O
Stargardt	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
was	O
analyzed	O
at	O
their	O
initial	O
and	O
most	O
recent	O
visits	O
.	O
	
The	O
stage	O
of	O
Stargardt	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
and	O
appearance	B-Characteristic
of	I-Characteristic
the	I-Characteristic
macula	I-Characteristic
were	O
recorded	O
.	O
	
The	O
diagnosis	O
and	O
stage	O
of	O
Stargardt	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
were	O
based	O
on	O
the	O
extent	O
and	O
appearance	O
of	O
fundus	B-Symptom
flecks	I-Symptom
.	O
	
Best	B-Characteristic
-	I-Characteristic
corrected	I-Characteristic
VA	I-Characteristic
,	O
stage	O
of	O
Stargardt	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
and	O
appearance	B-Characteristic
of	I-Characteristic
the	I-Characteristic
macula	I-Characteristic
at	O
the	O
initial	O
and	O
most	O
recent	O
visits	O
were	O
used	O
in	O
the	O
cross	O
-	O
sectional	O
analysis	O
.	O
	
At	O
their	O
initial	O
visit	O
,	O
199	O
patients	O
were	O
identified	O
as	O
having	O
stage	B-Disease
1	I-Disease
Stargardt	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
of	O
whom	O
97	O
.	O
5	O
%	O
maintained	O
20	B-Symptom
/	I-Symptom
200	I-Symptom
or	I-Symptom
better	I-Symptom
VA	I-Symptom
in	O
at	O
least	O
one	O
eye	B-Anatomy
.	O
	
One	O
hundred	O
eighty	O
-	O
five	O
were	O
identified	O
as	O
having	O
stage	B-Disease
2	I-Disease
or	I-Disease
stage	I-Disease
2	I-Disease
-	I-Disease
3	I-Disease
Stargardt	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
combined	O
,	O
of	O
whom	O
83	O
.	O
2	O
%	O
maintained	O
20	B-Symptom
/	I-Symptom
200	I-Symptom
VA	I-Symptom
or	I-Symptom
better	I-Symptom
.	O
	
Patients	O
with	O
stage	B-Disease
1	I-Disease
were	O
more	O
likely	O
to	O
maintain	O
20	B-Symptom
/	I-Symptom
200	I-Symptom
or	I-Symptom
better	I-Symptom
VA	I-Symptom
in	O
at	O
least	O
one	O
eye	B-Anatomy
when	O
compared	O
with	O
patients	O
with	O
stage	B-Disease
2	I-Disease
/	I-Disease
stage	I-Disease
2	I-Disease
-	I-Disease
3	I-Disease
Stargardt	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
chi2	O
(	O
1	O
)	O
=	O
21	O
.	O
25	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
Ninety	O
-	O
nine	O
percent	O
of	O
stage	B-Disease
1	I-Disease
patients	O
and	O
94	O
.	O
1	O
%	O
of	O
stage	B-Disease
2	I-Disease
/	I-Disease
stage	I-Disease
2	I-Disease
-	I-Disease
3	I-Disease
patients	O
maintained	O
20	B-Symptom
/	I-Symptom
400	I-Symptom
or	I-Symptom
better	I-Symptom
VA	I-Symptom
in	I-Symptom
at	I-Symptom
least	I-Symptom
one	I-Symptom
eye	I-Symptom
(	O
chi2	O
(	O
1	O
)	O
=	O
5	O
.	O
72	O
,	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O
	
Patients	O
with	O
stage	B-Disease
1	I-Disease
Stargardt	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
exhibiting	O
fundus	B-Symptom
flecks	I-Symptom
limited	O
to	O
the	O
posterior	B-Anatomy
pole	I-Anatomy
are	O
more	O
likely	O
to	O
maintain	O
a	O
level	O
of	O
VA	B-Symptom
at	I-Symptom
20	I-Symptom
/	I-Symptom
200	I-Symptom
or	I-Symptom
better	I-Symptom
when	O
compared	O
with	O
patients	O
with	O
stage	B-Disease
2	I-Disease
/	I-Disease
stage	I-Disease
2	I-Disease
-	I-Disease
3	I-Disease
disease	I-Disease
who	O
have	O
diffuse	B-Symptom
fundus	I-Symptom
flecks	I-Symptom
.	O
	
Nevertheless	O
,	O
over	O
80	O
%	O
of	O
the	O
patients	O
with	O
stage	B-Disease
2	I-Disease
/	I-Disease
stage	I-Disease
2	I-Disease
-	I-Disease
3	I-Disease
Stargardt	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
still	O
maintained	O
VA	B-Symptom
of	I-Symptom
20	I-Symptom
/	I-Symptom
200	I-Symptom
or	I-Symptom
better	I-Symptom
.	O
	
Only	O
5	O
.	O
9	O
%	O
of	O
patients	O
with	O
stage	B-Disease
2	I-Disease
/	I-Disease
stage	I-Disease
2	I-Disease
-	I-Disease
3	I-Disease
had	O
VA	B-Symptom
levels	I-Symptom
worse	I-Symptom
than	I-Symptom
20	I-Symptom
/	I-Symptom
400	I-Symptom
.	O
	
In	O
our	O
cohort	O
of	O
patients	O
with	O
Stargardt	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
and	O
diffuse	B-Symptom
fundus	I-Symptom
flecks	I-Symptom
,	O
the	O
majority	O
of	O
patients	O
did	O
not	O
lose	B-Symptom
VA	I-Symptom
to	O
a	O
greater	O
extent	O
than	O
those	O
with	O
localized	B-Symptom
flecks	I-Symptom
.	O
	
Ten	O
-	O
year	O
incidence	O
and	O
progression	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
:	O
the	O
blue	O
Mountains	O
Eye	O
Study	O
	
Purpose	O
:	O
To	O
assess	O
the	O
10	O
-	O
year	O
incidence	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
(	O
ARM	B-Disease
)	O
in	O
an	O
older	B-Characteristic
Australian	I-Characteristic
cohort	I-Characteristic
.	O
	
Design	O
:	O
Population	O
-	O
based	O
cohort	O
study	O
.	O
	
Participants	O
:	O
Three	O
thousand	O
six	O
hundred	O
fifty	O
-	O
four	O
Blue	O
Mountains	O
Eye	O
Study	O
participants	O
>	B-Characteristic
or	I-Characteristic
=	I-Characteristic
49	I-Characteristic
years	I-Characteristic
old	I-Characteristic
were	O
examined	O
during	O
1992	O
through	O
1994	O
;	O
2335	O
(	O
75	O
%	O
of	O
survivors	O
)	O
were	O
reexamined	O
after	O
5	O
years	O
(	O
1997	O
-	O
1999	O
)	O
and	O
1952	O
(	O
76	O
%	O
of	O
survivors	O
)	O
after	O
10	O
years	O
(	O
2002	O
-	O
2004	O
)	O
.	O
	
Methods	O
:	O
The	O
same	O
graders	O
performed	O
retinal	B-Diagnostic_tool
photographic	I-Diagnostic_tool
grading	I-Diagnostic_tool
in	O
all	O
examinations	O
,	O
using	O
the	O
Wisconsin	B-Classification_system
Age	I-Classification_system
-	I-Classification_system
Related	I-Classification_system
Maculopathy	I-Classification_system
Grading	I-Classification_system
System	O
.	O
	
Photographs	B-Diagnostic_tool
of	O
participants	O
with	O
ARM	B-Symptom
lesions	I-Symptom
at	O
any	O
of	O
the	O
examinations	O
were	O
subsequently	O
regraded	O
using	O
a	O
side	O
-	O
by	O
-	O
side	O
comparison	O
method	O
.	O
	
Main	O
outcome	O
measures	O
:	O
The	O
diagnosis	O
of	O
incident	B-Disease
late	I-Disease
ARM	I-Disease
was	O
given	O
if	O
neovascular	B-Symptom
ARM	I-Symptom
or	O
geographic	B-Symptom
atrophy	I-Symptom
was	O
detected	O
at	O
either	O
follow	O
-	O
up	O
examination	O
in	O
persons	O
free	O
of	O
these	O
lesions	O
at	O
baseline	O
.	O
	
Incident	B-Disease
early	I-Disease
ARM	I-Disease
was	O
diagnosed	O
if	O
early	B-Disease
ARM	I-Disease
(	O
soft	B-Symptom
indistinct	I-Symptom
or	I-Symptom
reticular	I-Symptom
drusen	I-Symptom
or	O
combined	B-Symptom
soft	I-Symptom
distinct	I-Symptom
drusen	I-Symptom
and	I-Symptom
retinal	I-Symptom
pigment	I-Symptom
abnormality	I-Symptom
)	O
was	O
present	O
in	O
persons	O
free	O
of	O
early	B-Disease
and	I-Disease
late	I-Disease
ARM	I-Disease
at	O
baseline	O
.	O
	
Age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
incidence	O
was	O
calculated	O
using	O
Kaplan	O
-	O
Meier	O
methods	O
to	O
incorporate	O
information	O
from	O
both	O
5	O
-	O
and	O
10	O
-	O
year	O
examinations	O
.	O
	
Discrete	O
logistic	O
models	O
were	O
used	O
to	O
assess	O
the	O
risk	O
of	O
incident	B-Disease
late	I-Disease
ARM	I-Disease
according	O
to	O
various	O
baseline	O
factors	O
,	O
including	O
early	B-Symptom
ARM	I-Symptom
lesion	I-Symptom
characteristics	O
.	O
	
Results	O
:	O
After	O
excluding	O
72	O
late	B-Disease
ARM	I-Disease
cases	O
present	O
at	O
baseline	O
,	O
2395	O
of	O
3582	O
subjects	O
at	O
risk	O
of	O
late	B-Disease
ARM	I-Disease
(	O
67	O
%	O
)	O
were	O
reexamined	O
at	O
either	O
follow	O
-	O
up	O
time	O
point	O
or	O
both	O
follow	O
-	O
up	O
time	O
points	O
.	O
	
Over	O
the	O
10	O
-	O
year	O
period	O
,	O
72	O
of	O
2395	O
subjects	O
(	O
3	O
.	O
7	O
%	O
)	O
developed	O
late	B-Disease
ARM	I-Disease
and	O
266	O
of	O
2255	O
subjects	O
(	O
14	O
.	O
1	O
%	O
)	O
developed	O
early	B-Disease
ARM	I-Disease
.	O
	
After	O
age	O
standardization	O
to	O
the	O
Beaver	O
Dam	O
Eye	O
Study	O
population	O
,	O
our	O
10	O
-	O
year	O
incidences	O
of	O
late	B-Disease
and	I-Disease
early	I-Disease
ARM	I-Disease
were	O
2	O
.	O
8	O
%	O
and	O
10	O
.	O
8	O
%	O
,	O
respectively	O
.	O
	
Baseline	O
age	B-Characteristic
and	O
early	B-Symptom
ARM	I-Symptom
lesion	I-Symptom
characteristics	O
and	O
severity	O
were	O
strong	O
predictors	O
of	O
late	B-Disease
ARM	I-Disease
incidence	O
.	O
	
Conclusions	O
:	O
Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
this	O
older	B-Characteristic
population	I-Characteristic
confirms	O
that	O
the	O
risk	O
of	O
ARM	B-Disease
progression	O
is	O
related	O
strongly	O
to	O
the	O
severity	O
of	O
early	B-Symptom
-	I-Symptom
stage	I-Symptom
lesions	I-Symptom
.	O
	
The	O
study	O
provides	O
evidence	O
-	O
based	O
criteria	O
for	O
identifying	O
persons	O
at	O
high	O
risk	O
of	O
developing	O
late	B-Disease
ARM	I-Disease
.	O
	
Retinal	B-Symptom
nerve	I-Symptom
fiber	I-Symptom
layer	I-Symptom
damage	I-Symptom
as	O
assessed	O
by	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
in	O
eyes	B-Anatomy
with	O
a	O
visual	B-Symptom
field	I-Symptom
defect	I-Symptom
detected	O
by	O
frequency	B-Diagnostic_tool
doubling	I-Diagnostic_tool
technology	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
but	O
not	O
by	O
standard	B-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
.	O
	
To	O
determine	O
whether	O
the	O
visual	B-Symptom
field	I-Symptom
(	I-Symptom
VF	I-Symptom
)	I-Symptom
loss	I-Symptom
detected	O
by	O
frequency	B-Diagnostic_tool
doubling	I-Diagnostic_tool
technology	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
(	O
FDT	B-Diagnostic_tool
)	O
but	O
not	O
by	O
standard	B-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
(	O
SAP	B-Diagnostic_tool
)	O
is	O
associated	O
with	O
retinal	B-Symptom
nerve	I-Symptom
fiber	I-Symptom
layer	I-Symptom
(	I-Symptom
RNFL	I-Symptom
)	I-Symptom
damage	I-Symptom
measured	O
using	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
.	O
	
Observational	O
case	O
-	O
control	O
study	O
.	O
	
Ninety	O
-	O
three	O
subjects	O
were	O
recruited	O
from	O
the	O
longitudinal	O
University	O
of	O
California	O
,	O
San	O
Diego	O
,	O
Diagnostic	O
Innovations	O
in	O
Glaucoma	B-Disease
Study	O
.	O
	
All	O
participants	O
had	O
>	O
or	O
=	O
2	O
reliable	O
SAP	B-Diagnostic_tool
-	I-Diagnostic_tool
Swedish	I-Diagnostic_tool
Interactive	I-Diagnostic_tool
Testing	I-Diagnostic_tool
Algorithm	I-Diagnostic_tool
and	O
FDT	B-Diagnostic_tool
24	I-Diagnostic_tool
-	I-Diagnostic_tool
2	I-Diagnostic_tool
tests	I-Diagnostic_tool
and	O
at	O
least	O
one	O
Stratus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
test	I-Diagnostic_tool
,	O
all	O
conducted	O
within	O
a	O
6	O
-	O
month	O
time	O
window	O
.	O
	
Retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
measured	O
with	O
OCT	B-Diagnostic_tool
and	O
the	O
number	O
of	O
sectors	O
with	O
OCT	B-Diagnostic_tool
-	O
measured	O
RNFL	B-Characteristic
thickness	I-Characteristic
lower	O
than	O
the	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
or	O
99	O
%	O
CI	O
based	O
on	O
the	O
instrument	O
'	O
s	O
normative	O
database	O
.	O
	
Compared	O
with	O
those	O
with	O
normal	O
SAP	B-Diagnostic_tool
and	O
FDT	B-Diagnostic_tool
results	O
,	O
a	O
significantly	O
higher	O
proportion	O
of	O
subjects	O
with	O
normal	O
SAP	B-Diagnostic_tool
and	O
abnormal	O
FDT	B-Diagnostic_tool
results	O
had	O
OCT	B-Diagnostic_tool
-	O
measured	O
RNFL	B-Characteristic
thickness	I-Characteristic
outside	O
95	O
%	O
limits	O
in	O
the	O
inferior	O
and	O
superior	O
quadrants	O
(	O
P	O
=	O
0	O
.	O
048	O
)	O
and	O
outside	O
99	O
%	O
limits	O
in	O
the	O
inferior	O
quadrant	O
(	O
P	O
=	O
0	O
.	O
010	O
)	O
.	O
	
When	O
SAP	B-Diagnostic_tool
is	O
within	O
normal	O
range	O
,	O
some	O
patients	O
with	O
VF	B-Symptom
loss	I-Symptom
detected	O
by	O
FDT	B-Diagnostic_tool
show	O
a	O
decreased	B-Characteristic
RNFL	I-Characteristic
thickness	I-Characteristic
,	O
possibly	O
indicating	O
the	O
presence	O
of	O
glaucomatous	B-Symptom
damage	I-Symptom
.	O
	
These	O
results	O
support	O
the	O
validity	O
of	O
FDT	B-Diagnostic_tool
as	O
a	O
tool	O
to	O
detect	O
early	B-Disease
glaucoma	I-Disease
.	O
	
Fifteen	O
-	O
year	O
cumulative	O
incidence	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
:	O
the	O
Beaver	O
Dam	O
Eye	O
Study	O
	
Purpose	O
:	O
To	O
describe	O
the	O
15	O
-	O
year	O
cumulative	O
incidence	O
of	O
signs	O
of	O
early	B-Disease
and	I-Disease
late	I-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Design	O
:	O
Population	O
-	O
based	O
cohort	O
study	O
.	O
	
Participants	O
:	O
We	O
included	O
3917	O
persons	O
,	O
43	B-Characteristic
to	I-Characteristic
86	I-Characteristic
years	I-Characteristic
of	I-Characteristic
age	I-Characteristic
at	O
the	O
time	O
of	O
a	O
baseline	O
examination	O
in	O
1988	O
through	O
1990	O
and	O
with	O
information	O
collected	O
in	O
follow	O
-	O
up	O
in	O
1993	O
through	O
1995	O
,	O
and	O
/	O
or	O
1998	O
through	O
2000	O
,	O
and	O
/	O
or	O
2003	O
through	O
2005	O
.	O
	
Methods	O
:	O
Grading	O
of	O
stereoscopic	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
using	O
the	O
Wisconsin	B-Classification_system
Age	I-Classification_system
-	I-Classification_system
Related	I-Classification_system
Maculopathy	I-Classification_system
Grading	I-Classification_system
System	I-Classification_system
.	O
	
Main	O
outcome	O
measures	O
:	O
Cumulative	O
incidence	O
of	O
drusen	B-Symptom
type	O
and	O
size	O
,	O
pigmentary	B-Symptom
abnormalities	I-Symptom
,	O
geographic	B-Symptom
atrophy	I-Symptom
,	O
and	O
exudative	B-Disease
AMD	I-Disease
accounting	O
for	O
competing	O
risk	O
of	O
death	O
.	O
	
Results	O
:	O
The	O
15	O
-	O
year	O
cumulative	O
incidence	O
was	O
14	O
.	O
3	O
%	O
for	O
early	B-Disease
AMD	I-Disease
(	O
the	O
presence	O
of	O
either	O
soft	B-Symptom
indistinct	I-Symptom
drusen	I-Symptom
or	O
the	O
presence	O
of	O
pigmentary	B-Symptom
abnormalities	I-Symptom
together	O
with	O
any	O
type	O
of	O
drusen	B-Symptom
)	O
and	O
3	O
.	O
1	O
%	O
for	O
late	B-Disease
AMD	I-Disease
(	O
presence	O
of	O
exudative	B-Disease
AMD	I-Disease
or	O
geographic	B-Symptom
atrophy	I-Symptom
)	O
.	O
	
There	O
was	O
an	O
increased	O
incidence	O
of	O
AMD	B-Symptom
lesions	I-Symptom
with	O
age	B-Characteristic
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
Individuals	O
>	B-Characteristic
or	I-Characteristic
=	I-Characteristic
75	I-Characteristic
years	I-Characteristic
of	I-Characteristic
age	I-Characteristic
at	O
baseline	O
had	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
higher	O
15	O
-	O
year	O
incidences	O
of	O
the	O
following	O
characteristics	O
than	O
people	O
43	B-Characteristic
to	I-Characteristic
54	I-Characteristic
years	I-Characteristic
of	I-Characteristic
age	I-Characteristic
:	O
larger	B-Symptom
drusen	I-Symptom
(	O
125	B-Dimension
mum	I-Dimension
in	I-Dimension
diameter	I-Dimension
,	O
24	O
.	O
1	O
%	O
vs	O
10	O
.	O
6	O
%	O
)	O
,	O
soft	B-Symptom
indistinct	I-Symptom
drusen	I-Symptom
(	O
18	O
.	O
7	O
%	O
vs	O
6	O
.	O
5	O
%	O
)	O
,	O
retinal	B-Symptom
pigmentary	I-Symptom
abnormalities	I-Symptom
(	O
20	O
.	O
2	O
%	O
vs	O
3	O
.	O
7	O
%	O
)	O
,	O
exudative	B-Disease
macular	I-Disease
degeneration	I-Disease
(	O
4	O
.	O
4	O
%	O
vs	O
0	O
.	O
4	O
%	O
)	O
,	O
and	O
pure	B-Symptom
geographic	I-Symptom
atrophy	I-Symptom
(	O
3	O
.	O
2	O
%	O
vs	O
0	O
%	O
)	O
.	O
	
Controlling	O
for	O
age	B-Characteristic
,	O
compared	O
with	O
those	O
with	O
small	O
numbers	O
of	O
only	O
small	B-Symptom
hard	I-Symptom
drusen	I-Symptom
(	I-Symptom
1	I-Symptom
-	I-Symptom
2	I-Symptom
)	I-Symptom
,	O
those	O
with	O
large	O
numbers	O
of	O
only	O
hard	B-Symptom
drusen	I-Symptom
(	I-Symptom
>	I-Symptom
or	I-Symptom
=	I-Symptom
8	I-Symptom
)	I-Symptom
had	O
an	O
increased	O
15	O
-	O
year	O
age	O
-	O
adjusted	O
incidence	O
of	O
both	O
soft	B-Symptom
indistinct	I-Symptom
drusen	I-Symptom
(	O
16	O
.	O
3	O
%	O
vs	O
4	O
.	O
7	O
%	O
)	O
and	O
pigmentary	B-Symptom
abnormalities	I-Symptom
(	O
10	O
.	O
6	O
%	O
vs	O
2	O
.	O
7	O
%	O
)	O
.	O
	
Eyes	B-Anatomy
with	O
soft	B-Symptom
indistinct	I-Symptom
drusen	I-Symptom
or	O
pigmentary	B-Symptom
abnormalities	I-Symptom
at	O
baseline	O
were	O
more	O
likely	O
to	O
develop	O
late	B-Disease
AMD	I-Disease
at	O
follow	O
-	O
up	O
than	O
eyes	B-Anatomy
without	O
these	O
lesions	O
(	O
17	O
.	O
8	O
%	O
vs	O
1	O
.	O
2	O
%	O
and	O
12	O
.	O
9	O
%	O
vs	O
1	O
.	O
7	O
%	O
,	O
respectively	O
)	O
.	O
	
Conclusions	O
:	O
We	O
document	O
the	O
long	O
-	O
term	O
incidence	O
of	O
signs	O
of	O
AMD	B-Disease
and	O
a	O
continuum	O
from	O
small	B-Symptom
hard	I-Symptom
drusen	I-Symptom
to	O
late	B-Disease
AMD	I-Disease
in	O
older	B-Characteristic
persons	I-Characteristic
in	O
the	O
population	O
.	O
	
The	O
15	O
-	O
year	O
cumulative	O
incidence	O
of	O
late	B-Disease
AMD	I-Disease
in	O
people	O
>	B-Characteristic
or	I-Characteristic
=	I-Characteristic
75	I-Characteristic
years	I-Characteristic
of	I-Characteristic
age	I-Characteristic
(	O
8	O
%	O
)	O
indicates	O
a	O
public	O
health	O
problem	O
of	O
significant	O
proportions	O
because	O
the	O
United	B-Characteristic
States	I-Characteristic
population	I-Characteristic
this	O
age	B-Characteristic
is	O
expected	O
to	O
increase	O
by	O
54	O
%	O
between	O
2005	O
and	O
2025	O
.	O
	
Cataract	B-Disease
surgery	O
is	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
photodynamic	O
therapy	O
for	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
.	O
	
To	O
investigate	O
the	O
association	O
between	O
cataract	B-Disease
surgery	O
and	O
the	O
rate	O
of	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
for	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Observational	O
population	O
-	O
based	O
retrospective	O
case	O
-	O
control	O
study	O
.	O
	
All	O
members	O
in	O
a	O
district	O
of	O
the	O
largest	O
health	O
maintenance	O
organization	O
(	O
HMO	O
)	O
in	O
Israel	B-Characteristic
>	I-Characteristic
50	I-Characteristic
years	I-Characteristic
old	I-Characteristic
on	O
January	O
1	O
,	O
2001	O
,	O
who	O
did	O
not	O
terminate	O
their	O
membership	O
through	O
May	O
31	O
,	O
2005	O
(	O
139	O
894	O
members	O
)	O
.	O
	
All	O
PDT	O
procedures	O
for	O
AMD	B-Disease
performed	O
in	O
the	O
study	O
population	O
between	O
January	O
1	O
,	O
2001	O
and	O
May	O
31	O
,	O
2005	O
(	O
283	O
patients	O
)	O
and	O
all	O
cataract	B-Disease
surgeries	O
performed	O
between	O
January	O
1	O
,	O
2001	O
and	O
December	O
31	O
,	O
2003	O
(	O
5913	O
patients	O
)	O
were	O
documented	O
.	O
	
We	O
extracted	O
clinical	O
information	O
from	O
the	O
chronic	O
disease	O
registry	O
of	O
the	O
HMO	O
as	O
well	O
as	O
demographic	O
and	O
socioeconomic	O
information	O
.	O
	
For	O
each	O
patient	O
that	O
underwent	O
cataract	B-Disease
surgery	O
,	O
5	O
HMO	O
members	O
matched	O
in	O
age	B-Characteristic
,	O
gender	B-Characteristic
,	O
chronic	B-Disease
diseases	I-Disease
(	O
systemic	B-Disease
hypertension	I-Disease
,	O
diabetes	B-Disease
,	O
hyperlipemia	B-Disease
,	O
and	O
ischemic	B-Disease
heart	I-Disease
disease	I-Disease
)	O
,	O
place	B-Characteristic
of	I-Characteristic
residence	I-Characteristic
,	O
country	B-Characteristic
of	I-Characteristic
birth	I-Characteristic
and	O
socioeconomic	B-Characteristic
status	I-Characteristic
,	O
who	O
did	O
not	O
undergo	O
cataract	B-Disease
surgery	O
,	O
were	O
randomly	O
chosen	O
as	O
controls	O
(	O
n	O
=	O
29	O
565	O
)	O
.	O
	
The	O
rate	O
for	O
undergoing	O
PDT	O
at	O
different	O
time	O
periods	O
after	O
cataract	B-Disease
surgery	O
.	O
	
Fifty	O
(	O
0	O
.	O
85	O
%	O
)	O
cataract	B-Disease
patients	O
and	O
94	O
control	O
cases	O
(	O
0	O
.	O
32	O
%	O
)	O
underwent	O
PDT	O
after	O
cataract	B-Disease
surgery	O
(	O
P	O
<	O
0	O
.	O
0001	O
,	O
chi	O
-	O
square	O
test	O
)	O
.	O
	
A	O
significant	O
rise	O
in	O
PDT	O
rate	O
was	O
noticed	O
in	O
cataract	B-Disease
patients	O
compared	O
to	O
controls	O
during	O
the	O
first	O
6	O
months	O
after	O
surgery	O
(	O
P	O
=	O
0	O
.	O
004	O
,	O
chi	O
-	O
square	O
test	O
)	O
.	O
	
Between	O
6	O
and	O
12	O
months	O
postoperatively	O
,	O
the	O
PDT	O
rates	O
were	O
similar	O
in	O
both	O
groups	O
.	O
	
However	O
,	O
a	O
more	O
significant	O
rise	O
in	O
PDT	O
rates	O
occurred	O
between	O
1	O
and	O
1	O
.	O
5	O
years	O
after	O
surgery	O
(	O
P	O
<	O
0	O
.	O
0001	O
,	O
chi	O
-	O
square	O
test	O
)	O
.	O
	
The	O
Kaplan	O
-	O
Meier	O
PDT	O
-	O
free	O
survival	O
curve	O
of	O
cataract	B-Disease
patients	O
was	O
significantly	O
worse	O
than	O
that	O
of	O
the	O
controls	O
(	O
P	O
<	O
0	O
.	O
0001	O
,	O
chi	O
-	O
square	O
test	O
;	O
P	O
=	O
33	O
.	O
7	O
,	O
log	O
-	O
rank	O
test	O
)	O
.	O
	
The	O
hazard	O
ratio	O
for	O
cataract	B-Disease
patients	O
compared	O
to	O
controls	O
to	O
undergo	O
PDT	O
after	O
surgery	O
was	O
2	O
.	O
7	O
(	O
confidence	O
interval	O
=	O
2	O
.	O
4	O
-	O
5	O
.	O
7	O
)	O
.	O
	
The	O
most	O
significant	O
factors	O
to	O
reduce	O
the	O
time	O
to	O
PDT	O
were	O
advanced	B-Characteristic
age	I-Characteristic
followed	O
by	O
having	O
had	O
cataract	B-Disease
surgery	O
,	O
place	B-Characteristic
of	I-Characteristic
birth	I-Characteristic
,	O
socioeconomic	B-Characteristic
status	I-Characteristic
,	O
and	O
hyperlipidemia	B-Symptom
(	O
Cox	O
proportional	O
hazards	O
survival	O
regression	O
)	O
.	O
	
We	O
identified	O
an	O
increased	O
rate	O
of	O
PDT	O
,	O
presumably	O
for	O
subfoveal	B-Disease
AMD	I-Disease
,	O
1	O
to	O
1	O
.	O
5	O
years	O
after	O
cataract	B-Disease
surgery	O
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomographic	I-Diagnostic_tool
pattern	O
may	O
predict	O
visual	O
outcome	O
after	O
intravitreal	O
triamcinolone	O
for	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
To	O
identify	O
an	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
pattern	O
predictive	O
of	O
visual	O
outcome	O
in	O
patients	O
with	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
who	O
underwent	O
a	O
single	O
dose	O
of	O
intravitreal	O
triamcinolone	O
.	O
	
Retrospective	O
case	O
analysis	O
with	O
prospective	O
data	O
collection	O
for	O
controls	O
.	O
	
Ninety	O
-	O
three	O
cases	O
and	O
25	O
controls	O
.	O
	
Two	O
independent	O
masked	O
observers	O
retrospectively	O
examined	O
preoperative	O
macular	B-Anatomy
OCTs	B-Diagnostic_tool
of	O
93	O
eyes	B-Anatomy
of	O
93	O
patients	O
who	O
were	O
given	O
a	O
single	O
dose	O
(	O
4	O
mg	O
in	O
0	O
.	O
1	O
ml	O
)	O
of	O
intravitreal	O
triamcinolone	O
for	O
DME	B-Disease
and	O
categorized	O
them	O
as	O
belonging	O
to	O
2	O
groups	O
:	O
1	O
,	O
comprised	O
of	O
eyes	B-Anatomy
with	O
high	B-Characteristic
reflectivity	I-Characteristic
(	O
bright	O
colors	O
)	O
from	O
inner	B-Anatomy
retinal	I-Anatomy
layers	I-Anatomy
,	O
and	O
2	O
,	O
comprised	O
of	O
eyes	B-Anatomy
that	O
had	O
low	B-Characteristic
reflectivity	I-Characteristic
(	O
darker	O
colors	O
)	O
from	O
inner	B-Anatomy
retinal	I-Anatomy
layers	I-Anatomy
.	O
	
Logarithm	O
of	O
the	O
minimum	B-Characteristic
angle	I-Characteristic
of	I-Characteristic
resolution	I-Characteristic
visual	I-Characteristic
acuity	I-Characteristic
(	O
VA	B-Characteristic
)	O
and	O
macular	B-Characteristic
thickness	I-Characteristic
measured	O
by	O
OCT	B-Diagnostic_tool
were	O
assessed	O
preoperatively	O
and	O
postoperatively	O
at	O
1	O
and	O
3	O
months	O
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomographic	I-Diagnostic_tool
appearance	O
of	O
inner	B-Anatomy
retinal	I-Anatomy
layers	I-Anatomy
.	O
	
All	O
patients	O
completed	O
3	O
months	O
of	O
follow	O
-	O
up	O
.	O
	
In	O
group	O
1	O
,	O
45	O
of	O
51	O
eyes	B-Anatomy
(	O
88	O
%	O
)	O
experienced	O
visual	O
improvement	O
of	O
>	O
or	O
=	O
2	O
lines	O
on	O
an	O
Early	B-Classification_system
Treatment	I-Classification_system
Diabetic	I-Classification_system
Retinopathy	I-Classification_system
Study	I-Classification_system
(	O
ETDRS	B-Classification_system
)	O
chart	O
at	O
1	O
month	O
of	O
follow	O
-	O
up	O
.	O
	
Forty	O
-	O
four	O
of	O
51	O
patients	O
(	O
86	O
%	O
)	O
experienced	O
visual	O
improvement	O
of	O
>	O
or	O
=	O
2	O
lines	O
on	O
an	O
ETDRS	B-Classification_system
chart	O
at	O
3	O
months	O
of	O
follow	O
-	O
up	O
.	O
	
In	O
group	O
2	O
,	O
18	O
of	O
42	O
patients	O
(	O
43	O
%	O
)	O
experienced	O
visual	O
improvement	O
of	O
>	O
or	O
=	O
1	O
lines	O
on	O
an	O
ETDRS	B-Classification_system
chart	O
at	O
1	O
and	O
3	O
months	O
of	O
follow	O
-	O
up	O
.	O
	
For	O
the	O
remaining	O
patients	O
,	O
VA	B-Characteristic
remained	O
unchanged	O
during	O
the	O
postoperative	O
course	O
of	O
3	O
months	O
.	O
	
Patients	O
in	O
whom	O
OCT	B-Diagnostic_tool
demonstrated	O
the	O
high	B-Characteristic
reflectivity	I-Characteristic
of	O
inner	B-Anatomy
retinal	I-Anatomy
layers	I-Anatomy
achieved	O
greater	O
VA	B-Characteristic
though	O
macular	B-Characteristic
thickness	I-Characteristic
decreased	O
significantly	O
after	O
intravitreal	O
triamcinolone	O
in	O
both	O
groups	O
.	O
	
It	O
may	O
be	O
hypothesized	O
that	O
a	O
lower	O
optical	B-Characteristic
reflectivity	I-Characteristic
of	I-Characteristic
inner	I-Characteristic
retinal	I-Characteristic
layers	I-Characteristic
is	O
related	O
to	O
the	O
atrophy	B-Symptom
of	I-Symptom
the	I-Symptom
inner	I-Symptom
retinal	I-Symptom
layers	I-Symptom
,	O
thus	O
resulting	O
in	O
a	O
failure	O
of	O
VA	B-Characteristic
recovery	O
in	O
these	O
patients	O
.	O
	
The	O
level	O
of	O
reflectivity	O
from	O
inner	B-Anatomy
retinal	I-Anatomy
layers	I-Anatomy
on	O
OCT	B-Diagnostic_tool
may	O
provide	O
objective	O
criteria	O
in	O
predicting	O
the	O
response	O
of	O
DME	B-Disease
to	O
intravitreal	O
triamcinolone	O
and	O
help	O
in	O
preoperative	O
counseling	O
of	O
patients	O
with	O
DME	B-Disease
.	O
	
Angiographic	B-Diagnostic_tool
and	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomographic	I-Diagnostic_tool
results	O
of	O
the	O
MARINA	O
study	O
of	O
ranibizumab	O
in	O
neovascular	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
.	O
	
To	O
assess	O
pharmacodynamic	O
responses	O
to	O
ranibizumab	O
,	O
an	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
A	O
(	O
VEGF	O
-	O
A	O
)	O
,	O
in	O
a	O
study	O
of	O
the	O
treatment	O
of	O
minimally	O
classic	O
or	O
occult	O
with	O
no	O
classic	B-Symptom
choroidal	I-Symptom
neovascularization	I-Symptom
secondary	O
to	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
(	O
designated	O
MARINA	O
[	O
Minimally	O
Classic	O
/	O
Occult	O
Trial	O
of	O
the	O
Anti	O
-	O
VEGF	O
Antibody	O
Ranibizumab	O
in	O
the	O
Treatment	O
of	O
Neovascular	B-Disease
AMD	I-Disease
]	O
)	O
and	O
to	O
compare	O
these	O
responses	O
with	O
those	O
in	O
a	O
sham	O
-	O
injection	O
control	O
group	O
.	O
	
Retrospective	O
(	O
prespecified	O
and	O
ad	O
hoc	O
)	O
analyses	O
of	O
24	O
-	O
month	O
data	O
.	O
	
Seven	O
hundred	O
sixteen	O
patients	O
,	O
randomized	O
to	O
0	O
.	O
3	O
-	O
mg	O
ranibizumab	O
(	O
n	O
=	O
238	O
)	O
,	O
0	O
.	O
5	O
-	O
mg	O
ranibizumab	O
(	O
n	O
=	O
240	O
)	O
,	O
or	O
a	O
sham	O
injection	O
(	O
n	O
=	O
238	O
)	O
.	O
	
Stereoscopic	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photography	I-Diagnostic_tool
and	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
FA	B-Diagnostic_tool
)	O
were	O
done	O
at	O
baseline	O
and	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
was	O
performed	O
at	O
a	O
subset	O
of	O
investigative	O
sites	O
(	O
46	O
patients	O
)	O
at	O
baseline	O
,	O
day	O
7	O
,	O
and	O
months	O
1	O
and	O
12	O
.	O
	
Prespecified	O
secondary	O
end	O
points	O
were	O
mean	O
change	O
from	O
baseline	O
in	O
total	B-Characteristic
area	I-Characteristic
of	I-Characteristic
choroidal	I-Characteristic
neovascularization	I-Characteristic
and	O
total	B-Characteristic
area	I-Characteristic
of	I-Characteristic
leakage	I-Characteristic
from	I-Characteristic
choroidal	I-Characteristic
neovascularization	I-Characteristic
at	O
months	O
12	O
and	O
24	O
.	O
	
Prespecified	O
exploratory	O
FA	B-Diagnostic_tool
end	O
points	O
included	O
mean	B-Characteristic
change	I-Characteristic
from	I-Characteristic
baseline	I-Characteristic
in	I-Characteristic
the	I-Characteristic
areas	I-Characteristic
of	I-Characteristic
the	I-Characteristic
choroidal	I-Characteristic
neovascularization	I-Characteristic
lesion	I-Characteristic
and	O
serous	B-Symptom
sensory	I-Symptom
retinal	I-Symptom
detachment	I-Symptom
(	O
SSRD	B-Symptom
)	O
at	O
months	O
12	O
and	O
24	O
.	O
	
Post	O
hoc	O
exploratory	O
FA	B-Diagnostic_tool
outcome	O
measures	O
included	O
the	O
proportion	O
of	O
patients	O
with	O
no	O
leakage	B-Symptom
from	I-Symptom
choroidal	I-Symptom
neovascularization	I-Symptom
and	O
mean	O
change	O
from	O
baseline	O
over	O
time	O
in	O
the	O
area	O
of	O
subretinal	B-Symptom
fibrous	I-Symptom
tissue	I-Symptom
/	I-Symptom
disciform	I-Symptom
scar	I-Symptom
.	O
	
The	O
prespecified	O
exploratory	O
end	O
point	O
for	O
OCT	B-Diagnostic_tool
was	O
mean	O
change	O
from	O
baseline	O
over	O
time	O
in	O
center	B-Characteristic
point	I-Characteristic
thickness	I-Characteristic
.	O
	
At	O
12	O
and	O
24	O
months	O
,	O
statistically	O
significant	O
benefits	O
of	O
ranibizumab	O
over	O
sham	O
treatment	O
were	O
observed	O
for	O
mean	O
change	O
from	O
baseline	O
in	O
the	O
areas	O
of	O
choroidal	B-Symptom
neovascularization	I-Symptom
lesion	I-Symptom
,	O
total	B-Characteristic
choroidal	I-Characteristic
neovascularization	I-Characteristic
,	O
leakage	B-Symptom
from	I-Symptom
choroidal	I-Symptom
neovascularization	I-Symptom
,	O
SSRD	B-Symptom
,	O
and	O
disciform	B-Symptom
scar	I-Symptom
/	I-Symptom
subretinal	I-Symptom
fibrosis	I-Symptom
.	O
	
At	O
12	O
months	O
(	O
final	O
OCT	B-Diagnostic_tool
)	O
,	O
the	O
mean	B-Characteristic
change	I-Characteristic
in	I-Characteristic
foveal	I-Characteristic
center	I-Characteristic
point	I-Characteristic
thickness	I-Characteristic
on	O
OCT	B-Diagnostic_tool
was	O
a	O
significant	O
decrease	O
in	O
the	O
ranibizumab	O
group	O
compared	O
with	O
the	O
sham	O
group	O
.	O
	
Patients	O
with	O
minimally	O
classic	O
or	O
occult	O
with	O
no	O
classic	B-Disease
neovascular	I-Disease
AMD	I-Disease
treated	O
with	O
ranibizumab	O
demonstrated	O
improvement	O
that	O
was	O
consistent	O
for	O
visual	B-Diagnostic_tool
acuity	I-Diagnostic_tool
,	O
FA	B-Diagnostic_tool
,	O
and	O
OCT	B-Diagnostic_tool
outcomes	O
and	O
superior	O
to	O
that	O
in	O
sham	O
-	O
treated	O
patients	O
.	O
	
The	O
natural	O
history	O
and	O
prognosis	O
of	O
neovascular	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
:	O
a	O
systematic	O
review	O
of	O
the	O
literature	O
and	O
meta	O
-	O
analysis	O
.	O
	
To	O
describe	O
the	O
natural	O
history	O
and	O
progression	O
of	O
visual	B-Symptom
loss	I-Symptom
in	O
eyes	B-Anatomy
with	O
untreated	O
neovascular	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O
	
Four	O
thousand	O
three	O
hundred	O
sixty	O
-	O
two	O
untreated	O
neovascular	B-Disease
AMD	I-Disease
patients	O
from	O
published	O
interventional	O
studies	O
.	O
	
A	O
systematic	O
review	O
of	O
the	O
literature	O
from	O
1980	O
to	O
August	O
2005	O
was	O
performed	O
.	O
	
Studies	O
reporting	O
disease	O
progression	O
outcomes	O
for	O
untreated	O
patients	O
with	O
neovascular	B-Disease
AMD	I-Disease
were	O
included	O
.	O
	
Outcome	O
measures	O
were	O
summarized	O
using	O
simple	O
counts	O
and	O
means	O
.	O
	
Random	O
effects	O
meta	O
-	O
analyses	O
were	O
conducted	O
and	O
tests	O
of	O
heterogeneity	O
were	O
performed	O
where	O
appropriate	O
.	O
	
Changes	O
in	O
visual	B-Symptom
acuity	I-Symptom
(	I-Symptom
VA	I-Symptom
)	I-Symptom
loss	I-Symptom
,	O
development	O
of	O
comorbidities	O
,	O
and	O
fellow	B-Characteristic
eye	I-Characteristic
involvement	I-Characteristic
.	O
	
Fifty	O
-	O
three	O
primary	O
studies	O
were	O
included	O
.	O
	
Nearly	O
half	O
of	O
the	O
studies	O
(	O
28	O
)	O
were	O
randomized	O
clinical	O
trials	O
.	O
	
The	O
quality	O
of	O
the	O
studies	O
was	O
high	O
,	O
with	O
over	O
80	O
%	O
providing	O
level	O
I	O
or	O
II	O
evidence	O
.	O
	
Mean	O
baseline	O
VA	B-Characteristic
among	O
study	O
patients	O
was	O
0	O
.	O
64	O
logarithm	B-Characteristic
of	I-Characteristic
the	I-Characteristic
minimum	I-Characteristic
angle	I-Characteristic
of	I-Characteristic
resolution	I-Characteristic
(	O
logMAR	B-Characteristic
)	O
(	O
approximately	O
20	O
/	O
87	O
Snellen	B-Characteristic
)	O
.	O
	
The	O
mean	O
VA	B-Characteristic
change	O
in	O
logMAR	B-Characteristic
progressed	O
from	O
0	O
.	O
1	O
(	O
1	O
line	O
lost	O
)	O
at	O
3	O
months	O
to	O
0	O
.	O
3	O
(	O
2	O
.	O
7	O
lines	O
lost	O
)	O
after	O
12	O
months	O
and	O
0	O
.	O
4	O
(	O
4	O
lines	O
lost	O
)	O
after	O
24	O
months	O
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
developed	O
severe	B-Symptom
vision	I-Symptom
loss	I-Symptom
(	O
>	O
6	O
lines	O
)	O
from	O
baseline	O
increased	O
from	O
21	O
.	O
3	O
%	O
at	O
6	O
months	O
to	O
41	O
.	O
9	O
%	O
by	O
3	O
years	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
VA	B-Symptom
worse	I-Symptom
than	I-Symptom
logMAR	I-Symptom
1	I-Symptom
.	I-Symptom
0	I-Symptom
(	I-Symptom
20	I-Symptom
/	I-Symptom
200	I-Symptom
Snellen	I-Symptom
)	I-Symptom
increased	O
from	O
19	O
.	O
7	O
%	O
at	O
baseline	O
to	O
75	O
.	O
7	O
%	O
by	O
3	O
years	O
.	O
	
Neovascular	B-Disease
AMD	I-Disease
developed	O
in	O
the	O
fellow	O
eye	B-Anatomy
in	O
12	O
.	O
2	O
%	O
of	O
patients	O
by	O
12	O
months	O
and	O
in	O
26	O
.	O
8	O
%	O
by	O
4	O
years	O
.	O
	
Meta	O
-	O
analyses	O
of	O
vision	O
outcome	O
by	O
subtype	O
of	O
neovascular	B-Disease
AMD	I-Disease
were	O
not	O
possible	O
.	O
	
A	O
doubling	B-Symptom
of	I-Symptom
the	I-Symptom
visual	I-Symptom
angle	I-Symptom
of	I-Symptom
presenting	I-Symptom
VA	I-Symptom
may	O
be	O
expected	O
to	O
occur	O
in	O
the	O
year	O
after	O
initial	O
presentation	O
in	O
eyes	B-Anatomy
with	O
untreated	O
neovascular	B-Disease
AMD	I-Disease
.	O
	
No	O
conclusions	O
can	O
be	O
drawn	O
as	O
to	O
the	O
differences	O
in	O
rates	O
of	O
disease	O
progression	O
by	O
neovascular	B-Disease
AMD	I-Disease
subtype	O
.	O
	
The	O
diversity	O
of	O
reporting	O
formats	O
,	O
paucity	O
of	O
long	O
-	O
term	O
natural	O
history	O
data	O
,	O
and	O
heterogeneity	O
among	O
the	O
reported	O
clinical	O
studies	O
impose	O
limits	O
to	O
the	O
clear	O
understanding	O
of	O
long	O
-	O
term	O
prognosis	O
for	O
visual	B-Characteristic
function	I-Characteristic
in	O
neovascular	B-Disease
AMD	I-Disease
.	O
	
Three	B-Diagnostic_tool
-	I-Diagnostic_tool
dimensional	I-Diagnostic_tool
imaging	I-Diagnostic_tool
of	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
in	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
.	O
	
To	O
study	O
the	O
pathomorphologic	O
features	O
of	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
(	O
CME	B-Disease
)	O
associated	O
with	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
by	O
three	B-Diagnostic_tool
-	I-Diagnostic_tool
dimensional	I-Diagnostic_tool
(	I-Diagnostic_tool
3D	I-Diagnostic_tool
)	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
and	O
to	O
study	O
the	O
relationship	O
of	O
the	O
ocular	O
findings	O
to	O
visual	B-Characteristic
function	I-Characteristic
.	O
	
Observational	O
case	O
series	O
.	O
	
Twenty	O
eyes	O
of	O
20	O
patients	O
with	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
.	O
	
A	O
prototype	O
3D	B-Diagnostic_tool
OCT	I-Diagnostic_tool
system	O
based	O
on	O
Fourier	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
OCT	I-Diagnostic_tool
technology	O
was	O
fabricated	O
for	O
patient	O
examination	O
in	O
this	O
study	O
.	O
	
This	O
system	O
uses	O
a	O
superluminescent	O
diode	O
,	O
which	O
has	O
a	O
center	O
wavelength	O
of	O
830	O
nm	O
and	O
a	O
bandwidth	O
of	O
50	O
nm	O
,	O
as	O
the	O
light	O
source	O
,	O
resulting	O
in	O
4	O
.	O
3	O
-	O
microm	O
axial	O
resolution	O
in	O
tissue	O
.	O
	
Data	O
acquisition	O
rates	O
of	O
approximately	O
18	O
700	O
axial	O
scans	O
per	O
second	O
and	O
a	O
sensitivity	O
of	O
98	O
dB	O
were	O
achieved	O
.	O
	
Three	B-Diagnostic_tool
-	I-Diagnostic_tool
dimensional	I-Diagnostic_tool
imaging	I-Diagnostic_tool
was	O
performed	O
by	O
volume	O
rendering	O
based	O
on	O
the	O
3D	O
data	O
set	O
acquired	O
with	O
a	O
raster	O
scan	O
of	O
256x256	O
axial	O
scans	O
.	O
	
Images	O
of	O
CME	B-Disease
pathologic	O
features	O
obtained	O
by	O
3D	B-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
by	O
Stratus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
Carl	O
Zeiss	O
,	O
Dublin	O
,	O
CA	O
)	O
.	O
	
The	O
3D	B-Diagnostic_tool
OCT	I-Diagnostic_tool
imaging	I-Diagnostic_tool
system	O
generates	O
a	O
realistic	O
3D	O
image	O
of	O
CME	B-Disease
with	O
high	O
resolution	O
.	O
	
In	O
16	O
eyes	B-Anatomy
,	O
3D	B-Diagnostic_tool
OCT	I-Diagnostic_tool
showed	O
large	B-Symptom
foveal	I-Symptom
cystoid	I-Symptom
spaces	I-Symptom
,	O
most	O
of	O
which	O
were	O
accompanied	O
by	O
small	B-Symptom
cystoid	I-Symptom
spaces	I-Symptom
in	I-Symptom
the	I-Symptom
parafoveal	I-Symptom
region	I-Symptom
.	O
	
Cystoid	B-Symptom
spaces	I-Symptom
were	O
seen	O
often	O
in	O
the	O
inner	B-Anatomy
nuclear	I-Anatomy
layer	I-Anatomy
and	O
outer	B-Anatomy
plexiform	I-Anatomy
layer	I-Anatomy
,	O
but	O
were	O
detected	O
to	O
some	O
extent	O
in	O
all	O
retinal	B-Anatomy
layers	I-Anatomy
.	O
	
The	O
3D	B-Diagnostic_tool
OCT	I-Diagnostic_tool
showed	O
clearly	O
a	O
thin	O
back	O
-	O
reflecting	O
line	O
corresponding	O
to	O
the	O
external	B-Anatomy
limiting	I-Anatomy
membrane	I-Anatomy
(	O
ELM	B-Anatomy
)	O
in	O
18	O
eyes	B-Anatomy
;	O
of	O
these	O
,	O
cystoid	B-Symptom
spaces	I-Symptom
were	O
located	O
on	O
the	O
inside	O
of	O
the	O
ELM	B-Anatomy
in	O
7	O
eyes	B-Anatomy
and	O
appeared	O
to	O
be	O
in	O
contact	O
with	O
the	O
ELM	B-Anatomy
in	O
9	O
eyes	B-Anatomy
.	O
	
In	O
2	O
eyes	B-Anatomy
,	O
the	O
ELM	B-Anatomy
line	O
could	O
not	O
be	O
seen	O
clearly	O
beneath	O
the	O
large	B-Symptom
foveal	I-Symptom
cystoid	I-Symptom
spaces	I-Symptom
.	O
	
Integrity	O
of	O
the	O
ELM	B-Anatomy
in	O
the	O
foveal	B-Anatomy
region	I-Anatomy
had	O
a	O
direct	O
correlation	O
with	O
visual	B-Characteristic
acuity	I-Characteristic
.	O
	
Observation	O
of	O
CME	B-Disease
using	O
3D	B-Diagnostic_tool
OCT	I-Diagnostic_tool
enabled	O
visualization	O
of	O
its	O
spatial	O
extent	O
in	O
each	O
retinal	B-Anatomy
layer	I-Anatomy
and	O
discernment	O
of	O
its	O
relationship	O
to	O
the	O
ELM	B-Anatomy
.	O
	
The	O
use	O
of	O
3D	B-Diagnostic_tool
OCT	I-Diagnostic_tool
thus	O
may	O
improve	O
the	O
monitoring	O
of	O
CME	B-Disease
progression	O
and	O
its	O
response	O
to	O
treatment	O
.	O
	
Prevalence	O
of	O
plateau	B-Disease
iris	I-Disease
in	O
primary	B-Disease
angle	I-Disease
closure	I-Disease
suspects	I-Disease
an	O
ultrasound	B-Diagnostic_tool
biomicroscopy	I-Diagnostic_tool
study	O
.	O
	
To	O
determine	O
the	O
prevalence	O
of	O
plateau	B-Disease
iris	I-Disease
in	O
a	O
cohort	O
of	O
primary	B-Disease
angle	I-Disease
closure	I-Disease
suspects	I-Disease
(	O
PACSs	B-Disease
)	O
using	O
ultrasound	B-Diagnostic_tool
biomicroscopy	I-Diagnostic_tool
(	O
UBM	B-Diagnostic_tool
)	O
.	O
	
Cross	O
-	O
sectional	O
observational	O
study	O
.	O
	
Subjects	O
over	B-Characteristic
the	I-Characteristic
age	I-Characteristic
of	I-Characteristic
50	I-Characteristic
years	I-Characteristic
diagnosed	O
as	O
PACSs	B-Disease
.	O
	
Subjects	O
were	O
randomized	O
to	O
undergo	O
laser	O
peripheral	O
iridotomy	O
(	O
LPI	O
)	O
in	O
one	O
eye	B-Anatomy
.	O
	
Ultrasound	B-Diagnostic_tool
biomicroscopy	I-Diagnostic_tool
was	O
performed	O
before	O
and	O
a	O
week	O
after	O
LPI	O
.	O
	
Ultrasound	B-Diagnostic_tool
biomicroscopy	I-Diagnostic_tool
images	I-Diagnostic_tool
were	O
qualitatively	O
assessed	O
using	O
standardized	O
criteria	O
.	O
	
Plateau	B-Disease
iris	I-Disease
was	O
defined	O
in	O
a	O
quadrant	O
by	O
the	O
presence	O
of	O
an	O
anteriorly	B-Symptom
directed	I-Symptom
ciliary	I-Symptom
body	I-Symptom
,	O
an	O
absent	B-Symptom
ciliary	I-Symptom
sulcus	I-Symptom
,	O
a	O
steep	B-Symptom
iris	I-Symptom
root	I-Symptom
from	I-Symptom
its	I-Symptom
point	I-Symptom
of	I-Symptom
insertion	I-Symptom
followed	I-Symptom
by	I-Symptom
a	I-Symptom
downward	I-Symptom
angulation	I-Symptom
from	I-Symptom
the	I-Symptom
corneoscleral	I-Symptom
wall	I-Symptom
,	O
presence	O
of	O
a	O
central	B-Symptom
flat	I-Symptom
iris	I-Symptom
plane	I-Symptom
,	O
and	O
irido	B-Symptom
-	I-Symptom
angle	I-Symptom
contact	I-Symptom
.	O
	
At	O
least	O
2	O
quadrants	O
had	O
to	O
fulfil	O
the	O
above	O
criteria	O
for	O
an	O
eye	B-Anatomy
to	O
be	O
defined	O
as	O
plateau	B-Disease
iris	I-Disease
.	O
	
Two	O
hundred	O
five	O
subjects	O
were	O
enrolled	O
;	O
UBM	B-Diagnostic_tool
images	I-Diagnostic_tool
of	O
167	O
subjects	O
were	O
available	O
for	O
analysis	O
.	O
	
Plateau	B-Disease
iris	I-Disease
was	O
found	O
in	O
54	O
of	O
167	O
(	O
32	O
.	O
3	O
%	O
)	O
PACS	B-Disease
eyes	B-Anatomy
after	O
LPI	O
.	O
	
Quadrantwise	O
analysis	O
showed	O
that	O
44	O
of	O
167	O
(	O
26	O
.	O
3	O
%	O
)	O
eyes	B-Anatomy
had	O
plateau	B-Disease
iris	I-Disease
in	O
1	O
quadrant	O
,	O
36	O
(	O
21	O
.	O
5	O
%	O
)	O
in	O
2	O
quadrants	O
,	O
16	O
(	O
9	O
.	O
5	O
%	O
)	O
in	O
3	O
quadrants	O
,	O
and	O
2	O
(	O
1	O
.	O
2	O
%	O
)	O
in	O
all	O
4	O
quadrants	O
.	O
	
Plateau	B-Disease
iris	I-Disease
was	O
most	O
commonly	O
observed	O
in	O
the	O
superior	O
and	O
inferior	O
quadrants	O
.	O
	
Using	O
standardized	O
UBM	B-Diagnostic_tool
criteria	O
,	O
plateau	B-Disease
iris	I-Disease
was	O
found	O
in	O
about	O
a	O
third	O
of	O
PACS	B-Disease
eyes	B-Anatomy
after	O
LPI	O
.	O
	
Prospective	O
longitudinal	O
studies	O
are	O
required	O
to	O
determine	O
the	O
clinical	O
significance	O
of	O
this	O
finding	O
for	O
the	O
management	O
of	O
PACSs	B-Disease
.	O
	
Reproducibility	O
of	O
pattern	B-Diagnostic_tool
electroretinogram	I-Diagnostic_tool
in	O
glaucoma	B-Disease
patients	O
with	O
a	O
range	O
of	O
severity	O
of	O
disease	O
with	O
the	O
new	O
glaucoma	B-Disease
paradigm	O
.	O
	
To	O
determine	O
the	O
reproducibility	O
of	O
the	O
pattern	B-Diagnostic_tool
electroretinogram	I-Diagnostic_tool
with	O
the	O
new	O
Pattern	B-Diagnostic_tool
Electroretinogram	I-Diagnostic_tool
for	I-Diagnostic_tool
Glaucoma	I-Diagnostic_tool
(	O
PERGLA	B-Diagnostic_tool
)	O
recording	O
paradigm	O
in	O
glaucoma	B-Disease
patients	O
with	O
a	O
range	O
of	O
severity	O
.	O
	
Experimental	O
study	O
.	O
	
Fifty	O
-	O
three	O
glaucoma	B-Disease
patients	O
were	O
recruited	O
for	O
the	O
study	O
(	O
mean	B-Characteristic
age	I-Characteristic
+	O
/	O
-	O
standard	O
deviation	O
[	O
SD	O
]	O
,	O
69	O
+	O
/	O
-	O
11	O
years	O
)	O
.	O
	
Their	O
mean	B-Characteristic
deviation	I-Characteristic
(	I-Characteristic
MD	I-Characteristic
)	I-Characteristic
global	I-Characteristic
indices	I-Characteristic
on	I-Characteristic
static	I-Characteristic
automatic	I-Characteristic
perimetry	I-Characteristic
ranged	O
from	O
2	O
.	O
16	O
to	O
-	O
31	O
.	O
36	O
decibels	O
(	O
mean	O
MD	O
,	O
-	O
9	O
.	O
05	O
)	O
.	O
	
All	O
patients	O
had	O
pattern	B-Diagnostic_tool
electroretinogram	I-Diagnostic_tool
recordings	I-Diagnostic_tool
done	O
5	O
times	O
by	O
the	O
same	O
operator	O
,	O
on	O
5	O
different	O
days	O
with	O
the	O
standardized	B-Diagnostic_tool
PERGLA	I-Diagnostic_tool
paradigm	O
.	O
	
Pattern	B-Characteristic
electroretinogram	I-Characteristic
amplitude	I-Characteristic
(	I-Characteristic
microvolts	I-Characteristic
)	I-Characteristic
,	O
phase	B-Characteristic
(	I-Characteristic
pi	I-Characteristic
radians	I-Characteristic
)	I-Characteristic
,	O
response	B-Characteristic
variability	I-Characteristic
(	I-Characteristic
coefficient	I-Characteristic
of	I-Characteristic
variation	I-Characteristic
[	I-Characteristic
CV	I-Characteristic
]	I-Characteristic
=	I-Characteristic
SD	I-Characteristic
/	I-Characteristic
mean	I-Characteristic
x	I-Characteristic
100	I-Characteristic
)	I-Characteristic
of	I-Characteristic
amplitude	I-Characteristic
and	I-Characteristic
phase	I-Characteristic
of	I-Characteristic
2	I-Characteristic
partial	I-Characteristic
averages	I-Characteristic
that	I-Characteristic
build	I-Characteristic
up	I-Characteristic
the	I-Characteristic
pattern	I-Characteristic
electroretinogram	I-Characteristic
waveform	I-Characteristic
,	O
interocular	B-Characteristic
asymmetry	I-Characteristic
in	I-Characteristic
amplitude	I-Characteristic
and	I-Characteristic
phase	I-Characteristic
(	I-Characteristic
in	I-Characteristic
terms	I-Characteristic
of	I-Characteristic
the	I-Characteristic
CV	I-Characteristic
generated	I-Characteristic
by	I-Characteristic
the	I-Characteristic
pattern	I-Characteristic
electroretinogram	I-Characteristic
software	I-Characteristic
)	I-Characteristic
,	O
signal	B-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
noise	I-Characteristic
(	I-Characteristic
S	I-Characteristic
/	I-Characteristic
N	I-Characteristic
)	I-Characteristic
ratio	I-Characteristic
,	O
SDs	O
,	O
CV	O
,	O
and	O
intraclass	B-Characteristic
correlation	I-Characteristic
coefficient	I-Characteristic
(	O
ICC	B-Characteristic
)	O
.	O
	
All	O
analyses	O
were	O
done	O
on	O
one	O
eye	B-Anatomy
of	O
each	O
subject	O
,	O
except	O
when	O
interocular	B-Characteristic
asymmetry	I-Characteristic
was	O
studied	O
.	O
	
The	O
CVs	O
of	O
intrasession	O
variabilities	O
in	O
amplitude	O
and	O
phase	O
were	O
12	O
.	O
08	O
%	O
and	O
2	O
.	O
20	O
%	O
,	O
respectively	O
,	O
and	O
those	O
of	O
intersession	O
variabilities	O
were	O
20	O
.	O
82	O
%	O
and	O
4	O
.	O
17	O
%	O
.	O
	
The	O
pattern	B-Diagnostic_tool
electroretinogram	I-Diagnostic_tool
produced	O
intersession	O
ICCs	B-Characteristic
in	O
amplitude	O
and	O
phase	O
of	O
0	O
.	O
791	O
and	O
0	O
.	O
765	O
,	O
respectively	O
.	O
	
These	O
ICCs	B-Characteristic
were	O
significantly	O
higher	O
than	O
the	O
ICCs	B-Characteristic
for	I-Characteristic
pattern	I-Characteristic
electroretinogram	I-Characteristic
interocular	I-Characteristic
asymmetry	I-Characteristic
in	I-Characteristic
amplitude	I-Characteristic
and	I-Characteristic
phase	I-Characteristic
(	O
0	O
.	O
659	O
[	O
P	O
<	O
0	O
.	O
05	O
]	O
and	O
0	O
.	O
571	O
[	O
P	O
<	O
0	O
.	O
05	O
]	O
,	O
respectively	O
)	O
.	O
	
On	O
average	O
,	O
the	O
pattern	B-Characteristic
electroretinogram	I-Characteristic
S	I-Characteristic
/	I-Characteristic
N	I-Characteristic
ratio	I-Characteristic
in	O
glaucomatous	B-Disease
patients	O
was	O
about	O
5	O
:	O
1	O
.	O
	
The	O
reproducibility	O
of	O
PERGLA	B-Diagnostic_tool
in	O
glaucomatous	B-Disease
patients	O
is	O
sufficiently	O
good	O
for	O
it	O
to	O
be	O
considered	O
a	O
useful	O
complementary	O
clinical	O
tool	O
.	O
	
Being	O
more	O
reproducible	O
,	O
direct	O
measures	O
of	O
amplitude	O
and	O
phase	O
should	O
be	O
more	O
useful	O
in	O
monitoring	O
progression	O
than	O
interocular	B-Characteristic
asymmetry	I-Characteristic
comparisons	O
.	O
	
The	O
relationship	O
of	O
macular	B-Characteristic
thickness	I-Characteristic
to	O
clinically	O
graded	O
diabetic	B-Disease
retinopathy	I-Disease
severity	O
in	O
eyes	B-Anatomy
without	O
clinically	O
detected	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
To	O
examine	O
the	O
relationship	O
of	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
measured	O
macular	B-Characteristic
thickness	I-Characteristic
to	O
retinopathy	B-Disease
severity	O
in	O
patients	O
with	O
diabetes	B-Disease
and	O
no	O
clinically	O
detectable	O
macular	B-Disease
edema	I-Disease
.	O
	
Retrospective	O
observational	O
case	O
series	O
.	O
	
Three	O
hundred	O
eighty	O
-	O
three	O
eyes	B-Anatomy
of	O
383	O
patients	O
of	O
a	O
private	O
retina	B-Anatomy
practice	O
;	O
including	O
100	O
normal	O
eyes	B-Anatomy
of	O
patients	O
without	O
diabetes	B-Disease
,	O
100	O
eyes	B-Anatomy
of	O
diabetics	B-Disease
without	O
retinopathy	B-Disease
,	O
100	O
eyes	B-Anatomy
of	O
diabetics	B-Disease
with	O
mild	B-Disease
to	I-Disease
moderate	I-Disease
retinopathy	I-Disease
,	O
35	O
eyes	B-Anatomy
of	O
diabetics	B-Disease
with	O
severe	B-Disease
nonproliferative	I-Disease
or	I-Disease
proliferative	I-Disease
retinopathy	I-Disease
,	O
and	O
48	O
eyes	B-Anatomy
of	O
diabetics	B-Disease
with	O
regressed	B-Disease
proliferative	I-Disease
retinopathy	I-Disease
.	O
	
Review	O
of	O
clinical	O
charts	O
and	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
measurements	O
.	O
	
Central	B-Characteristic
subfield	I-Characteristic
mean	I-Characteristic
thickness	I-Characteristic
(	O
CSMT	B-Characteristic
)	O
,	O
inner	B-Characteristic
and	I-Characteristic
outer	I-Characteristic
zone	I-Characteristic
measurements	I-Characteristic
,	O
and	O
total	B-Characteristic
macular	I-Characteristic
volume	I-Characteristic
.	O
	
Central	B-Characteristic
subfield	I-Characteristic
mean	I-Characteristic
thicknesses	I-Characteristic
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
)	O
were	O
208	O
+	O
/	O
-	O
22	O
,	O
198	O
+	O
/	O
-	O
25	O
,	O
204	O
+	O
/	O
-	O
26	O
,	O
224	O
+	O
/	O
-	O
38	O
,	O
and	O
205	O
+	O
/	O
-	O
27	O
microm	O
for	O
normals	O
,	O
eyes	B-Anatomy
of	O
diabetics	B-Disease
without	O
retinopathy	B-Disease
,	O
eyes	B-Anatomy
with	O
mild	B-Disease
to	I-Disease
moderate	I-Disease
nonproliferative	I-Disease
retinopathy	I-Disease
,	O
eyes	B-Anatomy
with	O
severe	B-Disease
nonproliferative	I-Disease
to	I-Disease
proliferative	I-Disease
retinopathy	I-Disease
,	O
and	O
eyes	B-Anatomy
with	O
regressed	B-Disease
proliferative	I-Disease
retinopathy	I-Disease
,	O
respectively	O
.	O
	
For	O
all	O
groups	O
,	O
mean	O
CSMT	B-Characteristic
was	O
larger	O
in	O
males	O
than	O
in	O
females	O
.	O
	
Statistically	O
significant	O
differences	O
by	O
gender	B-Characteristic
were	O
observed	O
for	O
normals	O
,	O
diabetics	B-Disease
without	O
retinopathy	B-Disease
,	O
and	O
diabetics	B-Disease
with	O
mild	B-Disease
to	I-Disease
moderate	I-Disease
nonproliferative	I-Disease
retinopathy	I-Disease
(	O
mean	O
differences	O
,	O
12	O
,	O
14	O
,	O
and	O
18	O
microm	O
,	O
respectively	O
;	O
Ps	O
=	O
0	O
.	O
0057	O
,	O
0	O
.	O
0057	O
,	O
and	O
0	O
.	O
0002	O
)	O
.	O
	
For	O
increasing	O
retinopathy	B-Disease
severity	O
,	O
the	O
probability	O
of	O
macular	B-Symptom
thickening	I-Symptom
detected	O
by	O
OCT	B-Diagnostic_tool
but	O
not	O
detected	O
by	O
clinical	O
examination	O
increased	O
.	O
	
Fifteen	O
percent	O
of	O
eyes	B-Anatomy
with	O
severe	B-Disease
nonproliferative	I-Disease
or	I-Disease
proliferative	I-Disease
retinopathy	I-Disease
and	O
no	O
clinically	O
detected	O
edema	B-Disease
had	O
OCT	B-Diagnostic_tool
-	O
measured	O
macular	B-Symptom
thickening	I-Symptom
.	O
	
Because	O
OCT	B-Diagnostic_tool
measurements	O
are	O
gender	O
dependent	O
,	O
gender	O
balance	O
or	O
statistical	O
adjustment	O
for	O
gender	O
imbalances	O
of	O
compared	O
groups	O
in	O
OCT	B-Diagnostic_tool
studies	O
of	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
is	O
important	O
.	O
	
As	O
retinopathy	B-Disease
severity	O
increases	O
,	O
the	O
probability	O
of	O
subclinical	B-Disease
edema	I-Disease
rises	O
.	O
	
Except	O
for	O
an	O
individual	O
baseline	O
measurement	O
possibly	O
useful	O
for	O
longitudinal	O
comparison	O
,	O
the	O
data	O
suggest	O
that	O
there	O
is	O
little	O
reason	O
routinely	O
to	O
obtain	O
OCT	B-Diagnostic_tool
in	O
eyes	B-Anatomy
with	O
diabetes	B-Disease
and	O
no	O
retinopathy	B-Disease
or	O
mild	B-Disease
to	I-Disease
moderate	I-Disease
diabetic	I-Disease
retinopathy	I-Disease
when	O
clinical	O
examination	O
fails	O
to	O
show	O
macular	B-Disease
edema	I-Disease
.	O
	
Characteristics	O
of	O
disc	B-Symptom
hemorrhage	I-Symptom
in	O
primary	B-Disease
angle	I-Disease
-	I-Disease
closure	I-Disease
glaucoma	I-Disease
.	O
	
To	O
analyze	O
the	O
characteristics	O
of	O
disc	B-Symptom
hemorrhage	I-Symptom
in	O
primary	B-Disease
angle	I-Disease
-	I-Disease
closure	I-Disease
glaucoma	I-Disease
(	O
PACG	B-Disease
)	O
.	O
	
Retrospective	O
noncomparative	O
case	O
series	O
.	O
	
Patients	O
seen	O
in	O
glaucoma	B-Disease
clinics	O
with	O
PACG	B-Disease
and	O
a	O
history	O
of	O
disc	B-Symptom
hemorrhage	I-Symptom
.	O
	
Goldmann	B-Diagnostic_tool
tonometry	I-Diagnostic_tool
,	O
gonioscopy	B-Diagnostic_tool
,	O
ophthalmoscopy	B-Diagnostic_tool
,	O
and	O
automated	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
.	O
	
Location	B-Characteristic
,	I-Characteristic
number	I-Characteristic
of	I-Characteristic
episodes	I-Characteristic
,	I-Characteristic
and	I-Characteristic
duration	I-Characteristic
of	I-Characteristic
disc	I-Characteristic
hemorrhage	I-Characteristic
;	O
comparison	O
of	O
intraocular	B-Characteristic
pressure	I-Characteristic
(	O
IOP	B-Characteristic
)	O
and	O
cup	B-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
disc	I-Characteristic
ratio	I-Characteristic
(	O
CDR	B-Characteristic
)	O
in	O
eyes	B-Anatomy
with	O
and	O
fellow	O
eyes	B-Anatomy
without	O
hemorrhage	B-Symptom
;	O
and	O
changes	O
of	O
CDR	B-Characteristic
and	O
visual	B-Characteristic
fields	I-Characteristic
(	O
VFs	B-Characteristic
)	O
on	O
follow	O
-	O
up	O
.	O
	
The	O
mean	O
duration	O
of	O
follow	O
-	O
up	O
was	O
109	O
.	O
2	O
+	O
/	O
-	O
63	O
months	O
(	O
range	O
,	O
7	O
-	O
261	O
)	O
.	O
	
Of	O
770	O
patients	O
with	O
PACG	B-Disease
,	O
44	O
(	O
5	O
.	O
7	O
%	O
)	O
had	O
disc	B-Symptom
hemorrhage	I-Symptom
at	O
some	O
point	O
in	O
their	O
history	O
,	O
of	O
whom	O
30	O
(	O
68	O
%	O
)	O
had	O
unilateral	O
and	O
14	O
(	O
32	O
%	O
)	O
had	O
bilateral	B-Symptom
hemorrhages	I-Symptom
,	O
either	O
alternately	O
or	O
simultaneously	O
in	O
both	O
eyes	B-Anatomy
.	O
	
There	O
were	O
a	O
total	O
of	O
111	O
hemorrhages	B-Symptom
in	O
58	O
eyes	B-Anatomy
,	O
including	O
23	O
eyes	B-Anatomy
(	O
40	O
%	O
)	O
with	O
recurrent	B-Symptom
hemorrhages	I-Symptom
.	O
	
Of	O
the	O
111	O
total	O
hemorrhages	B-Symptom
,	O
85	O
(	O
77	O
%	O
)	O
occurred	O
in	O
the	O
inferotemporal	B-Anatomy
and	I-Anatomy
19	I-Anatomy
(	I-Anatomy
17	I-Anatomy
%	I-Anatomy
)	I-Anatomy
in	I-Anatomy
the	I-Anatomy
superotemporal	I-Anatomy
sector	I-Anatomy
of	I-Anatomy
the	I-Anatomy
disc	I-Anatomy
.	O
	
Among	O
23	O
eyes	B-Anatomy
with	O
recurrent	B-Symptom
disc	I-Symptom
hemorrhages	I-Symptom
,	O
11	O
(	O
48	O
%	O
)	O
had	O
recurrence	O
in	O
the	O
same	O
sector	O
of	O
the	O
disc	B-Anatomy
.	O
	
The	O
average	O
duration	O
of	O
hemorrhages	B-Symptom
was	O
12	O
.	O
8	O
+	O
/	O
-	O
8	O
.	O
1	O
weeks	O
.	O
	
The	O
IOP	B-Characteristic
and	O
CDR	B-Characteristic
did	O
not	O
differ	O
significantly	O
between	O
eyes	B-Anatomy
with	O
and	O
fellow	O
eyes	B-Anatomy
without	O
hemorrhage	B-Symptom
.	O
	
For	O
patients	O
with	O
unilateral	B-Symptom
disc	I-Symptom
hemorrhage	I-Symptom
,	O
progressive	O
changes	O
in	O
the	O
CDR	B-Characteristic
were	O
found	O
in	O
both	O
the	O
eyes	B-Anatomy
with	O
and	O
fellow	O
eyes	B-Anatomy
without	O
disc	B-Symptom
hemorrhage	I-Symptom
,	O
but	O
VF	B-Symptom
defects	I-Symptom
worsened	O
only	O
in	O
eyes	B-Anatomy
with	O
disc	B-Symptom
hemorrhage	I-Symptom
.	O
	
The	O
incidence	O
of	O
disc	B-Symptom
hemorrhage	I-Symptom
in	O
patients	O
with	O
PACG	B-Disease
was	O
5	O
.	O
7	O
%	O
over	O
9	O
years	O
of	O
follow	O
-	O
up	O
.	O
	
Despite	O
its	O
relative	O
infrequency	O
,	O
disc	B-Symptom
hemorrhage	I-Symptom
in	O
PACG	B-Disease
was	O
associated	O
with	O
progression	B-Symptom
of	I-Symptom
glaucomatous	I-Symptom
optic	I-Symptom
neuropathy	I-Symptom
and	O
VF	B-Symptom
defects	I-Symptom
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
measurements	O
and	O
analysis	O
methods	O
in	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
studies	O
of	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
To	O
evaluate	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
measurements	O
and	O
methods	O
of	O
analysis	O
of	O
OCT	B-Diagnostic_tool
data	O
in	O
studies	O
of	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
.	O
	
Associations	O
of	O
pairs	O
of	O
OCT	B-Characteristic
variables	I-Characteristic
and	O
results	O
of	O
3	O
analysis	O
methods	O
using	O
data	O
from	O
2	O
studies	O
of	O
DME	B-Disease
.	O
	
Two	O
hundred	O
sixty	O
-	O
three	O
subjects	O
from	O
a	O
study	O
of	O
modified	O
Early	O
Treatment	O
of	O
Diabetic	B-Disease
Retinopathy	I-Disease
Study	O
(	O
mETDRS	O
)	O
versus	O
modified	O
macular	B-Anatomy
grid	O
(	O
MMG	O
)	O
photocoagulation	O
for	O
DME	B-Disease
and	O
96	O
subjects	O
from	O
a	O
study	O
of	O
diurnal	O
variation	O
of	O
DME	B-Disease
.	O
	
Correlations	O
were	O
calculated	O
for	O
pairs	O
of	O
OCT	B-Characteristic
variables	I-Characteristic
at	O
baseline	O
and	O
for	O
changes	O
in	O
the	O
variables	O
over	O
time	O
.	O
	
Distribution	O
of	O
OCT	B-Characteristic
measurement	I-Characteristic
changes	I-Characteristic
,	O
predictive	O
factors	O
for	O
OCT	B-Characteristic
measurement	I-Characteristic
changes	I-Characteristic
,	O
and	O
treatment	O
group	O
outcomes	O
were	O
compared	O
when	O
3	O
measures	O
of	O
change	B-Characteristic
in	I-Characteristic
macular	I-Characteristic
thickness	I-Characteristic
were	O
analyzed	O
:	O
absolute	B-Characteristic
change	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
,	O
relative	B-Characteristic
change	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
,	O
and	O
relative	B-Characteristic
change	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
thickening	I-Characteristic
.	O
	
Concordance	O
of	O
results	O
using	O
different	O
OCT	B-Characteristic
variables	I-Characteristic
and	O
analysis	O
methods	O
.	O
	
Center	B-Characteristic
point	I-Characteristic
thickness	I-Characteristic
correlated	O
highly	O
with	O
central	B-Characteristic
subfield	I-Characteristic
mean	I-Characteristic
thickness	I-Characteristic
(	O
CSMT	B-Characteristic
)	O
at	O
baseline	O
(	O
0	O
.	O
98	O
-	O
0	O
.	O
99	O
)	O
.	O
	
The	O
distributions	O
of	O
changes	O
in	O
CSMT	B-Characteristic
were	O
approximately	O
normally	O
distributed	O
for	O
absolute	B-Characteristic
change	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
and	O
relative	B-Characteristic
change	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
,	O
but	O
not	O
for	O
relative	B-Characteristic
change	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
thickening	I-Characteristic
.	O
	
Macular	B-Symptom
thinning	I-Symptom
in	O
the	O
mETDRS	O
group	O
was	O
significantly	O
greater	O
than	O
in	O
the	O
MMG	O
group	O
when	O
absolute	B-Characteristic
change	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
was	O
used	O
,	O
but	O
not	O
when	O
relative	B-Characteristic
change	I-Characteristic
in	I-Characteristic
thickness	I-Characteristic
and	O
relative	B-Characteristic
change	I-Characteristic
in	I-Characteristic
thickening	I-Characteristic
were	O
used	O
.	O
	
Relative	O
change	O
in	O
macular	B-Characteristic
thickening	I-Characteristic
provides	O
unstable	O
data	O
in	O
eyes	B-Anatomy
with	O
mild	O
degrees	O
of	O
baseline	O
thickening	O
,	O
unlike	O
the	O
situation	O
with	O
absolute	B-Characteristic
or	I-Characteristic
relative	I-Characteristic
change	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
.	O
	
Central	B-Characteristic
subfield	I-Characteristic
mean	I-Characteristic
thickness	I-Characteristic
is	O
the	O
preferred	O
OCT	B-Characteristic
measurement	I-Characteristic
for	O
the	O
central	B-Anatomy
macula	I-Anatomy
because	O
of	O
its	O
higher	O
reproducibility	O
and	O
correlation	O
with	O
other	O
measurements	O
of	O
the	O
central	B-Anatomy
macula	I-Anatomy
.	O
	
Total	B-Characteristic
macular	I-Characteristic
volume	I-Characteristic
may	O
be	O
preferred	O
when	O
the	O
central	B-Anatomy
macula	I-Anatomy
is	O
less	O
important	O
.	O
	
Absolute	B-Characteristic
change	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
is	O
the	O
preferred	O
analysis	O
method	O
in	O
studies	O
involving	O
eyes	B-Anatomy
with	O
mild	B-Characteristic
macular	I-Characteristic
thickening	I-Characteristic
.	O
	
Relative	B-Characteristic
change	I-Characteristic
in	I-Characteristic
thickening	I-Characteristic
may	O
be	O
preferable	O
when	O
retinal	B-Characteristic
thickening	I-Characteristic
is	O
more	O
severe	O
.	O
	
Relationship	O
between	O
optical	B-Characteristic
coherence	I-Characteristic
tomography	I-Characteristic
retinal	I-Characteristic
parameters	I-Characteristic
and	O
visual	B-Characteristic
acuity	I-Characteristic
in	O
neovascular	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
.	O
	
To	O
investigate	O
the	O
relationship	O
between	O
optical	B-Characteristic
coherence	I-Characteristic
tomography	I-Characteristic
(	I-Characteristic
OCT	I-Characteristic
)	I-Characteristic
-	I-Characteristic
derived	I-Characteristic
measurements	I-Characteristic
of	I-Characteristic
retinal	I-Characteristic
morphology	I-Characteristic
and	O
visual	B-Characteristic
acuity	I-Characteristic
in	O
patients	O
with	O
neovascular	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Retrospective	O
cross	O
-	O
sectional	O
study	O
.	O
	
A	O
total	O
of	O
216	O
consecutive	O
patients	O
(	O
216	O
eyes	B-Anatomy
)	O
newly	O
diagnosed	O
with	O
neovascular	B-Disease
AMD	I-Disease
who	O
underwent	O
StratusOCT	B-Diagnostic_tool
imaging	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O
	
Best	B-Characteristic
-	I-Characteristic
corrected	I-Characteristic
Snellen	I-Characteristic
visual	I-Characteristic
acuity	I-Characteristic
was	O
recorded	O
for	O
each	O
patient	O
.	O
	
Raw	O
exported	O
StratusOCT	B-Diagnostic_tool
images	I-Diagnostic_tool
for	O
each	O
patient	O
were	O
analyzed	O
using	O
publicly	O
available	O
custom	O
software	O
entitled	O
"	O
OCTOR	B-Diagnostic_tool
,	O
"	O
which	O
allows	O
the	O
precise	O
positioning	O
of	O
prespecified	O
boundaries	O
on	O
individual	O
B	O
-	O
scans	O
.	O
	
Thickness	O
and	O
volume	O
were	O
calculated	O
for	O
morphologic	B-Characteristic
parameters	I-Characteristic
of	O
interest	O
:	O
neurosensory	B-Anatomy
retina	I-Anatomy
,	O
subretinal	B-Symptom
fluid	I-Symptom
,	O
subretinal	B-Anatomy
tissue	I-Anatomy
(	O
SRT	B-Anatomy
)	O
,	O
and	O
pigment	B-Symptom
epithelial	I-Symptom
detachment	I-Symptom
.	O
	
OCT	B-Characteristic
-	I-Characteristic
derived	I-Characteristic
measurements	I-Characteristic
of	I-Characteristic
retinal	I-Characteristic
morphology	I-Characteristic
and	O
visual	B-Characteristic
acuity	I-Characteristic
.	O
	
An	O
increased	B-Symptom
total	I-Symptom
volume	I-Symptom
of	I-Symptom
SRT	I-Symptom
was	O
correlated	O
with	O
decreased	B-Symptom
visual	I-Symptom
acuity	I-Symptom
(	O
r	O
=	O
0	O
.	O
370	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
	
Decreased	B-Symptom
visual	I-Symptom
acuity	I-Symptom
was	O
also	O
modestly	O
correlated	O
with	O
increased	B-Symptom
thickness	I-Symptom
of	I-Symptom
the	I-Symptom
neurosensory	I-Symptom
retina	I-Symptom
at	I-Symptom
the	I-Symptom
foveal	I-Symptom
center	I-Symptom
point	I-Symptom
(	O
r	O
=	O
0	O
.	O
245	O
,	O
P	O
=	O
0	O
.	O
0004	O
)	O
.	O
	
No	O
statistically	O
significant	O
association	O
was	O
detected	O
between	O
visual	B-Characteristic
acuity	I-Characteristic
and	O
the	O
total	B-Characteristic
volume	I-Characteristic
of	I-Characteristic
subretinal	I-Characteristic
fluid	I-Characteristic
or	O
pigment	B-Symptom
epithelial	I-Symptom
detachment	I-Symptom
.	O
	
The	O
association	O
between	O
visual	B-Characteristic
acuity	I-Characteristic
and	O
both	O
the	O
neurosensory	B-Anatomy
retina	I-Anatomy
and	O
the	O
SRT	B-Anatomy
was	O
stronger	O
for	O
lesions	O
classified	O
as	O
minimally	O
classic	O
or	O
occult	O
on	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
.	O
	
For	O
occult	O
lesions	O
,	O
20	O
%	O
of	O
the	O
variation	O
in	O
visual	B-Characteristic
acuity	I-Characteristic
could	O
be	O
predicted	O
by	O
a	O
multiple	O
regression	O
model	O
that	O
incorporated	O
age	B-Characteristic
and	O
SRT	B-Characteristic
volume	I-Characteristic
,	O
whereas	O
,	O
for	O
minimally	O
classic	O
lesions	O
,	O
62	O
%	O
of	O
the	O
variation	O
in	O
visual	B-Characteristic
acuity	I-Characteristic
could	O
be	O
predicted	O
by	O
a	O
multiple	O
regression	O
model	O
that	O
incorporated	O
age	B-Characteristic
,	O
total	B-Characteristic
neurosensory	I-Characteristic
retinal	I-Characteristic
volume	I-Characteristic
,	O
and	O
total	B-Characteristic
SRT	I-Characteristic
volume	I-Characteristic
.	O
	
The	O
presence	O
of	O
increased	B-Symptom
SRT	I-Symptom
thickness	I-Symptom
and	I-Symptom
volume	I-Symptom
on	O
OCT	B-Diagnostic_tool
,	O
and	O
to	O
a	O
lesser	O
extent	O
increased	B-Symptom
neurosensory	I-Symptom
retinal	I-Symptom
thickness	I-Symptom
and	I-Symptom
volume	I-Symptom
,	O
is	O
associated	O
with	O
decreased	B-Symptom
visual	I-Symptom
acuity	I-Symptom
in	O
neovascular	B-Disease
AMD	I-Disease
.	O
	
However	O
,	O
because	O
of	O
the	O
complex	O
pathophysiology	O
of	O
neovascular	B-Disease
AMD	I-Disease
and	O
,	O
in	O
part	O
,	O
the	O
limitations	O
of	O
StratusOCT	B-Diagnostic_tool
,	O
these	O
factors	O
only	O
account	O
for	O
a	O
small	O
degree	O
of	O
the	O
variation	O
in	O
visual	B-Characteristic
acuity	I-Characteristic
that	O
these	O
patients	O
exhibit	O
.	O
	
The	O
detection	O
of	O
stronger	O
correlations	O
between	O
retinal	B-Anatomy
anatomy	I-Anatomy
and	O
visual	B-Characteristic
acuity	I-Characteristic
is	O
likely	O
to	O
require	O
the	O
use	O
of	O
more	O
advanced	O
imaging	O
modalities	O
.	O
	
Proprietary	O
or	O
commercial	O
disclosure	O
may	O
be	O
found	O
after	O
the	O
references	O
.	O
	
Ophthalmic	O
features	O
of	O
Joubert	B-Disease
syndrome	I-Disease
.	O
	
Joubert	B-Disease
syndrome	I-Disease
(	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	O
213300	O
)	O
is	O
a	O
rare	O
autosomal	B-Symptom
recessive	I-Symptom
congenital	I-Symptom
malformation	I-Symptom
of	I-Symptom
the	I-Symptom
brainstem	I-Symptom
and	I-Symptom
cerebellar	I-Symptom
vermis	I-Symptom
.	O
	
Diagnosis	O
is	O
based	O
on	O
characteristic	O
clinical	O
features	O
(	O
e	O
.	O
g	O
.	O
,	O
hypotonia	B-Symptom
,	O
episodic	B-Symptom
hyperpnea	I-Symptom
,	O
developmental	B-Symptom
delay	I-Symptom
,	O
progressive	B-Symptom
ataxia	I-Symptom
)	O
and	O
is	O
confirmed	O
by	O
distinctive	O
neuroradiologic	B-Symptom
findings	I-Symptom
(	O
e	O
.	O
g	O
.	O
,	O
the	O
"	B-Symptom
molar	I-Symptom
tooth	I-Symptom
"	I-Symptom
sign	I-Symptom
)	O
.	O
	
Variable	O
ophthalmic	O
features	O
have	O
been	O
mentioned	O
in	O
prior	O
reports	O
;	O
however	O
,	O
most	O
do	O
not	O
detail	O
eye	B-Anatomy
findings	O
and	O
the	O
few	O
that	O
do	O
were	O
before	O
the	O
publication	O
of	O
suggested	O
diagnostic	O
criteria	O
.	O
	
The	O
objective	O
of	O
the	O
current	O
study	O
is	O
to	O
describe	O
the	O
ophthalmic	O
phenotype	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
Joubert	B-Disease
syndrome	I-Disease
for	O
whom	O
the	O
diagnosis	O
was	O
made	O
using	O
current	O
diagnostic	O
criteria	O
.	O
	
Prospective	O
case	O
series	O
.	O
	
Eight	O
children	O
diagnosed	O
clinically	O
with	O
radiologic	O
confirmation	O
.	O
	
Ophthalmic	B-Diagnostic_tool
examination	I-Diagnostic_tool
and	O
visual	B-Diagnostic_tool
electrophysiology	I-Diagnostic_tool
.	O
	
Ocular	B-Diagnostic_tool
and	I-Diagnostic_tool
oculomotor	I-Diagnostic_tool
examination	I-Diagnostic_tool
(	O
as	O
allowed	O
by	O
patient	O
cooperation	O
)	O
,	O
electroretinography	B-Diagnostic_tool
,	O
flash	B-Diagnostic_tool
visual	I-Diagnostic_tool
-	I-Diagnostic_tool
evoked	I-Diagnostic_tool
potential	I-Diagnostic_tool
(	O
fVEP	B-Diagnostic_tool
)	O
.	O
	
Patients	O
'	O
ages	O
ranged	O
from	O
7	B-Characteristic
months	I-Characteristic
to	I-Characteristic
10	I-Characteristic
years	I-Characteristic
.	O
	
Saccadic	B-Symptom
dysfunction	I-Symptom
was	O
observed	O
in	O
all	O
cooperative	O
patients	O
(	O
6	O
/	O
6	O
)	O
;	O
compensatory	B-Symptom
head	I-Symptom
thrusts	I-Symptom
or	I-Symptom
turns	I-Symptom
were	O
present	O
in	O
all	O
except	O
the	O
youngest	O
patient	O
(	O
7	B-Characteristic
months	I-Characteristic
of	I-Characteristic
age	I-Characteristic
)	O
.	O
	
Most	O
patients	O
(	O
5	O
/	O
8	O
)	O
had	O
primary	B-Symptom
-	I-Symptom
position	I-Symptom
nystagmus	I-Symptom
(	O
see	O
-	O
saw	O
in	O
3	O
/	O
5	O
)	O
.	O
	
Abnormal	B-Symptom
pursuit	I-Symptom
(	O
3	O
/	O
7	O
)	O
and	O
a	O
dystrophic	B-Symptom
retinal	I-Symptom
appearance	I-Symptom
(	O
3	O
/	O
8	O
)	O
were	O
also	O
seen	O
.	O
	
One	O
patient	O
had	O
bilateral	B-Symptom
asymmetric	I-Symptom
ptosis	I-Symptom
with	I-Symptom
unilateral	I-Symptom
lid	I-Symptom
elevation	I-Symptom
during	I-Symptom
ipsilateral	I-Symptom
abduction	I-Symptom
.	O
	
Electroretinography	B-Diagnostic_tool
findings	O
were	O
normal	O
for	O
all	O
8	O
patients	O
.	O
	
Seven	O
patients	O
underwent	O
fVEP	B-Diagnostic_tool
;	O
6	O
were	O
abnormal	O
(	O
asymmetric	O
)	O
and	O
one	O
was	O
not	O
interpretable	O
because	O
of	O
study	O
artifact	O
.	O
	
Ophthalmologists	O
should	O
be	O
aware	O
that	O
saccadic	B-Symptom
dysfunction	I-Symptom
(	I-Symptom
typically	I-Symptom
with	I-Symptom
head	I-Symptom
thrusts	I-Symptom
)	I-Symptom
and	O
primary	B-Symptom
position	I-Symptom
nystagmus	I-Symptom
(	I-Symptom
typically	I-Symptom
see	I-Symptom
-	I-Symptom
saw	I-Symptom
)	I-Symptom
in	O
a	O
developmentally	B-Characteristic
delayed	I-Characteristic
child	I-Characteristic
suggest	O
the	O
diagnosis	O
of	O
Joubert	B-Disease
syndrome	I-Disease
,	O
especially	O
if	O
a	O
dystrophic	B-Symptom
retinal	I-Symptom
appearance	I-Symptom
is	O
also	O
present	O
.	O
	
Our	O
findings	O
of	O
asymmetric	B-Symptom
fVEPs	I-Symptom
and	O
see	B-Symptom
-	I-Symptom
saw	I-Symptom
nystagmus	I-Symptom
suggest	O
an	O
abnormality	B-Symptom
in	I-Symptom
optic	I-Symptom
nerve	I-Symptom
decussation	I-Symptom
,	O
consistent	O
with	O
the	O
concept	O
that	O
impaired	B-Symptom
axonal	I-Symptom
guidance	I-Symptom
occurs	O
in	O
patients	O
with	O
Joubert	B-Disease
syndrome	I-Disease
.	O
	
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
A	O
systematic	O
correlation	O
of	O
angiography	B-Diagnostic_tool
and	O
high	B-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
in	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
To	O
correlate	O
leakage	O
patterns	O
in	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
(	I-Diagnostic_tool
FA	I-Diagnostic_tool
)	I-Diagnostic_tool
images	I-Diagnostic_tool
and	O
retinal	B-Characteristic
morphologic	I-Characteristic
features	I-Characteristic
in	O
high	B-Diagnostic_tool
-	I-Diagnostic_tool
definition	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	I-Diagnostic_tool
HD	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	I-Diagnostic_tool
images	I-Diagnostic_tool
in	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
Prospective	O
pilot	O
study	O
and	O
case	O
series	O
.	O
	
Nine	O
consecutive	O
patients	O
(	O
10	O
eyes	B-Anatomy
)	O
with	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
All	O
patients	O
were	O
examined	O
using	O
FA	B-Diagnostic_tool
(	O
HRA	O
2	O
;	O
Heidelberg	O
Engineering	O
)	O
and	O
HD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
Carl	O
Zeiss	O
Meditec	O
;	O
resolution	O
,	O
512x128	O
pixels	O
,	O
5	O
.	O
8x5	O
.	O
8	O
mm	O
,	O
and	O
high	O
-	O
resolution	O
scans	O
consisting	O
of	O
4096	O
A	O
scans	O
)	O
on	O
the	O
same	O
day	O
.	O
	
Using	O
Adobe	O
Photoshop	O
(	O
CS2	O
Version	O
9	O
.	O
0	O
;	O
Adobe	O
Systems	O
Incorporated	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
a	O
grid	O
containing	O
15x7	O
fields	O
was	O
superimposed	O
on	O
the	O
HD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
en	I-Diagnostic_tool
face	I-Diagnostic_tool
image	I-Diagnostic_tool
and	O
a	O
late	B-Diagnostic_tool
-	I-Diagnostic_tool
phase	I-Diagnostic_tool
FA	I-Diagnostic_tool
image	I-Diagnostic_tool
according	O
to	O
retinal	B-Characteristic
landmarks	I-Characteristic
.	O
	
In	O
each	O
patient	O
,	O
a	O
standardized	O
analysis	O
of	O
105	O
subfields	O
was	O
performed	O
to	O
provide	O
a	O
characterization	O
of	O
the	O
type	B-Characteristic
of	I-Characteristic
vascular	I-Characteristic
leakage	I-Characteristic
in	I-Characteristic
FA	I-Characteristic
and	O
the	O
associated	O
retinal	B-Characteristic
morphologic	I-Characteristic
changes	I-Characteristic
in	O
corresponding	O
locations	O
.	O
	
Angiographic	B-Characteristic
leakage	I-Characteristic
type	I-Characteristic
and	O
structural	B-Characteristic
alteration	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
morphologic	I-Characteristic
features	I-Characteristic
in	I-Characteristic
OCT	I-Characteristic
.	O
	
There	O
was	O
a	O
high	O
consistency	O
between	O
FA	B-Diagnostic_tool
and	O
OCT	B-Diagnostic_tool
in	O
the	O
petaloid	B-Characteristic
pattern	I-Characteristic
of	I-Characteristic
hyperfluorescence	I-Characteristic
that	O
correlated	O
with	O
the	O
presence	O
of	O
large	B-Characteristic
cystic	I-Characteristic
spaces	I-Characteristic
in	I-Characteristic
the	I-Characteristic
outer	I-Characteristic
nuclear	I-Characteristic
layer	I-Characteristic
(	I-Characteristic
ONL	I-Characteristic
)	I-Characteristic
and	I-Characteristic
the	I-Characteristic
outer	I-Characteristic
plexiform	I-Characteristic
layer	I-Characteristic
(	I-Characteristic
OPL	I-Characteristic
)	I-Characteristic
with	O
or	O
without	O
subretinal	B-Symptom
fluid	I-Symptom
in	O
30	O
.	O
4	O
%	O
and	O
69	O
.	O
6	O
%	O
of	O
graded	O
fields	O
,	O
respectively	O
.	O
	
A	O
honeycomblike	B-Characteristic
pattern	I-Characteristic
of	I-Characteristic
hyperfluorescence	I-Characteristic
was	O
associated	O
with	O
swelling	B-Characteristic
and	I-Characteristic
cystic	I-Characteristic
spaces	I-Characteristic
in	I-Characteristic
ONL	I-Characteristic
,	I-Characteristic
OPL	I-Characteristic
,	I-Characteristic
the	I-Characteristic
inner	I-Characteristic
nuclear	I-Characteristic
,	I-Characteristic
and	I-Characteristic
the	I-Characteristic
inner	I-Characteristic
plexiform	I-Characteristic
layer	I-Characteristic
in	O
71	O
.	O
4	O
%	O
of	O
graded	O
fields	O
.	O
	
Diffuse	B-Characteristic
patterns	I-Characteristic
of	I-Characteristic
hyperfluorescence	I-Characteristic
did	O
not	O
correlate	O
with	O
characteristic	B-Characteristic
retinal	I-Characteristic
changes	I-Characteristic
in	I-Characteristic
HD	I-Characteristic
OCT	I-Characteristic
,	O
but	O
rather	O
showed	O
diversity	O
in	O
the	O
type	O
of	O
morphologic	O
alteration	O
.	O
	
The	O
presence	O
of	O
central	B-Symptom
fluid	I-Symptom
pooling	I-Symptom
,	O
such	O
as	O
subretinal	B-Symptom
fluid	I-Symptom
,	O
could	O
be	O
identified	O
only	O
by	O
HD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
not	O
by	O
FA	B-Diagnostic_tool
.	O
	
In	O
the	O
examined	O
patients	O
,	O
a	O
petaloid	B-Characteristic
pattern	I-Characteristic
and	I-Characteristic
a	I-Characteristic
honeycomb	I-Characteristic
pattern	I-Characteristic
of	I-Characteristic
hyperfluorescence	I-Characteristic
observed	I-Characteristic
in	I-Characteristic
FA	I-Characteristic
were	O
found	O
to	O
correlate	O
to	O
characteristic	B-Characteristic
changes	I-Characteristic
in	I-Characteristic
HD	I-Characteristic
OCT	I-Characteristic
,	I-Characteristic
whereas	O
a	O
diffuse	B-Characteristic
leakage	I-Characteristic
pattern	I-Characteristic
was	O
associated	O
with	O
nonuniform	B-Characteristic
changes	I-Characteristic
in	I-Characteristic
retinal	I-Characteristic
morphologic	I-Characteristic
features	I-Characteristic
.	O
	
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
SCORE	O
Study	O
report	O
1	O
:	O
baseline	O
associations	O
between	O
central	B-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
and	O
visual	B-Characteristic
acuity	I-Characteristic
in	O
patients	O
with	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
.	O
	
To	O
investigate	O
the	O
relationship	O
between	O
baseline	O
center	B-Characteristic
point	I-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
measured	O
by	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
and	O
best	B-Characteristic
-	I-Characteristic
corrected	I-Characteristic
visual	I-Characteristic
acuity	I-Characteristic
in	O
eyes	B-Anatomy
with	O
macular	B-Symptom
edema	I-Symptom
associated	O
with	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
and	O
to	O
investigate	O
other	O
factors	O
associated	O
with	O
baseline	O
visual	B-Characteristic
acuity	I-Characteristic
letter	I-Characteristic
score	I-Characteristic
.	O
	
The	O
Standard	O
Care	O
versus	O
COrticosteroid	O
for	O
REtinal	B-Disease
Vein	I-Disease
Occlusion	I-Disease
(	O
SCORE	O
)	O
Study	O
includes	O
2	O
multicenter	O
,	O
randomized	O
clinical	O
trials	O
:	O
one	O
evaluating	O
participants	O
with	O
central	B-Disease
retinal	I-Disease
vein	I-Disease
occlusion	I-Disease
(	O
CRVO	B-Disease
)	O
and	O
the	O
other	O
evaluating	O
participants	O
with	O
branch	B-Disease
retinal	I-Disease
vein	I-Disease
occlusion	I-Disease
(	O
BRVO	B-Disease
)	O
.	O
	
After	O
omitting	O
17	O
participants	O
with	O
missing	O
or	O
unreliable	O
OCT	B-Diagnostic_tool
measurements	O
,	O
analyses	O
proceeded	O
with	O
665	O
enrolled	O
SCORE	O
Study	O
participants	O
(	O
665	O
eyes	B-Anatomy
)	O
,	O
including	O
262	O
with	O
CRVO	B-Disease
and	O
403	O
with	O
BRVO	B-Disease
.	O
	
At	O
baseline	O
,	O
center	B-Characteristic
point	I-Characteristic
thickness	I-Characteristic
was	O
measured	O
by	O
OCT	B-Diagnostic_tool
(	O
Stratus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
3	I-Diagnostic_tool
[	O
n	O
=	O
663	O
]	O
and	O
OCT2	B-Diagnostic_tool
[	O
n	O
=	O
2	O
]	O
;	O
Carl	O
Zeiss	O
Meditech	O
,	O
Dublin	O
,	O
CA	O
)	O
,	O
and	O
visual	B-Characteristic
acuity	I-Characteristic
was	O
measured	O
by	O
the	O
electronic	O
Early	O
Treatment	O
Diabetic	B-Disease
Retinopathy	I-Disease
Study	O
(	O
E	O
-	O
ETDRS	O
)	O
methodology	O
.	O
	
Center	B-Characteristic
point	I-Characteristic
thickness	I-Characteristic
and	O
best	B-Characteristic
-	I-Characteristic
corrected	I-Characteristic
E	I-Characteristic
-	I-Characteristic
ETDRS	I-Characteristic
visual	I-Characteristic
acuity	I-Characteristic
letter	I-Characteristic
score	I-Characteristic
.	O
	
The	O
correlation	O
coefficient	O
for	O
the	O
association	O
between	O
baseline	O
OCT	B-Diagnostic_tool
-	O
measured	O
center	B-Characteristic
point	I-Characteristic
thickness	I-Characteristic
and	O
best	B-Characteristic
-	I-Characteristic
corrected	I-Characteristic
E	I-Characteristic
-	I-Characteristic
ETDRS	I-Characteristic
visual	I-Characteristic
acuity	I-Characteristic
letter	I-Characteristic
score	I-Characteristic
is	O
-	O
0	O
.	O
27	O
(	O
95	O
%	O
confidence	O
limit	O
:	O
-	O
0	O
.	O
38	O
to	O
-	O
0	O
.	O
16	O
)	O
for	O
participants	O
in	O
the	O
CRVO	B-Disease
trial	O
and	O
-	O
0	O
.	O
28	O
(	O
95	O
%	O
confidence	O
limit	O
:	O
-	O
0	O
.	O
37	O
to	O
-	O
0	O
.	O
19	O
)	O
in	O
the	O
BRVO	B-Disease
trial	O
.	O
	
Regression	O
modeling	O
estimated	O
the	O
following	O
decrease	O
in	O
baseline	O
visual	B-Characteristic
acuity	I-Characteristic
letter	I-Characteristic
score	I-Characteristic
for	O
every	O
100	O
-	O
microm	O
increase	O
in	O
OCT	B-Characteristic
-	I-Characteristic
measured	I-Characteristic
center	I-Characteristic
point	I-Characteristic
thickness	I-Characteristic
:	O
1	O
.	O
7	O
letters	O
(	O
P	O
=	O
0	O
.	O
0007	O
)	O
for	O
CRVO	B-Disease
and	O
1	O
.	O
9	O
letters	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
BRVO	B-Disease
.	O
	
On	O
the	O
basis	O
of	O
multivariate	O
regression	O
models	O
,	O
baseline	O
factors	O
significantly	O
associated	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
after	O
adjusting	O
for	O
multiple	O
testing	O
)	O
with	O
baseline	O
visual	B-Characteristic
acuity	I-Characteristic
letter	I-Characteristic
score	I-Characteristic
include	O
age	B-Characteristic
and	O
duration	B-Characteristic
of	I-Characteristic
macular	I-Characteristic
edema	I-Characteristic
for	O
CRVO	B-Disease
participants	O
and	O
center	B-Characteristic
point	I-Characteristic
thickness	I-Characteristic
and	O
presence	O
of	O
cystoid	B-Symptom
spaces	I-Symptom
for	O
BRVO	B-Disease
participants	O
.	O
	
The	O
correlation	O
between	O
OCT	B-Characteristic
-	I-Characteristic
measured	I-Characteristic
center	I-Characteristic
point	I-Characteristic
thickness	I-Characteristic
and	O
visual	B-Characteristic
acuity	I-Characteristic
letter	I-Characteristic
score	I-Characteristic
is	O
modest	O
.	O
	
OCT	B-Characteristic
-	I-Characteristic
measured	I-Characteristic
center	I-Characteristic
point	I-Characteristic
thickness	I-Characteristic
represents	O
a	O
useful	O
tool	O
for	O
the	O
detection	O
and	O
monitoring	O
of	O
macular	B-Symptom
edema	I-Symptom
in	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
,	O
but	O
it	O
cannot	O
reliably	O
substitute	O
for	O
visual	B-Characteristic
acuity	I-Characteristic
measurements	O
.	O
	
Comparison	O
of	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
versus	I-Diagnostic_tool
time	I-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
in	O
management	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
with	O
ranibizumab	O
.	O
	
To	O
compare	O
the	O
ability	O
to	O
delineate	O
and	O
detect	O
patterns	O
of	O
choroidal	B-Symptom
neovascularization	I-Symptom
(	O
CNV	B-Symptom
)	O
activity	O
in	O
patients	O
with	O
exudative	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
after	O
ranibizumab	O
treatment	O
between	O
time	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
TD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
and	O
4	O
different	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
devices	O
.	O
	
Prospective	O
,	O
consecutive	O
case	O
series	O
.	O
	
Sixty	O
-	O
one	O
eyes	B-Anatomy
of	O
58	O
patients	O
with	O
exudative	B-Disease
AMD	I-Disease
after	O
ranibizumab	O
treatment	O
were	O
included	O
in	O
this	O
study	O
.	O
	
All	O
patients	O
were	O
imaged	O
with	O
TD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
at	O
least	O
1	O
of	O
4	O
different	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
devices	O
at	O
the	O
same	O
visit	O
after	O
ranibizumab	O
treatment	O
.	O
	
The	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
were	O
analyzed	O
in	O
a	O
masked	O
fashion	O
by	O
2	O
independent	O
graders	O
(	O
KS	O
,	O
TY	O
)	O
to	O
delineate	O
and	O
detect	O
the	O
presence	O
of	O
CNV	B-Symptom
activity	O
defined	O
as	O
the	O
presence	O
of	O
subretinal	B-Symptom
fluid	I-Symptom
,	O
intraretinal	B-Symptom
cysts	I-Symptom
,	O
intraretinal	B-Symptom
fluid	I-Symptom
,	O
sub	B-Symptom
-	I-Symptom
retinal	I-Symptom
pigment	I-Symptom
epithelium	I-Symptom
(	I-Symptom
sub	I-Symptom
-	I-Symptom
RPE	I-Symptom
)	I-Symptom
fluid	I-Symptom
,	O
or	O
a	O
combination	O
thereof	O
.	O
	
The	O
automated	O
evaluation	O
of	O
retinal	B-Characteristic
thickness	I-Characteristic
also	O
was	O
analyzed	O
between	O
devices	O
.	O
	
Evidence	O
of	O
CNV	B-Symptom
activity	O
on	O
linear	O
B	O
-	O
scans	O
and	O
3	O
-	O
dimensional	O
so	O
-	O
called	O
cube	O
scans	O
on	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
linear	O
B	O
-	O
scan	O
on	O
TD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
.	O
	
In	O
linear	O
B	O
-	O
scan	O
mode	O
,	O
all	O
4	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
devices	O
were	O
superior	O
in	O
their	O
ability	O
to	O
delineate	O
sub	B-Symptom
-	I-Symptom
RPE	I-Symptom
fluid	I-Symptom
compared	O
with	O
TD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
Three	O
of	O
4	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
devices	O
were	O
superior	O
in	O
delineating	O
intraretinal	B-Symptom
fluid	I-Symptom
,	O
and	O
2	O
of	O
4	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
devices	O
were	O
superior	O
in	O
delineating	O
subretinal	B-Symptom
fluid	I-Symptom
and	O
intraretinal	B-Symptom
cysts	I-Symptom
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
In	O
the	O
3	O
-	O
dimensional	O
so	O
-	O
called	O
cube	O
mode	O
,	O
all	O
4	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
devices	O
were	O
superior	O
in	O
detecting	O
subretinal	B-Symptom
fluid	I-Symptom
and	O
2	O
of	O
4	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
devices	O
were	O
superior	O
in	O
detecting	O
sub	B-Symptom
-	I-Symptom
RPE	I-Symptom
and	I-Symptom
intraretinal	I-Symptom
fluid	I-Symptom
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
There	O
were	O
significant	O
correlations	O
in	O
center	B-Characteristic
point	I-Characteristic
thickness	I-Characteristic
between	O
all	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
devices	O
and	O
TD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
3	O
of	O
4	O
and	O
1	O
of	O
3	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
devices	O
showed	O
significant	O
differences	O
from	O
TD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
in	O
center	B-Characteristic
point	I-Characteristic
thickness	I-Characteristic
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
center	B-Characteristic
subfield	I-Characteristic
thickness	I-Characteristic
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
respectively	O
.	O
	
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
is	O
superior	O
to	O
TD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
in	O
evaluating	O
for	O
CNV	B-Symptom
activity	O
in	O
patients	O
with	O
wet	B-Disease
AMD	I-Disease
after	O
ranibizumab	O
injection	O
.	O
	
Retinal	B-Characteristic
thickness	I-Characteristic
measurements	O
between	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
TD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
also	O
were	O
significantly	O
different	O
.	O
	
Proprietary	O
or	O
commercial	O
disclosure	O
may	O
be	O
found	O
after	O
the	O
references	O
.	O
	
Sector	O
-	O
based	O
analysis	O
with	O
the	O
Heidelberg	B-Diagnostic_tool
Retinal	I-Diagnostic_tool
Tomograph	I-Diagnostic_tool
3	I-Diagnostic_tool
across	O
disc	O
sizes	O
and	O
glaucoma	B-Disease
stages	O
:	O
a	O
multicenter	O
study	O
.	O
	
To	O
investigate	O
the	O
ability	O
of	O
sectorial	O
analysis	O
using	O
the	O
Heidelberg	B-Diagnostic_tool
Retinal	I-Diagnostic_tool
Tomograph	I-Diagnostic_tool
3	I-Diagnostic_tool
(	O
HRT3	B-Diagnostic_tool
)	O
to	O
discriminate	O
between	O
healthy	O
and	O
glaucomatous	B-Disease
eyes	B-Anatomy
and	O
to	O
determine	O
whether	O
this	O
is	O
affected	O
by	O
disc	B-Characteristic
size	I-Characteristic
and	O
glaucoma	B-Disease
severity	O
.	O
	
Multicenter	O
,	O
cross	O
-	O
sectional	O
evaluation	O
of	O
diagnostic	O
tests	O
.	O
	
Two	O
hundred	O
thirty	O
-	O
three	O
eyes	B-Anatomy
from	O
137	O
normal	B-Characteristic
subjects	I-Characteristic
and	O
96	O
glaucoma	B-Disease
patients	O
classified	O
by	O
the	O
presence	O
of	O
a	O
repeatable	B-Symptom
visual	I-Symptom
field	I-Symptom
defect	I-Symptom
.	O
	
Participants	O
underwent	O
imaging	O
with	O
the	O
HRT3	B-Diagnostic_tool
,	O
and	O
the	O
diagnostic	O
accuracy	O
of	O
stereometric	B-Characteristic
parameters	I-Characteristic
,	O
Moorfields	B-Characteristic
regression	I-Characteristic
analysis	I-Characteristic
(	O
MRA	B-Characteristic
)	O
,	O
and	O
glaucoma	B-Characteristic
probability	I-Characteristic
score	I-Characteristic
(	O
GPS	B-Characteristic
)	O
were	O
analyzed	O
sectorially	O
by	O
glaucoma	B-Disease
stage	O
and	O
optic	B-Characteristic
disc	I-Characteristic
size	I-Characteristic
.	O
	
Sensitivity	O
,	O
specificity	O
,	O
positive	O
and	O
negative	O
predictive	O
values	O
,	O
and	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
characteristics	O
curve	O
(	O
AUC	O
)	O
.	O
	
Of	O
stereometric	B-Characteristic
parameters	I-Characteristic
,	O
the	O
cup	B-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
disc	I-Characteristic
area	I-Characteristic
ratio	I-Characteristic
of	I-Characteristic
the	I-Characteristic
inferotemporal	I-Characteristic
sector	I-Characteristic
had	O
the	O
largest	O
AUC	O
(	O
AUC	O
,	O
0	O
.	O
74	O
)	O
.	O
	
Both	O
MRA	B-Characteristic
and	O
GPS	B-Characteristic
algorithms	O
showed	O
the	O
best	O
diagnostic	O
accuracy	O
in	O
the	O
inferotemporal	B-Anatomy
sector	I-Anatomy
,	O
with	O
a	O
sensitivity	O
and	O
specificity	O
of	O
63	O
%	O
and	O
88	O
%	O
for	O
MRA	B-Characteristic
and	O
80	O
%	O
and	O
62	O
%	O
for	O
GPS	B-Characteristic
,	O
respectively	O
.	O
	
In	O
small	O
discs	O
,	O
sectorial	B-Diagnostic_tool
MRA	I-Diagnostic_tool
analysis	I-Diagnostic_tool
had	O
higher	O
diagnostic	O
accuracy	O
than	O
the	O
global	B-Diagnostic_tool
optic	I-Diagnostic_tool
nerve	I-Diagnostic_tool
head	I-Diagnostic_tool
(	I-Diagnostic_tool
ONH	I-Diagnostic_tool
)	I-Diagnostic_tool
analysis	I-Diagnostic_tool
(	O
sensitivity	O
of	O
70	O
%	O
and	O
specificity	O
of	O
82	O
%	O
in	O
the	O
inferonasal	B-Anatomy
sector	I-Anatomy
)	O
,	O
and	O
these	O
findings	O
were	O
confirmed	O
in	O
very	O
large	O
discs	O
(	O
sensitivity	O
of	O
74	O
%	O
and	O
specificity	O
of	O
85	O
%	O
in	O
the	O
inferotemporal	B-Anatomy
sector	I-Anatomy
)	O
.	O
	
Similarly	O
,	O
stereometric	B-Characteristic
parameters	I-Characteristic
discriminated	O
better	O
sectorially	O
rather	O
than	O
globally	O
,	O
with	O
different	O
parameters	O
giving	O
the	O
best	O
results	O
in	O
different	O
optic	B-Characteristic
disc	I-Characteristic
size	I-Characteristic
subgroups	O
.	O
	
MRA	B-Characteristic
sensitivity	I-Characteristic
was	O
weak	O
in	O
the	O
early	B-Disease
-	I-Disease
glaucoma	I-Disease
stage	O
,	O
with	O
slightly	O
higher	O
figures	O
if	O
considered	O
sectorially	O
rather	O
than	O
globally	O
.	O
	
GPS	B-Characteristic
diagnostic	I-Characteristic
accuracy	I-Characteristic
was	O
very	O
consistent	O
across	O
ONH	B-Anatomy
sectors	I-Anatomy
in	O
each	O
disc	B-Characteristic
size	I-Characteristic
and	O
glaucoma	B-Disease
stage	O
subgroup	O
,	O
with	O
no	O
single	O
sector	O
demonstrating	O
better	O
diagnostic	O
accuracy	O
than	O
the	O
global	O
analysis	O
.	O
	
Heidelberg	B-Diagnostic_tool
Retinal	I-Diagnostic_tool
Tomograph	I-Diagnostic_tool
3	I-Diagnostic_tool
sectorial	I-Diagnostic_tool
analysis	I-Diagnostic_tool
showed	O
moderate	O
diagnostic	O
performance	O
and	O
may	O
offer	O
potential	O
advantages	O
over	O
global	O
analysis	O
in	O
the	O
clinical	O
diagnostic	O
process	O
.	O
	
Small	B-Characteristic
discs	I-Characteristic
are	O
classified	O
more	O
accurately	O
by	O
examining	O
the	O
inferonasal	B-Anatomy
sector	I-Anatomy
,	O
whereas	O
larger	B-Characteristic
discs	I-Characteristic
are	O
classified	O
more	O
accurately	O
by	O
examining	O
the	O
inferotemporal	B-Anatomy
sector	I-Anatomy
.	O
	
Neither	O
HRT	B-Characteristic
parameters	I-Characteristic
nor	O
classification	B-Diagnostic_tool
algorithms	I-Diagnostic_tool
seem	O
to	O
be	O
good	O
at	O
the	O
earlier	O
stage	O
of	O
the	O
disease	O
.	O
	
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
Comparing	O
retinal	B-Characteristic
thickness	I-Characteristic
measurements	O
using	O
automated	B-Diagnostic_tool
fast	I-Diagnostic_tool
macular	I-Diagnostic_tool
thickness	I-Diagnostic_tool
map	I-Diagnostic_tool
versus	O
six	B-Diagnostic_tool
-	I-Diagnostic_tool
radial	I-Diagnostic_tool
line	I-Diagnostic_tool
scans	I-Diagnostic_tool
with	I-Diagnostic_tool
manual	I-Diagnostic_tool
measurements	I-Diagnostic_tool
.	O
	
To	O
compare	O
automated	O
retinal	B-Characteristic
thickness	I-Characteristic
values	O
generated	O
by	O
the	O
fast	B-Diagnostic_tool
macular	I-Diagnostic_tool
thickness	I-Diagnostic_tool
maps	I-Diagnostic_tool
(	O
FMTM	B-Diagnostic_tool
)	O
and	O
customized	B-Diagnostic_tool
6	I-Diagnostic_tool
-	I-Diagnostic_tool
radial	I-Diagnostic_tool
line	I-Diagnostic_tool
scans	I-Diagnostic_tool
(	O
RLS	B-Diagnostic_tool
)	O
versus	O
manual	O
retinal	B-Anatomy
measurements	O
on	O
Stratus	B-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
(	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
)	O
.	O
	
Prospective	O
,	O
observational	O
case	O
series	O
.	O
	
Patients	O
with	O
subfoveal	B-Symptom
choroidal	I-Symptom
neovascularization	I-Symptom
(	O
CNV	B-Symptom
)	O
caused	O
by	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
,	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
,	O
or	O
branch	B-Disease
/	I-Disease
central	I-Disease
retinal	I-Disease
vein	I-Disease
occlusion	I-Disease
(	O
RVO	B-Disease
)	O
.	O
	
Patients	O
were	O
prospectively	O
imaged	O
using	O
the	O
FMTM	B-Diagnostic_tool
and	O
customized	O
RLS	B-Diagnostic_tool
patterns	O
on	O
Stratus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
at	O
the	O
same	O
sitting	O
.	O
	
Each	O
scan	O
was	O
evaluated	O
for	O
errors	O
in	O
retinal	B-Anatomy
segmentation	O
(	O
i	O
.	O
e	O
.	O
,	O
correct	O
retinal	B-Anatomy
boundaries	O
[	O
CRB	O
]	O
)	O
.	O
	
Automated	O
values	O
were	O
recorded	O
while	O
central	B-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
measurements	O
were	O
determined	O
manually	O
for	O
both	O
patterns	O
.	O
	
The	O
presence	O
or	O
absence	O
of	O
epiretinal	B-Symptom
phenomenon	I-Symptom
,	O
cystoid	B-Symptom
spaces	I-Symptom
,	O
pigment	B-Symptom
epithelial	I-Symptom
detachment	I-Symptom
,	O
and	O
subretinal	B-Symptom
fluid	I-Symptom
was	O
also	O
noted	O
.	O
	
Errors	O
in	O
retinal	O
segmentation	O
at	O
and	O
outside	O
the	O
fovea	B-Anatomy
(	O
i	O
.	O
e	O
.	O
,	O
CRB	O
)	O
and	O
percentage	O
of	O
automated	O
values	O
within	O
a	O
clinically	O
acceptable	O
margin	O
(	O
+	O
/	O
-	O
25	O
mum	O
)	O
of	O
the	O
manual	O
central	B-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
.	O
	
A	O
total	O
of	O
147	O
eyes	B-Anatomy
of	O
147	O
patients	O
(	O
95	O
eyes	B-Anatomy
with	O
exudative	B-Disease
AMD	I-Disease
,	O
41	O
eyes	B-Anatomy
with	O
DME	B-Disease
,	O
and	O
11	O
eyes	B-Anatomy
with	O
macular	B-Disease
edema	I-Disease
caused	O
by	O
RVO	B-Disease
)	O
were	O
included	O
.	O
	
For	O
wet	B-Disease
AMD	I-Disease
,	O
the	O
total	O
number	O
of	O
CRB	O
at	O
the	O
fovea	B-Anatomy
and	O
outside	B-Anatomy
the	I-Anatomy
fovea	I-Anatomy
was	O
363	O
(	O
63	O
.	O
7	O
%	O
)	O
and	O
360	O
(	O
63	O
.	O
2	O
%	O
)	O
,	O
respectively	O
,	O
in	O
FMTM	B-Diagnostic_tool
and	O
428	O
(	O
75	O
.	O
1	O
%	O
)	O
and	O
426	O
(	O
74	O
.	O
7	O
%	O
)	O
,	O
respectively	O
,	O
in	O
RLS	B-Diagnostic_tool
(	O
P	O
<	O
0	O
.	O
0001	O
for	O
both	O
)	O
.	O
	
For	O
DME	B-Disease
and	O
RVO	B-Disease
,	O
the	O
total	O
number	O
of	O
CRB	O
at	O
the	O
fovea	B-Anatomy
and	O
outside	B-Anatomy
the	I-Anatomy
fovea	I-Anatomy
was	O
274	O
(	O
87	O
.	O
8	O
%	O
)	O
and	O
256	O
(	O
82	O
.	O
1	O
%	O
)	O
,	O
respectively	O
,	O
in	O
FMTM	B-Diagnostic_tool
and	O
287	O
(	O
92	O
.	O
0	O
%	O
)	O
and	O
270	O
(	O
86	O
.	O
5	O
%	O
)	O
,	O
respectively	O
,	O
in	O
RLS	B-Diagnostic_tool
(	O
P	O
=	O
0	O
.	O
11	O
,	O
P	O
=	O
0	O
.	O
15	O
,	O
respectively	O
)	O
.	O
	
Some	O
40	O
%	O
and	O
56	O
%	O
of	O
automated	O
foveal	B-Characteristic
center	I-Characteristic
point	I-Characteristic
thicknesses	I-Characteristic
on	O
FMTM	B-Diagnostic_tool
and	O
RLS	B-Diagnostic_tool
,	O
respectively	O
,	O
were	O
within	O
+	B-Dimension
/	I-Dimension
-	I-Dimension
25	I-Dimension
mum	I-Dimension
of	O
the	O
manual	O
central	B-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
for	O
AMD	B-Disease
(	O
P	O
=	O
0	O
.	O
042	O
)	O
,	O
versus	O
94	O
%	O
and	O
81	O
%	O
for	O
DME	B-Disease
and	O
RVO	B-Disease
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O
	
For	O
exudative	B-Disease
AMD	I-Disease
,	O
the	O
RLS	B-Diagnostic_tool
protocol	O
provides	O
fewer	O
segmentation	O
errors	O
than	O
the	O
FMTM	B-Diagnostic_tool
protocol	O
,	O
and	O
its	O
automated	O
retinal	B-Characteristic
thickness	I-Characteristic
values	O
(	O
e	O
.	O
g	O
.	O
,	O
foveal	B-Characteristic
center	I-Characteristic
point	I-Characteristic
,	O
central	B-Characteristic
subfield	I-Characteristic
)	O
correlate	O
better	O
with	O
manual	O
retinal	B-Characteristic
thickness	I-Characteristic
measurement	O
than	O
FMTM	B-Diagnostic_tool
.	O
	
In	O
DME	B-Disease
and	O
RVO	B-Disease
,	O
however	O
,	O
both	O
protocols	O
provide	O
similar	O
and	O
low	O
segmentation	O
errors	O
,	O
and	O
their	O
automated	O
results	O
are	O
close	O
to	O
manual	O
measurements	O
.	O
	
Proprietary	O
or	O
commercial	O
disclosure	O
may	O
be	O
found	O
after	O
the	O
references	O
.	O
	
Comparison	O
of	O
retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
measured	O
by	O
Cirrus	B-Diagnostic_tool
HD	I-Diagnostic_tool
and	I-Diagnostic_tool
Stratus	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
.	O
	
To	O
study	O
the	O
relationship	O
between	O
retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
(	I-Characteristic
RNFL	I-Characteristic
)	I-Characteristic
thickness	I-Characteristic
measured	O
by	O
time	B-Diagnostic_tool
domain	I-Diagnostic_tool
(	I-Diagnostic_tool
Stratus	I-Diagnostic_tool
)	I-Diagnostic_tool
and	I-Diagnostic_tool
spectral	I-Diagnostic_tool
domain	I-Diagnostic_tool
(	I-Diagnostic_tool
Cirrus	I-Diagnostic_tool
HD	I-Diagnostic_tool
)	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
.	O
	
Cross	O
-	O
sectional	O
study	O
.	O
	
Sixty	O
healthy	B-Characteristic
participants	I-Characteristic
,	O
48	O
glaucoma	B-Disease
suspects	I-Disease
,	O
and	O
55	O
subjects	O
with	O
glaucoma	B-Disease
.	O
	
Participants	O
were	O
imaged	O
by	O
a	O
single	O
trained	O
operator	O
using	O
the	O
Stratus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
fast	O
RNFL	O
scan	O
mode	O
)	O
and	O
Cirrus	B-Diagnostic_tool
HD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
optic	O
disc	O
cube	O
mode	O
)	O
at	O
the	O
same	O
visit	O
.	O
	
The	O
RNFL	B-Characteristic
thickness	I-Characteristic
as	O
measured	O
by	O
the	O
Stratus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
fast	O
RNFL	O
scan	O
mode	O
)	O
and	O
Cirrus	B-Diagnostic_tool
HD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
optic	O
disc	O
cube	O
mode	O
)	O
was	O
compared	O
(	O
paired	O
t	O
test	O
)	O
.	O
	
The	O
relationship	O
between	O
RNFL	B-Characteristic
thickness	I-Characteristic
measurements	O
of	O
the	O
2	O
OCTs	B-Diagnostic_tool
were	O
evaluated	O
using	O
a	O
Pearson	O
correlation	O
analysis	O
.	O
	
The	O
presence	O
of	O
abnormal	O
classification	O
,	O
as	O
determined	O
by	O
using	O
an	O
internal	O
normative	O
data	O
base	O
in	O
each	O
machine	O
was	O
compared	O
(	O
chi	O
-	O
square	O
test	O
)	O
.	O
	
The	O
sensitivity	O
and	O
specificity	O
of	O
normative	O
classification	O
of	O
2	O
OCT	B-Diagnostic_tool
measurements	O
were	O
calculated	O
.	O
	
Average	B-Characteristic
RNFL	I-Characteristic
thickness	I-Characteristic
as	O
determined	O
by	O
the	O
2	O
OCT	B-Diagnostic_tool
machines	O
was	O
correlated	O
(	O
r	O
=	O
0	O
.	O
94	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
was	O
significantly	O
different	O
with	O
the	O
2	O
machines	O
(	O
Stratus	O
,	O
98	O
.	O
0	O
mum	O
,	O
standard	O
deviation	O
[	O
SD	O
]	O
18	O
.	O
0	O
;	O
Cirrus	O
,	O
85	O
.	O
6	O
mum	O
,	O
SD	O
14	O
.	O
6	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
The	O
Cirrus	B-Diagnostic_tool
HD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
classified	O
a	O
significantly	O
higher	O
percentage	O
of	O
eyes	B-Anatomy
as	O
abnormal	O
(	O
Stratus	O
,	O
12	O
.	O
9	O
%	O
;	O
Cirrus	O
,	O
23	O
.	O
3	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
average	B-Characteristic
RNFL	I-Characteristic
thickness	I-Characteristic
.	O
	
Cirrus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
demonstrated	O
higher	O
sensitivity	O
and	O
specificity	O
(	O
63	O
.	O
6	O
%	O
and	O
100	O
%	O
)	O
than	O
Stratus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
40	O
.	O
0	O
%	O
and	O
96	O
.	O
7	O
%	O
)	O
in	O
normative	O
classification	O
of	O
average	B-Characteristic
RNFL	I-Characteristic
thickness	I-Characteristic
.	O
	
There	O
were	O
significant	O
differences	O
in	O
RNFL	B-Characteristic
thickness	I-Characteristic
and	O
normative	O
classification	O
as	O
determined	O
by	O
Stratus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
Cirrus	B-Diagnostic_tool
HD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
despite	O
an	O
excellent	O
correlation	O
of	O
RNFL	B-Characteristic
thickness	I-Characteristic
measurement	O
.	O
	
Overall	O
sensitivity	O
and	O
specificity	O
were	O
higher	O
with	O
Cirrus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
.	O
	
These	O
findings	O
are	O
particularly	O
relevant	O
when	O
an	O
individual	O
undergoes	O
longitudinal	O
follow	O
-	O
up	O
with	O
different	O
OCTs	B-Diagnostic_tool
.	O
	
Incidence	O
of	O
postvitrectomy	B-Disease
macular	I-Disease
edema	I-Disease
using	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
.	O
	
To	O
evaluate	O
the	O
incidence	O
,	O
effect	O
on	O
visual	O
recovery	O
,	O
and	O
predisposing	O
risk	O
factors	O
of	O
postvitrectomy	B-Disease
macular	I-Disease
edema	I-Disease
(	O
ME	B-Disease
)	O
.	O
	
Prospective	O
cohort	O
study	O
.	O
	
One	O
-	O
hundred	O
nine	O
eyes	B-Anatomy
undergoing	O
nonemergent	O
vitrectomy	O
surgery	O
.	O
	
Eyes	B-Anatomy
were	O
evaluated	O
for	O
postoperative	O
day	O
1	O
inflammation	B-Symptom
,	O
1	O
-	O
month	O
retinal	B-Characteristic
thickness	I-Characteristic
using	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
,	O
and	O
preoperative	O
and	O
1	O
-	O
month	O
postoperative	O
best	B-Characteristic
-	I-Characteristic
corrected	I-Characteristic
visual	I-Characteristic
acuity	I-Characteristic
(	O
BCVA	B-Characteristic
)	O
.	O
	
Macular	B-Disease
edema	I-Disease
was	O
defined	O
as	O
central	B-Symptom
subfield	I-Symptom
thickness	I-Symptom
>	B-Dimension
or	I-Dimension
=	I-Dimension
272	I-Dimension
microm	I-Dimension
.	O
	
Retinal	B-Characteristic
thickness	I-Characteristic
,	O
inflammation	B-Symptom
,	O
and	O
BCVA	B-Characteristic
.	O
	
Incidence	O
of	O
ME	B-Disease
on	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
was	O
47	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
37	O
%	O
-	O
56	O
%	O
)	O
.	O
	
Mean	O
1	O
-	O
month	O
visual	B-Characteristic
acuity	I-Characteristic
improved	O
3	O
.	O
3	O
lines	O
(	O
0	O
.	O
33	O
logarithm	O
of	O
minimum	O
angle	O
of	O
resolution	O
[	O
logMAR	O
]	O
units	O
)	O
to	O
20	O
/	O
80	O
(	O
+	O
1	O
)	O
(	O
0	O
.	O
58	O
+	O
/	O
-	O
0	O
.	O
46	O
logMAR	O
units	O
)	O
from	O
20	O
/	O
150	O
(	O
-	O
2	O
)	O
(	O
0	O
.	O
91	O
+	O
/	O
-	O
0	O
.	O
63	O
logMAR	O
units	O
)	O
before	O
surgery	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
Mean	O
1	O
-	O
month	O
center	B-Characteristic
point	I-Characteristic
thickness	I-Characteristic
(	O
CPT	B-Characteristic
)	O
,	O
central	B-Characteristic
subfield	I-Characteristic
(	O
CSF	B-Characteristic
)	O
,	O
and	O
total	B-Characteristic
macular	I-Characteristic
volume	I-Characteristic
were	O
265	O
+	O
/	O
-	O
107	O
microm	O
,	O
288	O
+	O
/	O
-	O
94	O
microm	O
,	O
and	O
7	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
2	O
mm	O
(	O
3	O
)	O
,	O
respectively	O
.	O
	
Severity	O
of	O
postoperative	B-Symptom
inflammation	I-Symptom
predicted	O
retinal	B-Symptom
thickness	I-Symptom
at	O
1	O
month	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
Intraoperative	B-Characteristic
epinephrine	I-Characteristic
use	I-Characteristic
was	O
associated	O
with	O
increased	O
postoperative	O
inflammation	B-Characteristic
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O
	
Eyes	B-Anatomy
with	O
greater	O
reduction	O
in	O
CSF	B-Characteristic
(	O
or	O
CPT	B-Characteristic
)	O
from	O
baseline	O
experienced	O
more	O
rapid	O
visual	O
recovery	O
(	O
r	O
=	O
-	O
0	O
.	O
36	O
;	O
95	O
%	O
CI	O
,	O
-	O
0	O
.	O
61	O
to	O
-	O
0	O
.	O
06	O
;	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O
	
Postvitrectomy	B-Disease
ME	I-Disease
is	O
common	O
and	O
delays	O
visual	O
recovery	O
.	O
	
Degree	O
of	O
postoperative	B-Symptom
inflammation	I-Symptom
is	O
an	O
important	O
risk	O
factor	O
for	O
ME	B-Disease
and	O
,	O
in	O
this	O
series	O
,	O
was	O
increased	O
in	O
the	O
setting	O
of	O
intraocular	O
epinephrine	O
.	O
	
Efforts	O
to	O
reduce	O
or	O
prevent	O
inflammation	B-Symptom
after	O
vitrectomy	O
should	O
be	O
beneficial	O
and	O
therefore	O
are	O
encouraged	O
.	O
	
Spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
imaging	I-Diagnostic_tool
of	O
geographic	B-Symptom
atrophy	I-Symptom
margins	O
.	O
	
To	O
test	O
in	O
vivo	O
whether	O
spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
provides	O
adequate	O
resolution	O
for	O
reproducible	O
measurement	O
of	O
photoreceptor	B-Anatomy
(	I-Anatomy
PR	I-Anatomy
)	I-Anatomy
layer	I-Anatomy
at	O
the	O
margins	O
of	O
geographic	B-Symptom
atrophy	I-Symptom
(	O
GA	B-Symptom
)	O
,	O
and	O
if	O
it	O
delineates	O
the	O
relationship	O
between	O
PR	B-Anatomy
layer	I-Anatomy
and	O
retinal	B-Anatomy
pigment	I-Anatomy
epithelium	I-Anatomy
at	O
the	O
margins	O
of	O
GA	B-Symptom
.	O
	
Prospective	O
consecutive	O
case	O
series	O
.	O
	
Patients	O
with	O
GA	B-Symptom
secondary	O
to	O
nonneovascular	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
identified	O
during	O
routine	O
follow	O
-	O
up	O
at	O
Duke	O
Eye	B-Anatomy
Center	O
between	O
January	O
3	O
,	O
2006	O
,	O
and	O
June	O
3	O
,	O
2007	O
,	O
and	O
who	O
consented	O
to	O
participate	O
in	O
this	O
study	O
.	O
	
We	O
used	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
to	O
image	O
eyes	B-Anatomy
.	O
	
Multiple	O
B	B-Diagnostic_tool
-	I-Diagnostic_tool
scans	I-Diagnostic_tool
from	O
each	O
eye	B-Anatomy
were	O
saved	O
and	O
independently	O
graded	O
by	O
2	O
graders	O
and	O
the	O
following	O
locations	O
were	O
marked	O
:	O
(	O
1	O
)	O
site	O
where	O
PR	B-Characteristic
thickness	I-Characteristic
began	O
to	O
decline	O
below	O
its	O
baseline	O
,	O
(	O
2	O
)	O
site	O
where	O
PR	B-Anatomy
layer	I-Anatomy
disappeared	O
,	O
and	O
(	O
3	O
)	O
site	O
of	O
the	O
GA	B-Symptom
margin	O
.	O
	
These	O
data	O
were	O
processed	O
to	O
calculate	O
the	O
locations	O
of	O
PR	B-Symptom
losses	I-Symptom
relative	O
to	O
GA	B-Symptom
margins	O
and	O
were	O
categorized	O
as	O
(	O
A	O
)	O
bridging	O
across	O
GA	B-Symptom
margins	O
,	O
(	O
B	O
)	O
entirely	O
within	O
GA	B-Symptom
margins	O
,	O
or	O
(	O
C	O
)	O
entirely	O
outside	O
GA	B-Symptom
margins	O
.	O
	
Location	O
of	O
PR	B-Symptom
loss	I-Symptom
(	O
bridging	O
across	O
GA	B-Symptom
margins	O
,	O
entirely	O
within	O
GA	B-Symptom
margins	O
,	O
or	O
entirely	O
outside	O
GA	B-Symptom
margins	O
)	O
was	O
calculated	O
.	O
	
Distances	O
from	O
the	O
GA	B-Symptom
margin	O
were	O
measured	O
for	O
beginning	O
and	O
ending	O
of	O
PR	B-Symptom
loss	I-Symptom
.	O
	
Interobserver	O
agreement	O
was	O
determined	O
for	O
categories	O
of	O
PR	B-Symptom
loss	I-Symptom
as	O
well	O
as	O
locations	O
of	O
PR	B-Symptom
loss	I-Symptom
relative	O
to	O
the	O
GA	B-Symptom
margin	O
.	O
	
We	O
analyzed	O
500	O
unique	O
scans	O
.	O
	
The	O
PR	B-Symptom
loss	I-Symptom
occurred	O
most	O
frequently	O
bridging	O
across	O
the	O
GA	B-Symptom
margin	O
(	O
65	O
%	O
scans	O
)	O
,	O
second	O
most	O
frequently	O
entirely	O
inside	O
the	O
GA	B-Symptom
margin	O
(	O
29	O
%	O
scans	O
)	O
,	O
and	O
least	O
frequently	O
entirely	O
outside	O
the	O
GA	B-Symptom
margin	O
(	O
6	O
%	O
scans	O
)	O
.	O
	
Loss	B-Symptom
of	I-Symptom
PR	I-Symptom
started	O
an	O
average	O
of	O
61	B-Dimension
microm	I-Dimension
(	O
standard	O
deviation	O
[	O
SD	O
]	O
+	O
/	O
-	O
235	O
)	O
outside	O
the	O
GA	B-Symptom
margin	O
,	O
ended	O
an	O
average	O
of	O
311	B-Dimension
+	I-Dimension
/	I-Dimension
-	I-Dimension
273	I-Dimension
microm	I-Dimension
inside	O
the	O
GA	B-Symptom
margin	O
,	O
and	O
spanned	O
an	O
average	O
of	O
372	B-Dimension
+	I-Dimension
/	I-Dimension
-	I-Dimension
179	I-Dimension
microm	I-Dimension
.	O
	
Relative	O
to	O
GA	B-Symptom
margins	O
in	O
non	B-Disease
-	I-Disease
neovascular	I-Disease
AMD	I-Disease
with	O
GA	B-Symptom
,	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
provides	O
adequate	O
resolution	O
for	O
quantifying	O
PR	B-Symptom
loss	I-Symptom
.	O
	
It	O
may	O
also	O
serve	O
as	O
a	O
means	O
of	O
tracking	O
disease	O
progression	O
in	O
future	O
interventional	O
trials	O
.	O
	
Proprietary	O
or	O
commercial	O
disclosure	O
may	O
be	O
found	O
after	O
the	O
references	O
.	O
	
Foveal	B-Symptom
ganglion	I-Symptom
cell	I-Symptom
layer	I-Symptom
damage	I-Symptom
in	O
ischemic	B-Disease
diabetic	I-Disease
maculopathy	I-Disease
:	O
correlation	O
of	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomographic	I-Diagnostic_tool
and	O
anatomic	O
changes	O
.	O
	
To	O
describe	O
the	O
morphologic	O
features	O
of	O
ischemic	B-Disease
diabetic	I-Disease
maculopathy	I-Disease
by	O
high	B-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
and	O
their	O
correlation	O
with	O
the	O
damaged	B-Symptom
foveal	I-Symptom
avascular	I-Symptom
zone	I-Symptom
(	O
FAZ	B-Anatomy
)	O
on	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
FA	B-Diagnostic_tool
)	O
.	O
	
Observational	O
case	O
series	O
.	O
	
One	O
hundred	O
twenty	O
-	O
four	O
eyes	B-Anatomy
of	O
63	O
patients	O
with	O
diabetic	B-Disease
retinopathy	I-Disease
and	O
acceptable	O
FA	B-Diagnostic_tool
and	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
were	O
studied	O
.	O
	
Twenty	O
-	O
three	O
normal	B-Characteristic
fellow	I-Characteristic
eyes	B-Anatomy
of	O
23	O
nondiabetic	O
patients	O
with	O
unilateral	B-Disease
acute	I-Disease
central	I-Disease
serous	I-Disease
choroidopathy	I-Disease
also	O
were	O
studied	O
.	O
	
High	B-Diagnostic_tool
-	I-Diagnostic_tool
speed	I-Diagnostic_tool
Fourier	I-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
OCT	I-Diagnostic_tool
was	I-Diagnostic_tool
used	I-Diagnostic_tool
with	I-Diagnostic_tool
a	I-Diagnostic_tool
speckle	I-Diagnostic_tool
noise	I-Diagnostic_tool
-	I-Diagnostic_tool
reduction	I-Diagnostic_tool
technique	I-Diagnostic_tool
to	O
obtain	O
detailed	O
horizontal	O
and	O
vertical	O
images	O
through	O
the	O
center	B-Anatomy
of	I-Anatomy
the	I-Anatomy
fovea	I-Anatomy
and	O
horizontal	O
raster	O
scans	O
every	O
100	O
microm	O
.	O
	
Foveal	B-Symptom
ganglion	I-Symptom
cell	I-Symptom
layer	I-Symptom
(	I-Symptom
GCL	I-Symptom
)	I-Symptom
damage	I-Symptom
was	O
identified	O
on	O
OCT	B-Diagnostic_tool
as	O
an	O
evident	B-Symptom
difference	I-Symptom
in	I-Symptom
foveal	I-Symptom
thickness	I-Symptom
and	I-Symptom
contour	I-Symptom
compared	I-Symptom
with	I-Symptom
a	I-Symptom
normal	I-Symptom
fovea	I-Symptom
or	O
as	O
asymmetry	B-Symptom
within	I-Symptom
the	I-Symptom
fovea	I-Symptom
.	O
	
Fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
was	O
performed	O
by	O
confocal	B-Diagnostic_tool
scanning	I-Diagnostic_tool
laser	I-Diagnostic_tool
ophthalmoscope	I-Diagnostic_tool
(	O
HRA	B-Diagnostic_tool
2	I-Diagnostic_tool
;	O
Heidelberg	O
Engineering	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
,	O
and	O
FAZ	B-Symptom
damage	I-Symptom
visible	O
during	O
the	O
FA	B-Diagnostic_tool
arterial	O
phase	O
was	O
graded	O
according	O
to	O
the	O
Early	B-Classification_system
Treatment	I-Classification_system
Diabetic	I-Classification_system
Retinopathy	I-Classification_system
Study	I-Classification_system
(	I-Classification_system
ETDRS	I-Classification_system
)	I-Classification_system
FA	I-Classification_system
grading	I-Classification_system
system	I-Classification_system
.	O
	
Correlations	O
were	O
sought	O
between	O
foveal	B-Symptom
GCL	I-Symptom
damage	I-Symptom
identified	O
on	O
OCT	B-Diagnostic_tool
and	O
FA	B-Characteristic
capillary	I-Characteristic
dropout	I-Characteristic
sites	I-Characteristic
.	O
	
Foveal	B-Symptom
GCL	I-Symptom
damage	I-Symptom
on	O
OCT	B-Diagnostic_tool
,	O
the	O
size	B-Characteristic
of	I-Characteristic
the	I-Characteristic
foveola	I-Characteristic
on	I-Characteristic
OCT	I-Characteristic
(	O
defined	O
as	O
the	O
area	B-Characteristic
of	I-Characteristic
GCL	I-Characteristic
thickness	I-Characteristic
<	O
10	O
microm	O
)	O
,	O
ETDRS	B-Characteristic
grading	I-Characteristic
of	I-Characteristic
FAZ	I-Characteristic
on	I-Characteristic
FA	I-Characteristic
,	O
and	O
visual	B-Characteristic
acuity	I-Characteristic
.	O
	
Among	O
the	O
124	O
eyes	B-Anatomy
with	O
diabetic	B-Disease
retinopathy	I-Disease
,	O
62	O
(	O
50	O
%	O
)	O
had	O
FA	B-Diagnostic_tool
evidence	O
of	O
either	O
FAZ	B-Symptom
damage	I-Symptom
higher	O
than	O
grade	O
1	O
or	O
FAZ	B-Symptom
capillary	I-Symptom
loss	I-Symptom
.	O
	
In	O
these	O
eyes	B-Anatomy
,	O
damage	B-Symptom
to	I-Symptom
the	I-Symptom
FAZ	I-Symptom
seen	O
on	O
FA	B-Diagnostic_tool
also	O
could	O
be	O
detected	O
on	O
OCT	B-Diagnostic_tool
(	O
positive	O
predictive	O
value	O
,	O
84	O
.	O
5	O
%	O
;	O
negative	O
predictive	O
value	O
,	O
72	O
.	O
9	O
%	O
)	O
,	O
and	O
locations	O
of	O
FAZ	B-Symptom
damage	I-Symptom
seen	O
on	O
FA	B-Diagnostic_tool
corresponded	O
well	O
with	O
sites	O
of	O
foveal	B-Symptom
GCL	I-Symptom
damage	I-Symptom
on	O
OCT	B-Diagnostic_tool
.	O
	
In	O
nondiabetic	O
,	O
normal	O
eyes	B-Anatomy
,	O
the	O
size	B-Characteristic
of	I-Characteristic
the	I-Characteristic
foveola	I-Characteristic
on	I-Characteristic
OCT	I-Characteristic
matched	O
the	O
size	B-Characteristic
of	I-Characteristic
the	I-Characteristic
FAZ	I-Characteristic
on	I-Characteristic
FA	I-Characteristic
.	O
	
Evidence	O
of	O
foveal	B-Symptom
GCL	I-Symptom
damage	I-Symptom
on	O
OCT	B-Diagnostic_tool
is	O
a	O
good	O
indicator	O
of	O
macular	B-Symptom
ischemic	I-Symptom
damage	I-Symptom
in	O
eyes	B-Anatomy
with	O
diabetic	B-Disease
retinopathy	I-Disease
.	O
	
Although	O
in	O
this	O
study	O
FA	B-Diagnostic_tool
was	O
more	O
sensitive	O
than	O
OCT	B-Diagnostic_tool
in	O
detecting	O
vascular	B-Symptom
damage	I-Symptom
,	O
OCT	B-Diagnostic_tool
provides	O
objective	O
results	O
and	O
seems	O
to	O
be	O
a	O
good	O
noninvasive	O
substitute	O
for	O
FA	B-Diagnostic_tool
.	O
	
Does	O
the	O
presence	O
of	O
an	O
epiretinal	B-Symptom
membrane	I-Symptom
alter	O
the	O
cleavage	O
plane	O
during	O
internal	B-Anatomy
limiting	I-Anatomy
membrane	I-Anatomy
peeling	O
?	O
	
To	O
determine	O
whether	O
the	O
presence	O
of	O
a	O
clinically	O
and	O
/	O
or	O
microscopically	O
detectable	O
epiretinal	B-Symptom
membrane	I-Symptom
(	O
ERM	B-Symptom
)	O
alters	O
the	O
cleavage	O
plane	O
during	O
internal	B-Anatomy
limiting	I-Anatomy
membrane	I-Anatomy
(	O
ILM	B-Anatomy
)	O
peeling	O
.	O
	
Retrospective	O
,	O
observational	O
,	O
immunohistochemical	O
study	O
of	O
ILM	B-Anatomy
specimens	O
using	O
archival	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
.	O
	
Fifty	O
-	O
one	O
patients	O
who	O
had	O
had	O
ILM	B-Anatomy
excision	O
.	O
	
Fifty	O
-	O
one	O
ILM	B-Anatomy
specimens	O
peeled	O
during	O
vitrectomy	O
for	O
various	O
etiologies	O
were	O
examined	O
by	O
light	B-Diagnostic_tool
microscopy	I-Diagnostic_tool
.	O
	
The	O
removal	O
of	O
ILM	B-Anatomy
was	O
assisted	O
using	O
Trypan	O
blue	O
(	O
n	O
=	O
30	O
)	O
,	O
indocyanine	O
green	O
(	O
n	O
=	O
7	O
)	O
,	O
or	O
brilliant	O
blue	O
G	O
(	O
n	O
=	O
14	O
)	O
.	O
	
Monoclonal	B-Characteristic
antibodies	I-Characteristic
to	I-Characteristic
glial	I-Characteristic
fibrillary	I-Characteristic
acidic	I-Characteristic
protein	I-Characteristic
and	I-Characteristic
to	I-Characteristic
neurofilament	I-Characteristic
protein	I-Characteristic
were	O
used	O
to	O
detect	O
glial	B-Anatomy
or	I-Anatomy
neuronal	I-Anatomy
cells	I-Anatomy
respectively	O
on	O
the	O
vitreous	B-Anatomy
or	I-Anatomy
retinal	I-Anatomy
surfaces	I-Anatomy
of	I-Anatomy
the	I-Anatomy
ILM	I-Anatomy
.	O
	
Specimens	O
were	O
divided	O
into	O
2	O
groups	O
:	O
ILM	B-Anatomy
peeled	O
for	O
full	B-Characteristic
-	I-Characteristic
thickness	I-Characteristic
macular	I-Characteristic
hole	I-Characteristic
(	O
MH	B-Characteristic
;	O
n	O
=	O
31	O
)	O
and	O
ILM	B-Anatomy
peeled	O
after	O
removal	O
of	O
clinically	O
detectable	O
ERM	B-Symptom
(	O
n	O
=	O
20	O
)	O
.	O
	
Primary	O
outcome	O
measure	O
was	O
the	O
localization	O
of	O
immunohistochemical	B-Characteristic
markers	I-Characteristic
to	O
neuronal	B-Anatomy
or	I-Anatomy
glial	I-Anatomy
cells	I-Anatomy
on	I-Anatomy
the	I-Anatomy
vitreous	I-Anatomy
or	I-Anatomy
retinal	I-Anatomy
surfaces	I-Anatomy
of	I-Anatomy
ILM	I-Anatomy
.	O
	
The	O
secondary	O
outcome	O
measure	O
was	O
the	O
correlation	O
of	O
the	O
results	O
of	O
the	O
primary	O
measure	O
with	O
the	O
dyes	O
used	O
to	O
facilitate	O
ILM	B-Anatomy
peeling	O
.	O
	
Glial	B-Anatomy
and	I-Anatomy
/	I-Anatomy
or	I-Anatomy
neuronal	I-Anatomy
cells	I-Anatomy
were	O
detected	O
on	O
the	O
retinal	B-Anatomy
surface	I-Anatomy
of	O
the	O
ILM	B-Anatomy
in	O
10	O
of	O
31	O
(	O
32	O
%	O
)	O
of	O
the	O
MH	B-Characteristic
ILM	I-Characteristic
specimens	O
and	O
in	O
13	O
of	O
20	O
(	O
65	O
%	O
)	O
of	O
the	O
ILM	B-Anatomy
peeled	O
after	O
ERM	B-Symptom
excision	O
;	O
the	O
difference	O
was	O
significant	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O
	
There	O
was	O
no	O
association	O
between	O
the	O
presence	O
of	O
neuronal	B-Anatomy
and	I-Anatomy
glial	I-Anatomy
cells	I-Anatomy
with	O
the	O
type	O
of	O
dye	O
used	O
(	O
P	O
=	O
0	O
.	O
2	O
)	O
.	O
	
Of	O
the	O
23	O
ILM	B-Anatomy
specimens	O
with	O
cells	O
attached	O
to	O
the	O
retinal	B-Anatomy
surface	I-Anatomy
,	O
21	O
(	O
91	O
%	O
)	O
were	O
associated	O
with	O
clinical	O
and	O
/	O
or	O
histologic	O
evidence	O
of	O
ERM	B-Symptom
and	O
2	O
(	O
9	O
%	O
)	O
were	O
not	O
.	O
	
The	O
correlation	O
between	O
the	O
presence	O
of	O
cells	B-Anatomy
on	I-Anatomy
the	I-Anatomy
vitreous	I-Anatomy
and	I-Anatomy
the	I-Anatomy
retinal	I-Anatomy
surfaces	I-Anatomy
of	I-Anatomy
ILM	I-Anatomy
was	O
high	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
	
The	O
findings	O
suggest	O
that	O
ERM	B-Symptom
may	O
be	O
associated	O
with	O
sub	B-Characteristic
-	I-Characteristic
ILM	I-Characteristic
changes	I-Characteristic
that	O
alter	O
the	O
plane	O
of	O
separation	O
during	O
ILM	B-Anatomy
peeling	O
.	O
	
This	O
study	O
does	O
not	O
confirm	O
any	O
influence	O
of	O
dyes	O
on	O
the	O
cleavage	O
plane	O
during	O
surgery	O
.	O
	
In	O
vivo	O
retinal	B-Anatomy
morphology	I-Anatomy
after	O
grid	O
laser	O
treatment	O
in	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
To	O
analyze	O
immediate	O
in	O
vivo	O
intraretinal	B-Symptom
morphologic	I-Symptom
changes	I-Symptom
secondary	O
to	O
standardized	O
grid	O
photocoagulation	O
using	O
spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
.	O
	
Prospective	O
clinical	O
trial	O
.	O
	
Thirteen	O
consecutive	O
patients	O
with	O
treatment	O
-	O
na	O
	O
ve	O
clinically	O
significant	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
.	O
	
Before	O
and	O
1	O
day	O
after	O
standardized	O
grid	O
photocoagulation	O
using	O
the	O
PASCAL	O
system	O
(	O
Pattern	O
Scan	O
Laser	O
,	O
OptiMedica	O
Corporation	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
,	O
Spectralis	B-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
Heidelberg	O
Engineering	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
examinations	O
based	O
on	O
an	O
eye	B-Diagnostic_tool
-	I-Diagnostic_tool
tracking	I-Diagnostic_tool
system	I-Diagnostic_tool
,	O
infrared	B-Diagnostic_tool
fundus	I-Diagnostic_tool
imaging	I-Diagnostic_tool
,	O
color	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photography	I-Diagnostic_tool
,	O
and	O
biomicroscopy	B-Diagnostic_tool
were	O
performed	O
.	O
	
A	O
standardized	O
visual	B-Diagnostic_tool
acuity	I-Diagnostic_tool
assessment	O
(	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
protocol	O
)	O
and	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
were	O
performed	O
at	O
baseline	O
.	O
	
Morphologic	B-Symptom
changes	I-Symptom
secondary	O
to	O
grid	O
laser	O
treatment	O
.	O
	
One	O
day	O
after	O
laser	O
therapy	O
,	O
immediate	O
morphologic	O
alterations	O
of	O
only	O
the	O
outer	B-Anatomy
retinal	I-Anatomy
layers	I-Anatomy
,	O
that	O
is	O
,	O
the	O
retinal	B-Anatomy
pigment	I-Anatomy
epithelium	I-Anatomy
(	O
RPE	B-Anatomy
)	O
,	O
the	O
photoreceptor	B-Anatomy
layer	I-Anatomy
(	O
PRL	B-Anatomy
)	O
,	O
and	O
the	O
outer	B-Anatomy
nuclear	I-Anatomy
layer	I-Anatomy
(	O
ONL	B-Anatomy
)	O
,	O
were	O
observed	O
.	O
	
The	O
shape	O
of	O
the	O
laser	O
-	O
induced	O
lesions	O
did	O
not	O
show	O
a	O
sagittal	O
alteration	O
pattern	O
throughout	O
all	O
3	O
of	O
the	O
layers	O
,	O
however	O
,	O
but	O
rather	O
seemed	O
to	O
follow	O
an	O
oblique	O
pathway	O
throughout	O
the	O
ONL	B-Anatomy
,	O
changing	O
direction	O
at	O
the	O
level	O
of	O
the	O
external	B-Anatomy
limiting	I-Anatomy
membrane	I-Anatomy
and	O
proceeding	O
sagittally	O
through	O
the	O
PRL	B-Anatomy
and	O
RPE	B-Anatomy
.	O
	
These	O
morphologic	B-Symptom
changes	I-Symptom
also	O
induced	O
biometric	B-Symptom
changes	I-Symptom
,	O
such	O
as	O
a	O
decrease	O
in	O
central	B-Symptom
retinal	I-Symptom
thickness	I-Symptom
combined	O
with	O
local	B-Symptom
thickening	I-Symptom
at	I-Symptom
the	I-Symptom
lesion	I-Symptom
site	I-Symptom
,	O
especially	O
in	O
the	O
PRL	B-Anatomy
.	O
	
Spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
provides	O
new	O
insight	O
into	O
the	O
immediate	O
morphologic	B-Symptom
changes	I-Symptom
after	O
laser	O
treatment	O
using	O
the	O
PASCAL	O
laser	O
system	O
.	O
	
Standardized	O
grid	O
photocoagulation	O
induces	O
characteristic	O
homogenous	O
alteration	O
in	O
the	O
neurosensoric	B-Anatomy
retinal	I-Anatomy
layers	I-Anatomy
.	O
	
Biometric	B-Symptom
changes	I-Symptom
,	O
indicating	O
an	O
immediate	O
effect	O
,	O
were	O
observed	O
within	O
1	O
day	O
after	O
treatment	O
.	O
	
Central	B-Characteristic
corneal	I-Characteristic
thickness	I-Characteristic
in	O
adult	B-Characteristic
South	I-Characteristic
Indians	I-Characteristic
:	O
the	O
Chennai	O
Glaucoma	B-Disease
Study	O
.	O
	
To	O
evaluate	O
the	O
characteristics	O
of	O
central	B-Characteristic
corneal	I-Characteristic
thickness	I-Characteristic
(	O
CCT	B-Characteristic
)	O
and	O
its	O
association	O
with	O
age	B-Characteristic
,	O
gender	B-Characteristic
,	O
and	O
intraocular	B-Characteristic
pressure	I-Characteristic
in	O
rural	B-Characteristic
and	I-Characteristic
urban	I-Characteristic
South	I-Characteristic
Indian	I-Characteristic
populations	I-Characteristic
.	O
	
Population	O
-	O
based	O
cross	O
-	O
sectional	O
study	O
.	O
	
Seven	O
thousand	O
seven	O
hundred	O
seventy	O
-	O
four	O
subjects	O
(	O
rural	O
-	O
to	O
-	O
urban	O
ratio	O
,	O
3924	O
:	O
3850	O
)	O
aged	B-Characteristic
40	I-Characteristic
years	I-Characteristic
and	I-Characteristic
older	I-Characteristic
were	O
examined	O
at	O
a	O
dedicated	O
facility	O
in	O
the	O
base	O
hospital	O
.	O
	
All	O
subjects	O
underwent	O
a	O
complete	O
ophthalmic	B-Diagnostic_tool
examination	I-Diagnostic_tool
that	O
included	O
CCT	B-Characteristic
measurements	O
with	O
an	O
ultrasonic	B-Diagnostic_tool
pachymeter	I-Diagnostic_tool
and	O
applanation	B-Diagnostic_tool
tonometry	I-Diagnostic_tool
.	O
	
Central	B-Characteristic
corneal	I-Characteristic
thickness	I-Characteristic
.	O
	
Of	O
the	O
7774	O
subjects	O
examined	O
,	O
974	O
had	O
undergone	O
cataract	B-Disease
surgery	O
and	O
were	O
excluded	O
.	O
	
The	O
remaining	O
6800	O
were	O
bilaterally	O
phakic	O
,	O
of	O
which	O
46	O
were	O
excluded	O
(	O
17	O
glaucoma	B-Disease
subjects	O
receiving	O
treatment	O
,	O
12	O
with	O
corneal	B-Characteristic
pathologic	I-Characteristic
features	I-Characteristic
and	O
17	O
with	O
incomplete	O
data	O
)	O
and	O
6754	O
subjects	O
data	O
were	O
analyzed	O
.	O
	
The	O
mean	O
CCT	B-Characteristic
for	O
the	O
population	O
was	O
511	O
.	O
4	O
+	O
/	O
-	O
33	O
.	O
5	O
microm	O
,	O
and	O
CCT	B-Characteristic
in	O
males	B-Characteristic
(	O
515	O
.	O
6	O
+	O
/	O
-	O
33	O
.	O
8	O
microm	O
)	O
was	O
significantly	O
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
greater	O
than	O
females	B-Characteristic
(	O
508	O
.	O
0	O
+	O
/	O
-	O
32	O
.	O
8	O
microm	O
)	O
.	O
	
The	O
CCT	B-Characteristic
was	O
significantly	O
greater	O
(	O
by	O
18	O
microm	O
)	O
in	O
the	O
urban	B-Characteristic
population	I-Characteristic
and	O
decreased	O
with	O
age	B-Characteristic
in	O
both	O
genders	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
	
The	O
decrease	O
per	O
decade	O
was	O
4	O
.	O
34	O
microm	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
3	O
.	O
24	O
-	O
5	O
.	O
44	O
)	O
in	O
the	O
rural	B-Characteristic
population	I-Characteristic
and	O
2	O
.	O
41	O
microm	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
25	O
-	O
3	O
.	O
53	O
)	O
in	O
the	O
urban	B-Characteristic
population	I-Characteristic
.	O
	
A	O
100	O
-	O
microm	O
increase	O
in	O
CCT	B-Characteristic
was	O
associated	O
with	O
a	O
1	O
.	O
96	O
-	O
mmHg	O
increase	O
in	O
intraocular	B-Characteristic
pressure	I-Characteristic
in	O
the	O
rural	B-Characteristic
population	I-Characteristic
,	O
versus	O
2	O
.	O
45	O
mmHg	O
for	O
every	O
100	O
microm	O
in	O
the	O
urban	B-Characteristic
population	I-Characteristic
.	O
	
In	O
this	O
population	O
-	O
based	O
study	O
,	O
females	B-Characteristic
and	O
subjects	O
living	O
in	O
a	O
rural	B-Characteristic
area	I-Characteristic
had	O
thinner	B-Symptom
corneas	I-Symptom
.	O
	
A	O
negative	O
association	O
with	O
age	B-Characteristic
and	O
a	O
positive	O
association	O
with	O
intraocular	B-Characteristic
pressure	I-Characteristic
were	O
seen	O
.	O
	
These	O
findings	O
will	O
have	O
implications	O
in	O
the	O
diagnosis	O
and	O
management	O
of	O
glaucoma	B-Disease
in	O
this	O
population	O
.	O
	
Proprietary	O
or	O
commercial	O
disclosure	O
may	O
be	O
found	O
after	O
the	O
references	O
.	O
	
Evaluation	O
of	O
morning	B-Disease
glory	I-Disease
syndrome	I-Disease
with	O
spectral	B-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
and	O
echography	B-Diagnostic_tool
.	O
	
To	O
evaluate	O
eyes	B-Anatomy
affected	O
by	O
morning	B-Disease
glory	I-Disease
syndrome	I-Disease
(	O
MGS	B-Disease
)	O
with	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
and	O
echography	B-Diagnostic_tool
.	O
	
Prospective	O
case	O
series	O
.	O
	
Nineteen	O
patients	O
(	O
22	O
eyes	B-Anatomy
)	O
with	O
MGS	B-Disease
observed	O
at	O
the	O
Eye	O
Department	O
,	O
University	O
of	O
Naples	O
Federico	O
II	O
,	O
Naples	O
,	O
Italy	O
.	O
	
All	O
patients	O
underwent	O
a	O
complete	O
ophthalmologic	B-Diagnostic_tool
examination	I-Diagnostic_tool
that	O
included	O
best	B-Diagnostic_tool
-	I-Diagnostic_tool
correct	I-Diagnostic_tool
visual	I-Diagnostic_tool
acuity	I-Diagnostic_tool
,	O
fundus	B-Diagnostic_tool
photography	I-Diagnostic_tool
,	O
and	O
echography	B-Diagnostic_tool
.	O
	
Nine	O
patients	O
underwent	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
high	B-Diagnostic_tool
-	I-Diagnostic_tool
frequency	I-Diagnostic_tool
B	I-Diagnostic_tool
-	I-Diagnostic_tool
scan	I-Diagnostic_tool
echography	I-Diagnostic_tool
(	I-Diagnostic_tool
20	I-Diagnostic_tool
MHz	I-Diagnostic_tool
)	I-Diagnostic_tool
.	O
	
Spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
and	O
echographic	B-Diagnostic_tool
findings	O
in	O
MGS	B-Disease
.	O
	
Spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
revealed	O
retinal	B-Symptom
detachment	I-Symptom
in	I-Symptom
the	I-Symptom
conus	I-Symptom
area	I-Symptom
of	O
5	O
eyes	B-Anatomy
:	O
4	O
with	O
noncontractile	B-Disease
MGS	I-Disease
(	O
NCMGS	B-Disease
)	O
and	O
1	O
with	O
contractile	B-Disease
MGS	I-Disease
(	O
CMGS	B-Disease
)	O
.	O
	
There	O
was	O
evidence	O
of	O
a	O
retinal	B-Symptom
break	I-Symptom
in	O
only	O
2	O
cases	O
.	O
	
All	O
5	O
eyes	B-Anatomy
had	O
an	O
abnormal	B-Symptom
communication	I-Symptom
between	I-Symptom
the	I-Symptom
subarachnoid	I-Symptom
space	I-Symptom
and	I-Symptom
the	I-Symptom
subretinal	I-Symptom
space	I-Symptom
.	O
	
Spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
did	O
not	O
reveal	O
differences	O
between	O
CMGS	B-Disease
and	O
NCMGS	B-Disease
.	O
	
Echographic	B-Diagnostic_tool
examination	I-Diagnostic_tool
did	O
not	O
reveal	O
any	O
anatomic	B-Symptom
abnormalities	I-Symptom
of	I-Symptom
the	I-Symptom
optic	I-Symptom
nerve	I-Symptom
or	I-Symptom
orbit	I-Symptom
.	O
	
Spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
provides	O
more	O
information	O
than	O
echography	B-Diagnostic_tool
about	O
the	O
posterior	B-Anatomy
pole	I-Anatomy
,	O
whereas	O
echographic	B-Diagnostic_tool
examination	I-Diagnostic_tool
is	O
the	O
only	O
technique	O
that	O
can	O
confirm	O
the	O
anatomic	B-Characteristic
integrity	I-Characteristic
of	I-Characteristic
the	I-Characteristic
optic	I-Characteristic
nerve	I-Characteristic
in	I-Characteristic
the	I-Characteristic
orbital	I-Characteristic
wall	I-Characteristic
.	O
	
Retinal	B-Symptom
detachment	I-Symptom
in	O
MGS	B-Disease
generally	O
is	O
ascribed	O
to	O
abnormal	B-Symptom
communication	I-Symptom
between	I-Symptom
the	I-Symptom
subretinal	I-Symptom
and	I-Symptom
subarachnoid	I-Symptom
or	I-Symptom
vitreous	I-Symptom
compartments	I-Symptom
.	O
	
These	O
data	O
suggest	O
that	O
myopialike	B-Symptom
retinal	I-Symptom
detachment	I-Symptom
without	I-Symptom
a	I-Symptom
retinal	I-Symptom
break	I-Symptom
may	O
result	O
from	O
tissue	B-Symptom
stretching	I-Symptom
around	I-Symptom
the	I-Symptom
peripapillary	I-Symptom
conus	I-Symptom
.	O
	
A	O
proposed	O
method	O
of	O
logarithmic	O
transformation	O
of	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
data	O
for	O
use	O
in	O
clinical	O
research	O
.	O
	
To	O
evaluate	O
a	O
logarithmic	O
transformation	O
of	O
retinal	B-Characteristic
thickness	I-Characteristic
measurements	O
from	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
as	O
a	O
new	O
approach	O
to	O
assess	O
clinically	O
meaningful	O
changes	O
in	O
retinal	B-Characteristic
thickness	I-Characteristic
.	O
	
Methodologic	O
,	O
evidence	O
-	O
based	O
review	O
.	O
	
Standard	O
published	O
approaches	O
for	O
assessing	O
change	O
in	O
retinal	B-Characteristic
thickness	I-Characteristic
over	O
time	O
,	O
as	O
measured	O
by	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
,	O
were	O
compared	O
with	O
a	O
new	O
approach	O
based	O
on	O
a	O
logarithmic	O
transformation	O
of	O
the	O
retinal	B-Characteristic
thickness	I-Characteristic
data	O
.	O
	
Comparative	O
examples	O
were	O
derived	O
using	O
published	O
data	O
from	O
a	O
clinical	O
trial	O
comparing	O
intravitreal	O
corticosteroid	O
injections	O
for	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
with	O
standard	O
laser	O
treatment	O
.	O
	
Comparative	O
examples	O
using	O
Diabetic	B-Disease
Retinopathy	I-Disease
Clinical	O
Research	O
Network	O
data	O
.	O
	
Logarithmic	O
transformation	O
of	O
retinal	B-Characteristic
thickness	I-Characteristic
data	O
results	O
in	O
a	O
more	O
normalized	O
distribution	O
of	O
OCT	B-Diagnostic_tool
data	O
and	O
allows	O
for	O
data	O
analyses	O
assessing	O
proportionate	O
changes	O
in	O
retinal	B-Characteristic
thickness	I-Characteristic
during	O
follow	O
-	O
up	O
.	O
	
For	O
analysis	O
of	O
grouped	O
data	O
,	O
a	O
logarithmic	B-Characteristic
transformation	I-Characteristic
of	I-Characteristic
the	I-Characteristic
OCT	I-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
measurements	I-Characteristic
(	O
logOCT	B-Characteristic
)	O
provides	O
several	O
analytic	O
advantages	O
.	O
	
Distributions	O
of	O
retinal	B-Characteristic
thickness	I-Characteristic
in	O
groups	O
of	O
eyes	B-Anatomy
with	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
,	O
and	O
many	O
other	O
causes	O
of	O
macular	B-Symptom
thickening	I-Symptom
,	O
tend	O
to	O
be	O
skewed	O
to	O
the	O
right	O
;	O
the	O
logOCT	B-Characteristic
transformation	O
tends	O
to	O
normalize	O
these	O
distributions	O
,	O
which	O
has	O
value	O
for	O
statistical	O
comparisons	O
.	O
	
For	O
assessing	O
whether	O
the	O
observed	O
OCT	B-Diagnostic_tool
change	O
in	O
a	O
patient	O
is	O
real	O
(	O
and	O
not	O
due	O
to	O
testing	O
variability	O
)	O
,	O
a	O
1	O
-	O
step	O
log	O
scale	O
change	O
exceeds	O
the	O
measurement	O
error	O
for	O
all	O
degrees	O
of	O
retinal	B-Characteristic
thickness	I-Characteristic
in	O
current	O
instruments	O
.	O
	
In	O
addition	O
,	O
this	O
log	O
scale	O
is	O
similar	O
to	O
the	O
logarithm	B-Characteristic
of	I-Characteristic
the	I-Characteristic
minimum	I-Characteristic
angle	I-Characteristic
of	I-Characteristic
resolution	I-Characteristic
(	O
logMAR	B-Characteristic
)	O
scale	O
used	O
for	O
visual	B-Characteristic
acuity	I-Characteristic
.	O
	
Steps	O
on	O
the	O
log	O
scale	O
for	O
change	O
in	O
thickness	O
seem	O
to	O
be	O
better	O
related	O
to	O
clinical	O
importance	O
than	O
the	O
actual	O
change	O
in	O
microns	O
because	O
each	O
step	O
on	O
the	O
log	O
scale	O
is	O
the	O
same	O
proportionate	O
change	O
in	O
thickness	O
,	O
with	O
a	O
3	O
-	O
step	O
change	O
equaling	O
a	O
halving	O
or	O
doubling	O
of	O
thickness	O
,	O
regardless	O
of	O
the	O
baseline	O
value	O
.	O
	
Transformation	O
of	O
OCT	B-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
data	O
to	O
logOCT	B-Characteristic
may	O
assist	O
in	O
the	O
assessment	O
of	O
clinically	O
meaningful	O
changes	O
in	O
retinal	B-Characteristic
thickness	I-Characteristic
just	O
as	O
use	O
of	O
the	O
logMAR	B-Characteristic
scale	O
has	O
helped	O
to	O
assess	O
clinically	O
meaningful	O
changes	O
in	O
visual	B-Characteristic
acuity	I-Characteristic
.	O
	
Prevalence	O
and	O
significance	O
of	O
subretinal	B-Symptom
drusenoid	I-Symptom
deposits	I-Symptom
(	O
reticular	B-Symptom
pseudodrusen	I-Symptom
)	O
in	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
	
Purpose	O
:	O
To	O
determine	O
the	O
prevalence	O
and	O
significance	O
of	O
subretinal	B-Symptom
drusenoid	I-Symptom
deposits	I-Symptom
(	O
reticular	B-Symptom
pseudodrusen	I-Symptom
)	O
among	O
patients	O
with	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Design	O
:	O
A	O
prospective	O
study	O
with	O
a	O
nested	O
case	O
-	O
control	O
study	O
of	O
consecutive	O
patients	O
with	O
AMD	B-Disease
seen	O
in	O
a	O
referral	O
retinal	O
practice	O
.	O
	
Participants	O
:	O
There	O
were	O
153	O
patients	O
with	O
AMD	B-Disease
,	O
131	O
of	O
whom	O
had	O
>	O
or	O
=	O
1	O
eye	B-Anatomy
with	O
late	B-Disease
AMD	I-Disease
,	O
which	O
was	O
defined	O
as	O
either	O
central	B-Symptom
geographic	I-Symptom
atrophy	I-Symptom
or	O
choroidal	B-Symptom
neovascularization	I-Symptom
.	O
	
The	O
control	O
group	O
consisted	O
of	O
101	O
patients	O
who	O
did	O
not	O
have	O
AMD	B-Disease
as	O
their	O
primary	O
diagnosis	O
,	O
central	B-Disease
serous	I-Disease
chorioretinopathy	I-Disease
,	O
high	B-Disease
myopia	I-Disease
,	O
retinal	B-Symptom
detachment	I-Symptom
,	O
or	O
laser	O
treatment	O
in	O
the	O
macular	B-Anatomy
area	I-Anatomy
.	I-Anatomy
	
Methods	O
:	O
The	O
presence	O
of	O
subretinal	B-Symptom
drusenoid	I-Symptom
deposits	I-Symptom
was	O
determined	O
by	O
2	O
methods	O
,	O
using	O
the	O
blue	B-Diagnostic_tool
channel	I-Diagnostic_tool
of	I-Diagnostic_tool
color	I-Diagnostic_tool
fundus	I-Diagnostic_tool
photograph	I-Diagnostic_tool
and	O
the	O
spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
sections	O
.	O
	
Soft	B-Symptom
drusen	I-Symptom
were	O
determined	O
from	O
color	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
and	O
confirmed	O
by	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
.	O
	
Main	O
outcome	O
measures	O
:	O
Prevalence	O
of	O
ocular	B-Symptom
risk	I-Symptom
factors	I-Symptom
and	O
subretinal	B-Symptom
drusenoid	I-Symptom
deposits	I-Symptom
in	I-Symptom
eyes	I-Symptom
with	O
AMD	B-Disease
and	O
their	O
association	O
with	O
late	B-Disease
AMD	I-Disease
.	O
	
Results	O
:	O
There	O
were	O
153	O
patients	O
who	O
had	O
any	O
form	O
of	O
AMD	B-Disease
,	O
with	O
a	O
mean	B-Characteristic
age	I-Characteristic
of	I-Characteristic
80	I-Characteristic
.	I-Characteristic
3	I-Characteristic
years	I-Characteristic
.	O
	
Subretinal	B-Symptom
drusenoid	I-Symptom
deposits	I-Symptom
were	O
diagnosed	O
in	O
the	O
case	O
group	O
in	O
13	O
(	O
8	O
.	O
7	O
%	O
)	O
of	O
right	O
and	O
18	O
(	O
12	O
.	O
0	O
%	O
)	O
of	O
left	B-Anatomy
eyes	I-Anatomy
using	O
the	O
blue	B-Diagnostic_tool
channel	I-Diagnostic_tool
of	I-Diagnostic_tool
the	I-Diagnostic_tool
color	I-Diagnostic_tool
photograph	I-Diagnostic_tool
and	O
in	O
58	O
(	O
38	O
.	O
4	O
%	O
)	O
of	O
right	O
and	O
54	O
(	O
35	O
.	O
8	O
%	O
)	O
of	O
left	B-Anatomy
eyes	I-Anatomy
using	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
.	O
	
Soft	B-Symptom
drusen	I-Symptom
and	O
subretinal	B-Symptom
drusenoid	I-Symptom
deposits	I-Symptom
detected	O
by	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
were	O
found	O
to	O
be	O
independently	O
correlated	O
with	O
late	B-Disease
AMD	I-Disease
(	O
soft	B-Symptom
drusen	I-Symptom
odds	O
ratio	O
=	O
16	O
.	O
66	O
[	O
P	O
<	O
0	O
.	O
001	O
]	O
;	O
subretinal	B-Symptom
drusenoid	I-Symptom
deposits	I-Symptom
as	O
detected	O
by	O
OCT	B-Diagnostic_tool
odds	O
ratio	O
=	O
2	O
.	O
64	O
[	O
P	O
=	O
0	O
.	O
034	O
]	O
)	O
.	O
	
In	O
the	O
control	O
group	O
,	O
subretinal	B-Symptom
drusenoid	I-Symptom
deposits	I-Symptom
were	O
diagnosed	O
in	O
6	O
(	O
6	O
.	O
5	O
%	O
)	O
of	O
right	O
and	O
6	O
(	O
6	O
.	O
3	O
%	O
)	O
of	O
left	B-Anatomy
eyes	I-Anatomy
using	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
.	I-Diagnostic_tool
	
Conclusions	O
:	O
Both	O
soft	B-Symptom
drusen	I-Symptom
and	O
subretinal	B-Symptom
drusenoid	I-Symptom
deposits	I-Symptom
occur	O
in	O
patients	O
with	O
AMD	B-Disease
and	O
both	O
are	O
significantly	O
associated	O
with	O
late	B-Disease
AMD	I-Disease
.	O
	
These	O
findings	O
suggest	O
that	O
detection	O
and	O
classification	O
of	O
drusen	B-Symptom
and	O
consequently	O
assignment	O
of	O
risk	O
should	O
be	O
based	O
on	O
a	O
methodology	O
that	O
includes	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
.	I-Diagnostic_tool
	
Foveal	B-Symptom
cystoid	I-Symptom
spaces	I-Symptom
are	O
associated	O
with	O
enlarged	B-Symptom
foveal	I-Symptom
avascular	I-Symptom
zone	I-Symptom
and	O
microaneurysms	B-Symptom
in	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
To	O
study	O
the	O
association	O
between	O
pathomorphology	B-Symptom
at	I-Symptom
the	I-Symptom
foveal	I-Symptom
center	I-Symptom
delineated	O
by	O
spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
and	O
vascular	B-Symptom
changes	I-Symptom
around	I-Symptom
the	I-Symptom
fovea	I-Symptom
in	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
FA	B-Diagnostic_tool
)	O
in	O
patients	O
with	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
.	O
	
Retrospective	O
,	O
observational	O
,	O
cross	O
-	O
sectional	O
study	O
.	O
	
Consecutive	O
series	O
of	O
86	O
eyes	B-Anatomy
from	O
72	O
patients	O
with	O
clinically	B-Disease
significant	I-Disease
macular	I-Disease
edema	I-Disease
(	O
CSME	B-Disease
)	O
on	O
which	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
FA	B-Diagnostic_tool
were	O
performed	O
on	O
the	O
same	O
day	O
.	O
	
Fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
using	O
HRA2	B-Diagnostic_tool
(	O
Heidelberg	O
Engineering	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
and	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
images	I-Diagnostic_tool
using	O
Spectralis	B-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
Heidelberg	O
Engineering	O
)	O
were	O
obtained	O
for	O
all	O
patients	O
.	O
	
Microaneurysms	B-Symptom
(	O
MAs	B-Symptom
)	O
in	O
the	O
perifoveal	B-Anatomy
capillary	I-Anatomy
network	I-Anatomy
(	O
PCN	B-Anatomy
)	O
and	O
foveal	B-Anatomy
avascular	I-Anatomy
zone	I-Anatomy
(	O
FAZ	B-Anatomy
)	O
in	O
the	O
FA	B-Diagnostic_tool
images	I-Diagnostic_tool
were	O
quantified	O
.	O
	
The	O
pathomorphology	B-Symptom
at	I-Symptom
the	I-Symptom
foveal	I-Symptom
center	I-Symptom
was	O
evaluated	O
in	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
.	O
	
We	O
then	O
investigated	O
the	O
association	O
between	O
pathologic	B-Symptom
perifoveal	I-Symptom
capillaries	I-Symptom
in	O
FA	B-Diagnostic_tool
and	O
the	O
neuroglial	B-Characteristic
morphology	I-Characteristic
in	O
OCT	B-Diagnostic_tool
.	O
	
The	O
relationship	O
between	O
pathologic	B-Symptom
changes	I-Symptom
in	I-Symptom
perifoveal	I-Symptom
capillaries	I-Symptom
in	O
FA	B-Diagnostic_tool
and	O
foveal	B-Symptom
pathomorphology	I-Symptom
in	O
OCT	B-Diagnostic_tool
.	O
	
According	O
to	O
the	O
foveal	B-Characteristic
morphology	I-Characteristic
in	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
,	O
44	O
eyes	B-Anatomy
presented	O
foveal	B-Symptom
cystoid	I-Symptom
spaces	I-Symptom
(	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
[	O
CME	B-Disease
]	O
)	O
,	O
25	O
eyes	B-Anatomy
had	O
serous	B-Symptom
retinal	I-Symptom
detachment	I-Symptom
(	O
SRD	B-Symptom
)	O
at	O
the	O
foveal	B-Anatomy
center	I-Anatomy
,	O
and	O
17	O
eyes	B-Anatomy
had	O
foveal	B-Symptom
thickening	I-Symptom
without	I-Symptom
cystoid	I-Symptom
spaces	I-Symptom
or	O
retinal	B-Symptom
detachment	I-Symptom
(	O
retinal	B-Symptom
swelling	I-Symptom
)	O
.	O
	
After	O
3	O
eyes	B-Anatomy
with	O
ischemic	B-Disease
maculopathy	I-Disease
were	O
excluded	O
,	O
the	O
relationship	O
was	O
evaluated	O
.	O
	
The	O
number	O
of	O
MAs	B-Symptom
in	O
the	O
PCN	B-Anatomy
was	O
significantly	O
greater	O
in	O
eyes	B-Anatomy
with	O
CME	B-Disease
(	O
3	O
.	O
20	O
	O
1	O
.	O
76	O
)	O
than	O
in	O
eyes	B-Anatomy
with	O
SRD	B-Symptom
(	O
0	O
.	O
40	O
	O
1	O
.	O
04	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
or	O
retinal	B-Symptom
swelling	I-Symptom
(	O
0	O
.	O
47	O
	O
0	O
.	O
72	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
	
In	O
addition	O
,	O
the	O
FAZ	B-Anatomy
in	O
the	O
eyes	B-Anatomy
with	O
CME	B-Disease
(	O
0	B-Dimension
.	I-Dimension
553	I-Dimension
	I-Dimension
0	I-Dimension
.	I-Dimension
323	I-Dimension
mm	I-Dimension
(	I-Dimension
2	I-Dimension
)	I-Dimension
)	O
was	O
significantly	O
larger	O
than	O
that	O
of	O
the	O
eyes	B-Anatomy
with	O
SRD	B-Symptom
(	O
0	B-Dimension
.	I-Dimension
302	I-Dimension
	I-Dimension
0	I-Dimension
.	I-Dimension
245	I-Dimension
mm	I-Dimension
(	I-Dimension
2	I-Dimension
)	I-Dimension
;	O
P	O
<	O
0	O
.	O
01	O
)	O
or	O
retinal	B-Symptom
swelling	I-Symptom
(	O
0	B-Dimension
.	I-Dimension
268	I-Dimension
	I-Dimension
0	I-Dimension
.	I-Dimension
142	I-Dimension
mm	I-Dimension
(	I-Dimension
2	I-Dimension
)	I-Dimension
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
	
These	O
associations	O
were	O
found	O
in	O
eyes	B-Anatomy
with	O
thickened	B-Symptom
posterior	I-Symptom
hyaloid	I-Symptom
membranes	I-Symptom
.	O
	
The	O
eyes	B-Anatomy
with	O
cystoid	B-Symptom
spaces	I-Symptom
at	I-Symptom
the	I-Symptom
foveal	I-Symptom
center	I-Symptom
delineated	O
by	O
OCT	B-Diagnostic_tool
had	O
more	O
MAs	B-Symptom
in	I-Symptom
the	I-Symptom
PCN	I-Symptom
and	O
larger	B-Symptom
FAZ	I-Symptom
in	O
FA	B-Diagnostic_tool
images	I-Diagnostic_tool
.	O
	
Progression	O
of	O
geographic	B-Symptom
atrophy	I-Symptom
in	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
imaged	O
with	O
spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
.	O
	
To	O
determine	O
the	O
area	O
and	O
enlargement	O
rate	O
(	O
ER	O
)	O
of	O
geographic	B-Symptom
atrophy	I-Symptom
(	O
GA	B-Symptom
)	O
in	O
patients	O
with	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
using	O
the	O
spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	I-Diagnostic_tool
SD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	I-Diagnostic_tool
fundus	I-Diagnostic_tool
image	I-Diagnostic_tool
.	O
	
Prospective	O
,	O
longitudinal	O
,	O
natural	O
history	O
study	O
.	O
	
Eighty	O
-	O
six	O
eyes	B-Anatomy
of	O
64	O
patients	O
with	O
	O
6	O
months	O
of	O
follow	O
-	O
up	O
.	O
	
Patients	O
with	O
GA	B-Symptom
secondary	O
to	O
AMD	B-Disease
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
Macular	B-Diagnostic_tool
scans	I-Diagnostic_tool
were	O
performed	O
using	O
the	O
Cirrus	B-Diagnostic_tool
SD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
)	O
.	O
	
The	O
areas	O
of	O
GA	B-Symptom
identified	O
on	O
the	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
fundus	I-Diagnostic_tool
images	I-Diagnostic_tool
were	O
quantified	O
using	O
a	O
digitizing	O
tablet	O
.	O
	
Reproducibility	O
of	O
these	O
measurements	O
was	O
assessed	O
and	O
the	O
ER	O
of	O
GA	B-Symptom
was	O
calculated	O
.	O
	
The	O
usefulness	O
of	O
performing	O
square	O
root	O
transformations	O
of	O
the	O
lesion	O
area	O
measurements	O
was	O
explored	O
.	O
	
Enlargement	O
rate	O
of	O
GA	B-Symptom
.	O
	
At	O
baseline	O
,	O
27	O
%	O
of	O
eyes	B-Anatomy
had	O
a	O
single	O
area	O
of	O
GA	B-Symptom
.	O
	
The	O
mean	O
total	O
area	O
at	O
baseline	O
was	O
4	O
.	O
59	O
mm	O
(	O
2	O
)	O
(	O
1	O
.	O
8	O
disc	O
areas	O
[	O
DA	O
]	O
)	O
.	O
	
The	O
mean	O
follow	O
-	O
up	O
time	O
was	O
1	O
.	O
24	O
years	O
.	O
	
Reproducibility	O
,	O
as	O
assessed	O
with	O
the	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
,	O
was	O
excellent	O
on	O
both	O
the	O
original	O
area	O
scale	O
(	O
ICC	O
=	O
0	O
.	O
995	O
)	O
and	O
the	O
square	O
root	O
scale	O
(	O
ICC	O
=	O
0	O
.	O
996	O
)	O
.	O
	
Intergrader	O
differences	O
were	O
not	O
an	O
important	O
source	O
of	O
variability	O
in	O
lesion	O
size	O
measurement	O
(	O
ICC	O
=	O
0	O
.	O
999	O
,	O
0	O
.	O
997	O
)	O
.	O
	
On	O
average	O
,	O
the	O
ER	O
of	O
GA	B-Symptom
per	O
year	O
was	O
1	O
.	O
2	O
mm	O
(	O
2	O
)	O
(	O
0	O
.	O
47	O
DA	O
;	O
range	O
,	O
0	O
.	O
01	O
-	O
3	O
.	O
62	O
mm	O
(	O
2	O
)	O
/	O
year	O
)	O
.	O
	
The	O
ER	O
correlated	O
with	O
the	O
initial	O
area	O
of	O
GA	B-Symptom
(	O
r	O
=	O
0	O
.	O
45	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
there	O
were	O
variable	O
growth	O
rates	O
for	O
any	O
given	O
baseline	O
area	O
.	O
	
When	O
the	O
square	O
root	O
transformation	O
of	O
the	O
lesion	O
area	O
measurements	O
was	O
used	O
as	O
a	O
measure	O
of	O
lesion	O
size	O
,	O
the	O
ER	O
(	O
0	O
.	O
28	O
mm	O
/	O
yr	O
)	O
was	O
not	O
correlated	O
with	O
baseline	O
size	O
(	O
r	O
=	O
-	O
0	O
.	O
09	O
;	O
P	O
=	O
0	O
.	O
40	O
)	O
.	O
	
In	O
this	O
cohort	O
of	O
lesions	O
,	O
no	O
correlation	O
was	O
found	O
between	O
ER	O
and	O
length	O
of	O
follow	O
-	O
up	O
.	O
	
Square	O
root	O
transformation	O
of	O
the	O
data	O
helped	O
to	O
facilitate	O
sample	O
size	O
estimates	O
for	O
controlled	O
clinical	O
trials	O
involving	O
GA	B-Symptom
.	O
	
The	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
fundus	I-Diagnostic_tool
image	I-Diagnostic_tool
can	O
be	O
used	O
to	O
visualize	O
and	O
quantify	O
GA	B-Symptom
.	O
	
Advantages	O
of	O
this	O
approach	O
include	O
the	O
convenience	O
and	O
assurance	O
of	O
using	O
a	O
single	O
imaging	O
technique	O
that	O
permits	O
simultaneous	O
visualization	O
of	O
GA	B-Symptom
along	O
with	O
the	O
loss	B-Symptom
of	I-Symptom
photoreceptors	I-Symptom
and	I-Symptom
the	I-Symptom
retinal	I-Symptom
pigment	I-Symptom
epithelium	I-Symptom
that	O
should	O
correlate	O
with	O
the	O
loss	B-Symptom
of	I-Symptom
visual	I-Symptom
function	I-Symptom
.	O
	
Detecting	O
and	O
treating	O
retinopathy	B-Disease
in	O
patients	O
with	O
type	B-Disease
I	I-Disease
diabetes	I-Disease
mellitus	I-Disease
.	O
	
A	O
health	O
policy	O
model	O
.	O
	
Diabetic	B-Disease
retinopathy	I-Disease
is	O
the	O
major	O
cause	O
of	O
new	O
cases	O
of	O
blindness	B-Symptom
among	O
working	B-Characteristic
-	I-Characteristic
age	I-Characteristic
Americans	I-Characteristic
.	O
	
The	O
authors	O
analyzed	O
the	O
medical	O
and	O
economic	O
implications	O
of	O
alternative	O
screening	O
strategies	O
for	O
detecting	O
retinopathy	B-Disease
in	O
a	O
diabetic	B-Characteristic
population	I-Characteristic
.	O
	
The	O
approaches	O
compared	O
included	O
dilated	B-Diagnostic_tool
fundus	I-Diagnostic_tool
examination	I-Diagnostic_tool
at	O
6	O
-	O
,	O
12	O
-	O
,	O
and	O
24	O
-	O
month	O
intervals	O
with	O
and	O
without	O
fundus	B-Diagnostic_tool
photography	I-Diagnostic_tool
.	O
	
Potential	O
savings	O
from	O
screening	O
and	O
treatment	O
are	O
based	O
on	O
amounts	O
paid	O
by	O
the	O
federal	O
government	O
for	O
blindness	B-Symptom
-	I-Symptom
related	I-Symptom
disability	I-Symptom
.	O
	
Screening	O
for	O
and	O
treating	O
retinopathy	B-Disease
in	O
patients	O
with	O
type	B-Disease
I	I-Disease
diabetes	I-Disease
mellitus	I-Disease
was	O
cost	O
-	O
effective	O
using	O
all	O
screening	O
strategies	O
.	O
	
Between	O
71	O
,	O
474	O
and	O
85	O
,	O
315	O
person	O
years	O
of	O
sight	O
and	O
76	O
,	O
886	O
and	O
94	O
,	O
705	O
person	O
years	O
of	O
reading	O
vision	O
can	O
be	O
saved	O
for	O
each	O
annual	O
cohort	O
of	O
patients	O
with	O
type	B-Disease
I	I-Disease
diabetes	I-Disease
mellitus	I-Disease
when	O
proper	O
laser	O
photocoagulation	O
is	O
administered	O
.	O
	
This	O
results	O
in	O
a	O
cost	O
savings	O
of	O
$	O
62	O
.	O
1	O
to	O
$	O
108	O
.	O
6	O
million	O
.	O
	
Annual	O
examination	O
of	O
all	O
diabetic	B-Disease
patients	O
and	O
semi	O
-	O
annual	O
examination	O
of	O
those	O
with	O
retinopathy	B-Disease
was	O
more	O
effective	O
than	O
annual	O
examination	O
with	O
fundus	B-Diagnostic_tool
photography	I-Diagnostic_tool
.	O
	
This	O
screening	O
strategy	O
is	O
consistent	O
with	O
the	O
Preferred	O
Practice	O
Pattern	O
for	O
Diabetic	B-Disease
Retinopathy	I-Disease
of	O
the	O
American	O
Academy	O
of	O
Ophthalmology	O
.	O
	
Optic	B-Anatomy
disc	I-Anatomy
evaluation	O
in	O
optic	B-Disease
neuropathies	I-Disease
:	O
the	O
optic	B-Anatomy
disc	I-Anatomy
assessment	O
project	O
.	O
	
Optic	B-Characteristic
nerve	I-Characteristic
morphology	I-Characteristic
is	O
affected	O
by	O
genetic	O
and	O
acquired	O
disease	O
.	O
	
Glaucoma	B-Disease
is	O
the	O
most	O
common	O
optic	B-Disease
neuropathy	I-Disease
;	O
autosomal	B-Disease
-	I-Disease
dominant	I-Disease
optic	I-Disease
atrophy	I-Disease
(	O
ADOA	B-Disease
)	O
and	O
Leber	B-Disease
'	I-Disease
s	I-Disease
hereditary	I-Disease
optic	I-Disease
neuropathy	I-Disease
(	O
LHON	B-Disease
)	O
are	O
the	O
most	O
prevalent	O
hereditary	B-Disease
optic	I-Disease
neuropathies	I-Disease
.	O
	
These	O
3	O
entities	O
can	O
exhibit	O
similar	O
topographical	B-Characteristic
changes	I-Characteristic
at	I-Characteristic
the	I-Characteristic
optic	I-Characteristic
nerve	I-Characteristic
head	I-Characteristic
.	O
	
Both	O
ADOA	B-Disease
and	O
LHON	B-Disease
have	O
been	O
reported	O
to	O
be	O
misdiagnosed	O
as	O
glaucoma	B-Disease
.	O
	
Our	O
aim	O
was	O
to	O
determine	O
whether	O
glaucoma	B-Disease
subspecialists	O
and	O
neuro	O
-	O
ophthalmologists	O
can	O
distinguish	O
these	O
diagnoses	O
on	O
optic	B-Anatomy
disc	I-Anatomy
assessment	O
alone	O
.	O
	
Observational	O
study	O
.	O
	
Twenty	O
-	O
three	O
optic	B-Anatomy
nerve	I-Anatomy
experts	O
.	O
	
We	O
randomized	O
and	O
masked	O
60	O
high	B-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
photographs	I-Diagnostic_tool
(	O
15	O
ADOA	B-Disease
images	O
,	O
15	O
LHON	B-Disease
,	O
15	O
glaucoma	B-Disease
,	O
and	O
15	O
normal	B-Characteristic
controls	I-Characteristic
)	O
.	O
	
Experts	O
were	O
asked	O
to	O
assess	O
the	O
discs	O
on	O
12	O
conventional	O
topographic	O
features	O
and	O
assign	O
a	O
presumptive	O
diagnosis	O
.	O
	
Intra	O
-	O
and	O
interanalysis	O
was	O
performed	O
using	O
the	O
index	O
of	O
qualitative	O
variation	O
and	O
absolute	O
deviation	O
.	O
	
Can	O
glaucoma	B-Disease
specialists	O
and	O
neuro	O
-	O
ophthalmologists	O
distinguish	O
among	O
the	O
disease	O
entities	O
by	O
optic	B-Anatomy
nerve	I-Anatomy
head	I-Anatomy
phenotype	O
.	O
	
The	O
correct	O
diagnosis	O
was	O
identified	O
in	O
85	O
%	O
,	O
75	O
%	O
,	O
27	O
%	O
,	O
and	O
16	O
%	O
of	O
the	O
normal	O
,	O
glaucoma	B-Disease
,	O
ADOA	B-Disease
,	O
and	O
LHON	B-Disease
disc	O
groups	O
,	O
respectively	O
.	O
	
The	O
proportion	O
of	O
correct	O
diagnoses	O
within	O
the	O
ADOA	B-Disease
and	O
LHON	B-Disease
groups	O
was	O
significantly	O
lower	O
than	O
both	O
normal	O
and	O
glaucomatous	B-Disease
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
Where	O
glaucoma	B-Disease
was	O
chosen	O
as	O
the	O
most	O
likely	O
diagnosis	O
,	O
61	O
%	O
were	O
glaucomatous	B-Disease
,	O
34	O
%	O
were	O
pathologic	O
but	O
nonglaucomatous	O
discs	O
,	O
and	O
5	O
%	O
were	O
normal	O
.	O
	
There	O
was	O
greater	O
agreement	O
for	O
individual	O
parameters	O
assessed	O
within	O
the	O
normal	O
disc	O
set	O
when	O
compared	O
with	O
pathologic	O
discs	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
The	O
only	O
parameter	O
to	O
have	O
a	O
significantly	O
greater	O
agreement	O
within	O
the	O
glaucomatous	B-Disease
disc	O
set	O
when	O
compared	O
with	O
ADOA	B-Disease
or	O
LHON	B-Disease
disc	O
sets	O
was	O
pallor	B-Symptom
,	O
whereby	O
experts	O
agreed	O
on	O
is	O
absence	O
in	O
the	O
glaucomatous	B-Disease
discs	O
but	O
were	O
not	O
in	O
agreement	O
on	O
its	O
presence	O
or	O
its	O
absence	O
in	O
the	O
ADOA	B-Disease
and	O
LHON	B-Disease
discs	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
	
Optic	B-Disease
neuropathies	I-Disease
can	O
result	O
in	O
similar	O
topographic	B-Characteristic
changes	I-Characteristic
at	I-Characteristic
the	I-Characteristic
optic	I-Characteristic
disc	I-Characteristic
,	O
particularly	O
in	O
late	O
-	O
stage	O
disease	O
,	O
making	O
it	O
difficult	O
to	O
differentiate	O
ADOA	B-Disease
and	O
LHON	B-Disease
from	O
glaucoma	B-Disease
based	O
on	O
disc	O
assessment	O
alone	O
.	O
	
Other	O
clinical	O
parameters	O
such	O
as	O
acuity	B-Characteristic
,	O
color	B-Characteristic
vision	I-Characteristic
,	O
history	B-Characteristic
of	I-Characteristic
visual	I-Characteristic
loss	I-Characteristic
,	O
and	O
family	B-Characteristic
history	I-Characteristic
are	O
required	O
to	O
make	O
an	O
accurate	O
diagnosis	O
.	O
	
Progressive	B-Disease
keratolysis	I-Disease
with	I-Disease
pseudopterygium	I-Disease
associated	O
with	O
erythema	B-Disease
elevatum	I-Disease
diutinum	I-Disease
.	O
	
To	O
report	O
a	O
patient	O
with	O
a	O
rare	O
case	O
of	O
progressive	B-Disease
keratolysis	I-Disease
with	I-Disease
pseudopterygium	I-Disease
associated	O
with	O
erythema	B-Disease
elevatum	I-Disease
diutinum	I-Disease
(	O
EED	B-Disease
)	O
.	O
	
Interventional	O
case	O
report	O
and	O
literature	O
review	O
.	O
	
One	O
patient	O
with	O
ocular	O
presentation	O
of	O
EED	B-Disease
was	O
identified	O
.	O
	
A	O
64	B-Characteristic
-	I-Characteristic
year	I-Characteristic
-	I-Characteristic
old	I-Characteristic
woman	I-Characteristic
presented	O
with	O
recurrent	B-Disease
pterygium	I-Disease
and	O
painful	B-Symptom
corneal	I-Symptom
thinning	I-Symptom
with	I-Symptom
impending	I-Symptom
perforation	I-Symptom
of	I-Symptom
the	I-Symptom
left	I-Symptom
eye	I-Symptom
.	O
	
Examination	O
revealed	O
intensely	O
inflamed	B-Symptom
pseudopterygium	I-Symptom
,	O
paracentral	B-Symptom
and	I-Symptom
peripheral	I-Symptom
corneal	I-Symptom
ulcerations	I-Symptom
,	O
and	O
descemetocele	B-Symptom
with	I-Symptom
a	I-Symptom
pinpoint	I-Symptom
leakage	I-Symptom
.	O
	
Clinical	O
course	O
and	O
laboratory	O
and	O
histopathologic	O
findings	O
.	O
	
Disseminated	O
skin	B-Symptom
lesions	I-Symptom
developed	I-Symptom
during	I-Symptom
hospital	I-Symptom
admission	I-Symptom
.	O
	
Examination	O
revealed	O
multiple	B-Symptom
,	I-Symptom
well	I-Symptom
-	I-Symptom
demarcated	I-Symptom
,	I-Symptom
discrete	I-Symptom
,	I-Symptom
red	I-Symptom
to	I-Symptom
violaceous	I-Symptom
,	I-Symptom
firm	I-Symptom
nodules	I-Symptom
and	I-Symptom
plaques	I-Symptom
on	I-Symptom
the	I-Symptom
knuckles	I-Symptom
and	I-Symptom
dorsum	I-Symptom
of	I-Symptom
the	I-Symptom
hands	I-Symptom
,	I-Symptom
and	I-Symptom
the	I-Symptom
extensor	I-Symptom
surface	I-Symptom
of	I-Symptom
the	I-Symptom
forearms	I-Symptom
,	I-Symptom
elbows	I-Symptom
,	I-Symptom
knees	I-Symptom
,	I-Symptom
right	I-Symptom
ankle	I-Symptom
,	I-Symptom
and	I-Symptom
buttocks	I-Symptom
.	O
	
A	O
skin	B-Diagnostic_tool
biopsy	I-Diagnostic_tool
of	O
the	O
recent	O
lesions	O
showed	O
a	O
dense	B-Symptom
and	I-Symptom
diffuse	I-Symptom
inflammatory	I-Symptom
cell	I-Symptom
infiltration	I-Symptom
,	O
predominantly	O
neutrophilic	B-Symptom
infiltrates	I-Symptom
and	I-Symptom
nuclear	I-Symptom
dust	I-Symptom
(	I-Symptom
leukocytoclasis	I-Symptom
)	I-Symptom
,	I-Symptom
located	I-Symptom
around	I-Symptom
small	I-Symptom
blood	I-Symptom
vessels	I-Symptom
in	I-Symptom
the	I-Symptom
dermis	I-Symptom
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
EED	B-Disease
.	O
	
The	O
diagnosis	O
of	O
progressive	B-Disease
keratolysis	I-Disease
with	I-Disease
pseudopterygium	I-Disease
associated	O
with	O
EED	B-Disease
was	O
made	O
.	O
	
Spontaneous	O
,	O
rapid	O
resolution	O
of	O
both	O
cutaneous	B-Symptom
and	I-Symptom
ocular	I-Symptom
lesions	I-Symptom
occurred	O
after	O
dapsone	O
therapy	O
.	O
	
Erythema	B-Disease
elevatum	I-Disease
diutinum	I-Disease
is	O
a	O
rare	B-Disease
,	I-Disease
chronic	I-Disease
,	I-Disease
and	I-Disease
recurrent	I-Disease
disease	I-Disease
that	O
has	O
both	O
dermatologic	B-Symptom
and	I-Symptom
ocular	I-Symptom
manifestations	I-Symptom
.	O
	
Peripheral	B-Symptom
ulcerative	I-Symptom
keratitis	I-Symptom
seems	O
to	O
be	O
the	O
most	O
common	O
ocular	O
finding	O
and	O
may	O
be	O
the	O
initial	O
presenting	O
feature	O
of	O
EED	B-Disease
.	O
	
Ophthalmologists	O
should	O
be	O
aware	O
of	O
this	O
rare	O
entity	O
in	O
the	O
differential	O
diagnosis	O
of	O
ulcerative	B-Disease
or	I-Disease
nonulcerative	I-Disease
peripheral	I-Disease
keratitis	I-Disease
.	O
	
Choroidal	B-Characteristic
thickness	I-Characteristic
in	O
polypoidal	B-Disease
choroidal	I-Disease
vasculopathy	I-Disease
and	O
exudative	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
.	O
	
To	O
compare	O
choroidal	B-Characteristic
thickness	I-Characteristic
between	O
eyes	B-Anatomy
with	O
polypoidal	B-Disease
choroidal	I-Disease
vasculopathy	I-Disease
(	O
PCV	B-Disease
)	O
and	O
eyes	B-Anatomy
with	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Observational	O
,	O
comparative	O
case	O
series	O
.	O
	
Twenty	O
-	O
five	O
eyes	B-Anatomy
with	O
PCV	B-Disease
,	O
14	O
uninvolved	O
fellow	O
eyes	B-Anatomy
with	O
PCV	B-Disease
,	O
30	O
eyes	B-Anatomy
with	O
exudative	B-Disease
AMD	I-Disease
,	O
17	O
eyes	B-Anatomy
with	O
early	B-Disease
AMD	I-Disease
,	O
and	O
20	O
eyes	B-Anatomy
of	O
age	B-Characteristic
-	I-Characteristic
matched	I-Characteristic
normal	I-Characteristic
subjects	I-Characteristic
.	O
	
Choroidal	B-Characteristic
thickness	I-Characteristic
was	O
measured	O
using	O
enhanced	B-Diagnostic_tool
-	I-Diagnostic_tool
depth	I-Diagnostic_tool
imaging	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
.	O
	
Subfoveal	B-Characteristic
choroidal	I-Characteristic
thickness	I-Characteristic
in	O
each	O
eye	B-Anatomy
was	O
analyzed	O
by	O
measurement	O
of	O
the	O
vertical	B-Characteristic
distance	I-Characteristic
from	I-Characteristic
the	I-Characteristic
Bruch	I-Characteristic
'	I-Characteristic
s	I-Characteristic
membrane	I-Characteristic
to	I-Characteristic
the	I-Characteristic
innermost	I-Characteristic
scleral	I-Characteristic
layer	I-Characteristic
.	O
	
Nasal	B-Characteristic
,	I-Characteristic
superior	I-Characteristic
,	I-Characteristic
temporal	I-Characteristic
,	I-Characteristic
and	I-Characteristic
inferior	I-Characteristic
choroidal	I-Characteristic
thicknesses	I-Characteristic
,	O
1500	O
	O
m	O
apart	O
from	O
the	O
foveal	B-Anatomy
center	I-Anatomy
,	O
were	O
also	O
evaluated	O
in	O
all	O
eyes	B-Anatomy
.	O
	
Choroidal	B-Characteristic
thickness	I-Characteristic
in	O
each	O
group	O
.	O
	
Mean	B-Characteristic
(	I-Characteristic
	I-Characteristic
standard	I-Characteristic
deviation	I-Characteristic
)	I-Characteristic
subfoveal	I-Characteristic
choroidal	I-Characteristic
thickness	I-Characteristic
in	O
eyes	B-Anatomy
with	O
PCV	B-Disease
and	O
in	O
their	O
uninvolved	O
fellow	O
eyes	B-Anatomy
was	O
438	O
.	O
3	O
	O
87	O
.	O
8	O
	O
m	O
and	O
372	O
.	O
9	O
	O
112	O
.	O
0	O
	O
m	O
,	O
respectively	O
,	O
which	O
was	O
significantly	O
greater	O
than	O
in	O
eyes	B-Anatomy
of	O
age	B-Characteristic
-	I-Characteristic
matched	I-Characteristic
normal	I-Characteristic
subjects	I-Characteristic
(	O
224	O
.	O
8	O
	O
52	O
.	O
9	O
	O
m	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
and	O
P	O
=	O
0	O
.	O
003	O
,	O
respectively	O
)	O
.	O
	
Subfoveal	B-Characteristic
choroidal	I-Characteristic
thickness	I-Characteristic
of	O
eyes	B-Anatomy
with	O
exudative	B-Disease
AMD	I-Disease
(	O
171	O
.	O
2	O
	O
38	O
.	O
5	O
	O
m	O
)	O
and	O
eyes	B-Anatomy
with	O
early	B-Disease
AMD	I-Disease
(	O
177	O
.	O
4	O
	O
49	O
.	O
7	O
	O
m	O
)	O
was	O
thinner	O
than	O
that	O
of	O
age	B-Characteristic
-	I-Characteristic
matched	I-Characteristic
normal	I-Characteristic
subjects	I-Characteristic
(	O
P	O
=	O
0	O
.	O
004	O
and	O
P	O
=	O
0	O
.	O
078	O
,	O
respectively	O
)	O
.	O
	
Choroidal	B-Characteristic
thickness	I-Characteristic
at	O
each	O
of	O
the	O
other	O
4	O
points	O
showed	O
a	O
similar	O
tendency	O
.	O
	
This	O
study	O
demonstrates	O
thickening	B-Characteristic
of	I-Characteristic
choroid	I-Characteristic
in	O
the	O
eyes	B-Anatomy
with	O
PCV	B-Disease
,	O
in	O
contrast	O
with	O
choroidal	B-Characteristic
thinning	I-Characteristic
observed	O
in	O
eyes	B-Anatomy
with	O
AMD	B-Disease
.	O
	
These	O
findings	O
suggest	O
involvement	O
of	O
different	O
pathogenic	O
mechanisms	O
in	O
PCV	B-Disease
from	O
those	O
in	O
exudative	B-Disease
AMD	I-Disease
.	O
	
Comparison	O
of	O
the	O
diagnostic	O
accuracies	O
of	O
the	O
Spectralis	B-Diagnostic_tool
,	I-Diagnostic_tool
Cirrus	I-Diagnostic_tool
,	I-Diagnostic_tool
and	I-Diagnostic_tool
RTVue	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
devices	O
in	O
glaucoma	B-Disease
.	O
	
To	O
compare	O
the	O
diagnostic	O
accuracies	O
of	O
retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
(	I-Characteristic
RNFL	I-Characteristic
)	I-Characteristic
thickness	I-Characteristic
measurements	O
obtained	O
with	O
the	O
Spectralis	B-Diagnostic_tool
(	O
Heidelberg	O
Engineering	O
,	O
Dossenheim	O
,	O
Germany	O
)	O
,	O
Cirrus	B-Diagnostic_tool
(	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
)	O
,	O
and	O
RTVue	B-Diagnostic_tool
(	O
Optovue	O
Inc	O
.	O
,	O
Fremont	O
,	O
CA	O
)	O
devices	O
for	O
the	O
detection	O
of	O
glaucoma	B-Disease
.	O
	
Diagnostic	O
,	O
case	O
-	O
control	O
study	O
.	O
	
A	O
total	O
of	O
233	O
(	O
107	O
healthy	O
,	O
126	O
glaucomatous	B-Disease
)	O
of	O
149	O
participants	O
from	O
the	O
longitudinal	O
Diagnostic	O
Innovations	O
in	O
Glaucoma	B-Disease
Study	O
(	O
DIGS	O
)	O
and	O
from	O
the	O
African	B-Characteristic
Descent	I-Characteristic
and	O
Glaucoma	B-Disease
Evaluation	O
Study	O
(	O
ADAGES	O
)	O
.	O
	
All	O
participants	O
underwent	O
RNFL	B-Characteristic
thickness	I-Characteristic
imaging	O
with	O
the	O
Spectralis	B-Diagnostic_tool
,	O
Cirrus	B-Diagnostic_tool
,	O
and	O
RTVue	B-Diagnostic_tool
devices	O
in	O
the	O
same	O
visit	O
.	O
	
Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
adjusted	O
for	O
age	B-Characteristic
and	O
race	B-Characteristic
were	O
obtained	O
for	O
quadrants	B-Characteristic
(	I-Characteristic
superior	I-Characteristic
,	I-Characteristic
nasal	I-Characteristic
,	I-Characteristic
inferior	I-Characteristic
,	I-Characteristic
temporal	I-Characteristic
)	I-Characteristic
and	I-Characteristic
global	I-Characteristic
RNFL	I-Characteristic
thickness	I-Characteristic
for	O
all	O
instruments	O
.	O
	
Areas	O
under	O
ROC	O
(	O
AUC	O
)	O
and	O
sensitivities	O
at	O
fixed	O
specificities	O
(	O
80	O
%	O
and	O
95	O
%	O
)	O
were	O
calculated	O
and	O
compared	O
.	O
	
Comparison	O
of	O
diagnostic	O
accuracy	O
using	O
AUCs	O
and	O
sensitivities	O
at	O
fixed	O
specificities	O
of	O
80	O
%	O
and	O
95	O
%	O
.	O
	
The	O
RNFL	B-Characteristic
thickness	I-Characteristic
parameter	O
with	O
the	O
largest	O
AUCs	O
was	O
the	O
superior	B-Anatomy
quadrant	I-Anatomy
for	O
the	O
Spectralis	B-Diagnostic_tool
(	O
0	O
.	O
88	O
)	O
and	O
the	O
global	B-Characteristic
RNFL	I-Characteristic
thickness	I-Characteristic
for	O
the	O
Cirrus	B-Diagnostic_tool
(	O
0	O
.	O
88	O
)	O
and	O
the	O
RTVue	B-Diagnostic_tool
(	O
0	O
.	O
87	O
)	O
.	O
	
The	O
pairwise	O
comparison	O
among	O
the	O
ROC	O
curves	O
showed	O
no	O
statistical	O
difference	O
for	O
all	O
parameters	O
except	O
for	O
the	O
nasal	B-Anatomy
quadrant	I-Anatomy
,	O
which	O
had	O
significantly	O
larger	O
AUC	O
in	O
the	O
Spectralis	B-Diagnostic_tool
and	O
RTVue	B-Diagnostic_tool
compared	O
with	O
the	O
Cirrus	B-Diagnostic_tool
(	O
P	O
<	O
0	O
.	O
03	O
for	O
both	O
comparisons	O
)	O
.	O
	
There	O
were	O
no	O
significant	O
differences	O
in	O
sensitivities	O
among	O
the	O
best	O
parameters	O
from	O
each	O
instrument	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
	
The	O
superior	B-Characteristic
quadrant	I-Characteristic
thickness	I-Characteristic
measured	O
with	O
the	O
Spectralis	B-Diagnostic_tool
had	O
sensitivity	O
of	O
81	O
.	O
9	O
%	O
at	O
a	O
fixed	O
specificity	O
of	O
80	O
%	O
and	O
70	O
%	O
at	O
a	O
fixed	O
specificity	O
of	O
95	O
%	O
.	O
	
The	O
global	B-Characteristic
thickness	I-Characteristic
measured	O
by	O
the	O
Cirrus	B-Diagnostic_tool
had	O
a	O
sensitivity	O
of	O
80	O
.	O
3	O
%	O
at	O
a	O
fixed	O
specificity	O
of	O
80	O
%	O
and	O
65	O
.	O
6	O
%	O
at	O
a	O
fixed	O
specificity	O
of	O
95	O
%	O
.	O
	
For	O
the	O
RTVue	B-Diagnostic_tool
,	O
the	O
global	B-Characteristic
thickness	I-Characteristic
had	O
a	O
sensitivity	O
of	O
77	O
.	O
9	O
%	O
at	O
a	O
fixed	O
specificity	O
of	O
80	O
%	O
and	O
62	O
.	O
1	O
%	O
at	O
a	O
fixed	O
specificity	O
of	O
95	O
%	O
.	O
	
Although	O
the	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optic	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
instruments	O
have	O
different	O
resolution	O
and	O
acquisition	O
rates	O
,	O
their	O
ability	O
to	O
detect	O
glaucoma	B-Disease
was	O
similar	O
.	O
	
Evaluation	O
of	O
retinal	B-Symptom
nerve	I-Symptom
fiber	I-Symptom
layer	I-Symptom
progression	I-Symptom
in	O
glaucoma	B-Disease
a	O
prospective	O
analysis	O
with	O
neuroretinal	B-Anatomy
rim	I-Anatomy
and	O
visual	B-Symptom
field	I-Symptom
progression	I-Symptom
.	O
	
To	O
evaluate	O
the	O
performance	O
of	O
progression	O
detection	O
and	O
the	O
rate	O
of	O
change	O
of	O
retinal	B-Anatomy
nerve	I-Anatomy
fiber	I-Anatomy
layer	I-Anatomy
(	O
RNFL	B-Anatomy
)	O
,	O
neuroretinal	B-Anatomy
rim	I-Anatomy
,	O
and	O
visual	B-Characteristic
field	I-Characteristic
measurements	O
in	O
glaucoma	B-Disease
.	O
	
Prospective	O
study	O
.	O
	
One	O
hundred	O
eight	O
eyes	B-Anatomy
of	O
70	O
glaucoma	B-Disease
patients	O
.	O
	
Patients	O
were	O
followed	O
up	O
every	O
4	O
months	O
for	O
at	O
least	O
2	O
.	O
9	O
years	O
(	O
median	O
,	O
3	O
.	O
2	O
years	O
)	O
for	O
measurement	O
of	O
RNFL	B-Characteristic
thickness	I-Characteristic
with	O
the	O
Stratus	B-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomograph	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
(	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
)	O
,	O
neuroretinal	B-Characteristic
rim	I-Characteristic
area	I-Characteristic
with	O
the	O
Heidelberg	B-Diagnostic_tool
Retinal	I-Diagnostic_tool
Tomograph	I-Diagnostic_tool
(	O
HRT	B-Diagnostic_tool
3	O
;	O
Heidelberg	O
Engineering	O
,	O
GmbH	O
,	O
Dossenheim	O
,	O
Germany	O
)	O
,	O
and	O
visual	B-Characteristic
field	I-Characteristic
with	O
the	O
Humphrey	B-Diagnostic_tool
Field	I-Diagnostic_tool
Analyzer	I-Diagnostic_tool
II	I-Diagnostic_tool
(	O
Carl	O
Zeiss	O
Meditec	O
)	O
.	O
	
Linear	O
regression	O
analyses	O
were	O
performed	O
between	O
visual	B-Characteristic
field	I-Characteristic
index	I-Characteristic
(	O
VFI	B-Characteristic
)	O
,	O
RNFL	B-Anatomy
,	O
and	O
neuroretinal	B-Anatomy
rim	I-Anatomy
measurements	O
and	O
age	B-Characteristic
,	O
with	O
progression	O
defined	O
when	O
a	O
significant	O
negative	O
trend	O
was	O
detected	O
.	O
	
The	O
agreement	O
among	O
structural	O
and	O
functional	O
measurements	O
was	O
evaluated	O
with	O
	O
statistics	O
.	O
	
The	O
mean	O
rate	O
of	O
change	O
was	O
estimated	O
with	O
linear	O
mixed	O
modeling	O
.	O
	
The	O
agreement	O
on	O
progression	O
detection	O
and	O
the	O
rate	O
of	O
change	O
of	O
RNFL	B-Anatomy
,	O
neuroretinal	B-Anatomy
rim	I-Anatomy
,	O
and	O
VFI	B-Characteristic
measurements	O
.	O
	
A	O
total	O
of	O
1105	O
OCT	B-Diagnostic_tool
,	O
1062	O
HRT	B-Diagnostic_tool
,	O
and	O
1099	O
visual	B-Characteristic
field	I-Characteristic
measurements	O
were	O
analyzed	O
.	O
	
The	O
agreement	O
of	O
progression	O
detection	O
among	O
the	O
3	O
investigations	O
was	O
poor	O
(	O
	O
	O
0	O
.	O
09	O
)	O
.	O
	
Ten	O
eyes	B-Anatomy
(	O
9	O
.	O
3	O
%	O
;	O
9	O
patients	O
)	O
showed	O
progression	O
by	O
average	O
RNFL	B-Characteristic
thickness	I-Characteristic
,	O
16	O
(	O
14	O
.	O
8	O
%	O
;	O
14	O
patients	O
)	O
by	O
global	O
neuroretinal	B-Characteristic
rim	I-Characteristic
area	I-Characteristic
,	O
and	O
35	O
(	O
32	O
.	O
4	O
%	O
;	O
31	O
patients	O
)	O
by	O
VFI	B-Characteristic
.	O
	
Only	O
1	O
eye	B-Anatomy
(	O
0	O
.	O
9	O
%	O
)	O
had	O
progression	O
detected	O
by	O
all	O
3	O
methods	O
.	O
	
There	O
were	O
large	O
variations	O
in	O
the	O
rate	O
of	O
change	O
of	O
VFI	B-Characteristic
,	O
average	O
RNFL	B-Characteristic
thickness	I-Characteristic
,	O
and	O
global	O
neuroretinal	B-Characteristic
rim	I-Characteristic
area	I-Characteristic
,	O
with	O
a	O
range	O
between	O
-	O
0	O
.	O
63	O
%	O
and	O
-	O
4	O
.	O
97	O
%	O
per	O
year	O
,	O
-	O
2	O
.	O
32	O
%	O
and	O
-	O
10	O
.	O
12	O
%	O
per	O
year	O
,	O
and	O
-	O
0	O
.	O
61	O
%	O
and	O
-	O
8	O
.	O
48	O
%	O
per	O
year	O
,	O
respectively	O
.	O
	
The	O
respective	O
mean	O
rate	O
estimates	O
were	O
-	O
1	O
.	O
15	O
%	O
per	O
year	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
-	O
1	O
.	O
56	O
%	O
to	O
-	O
0	O
.	O
73	O
%	O
)	O
,	O
-	O
0	O
.	O
70	O
%	O
per	O
year	O
(	O
95	O
%	O
CI	O
,	O
-	O
1	O
.	O
19	O
%	O
to	O
-	O
0	O
.	O
21	O
%	O
)	O
,	O
and	O
-	O
1	O
.	O
06	O
%	O
per	O
year	O
(	O
95	O
%	O
CI	O
,	O
-	O
1	O
.	O
56	O
%	O
to	O
-	O
0	O
.	O
55	O
%	O
)	O
.	O
	
The	O
agreement	O
of	O
progression	O
detection	O
among	O
RNFL	B-Anatomy
,	O
neuroretinal	B-Anatomy
rim	I-Anatomy
,	O
and	O
visual	B-Characteristic
field	I-Characteristic
measurements	O
was	O
poor	O
,	O
and	O
the	O
rate	O
of	O
RNFL	B-Anatomy
,	O
neuroretinal	B-Anatomy
rim	I-Anatomy
,	O
and	O
visual	B-Characteristic
field	I-Characteristic
progression	O
varied	O
considerably	O
within	O
and	O
between	O
subjects	O
.	O
	
Given	O
this	O
variability	O
,	O
interpretation	O
of	O
RNFL	B-Anatomy
,	O
neuroretinal	B-Anatomy
rim	I-Anatomy
,	O
and	O
VFI	B-Characteristic
progression	O
always	O
should	O
be	O
evaluated	O
on	O
an	O
individual	O
basis	O
.	O
	
Proprietary	O
or	O
commercial	O
disclosure	O
may	O
be	O
found	O
after	O
the	O
references	O
.	O
	
Retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
in	O
dominant	B-Disease
optic	I-Disease
atrophy	I-Disease
measurements	O
by	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
and	O
correlation	O
with	O
age	B-Characteristic
.	O
	
To	O
measure	O
the	O
retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
(	I-Characteristic
RNFL	I-Characteristic
)	I-Characteristic
thickness	I-Characteristic
by	O
means	O
of	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
in	O
patients	O
with	O
dominant	B-Disease
optic	I-Disease
atrophy	I-Disease
(	O
DOA	B-Disease
)	O
.	O
	
Cross	O
-	O
sectional	O
study	O
.	O
	
Thirty	O
-	O
three	O
patients	O
from	O
15	O
pedigrees	O
with	O
DOA	B-Disease
harboring	O
heterozygous	B-Characteristic
mutations	I-Characteristic
in	I-Characteristic
the	I-Characteristic
OPA1	I-Characteristic
gene	I-Characteristic
and	O
43	O
healthy	B-Characteristic
subjects	I-Characteristic
were	O
enrolled	O
.	O
	
The	O
RNFLs	B-Anatomy
of	O
DOA	B-Disease
patients	O
were	O
studied	O
by	O
OCT	B-Diagnostic_tool
and	O
compared	O
with	O
those	O
of	O
43	O
healthy	B-Characteristic
subjects	I-Characteristic
matched	O
for	O
age	B-Characteristic
and	O
optic	B-Characteristic
nerve	I-Characteristic
head	I-Characteristic
(	I-Characteristic
ONH	I-Characteristic
)	I-Characteristic
size	I-Characteristic
.	O
	
Retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
.	O
	
Dominant	B-Disease
optic	I-Disease
atrophy	I-Disease
patients	O
revealed	O
a	O
significant	B-Symptom
RNFL	I-Symptom
thickness	I-Symptom
reduction	I-Symptom
in	I-Symptom
all	I-Symptom
quadrants	I-Symptom
,	O
with	O
a	O
preferential	O
involvement	O
of	O
the	O
temporal	B-Anatomy
and	I-Anatomy
inferior	I-Anatomy
sectors	I-Anatomy
.	O
	
The	O
progressive	B-Symptom
decline	I-Symptom
of	I-Symptom
RNFL	I-Symptom
thickness	I-Symptom
with	I-Symptom
age	I-Symptom
was	O
similar	O
to	O
that	O
observed	O
in	O
healthy	B-Characteristic
subjects	I-Characteristic
and	O
was	O
more	O
evident	O
in	O
the	O
2	O
quadrants	O
with	O
higher	B-Symptom
residual	I-Symptom
amounts	I-Symptom
of	I-Symptom
fibers	I-Symptom
,	O
that	O
is	O
,	O
the	O
superior	O
and	O
the	O
inferior	O
.	O
	
The	O
temporal	B-Anatomy
quadrant	I-Anatomy
was	O
profoundly	O
depleted	B-Symptom
of	I-Symptom
fiber	I-Symptom
so	O
that	O
the	O
further	O
rate	O
of	O
loss	B-Symptom
of	I-Symptom
microns	I-Symptom
per	O
year	O
is	O
close	O
to	O
zero	O
,	O
whereas	O
the	O
nasal	B-Anatomy
quadrant	I-Anatomy
was	O
spared	O
the	O
most	O
by	O
neurodegeneration	B-Symptom
.	O
	
The	O
present	O
findings	O
,	O
taken	O
in	O
conjunction	O
with	O
the	O
authors	O
'	O
previous	O
description	O
of	O
small	B-Characteristic
ONH	I-Characteristic
size	I-Characteristic
in	O
DOA	B-Disease
,	O
strongly	O
suggest	O
that	O
patients	O
with	O
this	O
disease	O
are	O
born	B-Symptom
with	I-Symptom
fewer	I-Symptom
optic	I-Symptom
nerve	I-Symptom
axons	I-Symptom
and	O
support	O
the	O
hypothesis	O
that	O
subsequent	O
visual	B-Symptom
loss	I-Symptom
depends	O
on	O
further	O
age	B-Symptom
-	I-Symptom
related	I-Symptom
loss	I-Symptom
of	I-Symptom
fibers	I-Symptom
,	O
which	O
also	O
occurs	O
in	O
controls	O
.	O
	
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
Adjusting	O
intraocular	B-Characteristic
pressure	I-Characteristic
for	O
central	B-Characteristic
corneal	I-Characteristic
thickness	I-Characteristic
does	O
not	O
improve	O
prediction	O
models	O
for	O
primary	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
.	O
	
To	O
determine	O
if	O
the	O
accuracy	O
of	O
the	O
baseline	O
prediction	O
model	O
for	O
the	O
development	O
of	O
primary	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
(	O
POAG	B-Disease
)	O
in	O
patients	O
with	O
ocular	B-Symptom
hypertension	I-Symptom
can	O
be	O
improved	O
by	O
correcting	O
intraocular	B-Characteristic
pressure	I-Characteristic
(	O
IOP	B-Characteristic
)	O
for	O
central	B-Characteristic
corneal	I-Characteristic
thickness	I-Characteristic
(	O
CCT	B-Characteristic
)	O
.	O
	
Reanalysis	O
of	O
the	O
baseline	O
prediction	O
model	O
for	O
the	O
development	O
of	O
POAG	B-Disease
from	O
the	O
Ocular	O
Hypertension	O
Treatment	O
Study	O
(	O
OHTS	O
)	O
substituting	O
IOP	B-Characteristic
adjusted	O
for	O
CCT	B-Characteristic
using	O
5	O
different	O
correction	O
formulae	O
for	O
unadjusted	O
IOP	B-Characteristic
.	O
	
A	O
total	O
of	O
1433	O
of	O
1636	O
participants	O
randomized	O
to	O
OHTS	O
who	O
had	O
complete	O
baseline	O
data	O
for	O
factors	O
in	O
the	O
prediction	O
model	O
:	O
age	B-Characteristic
,	O
IOP	B-Characteristic
,	O
CCT	B-Characteristic
,	O
vertical	B-Characteristic
cup	I-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
disc	I-Characteristic
ratio	I-Characteristic
(	O
VCDR	B-Characteristic
)	O
,	O
and	O
pattern	B-Characteristic
standard	I-Characteristic
deviation	I-Characteristic
(	O
PSD	B-Characteristic
)	O
.	O
	
Reanalysis	O
of	O
the	O
prediction	O
model	O
for	O
the	O
risk	O
of	O
developing	O
POAG	B-Disease
using	O
the	O
same	O
baseline	O
variables	O
(	O
age	B-Characteristic
,	O
IOP	B-Characteristic
,	O
CCT	B-Characteristic
,	O
VCDR	B-Characteristic
,	O
and	O
PSD	B-Characteristic
)	O
except	O
that	O
IOP	B-Characteristic
was	O
adjusted	O
for	O
CCT	B-Characteristic
using	O
correction	O
formulae	O
.	O
	
A	O
separate	O
Cox	O
proportional	O
hazards	O
model	O
was	O
run	O
using	O
IOP	B-Characteristic
adjusted	O
for	O
CCT	B-Characteristic
by	O
each	O
of	O
the	O
5	O
formulae	O
published	O
to	O
date	O
.	O
	
Models	O
were	O
run	O
including	O
and	O
excluding	O
CCT	B-Characteristic
.	O
	
Predictive	O
accuracy	O
of	O
each	O
Cox	O
proportional	O
hazards	O
model	O
was	O
assessed	O
using	O
the	O
c	O
-	O
statistic	O
and	O
calibration	O
chi	O
-	O
square	O
.	O
	
C	O
-	O
statistics	O
for	O
prediction	O
models	O
that	O
used	O
IOP	B-Characteristic
adjusted	O
for	O
CCT	B-Characteristic
by	O
various	O
formulas	O
ranged	O
from	O
0	O
.	O
75	O
to	O
0	O
.	O
77	O
,	O
no	O
better	O
than	O
the	O
original	O
prediction	O
model	O
(	O
0	O
.	O
77	O
)	O
that	O
did	O
not	O
adjust	O
IOP	B-Characteristic
for	O
CCT	B-Characteristic
.	O
	
Calibration	O
chi	O
-	O
square	O
was	O
acceptable	O
for	O
all	O
models	O
.	O
	
Baseline	O
IOP	B-Characteristic
,	O
whether	O
adjusted	O
for	O
CCT	B-Characteristic
or	O
not	O
,	O
was	O
statistically	O
significant	O
in	O
all	O
models	O
including	O
those	O
with	O
CCT	B-Characteristic
in	O
the	O
same	O
model	O
.	O
	
The	O
CCT	B-Characteristic
was	O
statistically	O
significant	O
in	O
all	O
models	O
including	O
those	O
with	O
IOP	B-Characteristic
adjusted	O
for	O
CCT	B-Characteristic
in	O
the	O
same	O
model	O
.	O
	
The	O
calculation	O
of	O
individual	O
risk	O
for	O
developing	O
POAG	B-Disease
in	O
ocular	B-Symptom
hypertensive	I-Symptom
individuals	O
is	O
simpler	O
and	O
equally	O
accurate	O
using	O
IOP	B-Characteristic
and	O
CCT	B-Characteristic
as	O
measured	O
,	O
rather	O
than	O
applying	O
an	O
adjustment	O
formula	O
to	O
correct	O
IOP	B-Characteristic
for	O
CCT	B-Characteristic
.	O
	
Natural	O
history	O
of	O
drusen	B-Symptom
morphology	O
in	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
using	O
spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
.	O
	
To	O
characterize	O
the	O
natural	O
history	O
of	O
drusen	B-Symptom
using	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	I-Diagnostic_tool
SD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	I-Diagnostic_tool
imaging	I-Diagnostic_tool
of	O
eyes	B-Anatomy
from	O
patients	O
with	O
nonexudative	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Prospective	O
,	O
longitudinal	O
,	O
natural	O
history	O
study	O
.	O
	
We	O
included	O
143	O
eyes	B-Anatomy
of	O
100	O
patients	O
with	O
at	O
least	O
6	O
months	O
of	O
follow	O
-	O
up	O
.	O
	
Patients	O
with	O
drusen	B-Symptom
secondary	O
to	O
nonexudative	B-Disease
AMD	I-Disease
were	O
scanned	O
using	O
the	O
Cirrus	B-Diagnostic_tool
SD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
instrument	O
.	O
	
Eyes	B-Anatomy
were	O
imaged	O
using	O
the	O
200	O
	O
200	O
A	O
-	O
scan	O
raster	O
pattern	O
contained	O
within	O
a	O
6	O
	O
6	O
mm	O
area	O
.	O
	
Custom	O
software	O
was	O
used	O
to	O
quantify	O
volumetric	O
changes	O
in	O
drusen	B-Symptom
over	O
a	O
period	O
of	O
	O
6	O
months	O
and	O
for	O
as	O
long	O
as	O
24	O
months	O
.	O
	
Drusen	B-Characteristic
volume	I-Characteristic
and	O
drusen	B-Characteristic
area	I-Characteristic
were	O
measured	O
within	O
circular	O
regions	O
centered	O
at	O
the	O
fovea	B-Anatomy
having	O
diameters	O
of	O
3	O
and	O
5	O
mm	O
.	O
	
The	O
measurements	O
were	O
analyzed	O
using	O
a	O
suitable	O
scale	O
transformation	O
.	O
	
For	O
drusen	B-Characteristic
volume	I-Characteristic
,	O
a	O
cube	O
root	O
transformation	O
strategy	O
was	O
used	O
.	O
	
Change	O
in	O
drusen	B-Characteristic
volume	I-Characteristic
and	O
area	O
over	O
time	O
.	O
	
We	O
analyzed	O
143	O
eyes	B-Anatomy
of	O
100	O
patients	O
with	O
69	O
eyes	B-Anatomy
followed	O
for	O
6	O
months	O
,	O
106	O
eyes	B-Anatomy
followed	O
for	O
12	O
months	O
,	O
48	O
eyes	B-Anatomy
followed	O
for	O
18	O
months	O
,	O
and	O
48	O
eyes	B-Anatomy
followed	O
for	O
24	O
months	O
.	O
	
The	O
3	O
mm	O
circle	O
baseline	O
drusen	B-Characteristic
volume	I-Characteristic
ranged	O
from	O
0	B-Dimension
.	I-Dimension
0009	I-Dimension
to	I-Dimension
0	I-Dimension
.	I-Dimension
7479	I-Dimension
mm	I-Dimension
(	I-Dimension
3	I-Dimension
)	I-Dimension
or	O
0	B-Dimension
.	I-Dimension
10	I-Dimension
to	I-Dimension
0	I-Dimension
.	I-Dimension
91	I-Dimension
mm	I-Dimension
using	O
the	O
cube	O
root	O
scale	O
.	O
	
On	O
average	O
,	O
drusen	B-Characteristic
volume	I-Characteristic
and	O
drusen	B-Characteristic
area	I-Characteristic
increased	O
over	O
time	O
with	O
the	O
magnitude	O
of	O
the	O
increase	O
dependent	O
on	O
the	O
length	O
of	O
follow	O
-	O
up	O
(	O
P	O
=	O
0	O
.	O
001	O
,	O
3	O
mm	O
circle	O
)	O
.	O
	
In	O
the	O
eyes	B-Anatomy
with	O
a	O
decrease	O
in	O
drusen	B-Characteristic
volume	I-Characteristic
,	O
the	O
magnitude	O
of	O
this	O
decrease	O
was	O
dependent	O
on	O
the	O
baseline	O
drusen	B-Characteristic
volume	I-Characteristic
(	O
P	O
=	O
0	O
.	O
001	O
,	O
3	O
mm	O
circle	O
)	O
and	O
independent	O
of	O
the	O
follow	O
-	O
up	O
interval	O
.	O
	
After	O
12	O
months	O
,	O
drusen	B-Characteristic
volume	I-Characteristic
increased	O
in	O
48	O
%	O
of	O
eyes	B-Anatomy
,	O
remained	O
stable	O
in	O
40	O
%	O
,	O
and	O
decreased	O
in	O
12	O
%	O
.	O
	
Imaging	B-Diagnostic_tool
with	I-Diagnostic_tool
SD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
revealed	O
a	O
dynamic	O
,	O
undulating	O
growth	O
pattern	O
for	O
drusen	B-Symptom
with	O
a	O
tendency	O
for	O
drusen	B-Symptom
to	O
increase	O
in	O
volume	O
and	O
area	O
over	O
time	O
.	O
	
An	O
appreciation	O
of	O
the	O
quantitative	O
changes	O
in	O
drusen	B-Characteristic
volume	I-Characteristic
over	O
time	O
using	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
imaging	I-Diagnostic_tool
provides	O
a	O
novel	O
strategy	O
for	O
following	O
normal	O
disease	O
progression	O
and	O
for	O
identifying	O
novel	O
clinical	O
trial	O
end	O
points	O
to	O
be	O
used	O
when	O
investigating	O
therapies	O
for	O
the	O
treatment	O
of	O
nonexudative	B-Disease
AMD	I-Disease
.	O
	
Proprietary	O
or	O
commercial	O
disclosure	O
may	O
be	O
found	O
after	O
the	O
references	O
.	O
	
Relationship	O
between	O
fluorescein	B-Symptom
pooling	I-Symptom
and	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomographic	I-Diagnostic_tool
reflectivity	B-Characteristic
of	I-Characteristic
cystoid	I-Characteristic
spaces	I-Characteristic
in	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
To	O
study	O
the	O
characteristics	O
of	O
the	O
reflectivity	B-Characteristic
of	I-Characteristic
the	I-Characteristic
cystoid	I-Characteristic
spaces	I-Characteristic
and	O
serous	B-Symptom
retinal	I-Symptom
detachment	I-Symptom
(	O
SRD	B-Symptom
)	O
on	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
and	O
the	O
correlation	O
with	O
fluorescein	B-Symptom
findings	I-Symptom
in	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
.	O
	
Retrospective	O
,	O
observational	O
,	O
cross	O
-	O
sectional	O
study	O
.	O
	
Consecutive	O
134	O
eyes	O
of	O
114	O
patients	O
with	O
clinically	B-Disease
significant	I-Disease
macular	I-Disease
edema	I-Disease
for	O
whom	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
FA	B-Diagnostic_tool
)	O
were	O
performed	O
on	O
the	O
same	O
day	O
.	O
	
Fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
using	O
Heidelberg	B-Diagnostic_tool
Retina	I-Diagnostic_tool
Angiograph	I-Diagnostic_tool
2	I-Diagnostic_tool
(	O
Heidelberg	O
Engineering	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
and	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
using	O
Spectralis	B-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
Heidelberg	O
Engineering	O
)	O
were	O
obtained	O
.	O
	
The	O
reflectivity	B-Characteristic
of	I-Characteristic
the	I-Characteristic
cystoid	I-Characteristic
spaces	I-Characteristic
and	O
SRD	B-Symptom
on	O
the	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
was	O
evaluated	O
qualitatively	O
and	O
quantitatively	O
and	O
compared	O
with	O
the	O
fluorescein	B-Symptom
pooling	I-Symptom
intensity	O
on	O
FA	B-Diagnostic_tool
images	I-Diagnostic_tool
.	O
	
The	O
relationship	O
between	O
the	O
fluorescein	B-Symptom
pooling	I-Symptom
and	O
the	O
reflectivity	B-Characteristic
characteristics	I-Characteristic
of	I-Characteristic
the	I-Characteristic
cystoid	I-Characteristic
spaces	I-Characteristic
on	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
images	I-Diagnostic_tool
.	O
	
A	O
total	O
of	O
141	O
cystoid	B-Symptom
spaces	I-Symptom
in	O
101	O
eyes	B-Anatomy
were	O
delineated	O
on	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
,	O
and	O
138	O
spaces	O
(	O
97	O
.	O
9	O
%	O
)	O
had	O
fluorescein	B-Symptom
pooling	I-Symptom
.	O
	
Fifty	O
-	O
five	O
cystoid	B-Symptom
spaces	I-Symptom
(	O
39	O
.	O
9	O
%	O
)	O
with	O
marked	O
fluorescein	B-Symptom
pooling	I-Symptom
intensity	O
had	O
lower	B-Characteristic
reflectivity	I-Characteristic
on	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
than	O
those	O
with	O
modest	O
pooling	O
(	O
12	O
.	O
1	O
	O
10	O
.	O
4	O
vs	O
.	O
22	O
.	O
0	O
	O
15	O
.	O
4	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
The	O
heterogeneity	O
of	O
the	O
reflectivity	O
of	O
the	O
cystoid	B-Symptom
spaces	I-Symptom
on	O
the	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
was	O
associated	O
significantly	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
with	O
modest	O
fluorescein	B-Symptom
pooling	I-Symptom
.	O
	
The	O
hyperreflective	B-Symptom
foci	I-Symptom
in	I-Symptom
the	I-Symptom
cystoid	I-Symptom
spaces	I-Symptom
were	O
correlated	O
significantly	O
with	O
modest	O
fluorescein	B-Symptom
pooling	I-Symptom
and	O
higher	B-Characteristic
or	I-Characteristic
heterogeneous	I-Characteristic
reflectivity	I-Characteristic
on	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
(	O
P	O
<	O
0	O
.	O
001	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
and	O
P	O
=	O
0	O
.	O
005	O
,	O
respectively	O
)	O
.	O
	
In	O
addition	O
,	O
the	O
cystoid	B-Symptom
spaces	I-Symptom
with	I-Symptom
microaneurysms	I-Symptom
had	O
higher	O
or	O
heterogeneous	B-Characteristic
reflectivity	I-Characteristic
on	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
more	O
frequently	O
than	O
those	O
without	O
microaneurysms	B-Symptom
(	O
P	O
<	O
0	O
.	O
001	O
and	O
P	O
=	O
0	O
.	O
019	O
,	O
respectively	O
)	O
.	O
	
The	O
reflectivity	B-Characteristic
levels	I-Characteristic
in	I-Characteristic
the	I-Characteristic
SRD	I-Characteristic
were	O
significantly	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
lower	O
than	O
in	O
the	O
cystoid	B-Symptom
spaces	I-Symptom
,	O
and	O
only	O
1	O
eye	B-Anatomy
(	O
3	O
.	O
3	O
%	O
)	O
had	O
heterogeneous	B-Characteristic
reflectivity	I-Characteristic
on	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
.	O
	
The	O
results	O
provided	O
a	O
novel	O
interpretation	O
of	O
fluorescein	B-Symptom
pooling	I-Symptom
and	O
OCT	B-Diagnostic_tool
characteristics	O
of	O
cystoid	B-Symptom
spaces	I-Symptom
and	O
SRD	B-Symptom
in	O
DME	B-Disease
and	O
suggested	O
several	O
mechanisms	O
by	O
which	O
the	O
blood	B-Anatomy
-	I-Anatomy
retinal	I-Anatomy
barrier	I-Anatomy
is	O
disrupted	O
and	O
concomitant	B-Symptom
edematous	I-Symptom
changes	I-Symptom
develop	O
.	O
	
Correlation	O
of	O
fundus	B-Diagnostic_tool
autofluorescence	I-Diagnostic_tool
with	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
and	O
vision	O
in	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
To	O
investigate	O
the	O
correlation	O
between	O
fundus	B-Diagnostic_tool
autofluorescence	I-Diagnostic_tool
(	O
FAF	B-Diagnostic_tool
)	O
and	O
the	O
results	O
of	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
as	O
well	O
as	O
visual	B-Diagnostic_tool
acuity	I-Diagnostic_tool
(	O
VA	B-Diagnostic_tool
)	O
in	O
patients	O
with	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
and	O
to	O
determine	O
the	O
visual	O
prognostic	O
factors	O
.	O
	
Retrospective	O
,	O
interventional	O
case	O
series	O
.	O
	
Sixty	O
-	O
one	O
patients	O
with	O
DME	B-Disease
who	O
underwent	O
intravitreal	O
injection	O
of	O
bevacizumab	O
(	O
IVB	O
)	O
as	O
their	O
first	O
treatment	O
.	O
	
An	O
assessment	O
of	O
VA	B-Diagnostic_tool
and	O
FAF	B-Diagnostic_tool
and	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
images	O
were	O
obtained	O
before	O
and	O
after	O
IVB	O
(	O
pre	O
-	O
and	O
post	O
-	O
IVB	O
)	O
.	O
	
Foveal	B-Diagnostic_tool
FAF	I-Diagnostic_tool
was	O
graded	O
on	O
a	O
scale	O
of	O
1	O
to	O
4	O
.	O
	
The	O
presence	O
or	O
absence	O
of	O
FAF	B-Diagnostic_tool
at	O
the	O
foveola	B-Anatomy
was	O
also	O
determined	O
.	O
	
The	O
association	O
of	O
FAF	B-Diagnostic_tool
with	O
VA	B-Diagnostic_tool
and	O
the	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
results	O
,	O
including	O
central	B-Characteristic
macular	I-Characteristic
thickness	I-Characteristic
(	O
CMT	B-Characteristic
)	O
,	O
outer	B-Characteristic
nuclear	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
,	O
the	O
integrity	B-Characteristic
of	I-Characteristic
the	I-Characteristic
external	I-Characteristic
limiting	I-Characteristic
membrane	I-Characteristic
(	O
ELM	B-Anatomy
)	O
,	O
and	O
the	O
integrity	B-Characteristic
of	I-Characteristic
the	I-Characteristic
junction	I-Characteristic
between	I-Characteristic
the	I-Characteristic
inner	I-Characteristic
and	I-Characteristic
outer	I-Characteristic
segment	I-Characteristic
of	I-Characteristic
the	I-Characteristic
photoreceptor	I-Characteristic
(	O
IS	B-Anatomy
/	I-Anatomy
OS	I-Anatomy
)	O
.	O
	
Better	B-Characteristic
VA	I-Characteristic
,	O
preservation	B-Characteristic
of	I-Characteristic
the	I-Characteristic
ELM	I-Characteristic
,	I-Characteristic
and	I-Characteristic
IS	I-Characteristic
/	I-Characteristic
OS	I-Characteristic
pre	O
-	O
IVB	O
were	O
associated	O
with	O
better	B-Characteristic
VA	I-Characteristic
post	O
-	O
IVB	O
.	O
	
Of	O
the	O
types	O
of	O
DME	B-Disease
,	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
significantly	O
correlated	O
with	O
increased	B-Symptom
FAF	I-Symptom
at	O
the	O
foveola	B-Anatomy
.	O
	
A	O
higher	B-Symptom
level	I-Symptom
of	I-Symptom
FAF	I-Symptom
was	O
5	O
.	O
6	O
times	O
more	O
likely	O
to	O
occur	O
in	O
DME	B-Disease
with	O
a	O
defect	B-Symptom
in	I-Symptom
IS	I-Symptom
/	I-Symptom
OS	I-Symptom
and	O
10	O
times	O
more	O
likely	O
to	O
occur	O
with	O
each	O
10	B-Dimension
-	I-Dimension
	I-Dimension
m	I-Dimension
increase	O
in	O
CMT	B-Characteristic
.	O
	
Each	O
increase	O
by	O
a	O
factor	O
of	O
0	O
.	O
1	O
in	O
the	O
logarithm	B-Characteristic
of	I-Characteristic
the	I-Characteristic
minimum	I-Characteristic
angle	I-Characteristic
of	I-Characteristic
resolution	I-Characteristic
(	O
logMAR	B-Characteristic
)	O
pre	O
-	O
IVB	O
increased	O
the	O
probability	O
of	O
high	B-Symptom
FAF	I-Symptom
by	O
a	O
factor	O
of	O
1	O
.	O
73	O
.	O
	
Despite	O
severe	B-Disease
DME	I-Disease
,	O
fewer	O
eyes	B-Anatomy
with	O
a	O
low	B-Symptom
level	I-Symptom
of	I-Symptom
FAF	I-Symptom
exhibited	O
an	O
IS	B-Symptom
/	I-Symptom
OS	I-Symptom
defect	I-Symptom
and	O
large	B-Symptom
logMAR	I-Symptom
VA	I-Symptom
than	O
eyes	B-Anatomy
with	O
a	O
high	B-Symptom
level	I-Symptom
of	I-Symptom
FAF	I-Symptom
with	O
severe	B-Disease
DME	I-Disease
pre	O
-	O
IVB	O
.	O
	
The	O
average	B-Characteristic
grade	I-Characteristic
of	I-Characteristic
FAF	I-Characteristic
pre	O
-	O
IVB	O
was	O
higher	O
in	O
patients	O
with	O
decreased	B-Symptom
vision	I-Symptom
during	O
follow	O
-	O
up	O
than	O
in	O
patients	O
with	O
increased	O
or	O
unchanged	O
good	B-Characteristic
vision	I-Characteristic
.	O
	
The	O
strong	O
association	O
of	O
FAF	B-Diagnostic_tool
with	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
parameters	O
and	O
VA	B-Diagnostic_tool
in	O
patients	O
with	O
DME	B-Disease
could	O
aid	O
in	O
the	O
prediction	O
of	O
the	O
restoration	O
of	O
photoreceptor	B-Characteristic
integrity	I-Characteristic
and	O
subsequent	O
visual	O
recovery	O
,	O
especially	O
in	O
patients	O
with	O
severe	B-Disease
DME	I-Disease
,	O
in	O
whom	O
photoreceptor	B-Characteristic
integrity	I-Characteristic
before	O
treatment	O
could	O
not	O
be	O
adequately	O
evaluated	O
,	O
even	O
with	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
.	O
	
Hyporeflective	B-Symptom
wedge	I-Symptom
-	I-Symptom
shaped	I-Symptom
band	I-Symptom
in	O
geographic	B-Symptom
atrophy	I-Symptom
secondary	O
to	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
:	O
an	O
underreported	O
finding	O
.	O
	
To	O
describe	O
and	O
interpret	O
the	O
frequently	O
observed	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
finding	O
of	O
a	O
marked	O
hyporeflective	B-Symptom
wedge	I-Symptom
-	I-Symptom
shaped	I-Symptom
structure	I-Symptom
at	O
the	O
boundaries	O
of	O
the	O
areas	O
of	O
atrophy	B-Symptom
.	O
	
A	O
prospective	O
,	O
longitudinal	O
follow	O
-	O
up	O
study	O
.	O
	
Consecutive	O
patients	O
(	O
n	O
=	O
71	O
)	O
50	B-Characteristic
years	I-Characteristic
of	I-Characteristic
age	I-Characteristic
and	I-Characteristic
older	I-Characteristic
with	O
geographic	B-Symptom
atrophy	I-Symptom
(	O
GA	B-Symptom
)	O
secondary	O
to	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
were	O
examined	O
between	O
January	O
2010	O
and	O
June	O
2011	O
.	O
	
Patients	O
were	O
evaluated	O
with	O
the	O
use	O
of	O
imaging	O
techniques	O
that	O
included	O
35	B-Diagnostic_tool
	I-Diagnostic_tool
fundus	I-Diagnostic_tool
photography	I-Diagnostic_tool
,	O
infrared	B-Diagnostic_tool
,	O
fundus	B-Diagnostic_tool
autofluorescence	I-Diagnostic_tool
(	O
FAF	B-Diagnostic_tool
)	O
,	O
and	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
.	O
	
Visualization	O
of	O
the	O
fundus	B-Anatomy
with	O
FAF	B-Diagnostic_tool
was	O
done	O
simultaneously	O
with	O
OCT	B-Diagnostic_tool
.	O
	
Two	O
acquisition	O
protocols	O
were	O
followed	O
:	O
a	O
macular	B-Diagnostic_tool
cube	I-Diagnostic_tool
for	I-Diagnostic_tool
coverage	I-Diagnostic_tool
(	O
19	B-Diagnostic_tool
horizontal	I-Diagnostic_tool
B	I-Diagnostic_tool
-	I-Diagnostic_tool
scans	I-Diagnostic_tool
centered	I-Diagnostic_tool
on	I-Diagnostic_tool
the	I-Diagnostic_tool
fovea	I-Diagnostic_tool
)	O
and	O
high	B-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
horizontal	I-Diagnostic_tool
B	I-Diagnostic_tool
-	I-Diagnostic_tool
scan	I-Diagnostic_tool
for	O
qualitative	O
foveal	B-Anatomy
detail	O
.	O
	
Estimation	O
of	O
the	O
prevalence	O
of	O
a	O
hyporeflective	B-Symptom
wedge	I-Symptom
-	I-Symptom
shaped	I-Symptom
band	I-Symptom
among	O
patients	O
with	O
GA	B-Symptom
.	O
	
A	O
marked	O
hyporeflective	B-Symptom
wedge	I-Symptom
-	I-Symptom
shaped	I-Symptom
structure	I-Symptom
,	O
with	O
its	O
base	O
on	O
Bruch	B-Anatomy
'	I-Anatomy
s	I-Anatomy
membrane	I-Anatomy
and	O
its	O
apex	O
pointing	O
toward	O
the	O
inner	O
limit	O
of	O
the	O
outer	B-Anatomy
plexiform	I-Anatomy
layer	I-Anatomy
(	O
OPL	B-Anatomy
)	O
adjacent	O
to	O
the	O
margin	O
between	O
the	O
atrophied	O
area	O
and	O
the	O
preserved	O
retina	B-Anatomy
,	O
was	O
observed	O
in	O
72	O
.	O
9	O
%	O
of	O
eyes	B-Anatomy
(	O
70	O
/	O
96	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
63	O
.	O
9	O
-	O
82	O
.	O
0	O
)	O
.	O
	
This	O
hyporeflective	B-Symptom
band	I-Symptom
appeared	O
to	O
be	O
within	O
the	O
OPL	B-Anatomy
.	O
	
Using	O
eccentric	B-Diagnostic_tool
SD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
acquisition	I-Diagnostic_tool
,	O
the	O
boundaries	O
between	O
the	O
outer	B-Anatomy
nuclear	I-Anatomy
layer	I-Anatomy
(	O
ONL	B-Anatomy
)	O
and	O
Henle	B-Anatomy
'	I-Anatomy
s	I-Anatomy
fiber	I-Anatomy
layer	I-Anatomy
(	O
HFL	B-Anatomy
)	O
were	O
well	O
defined	O
,	O
showing	O
that	O
the	O
ONL	B-Anatomy
ends	O
before	O
the	O
margin	O
of	O
atrophy	B-Symptom
of	I-Symptom
the	I-Symptom
retinal	I-Symptom
pigment	I-Symptom
epithelium	I-Symptom
(	O
RPE	B-Anatomy
)	O
.	O
	
A	O
narrow	B-Symptom
hyperreflective	I-Symptom
band	I-Symptom
separated	O
the	O
margin	O
of	O
the	O
ONL	B-Anatomy
and	O
RPE	B-Anatomy
from	O
the	O
hyporeflective	B-Symptom
band	I-Symptom
,	O
already	O
within	O
the	O
atrophic	O
area	O
.	O
	
A	O
hyporeflective	B-Symptom
wedge	I-Symptom
-	I-Symptom
shaped	I-Symptom
structure	I-Symptom
appears	O
frequently	O
within	O
the	O
boundaries	O
of	O
the	O
OPL	B-Anatomy
in	O
patients	O
with	O
GA	B-Symptom
secondary	O
to	O
AMD	B-Disease
,	O
corresponding	O
to	O
an	O
increase	O
in	O
the	O
width	O
of	O
the	O
HFL	B-Anatomy
,	O
presumably	O
because	O
of	O
axonal	B-Symptom
swelling	I-Symptom
or	O
interaxonal	B-Symptom
edema	I-Symptom
.	O
	
This	O
finding	O
may	O
improve	O
the	O
interpretation	O
of	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
images	I-Diagnostic_tool
of	O
the	O
outer	B-Anatomy
layers	I-Anatomy
,	O
may	O
help	O
in	O
understanding	O
better	O
the	O
interactions	O
between	O
photoreceptor	B-Anatomy
cells	I-Anatomy
and	O
the	O
RPE	B-Anatomy
,	O
and	O
may	O
help	O
in	O
the	O
development	O
of	O
monitoring	O
techniques	O
and	O
therapies	O
for	O
GA	B-Symptom
secondary	O
to	O
AMD	B-Disease
.	O
	
Optic	B-Diagnostic_tool
disc	I-Diagnostic_tool
imaging	I-Diagnostic_tool
with	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
:	O
variability	O
and	O
agreement	O
study	O
with	O
Heidelberg	B-Diagnostic_tool
retinal	I-Diagnostic_tool
tomograph	I-Diagnostic_tool
.	O
	
To	O
evaluate	O
the	O
agreement	O
of	O
optic	B-Anatomy
disc	I-Anatomy
measurements	O
obtained	O
with	O
the	O
Cirrus	B-Diagnostic_tool
high	I-Diagnostic_tool
-	I-Diagnostic_tool
density	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
HD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
and	O
the	O
Heidelberg	B-Diagnostic_tool
retina	I-Diagnostic_tool
tomograph	I-Diagnostic_tool
(	O
HRT	B-Diagnostic_tool
)	O
and	O
compare	O
the	O
intervisit	O
,	O
test	O
-	O
retest	O
variability	O
between	O
the	O
instruments	O
.	O
	
Prospective	O
,	O
cross	O
-	O
sectional	O
study	O
.	O
	
Two	O
hundred	O
seven	O
subjects	O
(	O
109	O
glaucoma	B-Disease
and	O
98	O
normal	O
subjects	O
)	O
.	O
	
One	O
eye	B-Anatomy
from	O
each	O
individual	O
was	O
selected	O
randomly	O
for	O
optic	B-Diagnostic_tool
disc	I-Diagnostic_tool
imaging	I-Diagnostic_tool
by	O
the	O
Cirrus	B-Diagnostic_tool
HD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
the	O
HRT	B-Diagnostic_tool
.	O
	
Areas	B-Characteristic
of	I-Characteristic
the	I-Characteristic
optic	I-Characteristic
disc	I-Characteristic
and	I-Characteristic
the	I-Characteristic
cup	I-Characteristic
,	O
cup	B-Characteristic
volume	I-Characteristic
,	O
vertical	B-Characteristic
cup	I-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
disc	I-Characteristic
ratio	I-Characteristic
and	O
cup	B-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
disc	I-Characteristic
area	I-Characteristic
ratio	I-Characteristic
were	O
compared	O
between	O
the	O
instruments	O
.	O
	
The	O
OCT	B-Diagnostic_tool
measurements	O
were	O
corrected	O
for	O
ocular	O
magnification	O
using	O
the	O
Littman	O
'	O
s	O
formula	O
.	O
	
The	O
measurement	O
agreement	O
was	O
evaluated	O
with	O
the	O
Bland	O
-	O
Altman	O
plots	O
.	O
	
The	O
intervisit	O
test	O
-	O
retest	O
variability	O
was	O
examined	O
in	O
17	O
randomly	O
selected	O
glaucoma	B-Disease
patients	O
who	O
underwent	O
optic	B-Diagnostic_tool
disc	I-Diagnostic_tool
imaging	I-Diagnostic_tool
weekly	O
for	O
8	O
consecutive	O
weeks	O
.	O
	
The	O
intraclass	B-Characteristic
correlation	I-Characteristic
coefficients	I-Characteristic
(	O
ICC	B-Characteristic
)	O
and	O
the	O
reproducibility	O
coefficients	O
of	O
the	O
optic	B-Anatomy
disc	I-Anatomy
parameters	O
were	O
computed	O
.	O
	
Measurement	O
agreement	O
,	O
reproducibility	O
coefficients	O
,	O
and	O
ICCs	B-Characteristic
of	O
optic	B-Anatomy
disc	I-Anatomy
parameters	O
.	O
	
The	O
OCT	B-Diagnostic_tool
measured	O
smaller	O
optic	B-Characteristic
disc	I-Characteristic
and	I-Characteristic
rim	I-Characteristic
areas	I-Characteristic
and	O
greater	O
cup	B-Characteristic
volume	I-Characteristic
,	O
vertical	B-Characteristic
cup	I-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
disc	I-Characteristic
ratio	I-Characteristic
and	O
cup	B-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
disc	I-Characteristic
area	I-Characteristic
ratio	I-Characteristic
than	O
the	O
HRT	B-Diagnostic_tool
did	O
(	O
all	O
with	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
There	O
were	O
proportional	O
biases	O
in	O
the	O
Bland	O
-	O
Altman	O
plots	O
between	O
OCT	B-Diagnostic_tool
and	O
HRT	B-Diagnostic_tool
optic	B-Anatomy
disc	I-Anatomy
measurements	O
except	O
for	O
rim	B-Characteristic
area	I-Characteristic
and	O
cup	B-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
disc	I-Characteristic
area	I-Characteristic
ratio	I-Characteristic
.	O
	
The	O
95	O
%	O
limits	O
of	O
agreement	O
of	O
rim	B-Characteristic
area	I-Characteristic
ranged	O
between	O
-	O
0	O
.	O
28	O
and	O
0	O
.	O
88	O
mm	O
(	O
2	O
)	O
before	O
,	O
and	O
between	O
-	O
0	O
.	O
22	O
and	O
0	O
.	O
92	O
mm	O
(	O
2	O
)	O
after	O
correction	O
for	O
ocular	O
magnification	O
.	O
	
Both	O
OCT	B-Diagnostic_tool
and	O
HRT	B-Diagnostic_tool
showed	O
high	O
test	O
-	O
retest	O
reproducibility	O
with	O
ICCs	B-Characteristic
	O
0	O
.	O
921	O
.	O
	
Although	O
the	O
reproducibility	O
coefficient	O
of	O
OCT	B-Characteristic
rim	I-Characteristic
area	I-Characteristic
(	O
0	O
.	O
093	O
mm	O
(	O
2	O
)	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0	O
.	O
081	O
-	O
0	O
.	O
105	O
mm	O
(	O
2	O
)	O
)	O
was	O
significantly	O
smaller	O
than	O
that	O
of	O
the	O
HRT	B-Diagnostic_tool
(	O
0	O
.	O
186	O
mm	O
(	O
2	O
)	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
163	O
-	O
0	O
.	O
210	O
mm	O
(	O
2	O
)	O
;	O
P	O
=	O
.	O
018	O
)	O
,	O
there	O
were	O
no	O
differences	O
in	O
the	O
ICCs	B-Characteristic
between	O
the	O
instruments	O
.	O
	
Optic	B-Anatomy
disc	I-Anatomy
assessment	O
by	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
confocal	B-Diagnostic_tool
scanning	I-Diagnostic_tool
laser	I-Diagnostic_tool
ophthalmoscopy	I-Diagnostic_tool
demonstrates	O
poor	O
agreement	O
but	O
similarly	O
low	O
test	O
-	O
retest	O
variability	O
.	O
	
The	O
source	O
of	O
their	O
disagreement	O
and	O
its	O
effects	O
on	O
the	O
detection	O
of	O
progression	O
require	O
further	O
study	O
.	O
	
Baseline	O
risk	O
factors	O
that	O
predict	O
the	O
development	O
of	O
open	B-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
in	O
a	O
population	O
:	O
the	O
Los	B-Characteristic
Angeles	I-Characteristic
Latino	I-Characteristic
Eye	B-Anatomy
Study	O
.	O
	
To	O
determine	O
which	O
baseline	O
sociodemographic	B-Characteristic
,	O
lifestyle	B-Characteristic
,	O
anthropometric	B-Characteristic
,	O
clinical	B-Characteristic
,	O
and	O
ocular	B-Characteristic
risk	I-Characteristic
factors	I-Characteristic
predict	O
the	O
development	O
of	O
open	B-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
(	O
OAG	B-Disease
)	O
in	O
an	O
adult	B-Characteristic
population	O
.	O
	
A	O
population	O
-	O
based	O
,	O
prospective	O
cohort	O
study	O
.	O
	
A	O
total	O
of	O
3772	O
self	O
-	O
identified	O
Latinos	B-Characteristic
aged	I-Characteristic
	I-Characteristic
40	I-Characteristic
years	I-Characteristic
from	O
Los	B-Characteristic
Angeles	I-Characteristic
,	I-Characteristic
California	I-Characteristic
,	O
who	O
were	O
free	O
of	O
OAG	B-Disease
at	O
baseline	O
.	O
	
Participants	O
from	O
the	O
Los	B-Characteristic
Angeles	I-Characteristic
Latino	I-Characteristic
Eye	B-Anatomy
Study	O
had	O
standardized	O
study	O
visits	O
at	O
baseline	O
and	O
4	O
-	O
year	O
follow	O
-	O
up	O
with	O
structured	O
interviews	O
and	O
a	O
comprehensive	O
ophthalmologic	B-Diagnostic_tool
examination	I-Diagnostic_tool
.	O
	
We	O
defined	O
OAG	B-Disease
as	O
the	O
presence	O
of	O
an	O
open	B-Symptom
angle	I-Symptom
and	O
a	O
glaucomatous	B-Symptom
visual	I-Symptom
field	I-Symptom
abnormality	I-Symptom
and	O
/	O
or	O
evidence	O
of	O
glaucomatous	B-Symptom
optic	I-Symptom
nerve	I-Symptom
damage	I-Symptom
in	I-Symptom
	I-Symptom
1	I-Symptom
eye	I-Symptom
.	O
	
Multivariate	O
logistic	O
regression	O
with	O
stepwise	O
selection	O
was	O
performed	O
to	O
determine	O
which	O
potential	O
baseline	O
risk	O
factors	O
independently	O
predict	O
the	O
development	O
of	O
OAG	B-Disease
.	O
	
Odds	O
ratios	O
for	O
various	O
risk	O
factors	O
.	O
	
Over	O
the	O
4	O
-	O
year	O
follow	O
-	O
up	O
,	O
87	O
participants	O
developed	O
OAG	B-Disease
.	O
	
The	O
baseline	O
risk	O
factors	O
that	O
predict	O
the	O
development	O
of	O
OAG	B-Disease
include	O
older	B-Characteristic
age	I-Characteristic
(	O
odds	O
ratio	O
[	O
OR	O
]	O
per	O
decade	O
,	O
2	O
.	O
19	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
74	O
-	O
2	O
.	O
75	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
higher	B-Characteristic
intraocular	I-Characteristic
pressure	I-Characteristic
(	O
IOP	B-Characteristic
;	O
OR	O
per	O
mmHg	O
,	O
1	O
.	O
18	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
10	O
-	O
1	O
.	O
26	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	B-Characteristic
axial	I-Characteristic
length	I-Characteristic
(	O
OR	O
per	O
mm	O
,	O
1	O
.	O
48	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
22	O
-	O
1	O
.	O
80	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
thinner	B-Characteristic
central	I-Characteristic
cornea	I-Characteristic
(	O
OR	O
per	O
40	O
	O
m	O
thinner	O
,	O
1	O
.	O
30	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
00	O
-	O
1	O
.	O
70	O
;	O
P	O
=	O
0	O
.	O
050	O
)	O
,	O
higher	B-Characteristic
waist	I-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
hip	I-Characteristic
ratio	I-Characteristic
(	O
OR	O
per	O
0	O
.	O
05	O
higher	O
,	O
1	O
.	O
21	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
05	O
-	O
1	O
.	O
39	O
;	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
lack	B-Characteristic
of	I-Characteristic
vision	I-Characteristic
insurance	I-Characteristic
(	O
OR	O
,	O
2	O
.	O
08	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
26	O
-	O
3	O
.	O
41	O
;	O
P	O
=	O
0	O
.	O
004	O
)	O
.	O
	
Despite	O
a	O
mean	B-Symptom
baseline	I-Symptom
IOP	I-Symptom
of	I-Symptom
14	I-Symptom
mmHg	I-Symptom
in	O
Latinos	B-Characteristic
,	O
higher	O
IOP	B-Characteristic
is	O
an	O
important	O
risk	O
factor	O
for	O
developing	O
OAG	B-Disease
.	O
	
Biometric	O
measures	O
suggestive	O
of	O
less	O
structural	O
support	O
such	O
as	O
longer	B-Characteristic
axial	I-Characteristic
length	I-Characteristic
and	O
thin	B-Characteristic
central	I-Characteristic
corneal	I-Characteristic
thickness	I-Characteristic
were	O
identified	O
as	O
important	O
risk	O
factors	O
.	O
	
Lack	B-Characteristic
of	I-Characteristic
health	I-Characteristic
insurance	I-Characteristic
reduces	O
access	O
to	O
eye	B-Anatomy
care	O
and	O
increases	O
the	O
burden	O
of	O
OAG	B-Disease
by	O
reducing	O
the	O
likelihood	O
of	O
early	O
detection	O
and	O
treatment	O
of	O
OAG	B-Disease
.	O
	
The	O
authors	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
of	O
the	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
grading	O
reproducibility	O
during	O
the	O
Comparison	O
of	O
Age	B-Disease
-	I-Disease
related	I-Disease
Macular	I-Disease
Degeneration	I-Disease
Treatments	O
Trials	O
.	O
	
To	O
report	O
reading	O
center	O
reproducibility	O
during	O
grading	O
of	O
Stratus	B-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
(	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
)	O
images	O
obtained	O
during	O
the	O
Comparison	O
of	O
Age	B-Disease
-	I-Disease
Related	I-Disease
Macular	I-Disease
Degeneration	I-Disease
Treatments	O
Trials	O
(	O
CATT	O
)	O
.	O
	
Prospective	O
,	O
clinical	O
trial	O
.	O
	
Independent	O
reading	O
teams	O
reevaluated	O
270	O
OCT	B-Diagnostic_tool
scans	O
randomly	O
sampled	O
from	O
the	O
first	O
2	O
years	O
of	O
CATT	O
enrollment	O
.	O
	
To	O
assess	O
temporal	O
drift	O
,	O
a	O
cohort	O
of	O
23	O
scans	O
submitted	O
during	O
the	O
initial	O
portion	O
of	O
the	O
CATT	O
study	O
was	O
longitudinally	O
followed	O
with	O
serial	O
reproducibility	O
analysis	O
.	O
	
The	O
CATT	O
readers	O
performed	O
standardized	O
grading	O
of	O
OCT	B-Diagnostic_tool
images	O
.	O
	
A	O
reader	O
team	O
,	O
composed	O
of	O
2	O
independent	O
readers	O
and	O
a	O
senior	O
reader	O
,	O
evaluated	O
each	O
scan	O
.	O
	
Grading	O
included	O
the	O
CATT	O
OCT	B-Diagnostic_tool
end	O
points	O
of	O
total	B-Characteristic
thickness	I-Characteristic
at	I-Characteristic
the	I-Characteristic
foveal	I-Characteristic
center	I-Characteristic
point	I-Characteristic
and	O
intraretinal	B-Symptom
fluid	I-Symptom
(	O
IRF	B-Symptom
)	O
,	O
subretinal	B-Symptom
fluid	I-Symptom
(	O
SRF	B-Symptom
)	O
,	O
and	O
subretinal	B-Symptom
pigment	I-Symptom
epithelium	I-Symptom
(	I-Symptom
RPE	I-Symptom
)	I-Symptom
fluid	I-Symptom
.	O
	
Independent	O
reading	O
teams	O
masked	O
to	O
the	O
results	O
of	O
initial	O
grading	O
reevaluated	O
scans	O
to	O
determine	O
the	O
reproducibility	O
of	O
qualitative	O
grading	O
and	O
measurements	O
.	O
	
Categorical	O
grading	O
agreement	O
was	O
reported	O
using	O
percent	O
agreement	O
and	O
kappa	O
statistic	O
,	O
and	O
measurement	O
agreement	O
was	O
reported	O
using	O
intraclass	O
correlations	O
and	O
paired	O
differences	O
.	O
	
Reading	O
center	O
teams	O
reproducibly	O
graded	O
IRF	B-Symptom
(	O
percent	O
agreement	O
=	O
73	O
%	O
,	O
kappa	O
=	O
0	O
.	O
48	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0	O
.	O
38	O
-	O
0	O
.	O
58	O
)	O
,	O
SRF	B-Symptom
(	O
percent	O
agreement	O
=	O
90	O
%	O
;	O
kappa	O
=	O
0	O
.	O
80	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
73	O
-	O
0	O
.	O
87	O
)	O
,	O
and	O
sub	B-Symptom
-	I-Symptom
RPE	I-Symptom
fluid	I-Symptom
(	O
percent	O
agreement	O
88	O
%	O
;	O
kappa	O
=	O
0	O
.	O
75	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
67	O
-	O
0	O
.	O
83	O
)	O
.	O
	
For	O
independent	O
reading	O
center	O
team	O
measurements	O
of	O
total	B-Characteristic
thickness	I-Characteristic
at	I-Characteristic
the	I-Characteristic
foveal	I-Characteristic
center	I-Characteristic
point	I-Characteristic
,	O
the	O
intraclass	O
correlation	O
was	O
0	O
.	O
99	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
99	O
-	O
0	O
.	O
99	O
)	O
,	O
and	O
the	O
mean	O
paired	O
difference	O
between	O
reading	O
center	O
teams	O
was	O
4	O
	O
m	O
(	O
95	O
%	O
limits	O
of	O
agreement	O
,	O
-	O
55	O
to	O
47	O
	O
m	O
)	O
.	O
	
There	O
was	O
no	O
qualitative	O
or	O
quantitative	O
grading	O
drift	O
.	O
	
The	O
standardized	O
protocols	O
used	O
to	O
evaluate	O
OCT	B-Diagnostic_tool
scans	O
from	O
the	O
CATT	O
study	O
were	O
reproducible	O
.	O
	
The	O
methods	O
used	O
are	O
suitable	O
to	O
monitor	O
OCT	B-Diagnostic_tool
imaging	O
data	O
from	O
a	O
large	O
,	O
neovascular	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
,	O
interventional	O
,	O
multicenter	O
study	O
.	O
	
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
Determinants	O
and	O
two	O
-	O
year	O
change	O
in	O
anterior	B-Characteristic
chamber	I-Characteristic
angle	I-Characteristic
width	I-Characteristic
in	O
a	O
Chinese	B-Characteristic
population	I-Characteristic
.	O
	
To	O
study	O
the	O
population	O
distribution	O
and	O
longitudinal	O
changes	O
in	O
anterior	B-Characteristic
chamber	I-Characteristic
angle	I-Characteristic
width	I-Characteristic
and	O
its	O
determinants	O
among	O
Chinese	B-Characteristic
adults	I-Characteristic
.	O
	
Prospective	O
cohort	O
,	O
population	O
-	O
based	O
study	O
.	O
	
Persons	B-Characteristic
aged	I-Characteristic
35	I-Characteristic
years	I-Characteristic
or	O
more	O
residing	B-Characteristic
in	I-Characteristic
Guangzhou	I-Characteristic
,	I-Characteristic
China	I-Characteristic
,	O
who	O
had	O
not	O
previously	O
undergone	O
incisional	O
or	O
laser	O
eye	B-Anatomy
surgery	O
.	O
	
In	O
December	O
2008	O
and	O
December	O
2010	O
,	O
all	O
subjects	O
underwent	O
automated	O
keratometry	B-Diagnostic_tool
,	O
and	O
a	O
random	O
50	O
%	O
sample	O
had	O
anterior	B-Diagnostic_tool
segment	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
with	O
measurement	O
of	O
angle	B-Characteristic
-	I-Characteristic
opening	I-Characteristic
distance	I-Characteristic
at	I-Characteristic
500	I-Characteristic
	I-Characteristic
m	I-Characteristic
(	O
AOD500	B-Characteristic
)	O
,	O
angle	B-Characteristic
recess	I-Characteristic
area	I-Characteristic
(	O
ARA	B-Characteristic
)	O
,	O
iris	B-Characteristic
thickness	I-Characteristic
at	I-Characteristic
750	I-Characteristic
	I-Characteristic
m	I-Characteristic
(	O
IT750	B-Characteristic
)	O
,	O
iris	B-Characteristic
curvature	I-Characteristic
,	O
pupil	B-Characteristic
diameter	I-Characteristic
,	O
corneal	B-Characteristic
thickness	I-Characteristic
,	O
anterior	B-Characteristic
chamber	I-Characteristic
width	I-Characteristic
(	O
ACW	B-Characteristic
)	O
,	O
lens	B-Characteristic
vault	I-Characteristic
(	O
LV	B-Characteristic
)	O
,	O
and	O
lens	B-Characteristic
thickness	I-Characteristic
(	O
LT	B-Characteristic
)	O
and	O
measurement	O
of	O
axial	B-Characteristic
length	I-Characteristic
(	O
AL	B-Characteristic
)	O
and	O
anterior	B-Characteristic
chamber	I-Characteristic
depth	I-Characteristic
(	O
ACD	B-Characteristic
)	O
by	O
partial	B-Diagnostic_tool
coherence	I-Diagnostic_tool
laser	I-Diagnostic_tool
interferometry	I-Diagnostic_tool
.	O
	
Baseline	O
and	O
2	O
-	O
year	O
change	O
in	O
AOD500	B-Characteristic
and	O
ARA	B-Characteristic
in	O
the	O
right	O
eye	B-Anatomy
.	O
	
A	O
total	O
of	O
745	O
subjects	O
were	O
present	O
for	O
full	O
biometric	O
testing	O
in	O
both	O
2008	O
and	O
2010	O
(	O
mean	B-Characteristic
age	I-Characteristic
at	O
baseline	O
,	O
52	O
.	O
2	O
years	O
;	O
standard	O
deviation	O
[	O
SD	O
]	O
,	O
11	O
.	O
5	O
years	O
;	O
53	O
.	O
7	O
%	O
were	O
female	B-Characteristic
)	O
.	O
	
Test	O
completion	O
rates	O
in	O
2010	O
varied	O
from	O
77	O
.	O
3	O
%	O
(	O
AOD500	B-Characteristic
:	O
576	O
/	O
745	O
)	O
to	O
100	O
%	O
(	O
AL	B-Characteristic
)	O
.	O
	
Mean	B-Characteristic
AOD500	I-Characteristic
decreased	O
from	O
0	O
.	O
25	O
mm	O
(	O
SD	O
,	O
0	O
.	O
13	O
mm	O
)	O
in	O
2008	O
to	O
0	O
.	O
21	O
mm	O
(	O
SD	O
,	O
13	O
mm	O
)	O
in	O
2010	O
(	O
difference	O
,	O
-	O
0	O
.	O
04	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
-	O
0	O
.	O
05	O
to	O
-	O
0	O
.	O
03	O
)	O
.	O
	
The	O
ARA	B-Characteristic
decreased	O
from	O
21	O
.	O
5	O
	O
3	O
.	O
73	O
10	O
(	O
-	O
2	O
)	O
mm	O
(	O
2	O
)	O
to	O
21	O
.	O
0	O
	O
3	O
.	O
64	O
10	O
(	O
-	O
2	O
)	O
mm	O
(	O
2	O
)	O
(	O
difference	O
,	O
-	O
0	O
.	O
46	O
;	O
95	O
%	O
CI	O
,	O
-	O
0	O
.	O
52	O
to	O
-	O
0	O
.	O
41	O
)	O
.	O
	
The	O
decrease	O
in	O
both	O
was	O
most	O
pronounced	O
among	O
younger	B-Characteristic
subjects	I-Characteristic
and	O
those	O
with	O
baseline	O
AOD500	B-Characteristic
in	O
the	O
widest	O
quartile	O
at	O
baseline	O
.	O
	
The	O
following	O
baseline	O
variables	O
were	O
significantly	O
associated	O
with	O
a	O
greater	O
2	O
-	O
year	O
decrease	O
in	O
both	O
AOD500	B-Characteristic
and	O
ARA	B-Characteristic
:	O
deeper	B-Characteristic
ACD	I-Characteristic
,	O
steeper	B-Characteristic
iris	I-Characteristic
curvature	I-Characteristic
,	O
smaller	B-Characteristic
LV	I-Characteristic
,	O
greater	B-Characteristic
ARA	I-Characteristic
,	O
and	O
greater	B-Characteristic
AOD500	I-Characteristic
.	O
	
By	O
using	O
simple	O
regression	O
models	O
,	O
we	O
could	O
explain	O
52	O
%	O
to	O
58	O
%	O
and	O
93	O
%	O
of	O
variation	O
in	O
baseline	O
AOD500	B-Characteristic
and	O
ARA	B-Characteristic
,	O
respectively	O
,	O
but	O
only	O
27	O
%	O
and	O
16	O
%	O
of	O
variation	O
in	O
2	O
-	O
year	O
change	O
in	O
AOD500	B-Characteristic
and	O
ARA	B-Characteristic
,	O
respectively	O
.	O
	
Younger	B-Characteristic
persons	I-Characteristic
and	O
those	O
with	O
the	O
least	B-Characteristic
crowded	I-Characteristic
anterior	I-Characteristic
chambers	I-Characteristic
at	O
baseline	O
have	O
the	O
largest	O
2	O
-	O
year	O
decreases	O
in	O
AOD500	B-Characteristic
and	O
ARA	B-Characteristic
.	O
	
The	O
ability	O
to	O
predict	O
change	B-Characteristic
in	I-Characteristic
angle	I-Characteristic
width	I-Characteristic
based	O
on	O
demographic	B-Characteristic
and	I-Characteristic
biometric	I-Characteristic
factors	I-Characteristic
is	O
relatively	O
poor	O
,	O
which	O
may	O
have	O
implications	O
for	O
screening	O
.	O
	
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
Improving	O
awareness	O
,	O
identification	O
,	O
and	O
management	O
of	O
meibomian	B-Disease
gland	I-Disease
dysfunction	I-Disease
.	O
	
Ocular	B-Disease
surface	I-Disease
disorder	I-Disease
-	O
-	O
and	O
dry	B-Disease
eye	I-Disease
,	O
in	O
particular	O
-	O
-	O
is	O
a	O
leading	O
reason	O
for	O
visits	O
to	O
eye	B-Anatomy
care	O
professionals	O
.	O
	
It	O
has	O
been	O
generally	O
accepted	O
that	O
meibomian	B-Disease
gland	I-Disease
dysfunction	I-Disease
(	O
MGD	B-Disease
)	O
is	O
a	O
leading	O
cause	O
of	O
evaporative	B-Disease
dry	I-Disease
eye	I-Disease
,	O
as	O
well	O
as	O
being	O
associated	O
with	O
aqueous	B-Disease
-	I-Disease
deficient	I-Disease
dry	I-Disease
eye	I-Disease
.	O
	
Yet	O
,	O
researchers	O
and	O
clinicians	O
have	O
lacked	O
a	O
global	O
consensus	O
on	O
the	O
definition	O
of	O
MGD	B-Disease
,	O
its	O
epidemiology	O
,	O
pathophysiology	O
,	O
and	O
management	O
.	O
	
Various	O
systemic	O
diseases	O
and	O
medications	O
have	O
been	O
associated	O
with	O
the	O
progression	O
of	O
both	O
dry	B-Disease
eye	I-Disease
and	O
MGD	B-Disease
,	O
as	O
have	O
several	O
ocular	B-Disease
disorders	I-Disease
beyond	O
those	O
directly	O
affecting	O
the	O
surface	O
.	O
	
It	O
is	O
in	O
the	O
best	O
interest	O
of	O
patients	O
for	O
clinicians	O
to	O
be	O
able	O
to	O
better	O
identify	O
and	O
diagnose	O
MGD	B-Disease
,	O
differentiating	O
it	O
from	O
other	O
ocular	B-Disease
surface	I-Disease
disorders	I-Disease
,	O
and	O
to	O
recognize	O
the	O
effects	O
of	O
MGD	B-Disease
on	O
the	O
ocular	B-Anatomy
surface	I-Anatomy
,	O
and	O
thus	O
initiate	O
appropriate	O
therapy	O
.	O
	
This	O
CME	O
activity	O
provides	O
expert	O
insight	O
into	O
the	O
Tear	O
Film	O
and	O
Ocular	O
Surface	O
Society	O
'	O
s	O
International	O
Workshop	O
on	O
MGD	B-Disease
consensus	O
report	O
,	O
offering	O
practical	O
application	O
of	O
its	O
findings	O
to	O
better	O
manage	O
MGD	B-Disease
patient	O
care	O
,	O
particularly	O
for	O
those	O
patients	O
facing	O
or	O
undergoing	O
ocular	B-Anatomy
surgery	O
.	O
	
Clinical	O
classification	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
.	O
	
To	O
develop	O
a	O
clinical	O
classification	O
system	O
for	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
Evidence	O
-	O
based	O
investigation	O
,	O
using	O
a	O
modified	O
Delphi	O
process	O
.	O
	
Twenty	O
-	O
six	O
AMD	B-Disease
experts	O
,	O
1	O
neuro	O
-	O
ophthalmologist	O
,	O
2	O
committee	O
chairmen	O
,	O
and	O
1	O
methodologist	O
.	O
	
Each	O
committee	O
member	O
completed	O
an	O
online	O
assessment	O
of	O
statements	O
summarizing	O
current	O
AMD	B-Disease
classification	O
criteria	O
,	O
indicating	O
agreement	O
or	O
disagreement	O
with	O
each	O
statement	O
on	O
a	O
9	O
-	O
step	O
scale	O
.	O
	
The	O
group	O
met	O
,	O
reviewed	O
the	O
survey	O
results	O
,	O
discussed	O
the	O
important	O
components	O
of	O
a	O
clinical	O
classification	O
system	O
,	O
and	O
defined	O
new	O
data	O
analyses	O
needed	O
to	O
refine	O
a	O
classification	O
system	O
.	O
	
After	O
the	O
meeting	O
,	O
additional	O
data	O
analyses	O
from	O
large	O
studies	O
were	O
provided	O
to	O
the	O
committee	O
to	O
provide	O
risk	O
estimates	O
related	O
to	O
the	O
presence	O
of	O
various	O
AMD	B-Symptom
lesions	I-Symptom
.	O
	
Delphi	O
review	O
of	O
the	O
9	O
-	O
item	O
set	O
of	O
statements	O
resulting	O
from	O
the	O
meeting	O
.	O
	
Consensus	O
was	O
achieved	O
in	O
generating	O
a	O
basic	O
clinical	O
classification	O
system	O
based	O
on	O
fundus	B-Symptom
lesions	I-Symptom
assessed	O
within	B-Anatomy
2	I-Anatomy
disc	I-Anatomy
diameters	I-Anatomy
of	I-Anatomy
the	I-Anatomy
fovea	I-Anatomy
in	O
persons	O
older	B-Characteristic
than	I-Characteristic
55	I-Characteristic
years	I-Characteristic
.	O
	
The	O
committee	O
agreed	O
that	O
a	O
single	O
term	O
,	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
,	O
should	O
be	O
used	O
for	O
the	O
disease	O
.	O
	
Persons	O
with	O
no	O
visible	O
drusen	B-Symptom
or	O
pigmentary	B-Symptom
abnormalities	I-Symptom
should	O
be	O
considered	O
to	O
have	O
no	O
signs	O
of	O
AMD	B-Disease
.	O
	
Persons	O
with	O
small	B-Symptom
drusen	I-Symptom
(	O
<	B-Dimension
63	I-Dimension
	I-Dimension
m	I-Dimension
)	O
,	O
also	O
termed	O
drupelets	B-Symptom
,	O
should	O
be	O
considered	O
to	O
have	O
normal	B-Disease
aging	I-Disease
changes	O
with	O
no	O
clinically	O
relevant	O
increased	O
risk	O
of	O
late	B-Disease
AMD	I-Disease
developing	O
.	O
	
Persons	O
with	O
medium	B-Symptom
drusen	I-Symptom
(	O
	B-Dimension
63	I-Dimension
-	I-Dimension
<	I-Dimension
125	I-Dimension
	I-Dimension
m	I-Dimension
)	O
,	O
but	O
without	O
pigmentary	B-Symptom
abnormalities	I-Symptom
thought	O
to	O
be	O
related	O
to	O
AMD	B-Disease
,	O
should	O
be	O
considered	O
to	O
have	O
early	B-Disease
AMD	I-Disease
.	O
	
Persons	O
with	O
large	B-Symptom
drusen	I-Symptom
or	O
with	O
pigmentary	B-Symptom
abnormalities	I-Symptom
associated	I-Symptom
with	I-Symptom
at	I-Symptom
least	I-Symptom
medium	I-Symptom
drusen	I-Symptom
should	O
be	O
considered	O
to	O
have	O
intermediate	B-Disease
AMD	I-Disease
.	O
	
Persons	O
with	O
lesions	B-Symptom
associated	I-Symptom
with	I-Symptom
neovascular	I-Symptom
AMD	I-Symptom
or	O
geographic	B-Symptom
atrophy	I-Symptom
should	O
be	O
considered	O
to	O
have	O
late	B-Disease
AMD	I-Disease
.	O
	
Five	O
-	O
year	O
risks	O
of	O
progressing	O
to	O
late	B-Disease
AMD	I-Disease
are	O
estimated	O
to	O
increase	O
approximately	O
100	O
fold	O
,	O
ranging	O
from	O
a	O
0	O
.	O
5	O
%	O
5	O
-	O
year	O
risk	O
for	O
normal	B-Disease
aging	I-Disease
changes	O
to	O
a	O
50	O
%	O
risk	O
for	O
the	O
highest	O
intermediate	B-Disease
AMD	I-Disease
risk	O
group	O
.	O
	
The	O
proposed	O
basic	O
clinical	O
classification	O
scale	O
seems	O
to	O
be	O
of	O
value	O
in	O
predicting	O
the	O
risk	O
of	O
late	B-Disease
AMD	I-Disease
.	O
	
Incorporating	O
consistent	O
nomenclature	O
into	O
the	O
practice	O
patterns	O
of	O
all	O
eye	B-Anatomy
care	O
providers	O
may	O
improve	O
communication	O
and	O
patient	O
care	O
.	O
	
How	O
does	O
glaucoma	B-Disease
look	O
?	O
:	O
patient	O
perception	O
of	O
visual	B-Symptom
field	I-Symptom
loss	I-Symptom
.	O
	
To	O
explore	O
patient	O
perception	O
of	O
vision	B-Symptom
loss	I-Symptom
in	O
glaucoma	B-Disease
and	O
,	O
specifically	O
,	O
to	O
test	O
the	O
hypothesis	O
that	O
patients	O
do	O
not	O
recognize	O
their	O
impairment	O
as	O
a	O
black	B-Symptom
tunnel	I-Symptom
effect	I-Symptom
or	O
as	O
black	B-Symptom
patches	I-Symptom
in	I-Symptom
their	I-Symptom
field	I-Symptom
of	I-Symptom
view	I-Symptom
.	O
	
Clinic	O
-	O
based	O
cross	O
-	O
sectional	O
study	O
.	O
	
Fifty	O
patients	O
(	O
age	B-Characteristic
range	I-Characteristic
,	I-Characteristic
52	I-Characteristic
-	I-Characteristic
82	I-Characteristic
years	I-Characteristic
)	O
with	O
visual	B-Characteristic
acuity	I-Characteristic
better	I-Characteristic
than	I-Characteristic
20	I-Characteristic
/	I-Characteristic
30	I-Characteristic
and	O
with	O
a	O
range	O
of	O
glaucomatous	B-Symptom
visual	I-Symptom
field	I-Symptom
(	I-Symptom
VF	I-Symptom
)	I-Symptom
defects	I-Symptom
in	I-Symptom
both	I-Symptom
eyes	I-Symptom
,	O
excluding	O
those	O
with	O
very	O
advanced	O
disease	O
(	O
perimetrically	B-Symptom
blind	I-Symptom
)	O
.	O
	
Participants	O
underwent	O
monocular	B-Diagnostic_tool
VF	I-Diagnostic_tool
testing	I-Diagnostic_tool
in	O
both	B-Anatomy
eyes	I-Anatomy
using	O
a	O
Humphrey	B-Diagnostic_tool
Field	I-Diagnostic_tool
Analyzer	I-Diagnostic_tool
(	O
HFA	B-Diagnostic_tool
;	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
;	O
24	O
-	O
2	O
Swedish	O
interactive	O
threshold	O
algorithm	O
standard	O
tests	O
)	O
and	O
other	O
tests	O
of	O
visual	O
function	O
.	O
	
Participants	O
took	O
part	O
in	O
a	O
recorded	O
interview	O
during	O
which	O
they	O
were	O
asked	O
if	O
they	O
were	O
aware	O
of	O
their	O
VF	B-Symptom
loss	I-Symptom
;	O
if	O
so	O
,	O
there	O
were	O
encouraged	O
to	O
describe	O
it	O
in	O
their	O
own	O
words	O
.	O
	
Participants	O
were	O
shown	O
6	O
images	O
modified	O
in	O
a	O
variety	O
of	O
ways	O
on	O
a	O
computer	O
monitor	O
and	O
were	O
asked	O
to	O
select	O
the	O
image	O
that	O
most	O
closely	O
represented	O
their	O
perception	O
of	O
their	O
VF	B-Symptom
loss	I-Symptom
.	O
	
Forced	O
choice	O
of	O
an	O
image	O
best	O
representing	O
glaucomatous	B-Symptom
vision	I-Symptom
impairment	I-Symptom
.	O
	
Participants	O
had	O
a	O
range	O
of	O
VF	B-Symptom
defect	I-Symptom
severity	I-Symptom
:	O
average	O
HFA	B-Diagnostic_tool
mean	O
deviation	O
was	O
-	O
8	O
.	O
7	O
dB	O
(	O
standard	O
deviation	O
[	O
SD	O
]	O
,	O
5	O
.	O
8	O
dB	O
)	O
and	O
-	O
10	O
.	O
5	O
dB	O
(	O
SD	O
,	O
7	O
.	O
1	O
dB	O
)	O
in	O
the	O
right	O
and	O
left	O
eyes	B-Anatomy
,	O
respectively	O
.	O
	
Thirteen	O
patients	O
(	O
26	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
15	O
%	O
-	O
40	O
%	O
)	O
reported	O
being	O
completely	O
unaware	O
of	O
their	O
vision	B-Symptom
loss	I-Symptom
.	O
	
None	O
of	O
the	O
patients	O
chose	O
the	O
images	O
with	O
a	O
distinct	O
black	B-Symptom
tunnel	I-Symptom
effect	I-Symptom
or	O
black	B-Symptom
patches	I-Symptom
.	O
	
Only	O
2	O
patients	O
(	O
4	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
%	O
-	O
14	O
%	O
)	O
chose	O
the	O
image	O
with	O
a	O
tunnel	O
effect	O
with	O
blurred	O
edges	O
.	O
	
An	O
image	O
depicting	O
blurred	O
patches	O
and	O
another	O
with	O
missing	O
patches	O
was	O
chosen	O
by	O
54	O
%	O
(	O
95	O
%	O
CI	O
,	O
39	O
%	O
-	O
68	O
%	O
)	O
and	O
16	O
%	O
(	O
95	O
%	O
CI	O
,	O
7	O
%	O
-	O
29	O
%	O
)	O
of	O
the	O
patients	O
,	O
respectively	O
.	O
	
Content	O
analysis	O
of	O
the	O
transcripts	O
from	O
the	O
recorded	O
interviews	O
indicated	O
a	O
frequent	O
use	O
of	O
descriptors	O
of	O
visual	O
symptoms	O
associated	O
with	O
reported	O
blur	O
and	O
missing	O
features	O
.	O
	
Patients	O
with	O
glaucoma	B-Disease
do	O
not	O
perceive	O
their	O
vision	B-Symptom
loss	I-Symptom
as	O
a	O
black	B-Symptom
tunnel	I-Symptom
effect	I-Symptom
or	O
as	O
black	B-Symptom
patches	I-Symptom
masking	O
their	O
field	O
of	O
view	O
.	O
	
These	O
findings	O
are	O
important	O
in	O
the	O
context	O
of	O
depicting	O
the	O
effects	O
of	O
glaucomatous	B-Symptom
vision	I-Symptom
loss	I-Symptom
and	O
raising	O
awareness	O
for	O
glaucoma	B-Disease
detection	O
.	O
	
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
Anterior	B-Anatomy
chamber	I-Anatomy
angle	I-Anatomy
imaging	O
with	O
swept	B-Diagnostic_tool
-	I-Diagnostic_tool
source	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
:	O
measuring	O
peripheral	B-Symptom
anterior	I-Symptom
synechia	I-Symptom
in	O
glaucoma	B-Disease
.	O
	
To	O
investigate	O
the	O
use	O
of	O
swept	B-Diagnostic_tool
-	I-Diagnostic_tool
source	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
for	O
measuring	O
the	O
area	O
and	O
degree	O
of	O
peripheral	B-Symptom
anterior	I-Symptom
synechia	I-Symptom
(	O
PAS	B-Symptom
)	O
involvement	O
in	O
patients	O
with	O
angle	B-Disease
-	I-Disease
closure	I-Disease
glaucoma	I-Disease
.	O
	
Cross	O
-	O
sectional	O
study	O
.	O
	
Twenty	O
-	O
three	O
eyes	B-Anatomy
with	O
PAS	B-Symptom
(	O
detected	O
by	O
indentation	B-Diagnostic_tool
gonioscopy	I-Diagnostic_tool
)	O
from	O
20	O
patients	O
with	O
angle	B-Disease
-	I-Disease
closure	I-Disease
glaucoma	I-Disease
(	O
20	O
eyes	B-Anatomy
had	O
primary	B-Disease
angle	I-Disease
-	I-Disease
closure	I-Disease
glaucoma	I-Disease
and	O
3	O
eyes	B-Anatomy
had	O
angle	B-Disease
-	I-Disease
closure	I-Disease
glaucoma	I-Disease
secondary	O
to	O
chronic	B-Disease
anterior	I-Disease
uveitis	I-Disease
[	O
n	O
=	O
2	O
]	O
and	O
Axenfeld	B-Disease
-	I-Disease
Rieger	I-Disease
syndrome	I-Disease
[	O
n	O
=	O
1	O
]	O
)	O
.	O
	
The	O
anterior	B-Anatomy
chamber	I-Anatomy
angles	I-Anatomy
were	O
evaluated	O
with	O
indentation	B-Diagnostic_tool
gonioscopy	I-Diagnostic_tool
and	O
imaged	O
by	O
swept	B-Diagnostic_tool
-	I-Diagnostic_tool
source	I-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
Casia	B-Diagnostic_tool
OCT	I-Diagnostic_tool
,	O
Tomey	O
,	O
Nagoya	O
,	O
Japan	O
)	O
in	O
room	O
light	O
and	O
in	O
the	O
dark	O
using	O
the	O
"	O
angle	O
analysis	O
"	O
protocol	O
,	O
which	O
was	O
composed	O
of	O
128	O
radial	O
B	O
-	O
scans	O
each	O
with	O
512	O
A	O
-	O
scans	O
(	O
16	O
-	O
mm	O
scan	O
length	O
)	O
.	O
	
The	O
area	O
and	O
degree	O
of	O
PAS	B-Symptom
involvement	O
were	O
measured	O
in	O
each	O
eye	B-Anatomy
after	O
manual	O
detection	O
of	O
the	O
scleral	B-Anatomy
spur	I-Anatomy
and	O
the	O
anterior	B-Anatomy
irido	I-Anatomy
-	I-Anatomy
angle	I-Anatomy
adhesion	O
by	O
2	O
masked	O
observers	O
.	O
	
The	O
interobserver	O
variability	O
of	O
the	O
PAS	B-Symptom
measurements	O
was	O
calculated	O
.	O
	
The	O
agreement	O
of	O
PAS	B-Symptom
assessment	O
by	O
gonioscopy	B-Diagnostic_tool
and	O
OCT	B-Diagnostic_tool
,	O
the	O
area	O
and	O
the	O
degree	O
of	O
PAS	B-Symptom
involvement	O
,	O
and	O
the	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
of	O
interobserver	O
PAS	B-Symptom
measurements	O
.	O
	
The	O
area	O
of	O
PAS	B-Symptom
(	O
mean	O
	O
standard	O
deviation	O
)	O
was	O
20	O
.	O
8	O
	O
16	O
.	O
9	O
mm	O
(	O
2	O
)	O
(	O
range	O
,	O
3	O
.	O
9	O
-	O
74	O
.	O
9	O
mm	O
(	O
2	O
)	O
)	O
,	O
and	O
the	O
degree	O
of	O
PAS	B-Symptom
involvement	O
was	O
186	O
.	O
5	O
	O
79	O
.	O
9	O
degrees	O
(	O
range	O
,	O
42	O
-	O
314	O
degrees	O
)	O
.	O
	
There	O
was	O
no	O
difference	O
in	O
the	O
area	O
of	O
PAS	B-Symptom
(	O
P	O
=	O
0	O
.	O
90	O
)	O
and	O
the	O
degree	O
of	O
PAS	B-Symptom
involvement	O
(	O
P	O
=	O
0	O
.	O
95	O
)	O
between	O
images	O
obtained	O
in	O
room	O
light	O
and	O
in	O
the	O
dark	O
.	O
	
The	O
interobserver	O
ICCs	O
were	O
0	O
.	O
99	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0	O
.	O
98	O
-	O
1	O
.	O
00	O
)	O
for	O
the	O
area	O
of	O
PAS	B-Symptom
and	O
0	O
.	O
99	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
97	O
-	O
1	O
.	O
00	O
)	O
for	O
the	O
degree	O
of	O
PAS	B-Symptom
involvement	O
.	O
	
There	O
was	O
good	O
agreement	O
of	O
PAS	B-Symptom
assessment	O
between	O
gonioscopy	B-Diagnostic_tool
and	O
OCT	B-Diagnostic_tool
images	O
(	O
kappa	O
=	O
0	O
.	O
79	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
67	O
-	O
0	O
.	O
91	O
)	O
.	O
	
Swept	B-Diagnostic_tool
-	I-Diagnostic_tool
source	I-Diagnostic_tool
OCT	I-Diagnostic_tool
allows	O
visualization	O
and	O
reproducible	O
measurements	O
of	O
the	O
area	O
and	O
degree	O
of	O
PAS	B-Symptom
involvement	O
,	O
providing	O
a	O
new	O
paradigm	O
for	O
evaluation	O
of	O
PAS	B-Symptom
progression	O
and	O
risk	O
assessment	O
for	O
development	O
of	O
angle	B-Disease
-	I-Disease
closure	I-Disease
glaucoma	I-Disease
.	O
	
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
Screening	O
for	O
diabetic	B-Disease
retinopathy	I-Disease
with	O
or	O
without	O
a	O
copayment	O
in	O
a	O
randomized	O
controlled	O
trial	O
:	O
influence	O
of	O
the	O
inverse	O
care	O
law	O
.	O
	
To	O
examine	O
whether	O
the	O
inverse	O
care	O
law	O
operates	O
in	O
a	O
screening	O
program	O
for	O
diabetic	B-Disease
retinopathy	I-Disease
(	O
DR	B-Disease
)	O
based	O
on	O
fee	O
for	O
service	O
in	O
Hong	B-Characteristic
Kong	I-Characteristic
.	O
	
Randomized	O
controlled	O
trial	O
.	O
	
All	O
those	O
with	O
type	B-Disease
1	I-Disease
or	I-Disease
2	I-Disease
diabetes	I-Disease
from	O
2	O
clinics	O
were	O
recruited	O
.	O
	
Diabetic	B-Disease
retinopathy	I-Disease
screening	O
with	O
a	O
small	O
copayment	O
versus	O
free	O
access	O
in	O
a	O
publicly	O
funded	O
family	O
medicine	O
service	O
.	O
	
Uptake	O
of	O
screening	O
and	O
severity	O
of	O
DR	B-Disease
detected	O
.	O
	
Association	O
between	O
these	O
outcome	O
variables	O
and	O
independent	O
variables	O
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
models	O
and	O
reported	O
as	O
odds	O
ratios	O
(	O
ORs	O
)	O
.	O
	
After	O
randomization	O
,	O
1387	O
subjects	O
in	O
the	O
free	O
group	O
and	O
1379	O
subjects	O
in	O
the	O
pay	O
group	O
were	O
eligible	O
for	O
screening	O
,	O
and	O
94	O
.	O
9	O
%	O
(	O
1316	O
/	O
1387	O
)	O
and	O
92	O
.	O
6	O
%	O
(	O
1277	O
/	O
1379	O
)	O
,	O
respectively	O
,	O
agreed	O
to	O
participate	O
in	O
the	O
study	O
.	O
	
The	O
offer	O
of	O
screening	O
was	O
accepted	O
by	O
94	O
.	O
8	O
%	O
(	O
1247	O
/	O
1316	O
)	O
in	O
the	O
free	O
group	O
and	O
91	O
.	O
2	O
%	O
(	O
1164	O
/	O
1277	O
)	O
in	O
the	O
pay	O
group	O
,	O
and	O
the	O
final	O
uptake	O
ratios	O
were	O
88	O
.	O
5	O
%	O
(	O
1165	O
/	O
1316	O
)	O
and	O
82	O
.	O
4	O
%	O
(	O
1052	O
/	O
1277	O
)	O
,	O
respectively	O
(	O
Pearson	O
chi	O
=	O
19	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
Being	O
in	O
the	O
pay	O
group	O
was	O
associated	O
with	O
a	O
lower	O
uptake	O
of	O
screening	O
than	O
being	O
in	O
the	O
free	O
group	O
(	O
OR	O
,	O
0	O
.	O
59	O
;	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0	O
.	O
47	O
-	O
0	O
.	O
74	O
)	O
and	O
a	O
lower	O
detection	O
rate	O
of	O
DR	B-Disease
(	O
OR	O
,	O
0	O
.	O
73	O
;	O
CI	O
,	O
0	O
.	O
60	O
-	O
0	O
.	O
90	O
)	O
after	O
adjustment	O
for	O
potential	O
confounding	O
factors	O
.	O
	
Subjects	O
with	O
higher	B-Characteristic
socioeconomic	I-Characteristic
status	I-Characteristic
were	O
more	O
likely	O
to	O
attend	O
screening	O
and	O
had	O
a	O
lower	O
prevalence	O
of	O
DR	B-Disease
detected	O
.	O
	
The	O
inverse	O
care	O
law	O
seems	O
to	O
operate	O
in	O
a	O
preventive	O
intervention	O
when	O
a	O
relatively	O
small	O
copayment	O
is	O
applied	O
.	O
	
There	O
is	O
a	O
case	O
for	O
making	O
effective	O
preventive	O
services	O
free	O
of	O
charge	O
.	O
	
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
Subclinical	O
macular	B-Anatomy
findings	O
in	O
infants	B-Characteristic
screened	O
for	O
retinopathy	B-Disease
of	I-Disease
prematurity	I-Disease
with	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
.	O
	
To	O
evaluate	O
subclinical	O
macular	O
findings	O
in	O
premature	B-Characteristic
patients	I-Characteristic
at	O
risk	O
of	O
retinopathy	B-Disease
of	I-Disease
prematurity	I-Disease
(	O
ROP	B-Disease
)	O
with	O
the	O
use	O
of	O
handheld	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
.	O
	
Prospective	O
,	O
observational	O
case	O
series	O
.	O
	
Forty	O
-	O
nine	O
prematurely	B-Characteristic
born	I-Characteristic
neonates	I-Characteristic
.	O
	
Forty	O
-	O
nine	O
infants	B-Characteristic
were	O
imaged	O
using	O
a	O
handheld	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
.	O
	
Images	O
were	O
acquired	O
in	O
nonsedated	B-Characteristic
infants	I-Characteristic
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
.	O
	
Some	O
patients	O
were	O
followed	O
and	O
reimaged	O
over	O
the	O
course	O
of	O
several	O
weeks	O
.	O
	
A	O
total	O
of	O
300	O
total	O
images	O
were	O
acquired	O
and	O
evaluated	O
for	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
(	O
CME	B-Disease
)	O
and	O
persistence	O
of	O
inner	B-Symptom
retinal	I-Symptom
layers	I-Symptom
.	O
	
In	O
vivo	O
determination	O
of	O
foveal	B-Anatomy
retinal	I-Anatomy
lamination	O
,	O
image	O
analysis	O
,	O
and	O
clinical	O
observation	O
.	O
	
A	O
total	O
of	O
241	O
(	O
80	O
%	O
)	O
of	O
the	O
images	O
from	O
46	O
patients	O
were	O
usable	O
(	O
defined	O
as	O
having	O
scans	O
passing	O
through	O
the	O
fovea	B-Anatomy
with	O
clearly	O
identifiable	O
retinal	B-Anatomy
layers	I-Anatomy
)	O
.	O
	
Persistence	B-Symptom
of	I-Symptom
1	I-Symptom
or	I-Symptom
more	I-Symptom
inner	I-Symptom
retinal	I-Symptom
layers	I-Symptom
was	O
seen	O
in	O
43	O
of	O
the	O
patients	O
with	O
usable	O
images	O
(	O
93	O
%	O
)	O
.	O
	
Of	O
the	O
patients	O
with	O
at	O
least	O
1	O
persistent	B-Symptom
layer	I-Symptom
,	O
17	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
and	O
1	O
,	O
had	O
a	O
maximum	O
ROP	B-Characteristic
stage	I-Characteristic
of	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4A	O
,	O
respectively	O
.	O
	
Cystoid	B-Disease
macular	I-Disease
edema	I-Disease
was	O
seen	O
in	O
25	O
of	O
the	O
46	O
patients	O
(	O
54	O
%	O
)	O
during	O
1	O
or	O
more	O
imaging	O
sessions	O
.	O
	
Cystoid	B-Disease
macular	I-Disease
edema	I-Disease
was	O
present	O
in	O
9	O
,	O
1	O
,	O
5	O
,	O
9	O
,	O
and	O
1	O
patient	O
with	O
maximum	O
ROP	B-Characteristic
stage	I-Characteristic
of	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4A	O
,	O
respectively	O
.	O
	
Our	O
data	O
suggest	O
there	O
is	O
persistence	B-Symptom
of	I-Symptom
inner	I-Symptom
retinal	I-Symptom
layers	I-Symptom
in	O
premature	B-Characteristic
infants	I-Characteristic
regardless	O
of	O
maximal	B-Characteristic
ROP	I-Characteristic
stage	I-Characteristic
.	O
	
Subclinical	O
CME	B-Disease
is	O
seen	O
in	O
premature	B-Characteristic
infants	I-Characteristic
;	O
however	O
,	O
CME	B-Disease
does	O
not	O
appear	O
to	O
be	O
correlated	O
with	O
ROP	B-Characteristic
stage	I-Characteristic
.	O
	
This	O
suggests	O
that	O
there	O
may	O
be	O
other	O
causes	O
for	O
the	O
CME	B-Disease
seen	O
in	O
this	O
patient	O
population	O
.	O
	
Hand	O
-	O
held	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
imaging	I-Diagnostic_tool
is	O
a	O
viable	O
technique	O
for	O
evaluating	O
subclinical	B-Symptom
macular	I-Symptom
findings	I-Symptom
in	O
premature	B-Characteristic
infants	I-Characteristic
,	O
although	O
larger	O
datasets	O
are	O
needed	O
from	O
multiple	O
centers	O
to	O
further	O
evaluate	O
the	O
generalizability	O
of	O
these	O
findings	O
.	O
	
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O
	
Evaluation	O
of	O
ocular	B-Disease
surface	I-Disease
disease	I-Disease
in	O
patients	O
with	O
glaucoma	B-Disease
.	O
	
To	O
evaluate	O
the	O
subjective	O
and	O
objective	O
measures	O
of	O
ocular	B-Disease
surface	I-Disease
disease	I-Disease
in	O
patients	O
with	O
glaucoma	B-Disease
.	O
	
Cross	O
-	O
sectional	O
study	O
.	O
	
Sixty	O
-	O
four	O
glaucoma	B-Disease
subjects	O
with	O
bilateral	B-Symptom
visual	I-Symptom
field	I-Symptom
(	I-Symptom
VF	I-Symptom
)	I-Symptom
loss	I-Symptom
and	O
59	O
glaucoma	B-Disease
suspects	I-Disease
with	O
normal	B-Symptom
VFs	I-Symptom
.	O
	
Consecutive	O
patients	O
were	O
recruited	O
prospectively	O
from	O
the	O
Wilmer	O
Eye	O
Institute	O
Glaucoma	B-Disease
Clinic	O
.	O
	
Tear	B-Characteristic
film	I-Characteristic
breakup	I-Characteristic
time	I-Characteristic
(	O
TBUT	B-Characteristic
)	O
,	O
corneal	B-Characteristic
staining	I-Characteristic
score	I-Characteristic
(	O
0	O
-	O
15	O
)	O
,	O
and	O
Schirmer	B-Characteristic
'	I-Characteristic
s	I-Characteristic
test	I-Characteristic
results	I-Characteristic
were	O
included	O
as	O
objective	O
metrics	O
,	O
whereas	O
the	O
Ocular	B-Characteristic
Surface	I-Characteristic
Disease	I-Characteristic
Index	I-Characteristic
(	O
OSDI	B-Characteristic
)	O
questionnaire	O
was	O
administered	O
to	O
assess	O
symptoms	O
.	O
	
Total	B-Characteristic
OSDI	I-Characteristic
score	I-Characteristic
,	O
vision	B-Characteristic
-	I-Characteristic
related	I-Characteristic
subscore	I-Characteristic
(	O
derived	O
from	O
questions	O
about	O
vision	O
and	O
task	O
performance	O
)	O
,	O
and	O
discomfort	B-Characteristic
-	I-Characteristic
related	I-Characteristic
subscore	I-Characteristic
(	O
derived	O
from	O
questions	O
about	O
ocular	O
surface	O
discomfort	O
)	O
were	O
calculated	O
for	O
each	O
subject	O
.	O
	
Seventy	O
-	O
five	O
percent	O
(	O
48	O
/	O
64	O
)	O
of	O
glaucoma	B-Disease
subjects	O
and	O
41	O
%	O
(	O
24	O
/	O
59	O
)	O
of	O
glaucoma	B-Disease
suspects	I-Disease
were	O
receiving	O
topical	O
medications	O
.	O
	
The	O
corneal	B-Characteristic
staining	I-Characteristic
grade	I-Characteristic
was	O
greater	O
in	O
glaucoma	B-Disease
subjects	O
than	O
in	O
glaucoma	B-Disease
suspects	I-Disease
(	O
6	O
.	O
4	O
vs	O
.	O
4	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
groups	O
did	O
not	O
differ	O
with	O
regard	O
to	O
TBUT	B-Characteristic
or	O
Schirmer	B-Characteristic
'	I-Characteristic
s	I-Characteristic
results	I-Characteristic
(	O
P	O
>	O
0	O
.	O
20	O
for	O
both	O
)	O
.	O
	
Multivariate	O
regression	O
models	O
showed	O
that	O
topical	B-Characteristic
glaucoma	I-Characteristic
therapy	I-Characteristic
burden	I-Characteristic
was	O
associated	O
with	O
a	O
significantly	O
higher	O
total	B-Characteristic
corneal	I-Characteristic
staining	I-Characteristic
grade	I-Characteristic
(	O
	O
,	O
+	O
0	O
.	O
9	O
for	O
each	O
additional	O
glaucoma	O
drop	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0	O
.	O
5	O
-	O
1	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
not	O
with	O
TBUT	B-Characteristic
or	O
Schirmer	B-Characteristic
'	I-Characteristic
s	I-Characteristic
results	I-Characteristic
(	O
P	O
>	O
0	O
.	O
20	O
for	O
both	O
)	O
.	O
	
Glaucoma	B-Disease
subjects	O
had	O
significantly	O
higher	O
total	B-Characteristic
OSDI	I-Characteristic
scores	I-Characteristic
than	O
glaucoma	B-Disease
suspects	I-Disease
(	O
16	O
.	O
7	O
vs	O
.	O
7	O
.	O
9	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
This	O
largely	O
was	O
the	O
result	O
of	O
higher	O
vision	B-Characteristic
-	I-Characteristic
related	I-Characteristic
subscores	I-Characteristic
in	O
the	O
glaucoma	B-Disease
group	O
(	O
11	O
.	O
1	O
vs	O
.	O
3	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
Ocular	B-Characteristic
discomfort	I-Characteristic
-	I-Characteristic
related	I-Characteristic
subscores	I-Characteristic
,	O
however	O
,	O
were	O
similar	O
in	O
both	O
groups	O
(	O
5	O
.	O
7	O
vs	O
.	O
4	O
.	O
6	O
;	O
P	O
=	O
0	O
.	O
30	O
)	O
.	O
	
In	O
multivariate	O
analyses	O
,	O
each	O
5	O
-	O
decibel	O
decrement	O
in	O
better	B-Characteristic
-	I-Characteristic
eye	I-Characteristic
VF	I-Characteristic
mean	I-Characteristic
deviation	I-Characteristic
was	O
associated	O
with	O
a	O
4	O
.	O
7	O
-	O
point	O
increase	O
in	O
total	B-Characteristic
OSDI	I-Characteristic
score	I-Characteristic
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
9	O
-	O
7	O
.	O
5	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
a	O
3	O
.	O
7	O
-	O
point	O
increase	O
in	O
the	O
vision	B-Characteristic
-	I-Characteristic
related	I-Characteristic
subscore	I-Characteristic
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
7	O
-	O
5	O
.	O
6	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
did	O
not	O
predict	O
a	O
higher	O
discomfort	B-Characteristic
-	I-Characteristic
related	I-Characteristic
subscore	I-Characteristic
(	O
	O
,	O
1	O
.	O
1	O
point	O
;	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O
	
Topical	B-Characteristic
glaucoma	I-Characteristic
therapy	I-Characteristic
burden	I-Characteristic
was	O
not	O
associated	O
with	O
higher	O
total	B-Characteristic
OSDI	I-Characteristic
score	I-Characteristic
or	O
vision	B-Characteristic
-	I-Characteristic
or	I-Characteristic
discomfort	I-Characteristic
-	I-Characteristic
related	I-Characteristic
subscore	I-Characteristic
(	O
P	O
>	O
0	O
.	O
20	O
for	O
all	O
)	O
.	O
	
Glaucoma	B-Disease
is	O
associated	O
with	O
significant	O
ocular	B-Disease
surface	I-Disease
disease	I-Disease
,	O
and	O
topical	B-Characteristic
glaucoma	I-Characteristic
therapy	I-Characteristic
burden	I-Characteristic
seems	O
predictive	O
of	O
corneal	B-Characteristic
staining	I-Characteristic
severity	I-Characteristic
.	O
	
However	O
,	O
OSDI	B-Characteristic
is	O
a	O
poor	O
metric	O
for	O
capturing	O
ocular	B-Disease
surface	I-Disease
disease	I-Disease
in	O
glaucoma	B-Disease
because	O
symptoms	O
seem	O
to	O
be	O
related	O
largely	O
to	O
VF	B-Symptom
loss	I-Symptom
.	O
	
Modified	B-Diagnostic_tool
Allen	I-Diagnostic_tool
pictures	I-Diagnostic_tool
to	O
assess	O
amblyopia	B-Disease
in	O
young	B-Characteristic
children	I-Characteristic
.	O
	
To	O
produce	O
a	O
test	O
of	O
visual	B-Characteristic
acuity	I-Characteristic
for	O
young	B-Characteristic
children	I-Characteristic
that	O
is	O
more	O
sensitive	O
to	O
amblyopia	B-Disease
than	O
current	O
preschool	B-Diagnostic_tool
vision	I-Diagnostic_tool
tests	I-Diagnostic_tool
,	O
the	O
authors	O
surrounded	O
four	O
Allen	B-Diagnostic_tool
pictures	I-Diagnostic_tool
with	O
"	O
crowding	O
"	O
bars	O
.	O
	
This	O
modified	B-Diagnostic_tool
Allen	I-Diagnostic_tool
test	I-Diagnostic_tool
was	O
evaluated	O
by	O
measuring	O
acuity	B-Characteristic
of	I-Characteristic
amblyopic	I-Characteristic
children	I-Characteristic
(	O
n	O
=	O
28	O
)	O
and	O
children	B-Characteristic
(	O
n	O
=	O
10	O
)	O
and	O
adults	B-Characteristic
(	O
n	O
=	O
5	O
)	O
with	O
normal	O
eyes	B-Anatomy
.	O
	
Mean	B-Characteristic
acuities	I-Characteristic
of	I-Characteristic
amblyopic	I-Characteristic
eyes	I-Characteristic
for	O
the	O
modified	O
pictures	O
was	O
0	O
.	O
8	O
octaves	O
or	O
nearly	O
three	O
logMar	B-Diagnostic_tool
Snellen	I-Diagnostic_tool
lines	O
poorer	O
than	O
for	O
the	O
isolated	O
pictures	O
.	O
	
For	O
nonamblyopic	B-Characteristic
and	O
normal	B-Characteristic
eyes	B-Anatomy
modified	O
picture	O
acuity	O
averaged	O
0	O
.	O
1	O
to	O
0	O
.	O
4	O
octaves	O
poorer	O
than	O
isolated	O
picture	O
acuity	O
.	O
	
Average	O
acuities	O
of	O
amblyopic	B-Disease
eyes	B-Anatomy
(	O
n	O
=	O
22	O
)	O
for	O
the	O
modified	O
pictures	O
agreed	O
with	O
line	O
letter	O
acuities	O
.	O
	
These	O
results	O
suggest	O
that	O
the	O
modified	B-Diagnostic_tool
picture	I-Diagnostic_tool
test	I-Diagnostic_tool
induces	O
contour	O
interaction	O
similar	O
to	O
that	O
of	O
line	B-Diagnostic_tool
letter	I-Diagnostic_tool
tests	I-Diagnostic_tool
,	O
and	O
thus	O
,	O
is	O
a	O
more	O
sensitive	O
test	O
of	O
amblyopia	B-Disease
in	O
the	O
preschool	B-Characteristic
child	I-Characteristic
than	O
isolated	O
symbols	O
.	O
	
Peripheral	B-Symptom
lesions	I-Symptom
identified	O
by	O
mydriatic	B-Diagnostic_tool
ultrawide	I-Diagnostic_tool
field	I-Diagnostic_tool
imaging	I-Diagnostic_tool
:	O
distribution	O
and	O
potential	O
impact	O
on	O
diabetic	B-Disease
retinopathy	I-Disease
severity	O
.	O
	
To	O
assess	O
diabetic	B-Disease
retinopathy	I-Disease
(	O
DR	B-Disease
)	O
as	O
determined	O
by	O
lesions	O
identified	O
using	O
mydriatic	B-Diagnostic_tool
ultrawide	I-Diagnostic_tool
field	I-Diagnostic_tool
imaging	I-Diagnostic_tool
(	O
DiSLO200	B-Diagnostic_tool
;	O
Optos	O
plc	O
,	O
Scotland	O
,	O
UK	O
)	O
compared	O
with	O
Early	B-Diagnostic_tool
Treatment	I-Diagnostic_tool
Diabetic	I-Diagnostic_tool
Retinopathy	I-Diagnostic_tool
Study	I-Diagnostic_tool
(	I-Diagnostic_tool
ETDRS	I-Diagnostic_tool
)	I-Diagnostic_tool
7	I-Diagnostic_tool
-	I-Diagnostic_tool
standard	I-Diagnostic_tool
field	I-Diagnostic_tool
film	I-Diagnostic_tool
photography	I-Diagnostic_tool
.	O
	
Prospective	O
comparative	O
study	O
of	O
DiSLO200	B-Diagnostic_tool
,	O
ETDRS	B-Diagnostic_tool
7	I-Diagnostic_tool
-	I-Diagnostic_tool
standard	I-Diagnostic_tool
field	I-Diagnostic_tool
film	I-Diagnostic_tool
photographs	I-Diagnostic_tool
,	O
and	O
dilated	B-Diagnostic_tool
fundus	I-Diagnostic_tool
examination	I-Diagnostic_tool
(	O
DFE	B-Diagnostic_tool
)	O
.	O
	
A	O
total	O
of	O
206	O
eyes	B-Anatomy
of	O
103	O
diabetic	B-Disease
patients	O
selected	O
to	O
represent	O
all	O
levels	O
of	O
DR	B-Disease
.	O
	
Subjects	O
had	O
DiSLO200	B-Diagnostic_tool
,	O
ETDRS	B-Diagnostic_tool
7	I-Diagnostic_tool
-	I-Diagnostic_tool
standard	I-Diagnostic_tool
field	I-Diagnostic_tool
film	I-Diagnostic_tool
photographs	I-Diagnostic_tool
,	O
and	O
DFE	B-Diagnostic_tool
.	O
	
Images	O
were	O
graded	O
for	O
severity	O
and	O
distribution	O
of	O
DR	B-Symptom
lesions	I-Symptom
.	O
	
Discrepancies	O
were	O
adjudicated	O
,	O
and	O
images	O
were	O
compared	O
side	O
by	O
side	O
.	O
	
Distribution	O
of	O
hemorrhage	B-Symptom
and	I-Symptom
/	I-Symptom
or	I-Symptom
microaneurysm	I-Symptom
(	O
H	B-Symptom
/	I-Symptom
Ma	I-Symptom
)	O
,	O
venous	B-Symptom
beading	I-Symptom
(	O
VB	B-Symptom
)	O
,	O
intraretinal	B-Symptom
microvascular	I-Symptom
abnormality	I-Symptom
(	O
IRMA	B-Symptom
)	O
,	O
and	O
new	B-Symptom
vessels	I-Symptom
elsewhere	I-Symptom
(	O
NVE	B-Symptom
)	O
.	O
	
Kappa	O
(	O
	O
)	O
and	O
weighted	O
	O
statistics	O
for	O
agreement	O
.	O
	
The	O
distribution	O
of	O
DR	B-Disease
severity	O
by	O
ETDRS	B-Diagnostic_tool
7	I-Diagnostic_tool
-	I-Diagnostic_tool
standard	I-Diagnostic_tool
field	I-Diagnostic_tool
film	I-Diagnostic_tool
photographs	I-Diagnostic_tool
was	O
no	B-Characteristic
DR	I-Characteristic
12	O
.	O
5	O
%	O
;	O
nonproliferative	B-Disease
DR	I-Disease
mild	O
22	O
.	O
5	O
%	O
,	O
moderate	B-Disease
30	O
%	O
,	O
and	O
severe	B-Disease
/	I-Disease
very	I-Disease
severe	I-Disease
8	O
%	O
;	O
and	O
proliferative	B-Disease
DR	I-Disease
27	O
%	O
.	O
	
Diabetic	B-Disease
retinopathy	I-Disease
severity	O
between	O
DiSLO200	B-Diagnostic_tool
and	O
ETDRS	B-Diagnostic_tool
film	I-Diagnostic_tool
photographs	I-Diagnostic_tool
matched	O
in	O
80	O
%	O
of	O
eyes	B-Anatomy
(	O
weighted	O
	O
=	O
0	O
.	O
74	O
,	O
	O
=	O
0	O
.	O
84	O
)	O
and	O
was	O
within	O
1	O
level	O
in	O
94	O
.	O
5	O
%	O
of	O
eyes	B-Anatomy
.	O
	
DiSLO200	B-Diagnostic_tool
and	O
DFE	B-Diagnostic_tool
matched	O
in	O
58	O
.	O
8	O
%	O
of	O
eyes	B-Anatomy
(	O
weighted	O
	O
=	O
0	O
.	O
69	O
,	O
	O
=	O
0	O
.	O
47	O
)	O
and	O
were	O
within	O
1	O
level	O
in	O
91	O
.	O
2	O
%	O
of	O
eyes	B-Anatomy
.	O
	
Forty	O
eyes	B-Anatomy
(	O
20	O
%	O
)	O
had	O
DR	B-Disease
severity	O
discrepancies	O
between	O
DiSLO200	B-Diagnostic_tool
and	O
ETDRS	B-Diagnostic_tool
film	I-Diagnostic_tool
photographs	I-Diagnostic_tool
.	O
	
The	O
retinal	B-Symptom
lesions	I-Symptom
causing	O
discrepancies	O
were	O
H	B-Symptom
/	I-Symptom
Ma	I-Symptom
52	O
%	O
,	O
IRMA	B-Symptom
26	O
%	O
,	O
NVE	B-Symptom
17	O
%	O
,	O
and	O
VB	B-Symptom
4	O
%	O
.	O
	
Approximately	O
one	O
-	O
third	O
of	O
H	B-Symptom
/	I-Symptom
Ma	I-Symptom
,	O
IRMA	B-Symptom
,	O
and	O
NVE	B-Symptom
were	O
predominantly	O
outside	O
ETDRS	O
fields	O
.	O
	
Lesions	O
identified	O
on	O
DiSLO200	B-Diagnostic_tool
but	O
not	O
ETDRS	B-Diagnostic_tool
film	I-Diagnostic_tool
photographs	I-Diagnostic_tool
suggested	O
a	O
more	O
severe	O
DR	B-Disease
level	O
in	O
10	O
%	O
of	O
eyes	B-Anatomy
.	O
	
Distribution	O
in	O
the	O
temporal	B-Anatomy
,	I-Anatomy
superotemporal	I-Anatomy
,	I-Anatomy
inferotemporal	I-Anatomy
,	I-Anatomy
superonasal	I-Anatomy
,	I-Anatomy
and	I-Anatomy
inferonasal	I-Anatomy
fields	I-Anatomy
was	O
77	O
%	O
,	O
72	O
%	O
,	O
61	O
%	O
,	O
65	O
%	O
,	O
and	O
59	O
%	O
for	O
H	B-Symptom
/	I-Symptom
Ma	I-Symptom
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
;	O
22	O
%	O
,	O
24	O
%	O
,	O
21	O
%	O
,	O
28	O
%	O
,	O
and	O
22	O
%	O
for	O
VB	B-Symptom
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
;	O
52	O
%	O
,	O
40	O
%	O
,	O
29	O
%	O
,	O
47	O
%	O
,	O
and	O
36	O
%	O
for	O
IRMA	B-Symptom
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
and	O
8	O
%	O
,	O
4	O
%	O
,	O
4	O
%	O
,	O
8	O
%	O
,	O
and	O
5	O
%	O
for	O
NVE	B-Symptom
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O
	
All	O
lesions	O
were	O
more	O
frequent	O
in	O
the	O
temporal	B-Anatomy
fields	I-Anatomy
compared	O
with	O
the	O
nasal	B-Anatomy
fields	I-Anatomy
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
	
DiSLO200	B-Diagnostic_tool
images	I-Diagnostic_tool
had	O
substantial	O
agreement	O
with	O
ETDRS	B-Diagnostic_tool
film	I-Diagnostic_tool
photographs	I-Diagnostic_tool
and	O
DFE	B-Diagnostic_tool
in	O
determining	O
DR	B-Disease
severity	O
.	O
	
On	O
the	O
basis	O
of	O
DiSLO200	B-Diagnostic_tool
images	I-Diagnostic_tool
,	O
significant	O
nonuniform	O
distribution	O
of	O
DR	B-Symptom
lesions	I-Symptom
was	O
evident	O
across	O
the	O
retina	B-Anatomy
.	O
	
The	O
additional	O
peripheral	B-Symptom
lesions	I-Symptom
identified	O
by	O
DiSLO200	B-Diagnostic_tool
in	O
this	O
cohort	O
suggested	O
a	O
more	O
severe	O
assessment	O
of	O
DR	B-Disease
in	O
10	O
%	O
of	O
eyes	B-Anatomy
than	O
was	O
suggested	O
by	O
the	O
lesions	O
within	O
the	O
ETDRS	O
fields	O
.	O
	
However	O
,	O
the	O
implications	O
of	O
peripheral	B-Symptom
lesions	I-Symptom
on	O
DR	B-Characteristic
progression	I-Characteristic
within	O
a	O
specific	O
ETDRS	B-Characteristic
severity	I-Characteristic
level	O
over	O
time	O
are	O
unknown	O
and	O
need	O
to	O
be	O
evaluated	O
prospectively	O
.	O
	
Accuracy	O
of	O
matching	O
optic	B-Anatomy
discs	I-Anatomy
with	O
visual	B-Characteristic
fields	I-Characteristic
:	O
the	O
European	O
Structure	O
and	O
Function	O
Assessment	O
Trial	O
(	O
ESAFAT	O
)	O
.	O
	
To	O
determine	O
the	O
ability	O
of	O
ophthalmologists	O
across	O
Europe	O
to	O
match	O
stereoscopic	B-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
photographs	I-Diagnostic_tool
to	O
visual	B-Characteristic
fields	I-Characteristic
of	O
varying	O
severity	O
.	O
	
Evaluation	O
and	O
comparison	O
of	O
2	O
diagnostic	O
tests	O
.	O
	
A	O
total	O
of	O
109	O
of	O
260	O
invited	O
ophthalmologists	O
in	O
11	O
European	O
countries	O
.	O
	
These	O
had	O
participated	O
in	O
the	O
previous	O
European	O
Optic	B-Anatomy
Disc	I-Anatomy
Assessment	O
Trial	O
(	O
EODAT	O
)	O
,	O
a	O
trial	O
on	O
glaucoma	B-Disease
diagnostic	O
accuracy	O
based	O
on	O
optic	B-Anatomy
discs	I-Anatomy
only	O
.	O
	
Each	O
participant	O
matched	O
stereo	B-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
photographs	I-Diagnostic_tool
of	O
40	O
healthy	O
and	O
48	O
glaucomatous	B-Disease
eyes	B-Anatomy
to	O
a	O
visual	B-Characteristic
field	I-Characteristic
chosen	O
from	O
4	O
options	O
per	O
disc	B-Anatomy
.	O
	
The	O
4	O
presented	O
visual	B-Characteristic
fields	I-Characteristic
included	O
the	O
corresponding	O
one	O
and	O
3	O
other	O
visual	B-Characteristic
fields	I-Characteristic
,	O
varying	O
in	O
severity	O
.	O
	
The	O
matching	O
accuracy	O
and	O
any	O
inaccuracy	O
per	O
disease	O
severity	O
were	O
calculated	O
.	O
	
Classification	O
accuracy	O
(	O
as	O
glaucomatous	B-Disease
or	O
healthy	O
)	O
was	O
compared	O
with	O
EODAT	O
data	O
.	O
	
Duplicate	O
slides	O
allowed	O
for	O
the	O
assessment	O
of	O
intraobserver	O
agreement	O
.	O
	
Accuracy	O
of	O
matching	O
optic	B-Anatomy
discs	I-Anatomy
with	O
their	O
corresponding	O
visual	B-Characteristic
field	I-Characteristic
and	O
of	O
classifying	O
them	O
as	O
healthy	O
or	O
glaucomatous	B-Disease
;	O
intraobserver	O
agreement	O
(	O
	O
)	O
.	O
	
The	O
overall	O
accuracy	O
of	O
ophthalmologists	O
for	O
correctly	O
matching	O
stereoscopic	B-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
photographs	I-Diagnostic_tool
to	O
their	O
visual	B-Characteristic
fields	I-Characteristic
was	O
58	O
.	O
7	O
%	O
.	O
	
When	O
incorrectly	O
matched	O
,	O
the	O
observers	O
generally	O
overestimated	O
the	O
visual	B-Characteristic
field	I-Characteristic
severity	I-Characteristic
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
notably	O
in	O
eyes	B-Anatomy
with	O
early	B-Disease
glaucoma	I-Disease
.	O
	
The	O
intraobserver	O
agreement	O
was	O
,	O
on	O
average	O
,	O
moderate	O
(	O
0	O
.	O
52	O
)	O
.	O
	
European	O
ophthalmologists	O
correctly	O
matched	O
stereoscopic	B-Diagnostic_tool
optic	I-Diagnostic_tool
disc	I-Diagnostic_tool
photographs	I-Diagnostic_tool
to	O
their	O
corresponding	O
visual	B-Characteristic
field	I-Characteristic
in	O
only	O
approximately	O
59	O
%	O
of	O
cases	O
.	O
	
In	O
most	O
mismatches	O
,	O
the	O
clinicians	O
overestimated	O
the	O
visual	B-Symptom
field	I-Symptom
damage	I-Symptom
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
-	O
based	O
observation	O
of	O
the	O
natural	O
history	O
of	O
drusenoid	B-Symptom
lesion	I-Symptom
in	O
eyes	B-Anatomy
with	O
dry	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
.	O
	
To	O
use	O
spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
to	O
investigate	O
risk	O
factors	O
predictive	O
for	O
the	O
development	O
of	O
atrophy	B-Symptom
of	I-Symptom
drusenoid	I-Symptom
lesions	I-Symptom
(	O
DLs	B-Symptom
)	O
(	O
drusen	B-Symptom
and	O
drusenoid	B-Symptom
pigment	I-Symptom
epithelium	I-Symptom
detachment	I-Symptom
)	O
in	O
eyes	B-Anatomy
with	O
non	B-Disease
-	I-Disease
neovascular	I-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
NNVAMD	B-Disease
)	O
.	O
	
Cohort	O
study	O
.	O
	
Forty	O
-	O
one	O
eyes	B-Anatomy
from	O
29	O
patients	O
with	O
NNVAMD	B-Disease
.	O
	
Patients	O
with	O
NNVAMD	B-Disease
who	O
underwent	O
registered	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
imaging	I-Diagnostic_tool
over	O
a	O
minimum	O
period	O
of	O
6	O
months	O
were	O
reviewed	O
.	O
	
Drusenoid	B-Symptom
lesions	I-Symptom
that	O
were	O
accompanied	O
by	O
new	O
atrophy	B-Symptom
onset	O
at	O
6	O
months	O
or	O
last	O
follow	O
-	O
up	O
(	O
FUL	O
)	O
were	O
further	O
analyzed	O
.	O
	
Detailed	O
lesion	O
change	O
was	O
described	O
throughout	O
the	O
study	O
period	O
.	O
	
Odds	O
ratios	O
(	O
ORs	O
)	O
and	O
risk	O
for	O
new	O
local	B-Symptom
atrophy	I-Symptom
onset	O
were	O
calculated	O
.	O
	
Drusenoid	B-Symptom
lesion	I-Symptom
features	O
and	O
longitudinal	O
changes	O
in	O
features	O
,	O
including	O
maximum	B-Characteristic
lesion	I-Characteristic
height	I-Characteristic
,	O
lesion	B-Characteristic
diameter	I-Characteristic
,	O
lesion	B-Characteristic
internal	I-Characteristic
reflectivity	I-Characteristic
,	O
and	O
presence	O
and	O
extent	O
of	O
overlying	B-Symptom
intraretinal	I-Symptom
hyperreflective	I-Symptom
foci	I-Symptom
(	O
HRF	B-Symptom
)	O
.	O
	
Subfoveal	B-Characteristic
choroidal	I-Characteristic
thickness	I-Characteristic
(	O
SFCT	B-Characteristic
)	O
and	O
choroidal	B-Characteristic
thickness	I-Characteristic
(	O
CT	B-Characteristic
)	O
were	O
measured	O
below	O
each	O
lesion	O
.	O
	
A	O
total	O
of	O
543	O
individual	O
DLs	B-Symptom
were	O
identified	O
at	O
baseline	O
,	O
and	O
28	O
lesions	O
developed	O
during	O
follow	O
-	O
up	O
.	O
	
The	O
mean	O
follow	O
-	O
up	O
time	O
was	O
21	O
.	O
3	O
	O
8	O
.	O
6	O
months	O
(	O
range	O
,	O
6	O
-	O
44	O
months	O
)	O
.	O
	
Some	O
3	O
.	O
2	O
%	O
of	O
DLs	B-Symptom
(	O
18	O
/	O
571	O
)	O
progressed	O
to	O
atrophy	B-Symptom
within	O
18	O
.	O
3	O
	O
9	O
.	O
5	O
months	O
(	O
range	O
,	O
5	O
-	O
28	O
months	O
)	O
of	O
the	O
initial	O
visit	O
.	O
	
Drusenoid	B-Symptom
lesions	I-Symptom
with	I-Symptom
heterogeneous	I-Symptom
internal	I-Symptom
reflectivity	I-Symptom
were	O
significantly	O
associated	O
with	O
new	O
atrophy	B-Symptom
onset	O
at	O
6	O
months	O
(	O
OR	O
,	O
5	O
.	O
614	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
277	O
-	O
24	O
.	O
673	O
)	O
and	O
new	O
atrophy	B-Symptom
onset	O
at	O
FUL	O
(	O
OR	O
,	O
7	O
.	O
005	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
300	O
-	O
21	O
.	O
337	O
)	O
.	O
	
Lesions	O
with	O
the	O
presence	O
of	O
HRF	B-Symptom
were	O
significant	O
predictors	O
of	O
new	O
atrophy	B-Symptom
onset	O
at	O
6	O
months	O
(	O
OR	O
,	O
30	O
.	O
161	O
;	O
95	O
%	O
CI	O
,	O
4	O
.	O
766	O
-	O
190	O
.	O
860	O
)	O
and	O
FUL	O
(	O
OR	O
,	O
11	O
.	O
211	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
513	O
-	O
50	O
.	O
019	O
)	O
.	O
	
Lesions	O
with	O
a	O
baseline	O
maximum	O
height	O
>	B-Dimension
80	I-Dimension
	I-Dimension
m	I-Dimension
or	O
CT	B-Characteristic
	B-Dimension
135	I-Dimension
	I-Dimension
m	I-Dimension
showed	O
a	O
positive	O
association	O
with	O
the	O
new	O
atrophy	B-Symptom
onset	O
at	O
FUL	O
(	O
OR	O
,	O
7	O
.	O
886	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
105	O
-	O
29	O
.	O
538	O
and	O
OR	O
,	O
3	O
.	O
796	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
154	O
-	O
12	O
.	O
481	O
,	O
respectively	O
)	O
.	O
	
The	O
presence	O
of	O
HRF	B-Symptom
overlying	I-Symptom
DLs	I-Symptom
,	O
a	O
heterogeneous	O
internal	O
reflectivity	O
of	O
these	O
lesions	O
,	O
was	O
found	O
consistently	O
to	O
be	O
predictive	O
of	O
local	O
atrophy	B-Symptom
onset	O
in	O
the	O
ensuing	O
months	O
.	O
	
These	O
findings	O
provide	O
further	O
insight	O
into	O
the	O
natural	O
history	O
of	O
anatomic	O
change	O
occurring	O
in	O
patients	O
with	O
NNVAMD	B-Disease
.	O
	
Validity	O
of	O
self	O
-	O
report	O
in	O
type	B-Disease
1	I-Disease
diabetic	I-Disease
subjects	O
for	O
laser	O
treatment	O
of	O
retinopathy	B-Disease
.	O
	
This	O
study	O
sought	O
to	O
determine	O
the	O
validity	O
of	O
self	O
-	O
report	O
of	O
prior	O
panretinal	O
photocoagulation	O
(	O
PRP	O
)	O
and	O
focal	O
photocoagulation	O
(	O
FP	O
)	O
compared	O
with	O
fundus	B-Diagnostic_tool
photography	I-Diagnostic_tool
.	O
	
Prospective	O
cohort	O
study	O
.	O
	
One	O
thousand	O
three	O
hundred	O
sixty	O
-	O
three	O
type	B-Disease
1	I-Disease
diabetic	I-Disease
subjects	O
from	O
the	O
Epidemiology	O
of	O
Diabetes	B-Disease
Interventions	O
and	O
Complications	O
(	O
EDIC	O
)	O
study	O
,	O
a	O
subset	O
of	O
the	O
1441	O
subjects	O
originally	O
enrolled	O
in	O
the	O
multicenter	O
Diabetes	B-Disease
Control	O
and	O
Complications	O
Trial	O
.	O
	
At	O
each	O
annual	O
visit	O
,	O
subjects	O
were	O
asked	O
by	O
EDIC	O
staff	O
whether	O
they	O
had	O
undergone	O
PRP	O
,	O
FP	O
,	O
or	O
both	O
since	O
the	O
last	O
completed	O
annual	O
clinic	O
visit	O
.	O
	
Fundus	B-Diagnostic_tool
photographs	I-Diagnostic_tool
were	O
collected	O
from	O
one	O
quarter	O
of	O
the	O
cohort	O
each	O
year	O
and	O
from	O
the	O
entire	O
cohort	O
at	O
EDIC	O
years	O
4	O
and	O
10	O
.	O
	
Photographs	B-Diagnostic_tool
were	O
graded	O
for	O
the	O
presence	O
and	O
extent	O
of	O
PRP	O
and	O
FP	O
.	O
	
Seventeen	O
years	O
of	O
subject	O
reporting	O
and	O
photograph	B-Diagnostic_tool
grading	O
of	O
PRP	O
and	O
FP	O
were	O
compared	O
in	O
EDIC	O
subjects	O
.	O
	
The	O
	O
,	O
sensitivity	O
,	O
specificity	O
,	O
and	O
positive	O
and	O
negative	O
predictive	O
values	O
were	O
calculated	O
for	O
subject	O
-	O
reported	O
PRP	O
and	O
FP	O
.	O
	
Factors	O
influencing	O
subject	O
misreporting	O
were	O
investigated	O
.	O
	
For	O
subject	O
reporting	O
,	O
1244	O
(	O
96	O
%	O
)	O
of	O
1296	O
subjects	O
with	O
gradable	B-Diagnostic_tool
photographs	I-Diagnostic_tool
accurately	O
reported	O
whether	O
they	O
had	O
a	O
history	O
of	O
PRP	O
in	O
one	O
or	O
both	O
eyes	B-Anatomy
,	O
and	O
1259	O
(	O
97	O
.	O
5	O
%	O
)	O
of	O
1291	O
with	O
valid	O
photographs	B-Diagnostic_tool
correctly	O
reported	O
their	O
history	O
of	O
FP	O
.	O
	
For	O
PRP	O
and	O
FP	O
,	O
sensitivities	O
were	O
90	O
.	O
4	O
%	O
and	O
74	O
.	O
0	O
%	O
,	O
respectively	O
;	O
specificities	O
were	O
96	O
.	O
0	O
%	O
and	O
98	O
.	O
8	O
%	O
,	O
respectively	O
;	O
positive	O
predictive	O
values	O
were	O
75	O
.	O
9	O
%	O
and	O
80	O
.	O
3	O
%	O
,	O
respectively	O
;	O
negative	O
predictive	O
values	O
were	O
98	O
.	O
9	O
%	O
and	O
98	O
.	O
4	O
%	O
,	O
respectively	O
;	O
and	O
	O
values	O
were	O
0	O
.	O
80	O
and	O
0	O
.	O
76	O
,	O
respectively	O
.	O
	
Risk	O
factors	O
associated	O
with	O
misreporting	O
included	O
prior	O
laser	O
for	O
diabetic	B-Disease
retinopathy	I-Disease
and	O
prior	O
ocular	O
surgery	O
(	O
each	O
P	O
<	O
0	O
.	O
04	O
)	O
.	O
	
For	O
subjects	O
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
,	O
in	O
the	O
absence	O
of	O
a	O
clinical	O
examination	O
or	O
fundus	B-Diagnostic_tool
photographs	I-Diagnostic_tool
,	O
subject	O
self	O
-	O
report	O
could	O
be	O
a	O
reliable	O
tool	O
in	O
a	O
well	O
-	O
monitored	O
study	O
for	O
assessing	O
laser	O
treatment	O
type	O
in	O
diabetic	B-Disease
retinopathy	I-Disease
.	O
	
Fourier	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
imaging	O
in	O
keratoconus	B-Disease
:	O
a	O
corneal	B-Anatomy
structural	O
classification	O
.	O
	
To	O
study	O
corneal	B-Symptom
morphologic	I-Symptom
changes	I-Symptom
in	O
a	O
large	O
keratoconic	B-Disease
population	O
and	O
to	O
establish	O
a	O
structural	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
classification	O
.	O
	
Cross	O
-	O
sectional	O
,	O
observational	O
study	O
.	O
	
A	O
total	O
of	O
218	O
keratoconic	B-Disease
eyes	B-Anatomy
from	O
218	O
patients	O
and	O
34	O
eyes	B-Anatomy
from	O
34	O
normal	O
subjects	O
.	O
	
A	O
Fourier	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
OCT	I-Diagnostic_tool
system	O
with	O
5	O
-	O
	O
m	O
axial	O
resolution	O
was	O
used	O
.	O
	
For	O
each	O
patient	O
,	O
3	O
high	O
-	O
resolution	O
scans	O
were	O
made	O
across	O
the	O
keratoconus	B-Anatomy
cone	I-Anatomy
.	O
	
All	O
scans	O
were	O
analyzed	O
by	O
keratoconus	B-Disease
specialists	O
who	O
were	O
not	O
given	O
access	O
to	O
patients	O
'	O
clinical	O
and	O
topographic	O
data	O
,	O
and	O
who	O
established	O
an	O
OCT	B-Diagnostic_tool
classification	O
.	O
	
The	O
reproducibility	O
of	O
the	O
classification	O
and	O
its	O
correlation	O
with	O
clinical	O
and	O
paraclinical	O
characteristics	O
of	O
patients	O
with	O
keratoconus	B-Disease
were	O
evaluated	O
.	O
	
The	O
OCT	B-Diagnostic_tool
examinations	O
were	O
performed	O
every	O
4	O
months	O
to	O
follow	O
up	O
structural	B-Symptom
corneal	I-Symptom
changes	I-Symptom
.	O
	
Evaluation	O
of	O
the	O
structural	B-Symptom
corneal	I-Symptom
changes	I-Symptom
occurring	O
in	O
keratoconus	B-Disease
cases	O
with	O
various	O
stages	O
of	O
severity	O
based	O
on	O
OCT	B-Diagnostic_tool
findings	O
.	O
	
Fourier	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
OCT	I-Diagnostic_tool
classification	O
containing	O
5	O
distinct	O
keratoconus	B-Disease
stages	O
is	O
proposed	O
.	O
	
Stage	B-Disease
1	I-Disease
demonstrates	O
thinning	B-Symptom
of	I-Symptom
apparently	I-Symptom
normal	I-Symptom
epithelial	I-Symptom
and	I-Symptom
stromal	I-Symptom
layers	I-Symptom
at	I-Symptom
the	I-Symptom
conus	I-Symptom
.	O
	
Stage	B-Disease
2	I-Disease
demonstrates	O
hyperreflective	B-Symptom
anomalies	I-Symptom
occurring	I-Symptom
at	I-Symptom
the	I-Symptom
Bowman	I-Symptom
'	I-Symptom
s	I-Symptom
layer	I-Symptom
level	I-Symptom
with	I-Symptom
epithelial	I-Symptom
thickening	I-Symptom
at	I-Symptom
the	I-Symptom
conus	I-Symptom
.	O
	
Stage	B-Disease
3	I-Disease
demonstrates	O
posterior	B-Symptom
displacement	I-Symptom
of	I-Symptom
the	I-Symptom
hyperreflective	I-Symptom
structures	I-Symptom
occurring	I-Symptom
at	I-Symptom
the	I-Symptom
Bowman	I-Symptom
'	I-Symptom
s	I-Symptom
layer	I-Symptom
level	I-Symptom
with	I-Symptom
increased	I-Symptom
epithelial	I-Symptom
thickening	I-Symptom
and	I-Symptom
stromal	I-Symptom
thinning	I-Symptom
.	O
	
Stage	B-Disease
4	I-Disease
demonstrates	O
pan	B-Symptom
-	I-Symptom
stromal	I-Symptom
scar	I-Symptom
.	O
	
Stage	B-Disease
5	I-Disease
demonstrates	O
hydrops	B-Symptom
;	O
5a	B-Disease
,	I-Disease
acute	I-Disease
onset	I-Disease
:	O
Descemet	B-Symptom
'	I-Symptom
s	I-Symptom
membrane	I-Symptom
rupture	I-Symptom
and	I-Symptom
dilaceration	I-Symptom
of	I-Symptom
collagen	I-Symptom
lamellae	I-Symptom
with	I-Symptom
large	I-Symptom
fluid	I-Symptom
-	I-Symptom
filled	I-Symptom
intrastromal	I-Symptom
cysts	I-Symptom
;	O
5b	B-Disease
,	I-Disease
healing	I-Disease
stage	I-Disease
:	O
pan	B-Symptom
-	I-Symptom
stromal	I-Symptom
scarring	I-Symptom
with	I-Symptom
a	I-Symptom
remaining	I-Symptom
aspect	I-Symptom
of	I-Symptom
Descemet	I-Symptom
'	I-Symptom
s	I-Symptom
membrane	I-Symptom
rupture	I-Symptom
.	O
	
The	O
reproducibility	O
of	O
the	O
classification	O
was	O
very	O
high	O
between	O
the	O
corneal	B-Anatomy
specialist	O
observers	O
.	O
	
Clinical	O
and	O
paraclinical	O
characteristics	O
of	O
keratoconus	B-Disease
,	O
including	O
visual	B-Characteristic
acuity	I-Characteristic
,	O
corneal	B-Symptom
epithelium	I-Symptom
and	I-Symptom
stromal	I-Symptom
thickness	I-Symptom
changes	I-Symptom
,	O
corneal	B-Characteristic
topography	I-Characteristic
,	O
biomechanical	B-Characteristic
corneal	I-Characteristic
characteristics	I-Characteristic
,	O
and	O
microstructural	B-Symptom
changes	I-Symptom
observed	O
on	O
confocal	B-Diagnostic_tool
microscopy	I-Diagnostic_tool
,	O
were	O
concordant	O
with	O
our	O
OCT	B-Diagnostic_tool
grading	O
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
provides	O
an	O
accurate	O
assessment	O
of	O
structural	B-Symptom
changes	I-Symptom
occurring	O
in	O
keratoconus	B-Disease
eyes	B-Anatomy
.	O
	
These	O
changes	O
were	O
correlated	O
with	O
clinical	O
and	O
paraclinical	O
characteristics	O
of	O
patients	O
.	O
	
The	O
established	O
classification	O
not	O
only	O
allows	O
structural	O
follow	O
-	O
up	O
of	O
patients	O
with	O
keratoconus	B-Disease
but	O
also	O
provides	O
insight	O
into	O
the	O
pathogenesis	O
of	O
keratoconus	B-Disease
and	O
treatment	O
strategies	O
for	O
future	O
research	O
.	O
	
Ocular	B-Anatomy
manifestations	O
of	O
22q11	B-Characteristic
.	I-Characteristic
2	I-Characteristic
microduplication	I-Characteristic
.	O
	
To	O
report	O
a	O
new	O
ocular	B-Anatomy
manifestation	O
of	O
the	O
dup22q11	B-Disease
syndrome	I-Disease
and	O
explore	O
involved	O
genes	O
that	O
may	O
offer	O
insight	O
to	O
mechanisms	O
of	O
pathogenesis	O
.	O
	
Case	O
series	O
.	O
	
Two	O
male	B-Characteristic
patients	O
with	O
this	O
syndrome	O
diagnosed	O
with	O
dup22q11	B-Characteristic
.	I-Characteristic
2	I-Characteristic
.	O
	
Medical	O
records	O
were	O
reviewed	O
.	O
	
Duplication	O
was	O
detected	O
in	O
the	O
oligo	B-Diagnostic_tool
-	I-Diagnostic_tool
single	I-Diagnostic_tool
nucleotide	I-Diagnostic_tool
polymorphism	I-Diagnostic_tool
chromosomal	I-Diagnostic_tool
microarray	I-Diagnostic_tool
and	O
duplicated	O
genes	O
within	O
the	O
segment	O
where	O
determined	O
by	O
literature	O
and	O
database	O
review	O
.	O
	
Potential	O
associations	O
between	O
the	O
ophthalmologic	O
manifestations	O
and	O
their	O
physiopathology	O
were	O
investigated	O
.	O
	
Microarray	B-Diagnostic_tool
results	O
and	O
identification	O
of	O
candidate	O
genes	O
within	O
the	O
duplicated	O
segment	O
.	O
	
Our	O
patients	O
demonstrate	O
previously	O
unreported	O
findings	O
of	O
dup22q11	B-Characteristic
.	I-Characteristic
2	I-Characteristic
,	O
including	O
Marcus	B-Disease
Gunn	I-Disease
jaw	I-Disease
winking	I-Disease
,	O
Duane	B-Disease
'	I-Disease
s	I-Disease
retraction	I-Disease
syndrome	I-Disease
,	O
and	O
other	O
abnormal	B-Symptom
eye	I-Symptom
movements	I-Symptom
consistent	O
with	O
a	O
congenital	B-Disease
cranial	I-Disease
dysinnervation	I-Disease
disorder	I-Disease
(	O
CCDD	B-Disease
)	O
,	O
retinal	B-Symptom
vascular	I-Symptom
tortuosity	I-Symptom
,	O
and	O
primary	B-Disease
infantile	I-Disease
glaucoma	I-Disease
.	O
	
The	O
duplicated	O
segment	O
in	O
case	O
1	O
includes	O
SNAP29	B-Characteristic
,	O
which	O
could	O
be	O
linked	O
with	O
the	O
development	O
of	O
retinal	B-Symptom
vascular	I-Symptom
tortuosity	I-Symptom
,	O
and	O
MAPK1	B-Characteristic
,	O
which	O
seems	O
to	O
play	O
a	O
role	O
in	O
axonal	O
development	O
through	O
the	O
semaphorin	O
pathway	O
,	O
which	O
may	O
serve	O
as	O
a	O
candidate	O
gene	O
for	O
CCDD	B-Disease
.	O
	
In	O
case	O
2	O
,	O
the	O
CLDN5	B-Characteristic
gene	I-Characteristic
is	O
within	O
the	O
duplicated	O
segment	O
.	O
	
CLDN5	B-Characteristic
could	O
be	O
involved	O
in	O
the	O
pathophysiology	O
of	O
glaucoma	B-Disease
.	O
	
Our	O
cases	O
expand	O
the	O
ocular	B-Anatomy
phenotype	O
for	O
duplication	B-Characteristic
of	I-Characteristic
22q11	I-Characteristic
and	O
serve	O
to	O
identify	O
potential	O
candidate	O
genes	O
for	O
the	O
development	O
of	O
CCDD	B-Disease
,	O
retinal	B-Symptom
vascular	I-Symptom
tortuosity	I-Symptom
,	O
and	O
glaucoma	B-Disease
.	O
	
Evaluation	O
of	O
telemedicine	O
for	O
screening	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
in	O
the	O
Veterans	O
Health	O
Administration	O
.	O
	
To	O
explore	O
the	O
cost	O
-	O
effectiveness	O
of	O
telemedicine	O
for	O
the	O
screening	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
(	O
DR	B-Disease
)	O
and	O
identify	O
changes	O
within	O
the	O
demographics	O
of	O
a	O
patient	O
population	O
after	O
telemedicine	O
implementation	O
.	O
	
A	O
retrospective	O
medical	O
chart	O
review	O
(	O
cohort	O
study	O
)	O
was	O
conducted	O
.	O
	
A	O
total	O
of	O
900	O
type	B-Disease
1	I-Disease
and	I-Disease
type	I-Disease
2	I-Disease
diabetic	I-Disease
patients	O
enrolled	O
in	O
a	O
medical	O
system	O
with	O
a	O
telemedicine	O
screening	O
program	O
for	O
DR	B-Disease
.	O
	
The	O
cost	O
-	O
effectiveness	O
of	O
the	O
DR	B-Disease
telemedicine	O
program	O
was	O
determined	O
by	O
using	O
a	O
finite	O
-	O
horizon	O
,	O
discrete	O
time	O
,	O
discounted	O
Markov	B-Diagnostic_tool
decision	I-Diagnostic_tool
process	I-Diagnostic_tool
model	I-Diagnostic_tool
populated	O
by	O
parameters	O
and	O
testing	O
frequency	O
obtained	O
from	O
patient	O
records	O
.	O
	
The	O
model	O
estimated	O
the	O
progression	O
of	O
DR	B-Disease
and	O
determined	O
average	B-Characteristic
quality	I-Characteristic
-	I-Characteristic
adjusted	I-Characteristic
life	I-Characteristic
years	I-Characteristic
(	O
QALYs	B-Characteristic
)	O
saved	O
and	O
average	O
additional	O
cost	O
incurred	O
by	O
the	O
telemedicine	O
screening	O
program	O
.	O
	
Diabetic	B-Disease
retinopathy	I-Disease
,	O
macular	B-Disease
edema	I-Disease
,	O
blindness	B-Disease
,	O
and	O
associated	O
QALYs	B-Characteristic
.	O
	
The	O
results	O
indicate	O
that	O
telemedicine	O
screening	O
is	O
cost	O
-	O
effective	O
for	O
DR	B-Disease
under	O
most	O
conditions	O
.	O
	
On	O
average	O
,	O
it	O
is	O
cost	O
-	O
effective	O
for	O
patient	O
populations	O
of	O
>	O
3500	O
,	O
patients	B-Characteristic
aged	I-Characteristic
<	I-Characteristic
80	I-Characteristic
years	I-Characteristic
,	O
and	O
all	O
racial	O
groups	O
.	O
	
Observable	O
trends	O
were	O
identified	O
in	O
the	O
screening	O
population	O
since	O
the	O
implementation	O
of	O
telemedicine	O
screening	O
:	O
the	O
number	O
of	O
known	O
DR	B-Disease
cases	O
has	O
increased	O
,	O
the	O
overall	O
age	O
of	O
patients	O
receiving	O
screenings	O
has	O
decreased	O
,	O
the	O
percentage	O
of	O
nonwhites	B-Characteristic
receiving	O
screenings	O
has	O
increased	O
,	O
the	O
average	O
number	O
of	O
miles	O
traveled	O
by	O
a	O
patient	O
to	O
receive	O
a	O
screening	O
has	O
decreased	O
,	O
and	O
the	O
teleretinal	O
screening	O
participation	O
is	O
increasing	O
.	O
	
The	O
current	O
teleretinal	B-Diagnostic_tool
screening	I-Diagnostic_tool
program	I-Diagnostic_tool
is	O
effective	O
in	O
terms	O
of	O
being	O
cost	O
-	O
effective	O
and	O
increasing	O
population	O
reach	O
.	O
	
Future	O
screening	O
policies	O
should	O
give	O
consideration	O
to	O
the	O
age	O
of	O
patients	O
receiving	O
screenings	O
and	O
the	O
system	O
'	O
s	O
patient	O
pool	O
size	O
because	O
our	O
results	O
indicate	O
it	O
is	O
not	O
cost	O
-	O
effective	O
to	O
screen	O
patients	O
aged	B-Characteristic
older	I-Characteristic
than	I-Characteristic
80	I-Characteristic
years	I-Characteristic
or	O
in	O
populations	O
with	O
<	O
3500	O
patients	O
.	O
	
Quantitative	O
measurements	O
of	O
the	O
ciliary	B-Anatomy
body	I-Anatomy
in	O
eyes	B-Anatomy
with	O
malignant	B-Disease
glaucoma	I-Disease
after	O
trabeculectomy	O
using	O
ultrasound	B-Diagnostic_tool
biomicroscopy	I-Diagnostic_tool
.	O
	
To	O
evaluate	O
and	O
compare	O
the	O
structural	O
differences	O
of	O
the	O
ciliary	B-Anatomy
body	I-Anatomy
in	O
eyes	B-Anatomy
with	O
and	O
without	O
malignant	B-Disease
glaucoma	I-Disease
.	O
	
Cross	O
-	O
sectional	O
study	O
.	O
	
Twenty	O
-	O
seven	O
consecutive	O
patients	O
diagnosed	O
with	O
malignant	B-Disease
glaucoma	I-Disease
in	O
1	O
eye	B-Anatomy
after	O
trabeculectomy	O
were	O
recruited	O
.	O
	
They	O
were	O
all	O
originally	O
diagnosed	O
with	O
primary	B-Disease
angle	I-Disease
closure	I-Disease
(	O
PAC	B-Disease
)	O
or	O
PAC	B-Disease
glaucoma	I-Disease
(	O
PACG	B-Disease
)	O
.	O
	
Twenty	O
-	O
seven	O
PAC	B-Disease
/	O
PACG	B-Disease
eyes	B-Anatomy
of	O
27	O
patients	O
who	O
had	O
undergone	O
uneventful	O
trabeculectomy	O
in	O
the	O
same	O
period	O
were	O
also	O
recruited	O
.	O
	
They	O
were	O
comparable	O
with	O
the	O
fellow	O
eyes	B-Anatomy
of	O
the	O
malignant	B-Disease
glaucoma	I-Disease
patients	O
in	O
terms	O
of	O
surgical	O
type	O
,	O
glaucoma	B-Disease
type	O
,	O
and	O
stage	O
.	O
	
A	B-Diagnostic_tool
-	I-Diagnostic_tool
scan	I-Diagnostic_tool
ultrasonography	I-Diagnostic_tool
and	O
ultrasound	B-Diagnostic_tool
biomicroscopy	I-Diagnostic_tool
measurements	O
were	O
performed	O
on	O
the	O
eyes	B-Anatomy
with	O
malignant	B-Disease
glaucoma	I-Disease
,	O
the	O
fellow	O
eyes	B-Anatomy
of	O
the	O
patients	O
with	O
malignant	B-Disease
glaucoma	I-Disease
,	O
and	O
the	O
matched	O
eyes	B-Anatomy
.	O
	
Ciliary	B-Characteristic
body	I-Characteristic
parameters	I-Characteristic
included	O
maximum	B-Characteristic
ciliary	I-Characteristic
body	I-Characteristic
thickness	I-Characteristic
(	O
CBTmax	B-Characteristic
)	O
,	O
ciliary	B-Characteristic
body	I-Characteristic
thickness	I-Characteristic
at	I-Characteristic
the	I-Characteristic
point	I-Characteristic
of	I-Characteristic
the	I-Characteristic
scleral	I-Characteristic
spur	I-Characteristic
(	I-Characteristic
CBT0	I-Characteristic
)	I-Characteristic
and	I-Characteristic
1000	I-Characteristic
	I-Characteristic
m	I-Characteristic
from	I-Characteristic
the	I-Characteristic
scleral	I-Characteristic
spur	I-Characteristic
(	I-Characteristic
CBT1000	I-Characteristic
)	I-Characteristic
,	O
anterior	B-Characteristic
placement	I-Characteristic
of	I-Characteristic
the	I-Characteristic
ciliary	I-Characteristic
body	I-Characteristic
(	O
APCB	B-Characteristic
)	O
,	O
and	O
the	O
trabecular	B-Characteristic
-	I-Characteristic
ciliary	I-Characteristic
process	I-Characteristic
angle	I-Characteristic
(	O
TCA	B-Characteristic
)	O
.	O
	
Biometric	B-Characteristic
measurements	I-Characteristic
including	O
axial	B-Characteristic
length	I-Characteristic
,	O
central	B-Characteristic
anterior	I-Characteristic
chamber	I-Characteristic
depth	I-Characteristic
(	O
ACD	B-Characteristic
)	O
,	O
pupil	B-Characteristic
diameter	I-Characteristic
(	O
PD	B-Characteristic
)	O
,	O
anterior	B-Characteristic
chamber	I-Characteristic
width	I-Characteristic
,	O
and	O
lens	B-Characteristic
vault	I-Characteristic
(	O
LV	B-Characteristic
)	O
were	O
also	O
recorded	O
.	O
	
Average	O
CBTmax	B-Characteristic
were	O
0	O
.	O
545	O
	O
0	O
.	O
088	O
(	O
mean	O
	O
standard	O
deviation	O
)	O
,	O
0	O
.	O
855	O
	O
0	O
.	O
170	O
,	O
and	O
0	O
.	O
960	O
	O
0	O
.	O
127	O
mm	O
in	O
eyes	B-Anatomy
with	O
malignant	B-Disease
glaucoma	I-Disease
,	O
their	O
fellow	O
eyes	B-Anatomy
,	O
and	O
the	O
matched	O
eyes	B-Anatomy
,	O
respectively	O
.	O
	
Average	O
APCB	B-Characteristic
were	O
0	O
.	O
860	O
	O
0	O
.	O
176	O
,	O
0	O
.	O
608	O
	O
0	O
.	O
219	O
,	O
and	O
0	O
.	O
427	O
	O
0	O
.	O
139	O
mm	O
,	O
respectively	O
.	O
	
Average	O
TCA	B-Characteristic
were	O
18	O
.	O
49	O
	O
4	O
.	O
12	O
,	O
41	O
.	O
79	O
	O
17	O
.	O
27	O
,	O
and	O
48	O
.	O
53	O
	O
10	O
.	O
38	O
degrees	O
,	O
respectively	O
.	O
	
The	O
CBTmax	B-Characteristic
,	O
CBT0	B-Characteristic
,	O
CBT1000	B-Characteristic
,	O
and	O
TCA	B-Characteristic
were	O
smaller	O
,	O
whereas	O
APCB	B-Characteristic
was	O
larger	O
in	O
eyes	B-Anatomy
with	O
malignant	B-Disease
glaucoma	I-Disease
compared	O
with	O
their	O
fellow	O
eyes	B-Anatomy
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
	
The	O
fellow	O
eyes	B-Anatomy
had	O
larger	O
APCB	B-Characteristic
and	O
smaller	O
CBTmax	B-Characteristic
and	O
CBT0	B-Characteristic
than	O
the	O
matched	O
eyes	B-Anatomy
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
The	O
ACD	B-Characteristic
,	O
anterior	B-Characteristic
chamber	I-Characteristic
width	I-Characteristic
,	O
and	O
PD	B-Characteristic
were	O
smaller	O
,	O
whereas	O
LV	B-Characteristic
was	O
larger	O
in	O
eyes	B-Anatomy
with	O
malignant	B-Disease
glaucoma	I-Disease
compared	O
with	O
their	O
fellow	O
eyes	B-Anatomy
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
No	O
differences	O
were	O
found	O
in	O
the	O
ACD	B-Characteristic
,	O
anterior	B-Characteristic
chamber	I-Characteristic
width	I-Characteristic
,	O
PD	B-Characteristic
,	O
or	O
LV	B-Characteristic
between	O
the	O
fellow	O
eyes	B-Anatomy
of	O
malignant	B-Disease
glaucoma	I-Disease
and	O
matched	O
eyes	B-Anatomy
(	O
P	O
>	O
0	O
.	O
1	O
)	O
.	O
	
The	O
ciliary	B-Symptom
bodies	I-Symptom
were	I-Symptom
thinner	I-Symptom
and	I-Symptom
more	I-Symptom
anteriorly	I-Symptom
rotated	I-Symptom
in	O
eyes	B-Anatomy
with	O
malignant	B-Disease
glaucoma	I-Disease
as	O
well	O
as	O
in	O
their	O
fellow	O
eyes	B-Anatomy
,	O
which	O
may	O
be	O
the	O
predisposing	O
factor	O
for	O
malignant	B-Disease
glaucoma	I-Disease
.	O
	
Predicting	O
adherence	O
to	O
diabetic	B-Disease
eye	B-Anatomy
examinations	O
:	O
development	O
of	O
the	O
compliance	O
withAnnual	B-Classification_system
Diabetic	I-Classification_system
Eye	I-Classification_system
Exams	I-Classification_system
Survey	I-Classification_system
.	O
	
To	O
identify	O
variables	O
that	O
predict	O
adherence	O
with	O
annual	O
eye	B-Anatomy
examinations	O
using	O
the	O
Compliance	O
with	O
Annual	B-Classification_system
Diabetic	I-Classification_system
Eye	I-Classification_system
Exams	I-Classification_system
Survey	I-Classification_system
(	O
CADEES	B-Classification_system
)	O
,	O
a	O
new	O
questionnaire	O
designed	O
to	O
measure	O
health	O
beliefs	O
related	O
to	O
diabetic	B-Disease
retinopathy	I-Disease
and	O
annual	O
eye	B-Anatomy
examinations	O
.	O
	
Questionnaire	O
development	O
.	O
	
Three	O
hundred	O
sixteen	O
adults	B-Characteristic
with	O
diabetes	B-Disease
.	O
	
We	O
developed	O
the	O
CADEES	B-Classification_system
based	O
on	O
a	O
review	O
of	O
the	O
literature	O
,	O
the	O
framework	O
of	O
the	O
Health	O
Belief	O
Model	O
,	O
expert	O
opinion	O
,	O
and	O
pilot	O
study	O
data	O
.	O
	
To	O
examine	O
content	O
validity	O
,	O
we	O
analyzed	O
participant	O
responses	O
to	O
an	O
open	O
-	O
ended	O
question	O
asking	O
for	O
reasons	O
why	O
people	O
do	O
not	O
obtain	O
annual	O
eye	B-Anatomy
examinations	O
.	O
	
We	O
evaluated	O
construct	O
validity	O
with	O
principal	O
components	O
analysis	O
and	O
examined	O
internal	O
consistency	O
with	O
Cronbach	O
'	O
s	O
	O
.	O
	
To	O
assess	O
predictive	O
validity	O
,	O
we	O
used	O
multivariate	O
logistic	O
regression	O
with	O
self	O
-	O
reported	O
adherence	O
as	O
the	O
dependent	O
variable	O
.	O
	
Associations	O
with	O
self	O
-	O
reported	O
adherence	O
(	O
defined	O
as	O
having	O
a	O
dilated	O
eye	B-Anatomy
examination	O
in	O
the	O
past	O
year	O
)	O
.	O
	
The	O
content	O
analysis	O
showed	O
that	O
CADEES	B-Classification_system
items	O
covered	O
89	O
%	O
of	O
the	O
reasons	O
given	O
by	O
participants	O
for	O
not	O
obtaining	O
an	O
annual	O
eye	B-Anatomy
examination	O
.	O
	
The	O
principal	O
components	O
analysis	O
identified	O
3	O
informative	O
components	O
that	O
made	O
up	O
32	O
%	O
of	O
the	O
variance	O
.	O
	
Multivariate	O
logistic	O
regression	O
modeling	O
revealed	O
several	O
significant	O
predictors	O
of	O
adherence	O
,	O
including	O
beliefs	O
concerning	O
whether	O
insurance	O
covered	O
most	O
of	O
the	O
eye	B-Anatomy
examination	O
cost	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
whether	O
there	O
were	O
general	O
barriers	O
that	O
make	O
it	O
difficult	O
to	O
obtain	O
an	O
eye	B-Anatomy
examination	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
whether	O
obtaining	O
an	O
eye	B-Anatomy
examination	O
was	O
a	O
top	O
priority	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
and	O
whether	O
diabetic	B-Disease
eye	I-Disease
disease	I-Disease
can	O
be	O
seen	O
with	O
an	O
examination	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O
	
Lower	B-Characteristic
hemoglobin	I-Characteristic
A1c	I-Characteristic
levels	I-Characteristic
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
having	O
insurance	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
a	O
longer	O
duration	B-Characteristic
of	I-Characteristic
diabetes	I-Characteristic
(	O
P	O
=	O
0	O
.	O
02	O
)	O
also	O
were	O
associated	O
with	O
adherence	O
.	O
	
A	O
multivariate	O
model	O
containing	O
CADEES	B-Classification_system
items	O
and	O
demographic	O
variables	O
classified	O
cases	O
with	O
72	O
%	O
accuracy	O
and	O
explained	O
approximately	O
24	O
%	O
of	O
the	O
variance	O
in	O
adherence	O
.	O
	
The	O
CADEES	B-Classification_system
showed	O
good	O
content	O
and	O
predictive	O
validity	O
.	O
	
Although	O
additional	O
research	O
is	O
needed	O
before	O
finalizing	O
a	O
shorter	O
version	O
of	O
the	O
survey	O
,	O
our	O
findings	O
suggest	O
that	O
researchers	O
and	O
clinicians	O
may	O
be	O
able	O
to	O
improve	O
adherence	O
by	O
(	O
1	O
)	O
counseling	O
newly	O
diagnosed	O
patients	O
,	O
as	O
well	O
as	O
those	O
with	O
uncontrolled	B-Characteristic
blood	I-Characteristic
glucose	I-Characteristic
,	O
on	O
the	O
importance	O
of	O
annual	O
eye	B-Anatomy
examinations	O
and	O
(	O
2	O
)	O
discussing	O
perceived	O
barriers	O
and	O
misconceptions	O
.	O
	
Quantitative	O
assessment	O
of	O
retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
defect	I-Characteristic
depth	I-Characteristic
using	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
.	O
	
To	O
assess	O
quantitatively	O
the	O
depth	O
of	O
retinal	B-Symptom
nerve	I-Symptom
fiber	I-Symptom
layer	I-Symptom
(	I-Symptom
RNFL	I-Symptom
)	I-Symptom
defects	I-Symptom
using	O
a	O
Cirrus	B-Diagnostic_tool
high	I-Diagnostic_tool
-	I-Diagnostic_tool
definition	I-Diagnostic_tool
(	I-Diagnostic_tool
HD	I-Diagnostic_tool
)	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	I-Diagnostic_tool
-	I-Diagnostic_tool
derived	I-Diagnostic_tool
RNFL	I-Diagnostic_tool
thickness	I-Diagnostic_tool
deviation	I-Diagnostic_tool
map	I-Diagnostic_tool
.	O
	
Prospective	O
,	O
cross	O
-	O
sectional	O
study	O
.	O
	
Three	O
-	O
hundred	O
fifteen	O
eyes	B-Anatomy
with	O
localized	O
and	O
diffuse	O
RNFL	B-Symptom
defects	I-Symptom
of	O
315	O
glaucoma	B-Disease
patients	O
and	O
217	O
eyes	B-Anatomy
of	O
217	O
healthy	O
subjects	O
.	O
	
For	O
the	O
glaucoma	B-Disease
subjects	O
,	O
the	O
severity	O
of	O
the	O
RNFL	B-Symptom
defect	I-Symptom
was	O
graded	O
on	O
red	B-Diagnostic_tool
-	I-Diagnostic_tool
free	I-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
by	O
2	O
observers	O
using	O
a	O
standardized	O
protocol	O
with	O
a	O
3	O
-	O
level	O
grading	O
system	O
.	O
	
The	O
RNFL	B-Characteristic
defect	I-Characteristic
depth	I-Characteristic
on	O
the	O
RNFL	B-Diagnostic_tool
thickness	I-Diagnostic_tool
deviation	I-Diagnostic_tool
map	I-Diagnostic_tool
was	O
expressed	O
as	O
an	O
RNFL	B-Characteristic
defect	I-Characteristic
depth	I-Characteristic
percentage	I-Characteristic
index	I-Characteristic
(	O
RDPI	B-Characteristic
)	O
:	O
100	O
	O
(	O
1	O
-	O
[	O
summation	O
of	O
thicknesses	B-Characteristic
of	I-Characteristic
RNFL	I-Characteristic
defects	I-Characteristic
{	O
red	O
or	O
yellow	O
superpixels	O
}	O
/	O
summation	O
of	O
RNFL	B-Characteristic
thicknesses	I-Characteristic
of	O
upper	O
95th	O
percentile	O
range	O
of	O
age	B-Characteristic
-	I-Characteristic
matched	I-Characteristic
healthy	I-Characteristic
subjects	O
in	O
areas	O
corresponding	O
to	O
RNFL	B-Symptom
defects	I-Symptom
]	O
)	O
.	O
	
Retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
defect	I-Characteristic
depth	I-Characteristic
percentage	I-Characteristic
index	I-Characteristic
,	O
average	B-Characteristic
and	I-Characteristic
segmental	I-Characteristic
(	I-Characteristic
4	I-Characteristic
quadrants	I-Characteristic
and	I-Characteristic
12	I-Characteristic
clock	I-Characteristic
-	I-Characteristic
hour	I-Characteristic
sectors	I-Characteristic
)	I-Characteristic
circumpapillary	I-Characteristic
RNFL	I-Characteristic
(	I-Characteristic
cpRNFL	I-Characteristic
)	I-Characteristic
thicknesses	I-Characteristic
according	O
to	O
the	O
RNFL	B-Symptom
defect	I-Symptom
severity	O
,	O
and	O
the	O
area	B-Characteristic
under	I-Characteristic
the	I-Characteristic
receiver	I-Characteristic
operating	I-Characteristic
characteristic	I-Characteristic
curves	I-Characteristic
(	O
AUROCs	B-Characteristic
)	O
for	O
various	O
OCT	B-Diagnostic_tool
parameters	O
.	O
	
The	O
RDPIs	B-Characteristic
increased	O
with	O
the	O
increasing	O
severity	O
of	O
the	O
RNFL	B-Symptom
defect	I-Symptom
in	O
both	O
the	O
superior	B-Anatomy
and	I-Anatomy
inferior	I-Anatomy
hemifields	I-Anatomy
(	O
P	O
<	O
0	O
.	O
05	O
,	O
1	O
-	O
way	O
analysis	O
of	O
variance	O
test	O
with	O
Bonferroni	O
correction	O
)	O
.	O
	
The	O
AUROCs	B-Characteristic
of	O
the	O
RDPIs	B-Characteristic
(	O
0	O
.	O
969	O
and	O
0	O
.	O
975	O
in	O
the	O
superior	O
and	O
inferior	O
hemifields	O
,	O
respectively	O
)	O
were	O
larger	O
than	O
those	O
of	O
all	O
of	O
the	O
cpRNFL	B-Characteristic
thicknesses	I-Characteristic
in	O
discriminating	O
the	O
mild	B-Symptom
from	I-Symptom
the	I-Symptom
moderate	I-Symptom
RNFL	I-Symptom
defects	I-Symptom
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
Meanwhile	O
,	O
in	O
discriminating	O
the	O
moderate	B-Symptom
from	I-Symptom
the	I-Symptom
severe	I-Symptom
RNFL	I-Symptom
defects	I-Symptom
,	O
the	O
AUROCs	B-Characteristic
of	O
the	O
RDPIs	B-Characteristic
(	O
0	O
.	O
961	O
and	O
0	O
.	O
891	O
in	O
the	O
superior	O
and	O
inferior	O
hemifields	O
,	O
respectively	O
)	O
were	O
larger	O
than	O
those	O
of	O
the	O
cpRNFL	B-Characteristic
thicknesses	I-Characteristic
in	O
all	O
areas	O
except	O
the	O
inferior	B-Anatomy
quadrant	I-Anatomy
and	O
the	O
6	O
-	O
,	O
7	O
-	O
,	O
and	O
11	O
-	O
o	O
'	O
clock	O
sectors	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
The	O
RDPI	B-Characteristic
,	O
a	O
new	O
parameter	O
using	O
a	O
Cirrus	B-Diagnostic_tool
HD	I-Diagnostic_tool
OCT	I-Diagnostic_tool
-	I-Diagnostic_tool
derived	I-Diagnostic_tool
RNFL	I-Diagnostic_tool
thickness	I-Diagnostic_tool
deviation	I-Diagnostic_tool
map	I-Diagnostic_tool
,	O
can	O
be	O
a	O
useful	O
adjunct	O
tool	O
for	O
objective	O
quantification	O
of	O
RNFL	B-Characteristic
defect	I-Characteristic
depth	I-Characteristic
.	O
	
This	O
parameter	O
has	O
an	O
advantage	O
over	O
cpRNFL	B-Characteristic
thickness	I-Characteristic
in	O
discriminating	O
between	O
mild	B-Symptom
and	I-Symptom
moderate	I-Symptom
RNFL	I-Symptom
defects	I-Symptom
,	O
not	O
in	O
discriminating	O
between	O
moderate	B-Symptom
and	I-Symptom
severe	I-Symptom
defects	I-Symptom
.	O
	
A	O
risk	O
score	O
for	O
the	O
prediction	O
of	O
advanced	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
:	O
development	O
and	O
validation	O
in	O
2	O
prospective	O
cohorts	O
.	O
	
To	O
develop	O
a	O
clinical	O
eye	O
-	O
specific	O
prediction	O
model	O
for	O
advanced	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
	
The	O
Age	B-Classification_system
-	I-Classification_system
Related	I-Classification_system
Eye	I-Classification_system
Disease	I-Classification_system
Study	I-Classification_system
(	O
AREDS	B-Classification_system
)	O
cohort	O
followed	O
up	O
for	O
8	O
years	O
served	O
as	O
the	O
training	O
dataset	O
,	O
and	O
the	O
Blue	O
Mountains	O
Eye	B-Anatomy
Study	O
(	O
BMES	O
)	O
cohort	O
followed	O
up	O
for	O
10	O
years	O
served	O
as	O
the	O
validation	O
dataset	O
.	O
	
A	O
total	O
of	O
4507	O
AREDS	B-Classification_system
participants	O
(	O
contributing	O
1185	O
affected	O
vs	O
.	O
6992	O
unaffected	O
eyes	B-Anatomy
)	O
and	O
2169	O
BMES	O
participants	O
(	O
contributing	O
69	O
affected	O
vs	O
.	O
3694	O
unaffected	O
eyes	B-Anatomy
)	O
.	O
	
Using	O
Bayes	B-Diagnostic_tool
'	I-Diagnostic_tool
theorem	I-Diagnostic_tool
in	I-Diagnostic_tool
a	I-Diagnostic_tool
logistic	I-Diagnostic_tool
model	I-Diagnostic_tool
,	O
we	O
used	O
8	O
baseline	O
predictors	O
-	O
age	B-Characteristic
,	O
sex	B-Characteristic
,	O
education	B-Characteristic
level	I-Characteristic
,	O
race	B-Characteristic
,	O
smoking	B-Characteristic
status	I-Characteristic
,	O
and	O
presence	B-Symptom
of	I-Symptom
pigment	I-Symptom
abnormality	I-Symptom
,	O
soft	B-Symptom
drusen	I-Symptom
,	O
and	O
maximum	B-Characteristic
drusen	I-Characteristic
size	I-Characteristic
-	O
to	O
devise	O
and	O
validate	O
a	O
macular	B-Classification_system
risk	I-Classification_system
scoring	I-Classification_system
system	I-Classification_system
(	O
MRSS	B-Classification_system
)	O
.	O
	
We	O
assessed	O
the	O
performance	O
of	O
the	O
MRSS	B-Classification_system
by	O
calculating	O
sensitivity	O
,	O
specificity	O
,	O
and	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
i	O
.	O
e	O
.	O
,	O
c	O
-	O
index	O
)	O
.	O
	
Advanced	B-Disease
AMD	I-Disease
.	O
	
The	O
internally	O
validated	O
c	O
-	O
indexAREDS	O
(	O
0	O
.	O
88	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
87	O
-	O
0	O
.	O
89	O
)	O
and	O
the	O
externally	O
validated	O
c	O
-	O
indexBMES	O
(	O
0	O
.	O
91	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
88	O
-	O
0	O
.	O
95	O
)	O
suggested	O
excellent	O
performance	O
of	O
the	O
MRSS	B-Classification_system
.	O
	
The	O
sensitivity	O
and	O
specificity	O
at	O
the	O
optimal	O
macular	B-Characteristic
risk	I-Characteristic
score	I-Characteristic
cutoff	O
point	O
of	O
0	O
were	O
87	O
.	O
6	O
%	O
and	O
73	O
.	O
6	O
%	O
,	O
respectively	O
.	O
	
An	O
application	O
for	O
the	O
iPhone	O
and	O
iPad	O
also	O
was	O
developed	O
as	O
a	O
practical	O
tool	O
for	O
the	O
MRSS	B-Classification_system
.	O
	
The	O
MRSS	B-Classification_system
was	O
developed	O
and	O
validated	O
to	O
provide	O
satisfactory	O
accuracy	O
and	O
generalizability	O
.	O
	
It	O
may	O
be	O
used	O
to	O
screen	O
patients	O
at	O
risk	O
of	O
developing	O
advanced	B-Disease
AMD	I-Disease
.	O
	
Macular	B-Diagnostic_tool
ganglion	I-Diagnostic_tool
cell	I-Diagnostic_tool
analysis	I-Diagnostic_tool
for	O
early	O
detection	O
of	O
glaucoma	B-Disease
.	O
	
To	O
investigate	O
the	O
ability	O
of	O
Cirrus	B-Diagnostic_tool
high	I-Diagnostic_tool
-	I-Diagnostic_tool
definition	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
Cirrus	B-Diagnostic_tool
HD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
;	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
)	O
macular	B-Diagnostic_tool
ganglion	I-Diagnostic_tool
cell	I-Diagnostic_tool
analysis	I-Diagnostic_tool
(	O
GCA	B-Diagnostic_tool
)	O
sector	O
,	O
deviation	O
,	O
and	O
thickness	O
maps	O
to	O
detect	O
early	B-Disease
glaucoma	I-Disease
.	O
	
Cross	O
-	O
sectional	O
study	O
.	O
	
We	O
enrolled	O
131	O
eyes	B-Anatomy
with	O
early	B-Disease
glaucoma	I-Disease
(	O
mean	O
deviation	O
>	O
-	O
6	O
.	O
0	O
dB	O
)	O
and	O
132	O
age	B-Characteristic
-	I-Characteristic
and	I-Characteristic
refractive	I-Characteristic
error	I-Characteristic
-	I-Characteristic
matched	I-Characteristic
healthy	I-Characteristic
eyes	I-Characteristic
.	O
	
Macular	B-Diagnostic_tool
GCA	I-Diagnostic_tool
maps	I-Diagnostic_tool
were	O
obtained	O
using	O
Cirrus	B-Diagnostic_tool
HD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
.	O
	
The	O
location	O
,	O
angular	O
distance	O
,	O
and	O
width	O
of	O
circumpapillary	B-Symptom
retinal	I-Symptom
nerve	I-Symptom
fiber	I-Symptom
layer	I-Symptom
(	I-Symptom
RNFL	I-Symptom
)	I-Symptom
defects	I-Symptom
were	O
investigated	O
by	O
using	O
red	B-Diagnostic_tool
-	I-Diagnostic_tool
free	I-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
.	O
	
The	O
presence	O
of	O
a	O
structural	B-Symptom
abnormality	I-Symptom
in	O
the	O
GCA	B-Diagnostic_tool
map	I-Diagnostic_tool
was	O
defined	O
as	O
(	O
1	O
)	O
yellow	O
/	O
red	O
color	O
codes	O
in	O
the	O
sector	O
map	O
,	O
(	O
2	O
)	O
yellow	O
/	O
red	O
pixels	O
(	O
>	O
10	O
)	O
in	O
the	O
deviation	O
map	O
,	O
and	O
(	O
3	O
)	O
blue	O
areas	O
in	O
the	O
thickness	O
map	O
.	O
	
The	O
prevalence	O
of	O
and	O
factors	O
associated	O
with	O
the	O
presence	O
or	O
absence	O
of	O
abnormal	B-Symptom
GCA	I-Symptom
findings	O
were	O
assessed	O
.	O
	
Among	O
the	O
131	O
glaucomatous	B-Disease
eyes	B-Anatomy
,	O
105	O
(	O
80	O
.	O
2	O
%	O
)	O
,	O
115	O
(	O
87	O
.	O
8	O
%	O
)	O
,	O
and	O
104	O
(	O
79	O
.	O
4	O
%	O
)	O
showed	O
structural	B-Symptom
abnormalities	I-Symptom
in	O
the	O
GCA	B-Diagnostic_tool
sector	O
,	O
deviation	O
,	O
and	O
thickness	O
maps	O
,	O
respectively	O
.	O
	
The	O
absence	O
of	O
abnormal	B-Symptom
findings	I-Symptom
in	O
the	O
GCA	B-Diagnostic_tool
maps	I-Diagnostic_tool
of	O
glaucomatous	B-Disease
eyes	B-Anatomy
was	O
associated	O
with	O
the	O
presence	O
of	O
RNFL	B-Symptom
defects	I-Symptom
in	I-Symptom
the	I-Symptom
superior	I-Symptom
hemisphere	I-Symptom
,	O
a	O
greater	O
angular	B-Symptom
distance	I-Symptom
between	I-Symptom
the	I-Symptom
fovea	I-Symptom
and	O
the	O
RNFL	B-Symptom
defect	I-Symptom
,	O
a	O
narrower	B-Symptom
width	I-Symptom
of	I-Symptom
the	I-Symptom
RNFL	I-Symptom
defect	I-Symptom
,	O
less	B-Symptom
severe	I-Symptom
visual	I-Symptom
field	I-Symptom
defects	I-Symptom
,	O
or	O
an	O
isolated	B-Symptom
peripheral	I-Symptom
nasal	I-Symptom
step	I-Symptom
(	O
outside	O
10	O
degrees	O
of	O
fixation	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
A	O
greater	O
angular	B-Symptom
distance	I-Symptom
of	I-Symptom
the	I-Symptom
RNFL	I-Symptom
defect	I-Symptom
remained	O
significant	O
in	O
multivariate	O
analyses	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
Among	O
the	O
132	O
healthy	O
eyes	B-Anatomy
,	O
28	O
(	O
21	O
.	O
2	O
%	O
)	O
,	O
37	O
(	O
28	O
.	O
0	O
%	O
)	O
,	O
and	O
20	O
(	O
15	O
.	O
2	O
%	O
)	O
had	O
abnormal	O
findings	O
in	O
the	O
GCA	B-Diagnostic_tool
sector	O
,	O
deviation	O
,	O
and	O
thickness	O
maps	O
,	O
respectively	O
.	O
	
The	O
presence	O
of	O
abnormal	B-Symptom
GCA	I-Symptom
findings	I-Symptom
in	O
healthy	O
eyes	B-Anatomy
was	O
associated	O
with	O
a	O
higher	O
degree	O
of	O
myopic	B-Characteristic
refractive	I-Characteristic
error	I-Characteristic
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
Cirrus	B-Diagnostic_tool
HD	I-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
GCA	I-Diagnostic_tool
maps	I-Diagnostic_tool
showed	O
a	O
good	O
ability	O
to	O
detect	O
early	B-Disease
glaucoma	I-Disease
.	O
	
However	O
,	O
GCA	B-Diagnostic_tool
maps	I-Diagnostic_tool
did	O
not	O
show	O
abnormal	O
findings	O
in	O
glaucomatous	B-Disease
eyes	B-Anatomy
when	O
the	O
angular	B-Symptom
distance	I-Symptom
between	I-Symptom
fovea	I-Symptom
and	I-Symptom
RNFL	I-Symptom
defect	I-Symptom
was	I-Symptom
great	I-Symptom
.	O
	
These	O
findings	O
should	O
be	O
considered	O
when	O
diagnosing	O
early	B-Disease
glaucoma	I-Disease
using	O
GCA	B-Diagnostic_tool
maps	I-Diagnostic_tool
.	O
	
Visual	B-Characteristic
field	I-Characteristic
progression	I-Characteristic
in	O
glaucoma	B-Disease
:	O
what	O
is	O
the	O
specificity	O
of	O
the	O
Guided	B-Diagnostic_tool
Progression	I-Diagnostic_tool
Analysis	I-Diagnostic_tool
?	O
	
To	O
estimate	O
the	O
specificity	O
of	O
the	O
Guided	B-Diagnostic_tool
Progression	I-Diagnostic_tool
Analysis	I-Diagnostic_tool
(	O
GPA	B-Diagnostic_tool
)	O
(	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
)	O
in	O
individual	O
patients	O
with	O
glaucoma	B-Disease
.	O
	
Observational	O
cohort	O
study	O
.	O
	
Thirty	O
patients	O
with	O
open	B-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
.	O
	
In	O
30	O
patients	O
with	O
open	B-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
,	O
1	O
eye	B-Anatomy
(	O
median	O
mean	O
deviation	O
[	O
MD	O
]	O
,	O
-	O
2	O
.	O
5	O
decibels	O
[	O
dB	O
]	O
;	O
interquartile	O
range	O
,	O
-	O
4	O
.	O
4	O
to	O
-	O
1	O
.	O
3	O
dB	O
)	O
was	O
tested	O
12	O
times	O
over	O
3	O
months	O
(	O
Humphrey	B-Diagnostic_tool
Field	I-Diagnostic_tool
Analyzer	I-Diagnostic_tool
,	O
Carl	O
Zeiss	O
Meditec	O
;	O
SITA	O
Standard	O
,	O
24	O
-	O
2	O
)	O
.	O
	
"	O
Possible	O
progression	O
"	O
and	O
"	O
likely	O
progression	O
"	O
were	O
determined	O
with	O
the	O
GPA	B-Diagnostic_tool
.	O
	
These	O
analyses	O
were	O
repeated	O
after	O
the	O
order	O
of	O
the	O
tests	O
had	O
been	O
randomly	O
rearranged	O
(	O
1000	O
unique	O
permutations	O
)	O
.	O
	
Rate	O
of	O
false	O
-	O
positive	O
alerts	O
of	O
"	O
possible	O
progression	O
"	O
and	O
"	O
likely	O
progression	O
"	O
with	O
the	O
GPA	B-Diagnostic_tool
.	O
	
On	O
average	O
,	O
the	O
specificity	O
of	O
the	O
GPA	B-Diagnostic_tool
"	O
likely	O
progression	O
"	O
alert	O
was	O
high	O
-	O
for	O
the	O
entire	O
sample	O
,	O
the	O
mean	O
rate	O
of	O
false	O
-	O
positive	O
alerts	O
after	O
10	O
follow	O
-	O
up	O
tests	O
was	O
2	O
.	O
6	O
%	O
.	O
	
With	O
"	O
possible	O
progression	O
,	O
"	O
the	O
specificity	O
was	O
considerably	O
lower	O
(	O
false	O
-	O
positive	O
rate	O
,	O
18	O
.	O
5	O
%	O
)	O
.	O
	
Most	O
important	O
,	O
the	O
cumulative	O
rate	O
of	O
false	O
-	O
positive	O
alerts	O
varied	O
substantially	O
among	O
patients	O
,	O
from	O
<	O
1	O
%	O
to	O
80	O
%	O
with	O
"	O
possible	O
progression	O
"	O
and	O
from	O
<	O
0	O
.	O
1	O
%	O
to	O
20	O
%	O
with	O
"	O
likely	O
progression	O
.	O
	
"	O
Factors	O
associated	O
with	O
false	O
-	O
positive	O
alerts	O
were	O
visual	B-Characteristic
field	I-Characteristic
variability	I-Characteristic
(	O
standard	O
deviation	O
of	O
MD	O
,	O
Spearman	O
'	O
s	O
rho	O
=	O
0	O
.	O
41	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
the	O
reliability	O
indices	O
(	O
proportion	O
of	O
false	O
-	O
positive	O
and	O
false	O
-	O
negative	O
responses	O
,	O
fixation	O
losses	O
,	O
rho	O
>	O
0	O
.	O
31	O
,	O
P	O
	O
0	O
.	O
10	O
)	O
.	O
	
On	O
average	O
,	O
progression	O
criteria	O
currently	O
used	O
in	O
the	O
GPA	B-Diagnostic_tool
have	O
high	O
specificity	O
,	O
but	O
some	O
patients	O
are	O
more	O
likely	O
to	O
show	O
false	O
-	O
positive	O
alerts	O
than	O
others	O
.	O
	
This	O
is	O
a	O
natural	O
consequence	O
of	O
population	O
-	O
based	O
change	O
criteria	O
and	O
may	O
not	O
matter	O
in	O
clinical	O
trials	O
and	O
studies	O
in	O
which	O
large	O
groups	O
of	O
patients	O
are	O
compared	O
.	O
	
However	O
,	O
it	O
must	O
be	O
considered	O
when	O
the	O
GPA	B-Diagnostic_tool
is	O
used	O
in	O
clinical	O
practice	O
where	O
specificity	O
needs	O
to	O
be	O
controlled	O
for	O
individual	O
patients	O
.	O
	
Dominant	B-Disease
cystoid	I-Disease
macular	I-Disease
dystrophy	I-Disease
.	O
	
To	O
describe	O
the	O
clinical	O
characteristics	O
and	O
long	O
-	O
term	O
follow	O
-	O
up	O
in	O
patients	O
with	O
autosomal	B-Disease
dominant	I-Disease
cystoid	I-Disease
macular	I-Disease
dystrophy	I-Disease
(	O
DCMD	B-Disease
)	O
.	O
	
Retrospective	O
case	O
series	O
.	O
	
Ninety	O
-	O
seven	O
patients	O
with	O
DCMD	B-Disease
.	O
	
Extensive	O
ophthalmic	O
examination	O
,	O
including	O
visual	B-Characteristic
acuity	I-Characteristic
(	O
VA	B-Characteristic
)	O
,	O
fundus	B-Diagnostic_tool
photography	I-Diagnostic_tool
,	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
FA	B-Diagnostic_tool
)	O
,	O
fundus	B-Diagnostic_tool
autofluorescence	I-Diagnostic_tool
(	I-Diagnostic_tool
FAF	I-Diagnostic_tool
)	I-Diagnostic_tool
imaging	I-Diagnostic_tool
,	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
,	O
color	B-Diagnostic_tool
vision	I-Diagnostic_tool
testing	I-Diagnostic_tool
,	O
dark	B-Diagnostic_tool
adaptation	I-Diagnostic_tool
testing	I-Diagnostic_tool
,	O
full	B-Diagnostic_tool
-	I-Diagnostic_tool
field	I-Diagnostic_tool
electroretinography	I-Diagnostic_tool
(	O
ERG	B-Diagnostic_tool
)	O
,	O
and	O
electro	B-Diagnostic_tool
-	I-Diagnostic_tool
oculography	I-Diagnostic_tool
(	O
EOG	B-Diagnostic_tool
)	O
.	O
	
Blood	O
samples	O
were	O
obtained	O
for	O
DNA	O
extraction	O
and	O
subsequent	O
haplotype	B-Diagnostic_tool
analysis	I-Diagnostic_tool
.	O
	
Age	B-Characteristic
at	I-Characteristic
onset	I-Characteristic
,	O
VA	B-Characteristic
,	O
fundus	B-Characteristic
appearance	I-Characteristic
,	O
and	O
characteristics	O
on	O
FA	B-Diagnostic_tool
,	O
FAF	B-Diagnostic_tool
,	O
OCT	B-Diagnostic_tool
,	O
ERG	B-Diagnostic_tool
,	O
and	O
EOG	B-Diagnostic_tool
.	O
	
Cystoid	B-Symptom
fluid	I-Symptom
collections	I-Symptom
(	O
CFCs	B-Symptom
)	O
were	O
the	O
first	O
retinal	B-Symptom
abnormalities	I-Symptom
detectable	O
in	O
DCMD	B-Disease
,	O
developing	O
during	O
childhood	B-Characteristic
.	O
	
At	O
long	O
-	O
term	O
follow	O
-	O
up	O
,	O
the	O
CFCs	B-Symptom
decreased	O
in	O
size	O
and	O
number	O
,	O
and	O
eventually	O
disappeared	O
with	O
concurrent	O
development	O
of	O
progressive	B-Symptom
chorioretinal	I-Symptom
atrophy	I-Symptom
and	O
hyperpigmented	B-Symptom
deposits	I-Symptom
in	I-Symptom
the	I-Symptom
posterior	I-Symptom
pole	I-Symptom
.	O
	
Dominant	B-Disease
cystoid	I-Disease
macular	I-Disease
dystrophy	I-Disease
could	O
be	O
classified	O
into	O
3	O
stages	O
,	O
based	O
on	O
characteristics	O
on	O
ophthalmoscopy	B-Diagnostic_tool
,	O
FAF	B-Diagnostic_tool
,	O
FA	B-Diagnostic_tool
,	O
and	O
OCT	B-Diagnostic_tool
,	O
as	O
well	O
as	O
on	O
results	O
of	O
electrophysiologic	B-Diagnostic_tool
analysis	I-Diagnostic_tool
.	O
	
The	O
staging	O
system	O
correlated	O
with	O
age	B-Characteristic
and	O
VA	B-Characteristic
.	O
	
In	O
stage	B-Disease
1	I-Disease
DCMD	I-Disease
(	O
20	O
patients	O
;	O
22	O
%	O
)	O
,	O
patients	O
generally	O
were	O
younger	B-Characteristic
than	I-Characteristic
20	I-Characteristic
years	I-Characteristic
and	O
had	O
CFCs	B-Symptom
with	I-Symptom
fine	I-Symptom
folding	I-Symptom
of	I-Symptom
the	I-Symptom
internal	I-Symptom
limiting	I-Symptom
membrane	I-Symptom
and	O
mild	B-Symptom
pigment	I-Symptom
changes	I-Symptom
.	O
	
In	O
stage	B-Disease
2	I-Disease
DCMD	I-Disease
(	O
48	O
patients	O
;	O
52	O
%	O
)	O
,	O
the	O
CFCs	B-Symptom
tended	O
to	O
decrease	O
in	O
size	O
,	O
and	O
moderate	B-Symptom
macular	I-Symptom
chorioretinal	I-Symptom
atrophy	I-Symptom
developed	O
.	O
	
Patients	O
with	O
stage	B-Disease
3	I-Disease
DCMD	I-Disease
(	O
24	O
patients	O
;	O
26	O
%	O
)	O
generally	O
were	O
older	B-Characteristic
than	I-Characteristic
50	I-Characteristic
years	I-Characteristic
and	O
showed	O
profound	B-Symptom
chorioretinal	I-Symptom
atrophy	I-Symptom
,	O
as	O
well	O
as	O
coarse	B-Symptom
hyperpigmented	I-Symptom
deposits	I-Symptom
in	I-Symptom
the	I-Symptom
posterior	I-Symptom
pole	I-Symptom
.	O
	
Most	O
patients	O
were	O
(	O
highly	O
)	O
hyperopic	B-Symptom
(	O
72	O
patients	O
;	O
92	O
%	O
)	O
.	O
	
All	O
DCMD	B-Disease
patients	O
shared	O
the	O
disease	O
haplotype	B-Characteristic
at	I-Characteristic
the	I-Characteristic
DCMD	I-Characteristic
locus	I-Characteristic
at	I-Characteristic
7p15	I-Characteristic
.	I-Characteristic
3	I-Characteristic
.	O
	
Dominant	B-Disease
cystoid	I-Disease
macular	I-Disease
dystrophy	I-Disease
is	O
a	O
progressive	B-Disease
retinal	I-Disease
dystrophy	I-Disease
,	O
characterized	O
primarily	O
by	O
early	B-Symptom
-	I-Symptom
onset	I-Symptom
cystoid	I-Symptom
fluid	I-Symptom
collections	I-Symptom
in	I-Symptom
the	I-Symptom
neuroretina	I-Symptom
,	O
which	O
distinguishes	O
this	O
disorder	O
from	O
other	O
retinal	B-Disease
dystrophies	I-Disease
.	O
	
The	O
phenotypic	O
range	O
of	O
DCMD	B-Disease
can	O
be	O
classified	O
into	O
3	O
stages	O
.	O
	
The	O
genetic	O
locus	O
for	O
this	O
retinal	B-Disease
dystrophy	I-Disease
has	O
been	O
mapped	O
to	O
7p15	O
.	O
3	O
,	O
but	O
the	O
involved	O
gene	O
is	O
currently	O
unknown	O
.	O
	
Poorer	B-Symptom
neurodevelopmental	I-Symptom
outcomes	I-Symptom
associated	O
with	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
identified	O
in	O
preterm	B-Characteristic
infants	I-Characteristic
in	O
the	O
intensive	O
care	O
nursery	O
.	O
	
To	O
evaluate	O
the	O
association	O
between	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
(	O
CME	B-Disease
)	O
observed	O
in	O
very	B-Characteristic
preterm	I-Characteristic
infants	I-Characteristic
and	O
developmental	O
outcomes	O
at	O
18	B-Characteristic
to	I-Characteristic
24	I-Characteristic
months	I-Characteristic
corrected	I-Characteristic
age	I-Characteristic
.	O
	
Cohort	O
study	O
.	O
	
Infants	B-Characteristic
born	I-Characteristic
at	I-Characteristic
or	I-Characteristic
less	I-Characteristic
than	I-Characteristic
1500	I-Characteristic
g	I-Characteristic
or	I-Characteristic
at	I-Characteristic
or	I-Characteristic
less	I-Characteristic
than	I-Characteristic
30	I-Characteristic
weeks	I-Characteristic
postmenstrual	I-Characteristic
age	I-Characteristic
who	O
underwent	O
screening	O
for	O
retinopathy	B-Disease
of	I-Disease
prematurity	I-Disease
(	O
ROP	B-Disease
)	O
in	O
an	O
intensive	O
care	O
nursery	O
.	O
	
Bedside	O
handheld	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
;	O
Envisu	O
,	O
Bioptigen	O
,	O
Inc	O
,	O
Research	O
Triangle	O
Park	O
,	O
NC	O
)	O
imaging	O
was	O
obtained	O
from	O
preterm	B-Characteristic
infants	I-Characteristic
who	O
were	O
being	O
screened	O
for	O
ROP	B-Disease
and	O
graded	O
for	O
presence	O
of	O
CME	B-Disease
,	O
central	B-Characteristic
foveal	I-Characteristic
thickness	I-Characteristic
(	O
CFT	B-Characteristic
)	O
,	O
inner	B-Characteristic
nuclear	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
,	O
and	O
foveal	B-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
parafoveal	I-Characteristic
thickness	I-Characteristic
ratio	I-Characteristic
.	O
	
At	O
18	B-Characteristic
to	I-Characteristic
24	I-Characteristic
months	I-Characteristic
corrected	I-Characteristic
age	I-Characteristic
,	O
the	O
children	B-Characteristic
were	O
assessed	O
with	O
the	O
Bayley	B-Classification_system
Scales	I-Classification_system
of	I-Classification_system
Infant	I-Classification_system
and	I-Classification_system
Toddler	I-Classification_system
Development	I-Classification_system
,	I-Classification_system
Third	I-Classification_system
Edition	I-Classification_system
.	O
	
Scores	O
on	O
the	O
Bayley	B-Classification_system
cognitive	I-Classification_system
,	I-Classification_system
language	I-Classification_system
,	I-Classification_system
and	I-Classification_system
motor	I-Classification_system
subscales	I-Classification_system
.	O
	
Among	O
77	O
children	B-Characteristic
with	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
imaging	I-Diagnostic_tool
,	O
53	O
were	O
evaluated	O
with	O
the	O
Bayley	B-Classification_system
Scales	I-Classification_system
.	O
	
Compared	O
with	O
children	B-Characteristic
who	O
did	O
not	O
have	O
CME	B-Disease
as	O
infants	B-Characteristic
(	O
n	O
=	O
22	O
)	O
,	O
the	O
mean	O
score	O
for	O
children	B-Characteristic
who	O
had	O
CME	B-Disease
(	O
n	O
=	O
31	O
)	O
was	O
7	O
.	O
3	O
points	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
-	O
15	O
.	O
5	O
to	O
0	O
.	O
9	O
;	O
P	O
=	O
0	O
.	O
08	O
)	O
lower	O
on	O
the	O
cognitive	B-Classification_system
subscale	I-Classification_system
,	O
14	O
.	O
1	O
points	O
(	O
95	O
%	O
CI	O
,	O
-	O
22	O
.	O
7	O
to	O
-	O
5	O
.	O
5	O
;	O
P	O
=	O
0	O
.	O
002	O
)	O
lower	O
for	O
the	O
language	B-Classification_system
subscale	I-Classification_system
,	O
and	O
11	O
.	O
5	O
points	O
(	O
95	O
%	O
CI	O
,	O
-	O
21	O
.	O
6	O
to	O
-	O
1	O
.	O
3	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
lower	O
for	O
the	O
motor	B-Classification_system
subscale	I-Classification_system
.	O
	
Differences	O
were	O
maintained	O
after	O
adjusting	O
for	O
gestational	B-Characteristic
age	I-Characteristic
and	O
birth	B-Characteristic
weight	I-Characteristic
.	O
	
Severity	O
of	O
CME	B-Disease
,	O
as	O
assessed	O
by	O
foveal	B-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
parafoveal	I-Characteristic
thickness	I-Characteristic
ratio	I-Characteristic
,	O
within	O
the	O
CME	B-Disease
group	O
correlated	O
with	O
poorer	B-Characteristic
cognitive	I-Characteristic
(	I-Characteristic
R2	I-Characteristic
=	I-Characteristic
0	I-Characteristic
.	I-Characteristic
16	I-Characteristic
,	I-Characteristic
P	I-Characteristic
=	I-Characteristic
0	I-Characteristic
.	I-Characteristic
03	I-Characteristic
)	I-Characteristic
and	I-Characteristic
motor	I-Characteristic
(	I-Characteristic
R2	I-Characteristic
=	I-Characteristic
0	I-Characteristic
.	I-Characteristic
15	I-Characteristic
,	I-Characteristic
P	I-Characteristic
=	I-Characteristic
0	I-Characteristic
.	I-Characteristic
03	I-Characteristic
)	I-Characteristic
development	I-Characteristic
.	O
	
Cystoid	B-Disease
macular	I-Disease
edema	I-Disease
observed	O
on	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
in	O
very	O
preterm	B-Characteristic
infants	I-Characteristic
screened	O
for	O
ROP	B-Disease
is	O
associated	O
with	O
poorer	B-Characteristic
language	I-Characteristic
and	I-Characteristic
motor	I-Characteristic
skills	I-Characteristic
at	I-Characteristic
18	I-Characteristic
to	I-Characteristic
24	I-Characteristic
months	I-Characteristic
corrected	I-Characteristic
age	I-Characteristic
.	O
	
Evaluation	O
of	O
the	O
retina	B-Anatomy
with	O
SD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
may	O
serve	O
as	O
an	O
indicator	O
of	O
neurodevelopmental	B-Characteristic
health	I-Characteristic
for	O
very	B-Characteristic
preterm	I-Characteristic
infants	I-Characteristic
in	O
the	O
intensive	O
care	O
nursery	O
.	O
	
Threat	B-Symptom
to	I-Symptom
fixation	I-Symptom
at	O
diagnosis	O
and	O
lifetime	O
risk	O
of	O
visual	B-Symptom
impairment	I-Symptom
in	O
open	B-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
.	O
	
To	O
investigate	O
whether	O
threat	B-Symptom
to	I-Symptom
fixation	I-Symptom
(	O
TTF	B-Symptom
)	O
at	O
diagnosis	O
increases	O
the	O
risk	O
of	O
central	B-Symptom
vision	I-Symptom
loss	I-Symptom
and	O
glaucoma	B-Symptom
blindness	I-Symptom
.	O
	
Retrospective	O
cohort	O
study	O
.	O
	
A	O
total	O
of	O
309	O
patients	O
(	O
309	O
eyes	B-Anatomy
)	O
with	O
glaucoma	B-Disease
were	O
followed	O
up	O
until	O
death	O
;	O
203	O
patients	O
(	O
65	O
.	O
7	O
%	O
)	O
had	O
primary	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
,	O
and	O
106	O
patients	O
(	O
34	O
.	O
2	O
%	O
)	O
had	O
exfoliation	B-Disease
glaucoma	I-Disease
.	O
	
Study	O
eyes	B-Anatomy
were	O
divided	O
into	O
2	O
groups	O
according	O
to	O
TTF	B-Symptom
in	O
the	O
first	O
glaucomatous	B-Disease
visual	O
field	O
:	O
(	O
1	O
)	O
eyes	B-Anatomy
with	O
TTF	B-Symptom
,	O
defined	O
as	O
visual	B-Symptom
field	I-Symptom
loss	I-Symptom
(	O
VFL	B-Symptom
)	O
including	O
	O
1	O
of	O
the	O
4	O
innermost	O
points	O
depressed	O
at	O
P	O
<	O
1	O
%	O
level	O
in	O
24	O
-	O
2	O
or	O
30	O
-	O
2	O
Humphrey	O
fields	O
;	O
(	O
2	O
)	O
eyes	B-Anatomy
without	O
TTF	B-Symptom
,	O
defined	O
as	O
VFL	B-Symptom
only	O
outside	O
the	O
4	O
innermost	O
points	O
.	O
	
Lifetime	O
risk	O
of	O
visual	B-Symptom
acuity	I-Symptom
(	I-Symptom
VA	I-Symptom
)	I-Symptom
loss	I-Symptom
and	O
glaucoma	B-Symptom
blindness	I-Symptom
in	O
the	O
2	O
groups	O
was	O
compared	O
by	O
logistic	O
regression	O
analysis	O
.	O
	
A	O
matching	O
technique	O
was	O
used	O
to	O
adjust	O
for	O
differences	O
in	O
disease	O
stage	O
at	O
presentation	O
.	O
	
The	O
relative	O
influence	O
of	O
TTF	B-Symptom
on	O
the	O
risk	O
of	O
blindness	B-Symptom
in	O
the	O
2	O
matched	O
groups	O
was	O
analyzed	O
by	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O
	
Visual	B-Symptom
acuity	I-Symptom
<	I-Symptom
0	I-Symptom
.	I-Symptom
3	I-Symptom
and	O
blindness	B-Symptom
from	O
glaucoma	B-Disease
(	O
World	O
Health	O
Organization	O
criteria	O
)	O
at	O
last	O
visit	O
.	O
	
Threat	B-Symptom
to	I-Symptom
fixation	I-Symptom
was	O
detected	O
in	O
58	O
.	O
9	O
%	O
of	O
the	O
eyes	B-Anatomy
at	O
diagnosis	O
.	O
	
The	O
frequency	O
of	O
TTF	B-Symptom
increased	O
with	O
stage	O
of	O
glaucomatous	B-Symptom
loss	I-Symptom
:	O
28	O
.	O
3	O
%	O
in	O
eyes	B-Anatomy
with	O
mean	O
deviation	O
(	O
MD	O
)	O
>	O
-	O
6	O
.	O
00	O
decibels	O
(	O
dB	O
)	O
versus	O
95	O
.	O
7	O
%	O
with	O
MD	O
<	O
-	O
20	O
.	O
00	O
dB	O
.	O
	
Univariate	O
analysis	O
demonstrated	O
that	O
eyes	B-Anatomy
with	O
TTF	B-Symptom
at	O
presentation	O
compared	O
with	O
eyes	B-Anatomy
without	O
TTF	B-Symptom
became	O
blind	B-Symptom
more	O
often	O
(	O
56	O
/	O
182	O
[	O
30	O
.	O
8	O
%	O
]	O
vs	O
.	O
22	O
/	O
127	O
[	O
17	O
.	O
3	O
%	O
]	O
;	O
P	O
=	O
0	O
.	O
008	O
)	O
and	O
faster	O
(	O
mean	O
time	O
from	O
diagnosis	O
to	O
blindness	B-Symptom
,	O
84	O
.	O
6	O
	O
50	O
.	O
7	O
vs	O
.	O
126	O
.	O
7	O
	O
51	O
.	O
4	O
months	O
;	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O
	
However	O
,	O
in	O
multivariate	O
analysis	O
,	O
TTF	B-Symptom
was	O
not	O
an	O
independent	O
risk	O
factor	O
for	O
VA	B-Symptom
<	I-Symptom
0	I-Symptom
.	I-Symptom
3	I-Symptom
(	O
odds	O
ratio	O
,	O
1	O
.	O
43	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
75	O
-	O
2	O
.	O
74	O
)	O
or	O
blindness	B-Symptom
(	O
odds	O
ratio	O
,	O
1	O
.	O
03	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
52	O
-	O
2	O
.	O
01	O
)	O
.	O
	
With	O
regard	O
to	O
patient	O
survival	O
time	O
,	O
there	O
were	O
no	O
differences	O
between	O
eyes	B-Anatomy
with	O
TTF	B-Symptom
and	O
eyes	B-Anatomy
without	O
TTF	B-Symptom
after	O
adjusting	O
for	O
disparities	O
in	O
disease	O
severity	O
at	O
presentation	O
(	O
P	O
=	O
0	O
.	O
934	O
)	O
.	O
	
Including	O
TTF	B-Symptom
in	O
the	O
assessment	O
of	O
risk	O
for	O
glaucoma	B-Symptom
blindness	I-Symptom
did	O
not	O
add	O
any	O
important	O
information	O
when	O
the	O
stage	O
of	O
VFL	B-Symptom
was	O
taken	O
into	O
account	O
.	O
	
Comparison	O
between	O
ophthalmoscopy	B-Diagnostic_tool
and	O
fundus	B-Diagnostic_tool
photography	I-Diagnostic_tool
in	O
determining	O
severity	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
.	O
	
Diabetic	B-Disease
retinopathy	I-Disease
was	O
assessed	O
in	O
a	O
population	O
-	O
based	O
study	O
of	O
2708	O
diabetic	B-Disease
persons	O
in	O
southern	B-Characteristic
Wisconsin	I-Characteristic
.	O
	
The	O
retinopathy	B-Disease
levels	O
as	O
determined	O
by	O
ophthalmoscopy	B-Diagnostic_tool
and	O
by	O
the	O
grading	O
of	O
stereoscopic	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
were	O
compared	O
in	O
the	O
eyes	B-Anatomy
of	O
1949	O
persons	O
.	O
	
Ophthalmoscopy	B-Diagnostic_tool
was	O
performed	O
by	O
an	O
ophthalmologist	O
and	O
a	O
specially	O
trained	O
optometrist	O
and	O
ophthalmic	O
technician	O
.	O
	
Consultation	O
among	O
the	O
three	O
examiners	O
was	O
permitted	O
.	O
	
There	O
was	O
exact	O
agreement	O
between	O
ophthalmoscopy	B-Diagnostic_tool
and	O
grading	O
for	O
detecting	O
retinopathy	B-Disease
(	O
none	O
,	O
nonproliferative	B-Disease
,	O
proliferative	B-Disease
)	O
85	O
.	O
7	O
%	O
of	O
the	O
time	O
.	O
	
The	O
kappa	O
statistic	O
,	O
which	O
corrects	O
for	O
chance	O
agreement	O
,	O
was	O
0	O
.	O
749	O
.	O
	
There	O
were	O
no	O
significant	O
differences	O
among	O
the	O
three	O
ophthalmoscopists	O
.	O
	
Ophthalmoscopy	B-Diagnostic_tool
was	O
more	O
likely	O
to	O
disagree	O
with	O
fundus	B-Diagnostic_tool
photography	I-Diagnostic_tool
grading	O
in	O
eyes	B-Anatomy
with	O
less	O
severe	O
forms	O
of	O
retinopathy	B-Disease
and	O
in	O
patients	O
examined	O
early	O
in	O
the	O
study	O
.	O
	
Other	O
factors	O
found	O
to	O
influence	O
the	O
degree	O
of	O
agreement	O
were	O
age	B-Characteristic
,	O
visual	B-Characteristic
acuity	I-Characteristic
,	O
and	O
duration	B-Characteristic
of	I-Characteristic
diabetes	I-Characteristic
.	O
	
It	O
is	O
concluded	O
that	O
with	O
proper	O
training	O
ophthalmoscopy	B-Diagnostic_tool
can	O
be	O
an	O
acceptable	O
alternative	O
to	O
fundus	B-Diagnostic_tool
photography	I-Diagnostic_tool
in	O
certain	O
situations	O
.	O
	
Automated	O
Detection	O
of	O
Hemifield	B-Characteristic
Difference	I-Characteristic
across	O
Horizontal	B-Anatomy
Raphe	I-Anatomy
on	O
Ganglion	B-Diagnostic_tool
Cell	I-Diagnostic_tool
-	I-Diagnostic_tool
-	I-Diagnostic_tool
Inner	I-Diagnostic_tool
Plexiform	I-Diagnostic_tool
Layer	I-Diagnostic_tool
Thickness	I-Diagnostic_tool
Map	I-Diagnostic_tool
.	O
	
A	O
MATLAB	O
-	O
based	O
(	O
The	O
MathWorks	O
,	O
Inc	O
,	O
Natick	O
,	O
MA	O
)	O
computer	O
program	O
(	O
the	O
ganglion	B-Diagnostic_tool
cell	I-Diagnostic_tool
-	I-Diagnostic_tool
inner	I-Diagnostic_tool
plexiform	I-Diagnostic_tool
layer	I-Diagnostic_tool
[	I-Diagnostic_tool
GCIPL	I-Diagnostic_tool
]	I-Diagnostic_tool
hemifield	I-Diagnostic_tool
test	I-Diagnostic_tool
)	O
for	O
automated	O
detection	O
of	O
GCIPL	B-Characteristic
thickness	I-Characteristic
difference	I-Characteristic
across	I-Characteristic
the	I-Characteristic
horizontal	I-Characteristic
raphe	I-Characteristic
was	O
developed	O
,	O
and	O
its	O
glaucoma	B-Disease
diagnostic	O
performance	O
was	O
assessed	O
.	O
	
Cross	O
-	O
sectional	O
study	O
.	O
	
A	O
total	O
of	O
65	O
eyes	B-Anatomy
of	O
normal	O
,	O
healthy	O
subjects	O
along	O
with	O
162	O
eyes	B-Anatomy
of	O
patients	O
with	O
glaucoma	B-Disease
(	O
79	O
preperimetric	O
and	O
83	O
early	O
perimetric	O
)	O
.	O
	
Cirrus	B-Diagnostic_tool
high	I-Diagnostic_tool
-	I-Diagnostic_tool
definition	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
HD	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
(	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
)	O
was	O
used	O
to	O
scan	O
all	O
of	O
the	O
subjects	O
'	O
macular	B-Anatomy
and	I-Anatomy
optic	I-Anatomy
discs	I-Anatomy
.	O
	
A	O
positive	O
(	O
i	O
.	O
e	O
.	O
,	O
"	O
outside	O
normal	O
limits	O
"	O
)	O
GCIPL	B-Diagnostic_tool
hemifield	I-Diagnostic_tool
test	I-Diagnostic_tool
result	O
was	O
declared	O
if	O
the	O
following	O
3	O
conditions	O
were	O
all	O
met	O
:	O
(	O
1	O
)	O
The	O
reference	O
line	O
(	O
a	O
horizontal	O
line	O
dividing	O
the	O
superior	B-Anatomy
and	I-Anatomy
inferior	I-Anatomy
hemifields	I-Anatomy
)	O
is	O
continuously	O
detected	O
for	O
longer	O
than	O
one	O
-	O
half	O
of	O
the	O
distance	O
from	O
the	O
temporal	B-Anatomy
inner	I-Anatomy
elliptical	I-Anatomy
annulus	I-Anatomy
to	O
the	O
outer	B-Anatomy
elliptical	I-Anatomy
annulus	I-Anatomy
;	O
(	O
2	O
)	O
the	O
average	B-Characteristic
GCIPL	I-Characteristic
thickness	I-Characteristic
difference	I-Characteristic
within	I-Characteristic
10	I-Characteristic
pixels	I-Characteristic
of	I-Characteristic
the	I-Characteristic
reference	I-Characteristic
line	I-Characteristic
,	O
both	O
above	O
and	O
below	O
,	O
is	O
	B-Dimension
5	I-Dimension
	I-Dimension
m	I-Dimension
;	O
and	O
(	O
3	O
)	O
the	O
average	O
RGB	O
color	O
ranges	O
of	O
the	O
10	O
pixels	O
above	O
and	O
below	O
the	O
reference	O
line	O
display	O
blue	O
in	O
1	O
hemifield	B-Anatomy
and	O
red	O
/	O
yellow	O
/	O
white	O
in	O
the	O
other	O
hemifield	O
.	O
	
Comparison	O
of	O
diagnostic	O
ability	O
using	O
the	O
areas	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curves	O
(	O
AUCs	O
)	O
.	O
	
A	O
positive	O
GCIPL	B-Diagnostic_tool
hemifield	I-Diagnostic_tool
test	I-Diagnostic_tool
result	O
was	O
observed	O
more	O
frequently	O
in	O
the	O
glaucomatous	B-Disease
eyes	B-Anatomy
(	O
74	O
/	O
79	O
preperimetric	O
,	O
78	O
/	O
83	O
early	O
perimetric	O
)	O
than	O
in	O
the	O
normal	O
eyes	B-Anatomy
(	O
1	O
/	O
65	O
)	O
.	O
	
In	O
the	O
preperimetric	O
group	O
,	O
the	O
AUC	O
of	O
the	O
GCIPL	B-Diagnostic_tool
hemifield	I-Diagnostic_tool
test	I-Diagnostic_tool
(	O
0	O
.	O
967	O
;	O
sensitivity	O
94	O
.	O
94	O
%	O
,	O
specificity	O
98	O
.	O
46	O
%	O
)	O
was	O
greater	O
than	O
that	O
of	O
the	O
minimum	O
GCIPL	B-Characteristic
thickness	I-Characteristic
(	O
0	O
.	O
933	O
)	O
,	O
the	O
inferotemporal	B-Characteristic
GCIPL	I-Characteristic
thickness	I-Characteristic
(	O
0	O
.	O
907	O
)	O
,	O
and	O
the	O
average	O
GCIPL	B-Characteristic
thickness	I-Characteristic
(	O
0	O
.	O
899	O
)	O
(	O
P	O
=	O
0	O
.	O
09	O
,	O
0	O
.	O
06	O
,	O
and	O
0	O
.	O
03	O
,	O
respectively	O
)	O
.	O
	
In	O
the	O
early	O
perimetric	O
group	O
,	O
the	O
AUC	O
of	O
the	O
GCIPL	B-Diagnostic_tool
hemifield	I-Diagnostic_tool
test	I-Diagnostic_tool
(	O
0	O
.	O
962	O
;	O
sensitivity	O
93	O
.	O
98	O
%	O
,	O
specificity	O
96	O
.	O
46	O
%	O
)	O
was	O
greater	O
than	O
that	O
of	O
the	O
inferotemporal	B-Characteristic
GCIPL	I-Characteristic
thickness	I-Characteristic
(	O
0	O
.	O
938	O
)	O
,	O
the	O
minimum	O
GCIPL	B-Characteristic
thickness	I-Characteristic
(	O
0	O
.	O
919	O
)	O
,	O
and	O
the	O
average	O
GCIPL	B-Characteristic
thickness	I-Characteristic
(	O
0	O
.	O
912	O
)	O
(	O
P	O
=	O
0	O
.	O
38	O
,	O
0	O
.	O
17	O
,	O
and	O
0	O
.	O
11	O
,	O
respectively	O
)	O
.	O
	
For	O
discrimination	O
of	O
early	B-Symptom
glaucomatous	I-Symptom
structural	I-Symptom
loss	I-Symptom
,	O
most	O
notably	O
in	O
preperimetric	B-Disease
glaucoma	I-Disease
cases	O
,	O
identification	O
of	O
the	O
GCIPL	B-Characteristic
thickness	I-Characteristic
difference	I-Characteristic
across	I-Characteristic
the	I-Characteristic
horizontal	I-Characteristic
raphe	I-Characteristic
was	O
effective	O
.	O
	
Pupillary	B-Characteristic
Responses	I-Characteristic
to	I-Characteristic
High	I-Characteristic
-	I-Characteristic
Irradiance	I-Characteristic
Blue	I-Characteristic
Light	I-Characteristic
Correlate	O
with	O
Glaucoma	B-Disease
Severity	O
.	O
	
To	O
evaluate	O
whether	O
a	O
chromatic	B-Diagnostic_tool
pupillometry	I-Diagnostic_tool
test	I-Diagnostic_tool
can	O
be	O
used	O
to	O
detect	O
impaired	B-Symptom
function	I-Symptom
of	I-Symptom
intrinsically	I-Symptom
photosensitive	I-Symptom
retinal	I-Symptom
ganglion	I-Symptom
cells	I-Symptom
(	O
ipRGCs	B-Anatomy
)	O
in	O
patients	O
with	O
primary	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
(	O
POAG	B-Disease
)	O
and	O
to	O
determine	O
if	O
pupillary	B-Characteristic
responses	I-Characteristic
correlate	O
with	O
optic	B-Symptom
nerve	I-Symptom
damage	I-Symptom
and	O
visual	B-Symptom
loss	I-Symptom
.	O
	
Cross	O
-	O
sectional	O
study	O
.	O
	
One	O
hundred	O
sixty	O
-	O
one	O
healthy	O
controls	O
recruited	O
from	O
a	O
community	O
polyclinic	O
(	O
55	O
men	B-Characteristic
;	O
151	O
ethnic	B-Characteristic
Chinese	I-Characteristic
)	O
and	O
40	O
POAG	B-Disease
patients	O
recruited	O
from	O
a	O
glaucoma	B-Disease
clinic	O
(	O
22	O
men	B-Characteristic
;	O
35	O
ethnic	B-Characteristic
Chinese	I-Characteristic
)	O
50	B-Characteristic
years	I-Characteristic
of	I-Characteristic
age	I-Characteristic
or	I-Characteristic
older	I-Characteristic
.	O
	
Subjects	O
underwent	O
monocular	B-Diagnostic_tool
exposure	I-Diagnostic_tool
to	I-Diagnostic_tool
narrowband	I-Diagnostic_tool
blue	I-Diagnostic_tool
light	I-Diagnostic_tool
(	I-Diagnostic_tool
469	I-Diagnostic_tool
nm	I-Diagnostic_tool
)	I-Diagnostic_tool
or	I-Diagnostic_tool
red	I-Diagnostic_tool
light	I-Diagnostic_tool
(	I-Diagnostic_tool
631	I-Diagnostic_tool
nm	I-Diagnostic_tool
)	I-Diagnostic_tool
using	I-Diagnostic_tool
a	I-Diagnostic_tool
modified	I-Diagnostic_tool
Ganzfeld	I-Diagnostic_tool
dome	I-Diagnostic_tool
.	O
	
Each	O
light	O
stimulus	O
was	O
increased	O
gradually	O
over	O
2	O
minutes	O
to	O
activate	O
sequentially	O
the	O
rods	B-Anatomy
,	O
cones	B-Anatomy
,	O
and	O
ipRGCs	B-Anatomy
that	O
mediate	O
the	O
pupillary	B-Characteristic
light	I-Characteristic
reflex	I-Characteristic
.	O
	
Pupil	B-Characteristic
diameter	I-Characteristic
was	O
recorded	O
using	O
an	O
infrared	B-Diagnostic_tool
pupillography	I-Diagnostic_tool
system	O
.	O
	
Pupillary	B-Characteristic
responses	I-Characteristic
to	I-Characteristic
blue	I-Characteristic
light	I-Characteristic
and	I-Characteristic
red	I-Characteristic
light	I-Characteristic
were	O
compared	O
between	O
control	O
subjects	O
and	O
those	O
with	O
POAG	B-Disease
by	O
constructing	O
dose	O
-	O
response	O
curves	O
across	O
a	O
wide	O
range	O
of	O
corneal	B-Anatomy
irradiances	O
(	O
7	O
-	O
14	O
log	O
photons	O
/	O
cm	O
(	O
2	O
)	O
per	O
second	O
)	O
.	O
	
In	O
patients	O
with	O
POAG	B-Disease
,	O
pupillary	B-Characteristic
responses	I-Characteristic
were	O
evaluated	O
relative	O
to	O
standard	B-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
testing	I-Diagnostic_tool
(	O
Humphrey	B-Characteristic
Visual	I-Characteristic
Field	I-Characteristic
[	O
HVF	B-Characteristic
]	O
;	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
)	O
and	O
scanning	B-Diagnostic_tool
laser	I-Diagnostic_tool
ophthalmoscopy	I-Diagnostic_tool
parameters	O
(	O
Heidelberg	B-Diagnostic_tool
Retinal	I-Diagnostic_tool
Tomography	I-Diagnostic_tool
[	O
HRT	B-Diagnostic_tool
]	O
;	O
Heidelberg	O
Engineering	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O
	
The	O
pupillary	B-Characteristic
light	I-Characteristic
reflex	I-Characteristic
was	O
reduced	O
in	O
patients	O
with	O
POAG	B-Disease
only	O
at	O
higher	O
irradiance	O
levels	O
,	O
corresponding	O
to	O
the	O
range	O
of	O
activation	O
of	O
ipRGCs	B-Anatomy
.	O
	
Pupillary	B-Characteristic
responses	I-Characteristic
to	I-Characteristic
high	I-Characteristic
-	I-Characteristic
irradiance	I-Characteristic
blue	I-Characteristic
light	I-Characteristic
associated	O
more	O
strongly	O
with	O
disease	O
severity	O
compared	O
with	O
responses	B-Characteristic
to	I-Characteristic
red	I-Characteristic
light	I-Characteristic
,	O
with	O
a	O
significant	O
linear	O
correlation	O
observed	O
between	O
pupil	B-Characteristic
diameter	I-Characteristic
and	O
HVF	B-Characteristic
mean	O
deviation	O
(	O
r	O
=	O
-	O
0	O
.	O
44	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
as	O
well	O
as	O
HRT	B-Characteristic
linear	I-Characteristic
cup	I-Characteristic
-	I-Characteristic
to	I-Characteristic
-	I-Characteristic
disc	I-Characteristic
ratio	I-Characteristic
(	O
r	O
=	O
0	O
.	O
61	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
several	O
other	O
optic	B-Anatomy
nerve	I-Anatomy
head	I-Anatomy
parameters	O
.	O
	
In	O
glaucomatous	B-Disease
eyes	B-Anatomy
,	O
reduced	O
pupillary	B-Characteristic
responses	I-Characteristic
to	I-Characteristic
high	I-Characteristic
-	I-Characteristic
irradiance	I-Characteristic
blue	I-Characteristic
light	I-Characteristic
were	O
associated	O
with	O
greater	O
visual	B-Symptom
field	I-Symptom
loss	I-Symptom
and	O
optic	B-Symptom
disc	I-Symptom
cupping	I-Symptom
.	O
	
In	O
POAG	B-Disease
,	O
a	O
short	O
chromatic	B-Diagnostic_tool
pupillometry	I-Diagnostic_tool
test	I-Diagnostic_tool
that	O
evaluates	O
the	O
function	O
of	O
ipRGCs	B-Anatomy
can	O
be	O
used	O
to	O
estimate	O
the	O
degree	O
of	O
damage	B-Symptom
to	I-Symptom
retinal	I-Symptom
ganglion	I-Symptom
cells	I-Symptom
that	O
mediate	O
image	O
-	O
forming	O
vision	O
.	O
	
This	O
approach	O
could	O
prove	O
useful	O
in	O
detecting	O
glaucoma	B-Disease
.	O
	
First	O
Incidence	O
and	O
Progression	O
Study	O
for	O
Diabetic	B-Disease
Retinopathy	I-Disease
in	O
Portugal	B-Characteristic
,	O
the	O
RETINODIAB	O
Study	O
:	O
Evaluation	O
of	O
the	O
Screening	O
Program	O
for	O
Lisbon	B-Characteristic
Region	O
.	O
	
To	O
estimate	O
the	O
5	O
-	O
year	O
incidence	O
and	O
progression	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
(	O
DR	B-Disease
)	O
among	O
persons	O
with	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
(	O
DM	B-Disease
)	O
.	O
	
Population	O
-	O
based	O
,	O
prospective	O
,	O
cohort	O
study	O
.	O
	
The	O
RETINODIAB	O
(	O
Study	O
Group	O
for	O
Diabetic	B-Disease
Retinopathy	I-Disease
Screening	O
)	O
program	O
was	O
implemented	O
in	O
the	O
Lisbon	B-Characteristic
and	O
Tagus	B-Characteristic
Valley	I-Characteristic
area	O
between	O
July	O
2009	O
and	O
December	O
2014	O
.	O
	
A	O
total	O
of	O
109	O
543	O
readable	O
screening	O
examinations	O
were	O
performed	O
and	O
corresponded	O
to	O
56	O
903	O
patients	O
who	O
attended	O
the	O
screening	O
program	O
at	O
entry	O
.	O
	
A	O
total	O
of	O
30	O
641	O
patients	O
(	O
53	O
.	O
85	O
%	O
)	O
had	O
at	O
least	O
1	O
further	O
screening	O
event	O
within	O
the	O
study	O
period	O
and	O
were	O
included	O
in	O
the	O
analysis	O
.	O
	
Participants	O
underwent	O
two	O
45	B-Diagnostic_tool
	I-Diagnostic_tool
nonstereoscopic	I-Diagnostic_tool
retinal	I-Diagnostic_tool
digital	I-Diagnostic_tool
photographs	I-Diagnostic_tool
per	O
eye	B-Anatomy
according	O
to	O
RETINODIAB	O
protocol	O
.	O
	
All	O
images	O
were	O
graded	O
according	O
to	O
the	O
International	B-Classification_system
Clinical	I-Classification_system
Diabetic	I-Classification_system
Retinopathy	I-Classification_system
Scale	I-Classification_system
.	O
	
Referable	B-Disease
diabetic	I-Disease
retinopathy	I-Disease
(	O
RDR	B-Disease
)	O
was	O
defined	O
for	O
all	O
patients	O
graded	O
as	O
moderate	B-Disease
nonproliferative	I-Disease
DR	I-Disease
(	O
NPDR	B-Disease
)	O
,	O
severe	B-Disease
NPDR	I-Disease
,	O
or	O
proliferative	B-Disease
DR	I-Disease
(	O
PDR	B-Disease
)	O
,	O
with	O
or	O
without	O
maculopathy	B-Disease
or	O
mild	B-Disease
NPDR	I-Disease
with	O
maculopathy	B-Disease
.	O
	
Nonparametric	O
estimates	O
of	O
the	O
annual	O
and	O
cumulative	O
incidences	O
were	O
obtained	O
by	O
Turnbull	O
'	O
s	O
estimator	O
.	O
	
Associations	O
between	O
the	O
potential	O
risk	O
factors	O
and	O
the	O
time	O
to	O
onset	O
/	O
progression	O
of	O
retinopathy	B-Disease
were	O
assessed	O
through	O
a	O
parametric	O
survival	O
analysis	O
for	O
interval	O
-	O
censored	O
data	O
.	O
	
The	O
authors	O
estimated	O
the	O
onset	O
and	O
progression	O
incidence	O
rates	O
of	O
DR	B-Disease
.	O
	
Yearly	O
incidence	O
of	O
any	O
DR	B-Disease
in	O
patients	O
without	O
retinopathy	B-Disease
at	O
baseline	O
was	O
4	O
.	O
60	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
3	O
.	O
96	O
-	O
4	O
.	O
76	O
)	O
in	O
the	O
first	O
year	O
,	O
decreasing	O
to	O
3	O
.	O
87	O
%	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
57	O
-	O
5	O
.	O
78	O
)	O
in	O
the	O
fifth	O
year	O
.	O
	
In	O
participants	O
with	O
mild	B-Disease
NPDR	I-Disease
at	O
baseline	O
,	O
the	O
progression	O
rate	O
to	O
RDR	B-Disease
in	O
year	O
1	O
was	O
1	O
.	O
18	O
%	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
96	O
-	O
1	O
.	O
33	O
)	O
.	O
	
Incidence	O
of	O
any	O
DR	B-Disease
and	O
RDR	B-Disease
and	O
DR	B-Disease
progression	O
rate	O
were	O
associated	O
with	O
known	O
duration	O
of	O
diabetes	B-Disease
,	O
age	B-Characteristic
at	I-Characteristic
diagnosis	I-Characteristic
,	O
and	O
use	B-Characteristic
of	I-Characteristic
insulin	I-Characteristic
treatment	I-Characteristic
.	O
	
This	O
longitudinal	O
epidemiologic	O
study	O
provides	O
the	O
first	O
Portuguese	B-Characteristic
incidence	O
DR	B-Disease
data	O
in	O
a	O
large	O
-	O
scale	O
population	O
-	O
based	O
cohort	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
after	O
a	O
5	O
-	O
year	O
follow	O
-	O
up	O
.	O
	
Duration	B-Characteristic
of	I-Characteristic
diabetes	I-Characteristic
,	O
age	B-Characteristic
at	I-Characteristic
diagnosis	I-Characteristic
,	O
and	O
insulin	B-Characteristic
treatment	I-Characteristic
were	O
associated	O
with	O
increasing	O
risk	O
of	O
incidence	O
and	O
progression	O
of	O
DR	B-Disease
.	O
	
A	O
personalized	O
schedule	O
distribution	O
of	O
screening	O
intervals	O
according	O
to	O
the	O
individual	O
patient	O
'	O
s	O
profile	O
should	O
be	O
implemented	O
,	O
with	O
resulting	O
benefits	O
in	O
terms	O
of	O
health	O
costs	O
.	O
	
The	O
Natural	O
History	O
of	O
the	O
Progression	O
of	O
Atrophy	B-Symptom
Secondary	O
to	O
Stargardt	B-Disease
Disease	I-Disease
(	O
ProgStar	O
)	O
Studies	O
:	O
Design	O
and	O
Baseline	O
Characteristics	O
:	O
ProgStar	O
Report	O
No	O
.	O
1	O
.	O
	
To	O
describe	O
the	O
design	O
and	O
baseline	O
characteristics	O
of	O
patients	O
enrolled	O
into	O
2	O
natural	O
history	O
studies	O
of	O
Stargardt	B-Disease
disease	I-Disease
(	O
STGD1	B-Disease
)	O
.	O
	
Multicenter	O
retrospective	O
and	O
prospective	O
cohort	O
studies	O
.	O
	
Three	O
hundred	O
sixty	O
-	O
five	O
unique	O
patients	O
aged	B-Characteristic
6	I-Characteristic
years	I-Characteristic
and	I-Characteristic
older	I-Characteristic
at	O
baseline	O
harboring	O
disease	B-Characteristic
-	I-Characteristic
causing	I-Characteristic
variants	I-Characteristic
in	I-Characteristic
the	I-Characteristic
ABCA4	I-Characteristic
gene	I-Characteristic
and	O
with	O
specified	O
ocular	B-Symptom
lesions	I-Symptom
were	O
enrolled	O
from	O
9	O
centers	O
in	O
the	O
United	B-Characteristic
States	I-Characteristic
and	O
Europe	B-Characteristic
.	O
	
In	O
the	O
retrospective	O
study	O
,	O
patients	O
contributed	O
medical	B-Diagnostic_tool
record	I-Diagnostic_tool
data	I-Diagnostic_tool
from	O
at	O
least	O
2	O
and	O
up	O
to	O
4	O
visits	O
for	O
at	O
least	O
1	O
examination	O
modality	O
:	O
fundus	B-Diagnostic_tool
autofluorescence	I-Diagnostic_tool
(	O
FAF	B-Diagnostic_tool
)	O
,	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
(	I-Diagnostic_tool
SD	I-Diagnostic_tool
)	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
,	O
and	O
/	O
or	O
microperimetry	B-Diagnostic_tool
(	O
MP	B-Diagnostic_tool
)	O
.	O
	
The	O
total	O
observational	O
period	O
was	O
at	O
least	O
2	O
years	O
and	O
up	O
to	O
5	O
years	O
between	O
single	O
visits	O
.	O
	
Demographic	B-Characteristic
and	O
visual	B-Characteristic
acuity	I-Characteristic
(	O
VA	B-Characteristic
)	O
data	O
also	O
were	O
obtained	O
.	O
	
In	O
the	O
prospective	O
study	O
,	O
eligible	O
patients	O
were	O
examined	O
at	O
baseline	O
using	O
a	O
standard	O
protocol	O
,	O
with	O
6	O
-	O
month	O
follow	O
-	O
up	O
visits	O
planned	O
for	O
a	O
2	O
-	O
year	O
period	O
for	O
serial	O
Early	B-Diagnostic_tool
Treatment	I-Diagnostic_tool
Diabetic	I-Diagnostic_tool
Retinopathy	I-Diagnostic_tool
Study	I-Diagnostic_tool
(	I-Diagnostic_tool
ETDRS	I-Diagnostic_tool
)	I-Diagnostic_tool
best	I-Diagnostic_tool
-	I-Diagnostic_tool
corrected	I-Diagnostic_tool
VA	I-Diagnostic_tool
,	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
,	O
FAF	B-Diagnostic_tool
,	O
and	O
MP	B-Diagnostic_tool
.	O
	
Design	O
and	O
rationale	O
of	O
a	O
multicenter	O
study	O
to	O
determine	O
the	O
progression	O
of	O
STGD1	B-Disease
in	O
2	O
large	O
retrospective	O
and	O
prospective	O
international	O
cohorts	O
.	O
	
Detailed	O
baseline	O
characteristics	O
of	O
both	O
cohorts	O
are	O
presented	O
,	O
including	O
demographics	B-Characteristic
,	O
and	O
structural	B-Characteristic
and	I-Characteristic
functional	I-Characteristic
retinal	I-Characteristic
metrics	I-Characteristic
.	O
	
Into	O
the	O
retrospective	O
study	O
,	O
251	O
patients	O
(	O
458	O
eyes	B-Anatomy
)	O
were	O
enrolled	O
;	O
mean	O
follow	O
-	O
up	O
	O
standard	O
deviation	O
was	O
3	O
.	O
9	O
	O
1	O
.	O
6	O
years	O
.	O
	
At	O
baseline	O
,	O
36	O
%	O
had	O
no	O
or	O
mild	B-Symptom
VA	I-Symptom
loss	I-Symptom
,	O
and	O
47	O
%	O
of	O
the	O
study	O
eyes	B-Anatomy
had	O
areas	O
of	O
definitely	B-Symptom
decreased	I-Symptom
autofluorescence	I-Symptom
(	O
DDAF	B-Symptom
)	O
with	O
an	O
average	O
lesion	O
area	O
of	O
2	B-Dimension
.	I-Dimension
5	I-Dimension
	I-Dimension
2	I-Dimension
.	I-Dimension
9	I-Dimension
mm	I-Dimension
(	I-Dimension
2	I-Dimension
)	I-Dimension
(	O
range	O
,	O
0	O
.	O
02	O
-	O
16	O
.	O
03	O
mm	O
(	O
2	O
)	O
)	O
.	O
	
Two	O
hundred	O
fifty	O
-	O
nine	O
patients	O
(	O
489	O
eyes	B-Anatomy
)	O
were	O
enrolled	O
in	O
the	O
prospective	O
study	O
.	O
	
At	O
baseline	O
,	O
20	O
%	O
had	O
no	B-Symptom
or	I-Symptom
mild	I-Symptom
VA	I-Symptom
loss	I-Symptom
,	O
and	O
64	O
%	O
had	O
areas	O
of	O
DDAF	B-Symptom
with	O
an	O
average	O
lesion	O
area	O
of	O
4	B-Dimension
.	I-Dimension
0	I-Dimension
	I-Dimension
4	I-Dimension
.	I-Dimension
4	I-Dimension
mm	I-Dimension
(	I-Dimension
2	I-Dimension
)	I-Dimension
(	O
range	O
,	O
0	O
.	O
03	O
-	O
24	O
.	O
24	O
mm	O
(	O
2	O
)	O
)	O
.	O
	
The	O
mean	B-Characteristic
retinal	I-Characteristic
sensitivity	I-Characteristic
with	O
MP	B-Diagnostic_tool
was	O
10	B-Dimension
.	I-Dimension
8	I-Dimension
	I-Dimension
5	I-Dimension
.	I-Dimension
0	I-Dimension
dB	I-Dimension
.	O
	
The	O
ProgStar	O
cohorts	O
have	O
baseline	O
characteristics	O
that	O
encompass	O
a	O
wide	O
range	O
of	O
disease	O
severity	O
and	O
are	O
expected	O
to	O
provide	O
valuable	O
data	O
on	O
progression	O
based	O
on	O
serial	O
quantitative	O
measurements	O
derived	O
from	O
multiple	O
methods	O
,	O
which	O
will	O
be	O
critical	O
to	O
the	O
design	O
of	O
planned	O
clinical	O
trials	O
.	O
	
Visual	B-Symptom
Field	I-Symptom
Change	I-Symptom
and	O
24	B-Characteristic
-	I-Characteristic
Hour	I-Characteristic
IOP	I-Characteristic
-	I-Characteristic
Related	I-Characteristic
Profile	I-Characteristic
with	O
a	O
Contact	B-Diagnostic_tool
Lens	I-Diagnostic_tool
Sensor	I-Diagnostic_tool
in	O
Treated	O
Glaucoma	B-Disease
Patients	O
.	O
	
To	O
test	O
the	O
hypothesis	O
that	O
a	O
24	O
-	O
hour	O
recording	O
of	O
intraocular	B-Characteristic
pressure	I-Characteristic
(	O
IOP	B-Characteristic
)	O
-	O
related	O
measurements	O
derived	O
from	O
a	O
contact	B-Diagnostic_tool
lens	I-Diagnostic_tool
sensor	I-Diagnostic_tool
(	O
CLS	B-Diagnostic_tool
)	O
correlates	O
to	O
the	O
rate	B-Characteristic
of	I-Characteristic
visual	I-Characteristic
field	I-Characteristic
progression	I-Characteristic
in	O
treated	O
glaucomatous	B-Disease
eyes	B-Anatomy
.	O
	
Prospective	O
,	O
cross	O
-	O
sectional	O
study	O
.	O
	
Forty	O
treated	O
glaucomatous	B-Disease
patients	O
with	O
8	O
or	O
more	O
24	O
-	O
2	O
visual	B-Diagnostic_tool
field	I-Diagnostic_tool
tests	I-Diagnostic_tool
.	O
	
Twenty	O
-	O
four	O
-	O
hour	O
recording	O
with	O
a	O
CLS	B-Diagnostic_tool
that	O
provides	O
IOP	B-Characteristic
-	I-Characteristic
related	I-Characteristic
measurements	I-Characteristic
.	O
	
Rates	O
of	O
visual	B-Characteristic
field	I-Characteristic
mean	O
deviation	O
(	O
MD	O
)	O
change	O
before	O
and	O
at	O
the	O
time	O
of	O
CLS	B-Diagnostic_tool
recording	O
and	O
CLS	B-Diagnostic_tool
parameters	O
,	O
namely	O
number	O
of	O
large	O
peaks	O
,	O
mean	O
peak	O
ratio	O
,	O
wake	O
-	O
to	O
-	O
sleep	O
slope	O
,	O
amplitude	O
and	O
area	O
under	O
the	O
cosine	O
curve	O
,	O
and	O
variability	O
from	O
the	O
mean	O
.	O
	
When	O
comparing	O
the	O
rate	O
of	O
MD	O
change	O
before	O
and	O
at	O
the	O
time	O
of	O
CLS	B-Diagnostic_tool
recording	O
of	O
all	O
patients	O
,	O
the	O
average	O
slope	O
was	O
-	O
0	O
.	O
05	O
dB	O
/	O
year	O
faster	O
in	O
the	O
beginning	O
compared	O
with	O
the	O
end	O
(	O
P	O
=	O
0	O
.	O
087	O
)	O
,	O
suggesting	O
a	O
deceleration	O
of	O
progression	O
by	O
the	O
time	O
of	O
CLS	B-Diagnostic_tool
recording	O
.	O
	
The	O
number	O
of	O
long	O
peaks	O
and	O
the	O
mean	O
peak	O
ratio	O
when	O
patients	O
were	O
awake	O
were	O
the	O
best	O
predictors	O
of	O
faster	O
progression	O
.	O
	
The	O
combination	O
of	O
CLS	B-Diagnostic_tool
parameters	O
provided	O
better	O
measures	O
of	O
goodness	O
of	O
fit	O
than	O
Goldmann	B-Diagnostic_tool
IOP	I-Diagnostic_tool
parameters	O
(	O
mean	O
,	O
peak	O
,	O
and	O
fluctuation	O
)	O
in	O
the	O
same	O
period	O
.	O
	
Intraocular	B-Characteristic
pressure	I-Characteristic
-	I-Characteristic
related	I-Characteristic
parameters	I-Characteristic
obtained	O
with	O
24	O
-	O
hour	O
recording	O
with	O
a	O
CLS	B-Diagnostic_tool
were	O
associated	O
with	O
the	O
rate	B-Characteristic
of	I-Characteristic
visual	I-Characteristic
field	I-Characteristic
progression	I-Characteristic
in	O
treated	O
glaucomatous	B-Disease
eyes	B-Anatomy
.	O
	
This	O
technology	O
may	O
be	O
useful	O
in	O
detecting	O
eyes	B-Anatomy
at	O
higher	O
risk	O
of	O
glaucoma	B-Disease
progression	O
while	O
receiving	O
treatment	O
.	O
	
Macular	B-Characteristic
versus	I-Characteristic
Retinal	I-Characteristic
Nerve	I-Characteristic
Fiber	I-Characteristic
Layer	I-Characteristic
Parameters	I-Characteristic
for	O
Diagnosing	O
Manifest	O
Glaucoma	B-Disease
:	O
A	O
Systematic	O
Review	O
of	O
Diagnostic	O
Accuracy	O
Studies	O
.	O
	
Macular	B-Characteristic
parameters	I-Characteristic
have	O
been	O
proposed	O
as	O
an	O
alternative	O
to	O
retinal	B-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
(	I-Characteristic
RNFL	I-Characteristic
)	I-Characteristic
parameters	I-Characteristic
to	O
diagnose	O
glaucoma	B-Disease
.	O
	
Comparing	O
the	O
diagnostic	O
accuracy	O
of	O
macular	B-Characteristic
parameters	I-Characteristic
,	O
specifically	O
the	O
ganglion	B-Anatomy
cell	I-Anatomy
complex	I-Anatomy
(	O
GCC	B-Anatomy
)	O
and	O
ganglion	B-Anatomy
cell	I-Anatomy
inner	I-Anatomy
plexiform	I-Anatomy
layer	I-Anatomy
(	O
GCIPL	B-Anatomy
)	O
,	O
with	O
the	O
accuracy	O
of	O
RNFL	B-Characteristic
parameters	I-Characteristic
for	O
detecting	O
manifest	O
glaucoma	B-Disease
is	O
important	O
to	O
guide	O
clinical	O
practice	O
and	O
future	O
research	O
.	O
	
Studies	O
using	O
spectral	B-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
and	O
reporting	O
macular	B-Characteristic
parameters	I-Characteristic
were	O
included	O
if	O
they	O
allowed	O
the	O
extraction	O
of	O
accuracy	O
data	O
for	O
diagnosing	O
manifest	O
glaucoma	B-Disease
,	O
as	O
confirmed	O
with	O
automated	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
or	O
a	O
clinician	O
'	O
s	O
optic	B-Diagnostic_tool
nerve	I-Diagnostic_tool
head	I-Diagnostic_tool
(	I-Diagnostic_tool
ONH	I-Diagnostic_tool
)	I-Diagnostic_tool
assessment	I-Diagnostic_tool
.	O
	
Cross	O
-	O
sectional	O
cohort	O
studies	O
and	O
case	O
-	O
control	O
studies	O
were	O
included	O
.	O
	
The	O
QUADAS	O
2	O
tool	O
was	O
used	O
to	O
assess	O
methodological	O
quality	O
.	O
	
Only	O
direct	O
comparisons	O
of	O
macular	B-Characteristic
versus	I-Characteristic
RNFL	I-Characteristic
parameters	I-Characteristic
(	O
i	O
.	O
e	O
.	O
,	O
in	O
the	O
same	O
study	O
)	O
were	O
conducted	O
.	O
	
Summary	O
sensitivity	O
and	O
specificity	O
of	O
each	O
macular	B-Characteristic
or	I-Characteristic
RNFL	I-Characteristic
parameter	I-Characteristic
were	O
reported	O
,	O
and	O
the	O
relative	O
diagnostic	O
odds	O
ratio	O
(	O
DOR	O
)	O
was	O
calculated	O
in	O
hierarchical	O
summary	O
receiver	O
operating	O
characteristic	O
(	O
HSROC	O
)	O
models	O
to	O
compare	O
them	O
.	O
	
Thirty	O
-	O
four	O
studies	O
investigated	O
macular	B-Characteristic
parameters	I-Characteristic
using	O
RTVue	B-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
Optovue	O
Inc	O
.	O
,	O
Fremont	O
,	O
CA	O
)	O
(	O
19	O
studies	O
,	O
3094	O
subjects	O
)	O
,	O
Cirrus	B-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
Carl	O
Zeiss	O
Meditec	O
Inc	O
.	O
,	O
Dublin	O
,	O
CA	O
)	O
(	O
14	O
studies	O
,	O
2164	O
subjects	O
)	O
,	O
or	O
3D	B-Diagnostic_tool
Topcon	I-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
Topcon	O
,	O
Inc	O
.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
(	O
4	O
studies	O
,	O
522	O
subjects	O
)	O
.	O
	
Thirty	O
-	O
two	O
of	O
these	O
studies	O
allowed	O
comparisons	O
between	O
macular	B-Characteristic
and	I-Characteristic
RNFL	I-Characteristic
parameters	I-Characteristic
.	O
	
Studies	O
generally	O
reported	O
sensitivities	O
at	O
fixed	O
specificities	O
,	O
more	O
commonly	O
0	O
.	O
90	O
or	O
0	O
.	O
95	O
,	O
with	O
sensitivities	O
of	O
most	O
best	O
-	O
performing	O
parameters	O
between	O
0	O
.	O
65	O
and	O
0	O
.	O
75	O
.	O
	
For	O
all	O
OCT	B-Diagnostic_tool
devices	O
,	O
compared	O
with	O
RNFL	B-Characteristic
parameters	I-Characteristic
,	O
macular	B-Characteristic
parameters	I-Characteristic
were	O
similarly	O
or	O
slightly	O
less	O
accurate	O
for	O
detecting	O
glaucoma	B-Disease
at	O
the	O
highest	O
reported	O
specificity	O
,	O
which	O
was	O
confirmed	O
in	O
analyses	O
at	O
the	O
lowest	O
specificity	O
.	O
	
Included	O
studies	O
suffered	O
from	O
limitations	O
,	O
especially	O
the	O
case	O
-	O
control	O
study	O
design	O
,	O
which	O
is	O
known	O
to	O
overestimate	O
accuracy	O
.	O
	
However	O
,	O
this	O
flaw	O
is	O
less	O
relevant	O
as	O
a	O
source	O
of	O
bias	O
in	O
direct	O
comparisons	O
conducted	O
within	O
studies	O
.	O
	
With	O
the	O
use	O
of	O
OCT	B-Diagnostic_tool
,	O
RNFL	B-Characteristic
parameters	I-Characteristic
are	O
still	O
preferable	O
to	O
macular	B-Characteristic
parameters	I-Characteristic
for	O
diagnosing	O
manifest	O
glaucoma	B-Disease
,	O
but	O
the	O
differences	O
are	O
small	O
.	O
	
Because	O
of	O
high	O
heterogeneity	O
,	O
direct	O
comparative	O
or	O
randomized	O
studies	O
of	O
OCT	B-Diagnostic_tool
devices	O
or	O
OCT	B-Characteristic
parameters	I-Characteristic
and	O
diagnostic	O
strategies	O
are	O
essential	O
.	O
	
Prospective	O
Study	O
of	O
Oral	B-Characteristic
Health	I-Characteristic
and	O
Risk	O
of	O
Primary	B-Disease
Open	I-Disease
-	I-Disease
Angle	I-Disease
Glaucoma	I-Disease
in	O
Men	B-Characteristic
:	O
Data	O
from	O
the	O
Health	O
Professionals	O
Follow	O
-	O
up	O
Study	O
.	O
	
Tooth	B-Disease
loss	I-Disease
or	O
periodontal	B-Disease
disease	I-Disease
is	O
associated	O
with	O
systemic	B-Symptom
endothelial	I-Symptom
dysfunction	I-Symptom
,	O
which	O
has	O
been	O
implicated	O
in	O
primary	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
(	O
POAG	B-Disease
)	O
.	O
	
The	O
relationship	O
between	O
oral	B-Characteristic
health	I-Characteristic
and	O
POAG	B-Disease
has	O
received	O
limited	O
attention	O
.	O
	
Thus	O
,	O
we	O
evaluated	O
the	O
association	O
between	O
oral	B-Characteristic
health	I-Characteristic
history	I-Characteristic
and	O
risk	O
of	O
POAG	B-Disease
and	O
POAG	B-Disease
subtypes	I-Disease
.	O
	
Prospective	O
cohort	O
study	O
.	O
	
Health	O
Professionals	O
Follow	O
-	O
up	O
Study	O
participants	O
(	O
40	O
536	O
men	B-Characteristic
)	O
followed	O
biennially	O
from	O
1986	O
to	O
2012	O
.	O
	
At	O
each	O
2	O
-	O
year	O
risk	O
period	O
,	O
eligible	O
participants	O
were	O
aged	B-Characteristic
40	I-Characteristic
+	I-Characteristic
years	I-Characteristic
,	O
were	O
free	O
of	O
POAG	B-Disease
,	O
and	O
reported	O
eye	B-Anatomy
examinations	O
.	O
	
By	O
using	O
validated	O
questions	O
,	O
we	O
updated	O
participants	O
'	O
status	O
on	O
number	B-Characteristic
of	I-Characteristic
natural	I-Characteristic
teeth	I-Characteristic
,	O
teeth	B-Characteristic
lost	I-Characteristic
,	O
periodontal	B-Symptom
disease	I-Symptom
with	I-Symptom
bone	I-Symptom
loss	I-Symptom
,	O
and	O
root	B-Characteristic
canal	I-Characteristic
treatments	I-Characteristic
.	O
	
During	O
follow	O
-	O
up	O
,	O
485	O
incident	O
cases	O
of	O
POAG	B-Disease
were	O
confirmed	O
with	O
medical	O
records	O
and	O
classified	O
into	O
subtypes	O
defined	O
by	O
intraocular	B-Symptom
pressure	I-Symptom
(	O
IOP	B-Symptom
;	O
	B-Dimension
or	I-Dimension
<	I-Dimension
22	I-Dimension
mmHg	I-Dimension
)	O
or	O
visual	B-Symptom
field	I-Symptom
(	I-Symptom
VF	I-Symptom
)	I-Symptom
loss	I-Symptom
pattern	O
at	O
diagnosis	O
(	O
peripheral	B-Symptom
loss	I-Symptom
only	O
or	O
early	B-Symptom
paracentral	I-Symptom
loss	I-Symptom
)	O
.	O
	
Multivariable	O
relative	O
risks	O
(	O
MVRRs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
estimated	O
.	O
	
Number	B-Characteristic
of	I-Characteristic
natural	I-Characteristic
teeth	I-Characteristic
,	O
periodontal	B-Disease
disease	I-Disease
,	O
and	O
root	B-Characteristic
canal	I-Characteristic
treatment	I-Characteristic
were	O
not	O
associated	O
with	O
POAG	B-Disease
.	O
	
However	O
,	O
compared	O
with	O
no	O
report	O
of	O
tooth	B-Symptom
loss	I-Symptom
,	O
a	O
report	O
of	O
losing	B-Symptom
teeth	I-Symptom
within	I-Symptom
the	I-Symptom
past	I-Symptom
2	I-Symptom
years	I-Symptom
was	O
associated	O
with	O
a	O
1	O
.	O
45	O
-	O
fold	O
increased	O
risk	O
of	O
POAG	B-Disease
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
-	O
1	O
.	O
97	O
)	O
;	O
in	O
particular	O
,	O
a	O
report	O
within	O
the	O
past	O
2	O
years	O
of	O
both	O
losing	B-Symptom
teeth	I-Symptom
and	O
having	O
a	O
prevalent	O
diagnosis	O
of	O
periodontal	B-Disease
disease	I-Disease
was	O
associated	O
with	O
a	O
1	O
.	O
85	O
-	O
fold	O
increased	O
risk	O
of	O
POAG	B-Disease
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
07	O
-	O
3	O
.	O
18	O
)	O
.	O
	
The	O
associations	O
with	O
recent	B-Symptom
tooth	I-Symptom
loss	I-Symptom
were	O
not	O
significantly	O
different	O
for	O
the	O
POAG	B-Disease
subtypes	I-Disease
(	O
P	O
for	O
heterogeneity	O
	O
0	O
.	O
36	O
)	O
,	O
although	O
associations	O
were	O
strongest	O
in	O
relation	O
to	O
the	O
POAG	B-Disease
subtypes	I-Disease
with	O
IOP	B-Symptom
<	B-Dimension
22	I-Dimension
mmHg	I-Dimension
(	O
MVRR	O
,	O
1	O
.	O
93	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
09	O
-	O
3	O
.	O
43	O
)	O
and	O
early	B-Symptom
paracentral	I-Symptom
VF	I-Symptom
loss	I-Symptom
(	O
MVRR	O
,	O
2	O
.	O
27	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
32	O
-	O
3	O
.	O
88	O
)	O
.	O
	
Although	O
the	O
number	B-Characteristic
of	I-Characteristic
natural	I-Characteristic
teeth	I-Characteristic
was	O
not	O
associated	O
with	O
risk	O
of	O
POAG	B-Disease
,	O
recent	B-Symptom
tooth	I-Symptom
loss	I-Symptom
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
POAG	B-Disease
.	O
	
Because	O
these	O
findings	O
may	O
be	O
due	O
to	O
chance	O
,	O
they	O
need	O
confirmation	O
in	O
larger	O
studies	O
.	O
	
Optical	B-Diagnostic_tool
Coherence	I-Diagnostic_tool
Tomography	I-Diagnostic_tool
Angiography	I-Diagnostic_tool
of	O
DME	B-Disease
and	O
Its	O
Association	O
with	O
Anti	O
-	O
VEGF	O
Treatment	O
Response	O
.	O
	
To	O
investigate	O
the	O
structural	O
integrity	O
of	O
the	O
superficial	B-Anatomy
capillary	I-Anatomy
plexuses	I-Anatomy
(	O
SCPs	B-Anatomy
)	O
and	O
deep	B-Anatomy
capillary	I-Anatomy
plexuses	I-Anatomy
(	O
DCPs	B-Anatomy
)	O
using	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	I-Diagnostic_tool
OCT	I-Diagnostic_tool
)	I-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
OCTA	B-Diagnostic_tool
)	O
in	O
patients	O
with	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
and	O
its	O
association	O
with	O
the	O
response	O
to	O
anti	O
-	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
treatment	O
.	O
	
Retrospective	O
,	O
case	O
-	O
control	O
study	O
.	O
	
We	O
included	O
51	O
DME	B-Disease
eyes	B-Anatomy
with	O
a	O
poor	O
response	O
to	O
anti	O
-	O
VEGF	O
agents	O
and	O
32	O
age	B-Characteristic
-	O
matched	O
DME	B-Disease
eyes	B-Anatomy
with	O
a	O
good	O
response	O
to	O
anti	O
-	O
VEGF	O
treatment	O
,	O
along	O
with	O
20	O
fellow	O
eyes	B-Anatomy
without	O
DME	B-Disease
from	O
the	O
cases	O
and	O
controls	O
.	O
	
The	O
medical	O
records	O
,	O
including	O
OCTA	B-Diagnostic_tool
and	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
,	O
were	O
reviewed	O
and	O
compared	O
between	O
the	O
groups	O
.	O
	
En	O
face	O
OCTA	B-Diagnostic_tool
images	O
of	O
the	O
SCP	B-Anatomy
and	O
DCP	B-Anatomy
were	O
obtained	O
for	O
each	O
eye	B-Anatomy
.	O
	
An	O
anti	O
-	O
VEGF	O
responder	O
was	O
defined	O
by	O
a	O
reduction	O
of	O
more	O
than	O
50	O
	O
m	O
in	O
central	B-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
after	O
3	O
consecutive	O
anti	O
-	O
VEGF	O
treatments	O
.	O
	
A	O
poor	O
responder	O
was	O
defined	O
by	O
a	O
reduction	O
of	O
less	O
than	O
50	O
	O
m	O
or	O
an	O
increase	O
in	O
central	B-Characteristic
retinal	I-Characteristic
thickness	I-Characteristic
after	O
3	O
monthly	O
injections	O
.	O
	
We	O
measured	O
the	O
vascular	B-Characteristic
density	I-Characteristic
and	O
foveal	B-Characteristic
avascular	I-Characteristic
zone	I-Characteristic
(	I-Characteristic
FAZ	I-Characteristic
)	I-Characteristic
area	I-Characteristic
and	O
counted	O
the	O
number	B-Characteristic
of	I-Characteristic
microaneurysms	I-Characteristic
in	I-Characteristic
each	I-Characteristic
layer	I-Characteristic
.	O
	
The	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
images	O
were	O
compared	O
with	O
OCTA	B-Diagnostic_tool
findings	O
.	O
	
Compared	O
with	O
non	B-Disease
-	I-Disease
DME	I-Disease
eyes	B-Anatomy
,	O
DME	B-Disease
eyes	B-Anatomy
had	O
a	O
lower	B-Characteristic
vascular	I-Characteristic
density	I-Characteristic
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
larger	B-Characteristic
FAZ	I-Characteristic
area	I-Characteristic
(	I-Characteristic
P	I-Characteristic
<	I-Characteristic
0	I-Characteristic
.	I-Characteristic
001	I-Characteristic
)	I-Characteristic
in	I-Characteristic
the	I-Characteristic
DCP	I-Characteristic
and	O
more	B-Symptom
microaneurysms	I-Symptom
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
both	O
layers	O
.	O
	
Although	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
SCP	B-Anatomy
between	O
anti	O
-	O
VEGF	O
responders	O
and	O
poor	O
responders	O
,	O
poor	O
responders	O
tended	O
to	O
show	O
greater	O
damage	O
and	O
more	B-Symptom
microaneurysms	I-Symptom
in	I-Symptom
the	I-Symptom
DCP	I-Symptom
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
a	O
larger	B-Symptom
FAZ	I-Symptom
area	I-Symptom
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
The	O
topographic	O
location	O
of	O
the	O
disrupted	B-Symptom
synaptic	I-Symptom
portion	I-Symptom
of	I-Symptom
the	I-Symptom
outer	I-Symptom
plexiform	I-Symptom
layer	I-Symptom
(	O
OPL	B-Anatomy
)	O
in	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
exactly	O
corresponded	O
to	O
the	O
nonflow	O
area	O
of	O
the	O
DCP	B-Anatomy
in	O
OCTA	B-Diagnostic_tool
.	O
	
Compared	O
with	O
DME	B-Disease
eyes	B-Anatomy
that	O
responded	O
to	O
anti	O
-	O
VEGF	O
treatment	O
,	O
poor	O
responders	O
show	O
significant	O
damage	O
to	O
the	O
integrity	O
of	O
the	O
DCP	B-Anatomy
,	O
but	O
not	O
the	O
SCP	B-Anatomy
.	O
	
The	O
degree	O
of	O
OPL	B-Symptom
disruption	I-Symptom
in	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
corresponds	O
well	O
with	O
the	O
extent	O
of	O
DCP	B-Symptom
loss	I-Symptom
in	O
DME	B-Disease
eyes	B-Anatomy
.	O
	
The	O
extent	O
of	O
DCP	B-Symptom
loss	I-Symptom
and	O
the	O
corresponding	O
OPL	B-Symptom
disruption	I-Symptom
could	O
be	O
useful	O
predictors	O
of	O
responsiveness	O
to	O
anti	O
-	O
VEGF	O
treatment	O
.	O
	
Optical	B-Diagnostic_tool
Coherence	I-Diagnostic_tool
Tomography	I-Diagnostic_tool
Reflective	B-Symptom
Drusen	I-Symptom
Substructures	I-Symptom
Predict	O
Progression	O
to	O
Geographic	B-Symptom
Atrophy	I-Symptom
in	O
Age	B-Disease
-	I-Disease
related	I-Disease
Macular	I-Disease
Degeneration	I-Disease
.	O
	
Structural	O
and	O
compositional	O
heterogeneity	O
within	O
drusen	B-Symptom
comprising	O
lipids	O
,	O
carbohydrates	O
,	O
and	O
proteins	O
have	O
been	O
previously	O
described	O
.	O
	
We	O
sought	O
to	O
detect	O
and	O
define	O
phenotypic	O
patterns	O
of	O
drusen	B-Symptom
heterogeneity	O
in	O
the	O
form	O
of	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
-	O
reflective	B-Symptom
drusen	I-Symptom
substructures	I-Symptom
(	O
ODS	B-Symptom
)	O
and	O
examine	O
their	O
associations	O
with	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
-	O
related	O
features	O
and	O
AMD	B-Disease
progression	O
.	O
	
Retrospective	O
analysis	O
in	O
a	O
prospective	O
study	O
.	O
	
Patients	O
with	O
intermediate	B-Disease
AMD	I-Disease
(	O
n	O
=	O
349	O
)	O
enrolled	O
in	O
the	O
multicenter	O
Age	O
-	O
Related	O
Eye	B-Anatomy
Disease	O
Study	O
2	O
(	O
AREDS2	O
)	O
ancillary	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
)	O
study	O
.	O
	
Baseline	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
scans	O
of	O
1	O
eye	B-Anatomy
per	O
patient	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
ODS	B-Symptom
.	O
	
Cross	O
-	O
sectional	O
and	O
longitudinal	O
associations	O
of	O
ODS	B-Symptom
presence	O
with	O
AMD	B-Disease
-	O
related	O
features	O
visible	O
on	O
SD	B-Diagnostic_tool
OCT	I-Diagnostic_tool
and	O
color	B-Diagnostic_tool
photographs	I-Diagnostic_tool
,	O
including	O
drusen	B-Characteristic
volume	I-Characteristic
,	O
geographic	B-Symptom
atrophy	I-Symptom
(	O
GA	B-Symptom
)	O
,	O
and	O
preatrophic	B-Characteristic
features	I-Characteristic
,	O
were	O
evaluated	O
for	O
the	O
entire	O
macular	B-Anatomy
region	O
.	O
	
Similar	O
associations	O
were	O
also	O
made	O
locally	O
within	O
a	O
0	O
.	O
5	O
-	O
mm	O
-	O
diameter	O
region	O
around	O
individual	O
ODS	B-Symptom
and	O
corresponding	O
control	O
region	O
without	O
ODS	B-Symptom
in	O
the	O
same	O
eye	B-Anatomy
.	O
	
Preatrophy	B-Symptom
SD	I-Symptom
OCT	I-Symptom
changes	I-Symptom
and	O
GA	B-Symptom
,	O
central	B-Symptom
GA	I-Symptom
,	O
and	O
choroidal	B-Symptom
neovascularization	I-Symptom
(	O
CNV	B-Symptom
)	O
from	O
color	B-Diagnostic_tool
photographs	I-Diagnostic_tool
.	O
	
Four	O
phenotypic	O
subtypes	O
of	O
ODS	B-Symptom
were	O
defined	O
:	O
low	B-Symptom
reflective	I-Symptom
cores	I-Symptom
,	O
high	B-Symptom
reflective	I-Symptom
cores	I-Symptom
,	O
conical	B-Symptom
debris	I-Symptom
,	O
and	O
split	B-Symptom
drusen	I-Symptom
.	O
	
Among	O
the	O
349	O
participants	O
,	O
there	O
were	O
307	O
eligible	O
eyes	B-Anatomy
and	O
74	O
(	O
24	O
%	O
)	O
had	O
at	O
least	O
1	O
ODS	B-Symptom
.	O
	
The	O
ODS	B-Symptom
at	O
baseline	O
were	O
associated	O
with	O
(	O
1	O
)	O
greater	O
macular	B-Symptom
drusen	I-Symptom
volume	O
at	O
baseline	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
(	O
2	O
)	O
development	O
of	O
preatrophic	B-Symptom
changes	I-Symptom
at	O
year	O
2	O
(	O
P	O
=	O
0	O
.	O
001	O
-	O
0	O
.	O
01	O
)	O
,	O
and	O
(	O
3	O
)	O
development	O
of	O
macular	B-Symptom
GA	I-Symptom
(	O
P	O
=	O
0	O
.	O
005	O
)	O
and	O
preatrophic	B-Symptom
changes	I-Symptom
at	O
year	O
3	O
(	O
P	O
=	O
0	O
.	O
002	O
-	O
0	O
.	O
008	O
)	O
,	O
but	O
not	O
development	O
of	O
CNV	B-Symptom
.	O
	
The	O
ODS	B-Symptom
at	O
baseline	O
in	O
a	O
local	O
region	O
were	O
associated	O
with	O
(	O
1	O
)	O
presence	O
of	O
preatrophy	B-Symptom
changes	I-Symptom
at	O
baseline	O
(	O
P	O
=	O
0	O
.	O
02	O
-	O
0	O
.	O
03	O
)	O
and	O
(	O
2	O
)	O
development	O
of	O
preatrophy	B-Symptom
changes	I-Symptom
at	O
years	O
2	O
and	O
3	O
within	O
the	O
region	O
(	O
P	O
=	O
0	O
.	O
008	O
-	O
0	O
.	O
05	O
)	O
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
-	O
reflective	B-Symptom
drusen	I-Symptom
substructures	I-Symptom
are	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
-	O
based	O
biomarkers	O
of	O
progression	O
to	O
GA	B-Symptom
,	O
but	O
not	O
to	O
CNV	B-Symptom
,	O
in	O
eyes	B-Anatomy
with	O
intermediate	B-Disease
AMD	I-Disease
.	O
	
Optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
-	O
reflective	B-Symptom
drusen	I-Symptom
substructures	I-Symptom
may	O
be	O
a	O
clinical	O
entity	O
helpful	O
in	O
monitoring	O
AMD	B-Disease
progression	O
and	O
informing	O
mechanisms	O
in	O
GA	B-Symptom
pathogenesis	O
.	O
	
Long	O
-	O
term	O
Effects	O
of	O
Intravitreal	O
0	O
.	O
19	O
mg	O
Fluocinolone	O
Acetonide	O
Implant	O
on	O
Progression	O
and	O
Regression	O
of	O
Diabetic	B-Disease
Retinopathy	I-Disease
.	O
	
To	O
investigate	O
the	O
effects	O
of	O
fluocinolone	O
acetonide	O
(	O
FAc	O
)	O
on	O
the	O
progression	O
to	O
proliferative	B-Disease
diabetic	I-Disease
retinopathy	I-Disease
(	O
PDR	B-Disease
)	O
and	O
the	O
impact	O
of	O
FAc	O
on	O
changes	O
in	O
Early	O
Treatment	O
Diabetic	B-Disease
Retinopathy	I-Disease
Study	O
(	O
ETDRS	O
)	O
diabetic	B-Classification_system
retinopathy	I-Classification_system
(	I-Classification_system
DR	I-Classification_system
)	I-Classification_system
severity	I-Classification_system
scale	I-Classification_system
(	O
DRSS	B-Classification_system
)	O
grade	O
during	O
the	O
Fluocinolone	O
Acetonide	O
in	O
Diabetic	B-Disease
Macular	I-Disease
Edema	I-Disease
(	O
FAME	O
)	O
A	O
and	O
B	O
Phase	O
III	O
clinical	O
trials	O
.	O
	
Post	O
hoc	O
analysis	O
of	O
data	O
from	O
the	O
36	O
-	O
month	O
prospective	O
,	O
randomized	O
,	O
FAME	O
A	O
and	O
B	O
trials	O
.	O
	
Patients	O
with	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
who	O
received	O
sham	O
control	O
or	O
FAc	O
0	O
.	O
2	O
or	O
0	O
.	O
5	O
	O
g	O
/	O
day	O
.	O
	
A	O
masked	O
reading	O
center	O
(	O
University	O
of	O
Wisconsin	O
-	O
Madison	O
)	O
determined	O
DRSS	B-Classification_system
grade	O
and	O
retinal	B-Characteristic
perfusion	I-Characteristic
status	O
using	O
standard	O
7	B-Diagnostic_tool
-	I-Diagnostic_tool
field	I-Diagnostic_tool
stereo	I-Diagnostic_tool
fundus	I-Diagnostic_tool
photography	I-Diagnostic_tool
and	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
,	O
respectively	O
.	O
	
Retinopathy	B-Disease
changes	O
over	O
time	O
were	O
determined	O
by	O
DRSS	B-Classification_system
step	O
differences	O
from	O
baseline	O
to	O
month	O
36	O
.	O
	
Pairwise	O
comparisons	O
between	O
the	O
3	O
treatment	O
groups	O
were	O
performed	O
using	O
a	O
log	O
-	O
rank	O
test	O
without	O
adjustment	O
for	O
covariates	O
,	O
with	O
the	O
primary	O
comparison	O
between	O
sham	O
control	O
and	O
0	O
.	O
2	O
	O
g	O
/	O
day	O
FAc	O
.	O
	
Study	O
eye	B-Anatomy
progression	O
to	O
PDR	B-Disease
based	O
on	O
a	O
composite	O
clinical	O
outcome	O
of	O
(	O
1	O
)	O
progression	O
from	O
nonproliferative	B-Disease
diabetic	I-Disease
retinopathy	I-Disease
(	O
NPDR	B-Disease
)	O
to	O
PDR	B-Disease
based	O
on	O
graded	O
fundus	B-Diagnostic_tool
photographs	I-Diagnostic_tool
,	O
(	O
2	O
)	O
panretinal	B-Diagnostic_tool
photocoagulation	I-Diagnostic_tool
(	O
PRP	B-Diagnostic_tool
)	O
,	O
or	O
(	O
3	O
)	O
pars	B-Diagnostic_tool
plana	I-Diagnostic_tool
vitrectomy	I-Diagnostic_tool
(	O
PPV	B-Diagnostic_tool
)	O
for	O
PDR	B-Disease
;	O
and	O
study	O
eye	B-Anatomy
changes	O
on	O
the	O
DRSS	B-Classification_system
.	O
	
In	O
the	O
integrated	O
FAME	O
data	O
set	O
,	O
compared	O
with	O
sham	O
control	O
-	O
treated	O
subjects	O
,	O
time	O
to	O
first	O
PDR	B-Disease
event	O
was	O
significantly	O
delayed	O
in	O
subjects	O
treated	O
with	O
FAc	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
this	O
effect	O
was	O
confirmed	O
in	O
subgroups	O
with	O
more	O
severe	O
DR	B-Disease
and	O
chronic	B-Disease
DME	I-Disease
at	O
baseline	O
.	O
	
In	O
addition	O
,	O
subjects	O
with	O
retinal	B-Symptom
nonperfusion	I-Symptom
at	O
baseline	O
showed	O
greater	O
reduction	O
in	O
progression	O
to	O
PDR	B-Disease
with	O
FAc	O
treatment	O
.	O
	
Both	O
FAc	O
dosages	O
demonstrated	O
statistically	O
significant	O
improvements	O
in	O
mean	O
DR	B-Disease
severity	O
compared	O
with	O
sham	O
treatment	O
at	O
months	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O
	
Numerically	O
more	O
subjects	O
who	O
received	O
FAc	O
experienced	O
2	O
-	O
or	O
-	O
more	O
-	O
or	O
3	O
-	O
or	O
-	O
more	O
-	O
step	O
improvements	O
in	O
DR	B-Disease
severity	O
compared	O
with	O
subjects	O
who	O
received	O
sham	O
;	O
conversely	O
,	O
fewer	O
subjects	O
treated	O
with	O
FAc	O
experienced	O
2	O
-	O
or	O
-	O
more	O
-	O
or	O
3	O
-	O
or	O
-	O
more	O
-	O
step	O
worsening	O
in	O
DR	B-Disease
severity	O
.	O
	
The	O
3	O
-	O
or	O
-	O
more	O
-	O
step	O
improvement	O
with	O
0	O
.	O
5	O
	O
g	O
/	O
day	O
FAc	O
was	O
statistically	O
significantly	O
different	O
from	O
sham	O
control	O
.	O
	
In	O
subjects	O
with	O
DME	B-Disease
,	O
sustained	O
intraocular	O
delivery	O
of	O
FAc	O
slows	O
development	O
of	O
PDR	B-Disease
and	O
slows	O
progression	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
.	O
	
Imaging	O
Protocols	O
in	O
Clinical	O
Studies	O
in	O
Advanced	B-Disease
Age	I-Disease
-	I-Disease
Related	I-Disease
Macular	I-Disease
Degeneration	I-Disease
:	O
Recommendations	O
from	O
Classification	O
of	O
Atrophy	B-Symptom
Consensus	O
Meetings	O
.	O
	
To	O
summarize	O
the	O
results	O
of	O
2	O
consensus	O
meetings	O
(	O
Classification	O
of	O
Atrophy	B-Symptom
Meeting	O
[	O
CAM	O
]	O
)	O
on	O
conventional	O
and	O
advanced	O
imaging	O
modalities	O
used	O
to	O
detect	O
and	O
quantify	O
atrophy	B-Symptom
due	O
to	O
late	B-Disease
-	I-Disease
stage	I-Disease
non	I-Disease
-	I-Disease
neovascular	I-Disease
and	I-Disease
neovascular	I-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
and	O
to	O
provide	O
recommendations	O
on	O
the	O
use	O
of	O
these	O
modalities	O
in	O
natural	O
history	O
studies	O
and	O
interventional	O
clinical	O
trials	O
.	O
	
Systematic	O
debate	O
on	O
the	O
relevance	O
of	O
distinct	O
imaging	O
modalities	O
held	O
in	O
2	O
consensus	O
meetings	O
.	O
	
A	O
panel	O
of	O
retina	B-Anatomy
specialists	O
.	O
	
During	O
the	O
CAM	O
,	O
a	O
consortium	O
of	O
international	O
experts	O
evaluated	O
the	O
advantages	O
and	O
disadvantages	O
of	O
various	O
imaging	O
modalities	O
on	O
the	O
basis	O
of	O
the	O
collective	O
analysis	O
of	O
a	O
large	O
series	O
of	O
clinical	O
cases	O
.	O
	
A	O
systematic	O
discussion	O
on	O
the	O
role	O
of	O
each	O
modality	O
in	O
future	O
studies	O
in	O
non	B-Disease
-	I-Disease
neovascular	I-Disease
and	I-Disease
neovascular	I-Disease
AMD	I-Disease
was	O
held	O
.	O
	
Advantages	O
and	O
disadvantages	O
of	O
current	O
retinal	B-Diagnostic_tool
imaging	I-Diagnostic_tool
technologies	I-Diagnostic_tool
and	O
recommendations	O
for	O
their	O
use	O
in	O
advanced	B-Disease
AMD	I-Disease
trials	O
.	O
	
Imaging	O
protocols	O
to	O
detect	O
,	O
quantify	O
,	O
and	O
monitor	O
progression	O
of	O
atrophy	B-Symptom
should	O
include	O
color	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photography	I-Diagnostic_tool
(	O
CFP	B-Diagnostic_tool
)	O
,	O
confocal	B-Diagnostic_tool
fundus	I-Diagnostic_tool
autofluorescence	I-Diagnostic_tool
(	O
FAF	B-Diagnostic_tool
)	O
,	O
confocal	B-Diagnostic_tool
near	I-Diagnostic_tool
-	I-Diagnostic_tool
infrared	I-Diagnostic_tool
reflectance	I-Diagnostic_tool
(	O
NIR	B-Diagnostic_tool
)	O
,	O
and	O
high	B-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
optical	I-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
volume	I-Diagnostic_tool
scans	I-Diagnostic_tool
.	O
	
These	O
images	O
should	O
be	O
acquired	O
at	O
regular	O
intervals	O
throughout	O
the	O
study	O
.	O
	
In	O
studies	O
of	O
non	B-Disease
-	I-Disease
neovascular	I-Disease
AMD	I-Disease
(	O
without	O
evident	O
signs	O
of	O
active	B-Symptom
or	I-Symptom
regressed	I-Symptom
neovascularization	I-Symptom
[	O
NV	B-Symptom
]	O
at	O
baseline	O
)	O
,	O
CFP	B-Diagnostic_tool
may	O
be	O
sufficient	O
at	O
baseline	O
and	O
end	O
-	O
of	O
-	O
study	O
visit	O
.	O
	
Fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
FA	B-Diagnostic_tool
)	O
may	O
become	O
necessary	O
to	O
evaluate	O
for	O
NV	B-Symptom
at	O
any	O
visit	O
during	O
the	O
study	O
.	O
	
Indocyanine	B-Diagnostic_tool
-	I-Diagnostic_tool
green	I-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
ICG	B-Diagnostic_tool
-	I-Diagnostic_tool
A	I-Diagnostic_tool
)	O
may	O
be	O
considered	O
at	O
baseline	O
under	O
certain	O
conditions	O
.	O
	
For	O
studies	O
in	O
patients	O
with	O
neovascular	B-Disease
AMD	I-Disease
,	O
increased	O
need	O
for	O
visualization	O
of	O
the	O
vasculature	B-Anatomy
must	O
be	O
taken	O
into	O
account	O
.	O
	
Accordingly	O
,	O
these	O
studies	O
should	O
include	O
FA	B-Diagnostic_tool
(	O
recommended	O
at	O
baseline	O
and	O
selected	O
follow	O
-	O
up	O
visits	O
)	O
and	O
ICG	B-Diagnostic_tool
-	I-Diagnostic_tool
A	I-Diagnostic_tool
under	O
certain	O
conditions	O
.	O
	
A	O
multimodal	O
imaging	O
approach	O
is	O
recommended	O
in	O
clinical	O
studies	O
for	O
the	O
optimal	O
detection	O
and	O
measurement	O
of	O
atrophy	B-Symptom
and	O
its	O
associated	O
features	O
.	O
	
Specific	O
validation	O
studies	O
will	O
be	O
necessary	O
to	O
determine	O
the	O
best	O
combination	O
of	O
imaging	O
modalities	O
,	O
and	O
these	O
recommendations	O
will	O
need	O
to	O
be	O
updated	O
as	O
new	O
imaging	O
technologies	O
become	O
available	O
in	O
the	O
future	O
.	O
	
Frequency	O
of	O
Testing	O
to	O
Detect	O
Visual	B-Characteristic
Field	I-Characteristic
Progression	I-Characteristic
Derived	O
Using	O
a	O
Longitudinal	O
Cohort	O
of	O
Glaucoma	B-Disease
Patients	O
.	O
	
To	O
determine	O
the	O
time	O
required	O
to	O
detect	O
statistically	O
significant	O
progression	O
for	O
different	O
rates	O
of	O
visual	B-Symptom
field	I-Symptom
loss	I-Symptom
using	O
standard	B-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
(	O
SAP	B-Diagnostic_tool
)	O
when	O
considering	O
different	O
frequencies	O
of	O
testing	O
using	O
a	O
follow	O
-	O
up	O
scheme	O
that	O
resembles	O
clinical	O
practice	O
.	O
	
Observational	O
cohort	O
study	O
.	O
	
One	O
thousand	O
seventy	O
-	O
two	O
eyes	B-Anatomy
of	O
665	O
patients	O
with	O
glaucoma	B-Disease
followed	O
up	O
over	O
an	O
average	O
of	O
4	O
.	O
3	O
	O
0	O
.	O
9	O
years	O
.	O
	
Participants	O
with	O
5	O
or	O
more	O
visual	B-Diagnostic_tool
field	I-Diagnostic_tool
tests	I-Diagnostic_tool
over	O
a	O
2	O
-	O
to	O
5	O
-	O
year	O
period	O
were	O
included	O
to	O
derive	O
the	O
longitudinal	O
measurement	O
variability	O
of	O
SAP	B-Characteristic
mean	I-Characteristic
deviation	I-Characteristic
(	O
MD	O
)	O
using	O
linear	O
regressions	O
.	O
	
Estimates	O
of	O
variability	O
then	O
were	O
used	O
to	O
reconstruct	O
real	O
-	O
world	O
visual	B-Characteristic
field	I-Characteristic
data	O
by	O
computer	O
simulation	O
to	O
evaluate	O
the	O
time	O
required	O
to	O
detect	O
progression	O
for	O
various	O
rates	O
of	O
visual	B-Symptom
field	I-Symptom
loss	I-Symptom
and	O
different	O
frequencies	O
of	O
testing	O
.	O
	
The	O
evaluation	O
was	O
performed	O
using	O
a	O
follow	O
-	O
up	O
scheme	O
that	O
resembled	O
clinical	O
practice	O
by	O
requiring	O
a	O
set	O
of	O
2	O
baseline	O
tests	O
and	O
a	O
confirmatory	O
test	O
to	O
identify	O
progression	O
.	O
	
Time	O
(	O
in	O
years	O
)	O
required	O
to	O
detect	O
progression	O
.	O
	
The	O
time	O
required	O
to	O
detect	O
a	O
statistically	O
significant	O
negative	O
MD	O
slope	O
decreased	O
as	O
the	O
frequency	O
of	O
testing	O
increased	O
,	O
albeit	O
not	O
proportionally	O
.	O
	
For	O
example	O
,	O
80	O
%	O
of	O
eyes	B-Anatomy
with	O
an	O
MD	O
loss	O
of	O
-	O
2	O
dB	O
/	O
year	O
would	O
be	O
detected	O
after	O
3	O
.	O
3	O
,	O
2	O
.	O
4	O
,	O
and	O
2	O
.	O
1	O
years	O
when	O
testing	O
is	O
performed	O
once	O
,	O
twice	O
,	O
and	O
thrice	O
per	O
year	O
,	O
respectively	O
.	O
	
For	O
eyes	B-Anatomy
with	O
an	O
MD	O
loss	O
of	O
-	O
0	O
.	O
5	O
dB	O
/	O
year	O
,	O
progression	O
can	O
be	O
detected	O
with	O
80	O
%	O
power	O
after	O
7	O
.	O
3	O
,	O
5	O
.	O
7	O
,	O
and	O
5	O
.	O
0	O
years	O
,	O
respectively	O
.	O
	
This	O
study	O
provides	O
information	O
on	O
the	O
time	O
required	O
to	O
detect	O
progression	O
using	O
MD	O
trend	O
analysis	O
in	O
glaucoma	B-Disease
eyes	B-Anatomy
when	O
different	O
testing	O
frequencies	O
are	O
used	O
.	O
	
The	O
smaller	O
gains	O
in	O
the	O
time	O
to	O
detect	O
progression	O
when	O
testing	O
is	O
increased	O
from	O
twice	O
to	O
thrice	O
per	O
year	O
suggests	O
that	O
obtaining	O
2	O
reliable	O
tests	O
at	O
baseline	O
followed	O
by	O
semiannual	O
testing	O
and	O
confirmation	O
of	O
progression	O
through	O
repeat	O
testing	O
in	O
the	O
initial	O
years	O
of	O
follow	O
-	O
up	O
may	O
provide	O
a	O
good	O
compromise	O
for	O
detecting	O
progression	O
,	O
while	O
minimizing	O
the	O
burden	O
on	O
health	O
care	O
resources	O
in	O
clinical	O
practice	O
.	O
	
Trend	O
-	O
based	O
Analysis	O
of	O
Ganglion	B-Characteristic
Cell	I-Characteristic
-	I-Characteristic
Inner	I-Characteristic
Plexiform	I-Characteristic
Layer	I-Characteristic
Thickness	I-Characteristic
Changes	I-Characteristic
on	O
Optical	B-Diagnostic_tool
Coherence	I-Diagnostic_tool
Tomography	I-Diagnostic_tool
in	O
Glaucoma	B-Characteristic
Progression	I-Characteristic
.	O
	
To	O
evaluate	O
the	O
rate	B-Characteristic
of	I-Characteristic
thinning	I-Characteristic
in	I-Characteristic
ganglion	I-Characteristic
cell	I-Characteristic
-	I-Characteristic
inner	I-Characteristic
plexiform	I-Characteristic
layer	I-Characteristic
(	I-Characteristic
GCIPL	I-Characteristic
)	I-Characteristic
thickness	I-Characteristic
by	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
in	O
glaucomatous	B-Disease
eyes	B-Anatomy
and	O
to	O
use	O
a	O
trend	O
-	O
based	O
approach	O
to	O
determine	O
its	O
diagnostic	O
ability	O
for	O
detecting	O
glaucoma	B-Characteristic
progression	I-Characteristic
.	O
	
Prospective	O
,	O
observational	O
study	O
.	O
	
Sixty	O
-	O
five	O
patients	O
with	O
primary	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
with	O
a	O
minimum	O
3	O
-	O
year	O
follow	O
-	O
up	O
involving	O
serial	O
spectral	B-Diagnostic_tool
-	I-Diagnostic_tool
domain	I-Diagnostic_tool
OCT	I-Diagnostic_tool
measurement	O
of	O
GCIPL	B-Characteristic
thickness	I-Characteristic
.	O
	
Patients	O
were	O
divided	O
into	O
a	O
nonprogressor	B-Characteristic
group	I-Characteristic
(	O
n	O
=	O
38	O
)	O
and	O
a	O
progressor	B-Characteristic
group	I-Characteristic
(	O
n	O
=	O
27	O
)	O
on	O
the	O
basis	O
of	O
serial	O
red	B-Diagnostic_tool
-	I-Diagnostic_tool
free	I-Diagnostic_tool
photography	I-Diagnostic_tool
or	O
visual	B-Diagnostic_tool
field	I-Diagnostic_tool
tests	I-Diagnostic_tool
.	O
	
The	O
rates	B-Characteristic
of	I-Characteristic
GCIPL	I-Characteristic
thinning	I-Characteristic
in	I-Characteristic
the	I-Characteristic
global	I-Characteristic
region	I-Characteristic
,	O
affected	O
hemifield	B-Anatomy
,	O
and	O
6	O
macular	B-Anatomy
sectors	O
,	O
and	O
the	O
minimum	O
thickness	O
,	O
were	O
determined	O
by	O
linear	O
regression	O
and	O
compared	O
between	O
groups	O
.	O
	
The	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curves	O
(	O
AUCs	O
)	O
were	O
calculated	O
for	O
each	O
parameter	O
.	O
	
The	O
GCIPL	B-Characteristic
thinning	I-Characteristic
rates	I-Characteristic
were	O
compared	O
between	O
affected	O
hemifields	B-Anatomy
and	O
unaffected	O
hemifields	B-Anatomy
.	O
	
The	O
macular	B-Characteristic
GCIPL	I-Characteristic
thinning	I-Characteristic
rates	I-Characteristic
in	O
the	O
progressor	B-Characteristic
and	I-Characteristic
nonprogressor	I-Characteristic
groups	I-Characteristic
and	O
the	O
ability	O
of	O
the	O
GCIPL	B-Characteristic
thinning	I-Characteristic
rate	I-Characteristic
to	O
diagnose	O
glaucoma	B-Characteristic
progression	I-Characteristic
.	O
	
The	O
GCIPL	B-Characteristic
thinning	I-Characteristic
rate	I-Characteristic
was	O
significantly	O
faster	O
in	O
progressors	B-Characteristic
than	O
in	O
nonprogressors	B-Characteristic
in	O
the	O
global	B-Anatomy
area	I-Anatomy
(	O
P	O
<	O
0	O
.	O
001	O
)	O
;	O
in	O
the	O
affected	O
hemifield	B-Anatomy
(	O
P	O
=	O
0	O
.	O
001	O
)	O
;	O
in	O
the	O
temporal	B-Anatomy
,	I-Anatomy
vertical	I-Anatomy
,	I-Anatomy
and	I-Anatomy
nasal	I-Anatomy
sectors	I-Anatomy
of	O
the	O
affected	O
hemifield	B-Anatomy
(	O
P	O
=	O
0	O
.	O
017	O
,	O
0	O
.	O
032	O
,	O
and	O
0	O
.	O
030	O
,	O
respectively	O
)	O
;	O
and	O
in	O
the	O
minimum	O
GCIPL	B-Characteristic
thickness	I-Characteristic
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
In	O
the	O
temporal	B-Anatomy
sectors	I-Anatomy
,	O
the	O
GCIPL	B-Characteristic
thinning	I-Characteristic
rates	I-Characteristic
were	O
significantly	O
faster	O
in	O
the	O
affected	O
than	O
in	O
the	O
unaffected	O
hemifield	B-Anatomy
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O
	
The	O
best	O
GCIPL	B-Characteristic
parameters	I-Characteristic
were	O
the	O
global	B-Characteristic
(	I-Characteristic
AUC	I-Characteristic
=	I-Characteristic
0	I-Characteristic
.	I-Characteristic
791	I-Characteristic
)	I-Characteristic
,	I-Characteristic
minimum	I-Characteristic
(	I-Characteristic
AUC	I-Characteristic
=	I-Characteristic
0	I-Characteristic
.	I-Characteristic
755	I-Characteristic
)	I-Characteristic
,	I-Characteristic
inferior	I-Characteristic
hemifield	I-Characteristic
(	I-Characteristic
AUC	I-Characteristic
=	I-Characteristic
0	I-Characteristic
.	I-Characteristic
708	I-Characteristic
)	I-Characteristic
,	I-Characteristic
and	I-Characteristic
affected	I-Characteristic
hemifield	I-Characteristic
(	I-Characteristic
AUC	I-Characteristic
=	I-Characteristic
0	I-Characteristic
.	I-Characteristic
702	I-Characteristic
)	I-Characteristic
thinning	I-Characteristic
rates	I-Characteristic
.	O
	
The	O
global	B-Characteristic
circumpapillary	I-Characteristic
retinal	I-Characteristic
nerve	I-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
thinning	I-Characteristic
rate	I-Characteristic
correlated	O
significantly	O
with	O
the	O
global	B-Characteristic
and	I-Characteristic
inferotemporal	I-Characteristic
sector	I-Characteristic
GCIPL	I-Characteristic
thinning	I-Characteristic
rates	I-Characteristic
(	O
rho	O
=	O
0	O
.	O
259	O
and	O
0	O
.	O
366	O
,	O
respectively	O
)	O
.	O
	
The	O
GCIPL	B-Characteristic
thinning	I-Characteristic
rate	I-Characteristic
on	O
OCT	B-Diagnostic_tool
was	O
significantly	O
faster	O
for	O
patients	O
with	O
glaucoma	B-Disease
with	O
progression	O
than	O
for	O
those	O
without	O
progression	O
.	O
	
The	O
GCIPL	B-Characteristic
thinning	I-Characteristic
rate	I-Characteristic
of	I-Characteristic
the	I-Characteristic
temporal	I-Characteristic
sector	I-Characteristic
was	O
faster	O
in	O
the	O
affected	O
than	O
in	O
the	O
unaffected	O
hemifield	B-Anatomy
,	O
suggesting	O
that	O
the	O
glaucomatous	B-Symptom
damage	I-Symptom
may	O
progress	O
locally	O
in	O
a	O
specific	O
sequence	O
.	O
	
Trend	O
-	O
based	O
analysis	O
of	O
GCIPL	B-Characteristic
thickness	I-Characteristic
on	O
OCT	B-Diagnostic_tool
may	O
be	O
useful	O
for	O
assessing	O
glaucoma	B-Characteristic
progression	I-Characteristic
objectively	O
and	O
quantitatively	O
.	O
	
Baseline	O
Factors	O
Affecting	O
Changes	O
in	O
Diabetic	B-Classification_system
Retinopathy	I-Classification_system
Severity	I-Classification_system
Scale	I-Classification_system
Score	I-Classification_system
After	O
Intravitreal	O
Aflibercept	O
or	O
Laser	O
for	O
Diabetic	B-Disease
Macular	I-Disease
Edema	I-Disease
:	O
Post	O
Hoc	O
Analyses	O
from	O
VISTA	O
and	O
VIVID	O
.	O
	
To	O
evaluate	O
whether	O
select	O
baseline	O
systemic	O
and	O
ocular	O
factors	O
influence	O
	B-Classification_system
2	I-Classification_system
-	I-Classification_system
step	I-Classification_system
improvement	I-Classification_system
in	I-Classification_system
the	I-Classification_system
Diabetic	I-Classification_system
Retinopathy	I-Classification_system
Severity	I-Classification_system
Scale	I-Classification_system
(	I-Classification_system
DRSS	I-Classification_system
)	I-Classification_system
score	I-Classification_system
at	O
week	O
100	O
in	O
VISTA	O
and	O
VIVID	O
.	O
	
Post	O
hoc	O
analysis	O
of	O
2	O
similarly	O
designed	O
phase	O
3	O
trials	O
,	O
VISTA	O
and	O
VIVID	O
.	O
	
Total	O
of	O
456	O
patients	O
with	O
center	O
-	O
involved	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
.	O
	
VISTA	O
and	O
VIVID	O
randomized	O
872	O
DME	B-Disease
patients	O
to	O
receive	O
intravitreal	O
aflibercept	O
injection	O
(	O
IAI	O
)	O
2	O
mg	O
every	O
4	O
weeks	O
(	O
2q4	O
)	O
,	O
IAI	O
2	O
mg	O
every	O
8	O
weeks	O
after	O
5	O
monthly	O
doses	O
(	O
2q8	O
)	O
,	O
or	O
macular	O
laser	O
photocoagulation	O
.	O
	
This	O
post	O
hoc	O
analysis	O
evaluated	O
the	O
influence	O
of	O
select	O
baseline	O
factors	O
on	O
	B-Classification_system
2	I-Classification_system
-	I-Classification_system
step	I-Classification_system
DRSS	I-Classification_system
score	I-Classification_system
improvement	O
by	O
logistic	O
regression	O
in	O
an	O
integrated	O
VISTA	O
and	O
VIVID	O
dataset	O
using	O
observed	O
cases	O
(	O
n	O
=	O
456	O
)	O
with	O
patients	O
in	O
each	O
treatment	O
group	O
divided	O
into	O
tertiles	O
based	O
on	O
each	O
characteristic	O
.	O
	
Proportion	O
of	O
patients	O
with	O
	B-Classification_system
2	I-Classification_system
-	I-Classification_system
step	I-Classification_system
improvement	I-Classification_system
in	I-Classification_system
DRSS	I-Classification_system
score	I-Classification_system
from	O
baseline	O
at	O
week	O
100	O
by	O
age	B-Characteristic
,	O
duration	B-Characteristic
of	I-Characteristic
diabetes	I-Characteristic
,	O
hemoglobin	B-Characteristic
A1c	I-Characteristic
(	O
HbA1c	B-Characteristic
)	O
,	O
body	B-Characteristic
mass	I-Characteristic
index	I-Characteristic
(	O
BMI	B-Characteristic
)	O
,	O
best	B-Characteristic
-	I-Characteristic
corrected	I-Characteristic
visual	I-Characteristic
acuity	I-Characteristic
(	O
BCVA	B-Characteristic
)	O
,	O
central	B-Characteristic
subfield	I-Characteristic
thickness	I-Characteristic
(	O
CST	B-Characteristic
)	O
,	O
and	O
DRSS	B-Classification_system
score	I-Classification_system
.	O
	
At	O
week	O
100	O
,	O
10	O
.	O
1	O
%	O
,	O
34	O
.	O
3	O
%	O
,	O
and	O
37	O
.	O
6	O
%	O
of	O
patients	O
in	O
the	O
laser	O
,	O
2q4	O
,	O
and	O
2q8	O
groups	O
experienced	O
a	O
	B-Classification_system
2	I-Classification_system
-	I-Classification_system
step	I-Classification_system
DRSS	I-Classification_system
score	I-Classification_system
improvement	O
,	O
respectively	O
.	O
	
Age	B-Characteristic
,	O
duration	B-Characteristic
of	I-Characteristic
diabetes	I-Characteristic
,	O
HbA1c	B-Characteristic
,	O
BMI	B-Characteristic
,	O
BCVA	B-Characteristic
,	O
and	O
CST	B-Characteristic
had	O
no	O
impact	O
on	O
the	O
ability	O
to	O
achieve	O
	O
2	O
-	O
step	O
improvement	O
in	O
DRSS	B-Classification_system
score	I-Classification_system
.	O
	
Initial	O
DRSS	B-Classification_system
score	I-Classification_system
was	O
the	O
only	O
factor	O
significantly	O
associated	O
with	O
	B-Classification_system
2	I-Classification_system
-	I-Classification_system
step	I-Classification_system
DRSS	I-Classification_system
score	I-Classification_system
improvement	O
in	O
all	O
treatment	O
groups	O
at	O
weeks	O
24	O
,	O
52	O
,	O
76	O
,	O
and	O
100	O
.	O
	
Relatively	O
higher	O
proportions	O
of	O
IAI	O
-	O
treated	O
patients	O
with	O
worse	O
BCVA	B-Characteristic
or	O
thicker	O
CST	B-Characteristic
experienced	O
	B-Classification_system
2	I-Classification_system
-	I-Classification_system
step	I-Classification_system
DRSS	I-Classification_system
score	I-Classification_system
improvement	O
compared	O
with	O
those	O
with	O
better	O
BCVA	B-Characteristic
or	O
thinner	O
CST	B-Characteristic
,	O
respectively	O
,	O
but	O
these	O
associations	O
were	O
not	O
statistically	O
significant	O
.	O
	
A	O
strong	O
association	O
was	O
present	O
between	O
baseline	B-Classification_system
DRSS	I-Classification_system
score	I-Classification_system
and	O
	B-Classification_system
2	I-Classification_system
-	I-Classification_system
step	I-Classification_system
DRSS	I-Classification_system
score	I-Classification_system
improvement	O
at	O
week	O
100	O
for	O
DME	B-Disease
patients	O
in	O
VISTA	O
and	O
VIVID	O
.	O
	
Idiopathic	B-Disease
Acute	I-Disease
Exudative	I-Disease
Polymorphous	I-Disease
Vitelliform	I-Disease
Maculopathy	I-Disease
:	O
Clinical	O
Spectrum	O
and	O
Multimodal	O
Imaging	O
Characteristics	O
.	O
	
To	O
describe	O
clinical	O
findings	O
in	O
patients	O
with	O
acute	B-Disease
exudative	I-Disease
polymorphous	I-Disease
vitelliform	I-Disease
maculopathy	I-Disease
(	O
AEPVM	B-Disease
)	O
.	O
	
Retrospective	O
,	O
observational	O
,	O
multicenter	O
case	O
series	O
review	O
.	O
	
Consecutive	O
patients	O
diagnosed	O
with	O
idiopathic	B-Disease
AEPVM	I-Disease
.	O
	
Review	O
of	O
clinical	B-Diagnostic_tool
charts	I-Diagnostic_tool
,	O
multimodal	B-Diagnostic_tool
imaging	I-Diagnostic_tool
,	O
electrophysiologic	B-Characteristic
findings	I-Characteristic
,	O
and	O
genetic	B-Characteristic
findings	I-Characteristic
in	O
previously	O
unpublished	O
patients	O
and	O
review	O
of	O
the	O
literature	O
.	O
	
Clinical	O
features	O
of	O
idiopathic	B-Disease
AEPVM	I-Disease
and	O
differential	O
diagnosis	O
.	O
	
Eighteen	O
patients	O
(	O
age	B-Characteristic
range	I-Characteristic
,	I-Characteristic
21	I-Characteristic
-	I-Characteristic
74	I-Characteristic
years	I-Characteristic
)	O
with	O
typical	O
features	O
of	O
AEPVM	B-Disease
,	O
including	O
initial	O
localized	B-Symptom
,	I-Symptom
serous	I-Symptom
detachments	I-Symptom
followed	I-Symptom
by	I-Symptom
the	I-Symptom
development	I-Symptom
of	I-Symptom
characteristic	I-Symptom
yellow	I-Symptom
-	I-Symptom
white	I-Symptom
deposits	I-Symptom
in	I-Symptom
the	I-Symptom
vitelliform	I-Symptom
space	I-Symptom
.	O
	
Over	O
time	O
,	O
this	O
hyperautofluorescent	O
material	O
gravitated	O
within	O
the	O
larger	O
lesions	O
,	O
resulting	O
in	O
typical	O
curvilinear	O
deposits	O
characteristic	O
of	O
later	O
stages	O
.	O
	
Symptoms	O
and	O
clinical	O
findings	O
lasted	O
from	O
weeks	O
to	O
several	O
years	O
.	O
	
Some	O
patients	O
showed	O
previously	O
undescribed	O
features	O
such	O
as	O
fluorescein	B-Symptom
-	I-Symptom
negative	I-Symptom
intraretinal	I-Symptom
cystic	I-Symptom
changes	I-Symptom
,	O
choroidal	B-Symptom
neovascularization	I-Symptom
,	O
serous	B-Symptom
retinal	I-Symptom
elevations	I-Symptom
mimicking	I-Symptom
retinal	I-Symptom
folds	I-Symptom
,	O
increased	B-Symptom
choroidal	I-Symptom
thickness	I-Symptom
,	O
lack	B-Symptom
of	I-Symptom
rapid	I-Symptom
visual	I-Symptom
recovery	I-Symptom
,	O
and	O
recurrence	B-Symptom
years	I-Symptom
after	I-Symptom
complete	I-Symptom
resolution	I-Symptom
of	I-Symptom
initial	I-Symptom
manifestations	I-Symptom
.	O
	
Acute	B-Disease
exudative	I-Disease
polymorphous	I-Disease
vitelliform	I-Disease
maculopathy	I-Disease
can	O
present	O
with	O
a	O
more	O
variable	O
natural	O
course	O
than	O
previously	O
described	O
.	O
	
Paraneoplastic	B-Disease
retinopathy	I-Disease
and	O
autosomal	B-Disease
recessive	I-Disease
bestrophinopathy	I-Disease
closely	O
resemble	O
AEPVM	B-Disease
,	O
necessitating	O
medical	O
and	O
hereditary	O
evaluation	O
to	O
exclude	O
these	O
clinical	O
possibilities	O
.	O
	
This	O
series	O
of	O
patients	O
with	O
AEPVM	B-Disease
expands	O
the	O
clinical	O
spectrum	O
of	O
the	O
disorder	O
,	O
including	O
demographics	B-Characteristic
,	O
clinical	B-Characteristic
manifestations	I-Characteristic
,	O
imaging	B-Characteristic
features	I-Characteristic
,	O
natural	B-Characteristic
course	I-Characteristic
,	O
and	O
visual	B-Characteristic
prognosis	I-Characteristic
.	O
	
Will	O
Perimetry	B-Diagnostic_tool
Be	O
Performed	O
to	O
Monitor	O
Glaucoma	B-Disease
in	O
2025	O
?	O
	
Visual	B-Diagnostic_tool
field	I-Diagnostic_tool
testing	I-Diagnostic_tool
has	O
played	O
an	O
essential	O
role	O
in	O
the	O
diagnosis	O
and	O
management	O
of	O
glaucoma	B-Disease
for	O
more	O
than	O
a	O
century	O
.	O
	
Methods	B-Diagnostic_tool
to	I-Diagnostic_tool
examine	I-Diagnostic_tool
the	I-Diagnostic_tool
visual	I-Diagnostic_tool
field	I-Diagnostic_tool
have	O
been	O
refined	O
from	O
early	O
kinetic	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
to	O
current	O
standard	B-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
(	O
SAP	B-Diagnostic_tool
)	O
.	O
	
Clinicians	O
now	O
use	O
SAP	B-Diagnostic_tool
for	O
the	O
diagnosis	O
and	O
management	O
of	O
glaucoma	B-Disease
throughout	O
the	O
world	O
.	O
	
Various	O
testing	O
paradigms	O
and	O
analytic	O
methods	O
have	O
been	O
developed	O
to	O
simplify	O
the	O
diagnosis	O
of	O
glaucoma	B-Disease
and	O
the	O
interpretation	O
of	O
progression	O
.	O
	
Moreover	O
,	O
strategies	O
have	O
been	O
implemented	O
to	O
improve	O
patient	O
experience	O
with	O
visual	B-Diagnostic_tool
field	I-Diagnostic_tool
testing	I-Diagnostic_tool
and	O
to	O
increase	O
reliability	O
.	O
	
Objective	B-Diagnostic_tool
functional	I-Diagnostic_tool
tests	I-Diagnostic_tool
,	O
such	O
as	O
electroretinography	B-Diagnostic_tool
,	O
provide	O
an	O
alternative	O
to	O
subjective	O
visual	B-Diagnostic_tool
field	I-Diagnostic_tool
testing	I-Diagnostic_tool
but	O
are	O
not	O
yet	O
ready	O
for	O
widespread	O
adoption	O
.	O
	
Standard	B-Diagnostic_tool
automated	I-Diagnostic_tool
perimetry	I-Diagnostic_tool
is	O
being	O
adapted	O
and	O
improved	O
constantly	O
.	O
	
New	O
devices	O
may	O
allow	O
patients	O
to	O
complete	O
visual	B-Diagnostic_tool
field	I-Diagnostic_tool
tests	I-Diagnostic_tool
at	O
home	O
,	O
which	O
could	O
relieve	O
patients	O
and	O
clinicians	O
from	O
in	O
-	O
office	O
testing	O
and	O
allow	O
for	O
more	O
frequent	O
examinations	O
.	O
	
Glaucoma	B-Disease
detection	O
and	O
progression	O
analysis	O
also	O
are	O
incorporating	O
progressively	O
more	O
information	O
and	O
will	O
be	O
improved	O
as	O
deep	O
learning	O
strategies	O
are	O
applied	O
.	O
	
Finally	O
,	O
perimetric	B-Diagnostic_tool
and	I-Diagnostic_tool
structural	I-Diagnostic_tool
testing	I-Diagnostic_tool
likely	O
will	O
become	O
more	O
closely	O
intertwined	O
as	O
testing	O
platforms	O
and	O
progression	O
analysis	O
incorporate	O
both	O
of	O
these	O
measures	O
.	O
	
Visual	B-Diagnostic_tool
field	I-Diagnostic_tool
testing	I-Diagnostic_tool
will	O
continue	O
to	O
have	O
an	O
important	O
role	O
in	O
the	O
diagnosis	O
and	O
management	O
of	O
glaucoma	B-Disease
.	O
	
Posterior	B-Symptom
Vitreous	I-Symptom
Detachment	I-Symptom
and	O
the	O
Posterior	B-Anatomy
Hyaloid	I-Anatomy
Membrane	I-Anatomy
.	O
	
Despite	O
posterior	B-Symptom
vitreous	I-Symptom
detachment	I-Symptom
being	O
a	O
common	O
ocular	O
event	O
affecting	O
most	O
individuals	O
in	O
an	O
aging	B-Characteristic
population	I-Characteristic
,	O
there	O
is	O
little	O
consensus	O
regarding	O
its	O
precise	O
anatomic	O
definition	O
.	O
	
We	O
investigated	O
the	O
morphologic	O
appearance	O
and	O
molecular	O
composition	O
of	O
the	O
posterior	B-Anatomy
hyaloid	I-Anatomy
membrane	I-Anatomy
to	O
determine	O
whether	O
the	O
structure	O
clinically	O
observed	O
enveloping	O
the	O
posterior	B-Anatomy
vitreous	I-Anatomy
surface	I-Anatomy
after	O
posterior	B-Symptom
vitreous	I-Symptom
detachment	I-Symptom
is	O
a	O
true	O
basement	B-Anatomy
membrane	I-Anatomy
and	O
to	O
postulate	O
its	O
origin	O
.	O
	
Understanding	O
the	O
relationship	O
between	O
the	O
vitreous	B-Anatomy
(	O
in	O
both	O
its	O
attached	O
and	O
detached	O
state	O
)	O
and	O
the	O
internal	B-Anatomy
limiting	I-Anatomy
membrane	I-Anatomy
of	I-Anatomy
the	I-Anatomy
retina	I-Anatomy
is	O
essential	O
to	O
understanding	O
the	O
cause	O
of	O
rhegmatogenous	B-Symptom
retinal	I-Symptom
detachment	I-Symptom
and	O
vitreoretinal	B-Disease
interface	I-Disease
disorders	I-Disease
,	O
as	O
well	O
as	O
potential	O
future	O
prophylactic	O
and	O
treatment	O
strategies	O
.	O
	
Clinicohistologic	O
correlation	O
study	O
.	O
	
Thirty	O
-	O
six	O
human	O
donor	O
globes	O
.	O
	
Vitreous	B-Anatomy
bodies	I-Anatomy
identified	O
to	O
have	O
posterior	B-Symptom
vitreous	I-Symptom
detachment	I-Symptom
were	O
examined	O
with	O
phase	B-Diagnostic_tool
-	I-Diagnostic_tool
contrast	I-Diagnostic_tool
microscopy	I-Diagnostic_tool
and	O
confocal	B-Diagnostic_tool
microscopy	I-Diagnostic_tool
after	O
immunohistochemically	O
staining	O
for	O
collagen	B-Characteristic
IV	I-Characteristic
basement	I-Characteristic
membrane	I-Characteristic
markers	I-Characteristic
,	O
in	O
addition	O
to	O
extracellular	B-Characteristic
proteins	I-Characteristic
that	O
characterize	O
the	O
vitreoretinal	B-Anatomy
junction	I-Anatomy
(	O
fibronectin	B-Anatomy
,	O
laminin	B-Anatomy
)	O
and	O
vitreous	B-Anatomy
gel	I-Anatomy
(	O
opticin	B-Anatomy
)	O
markers	O
.	O
	
The	O
posterior	B-Anatomy
retina	I-Anatomy
similarly	O
was	O
stained	O
to	O
evaluate	O
the	O
internal	B-Anatomy
limiting	I-Anatomy
membrane	I-Anatomy
.	O
	
Findings	O
were	O
correlated	O
to	O
the	O
clinical	O
appearance	O
of	O
the	O
posterior	B-Anatomy
hyaloid	I-Anatomy
membrane	I-Anatomy
observed	O
during	O
slit	B-Diagnostic_tool
-	I-Diagnostic_tool
lamp	I-Diagnostic_tool
biomicroscopy	I-Diagnostic_tool
after	O
posterior	B-Symptom
vitreous	I-Symptom
detachment	I-Symptom
and	O
compared	O
with	O
previously	O
published	O
studies	O
.	O
	
Morphologic	O
appearance	O
and	O
molecular	O
composition	O
of	O
the	O
posterior	B-Anatomy
hyaloid	I-Anatomy
membrane	I-Anatomy
.	O
	
Phase	B-Diagnostic_tool
-	I-Diagnostic_tool
contrast	I-Diagnostic_tool
microscopy	I-Diagnostic_tool
consistently	O
identified	O
a	O
creased	B-Symptom
and	I-Symptom
distinct	I-Symptom
glassy	I-Symptom
membranous	I-Symptom
sheet	I-Symptom
enveloping	I-Symptom
the	I-Symptom
posterior	I-Symptom
vitreous	I-Symptom
surface	I-Symptom
,	O
correlating	O
closely	O
with	O
the	O
posterior	B-Anatomy
hyaloid	I-Anatomy
membrane	I-Anatomy
observed	O
during	O
slit	B-Diagnostic_tool
-	I-Diagnostic_tool
lamp	I-Diagnostic_tool
biomicroscopy	I-Diagnostic_tool
in	O
patients	O
with	O
posterior	B-Symptom
vitreous	I-Symptom
detachment	I-Symptom
.	O
	
Immunofluorescent	B-Diagnostic_tool
confocal	I-Diagnostic_tool
micrographs	I-Diagnostic_tool
demonstrated	O
the	O
enveloping	B-Anatomy
membranous	I-Anatomy
structure	I-Anatomy
identified	O
on	O
phase	B-Diagnostic_tool
-	I-Diagnostic_tool
contrast	I-Diagnostic_tool
microscopy	I-Diagnostic_tool
to	O
show	O
positive	O
stain	O
results	O
for	O
type	O
IV	O
collagen	O
.	O
	
Immunofluorescence	B-Diagnostic_tool
of	O
the	O
residual	O
intact	O
internal	B-Anatomy
limiting	I-Anatomy
membrane	I-Anatomy
on	O
the	O
retinal	B-Anatomy
surface	I-Anatomy
also	O
showed	O
positive	O
stain	O
results	O
for	O
type	O
IV	O
collagen	O
.	O
	
The	O
results	O
of	O
this	O
study	O
provide	O
immunohistochemical	O
evidence	O
that	O
the	O
posterior	B-Anatomy
hyaloid	I-Anatomy
membrane	I-Anatomy
is	O
a	O
true	O
basement	B-Anatomy
membrane	I-Anatomy
enveloping	O
the	O
posterior	B-Anatomy
hyaloid	I-Anatomy
surface	I-Anatomy
.	O
	
Because	O
this	O
membranous	O
structure	O
is	O
observed	O
only	O
after	O
posterior	B-Symptom
vitreous	I-Symptom
detachment	I-Symptom
,	O
the	O
results	O
of	O
this	O
study	O
indicate	O
that	O
it	O
forms	O
part	O
of	O
the	O
internal	B-Anatomy
limiting	I-Anatomy
membrane	I-Anatomy
when	O
the	O
vitreous	B-Anatomy
is	O
in	O
its	O
attached	O
state	O
.	O
	
Update	O
in	O
Current	O
Diagnostics	O
and	O
Therapeutics	O
of	O
Dry	B-Disease
Eye	I-Disease
Disease	I-Disease
.	O
	
Dry	B-Disease
eye	I-Disease
disease	I-Disease
(	O
DED	B-Disease
)	O
represents	O
a	O
heterogeneous	O
group	O
of	O
conditions	O
with	O
tear	B-Symptom
film	I-Symptom
insufficiency	I-Symptom
and	O
signs	O
and	O
/	O
or	O
symptoms	O
of	O
ocular	B-Symptom
surface	I-Symptom
irritation	I-Symptom
.	O
	
The	O
clinical	O
manifestations	O
of	O
DED	B-Disease
can	O
be	O
highly	O
variable	O
;	O
hence	O
the	O
diagnosis	O
is	O
often	O
based	O
on	O
a	O
combination	O
of	O
symptoms	O
,	O
signs	O
,	O
and	O
clinical	O
tests	O
,	O
given	O
that	O
any	O
one	O
of	O
these	O
alone	O
would	O
miss	O
a	O
significant	O
number	O
of	O
patients	O
.	O
	
Similarly	O
,	O
the	O
treatment	O
must	O
often	O
be	O
tailored	O
to	O
each	O
patient	O
by	O
targeting	O
the	O
specific	O
mechanisms	O
involved	O
in	O
his	O
or	O
her	O
disease	O
.	O
	
The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
summarize	O
recent	O
advances	O
that	O
have	O
allowed	O
us	O
to	O
better	O
recognize	O
,	O
categorize	O
,	O
and	O
treat	O
patients	O
with	O
DED	B-Disease
.	O
	
The	O
most	O
notable	O
new	O
diagnostic	O
tests	O
in	O
DED	B-Disease
are	O
tear	B-Diagnostic_tool
film	I-Diagnostic_tool
osmolarity	I-Diagnostic_tool
,	O
inflammatory	B-Diagnostic_tool
biomarkers	I-Diagnostic_tool
,	O
and	O
meibomian	B-Diagnostic_tool
gland	I-Diagnostic_tool
imaging	I-Diagnostic_tool
.	O
	
Therapeutically	O
,	O
anti	O
-	O
inflammatory	O
therapy	O
,	O
meibomian	O
gland	O
heating	O
and	O
expression	O
,	O
and	O
scleral	O
contact	O
lenses	O
are	O
some	O
of	O
the	O
latest	O
options	O
available	O
for	O
treating	O
DED	B-Disease
.	O
	
The	O
Progression	O
of	O
Geographic	B-Disease
Atrophy	I-Disease
Secondary	O
to	O
Age	B-Disease
-	I-Disease
Related	I-Disease
Macular	I-Disease
Degeneration	I-Disease
.	O
	
Geographic	B-Disease
atrophy	I-Disease
(	O
GA	B-Disease
)	O
is	O
an	O
advanced	O
form	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
that	O
leads	O
to	O
progressive	O
and	O
irreversible	B-Symptom
loss	I-Symptom
of	I-Symptom
visual	I-Symptom
function	I-Symptom
.	O
	
Geographic	B-Disease
atrophy	I-Disease
is	O
defined	O
by	O
the	O
presence	O
of	O
sharply	B-Symptom
demarcated	I-Symptom
atrophic	I-Symptom
lesions	I-Symptom
of	I-Symptom
the	I-Symptom
outer	I-Symptom
retina	I-Symptom
,	O
resulting	O
from	O
loss	B-Symptom
of	I-Symptom
photoreceptors	I-Symptom
,	I-Symptom
retinal	I-Symptom
pigment	I-Symptom
epithelium	I-Symptom
(	I-Symptom
RPE	I-Symptom
)	I-Symptom
,	I-Symptom
and	I-Symptom
underlying	I-Symptom
choriocapillaris	I-Symptom
.	O
	
These	O
lesions	O
typically	O
appear	O
first	O
in	O
the	O
perifoveal	B-Anatomy
macula	I-Anatomy
,	O
initially	O
sparing	O
the	O
foveal	B-Anatomy
center	I-Anatomy
,	O
and	O
over	O
time	O
often	O
expand	O
and	O
coalesce	O
to	O
include	O
the	O
fovea	B-Anatomy
.	O
	
Although	O
the	O
kinetics	O
of	O
GA	B-Disease
progression	O
are	O
highly	O
variable	O
among	O
individual	O
patients	O
,	O
a	O
growing	O
body	O
of	O
evidence	O
suggests	O
that	O
specific	O
characteristics	O
may	O
be	O
important	O
in	O
predicting	O
disease	O
progression	O
and	O
outcomes	O
.	O
	
This	O
review	O
synthesizes	O
current	O
understanding	O
of	O
GA	B-Disease
progression	O
in	O
AMD	B-Disease
and	O
the	O
factors	O
known	O
or	O
postulated	O
to	O
be	O
relevant	O
to	O
GA	B-Symptom
lesion	I-Symptom
enlargement	I-Symptom
,	O
including	O
both	O
affected	O
and	O
fellow	O
eye	B-Anatomy
characteristics	O
.	O
	
In	O
addition	O
,	O
the	O
roles	O
of	O
genetic	O
,	O
environmental	O
,	O
and	O
demographic	O
factors	O
in	O
GA	B-Symptom
lesion	I-Symptom
enlargement	O
are	O
discussed	O
.	O
	
Overall	O
,	O
GA	B-Disease
progression	O
rates	O
reported	O
in	O
the	O
literature	O
for	O
total	O
study	O
populations	O
range	O
from	O
0	O
.	O
53	O
to	O
2	O
.	O
6	O
mm	O
2	O
	
Personalized	O
Prediction	O
of	O
Glaucoma	B-Disease
Progression	O
Under	O
Different	O
Target	O
Intraocular	B-Characteristic
Pressure	I-Characteristic
Levels	I-Characteristic
Using	O
Filtered	B-Diagnostic_tool
Forecasting	I-Diagnostic_tool
Methods	I-Diagnostic_tool
.	O
	
To	O
generate	O
personalized	O
forecasts	O
of	O
how	O
patients	O
with	O
open	B-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
(	O
OAG	B-Disease
)	O
experience	O
disease	O
progression	O
at	O
different	O
intraocular	B-Characteristic
pressure	I-Characteristic
(	O
IOP	B-Characteristic
)	O
levels	O
to	O
aid	O
clinicians	O
with	O
setting	O
personalized	O
target	O
IOPs	B-Characteristic
.	O
	
Secondary	O
analyses	O
using	O
longitudinal	O
data	O
from	O
2	O
randomized	O
controlled	O
trials	O
.	O
	
Participants	O
with	O
moderate	B-Disease
or	I-Disease
advanced	I-Disease
OAG	I-Disease
from	O
the	O
Collaborative	O
Initial	O
Glaucoma	B-Disease
Treatment	O
Study	O
(	O
CIGTS	O
)	O
or	O
the	O
Advanced	B-Disease
Glaucoma	I-Disease
Intervention	O
Study	O
(	O
AGIS	O
)	O
.	O
	
By	O
using	O
perimetric	O
and	O
tonometric	O
data	O
from	O
trial	O
participants	O
,	O
we	O
developed	O
and	O
validated	O
Kalman	O
Filter	O
(	O
KF	O
)	O
models	O
for	O
fast	O
-	O
,	O
slow	O
-	O
,	O
and	O
nonprogressing	O
patients	O
with	O
OAG	B-Disease
.	O
	
The	O
KF	O
can	O
generate	O
personalized	O
and	O
dynamically	O
updated	O
forecasts	O
of	O
OAG	B-Disease
progression	O
under	O
different	O
target	O
IOP	B-Characteristic
levels	O
.	O
	
For	O
each	O
participant	O
,	O
we	O
determined	O
how	O
mean	O
deviation	O
(	O
MD	O
)	O
would	O
change	O
if	O
the	O
patient	O
maintains	O
his	O
/	O
her	O
IOP	B-Characteristic
at	O
1	O
of	O
7	O
levels	O
(	O
6	O
,	O
9	O
,	O
12	O
,	O
15	O
,	O
18	O
,	O
21	O
,	O
or	O
24	O
mmHg	O
)	O
over	O
the	O
next	O
5	O
years	O
.	O
	
We	O
also	O
model	O
and	O
predict	O
changes	O
to	O
MD	O
over	O
the	O
same	O
time	O
horizon	O
if	O
IOP	B-Characteristic
is	O
increased	O
or	O
decreased	O
by	O
3	O
,	O
6	O
,	O
and	O
9	O
mmHg	O
from	O
the	O
level	O
attained	O
in	O
the	O
trials	O
.	O
	
Personalized	O
estimates	O
of	O
the	O
change	O
in	O
MD	O
under	O
different	O
target	O
IOP	B-Characteristic
levels	O
.	O
	
A	O
total	O
of	O
571	O
participants	O
(	O
mean	O
age	O
,	O
64	O
.	O
2	O
years	O
;	O
standard	O
deviation	O
,	O
10	O
.	O
9	O
)	O
were	O
followed	O
for	O
a	O
mean	O
of	O
6	O
.	O
5	O
years	O
(	O
standard	O
deviation	O
,	O
2	O
.	O
8	O
)	O
.	O
	
Our	O
models	O
predicted	O
that	O
,	O
on	O
average	O
,	O
fast	O
progressors	O
would	O
lose	O
2	O
.	O
1	O
,	O
6	O
.	O
7	O
,	O
and	O
11	O
.	O
2	O
decibels	O
(	O
dB	O
)	O
MD	O
under	O
target	O
IOPs	B-Characteristic
of	O
6	O
,	O
15	O
,	O
and	O
24	O
mmHg	O
,	O
respectively	O
,	O
over	O
5	O
years	O
.	O
	
In	O
contrast	O
,	O
on	O
average	O
,	O
slow	O
progressors	O
would	O
lose	O
0	O
.	O
8	O
,	O
2	O
.	O
1	O
,	O
and	O
4	O
.	O
1	O
dB	O
MD	O
under	O
the	O
same	O
target	O
IOPs	B-Characteristic
and	O
time	O
frame	O
.	O
	
When	O
using	O
our	O
tool	O
to	O
quantify	O
the	O
OAG	B-Disease
progression	O
dynamics	O
for	O
all	O
571	O
patients	O
,	O
we	O
found	O
no	O
statistically	O
significant	O
differences	O
over	O
5	O
years	O
between	O
progression	O
for	O
black	B-Characteristic
versus	I-Characteristic
white	I-Characteristic
,	O
male	B-Characteristic
versus	I-Characteristic
female	I-Characteristic
,	O
and	O
CIGTS	O
versus	O
AGIS	O
participants	O
under	O
different	O
target	O
IOPs	B-Characteristic
(	O
P	O
>	O
0	O
.	O
05	O
for	O
all	O
)	O
.	O
	
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
clinical	O
decision	O
-	O
making	O
tool	O
that	O
generates	O
personalized	O
forecasts	O
of	O
the	O
trajectory	O
of	O
OAG	B-Disease
progression	O
at	O
different	O
target	O
IOP	B-Characteristic
levels	O
.	O
	
This	O
approach	O
can	O
help	O
clinicians	O
determine	O
appropriate	O
,	O
personalized	O
target	O
IOPs	B-Characteristic
for	O
patients	O
with	O
OAG	B-Disease
.	O
	
Fully	O
Automated	O
Detection	O
and	O
Quantification	O
of	O
Macular	B-Symptom
Fluid	I-Symptom
in	O
OCT	B-Diagnostic_tool
Using	O
Deep	B-Diagnostic_tool
Learning	I-Diagnostic_tool
.	O
	
Development	O
and	O
validation	O
of	O
a	O
fully	O
automated	O
method	O
to	O
detect	O
and	O
quantify	O
macular	B-Symptom
fluid	I-Symptom
in	O
conventional	O
OCT	B-Diagnostic_tool
images	I-Diagnostic_tool
.	O
	
Development	O
of	O
a	O
diagnostic	O
modality	O
.	O
	
The	O
clinical	O
dataset	O
for	O
fluid	O
detection	O
consisted	O
of	O
1200	O
OCT	B-Diagnostic_tool
volumes	I-Diagnostic_tool
of	O
patients	O
with	O
neovascular	B-Disease
age	I-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
,	O
n	O
=	O
400	O
)	O
,	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
,	O
n	O
=	O
400	O
)	O
,	O
or	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
(	O
RVO	B-Disease
,	O
n	O
=	O
400	O
)	O
acquired	O
with	O
Zeiss	B-Diagnostic_tool
Cirrus	I-Diagnostic_tool
(	O
Carl	O
Zeiss	O
Meditec	O
,	O
Dublin	O
,	O
CA	O
)	O
(	O
n	O
=	O
600	O
)	O
or	O
Heidelberg	B-Diagnostic_tool
Spectralis	I-Diagnostic_tool
(	O
Heidelberg	O
Engineering	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
(	O
n	O
=	O
600	O
)	O
OCT	B-Diagnostic_tool
devices	O
.	O
	
A	O
method	O
based	O
on	O
deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
to	O
automatically	O
detect	O
and	O
quantify	O
intraretinal	B-Symptom
cystoid	I-Symptom
fluid	I-Symptom
(	O
IRC	B-Symptom
)	O
and	O
subretinal	B-Symptom
fluid	I-Symptom
(	O
SRF	B-Symptom
)	O
was	O
developed	O
.	O
	
The	O
performance	O
of	O
the	O
algorithm	O
in	O
accurately	O
identifying	O
fluid	O
localization	O
and	O
extent	O
was	O
evaluated	O
against	O
a	O
manual	O
consensus	O
reading	O
of	O
2	O
masked	O
reading	O
center	O
graders	O
.	O
	
Performance	O
of	O
a	O
fully	O
automated	O
method	O
to	O
accurately	O
detect	O
,	O
differentiate	O
,	O
and	O
quantify	O
intraretinal	B-Symptom
and	I-Symptom
SRF	I-Symptom
using	O
area	O
under	O
the	O
receiver	O
operating	O
characteristics	O
curves	O
,	O
precision	O
,	O
and	O
recall	O
.	O
	
The	O
newly	O
designed	O
,	O
fully	O
automated	O
diagnostic	O
method	O
based	O
on	O
deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
achieved	O
optimal	O
accuracy	O
for	O
the	O
detection	O
and	O
quantification	O
of	O
IRC	B-Symptom
for	O
all	O
3	O
macular	B-Anatomy
pathologies	O
with	O
a	O
mean	O
accuracy	O
(	O
AUC	O
)	O
of	O
0	O
.	O
94	O
(	O
range	O
,	O
0	O
.	O
91	O
-	O
0	O
.	O
97	O
)	O
,	O
a	O
mean	O
precision	O
of	O
0	O
.	O
91	O
,	O
and	O
a	O
mean	O
recall	O
of	O
0	O
.	O
84	O
.	O
	
The	O
detection	O
and	O
measurement	O
of	O
SRF	B-Symptom
were	O
also	O
highly	O
accurate	O
with	O
an	O
AUC	O
of	O
0	O
.	O
92	O
(	O
range	O
,	O
0	O
.	O
86	O
-	O
0	O
.	O
98	O
)	O
,	O
a	O
mean	O
precision	O
of	O
0	O
.	O
61	O
,	O
and	O
a	O
mean	O
recall	O
of	O
0	O
.	O
81	O
,	O
with	O
superior	O
performance	O
in	O
neovascular	B-Disease
AMD	I-Disease
and	O
RVO	B-Disease
compared	O
with	O
DME	B-Disease
,	O
which	O
was	O
represented	O
rarely	O
in	O
the	O
population	O
studied	O
.	O
	
High	O
linear	O
correlation	O
was	O
confirmed	O
between	O
automated	O
and	O
manual	O
fluid	O
localization	O
and	O
quantification	O
,	O
yielding	O
an	O
average	O
Pearson	O
'	O
s	O
correlation	O
coefficient	O
of	O
0	O
.	O
90	O
for	O
IRC	B-Symptom
and	O
of	O
0	O
.	O
96	O
for	O
SRF	B-Symptom
.	O
	
Deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
in	O
retinal	B-Diagnostic_tool
image	I-Diagnostic_tool
analysis	I-Diagnostic_tool
achieves	O
excellent	O
accuracy	O
for	O
the	O
differential	O
detection	O
of	O
retinal	B-Symptom
fluid	I-Symptom
types	O
across	O
the	O
most	O
prevalent	O
exudative	B-Disease
macular	I-Disease
diseases	I-Disease
and	O
OCT	B-Diagnostic_tool
devices	O
.	O
	
Furthermore	O
,	O
quantification	O
of	O
fluid	O
achieves	O
a	O
high	O
level	O
of	O
concordance	O
with	O
manual	O
expert	O
assessment	O
.	O
	
Fully	O
automated	O
analysis	O
of	O
retinal	B-Diagnostic_tool
OCT	I-Diagnostic_tool
images	I-Diagnostic_tool
from	O
clinical	O
routine	O
provides	O
a	O
promising	O
horizon	O
in	O
improving	O
accuracy	O
and	O
reliability	O
of	O
retinal	B-Anatomy
diagnosis	O
for	O
research	O
and	O
clinical	O
practice	O
in	O
ophthalmology	O
.	O
	
The	O
DISCOVER	O
Study	O
3	O
-	O
Year	O
Results	O
:	O
Feasibility	O
and	O
Usefulness	O
of	O
Microscope	B-Diagnostic_tool
-	I-Diagnostic_tool
Integrated	I-Diagnostic_tool
Intraoperative	I-Diagnostic_tool
OCT	I-Diagnostic_tool
during	O
Ophthalmic	O
Surgery	O
.	O
	
To	O
report	O
the	O
3	O
-	O
year	O
assessment	O
of	O
feasibility	O
and	O
usefulness	O
of	O
microscope	B-Diagnostic_tool
-	I-Diagnostic_tool
integrated	I-Diagnostic_tool
intraoperative	I-Diagnostic_tool
OCT	I-Diagnostic_tool
(	O
iOCT	B-Diagnostic_tool
)	O
during	O
ophthalmic	O
surgery	O
.	O
	
Prospective	O
,	O
consecutive	O
case	O
series	O
.	O
	
Adult	O
participants	O
undergoing	O
incisional	O
ophthalmic	O
surgery	O
with	O
iOCT	B-Diagnostic_tool
imaging	O
who	O
consented	O
to	O
be	O
enrolled	O
in	O
the	O
Determination	O
of	O
Feasibility	O
of	O
Intraoperative	B-Diagnostic_tool
Spectral	I-Diagnostic_tool
-	I-Diagnostic_tool
Domain	I-Diagnostic_tool
Microscope	I-Diagnostic_tool
Combined	I-Diagnostic_tool
/	I-Diagnostic_tool
Integrated	I-Diagnostic_tool
OCT	I-Diagnostic_tool
Visualization	O
during	O
En	O
Face	O
Retinal	O
and	O
Ophthalmic	O
Surgery	O
(	O
DISCOVER	O
)	O
study	O
.	O
	
The	O
DISCOVER	O
study	O
is	O
a	O
single	O
-	O
site	O
,	O
multisurgeon	O
,	O
institutional	O
review	O
board	O
-	O
approved	O
investigational	O
device	O
prospective	O
study	O
.	O
	
Participants	O
included	O
patients	O
undergoing	O
anterior	O
or	O
posterior	O
segment	O
surgery	O
who	O
underwent	O
iOCT	B-Diagnostic_tool
imaging	O
with	O
1	O
of	O
3	O
prototype	O
microscope	B-Diagnostic_tool
-	I-Diagnostic_tool
integrated	I-Diagnostic_tool
iOCT	I-Diagnostic_tool
systems	O
(	O
i	O
.	O
e	O
.	O
,	O
Zeiss	O
Rescan	O
700	O
,	O
Leica	O
EnFocus	O
,	O
or	O
Cole	O
Eye	O
iOCT	B-Diagnostic_tool
systems	O
)	O
.	O
	
Clinical	O
characteristics	O
were	O
documented	O
,	O
iOCT	B-Diagnostic_tool
was	O
directed	O
by	O
the	O
operating	O
surgeon	O
at	O
predetermined	O
surgical	O
time	O
points	O
,	O
and	O
each	O
surgeon	O
completed	O
a	O
questionnaire	O
after	O
surgery	O
to	O
evaluate	O
the	O
usefulness	O
of	O
iOCT	B-Diagnostic_tool
during	O
surgery	O
.	O
	
Feasibility	O
of	O
iOCT	B-Diagnostic_tool
based	O
ability	O
to	O
obtain	O
an	O
OCT	B-Diagnostic_tool
image	I-Diagnostic_tool
during	O
surgery	O
and	O
usefulness	O
of	O
iOCT	B-Diagnostic_tool
based	O
on	O
surgeon	O
reporting	O
during	O
surgery	O
.	O
	
Eight	O
hundred	O
thirty	O
-	O
seven	O
eyes	B-Anatomy
(	O
244	O
anterior	O
segment	O
cases	O
and	O
593	O
posterior	O
segment	O
cases	O
)	O
were	O
enrolled	O
in	O
the	O
DISCOVER	O
study	O
.	O
	
Intraoperative	B-Diagnostic_tool
OCT	I-Diagnostic_tool
demonstrated	O
feasibility	O
with	O
successful	O
image	O
acquisition	O
in	O
820	O
eyes	B-Anatomy
(	O
98	O
.	O
0	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
96	O
.	O
8	O
%	O
-	O
98	O
.	O
8	O
%	O
)	O
.	O
	
In	O
106	O
anterior	O
segment	O
cases	O
(	O
43	O
.	O
4	O
%	O
;	O
95	O
%	O
CI	O
,	O
37	O
.	O
1	O
%	O
-	O
49	O
.	O
9	O
%	O
)	O
,	O
the	O
surgeons	O
indicated	O
that	O
the	O
iOCT	B-Diagnostic_tool
information	O
impacted	O
their	O
surgical	O
decision	O
making	O
and	O
altered	O
the	O
procedure	O
.	O
	
In	O
posterior	O
segment	O
procedures	O
,	O
surgeons	O
reported	O
that	O
iOCT	B-Diagnostic_tool
enabled	O
altered	O
surgical	O
decision	O
making	O
during	O
the	O
procedure	O
in	O
173	O
cases	O
(	O
29	O
.	O
2	O
%	O
;	O
95	O
%	O
CI	O
,	O
25	O
.	O
5	O
%	O
-	O
33	O
.	O
0	O
%	O
)	O
.	O
	
The	O
DISCOVER	O
iOCT	B-Diagnostic_tool
study	O
demonstrated	O
both	O
generalized	O
feasibility	O
and	O
usefulness	O
based	O
on	O
the	O
surgeon	O
-	O
reported	O
impact	O
on	O
surgical	O
decision	O
making	O
.	O
	
This	O
large	O
-	O
scale	O
study	O
confirmed	O
similar	O
findings	O
from	O
other	O
studies	O
on	O
the	O
potential	O
value	O
and	O
impact	O
of	O
iOCT	B-Diagnostic_tool
on	O
ophthalmic	O
surgery	O
.	O
	
Grader	O
Variability	O
and	O
the	O
Importance	O
of	O
Reference	O
Standards	O
for	O
Evaluating	O
Machine	O
Learning	O
Models	O
for	O
Diabetic	B-Disease
Retinopathy	I-Disease
.	O
	
Use	O
adjudication	O
to	O
quantify	O
errors	O
in	O
diabetic	B-Disease
retinopathy	I-Disease
(	O
DR	B-Disease
)	O
grading	O
based	O
on	O
individual	O
graders	O
and	O
majority	O
decision	O
,	O
and	O
to	O
train	O
an	O
improved	O
automated	O
algorithm	O
for	O
DR	B-Disease
grading	O
.	O
	
Retrospective	O
analysis	O
.	O
	
Retinal	B-Diagnostic_tool
fundus	I-Diagnostic_tool
images	I-Diagnostic_tool
from	O
DR	B-Disease
screening	O
programs	O
.	O
	
Images	O
were	O
each	O
graded	O
by	O
the	O
algorithm	O
,	O
U	O
.	O
S	O
.	O
board	O
-	O
certified	O
ophthalmologists	O
,	O
and	O
retinal	B-Anatomy
specialists	O
.	O
	
The	O
adjudicated	O
consensus	O
of	O
the	O
retinal	B-Anatomy
specialists	O
served	O
as	O
the	O
reference	O
standard	O
.	O
	
For	O
agreement	O
between	O
different	O
graders	O
as	O
well	O
as	O
between	O
the	O
graders	O
and	O
the	O
algorithm	O
,	O
we	O
measured	O
the	O
(	O
quadratic	O
-	O
weighted	O
)	O
kappa	O
score	O
.	O
	
To	O
compare	O
the	O
performance	O
of	O
different	O
forms	O
of	O
manual	O
grading	O
and	O
the	O
algorithm	O
for	O
various	O
DR	B-Disease
severity	O
cutoffs	O
(	O
e	O
.	O
g	O
.	O
,	O
mild	B-Disease
or	I-Disease
worse	I-Disease
DR	I-Disease
,	O
moderate	B-Disease
or	I-Disease
worse	I-Disease
DR	I-Disease
)	O
,	O
we	O
measured	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
,	O
sensitivity	O
,	O
and	O
specificity	O
.	O
	
Of	O
the	O
193	O
discrepancies	O
between	O
adjudication	O
by	O
retinal	O
specialists	O
and	O
majority	O
decision	O
of	O
ophthalmologists	O
,	O
the	O
most	O
common	O
were	O
missing	O
microaneurysm	B-Symptom
(	O
MAs	B-Symptom
)	O
(	O
36	O
%	O
)	O
,	O
artifacts	O
(	O
20	O
%	O
)	O
,	O
and	O
misclassified	O
hemorrhages	B-Symptom
(	O
16	O
%	O
)	O
.	O
	
Relative	O
to	O
the	O
reference	O
standard	O
,	O
the	O
kappa	O
for	O
individual	O
retinal	B-Anatomy
specialists	O
,	O
ophthalmologists	O
,	O
and	O
algorithm	O
ranged	O
from	O
0	O
.	O
82	O
to	O
0	O
.	O
91	O
,	O
0	O
.	O
80	O
to	O
0	O
.	O
84	O
,	O
and	O
0	O
.	O
84	O
,	O
respectively	O
.	O
	
For	O
moderate	B-Disease
or	I-Disease
worse	I-Disease
DR	I-Disease
,	O
the	O
majority	O
decision	O
of	O
ophthalmologists	O
had	O
a	O
sensitivity	O
of	O
0	O
.	O
838	O
and	O
specificity	O
of	O
0	O
.	O
981	O
.	O
	
The	O
algorithm	O
had	O
a	O
sensitivity	O
of	O
0	O
.	O
971	O
,	O
specificity	O
of	O
0	O
.	O
923	O
,	O
and	O
AUC	O
of	O
0	O
.	O
986	O
.	O
	
For	O
mild	B-Disease
or	I-Disease
worse	I-Disease
DR	I-Disease
,	O
the	O
algorithm	O
had	O
a	O
sensitivity	O
of	O
0	O
.	O
970	O
,	O
specificity	O
of	O
0	O
.	O
917	O
,	O
and	O
AUC	O
of	O
0	O
.	O
986	O
.	O
	
By	O
using	O
a	O
small	O
number	O
of	O
adjudicated	O
consensus	O
grades	O
as	O
a	O
tuning	O
dataset	O
and	O
higher	B-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
images	I-Diagnostic_tool
as	O
input	O
,	O
the	O
algorithm	O
improved	O
in	O
AUC	O
from	O
0	O
.	O
934	O
to	O
0	O
.	O
986	O
for	O
moderate	B-Disease
or	I-Disease
worse	I-Disease
DR	I-Disease
.	O
	
Adjudication	O
reduces	O
the	O
errors	O
in	O
DR	B-Disease
grading	O
.	O
	
A	O
small	O
set	O
of	O
adjudicated	O
DR	B-Disease
grades	O
allows	O
substantial	O
improvements	O
in	O
algorithm	O
performance	O
.	O
	
The	O
resulting	O
algorithm	O
'	O
s	O
performance	O
was	O
on	O
par	O
with	O
that	O
of	O
individual	O
U	O
.	O
S	O
.	O
	
Board	O
-	O
Certified	O
ophthalmologists	O
and	O
retinal	B-Anatomy
specialists	O
.	O
	
The	O
Relationship	O
of	O
Retinal	B-Characteristic
Vessel	I-Characteristic
Geometric	I-Characteristic
Characteristics	I-Characteristic
to	O
the	O
Incidence	O
and	O
Progression	O
of	O
Diabetic	B-Disease
Retinopathy	I-Disease
.	O
	
To	O
examine	O
the	O
relationships	O
of	O
retinal	B-Characteristic
vessel	I-Characteristic
geometric	I-Characteristic
characteristics	I-Characteristic
(	O
RVGCs	B-Characteristic
)	O
to	O
the	O
incidence	O
and	O
progression	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
(	O
DR	B-Disease
)	O
.	O
	
Observational	O
,	O
prospective	O
cohort	O
study	O
.	O
	
Nine	O
hundred	O
ninety	O
-	O
six	O
persons	O
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
mellitus	I-Disease
(	O
T1DM	B-Disease
)	O
and	O
1370	O
persons	O
with	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
(	O
T2DM	B-Disease
)	O
seen	O
at	O
a	O
baseline	O
examination	O
who	O
were	O
eligible	O
for	O
follow	O
-	O
up	O
examinations	O
at	O
subsequent	O
5	O
-	O
year	O
intervals	O
.	O
	
A	O
total	O
of	O
3846	O
person	O
-	O
interval	O
data	O
from	O
these	O
follow	O
-	O
up	O
examinations	O
are	O
the	O
basis	O
for	O
the	O
analyses	O
.	O
	
Diabetic	B-Disease
retinopathy	I-Disease
and	O
macular	B-Disease
edema	I-Disease
were	O
assessed	O
by	O
grading	O
of	O
30	B-Diagnostic_tool
	I-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
color	I-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
.	O
	
Retinal	B-Characteristic
vessel	I-Characteristic
geometric	I-Characteristic
characteristics	I-Characteristic
were	O
assessed	O
using	O
the	O
Singapore	O
I	O
Vessel	O
Assessment	O
program	O
from	O
a	O
digitized	O
copy	O
of	O
1	O
of	O
the	O
field	O
1	O
fundus	B-Diagnostic_tool
photographs	I-Diagnostic_tool
obtained	O
at	O
baseline	O
and	O
follow	O
-	O
up	O
.	O
	
The	O
5	O
-	O
year	O
incidence	O
of	O
any	O
DR	B-Disease
,	O
progression	O
of	O
DR	B-Disease
,	O
and	O
incidence	O
of	O
proliferative	B-Disease
diabetic	I-Disease
retinopathy	I-Disease
(	O
PDR	B-Disease
)	O
and	O
clinically	B-Disease
significant	I-Disease
macular	I-Disease
edema	I-Disease
(	O
CSME	B-Disease
)	O
in	O
right	O
eyes	B-Anatomy
.	O
	
Incident	O
DR	B-Disease
occurred	O
in	O
45	O
%	O
,	O
progression	O
in	O
32	O
%	O
,	O
PDR	B-Disease
in	O
10	O
%	O
,	O
and	O
CSME	B-Disease
in	O
5	O
%	O
.	O
	
While	O
adjusting	O
for	O
glycated	O
hemoglobin	O
,	O
duration	O
of	O
diabetes	B-Disease
,	O
and	O
other	O
factors	O
,	O
retinal	B-Characteristic
arteriolar	I-Characteristic
simple	I-Characteristic
tortuosity	I-Characteristic
was	O
associated	O
significantly	O
with	O
the	O
incidence	O
of	O
any	O
DR	B-Disease
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1	O
.	O
17	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
35	O
)	O
.	O
	
Retinal	B-Characteristic
venular	I-Characteristic
branching	I-Characteristic
angle	I-Characteristic
was	O
associated	O
significantly	O
with	O
progression	O
of	O
DR	B-Disease
(	O
OR	O
,	O
1	O
.	O
18	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
03	O
-	O
1	O
.	O
36	O
)	O
,	O
retinal	B-Characteristic
venular	I-Characteristic
curvature	I-Characteristic
tortuosity	I-Characteristic
was	O
associated	O
significantly	O
with	O
the	O
incidence	O
of	O
PDR	B-Disease
(	O
OR	O
,	O
1	O
.	O
15	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
30	O
)	O
,	O
and	O
retinal	B-Characteristic
venular	I-Characteristic
branching	I-Characteristic
angle	I-Characteristic
(	O
OR	O
,	O
1	O
.	O
41	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
10	O
-	O
1	O
.	O
82	O
)	O
was	O
associated	O
significantly	O
with	O
the	O
incidence	O
of	O
CSME	B-Disease
.	O
	
There	O
were	O
no	O
significant	O
associations	O
of	O
other	O
RVGCs	B-Characteristic
with	O
any	O
of	O
the	O
DR	B-Disease
outcomes	O
in	O
the	O
full	O
multivariate	O
model	O
.	O
	
Inclusion	O
of	O
all	O
possible	O
RVGCs	B-Characteristic
did	O
not	O
improve	O
the	O
predictive	O
value	O
of	O
the	O
models	O
that	O
already	O
included	O
retinal	B-Characteristic
vessel	I-Characteristic
diameter	I-Characteristic
and	O
baseline	O
DR	B-Disease
severity	O
level	O
.	O
	
Retinal	B-Characteristic
vessel	I-Characteristic
geometric	I-Characteristic
characteristics	I-Characteristic
of	I-Characteristic
the	I-Characteristic
retinal	I-Characteristic
venules	I-Characteristic
were	O
associated	O
with	O
progression	O
of	O
DR	B-Disease
;	O
however	O
,	O
most	O
of	O
the	O
RVGCs	B-Characteristic
measured	O
from	O
digitized	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
added	O
little	O
to	O
the	O
assessment	O
of	O
risk	O
of	O
incidence	O
and	O
progression	O
of	O
DR	B-Disease
when	O
other	O
risk	O
factors	O
were	O
considered	O
in	O
T1DM	B-Disease
and	O
T2DM	B-Disease
.	O
	
DeepSeeNet	B-Diagnostic_tool
:	O
A	O
Deep	B-Diagnostic_tool
Learning	I-Diagnostic_tool
Model	I-Diagnostic_tool
for	O
Automated	O
Classification	O
of	O
Patient	O
-	O
based	O
Age	B-Disease
-	I-Disease
related	I-Disease
Macular	I-Disease
Degeneration	I-Disease
Severity	O
from	O
Color	B-Diagnostic_tool
Fundus	I-Diagnostic_tool
Photographs	I-Diagnostic_tool
.	O
	
In	O
assessing	O
the	O
severity	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
,	O
the	O
Age	B-Classification_system
-	I-Classification_system
Related	I-Classification_system
Eye	I-Classification_system
Disease	I-Classification_system
Study	I-Classification_system
(	I-Classification_system
AREDS	I-Classification_system
)	I-Classification_system
Simplified	I-Classification_system
Severity	I-Classification_system
Scale	I-Classification_system
predicts	O
the	O
risk	O
of	O
progression	O
to	O
late	B-Disease
AMD	I-Disease
.	O
	
However	O
,	O
its	O
manual	O
use	O
requires	O
the	O
time	O
-	O
consuming	O
participation	O
of	O
expert	O
practitioners	O
.	O
	
Although	O
several	O
automated	O
deep	O
learning	O
systems	O
have	O
been	O
developed	O
for	O
classifying	O
color	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
(	O
CFP	B-Diagnostic_tool
)	O
of	O
individual	O
eyes	B-Anatomy
by	O
AREDS	O
severity	O
score	O
,	O
none	O
to	O
date	O
has	O
used	O
a	O
patient	O
-	O
based	O
scoring	O
system	O
that	O
uses	O
images	O
from	O
both	O
eyes	B-Anatomy
to	O
assign	O
a	O
severity	O
score	O
.	O
	
DeepSeeNet	B-Diagnostic_tool
,	O
a	O
deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
model	I-Diagnostic_tool
,	O
was	O
developed	O
to	O
classify	O
patients	O
automatically	O
by	O
the	O
AREDS	B-Classification_system
Simplified	I-Classification_system
Severity	I-Classification_system
Scale	I-Classification_system
(	O
score	O
0	O
-	O
5	O
)	O
using	O
bilateral	O
CFP	B-Diagnostic_tool
.	O
	
DeepSeeNet	B-Diagnostic_tool
was	O
trained	O
on	O
58	O
402	O
and	O
tested	O
on	O
900	O
images	O
from	O
the	O
longitudinal	O
follow	O
-	O
up	O
of	O
4549	O
participants	O
from	O
AREDS	O
.	O
	
Gold	O
standard	O
labels	O
were	O
obtained	O
using	O
reading	O
center	O
grades	O
.	O
	
DeepSeeNet	B-Diagnostic_tool
simulates	O
the	O
human	O
grading	O
process	O
by	O
first	O
detecting	O
individual	O
AMD	B-Disease
risk	O
factors	O
(	O
drusen	B-Symptom
size	I-Symptom
,	O
pigmentary	B-Symptom
abnormalities	I-Symptom
)	O
for	O
each	O
eye	B-Anatomy
and	O
then	O
calculating	O
a	O
patient	O
-	O
based	O
AMD	B-Disease
severity	O
score	O
using	O
the	O
AREDS	B-Classification_system
Simplified	I-Classification_system
Severity	I-Classification_system
Scale	I-Classification_system
.	O
	
Overall	O
accuracy	O
,	O
specificity	O
,	O
sensitivity	O
,	O
Cohen	O
'	O
s	O
kappa	O
,	O
and	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
.	O
	
The	O
performance	O
of	O
DeepSeeNet	B-Diagnostic_tool
was	O
compared	O
with	O
that	O
of	O
retinal	O
specialists	O
.	O
	
DeepSeeNet	B-Diagnostic_tool
performed	O
better	O
on	O
patient	O
-	O
based	O
classification	O
(	O
accuracy	O
=	O
0	O
.	O
671	O
;	O
kappa	O
=	O
0	O
.	O
558	O
)	O
than	O
retinal	O
specialists	O
(	O
accuracy	O
=	O
0	O
.	O
599	O
;	O
kappa	O
=	O
0	O
.	O
467	O
)	O
with	O
high	O
AUC	O
in	O
the	O
detection	O
of	O
large	B-Symptom
drusen	I-Symptom
(	O
0	O
.	O
94	O
)	O
,	O
pigmentary	B-Symptom
abnormalities	I-Symptom
(	O
0	O
.	O
93	O
)	O
,	O
and	O
late	B-Disease
AMD	I-Disease
(	O
0	O
.	O
97	O
)	O
.	O
	
DeepSeeNet	B-Diagnostic_tool
also	O
outperformed	O
retinal	O
specialists	O
in	O
the	O
detection	O
of	O
large	B-Symptom
drusen	I-Symptom
(	O
accuracy	O
0	O
.	O
742	O
vs	O
.	O
0	O
.	O
696	O
;	O
kappa	O
0	O
.	O
601	O
vs	O
.	O
0	O
.	O
517	O
)	O
and	O
pigmentary	B-Symptom
abnormalities	I-Symptom
(	O
accuracy	O
0	O
.	O
890	O
vs	O
.	O
0	O
.	O
813	O
;	O
kappa	O
0	O
.	O
723	O
vs	O
.	O
0	O
.	O
535	O
)	O
but	O
showed	O
lower	O
performance	O
in	O
the	O
detection	O
of	O
late	B-Disease
AMD	I-Disease
(	O
accuracy	O
0	O
.	O
967	O
vs	O
.	O
0	O
.	O
973	O
;	O
kappa	O
0	O
.	O
663	O
vs	O
.	O
0	O
.	O
754	O
)	O
.	O
	
By	O
simulating	O
the	O
human	O
grading	O
process	O
,	O
DeepSeeNet	B-Diagnostic_tool
demonstrated	O
high	O
accuracy	O
with	O
increased	O
transparency	O
in	O
the	O
automated	O
assignment	O
of	O
individual	O
patients	O
to	O
AMD	B-Disease
risk	O
categories	O
based	O
on	O
the	O
AREDS	B-Classification_system
Simplified	I-Classification_system
Severity	I-Classification_system
Scale	I-Classification_system
.	O
	
These	O
results	O
highlight	O
the	O
potential	O
of	O
deep	O
learning	O
to	O
assist	O
and	O
enhance	O
clinical	O
decision	O
-	O
making	O
in	O
patients	O
with	O
AMD	B-Disease
,	O
such	O
as	O
early	B-Disease
AMD	I-Disease
detection	O
and	O
risk	O
prediction	O
for	O
developing	O
late	B-Disease
AMD	I-Disease
.	O
	
DeepSeeNet	B-Diagnostic_tool
is	O
publicly	O
available	O
on	O
https	O
:	O
/	O
/	O
github	O
.	O
com	O
/	O
ncbi	O
-	O
nlp	O
/	O
DeepSeeNet	O
.	O
	
Using	O
a	O
Deep	B-Diagnostic_tool
Learning	I-Diagnostic_tool
Algorithm	I-Diagnostic_tool
and	I-Diagnostic_tool
Integrated	I-Diagnostic_tool
Gradients	I-Diagnostic_tool
Explanation	I-Diagnostic_tool
to	O
Assist	O
Grading	O
for	O
Diabetic	B-Disease
Retinopathy	I-Disease
.	O
	
To	O
understand	O
the	O
impact	O
of	O
deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
diabetic	I-Diagnostic_tool
retinopathy	I-Diagnostic_tool
(	I-Diagnostic_tool
DR	I-Diagnostic_tool
)	I-Diagnostic_tool
algorithms	I-Diagnostic_tool
on	O
physician	O
readers	O
in	O
computer	O
-	O
assisted	O
settings	O
.	O
	
Evaluation	O
of	O
diagnostic	O
technology	O
.	O
	
One	O
thousand	O
seven	O
hundred	O
ninety	O
-	O
six	O
retinal	O
fundus	B-Diagnostic_tool
images	I-Diagnostic_tool
from	O
1612	O
diabetic	B-Disease
patients	O
.	O
	
Ten	O
ophthalmologists	O
(	O
5	O
general	O
ophthalmologists	O
,	O
4	O
retina	B-Anatomy
specialists	O
,	O
1	O
retina	B-Anatomy
fellow	O
)	O
read	O
images	O
for	O
DR	B-Disease
severity	O
based	O
on	O
the	O
International	B-Diagnostic_tool
Clinical	I-Diagnostic_tool
Diabetic	I-Diagnostic_tool
Retinopathy	I-Diagnostic_tool
disease	I-Diagnostic_tool
severity	I-Diagnostic_tool
scale	I-Diagnostic_tool
in	O
each	O
of	O
3	O
conditions	O
:	O
unassisted	O
,	O
grades	O
only	O
,	O
or	O
grades	O
plus	O
heatmap	O
.	O
	
Grades	O
-	O
only	O
assistance	O
comprised	O
a	O
histogram	O
of	O
DR	B-Disease
predictions	O
(	O
grades	O
)	O
from	O
a	O
trained	O
deep	O
-	O
learning	O
model	O
.	O
	
For	O
grades	O
plus	O
heatmap	O
,	O
we	O
additionally	O
showed	O
explanatory	O
heatmaps	O
.	O
	
For	O
each	O
experiment	O
arm	O
,	O
we	O
computed	O
sensitivity	O
and	O
specificity	O
of	O
each	O
reader	O
and	O
the	O
algorithm	O
for	O
different	O
levels	O
of	O
DR	B-Disease
severity	O
against	O
an	O
adjudicated	O
reference	O
standard	O
.	O
	
We	O
also	O
measured	O
accuracy	O
(	O
exact	O
5	O
-	O
class	O
level	O
agreement	O
and	O
Cohen	O
'	O
s	O
quadratically	O
weighted	O
	O
)	O
,	O
reader	O
-	O
reported	O
confidence	O
(	O
5	O
-	O
point	O
Likert	O
scale	O
)	O
,	O
and	O
grading	O
time	O
.	O
	
Readers	O
graded	O
more	O
accurately	O
with	O
model	O
assistance	O
than	O
without	O
for	O
the	O
grades	O
-	O
only	O
condition	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
Grades	O
plus	O
heatmaps	O
improved	O
accuracy	O
for	O
patients	O
with	O
DR	B-Disease
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
reduced	O
accuracy	O
for	O
patients	O
without	O
DR	B-Disease
(	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O
	
Both	O
forms	O
of	O
assistance	O
increased	O
readers	O
'	O
sensitivity	O
moderate	O
-	O
or	O
-	O
worse	O
DR	B-Disease
:	O
unassisted	O
:	O
mean	O
,	O
79	O
.	O
4	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
72	O
.	O
3	O
%	O
-	O
86	O
.	O
5	O
%	O
]	O
;	O
grades	O
only	O
:	O
mean	O
,	O
87	O
.	O
5	O
%	O
[	O
95	O
%	O
CI	O
,	O
85	O
.	O
1	O
%	O
-	O
89	O
.	O
9	O
%	O
]	O
;	O
grades	O
plus	O
heatmap	O
:	O
mean	O
,	O
88	O
.	O
7	O
%	O
[	O
95	O
%	O
CI	O
,	O
84	O
.	O
9	O
%	O
-	O
92	O
.	O
5	O
%	O
]	O
without	O
a	O
corresponding	O
drop	O
in	O
specificity	O
(	O
unassisted	O
:	O
mean	O
,	O
96	O
.	O
6	O
%	O
[	O
95	O
%	O
CI	O
,	O
95	O
.	O
9	O
%	O
-	O
97	O
.	O
4	O
%	O
]	O
;	O
grades	O
only	O
:	O
mean	O
,	O
96	O
.	O
1	O
%	O
[	O
95	O
%	O
CI	O
,	O
95	O
.	O
5	O
%	O
-	O
96	O
.	O
7	O
%	O
]	O
;	O
grades	O
plus	O
heatmap	O
:	O
mean	O
,	O
95	O
.	O
5	O
%	O
[	O
95	O
%	O
CI	O
,	O
94	O
.	O
8	O
%	O
-	O
96	O
.	O
1	O
%	O
]	O
)	O
.	O
	
Algorithmic	O
assistance	O
increased	O
the	O
accuracy	O
of	O
retina	B-Anatomy
specialists	O
above	O
that	O
of	O
the	O
unassisted	O
reader	O
or	O
model	O
alone	O
;	O
and	O
increased	O
grading	O
confidence	O
and	O
grading	O
time	O
across	O
all	O
readers	O
.	O
	
For	O
most	O
cases	O
,	O
grades	O
plus	O
heatmap	O
was	O
only	O
as	O
effective	O
as	O
grades	O
only	O
.	O
	
Over	O
the	O
course	O
of	O
the	O
experiment	O
,	O
grading	O
time	O
decreased	O
across	O
all	O
conditions	O
,	O
although	O
most	O
sharply	O
for	O
grades	O
plus	O
heatmap	O
.	O
	
Deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
algorithms	I-Diagnostic_tool
can	O
improve	O
the	O
accuracy	O
of	O
,	O
and	O
confidence	O
in	O
,	O
DR	B-Disease
diagnosis	O
in	O
an	O
assisted	O
read	O
setting	O
.	O
	
They	O
also	O
may	O
increase	O
grading	O
time	O
,	O
although	O
these	O
effects	O
may	O
be	O
ameliorated	O
with	O
experience	O
.	O
	
A	O
Deep	B-Diagnostic_tool
Learning	I-Diagnostic_tool
Approach	O
for	O
Automated	O
Detection	O
of	O
Geographic	B-Symptom
Atrophy	I-Symptom
from	O
Color	B-Diagnostic_tool
Fundus	I-Diagnostic_tool
Photographs	I-Diagnostic_tool
.	O
	
To	O
assess	O
the	O
utility	O
of	O
deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
in	O
the	O
detection	O
of	O
geographic	B-Symptom
atrophy	I-Symptom
(	O
GA	B-Symptom
)	O
from	O
color	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
and	O
to	O
explore	O
potential	O
utility	O
in	O
detecting	O
central	B-Symptom
GA	I-Symptom
(	O
CGA	B-Symptom
)	O
.	O
	
A	O
deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
model	I-Diagnostic_tool
was	O
developed	O
to	O
detect	O
the	O
presence	O
of	O
GA	B-Symptom
in	O
color	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
,	O
and	O
2	O
additional	O
models	B-Diagnostic_tool
were	O
developed	O
to	O
detect	O
CGA	B-Symptom
in	O
different	O
scenarios	O
.	O
	
A	O
total	O
of	O
59	O
812	O
color	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
from	O
longitudinal	O
follow	O
-	O
up	O
of	O
4582	O
participants	O
in	O
the	O
Age	B-Disease
-	I-Disease
Related	I-Disease
Eye	I-Disease
Disease	I-Disease
Study	O
(	O
AREDS	O
)	O
dataset	O
.	O
	
Gold	O
standard	O
labels	O
were	O
from	O
human	O
expert	O
reading	O
center	O
graders	O
using	O
a	O
standardized	O
protocol	O
.	O
	
A	O
deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
model	I-Diagnostic_tool
was	O
trained	O
to	O
use	O
color	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
to	O
predict	O
GA	B-Symptom
presence	O
from	O
a	O
population	O
of	O
eyes	B-Anatomy
with	O
no	O
AMD	B-Disease
to	O
advanced	B-Disease
AMD	I-Disease
.	O
	
A	O
second	O
model	B-Diagnostic_tool
was	O
trained	O
to	O
predict	O
CGA	B-Symptom
presence	O
from	O
the	O
same	O
population	O
.	O
	
A	O
third	O
model	B-Diagnostic_tool
was	O
trained	O
to	O
predict	O
CGA	B-Symptom
presence	O
from	O
the	O
subset	O
of	O
eyes	B-Anatomy
with	O
GA	B-Symptom
.	O
	
For	O
training	O
and	O
testing	O
,	O
5	O
-	O
fold	O
cross	O
-	O
validation	O
was	O
used	O
.	O
	
For	O
comparison	O
with	O
human	O
clinician	O
performance	O
,	O
model	O
performance	O
was	O
compared	O
with	O
that	O
of	O
88	O
retinal	B-Anatomy
specialists	O
.	O
	
Area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
,	O
accuracy	O
,	O
sensitivity	O
,	O
specificity	O
,	O
and	O
precision	O
.	O
	
The	O
deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
models	I-Diagnostic_tool
(	O
GA	B-Symptom
detection	O
,	O
CGA	B-Symptom
detection	O
from	O
all	O
eyes	B-Anatomy
,	O
and	O
centrality	O
detection	O
from	O
GA	B-Symptom
eyes	B-Anatomy
)	O
had	O
AUCs	O
of	O
0	O
.	O
933	O
-	O
0	O
.	O
976	O
,	O
0	O
.	O
939	O
-	O
0	O
.	O
976	O
,	O
and	O
0	O
.	O
827	O
-	O
0	O
.	O
888	O
,	O
respectively	O
.	O
	
The	O
GA	B-Diagnostic_tool
detection	I-Diagnostic_tool
model	I-Diagnostic_tool
had	O
accuracy	O
,	O
sensitivity	O
,	O
specificity	O
,	O
and	O
precision	O
of	O
0	O
.	O
965	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0	O
.	O
959	O
-	O
0	O
.	O
971	O
)	O
,	O
0	O
.	O
692	O
(	O
0	O
.	O
560	O
-	O
0	O
.	O
825	O
)	O
,	O
0	O
.	O
978	O
(	O
0	O
.	O
970	O
-	O
0	O
.	O
985	O
)	O
,	O
and	O
0	O
.	O
584	O
(	O
0	O
.	O
491	O
-	O
0	O
.	O
676	O
)	O
,	O
respectively	O
,	O
compared	O
with	O
0	O
.	O
975	O
(	O
0	O
.	O
971	O
-	O
0	O
.	O
980	O
)	O
,	O
0	O
.	O
588	O
(	O
0	O
.	O
468	O
-	O
0	O
.	O
707	O
)	O
,	O
0	O
.	O
982	O
(	O
0	O
.	O
978	O
-	O
0	O
.	O
985	O
)	O
,	O
and	O
0	O
.	O
368	O
(	O
0	O
.	O
230	O
-	O
0	O
.	O
505	O
)	O
for	O
the	O
retinal	O
specialists	O
.	O
	
The	O
CGA	B-Diagnostic_tool
detection	I-Diagnostic_tool
model	I-Diagnostic_tool
had	O
values	O
of	O
0	O
.	O
966	O
(	O
0	O
.	O
957	O
-	O
0	O
.	O
975	O
)	O
,	O
0	O
.	O
763	O
(	O
0	O
.	O
641	O
-	O
0	O
.	O
885	O
)	O
,	O
0	O
.	O
971	O
(	O
0	O
.	O
960	O
-	O
0	O
.	O
982	O
)	O
,	O
and	O
0	O
.	O
394	O
(	O
0	O
.	O
341	O
-	O
0	O
.	O
448	O
)	O
.	O
	
The	O
centrality	B-Diagnostic_tool
detection	I-Diagnostic_tool
model	I-Diagnostic_tool
had	O
values	O
of	O
0	O
.	O
762	O
(	O
0	O
.	O
725	O
-	O
0	O
.	O
799	O
)	O
,	O
0	O
.	O
782	O
(	O
0	O
.	O
618	O
-	O
0	O
.	O
945	O
)	O
,	O
0	O
.	O
729	O
(	O
0	O
.	O
543	O
-	O
0	O
.	O
916	O
)	O
,	O
and	O
0	O
.	O
799	O
(	O
0	O
.	O
710	O
-	O
0	O
.	O
888	O
)	O
.	O
	
A	O
deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
model	I-Diagnostic_tool
demonstrated	O
high	O
accuracy	O
for	O
the	O
automated	O
detection	O
of	O
GA	B-Symptom
.	O
	
The	O
AUC	O
was	O
noninferior	O
to	O
that	O
of	O
human	O
retinal	O
specialists	O
.	O
	
Deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
approaches	O
may	O
also	O
be	O
applied	O
to	O
the	O
identification	O
of	O
CGA	B-Symptom
.	O
	
The	O
code	O
and	O
pretrained	O
models	O
are	O
publicly	O
available	O
at	O
https	O
:	O
/	O
/	O
github	O
.	O
com	O
/	O
ncbi	O
-	O
nlp	O
/	O
DeepSeeNet	O
.	O
	
OCT	B-Diagnostic_tool
Angiography	I-Diagnostic_tool
Metrics	O
Predict	O
Progression	O
of	O
Diabetic	B-Disease
Retinopathy	I-Disease
and	O
Development	O
of	O
Diabetic	B-Disease
Macular	I-Disease
Edema	I-Disease
:	O
A	O
Prospective	O
Study	O
.	O
	
To	O
prospectively	O
determine	O
the	O
relationship	O
of	O
OCT	B-Diagnostic_tool
angiography	I-Diagnostic_tool
(	O
OCTA	B-Diagnostic_tool
)	O
metrics	O
to	O
diabetic	B-Disease
retinopathy	I-Disease
(	O
DR	B-Disease
)	O
progression	O
and	O
development	O
of	O
diabetic	B-Disease
macular	I-Disease
edema	I-Disease
(	O
DME	B-Disease
)	O
.	O
	
Prospective	O
,	O
observational	O
study	O
.	O
	
A	O
total	O
of	O
205	O
eyes	B-Anatomy
from	O
129	O
patients	O
with	O
diabetes	B-Disease
mellitus	I-Disease
followed	O
up	O
for	O
at	O
least	O
2	O
years	O
.	O
	
All	O
participants	O
underwent	O
OCTA	B-Diagnostic_tool
with	O
a	O
swept	B-Diagnostic_tool
-	I-Diagnostic_tool
source	I-Diagnostic_tool
OCT	I-Diagnostic_tool
device	I-Diagnostic_tool
(	O
DRI	B-Diagnostic_tool
-	I-Diagnostic_tool
OCT	I-Diagnostic_tool
Triton	I-Diagnostic_tool
,	O
Topcon	O
,	O
Inc	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O
	
Individual	O
OCTA	B-Diagnostic_tool
images	I-Diagnostic_tool
of	O
superficial	B-Anatomy
capillary	I-Anatomy
plexus	I-Anatomy
(	O
SCP	B-Anatomy
)	O
and	O
deep	B-Anatomy
capillary	I-Anatomy
plexus	I-Anatomy
(	O
DCP	B-Anatomy
)	O
were	O
generated	O
by	O
IMAGEnet6	O
(	O
Basic	O
License	O
10	O
)	O
.	O
	
After	O
a	O
quality	O
check	O
,	O
automated	O
measurements	O
of	O
foveal	B-Characteristic
avascular	I-Characteristic
zone	I-Characteristic
(	I-Characteristic
FAZ	I-Characteristic
)	I-Characteristic
area	I-Characteristic
,	O
FAZ	B-Characteristic
circularity	I-Characteristic
,	O
vessel	B-Characteristic
density	I-Characteristic
(	O
VD	B-Characteristic
)	O
,	O
and	O
fractal	B-Characteristic
dimension	I-Characteristic
(	O
FD	B-Characteristic
)	O
of	O
both	O
SCP	B-Anatomy
and	O
DCP	B-Anatomy
were	O
then	O
obtained	O
.	O
	
Progression	O
of	O
DR	B-Disease
and	O
development	O
of	O
DME	B-Disease
.	O
	
Over	O
a	O
median	O
follow	O
-	O
up	O
of	O
27	O
.	O
14	O
months	O
(	O
interquartile	O
range	O
,	O
24	O
.	O
16	O
-	O
30	O
.	O
41	O
months	O
)	O
,	O
28	O
of	O
the	O
205	O
eyes	B-Anatomy
(	O
13	O
.	O
66	O
%	O
)	O
developed	O
DR	B-Disease
progression	O
.	O
	
Of	O
the	O
194	O
eyes	B-Anatomy
without	O
DME	B-Disease
at	O
baseline	O
,	O
17	O
(	O
8	O
.	O
76	O
%	O
)	O
developed	O
DME	B-Disease
.	O
	
Larger	B-Characteristic
FAZ	I-Characteristic
area	I-Characteristic
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1	O
.	O
829	O
per	O
SD	O
increase	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
332	O
-	O
2	O
.	O
512	O
)	O
,	O
lower	B-Characteristic
VD	I-Characteristic
(	O
HR	O
,	O
1	O
.	O
908	O
per	O
SD	O
decrease	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
303	O
-	O
2	O
.	O
793	O
)	O
,	O
and	O
lower	B-Characteristic
FD	I-Characteristic
(	O
HR	O
,	O
4	O
.	O
464	O
per	O
SD	O
decrease	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
337	O
-	O
14	O
.	O
903	O
)	O
of	O
DCP	B-Anatomy
were	O
significantly	O
associated	O
with	O
DR	B-Disease
progression	O
after	O
adjusting	O
for	O
established	O
risk	O
factors	O
(	O
DR	B-Characteristic
severity	I-Characteristic
,	O
glycated	B-Characteristic
hemoglobin	I-Characteristic
,	O
duration	B-Characteristic
of	I-Characteristic
diabetes	I-Characteristic
,	O
age	B-Characteristic
,	O
and	O
mean	B-Characteristic
arterial	I-Characteristic
blood	I-Characteristic
pressure	I-Characteristic
at	O
baseline	O
)	O
.	O
	
Lower	B-Characteristic
VD	I-Characteristic
of	I-Characteristic
SCP	I-Characteristic
(	O
HR	O
,	O
1	O
.	O
789	O
per	O
SD	O
decrease	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
027	O
-	O
4	O
.	O
512	O
)	O
was	O
associated	O
with	O
DME	B-Disease
development	O
.	O
	
Compared	O
with	O
the	O
model	O
with	O
established	O
risk	O
factors	O
alone	O
,	O
the	O
addition	O
of	O
OCTA	B-Diagnostic_tool
metrics	O
improved	O
the	O
predictive	O
discrimination	O
of	O
DR	B-Disease
progression	O
(	O
FAZ	B-Characteristic
area	I-Characteristic
of	I-Characteristic
DCP	I-Characteristic
,	O
C	O
-	O
statistics	O
0	O
.	O
723	O
vs	O
.	O
0	O
.	O
677	O
,	O
P	O
<	O
0	O
.	O
001	O
;	O
VD	B-Characteristic
of	I-Characteristic
DCP	I-Characteristic
,	O
C	O
-	O
statistics	O
0	O
.	O
727	O
vs	O
.	O
0	O
.	O
677	O
,	O
P	O
=	O
0	O
.	O
001	O
;	O
FD	B-Characteristic
of	I-Characteristic
DCP	I-Characteristic
,	O
C	O
-	O
statistics	O
0	O
.	O
738	O
vs	O
.	O
0	O
.	O
677	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
DME	B-Disease
development	O
(	O
VD	B-Characteristic
of	I-Characteristic
SCP	I-Characteristic
,	O
C	O
-	O
statistics	O
0	O
.	O
904	O
vs	O
.	O
0	O
.	O
875	O
,	O
P	O
=	O
0	O
.	O
036	O
)	O
.	O
	
The	O
FAZ	B-Characteristic
area	I-Characteristic
,	O
VD	B-Characteristic
,	O
and	O
FD	B-Characteristic
of	I-Characteristic
DCP	I-Characteristic
predict	O
DR	B-Disease
progression	O
,	O
whereas	O
VD	B-Characteristic
of	I-Characteristic
SCP	I-Characteristic
predicts	O
DME	B-Disease
development	O
.	O
	
Our	O
findings	O
provide	O
evidence	O
to	O
support	O
that	O
OCTA	B-Diagnostic_tool
metrics	O
improve	O
the	O
evaluation	O
of	O
risk	O
of	O
DR	B-Disease
progression	O
and	O
DME	B-Disease
development	O
beyond	O
traditional	O
risk	O
factors	O
.	O
	
Diagnostic	O
Accuracy	O
of	O
Technology	O
-	O
based	O
Eye	B-Anatomy
Care	O
Services	O
:	O
The	O
Technology	O
-	O
based	O
Eye	B-Anatomy
Care	O
Services	O
Compare	O
Trial	O
Part	O
I	O
.	O
	
Ophthalmologic	O
telemedicine	O
has	O
the	O
ability	O
to	O
provide	O
eye	B-Anatomy
care	O
for	O
patients	O
remotely	O
,	O
and	O
many	O
countries	O
have	O
used	O
screening	O
tele	O
-	O
ophthalmology	O
programs	O
for	O
several	O
years	O
.	O
	
One	O
such	O
initiative	O
at	O
the	O
Veterans	O
Affairs	O
(	O
VA	O
)	O
Healthcare	O
System	O
is	O
Technology	O
-	O
based	O
Eye	B-Anatomy
Care	O
Services	O
(	O
TECS	O
)	O
.	O
	
The	O
TECS	O
services	O
are	O
located	O
in	O
primary	O
care	O
clinics	O
and	O
provide	O
basic	O
screening	O
eye	B-Anatomy
care	O
,	O
including	O
vision	O
,	O
refraction	O
,	O
and	O
retinal	B-Diagnostic_tool
photography	I-Diagnostic_tool
.	O
	
Eye	B-Anatomy
care	O
providers	O
(	O
"	O
readers	O
"	O
)	O
review	O
the	O
clinical	O
data	O
and	O
recommend	O
appropriate	O
follow	O
-	O
up	O
.	O
	
One	O
of	O
the	O
most	O
common	O
referrals	O
from	O
TECS	O
has	O
been	O
for	O
glaucoma	B-Disease
,	O
and	O
this	O
study	O
was	O
powered	O
for	O
glaucoma	B-Disease
/	O
glaucoma	B-Disease
suspect	I-Disease
detection	O
.	O
	
The	O
current	O
study	O
was	O
undertaken	O
to	O
identify	O
aspects	O
of	O
the	O
protocol	O
that	O
could	O
be	O
refined	O
to	O
enhance	O
accuracy	O
.	O
	
Prospective	O
comparison	O
between	O
the	O
standard	O
TECS	O
protocol	O
versus	O
a	O
face	B-Diagnostic_tool
-	I-Diagnostic_tool
to	I-Diagnostic_tool
-	I-Diagnostic_tool
face	I-Diagnostic_tool
(	I-Diagnostic_tool
FTF	I-Diagnostic_tool
)	I-Diagnostic_tool
examination	I-Diagnostic_tool
on	O
256	O
patients	O
,	O
all	O
of	O
whom	O
had	O
no	O
known	O
history	O
of	O
significant	O
ocular	B-Disease
disease	I-Disease
.	O
	
Patients	O
with	O
no	O
known	O
ocular	O
disease	O
who	O
were	O
scheduled	O
for	O
an	O
in	O
-	O
person	O
eye	B-Anatomy
appointment	O
at	O
the	O
Atlanta	O
VA	O
.	O
	
Patients	O
underwent	O
screening	O
through	O
the	O
TECS	O
protocol	O
and	O
received	O
an	O
FTF	B-Diagnostic_tool
examination	I-Diagnostic_tool
on	O
the	O
same	O
day	O
(	O
gold	O
standard	O
)	O
.	O
	
The	O
TECS	O
readers	O
were	O
masked	O
to	O
the	O
results	O
of	O
the	O
FTF	B-Diagnostic_tool
examination	I-Diagnostic_tool
.	O
	
Percent	O
agreement	O
,	O
kappa	O
,	O
sensitivity	O
,	O
and	O
specificity	O
were	O
calculated	O
for	O
the	O
TECS	O
readers	O
'	O
interpretations	O
versus	O
the	O
FTF	B-Diagnostic_tool
examination	I-Diagnostic_tool
.	O
	
The	O
TECS	O
readers	O
showed	O
substantial	O
agreement	O
for	O
cataract	B-Disease
(	O
	O
	O
0	O
.	O
71	O
)	O
and	O
diabetic	B-Disease
retinopathy	I-Disease
(	O
	O
	O
0	O
.	O
61	O
)	O
and	O
moderate	O
to	O
substantial	O
agreement	O
for	O
glaucoma	B-Disease
/	O
glaucoma	B-Disease
suspect	I-Disease
(	O
	O
	O
0	O
.	O
52	O
)	O
compared	O
with	O
an	O
FTF	B-Diagnostic_tool
examination	I-Diagnostic_tool
.	O
	
Age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
showed	O
moderate	O
agreement	O
(	O
	O
	O
0	O
.	O
34	O
)	O
.	O
	
Percent	O
agreement	O
with	O
the	O
TECS	B-Diagnostic_tool
protocol	I-Diagnostic_tool
was	O
high	O
(	O
84	O
.	O
3	O
%	O
-	O
98	O
.	O
4	O
%	O
)	O
for	O
each	O
of	O
the	O
disease	O
categories	O
.	O
	
Overall	O
sensitivity	O
and	O
specificity	O
were	O
	O
75	O
%	O
and	O
	O
55	O
%	O
,	O
respectively	O
,	O
for	O
any	O
diagnosis	O
resulting	O
in	O
referral	O
.	O
	
Inter	O
-	O
reader	O
and	O
intra	O
-	O
reader	O
agreement	O
was	O
substantial	O
for	O
most	O
diagnoses	O
(	O
	O
>	O
0	O
.	O
61	O
)	O
with	O
percent	O
agreements	O
ranging	O
from	O
66	O
%	O
to	O
99	O
%	O
.	O
	
Our	O
results	O
indicate	O
that	O
the	O
standard	O
TECS	B-Diagnostic_tool
protocol	I-Diagnostic_tool
is	O
accurate	O
when	O
compared	O
with	O
an	O
FTF	B-Diagnostic_tool
examination	I-Diagnostic_tool
for	O
the	O
detection	O
of	O
common	O
eye	B-Disease
diseases	I-Disease
.	O
	
The	O
inclusion	O
of	O
additional	O
testing	O
such	O
as	O
OCT	B-Diagnostic_tool
could	O
further	O
enhance	O
diagnostic	O
capability	O
.	O
	
Deep	B-Diagnostic_tool
Learning	I-Diagnostic_tool
and	O
Glaucoma	B-Disease
Specialists	O
:	O
The	O
Relative	O
Importance	O
of	O
Optic	B-Anatomy
Disc	I-Anatomy
Features	O
to	O
Predict	O
Glaucoma	B-Disease
Referral	O
in	O
Fundus	B-Diagnostic_tool
Photographs	I-Diagnostic_tool
.	O
	
To	O
develop	O
and	O
validate	O
a	O
deep	B-Diagnostic_tool
learning	I-Diagnostic_tool
(	O
DL	B-Diagnostic_tool
)	O
algorithm	O
that	O
predicts	O
referable	B-Disease
glaucomatous	I-Disease
optic	I-Disease
neuropathy	I-Disease
(	O
GON	B-Disease
)	O
and	O
optic	B-Anatomy
nerve	I-Anatomy
head	I-Anatomy
(	O
ONH	B-Anatomy
)	O
features	O
from	O
color	B-Diagnostic_tool
fundus	I-Diagnostic_tool
images	I-Diagnostic_tool
,	O
to	O
determine	O
the	O
relative	O
importance	O
of	O
these	O
features	O
in	O
referral	O
decisions	O
by	O
glaucoma	B-Disease
specialists	O
(	O
GSs	O
)	O
and	O
the	O
algorithm	O
,	O
and	O
to	O
compare	O
the	O
performance	O
of	O
the	O
algorithm	O
with	O
eye	B-Anatomy
care	O
providers	O
.	O
	
Development	O
and	O
validation	O
of	O
an	O
algorithm	O
.	O
	
Fundus	B-Diagnostic_tool
images	I-Diagnostic_tool
from	O
screening	O
programs	O
,	O
studies	O
,	O
and	O
a	O
glaucoma	B-Disease
clinic	O
.	O
	
A	O
DL	B-Diagnostic_tool
algorithm	O
was	O
trained	O
using	O
a	O
retrospective	O
dataset	O
of	O
86	O
618	O
images	O
,	O
assessed	O
for	O
glaucomatous	B-Disease
ONH	B-Anatomy
features	O
and	O
referable	B-Disease
GON	I-Disease
(	O
defined	O
as	O
ONH	B-Anatomy
appearance	O
worrisome	O
enough	O
to	O
justify	O
referral	O
for	O
comprehensive	O
examination	O
)	O
by	O
43	O
graders	O
.	O
	
The	O
algorithm	O
was	O
validated	O
using	O
3	O
datasets	O
:	O
dataset	O
A	O
(	O
1205	O
images	O
,	O
1	O
image	O
/	O
patient	O
;	O
18	O
.	O
1	O
%	O
referable	O
)	O
,	O
images	O
adjudicated	O
by	O
panels	O
of	O
GSs	O
;	O
dataset	O
B	O
(	O
9642	O
images	O
,	O
1	O
image	O
/	O
patient	O
;	O
9	O
.	O
2	O
%	O
referable	O
)	O
,	O
images	O
from	O
a	O
diabetic	B-Disease
teleretinal	O
screening	O
program	O
;	O
and	O
dataset	O
C	O
(	O
346	O
images	O
,	O
1	O
image	O
/	O
patient	O
;	O
81	O
.	O
7	O
%	O
referable	O
)	O
,	O
images	O
from	O
a	O
glaucoma	B-Disease
clinic	O
.	O
	
The	O
algorithm	O
was	O
evaluated	O
using	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
AUC	O
)	O
,	O
sensitivity	O
,	O
and	O
specificity	O
for	O
referable	B-Disease
GON	I-Disease
and	O
glaucomatous	B-Disease
ONH	B-Anatomy
features	O
.	O
	
The	O
algorithm	O
'	O
s	O
AUC	O
for	O
referable	B-Disease
GON	I-Disease
was	O
0	O
.	O
945	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0	O
.	O
929	O
-	O
0	O
.	O
960	O
)	O
in	O
dataset	O
A	O
,	O
0	O
.	O
855	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
841	O
-	O
0	O
.	O
870	O
)	O
in	O
dataset	O
B	O
,	O
and	O
0	O
.	O
881	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
838	O
-	O
0	O
.	O
918	O
)	O
in	O
dataset	O
C	O
.	O
	
Algorithm	O
AUCs	O
ranged	O
between	O
0	O
.	O
661	O
and	O
0	O
.	O
973	O
for	O
glaucomatous	B-Disease
ONH	B-Anatomy
features	O
.	O
	
The	O
algorithm	O
showed	O
significantly	O
higher	O
sensitivity	O
than	O
7	O
of	O
10	O
graders	O
not	O
involved	O
in	O
determining	O
the	O
reference	O
standard	O
,	O
including	O
2	O
of	O
3	O
GSs	O
,	O
and	O
showed	O
higher	O
specificity	O
than	O
3	O
graders	O
(	O
including	O
1	O
GS	O
)	O
,	O
while	O
remaining	O
comparable	O
to	O
others	O
.	O
	
For	O
both	O
GSs	O
and	O
the	O
algorithm	O
,	O
the	O
most	O
crucial	O
features	O
related	O
to	O
referable	B-Disease
GON	I-Disease
were	O
:	O
presence	O
of	O
vertical	B-Symptom
cup	I-Symptom
-	I-Symptom
to	I-Symptom
-	I-Symptom
disc	I-Symptom
ratio	I-Symptom
of	I-Symptom
0	I-Symptom
.	I-Symptom
7	I-Symptom
or	I-Symptom
more	I-Symptom
,	O
neuroretinal	B-Symptom
rim	I-Symptom
notching	I-Symptom
,	O
retinal	B-Symptom
nerve	I-Symptom
fiber	I-Symptom
layer	I-Symptom
defect	I-Symptom
,	O
and	O
bared	B-Symptom
circumlinear	I-Symptom
vessels	I-Symptom
.	O
	
A	O
DL	B-Diagnostic_tool
algorithm	O
trained	O
on	O
fundus	B-Diagnostic_tool
images	I-Diagnostic_tool
alone	O
can	O
detect	O
referable	B-Disease
GON	I-Disease
with	O
higher	O
sensitivity	O
than	O
and	O
comparable	O
specificity	O
to	O
eye	B-Anatomy
care	O
providers	O
.	O
	
The	O
algorithm	O
maintained	O
good	O
performance	O
on	O
an	O
independent	O
dataset	O
with	O
diagnoses	O
based	O
on	O
a	O
full	O
glaucoma	B-Disease
workup	O
.	O
	
Chronic	B-Symptom
hematic	I-Symptom
cyst	I-Symptom
of	I-Symptom
the	I-Symptom
orbit	I-Symptom
.	O
	
Role	O
of	O
magnetic	B-Diagnostic_tool
resonance	I-Diagnostic_tool
imaging	I-Diagnostic_tool
in	O
diagnosis	O
.	O
	
Chronic	B-Symptom
hematic	I-Symptom
cysts	I-Symptom
of	I-Symptom
the	I-Symptom
orbit	I-Symptom
are	O
rare	O
causes	O
of	O
proptosis	B-Disease
.	O
	
They	O
progressively	O
enlarge	O
causing	O
expansion	B-Symptom
or	I-Symptom
erosion	I-Symptom
of	I-Symptom
the	I-Symptom
orbital	I-Symptom
bones	I-Symptom
and	O
may	O
give	O
the	O
appearance	O
on	O
computed	B-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
CT	B-Diagnostic_tool
)	O
scan	O
of	O
a	O
malignant	B-Symptom
orbital	I-Symptom
process	I-Symptom
.	O
	
Hematic	B-Symptom
cysts	I-Symptom
have	O
a	O
characteristic	O
appearance	O
on	O
magnetic	B-Diagnostic_tool
resonance	I-Diagnostic_tool
imaging	I-Diagnostic_tool
(	O
MRI	B-Diagnostic_tool
)	O
which	O
is	O
virtually	O
pathognomic	O
.	O
	
The	O
authors	O
present	O
two	O
cases	O
in	O
which	O
MRI	B-Diagnostic_tool
was	O
used	O
to	O
establish	O
the	O
diagnosis	O
.	O
	
Evaluation	O
of	O
diagnostic	O
tools	O
for	O
adult	B-Disease
chlamydial	I-Disease
keratoconjunctivitis	I-Disease
.	O
	
Conjunctival	O
smears	O
and	O
serum	O
specimens	O
of	O
150	O
patients	O
with	O
presumed	O
chlamydial	B-Disease
keratoconjunctivitis	I-Disease
were	O
evaluated	O
over	O
a	O
period	O
of	O
16	O
months	O
and	O
compared	O
to	O
age	B-Characteristic
-	O
and	O
sex	B-Characteristic
-	O
matched	O
healthy	O
controls	O
.	O
	
Sensitivity	O
,	O
specificity	O
,	O
and	O
predictive	O
values	O
of	O
fluorescent	B-Diagnostic_tool
monoclonal	I-Diagnostic_tool
antibody	I-Diagnostic_tool
(	I-Diagnostic_tool
FMAb	I-Diagnostic_tool
)	I-Diagnostic_tool
direct	I-Diagnostic_tool
tests	I-Diagnostic_tool
,	O
IgG	B-Diagnostic_tool
single	I-Diagnostic_tool
antigen	I-Diagnostic_tool
tests	I-Diagnostic_tool
for	I-Diagnostic_tool
the	I-Diagnostic_tool
detection	I-Diagnostic_tool
of	I-Diagnostic_tool
serum	I-Diagnostic_tool
antibody	I-Diagnostic_tool
(	O
IgG	B-Diagnostic_tool
-	I-Diagnostic_tool
IFT	I-Diagnostic_tool
)	O
,	O
and	O
IgA	B-Diagnostic_tool
and	I-Diagnostic_tool
IgG	I-Diagnostic_tool
immunoperoxidase	I-Diagnostic_tool
tests	I-Diagnostic_tool
(	O
IgA	B-Diagnostic_tool
-	I-Diagnostic_tool
IPAs	I-Diagnostic_tool
and	I-Diagnostic_tool
IgG	I-Diagnostic_tool
-	I-Diagnostic_tool
IPAs	I-Diagnostic_tool
)	O
for	O
serum	O
antibody	O
were	O
compared	O
to	O
McCoy	B-Diagnostic_tool
cell	I-Diagnostic_tool
culture	I-Diagnostic_tool
techniques	I-Diagnostic_tool
in	O
a	O
nonoptimized	O
clinical	O
setting	O
.	O
	
Thus	O
,	O
FMAb	B-Diagnostic_tool
sensitivity	O
was	O
100	O
%	O
,	O
specificity	O
was	O
52	O
%	O
,	O
and	O
predictive	O
value	O
was	O
30	O
%	O
.	O
	
IgG	B-Diagnostic_tool
-	I-Diagnostic_tool
IFT	I-Diagnostic_tool
sensitivity	O
was	O
94	O
%	O
,	O
specificity	O
was	O
67	O
%	O
,	O
and	O
predictive	O
value	O
was	O
37	O
%	O
.	O
	
IgA	B-Diagnostic_tool
-	I-Diagnostic_tool
IPA	I-Diagnostic_tool
sensitivity	O
was	O
100	O
%	O
,	O
specificity	O
was	O
70	O
%	O
,	O
and	O
predictive	O
value	O
was	O
40	O
%	O
.	O
	
The	O
IgG	B-Diagnostic_tool
-	I-Diagnostic_tool
IPA	I-Diagnostic_tool
was	O
sensitive	O
but	O
nonspecific	O
.	O
	
With	O
respect	O
to	O
the	O
current	O
epidemiologic	O
situation	O
in	O
our	O
area	O
,	O
FMAb	B-Diagnostic_tool
and	O
IgA	B-Diagnostic_tool
-	I-Diagnostic_tool
IPA	I-Diagnostic_tool
in	O
addition	O
to	O
McCoy	B-Diagnostic_tool
cell	I-Diagnostic_tool
culture	I-Diagnostic_tool
techniques	I-Diagnostic_tool
may	O
represent	O
valuable	O
diagnostic	O
tools	O
for	O
the	O
detection	O
of	O
chlamydial	B-Disease
disease	I-Disease
.	O
	
Infectious	B-Disease
retinitis	I-Disease
.	O
	
Diagnostic	O
modalities	O
.	O
	
Advances	O
in	O
surgical	O
techniques	O
have	O
made	O
vitreoretinal	B-Diagnostic_tool
and	I-Diagnostic_tool
sclerochorio	I-Diagnostic_tool
-	I-Diagnostic_tool
retinal	I-Diagnostic_tool
biopsies	I-Diagnostic_tool
part	O
of	O
the	O
available	O
diagnostic	O
armamentarium	O
of	O
the	O
ophthalmologist	O
.	O
	
Special	O
studies	O
can	O
be	O
performed	O
on	O
tissue	O
obtained	O
in	O
this	O
way	O
in	O
order	O
to	O
provide	O
a	O
specific	O
etiologic	O
diagnosis	O
of	O
virus	B-Disease
associated	I-Disease
pathology	I-Disease
.	O
	
The	O
advantages	O
and	O
disadvantages	O
of	O
immunopathologic	B-Diagnostic_tool
and	I-Diagnostic_tool
ultrastructural	I-Diagnostic_tool
methods	O
,	O
tissue	O
culture	O
,	O
and	O
nucleic	B-Diagnostic_tool
acid	I-Diagnostic_tool
hybridization	I-Diagnostic_tool
techniques	I-Diagnostic_tool
for	O
viral	O
identification	O
are	O
compared	O
and	O
discussed	O
.	O
	
Pseudophakic	B-Disease
and	I-Disease
aphakic	I-Disease
retinal	I-Disease
detachment	I-Disease
mimicking	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
.	O
	
Seventeen	O
eyes	B-Anatomy
of	O
patients	O
who	O
were	O
being	O
followed	O
by	O
their	O
ophthalmologists	O
for	O
aphakic	B-Disease
(	I-Disease
8	I-Disease
eyes	I-Disease
)	I-Disease
or	I-Disease
pseudophakic	I-Disease
(	I-Disease
9	I-Disease
eyes	I-Disease
)	I-Disease
cystoid	I-Disease
macular	I-Disease
edema	I-Disease
(	O
CME	B-Disease
)	O
were	O
examined	O
on	O
referral	O
.	O
	
All	O
eyes	B-Anatomy
showed	O
retinal	B-Symptom
detachment	I-Symptom
(	O
RD	B-Symptom
)	O
,	O
and	O
eight	O
eyes	B-Anatomy
had	O
CME	B-Disease
with	O
RD	B-Symptom
.	O
	
Most	O
RDs	B-Symptom
were	O
inferior	O
and	O
shallow	O
.	O
	
Proliferative	B-Disease
vitreoretinopathy	I-Disease
(	O
PVR	B-Disease
)	O
was	O
noted	O
in	O
15	O
eyes	B-Anatomy
(	O
88	O
.	O
2	O
%	O
)	O
.	O
	
There	O
was	O
history	O
of	O
vitreous	B-Symptom
loss	I-Symptom
during	O
the	O
last	O
intraocular	O
surgery	O
in	O
88	O
.	O
2	O
%	O
eyes	B-Anatomy
.	O
	
Visual	B-Characteristic
acuity	I-Characteristic
ranged	O
from	O
20	O
/	O
40	O
to	O
hand	O
movements	O
.	O
	
Fundus	B-Anatomy
view	O
was	O
hazy	O
in	O
most	O
eyes	B-Anatomy
,	O
and	O
indirect	B-Diagnostic_tool
ophthalmoscopy	I-Diagnostic_tool
was	O
most	O
useful	O
in	O
detecting	O
RD	B-Symptom
.	O
	
Retinal	B-Anatomy
reattachment	O
with	O
scleral	O
buckling	O
and	O
/	O
or	O
vitrectomy	O
was	O
achieved	O
in	O
16	O
eyes	B-Anatomy
(	O
94	O
.	O
1	O
%	O
)	O
.	O
	
Postoperative	O
visual	O
recovery	O
was	O
jeopardized	O
due	O
to	O
longstanding	O
macular	B-Symptom
detachment	I-Symptom
of	O
greater	O
than	O
1	O
month	O
in	O
11	O
eyes	B-Anatomy
(	O
64	O
.	O
7	O
%	O
)	O
.	O
	
Eight	O
eyes	B-Anatomy
(	O
47	O
%	O
)	O
achieved	O
20	B-Characteristic
/	I-Characteristic
50	I-Characteristic
vision	I-Characteristic
whereas	O
25	O
%	O
did	O
not	O
improve	O
to	O
better	O
than	O
20	O
/	O
400	O
.	O
	
Factors	O
leading	O
to	O
failure	O
in	O
making	O
the	O
correct	O
diagnosis	O
and	O
their	O
prevention	O
are	O
discussed	O
.	O
	
The	O
association	O
of	O
iris	B-Characteristic
color	I-Characteristic
with	O
eye	B-Disease
disease	I-Disease
in	O
diabetes	B-Disease
.	O
	
Iris	B-Characteristic
(	I-Characteristic
eye	I-Characteristic
)	I-Characteristic
color	I-Characteristic
was	O
examined	O
for	O
its	O
effect	O
on	O
eye	B-Disease
disease	I-Disease
in	O
a	O
population	O
-	O
based	O
study	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
in	O
Wisconsin	O
.	O
	
Eye	B-Characteristic
color	I-Characteristic
was	O
determined	O
by	O
comparing	O
the	O
iris	B-Anatomy
in	O
a	O
red	B-Diagnostic_tool
reflex	I-Diagnostic_tool
photograph	I-Diagnostic_tool
with	I-Diagnostic_tool
standard	I-Diagnostic_tool
photographs	I-Diagnostic_tool
.	O
	
In	O
younger	B-Characteristic
-	I-Characteristic
onset	I-Characteristic
diabetic	I-Characteristic
persons	I-Characteristic
(	O
N	O
=	O
996	O
)	O
,	O
macular	B-Disease
edema	I-Disease
was	O
more	O
prevalent	O
in	O
persons	O
with	O
blue	B-Characteristic
or	I-Characteristic
grey	I-Characteristic
eyes	I-Characteristic
(	O
12	O
%	O
)	O
compared	O
with	O
intermediate	O
(	O
9	O
%	O
)	O
or	O
brown	O
(	O
6	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O
	
Cataracts	B-Disease
were	O
more	O
prevalent	O
in	O
blue	B-Characteristic
or	I-Characteristic
grey	I-Characteristic
eyes	I-Characteristic
(	O
32	O
%	O
)	O
compared	O
with	O
intermediate	O
(	O
22	O
%	O
)	O
or	O
brown	O
(	O
20	O
%	O
)	O
in	O
the	O
younger	B-Characteristic
-	I-Characteristic
onset	I-Characteristic
group	I-Characteristic
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
	
In	O
older	B-Characteristic
-	I-Characteristic
onset	I-Characteristic
persons	I-Characteristic
(	O
N	O
=	O
1370	O
)	O
,	O
intraocular	B-Characteristic
pressure	I-Characteristic
(	O
IOP	B-Characteristic
)	O
was	O
higher	O
in	O
persons	O
with	O
brown	B-Characteristic
eyes	I-Characteristic
(	O
17	B-Dimension
.	I-Dimension
8	I-Dimension
mmHg	I-Dimension
)	O
compared	O
with	O
blue	O
or	O
grey	O
(	O
17	B-Dimension
.	I-Dimension
1	I-Dimension
mmHg	I-Dimension
)	O
or	O
intermediate	O
(	O
16	O
.	O
6	O
mmHg	O
)	O
(	O
P	O
=	O
0	O
.	O
012	O
)	O
.	O
	
Eye	B-Characteristic
color	I-Characteristic
was	O
not	O
associated	O
significantly	O
with	O
diabetic	B-Disease
retinopathy	I-Disease
in	O
either	O
the	O
younger	B-Characteristic
-	I-Characteristic
or	I-Characteristic
older	I-Characteristic
-	I-Characteristic
onset	I-Characteristic
group	I-Characteristic
or	O
with	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
or	O
glaucoma	B-Disease
in	O
the	O
older	B-Characteristic
-	I-Characteristic
onset	I-Characteristic
group	I-Characteristic
.	O
	
Diabetic	B-Disease
retinopathy	I-Disease
as	O
detected	O
using	O
ophthalmoscopy	B-Diagnostic_tool
,	O
a	O
nonmydriatic	B-Diagnostic_tool
camera	I-Diagnostic_tool
and	O
a	O
standard	O
fundus	B-Diagnostic_tool
camera	I-Diagnostic_tool
.	O
	
The	O
study	O
was	O
performed	O
to	O
evaluate	O
whether	O
the	O
severity	B-Characteristic
of	I-Characteristic
diabetic	I-Characteristic
retinopathy	I-Characteristic
as	O
assessed	O
by	O
three	O
alternative	O
methods	O
was	O
concordant	O
with	O
the	O
severity	B-Characteristic
of	I-Characteristic
retinopathy	I-Characteristic
as	O
determined	O
from	O
30	B-Diagnostic_tool
degrees	I-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
photographs	I-Diagnostic_tool
.	O
	
The	O
three	O
methods	O
were	O
direct	O
ophthalmoscopy	B-Diagnostic_tool
through	I-Diagnostic_tool
an	I-Diagnostic_tool
undilated	I-Diagnostic_tool
pupil	I-Diagnostic_tool
,	O
nonstereoscopic	B-Diagnostic_tool
45	I-Diagnostic_tool
degrees	I-Diagnostic_tool
retinal	I-Diagnostic_tool
photography	I-Diagnostic_tool
through	I-Diagnostic_tool
a	I-Diagnostic_tool
pharmacologically	I-Diagnostic_tool
undilated	I-Diagnostic_tool
pupil	I-Diagnostic_tool
and	O
nonstereoscopic	B-Diagnostic_tool
45	I-Diagnostic_tool
degrees	I-Diagnostic_tool
photography	I-Diagnostic_tool
through	I-Diagnostic_tool
a	I-Diagnostic_tool
dilated	I-Diagnostic_tool
pupil	I-Diagnostic_tool
.	O
	
A	O
single	O
45	B-Diagnostic_tool
degrees	I-Diagnostic_tool
photograph	I-Diagnostic_tool
centered	I-Diagnostic_tool
between	I-Diagnostic_tool
the	I-Diagnostic_tool
disc	I-Diagnostic_tool
and	I-Diagnostic_tool
fovea	I-Diagnostic_tool
was	O
taken	O
and	O
direct	O
ophthalmoscopy	B-Diagnostic_tool
was	O
performed	O
on	O
99	O
persons	O
prior	O
to	O
pharmacological	O
dilation	O
of	O
the	O
pupil	B-Anatomy
.	O
	
After	O
dilation	O
,	O
another	O
45	B-Diagnostic_tool
degrees	I-Diagnostic_tool
photograph	I-Diagnostic_tool
was	O
taken	O
of	O
the	O
same	O
field	O
,	O
as	O
well	O
as	O
30	B-Diagnostic_tool
degrees	I-Diagnostic_tool
stereoscopic	I-Diagnostic_tool
color	I-Diagnostic_tool
photographs	I-Diagnostic_tool
of	I-Diagnostic_tool
DRS	I-Diagnostic_tool
fields	I-Diagnostic_tool
1	I-Diagnostic_tool
,	I-Diagnostic_tool
2	I-Diagnostic_tool
and	I-Diagnostic_tool
4	I-Diagnostic_tool
(	O
modified	O
)	O
.	O
	
Corresponding	O
photographic	O
fields	O
were	O
graded	O
by	O
masked	O
,	O
trained	O
graders	O
for	O
the	O
severity	B-Characteristic
of	I-Characteristic
retinopathy	I-Characteristic
and	O
for	O
the	O
presence	O
of	O
specified	O
diabetic	B-Symptom
lesions	I-Symptom
using	O
the	O
Modified	B-Classification_system
Airlie	I-Classification_system
House	I-Classification_system
Classification	I-Classification_system
scheme	O
.	O
	
For	O
three	O
levels	O
of	O
severity	B-Characteristic
of	I-Characteristic
retinopathy	I-Characteristic
(	O
none	O
,	O
nonproliferative	B-Disease
or	O
proliferative	B-Disease
)	O
exact	O
agreement	O
between	O
direct	O
ophthalmoscopy	B-Diagnostic_tool
and	O
grading	O
of	O
retinopathy	B-Disease
from	O
stereoscopic	B-Diagnostic_tool
photographs	I-Diagnostic_tool
taken	O
with	O
the	O
standard	O
30	B-Diagnostic_tool
degrees	I-Diagnostic_tool
camera	I-Diagnostic_tool
was	O
54	O
.	O
3	O
%	O
(	O
n	O
=	O
94	O
)	O
.	O
	
For	O
four	O
levels	O
of	O
severity	B-Characteristic
of	I-Characteristic
retinopathy	I-Characteristic
(	O
none	O
,	O
microaneurysms	B-Symptom
only	O
,	O
all	O
other	O
nonproliferative	B-Disease
retinopathy	I-Disease
and	O
proliferative	B-Disease
retinopathy	I-Disease
)	O
,	O
exact	O
agreement	O
between	O
gradings	O
of	O
retinopathy	B-Disease
of	O
the	O
45	B-Diagnostic_tool
degrees	I-Diagnostic_tool
photographs	I-Diagnostic_tool
taken	I-Diagnostic_tool
through	I-Diagnostic_tool
undilated	I-Diagnostic_tool
pupils	I-Diagnostic_tool
and	O
30	B-Diagnostic_tool
degrees	I-Diagnostic_tool
photographs	I-Diagnostic_tool
taken	I-Diagnostic_tool
through	I-Diagnostic_tool
dilated	I-Diagnostic_tool
pupils	I-Diagnostic_tool
was	O
82	O
.	O
5	O
%	O
(	O
n	O
=	O
63	O
)	O
;	O
and	O
for	O
45	B-Diagnostic_tool
degrees	I-Diagnostic_tool
photographs	I-Diagnostic_tool
and	I-Diagnostic_tool
30	I-Diagnostic_tool
degrees	I-Diagnostic_tool
photographs	I-Diagnostic_tool
taken	I-Diagnostic_tool
through	I-Diagnostic_tool
dilated	I-Diagnostic_tool
pupils	I-Diagnostic_tool
it	O
was	O
86	O
.	O
5	O
%	O
(	O
n	O
=	O
74	O
)	O
.	O
	
These	O
data	O
suggest	O
that	O
45	B-Diagnostic_tool
degrees	I-Diagnostic_tool
nonstereoscopic	I-Diagnostic_tool
fundus	I-Diagnostic_tool
photographs	I-Diagnostic_tool
,	O
when	O
graded	O
according	O
to	O
a	O
standard	O
classification	O
scheme	O
,	O
provide	O
reasonably	O
reliable	O
photographic	O
representation	O
of	O
the	O
severity	B-Characteristic
of	I-Characteristic
retinopathy	I-Characteristic
when	O
broad	O
overall	O
categories	O
are	O
used	O
.	O
	
Quantitative	O
office	O
perimetry	B-Diagnostic_tool
.	O
	
This	O
study	O
presents	O
a	O
preliminary	O
comparison	O
of	O
six	O
commercially	O
-	O
available	O
automated	O
threshold	O
static	O
parameters	O
,	O
consisting	O
of	O
three	O
projection	B-Diagnostic_tool
perimeters	I-Diagnostic_tool
(	O
Humphrey	B-Diagnostic_tool
Field	I-Diagnostic_tool
Analyzer	I-Diagnostic_tool
,	O
Squid	B-Diagnostic_tool
,	O
and	O
Octopus	B-Diagnostic_tool
500	I-Diagnostic_tool
)	O
and	O
three	O
light	B-Diagnostic_tool
-	I-Diagnostic_tool
emitting	I-Diagnostic_tool
diode	I-Diagnostic_tool
(	I-Diagnostic_tool
LED	I-Diagnostic_tool
)	I-Diagnostic_tool
perimeters	I-Diagnostic_tool
(	O
Dicon	B-Diagnostic_tool
2000	I-Diagnostic_tool
,	O
Fieldmaster	B-Diagnostic_tool
50	I-Diagnostic_tool
,	O
and	O
Digilab	B-Diagnostic_tool
350	I-Diagnostic_tool
)	O
.	O
	
Eighteen	O
individuals	O
were	O
included	O
in	O
the	O
study	O
:	O
6	O
normal	O
observers	O
(	O
31	O
-	O
58	O
years	O
old	O
)	O
,	O
six	O
patients	O
with	O
glaucomatous	B-Symptom
field	I-Symptom
loss	I-Symptom
in	O
both	O
eyes	B-Anatomy
(	O
55	O
-	O
70	O
years	O
old	O
)	O
,	O
and	O
six	O
patients	O
with	O
neuro	B-Symptom
-	I-Symptom
ophthalmologic	I-Symptom
or	I-Symptom
retinal	I-Symptom
visual	I-Symptom
field	I-Symptom
abnormalities	I-Symptom
in	O
both	O
eyes	B-Anatomy
(	O
12	O
-	O
61	O
years	O
old	O
)	O
.	O
	
Three	O
aspects	O
of	O
quantitative	O
testing	O
were	O
evaluated	O
:	O
(	O
1	O
)	O
the	O
patients	O
'	O
and	O
normal	O
observers	O
'	O
acceptance	O
and	O
subjective	O
impressions	O
of	O
the	O
test	O
procedure	O
;	O
(	O
2	O
)	O
the	O
technician	O
'	O
s	O
ease	O
of	O
operating	O
the	O
device	O
and	O
related	O
tasks	O
;	O
and	O
(	O
3	O
)	O
practitioner	O
-	O
oriented	O
considerations	O
such	O
as	O
test	O
-	O
retest	O
reliability	O
,	O
comparability	O
of	O
test	O
results	O
and	O
testing	O
time	O
.	O
	
Our	O
results	O
showed	O
that	O
no	O
device	O
was	O
clearly	O
superior	O
to	O
the	O
others	O
in	O
all	O
respects	O
.	O
	
Patients	O
were	O
most	O
favorably	O
impressed	O
with	O
the	O
Octopus	B-Diagnostic_tool
500	I-Diagnostic_tool
,	O
Squid	B-Diagnostic_tool
,	O
and	O
the	O
Fieldmaster	B-Diagnostic_tool
50	I-Diagnostic_tool
,	O
while	O
technician	O
impressions	O
were	O
most	O
favorable	O
to	O
the	O
Humphrey	B-Diagnostic_tool
Field	I-Diagnostic_tool
Analyzer	I-Diagnostic_tool
and	O
the	O
Squid	B-Diagnostic_tool
.	O
	
The	O
projection	B-Diagnostic_tool
perimeters	I-Diagnostic_tool
(	O
Humphrey	B-Diagnostic_tool
Field	I-Diagnostic_tool
Analyzer	I-Diagnostic_tool
,	O
Squid	B-Diagnostic_tool
,	O
and	O
Octopus	B-Diagnostic_tool
500	I-Diagnostic_tool
)	O
were	O
the	O
easiest	O
to	O
perform	O
cross	O
-	O
comparisons	O
of	O
test	O
results	O
,	O
although	O
there	O
was	O
considerable	O
variation	O
in	O
the	O
clarity	O
of	O
data	O
interpretation	O
from	O
one	O
case	O
to	O
another	O
.	O
	
Test	O
-	O
retest	O
reliability	O
and	O
the	O
time	O
of	O
testing	O
varied	O
among	O
the	O
six	O
automated	O
perimeters	B-Diagnostic_tool
.	O
	
The	O
occurrence	O
of	O
primary	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
in	O
the	O
fellow	O
eye	B-Anatomy
of	O
patients	O
with	O
unilateral	B-Disease
angle	I-Disease
-	I-Disease
cleavage	I-Disease
glaucoma	I-Disease
.	O
	
The	O
late	B-Disease
onset	I-Disease
of	I-Disease
glaucoma	I-Disease
occurs	O
in	O
approximately	O
7	O
%	O
of	O
eyes	B-Anatomy
with	O
traumatic	B-Symptom
angle	I-Symptom
cleavage	I-Symptom
.	O
	
We	O
studied	O
13	O
patients	O
who	O
developed	O
glaucoma	B-Disease
in	O
the	O
angle	B-Symptom
-	I-Symptom
cleavage	I-Symptom
eye	I-Symptom
at	O
an	O
average	O
of	O
34	O
years	O
following	O
trauma	B-Symptom
.	O
	
Ten	O
of	O
the	O
13	O
patients	O
had	O
270	B-Symptom
degrees	I-Symptom
or	I-Symptom
more	I-Symptom
of	I-Symptom
angle	I-Symptom
cleavage	I-Symptom
.	O
	
At	O
the	O
time	O
of	O
the	O
initial	O
diagnosis	O
of	O
angle	B-Disease
cleavage	I-Disease
glaucoma	I-Disease
,	O
there	O
were	O
no	O
optic	B-Symptom
disc	I-Symptom
or	I-Symptom
visual	I-Symptom
field	I-Symptom
abnormalities	I-Symptom
in	O
the	O
fellow	O
eyes	B-Anatomy
.	O
	
After	O
a	O
mean	O
follow	O
-	O
up	O
of	O
7	O
.	O
7	O
years	O
,	O
all	O
13	O
patients	O
were	O
reevaluated	O
.	O
	
In	O
addition	O
to	O
standard	O
examination	O
techniques	O
,	O
all	O
underwent	O
disc	B-Diagnostic_tool
photos	I-Diagnostic_tool
,	O
goniophotos	B-Diagnostic_tool
,	O
and	O
Octopus	B-Diagnostic_tool
perimetry	I-Diagnostic_tool
.	O
	
Seven	O
of	O
13	O
patients	O
(	O
55	O
%	O
)	O
had	O
either	O
frank	O
glaucomatous	B-Symptom
or	I-Symptom
suspicious	I-Symptom
Octopus	I-Symptom
visual	I-Symptom
field	I-Symptom
abnormalities	I-Symptom
in	O
the	O
fellow	O
eyes	B-Anatomy
.	O
	
Patients	O
with	O
angle	B-Disease
-	I-Disease
cleavage	I-Disease
glaucoma	I-Disease
appear	O
to	O
have	O
at	O
least	O
a	O
50	O
%	O
chance	O
of	O
developing	O
open	B-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
in	O
the	O
non	O
-	O
traumatized	O
fellow	O
eyes	B-Anatomy
.	O
	
Natural	O
history	O
of	O
senile	B-Disease
disciform	I-Disease
macular	I-Disease
dystrophy	I-Disease
.	O
	
Twenty	O
-	O
nine	O
patients	O
with	O
severe	B-Symptom
visual	I-Symptom
loss	I-Symptom
in	O
one	O
eye	B-Anatomy
from	O
disciform	B-Disease
macular	I-Disease
dystrophy	I-Disease
were	O
prospectively	O
studied	O
for	O
the	O
incidence	O
of	O
visual	B-Symptom
loss	I-Symptom
in	O
the	O
fellow	O
eye	B-Anatomy
.	O
	
Four	O
developed	O
such	O
loss	O
in	O
the	O
second	O
eye	B-Anatomy
during	O
a	O
mean	O
period	O
of	O
follow	O
-	O
up	O
of	O
32	O
months	O
from	O
the	O
time	O
of	O
onset	O
of	O
visual	B-Symptom
loss	I-Symptom
in	O
the	O
first	O
eye	B-Anatomy
,	O
an	O
annual	O
incidence	O
rate	O
of	O
5	O
.	O
2	O
%	O
.	O
	
The	O
degree	O
of	O
drusen	B-Symptom
and	O
retinal	B-Symptom
pigment	I-Symptom
epithelial	I-Symptom
and	I-Symptom
subretinal	I-Symptom
pigment	I-Symptom
epithelial	I-Symptom
pathology	I-Symptom
correlated	O
positively	O
with	O
the	O
incidence	O
of	O
visual	B-Symptom
loss	I-Symptom
in	O
the	O
fellow	O
eye	B-Anatomy
.	O
	
Diabetic	B-Disease
retinopathy	I-Disease
in	O
Joslin	O
Clinic	O
patients	O
with	O
adult	B-Disease
-	I-Disease
onset	I-Disease
diabetes	I-Disease
.	O
	
While	O
only	O
a	O
small	O
proportion	O
of	O
adult	B-Disease
-	I-Disease
onset	I-Disease
diabetic	I-Disease
patients	O
develop	O
vision	B-Disease
threatening	I-Disease
retinopathy	I-Disease
,	O
this	O
group	O
makes	O
up	O
a	O
major	O
portion	O
of	O
those	O
diabetics	B-Disease
seeking	O
ophthalmologic	O
care	O
.	O
	
Fifty	O
-	O
three	O
percent	O
of	O
patients	O
having	O
fundus	B-Diagnostic_tool
photographs	I-Diagnostic_tool
at	O
the	O
W	O
.	O
P	O
.	O
	
Beetham	O
Eye	B-Anatomy
Unit	O
of	O
the	O
Joslin	O
Clinic	O
developed	O
diabetes	B-Disease
at	O
the	O
age	B-Characteristic
of	I-Characteristic
20	I-Characteristic
or	I-Characteristic
over	I-Characteristic
,	O
and	O
almost	O
30	O
%	O
at	O
the	O
age	B-Characteristic
of	I-Characteristic
40	I-Characteristic
or	I-Characteristic
over	I-Characteristic
.	O
	
Twenty	O
-	O
two	O
percent	O
of	O
all	O
patients	O
seen	O
with	O
proliferative	B-Disease
retinopathy	I-Disease
were	O
in	O
this	O
latter	O
group	O
.	O
	
Ten	O
of	O
54	O
patients	O
with	O
proliferative	B-Disease
retinopathy	I-Disease
in	O
the	O
greater	O
than	O
or	O
equal	O
to	O
40	O
onset	O
group	O
were	O
not	O
taking	O
insulin	O
.	O
	
The	O
older	B-Characteristic
onset	I-Characteristic
patients	I-Characteristic
who	O
developed	O
proliferative	B-Disease
retinopathy	I-Disease
did	O
so	O
after	O
shorter	O
durations	O
of	O
diabetes	B-Disease
and	O
with	O
more	O
visual	B-Symptom
disability	I-Symptom
than	O
younger	B-Characteristic
onset	I-Characteristic
patients	I-Characteristic
.	O
	
Macular	B-Disease
edema	I-Disease
was	O
more	O
common	O
in	O
adult	B-Characteristic
-	I-Characteristic
onset	I-Characteristic
patients	I-Characteristic
,	O
and	O
its	O
presence	O
in	O
a	O
patient	B-Characteristic
less	I-Characteristic
than	I-Characteristic
50	I-Characteristic
years	I-Characteristic
old	I-Characteristic
was	O
usually	O
associated	O
with	O
proliferative	B-Disease
or	I-Disease
preproliferative	I-Disease
retinopathy	I-Disease
.	O
	
Prognosis	O
of	O
patients	O
with	O
bilateral	B-Symptom
macular	I-Symptom
drusen	I-Symptom
.	O
	
Of	O
71	O
patients	O
with	O
only	O
bilateral	B-Symptom
macular	I-Symptom
drusen	I-Symptom
,	O
8	O
eyes	B-Anatomy
in	O
7	O
patients	O
(	O
9	O
.	O
9	O
%	O
)	O
developed	O
exudative	B-Disease
maculopathy	I-Disease
over	O
an	O
average	O
follow	O
-	O
up	O
of	O
4	O
.	O
3	O
years	O
(	O
14	O
.	O
5	O
%	O
cumulative	O
risk	O
)	O
.	O
	
Severe	B-Symptom
visual	I-Symptom
loss	I-Symptom
due	O
to	O
exudative	B-Disease
maculopathy	I-Disease
occurred	O
in	O
7	O
eyes	B-Anatomy
of	O
6	O
patients	O
(	O
8	O
.	O
5	O
%	O
)	O
for	O
a	O
5	O
-	O
year	O
cumulative	O
risk	O
of	O
12	O
.	O
7	O
%	O
.	O
	
Features	O
of	O
the	O
drusen	B-Symptom
were	O
analyzed	O
,	O
but	O
only	O
the	O
association	O
with	O
focal	B-Symptom
hyperpigmentation	I-Symptom
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
more	O
than	O
minimal	O
drusen	B-Symptom
confluence	I-Symptom
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
statistically	O
significant	O
.	O
	
Older	B-Characteristic
patients	I-Characteristic
had	O
more	O
severe	B-Symptom
drusen	I-Symptom
.	I-Symptom
	
Photostress	B-Characteristic
test	I-Characteristic
delay	I-Characteristic
did	O
not	O
correlate	O
with	O
visual	B-Characteristic
acuity	I-Characteristic
,	O
age	B-Characteristic
,	O
or	O
severity	B-Characteristic
of	I-Characteristic
drusen	I-Characteristic
.	O
	
Systemic	B-Disease
uveitis	I-Disease
syndromes	I-Disease
in	O
childhood	B-Characteristic
:	O
an	O
analysis	O
of	O
340	O
cases	O
.	O
	
Three	O
hundred	O
forty	O
patients	O
with	O
anterior	B-Disease
uveitis	I-Disease
associated	O
with	O
a	O
specific	O
systemic	O
disease	O
are	O
described	O
.	O
	
All	O
patients	O
developed	O
uveitis	B-Disease
or	O
the	O
systemic	O
disease	O
,	O
or	O
both	O
,	O
prior	B-Characteristic
to	I-Characteristic
the	I-Characteristic
age	I-Characteristic
of	I-Characteristic
16	I-Characteristic
years	I-Characteristic
,	O
By	O
far	O
the	O
most	O
frequent	O
systemic	O
disorder	O
was	O
a	O
sero	B-Disease
-	I-Disease
negative	I-Disease
arthritis	I-Disease
.	O
	
Others	O
included	O
sarcoidosis	B-Disease
,	O
Beh	B-Disease
	I-Disease
et	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
the	O
Vogt	B-Disease
-	I-Disease
Koyanagi	I-Disease
-	I-Disease
Harada	I-Disease
syndrome	I-Disease
,	O
and	O
arteritis	B-Disease
.	O
	
Children	B-Characteristic
with	O
pauciarticular	B-Disease
juvenile	I-Disease
chronic	I-Disease
arthritis	I-Disease
,	O
especially	O
when	O
associated	O
with	O
antinuclear	B-Characteristic
antibodies	I-Characteristic
,	O
are	O
at	O
particular	O
risk	O
of	O
developing	O
chronic	B-Disease
uveitis	I-Disease
and	O
they	O
should	O
be	O
screened	O
at	O
frequent	O
intervals	O
,	O
even	O
if	O
asymptomatic	O
.	O
	
Treatment	O
of	O
secondary	B-Disease
cataracts	I-Disease
in	O
children	B-Characteristic
using	O
vitreous	O
cutters	O
usually	O
gives	O
good	O
results	O
.	O
	
The	O
most	O
devastating	O
complication	O
of	O
chronic	B-Disease
uveitis	I-Disease
is	O
secondary	B-Disease
glaucoma	I-Disease
.	O
	
Classification	O
of	O
central	B-Disease
retinal	I-Disease
vein	I-Disease
occlusion	I-Disease
.	O
	
Our	O
prospective	O
clinical	O
study	O
of	O
360	O
eyes	B-Anatomy
with	O
central	B-Disease
retinal	I-Disease
vein	I-Disease
occlusion	I-Disease
(	O
CRVO	B-Disease
)	O
and	O
our	O
experimental	O
studies	O
on	O
CRVO	B-Disease
in	O
54	O
eyes	B-Anatomy
of	O
rhesus	O
monkeys	O
have	O
shown	O
that	O
CRVO	B-Disease
consists	O
of	O
the	O
following	O
two	O
distinct	O
entities	O
:	O
(	O
1	O
)	O
Nonischemic	B-Disease
CRVO	I-Disease
in	O
which	O
there	O
is	O
essentially	O
a	O
stasis	B-Symptom
of	I-Symptom
retinal	I-Symptom
venous	I-Symptom
circulation	I-Symptom
;	O
we	O
call	O
it	O
venous	B-Disease
stasis	I-Disease
retinopathy	I-Disease
(	O
VSR	B-Disease
)	O
.	O
	
(	O
2	O
)	O
Ischemic	B-Disease
CRVO	I-Disease
:	O
We	O
call	O
this	O
hemorrhagic	B-Disease
retinopathy	I-Disease
(	O
HR	B-Disease
)	O
.	O
	
Our	O
prospective	O
clinical	O
studies	O
have	O
revealed	O
that	O
it	O
is	O
absolutely	O
essential	O
to	O
differentiate	O
CRVO	B-Disease
into	O
VSR	B-Disease
and	O
HR	B-Disease
because	O
of	O
their	O
very	O
different	O
prognoses	O
and	O
management	O
.	O
	
VSR	B-Disease
is	O
a	O
benign	B-Disease
and	I-Disease
self	I-Disease
-	I-Disease
limited	I-Disease
condition	I-Disease
,	O
while	O
HR	B-Disease
is	O
a	O
severe	B-Disease
,	I-Disease
potentially	I-Disease
blinding	I-Disease
disorder	I-Disease
.	O
	
Lumping	O
the	O
two	O
types	O
of	O
CRVO	B-Disease
together	O
as	O
one	O
disease	O
has	O
caused	O
much	O
confusion	O
concerning	O
the	O
prognosis	O
and	O
management	O
of	O
CRVO	B-Disease
.	O
	
The	O
basis	O
of	O
such	O
a	O
classification	O
and	O
differential	O
diagnosis	O
of	O
VSR	B-Disease
and	O
HR	B-Disease
is	O
discussed	O
at	O
length	O
.	O
	
Adenoma	B-Characteristic
of	I-Characteristic
the	I-Characteristic
iris	I-Characteristic
-	I-Characteristic
pigment	I-Characteristic
epithelium	I-Characteristic
.	O
	
An	O
11	B-Characteristic
-	I-Characteristic
year	I-Characteristic
-	I-Characteristic
old	I-Characteristic
boy	I-Characteristic
was	O
noted	O
to	O
have	O
a	O
multinodular	B-Characteristic
tumor	I-Characteristic
involving	I-Characteristic
the	I-Characteristic
peripheral	I-Characteristic
iris	I-Characteristic
and	I-Characteristic
trabecular	I-Characteristic
meshwork	I-Characteristic
in	I-Characteristic
his	I-Characteristic
left	I-Characteristic
eye	I-Characteristic
.	O
	
During	O
the	O
next	O
12	O
years	O
,	O
the	O
lesion	O
slowly	O
enlarged	O
and	O
produced	O
pigmentary	B-Symptom
dispersion	I-Symptom
in	I-Symptom
the	I-Symptom
anterior	I-Symptom
chamber	I-Symptom
and	O
glaucomatous	B-Symptom
changes	I-Symptom
in	I-Symptom
the	I-Symptom
optic	I-Symptom
disc	I-Symptom
.	O
	
Histopathologic	O
examination	O
of	O
the	O
tumor	O
after	O
its	O
removal	O
by	O
iridocyclectomy	O
revealed	O
features	O
consistent	O
with	O
the	O
diagnosis	O
of	O
adenoma	B-Characteristic
of	I-Characteristic
the	I-Characteristic
iris	I-Characteristic
-	I-Characteristic
pigment	I-Characteristic
epithelium	I-Characteristic
.	O
	
A	O
correlation	O
between	O
the	O
clinical	O
and	O
histopathologic	O
features	O
is	O
presented	O
.	O
	
Clinical	O
features	O
that	O
can	O
be	O
helpful	O
in	O
differentiating	O
an	O
adenoma	B-Characteristic
of	I-Characteristic
the	I-Characteristic
iris	I-Characteristic
-	I-Characteristic
pigment	I-Characteristic
epithelium	I-Characteristic
from	O
a	O
malignant	B-Symptom
melanoma	I-Symptom
are	O
discussed	O
.	O
	
Retinopathy	B-Disease
in	O
adolescents	B-Characteristic
and	O
young	B-Characteristic
adults	I-Characteristic
with	O
onset	B-Disease
of	I-Disease
insulin	I-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
in	O
childhood	B-Characteristic
.	O
	
Retinal	B-Anatomy
studies	O
were	O
done	O
in	O
181	O
postpubescent	O
,	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetic	I-Disease
patients	O
who	O
developed	O
diabetes	B-Disease
before	B-Characteristic
the	I-Characteristic
age	I-Characteristic
of	I-Characteristic
20	I-Characteristic
.	O
	
Retinal	B-Anatomy
studies	O
included	O
serial	O
direct	B-Diagnostic_tool
ophthalmoscopic	I-Diagnostic_tool
examinations	I-Diagnostic_tool
,	O
stereoscopic	B-Diagnostic_tool
fundus	I-Diagnostic_tool
photography	I-Diagnostic_tool
and	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
.	O
	
At	O
the	O
time	O
of	O
retinal	B-Anatomy
studies	O
,	O
muscle	B-Diagnostic_tool
biopsies	I-Diagnostic_tool
also	O
were	O
done	O
to	O
measure	O
capillary	B-Characteristic
basement	I-Characteristic
membrane	I-Characteristic
thickness	I-Characteristic
(	O
CBMT	B-Characteristic
)	O
as	O
an	O
index	O
of	O
early	O
microvascular	B-Symptom
changes	I-Symptom
in	I-Symptom
skeletal	I-Symptom
muscles	I-Symptom
.	O
	
Assessment	O
of	O
clinical	O
metabolic	O
control	O
,	O
interpretation	O
of	O
retinal	B-Anatomy
findings	O
,	O
and	O
CBMT	B-Characteristic
were	O
done	O
independently	O
.	O
	
No	O
retinopathy	B-Disease
was	O
detected	O
in	O
patients	O
observed	O
continuously	O
and	O
known	O
to	O
have	O
been	O
in	O
higher	O
degrees	O
of	O
metabolic	O
control	O
.	O
	
Twenty	O
-	O
five	O
patients	O
in	O
lower	O
degrees	O
of	O
control	O
for	O
extended	O
periods	O
had	O
retinopathy	B-Disease
.	O
	
CBMT	B-Characteristic
was	O
found	O
to	O
be	O
labile	O
and	O
to	O
progress	O
or	O
regress	O
within	O
a	O
year	O
depending	O
on	O
the	O
degree	O
of	O
control	O
.	O
	
All	O
patients	O
in	O
lower	O
degrees	O
of	O
control	O
with	O
retinopathy	B-Disease
had	O
increased	O
CBMT	B-Characteristic
,	O
but	O
if	O
they	O
subsequently	O
attained	O
and	O
maintained	O
a	O
high	O
degree	O
of	O
control	O
for	O
a	O
year	O
,	O
then	O
CBMT	B-Characteristic
diminished	O
and	O
there	O
was	O
no	O
progression	O
of	O
retinopathy	B-Disease
.	O
	
Our	O
study	O
demonstrates	O
that	O
a	O
high	O
degree	O
of	O
metabolic	O
control	O
delays	O
,	O
and	O
may	O
prevent	O
,	O
microvascular	B-Symptom
changes	I-Symptom
,	O
and	O
confirms	O
other	O
studies	O
indicating	O
that	O
most	O
postpubescent	B-Characteristic
,	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetic	I-Disease
patients	O
will	O
develop	O
retinopathy	B-Disease
within	O
15	O
years	O
unless	O
a	O
relatively	O
high	O
degree	O
of	O
control	O
is	O
maintained	O
.	O
	
Noninvasive	O
carotid	B-Anatomy
evaluation	O
using	O
pulsed	B-Diagnostic_tool
Doppler	I-Diagnostic_tool
imaging	I-Diagnostic_tool
for	O
patients	O
with	O
ophthalmic	B-Disease
disorders	I-Disease
.	O
	
Pulsed	B-Diagnostic_tool
Doppler	I-Diagnostic_tool
imaging	I-Diagnostic_tool
provides	O
an	O
accurate	O
,	O
noninvasive	O
technique	O
for	O
evaluation	O
of	O
the	O
carotid	B-Anatomy
bifurcation	I-Anatomy
.	O
	
We	O
have	O
found	O
it	O
useful	O
in	O
evaluating	O
patients	O
with	O
amaurosis	B-Symptom
fugax	I-Symptom
and	O
ocular	B-Symptom
emboli	I-Symptom
.	O
	
It	O
can	O
also	O
be	O
used	O
to	O
evaluate	O
blood	O
flow	O
within	O
ocular	B-Symptom
and	I-Symptom
orbital	I-Symptom
tumors	I-Symptom
.	O
	
The	O
continuous	B-Diagnostic_tool
wave	I-Diagnostic_tool
Doppler	I-Diagnostic_tool
is	O
useful	O
for	O
detection	O
of	O
abnormal	B-Symptom
orbital	I-Symptom
blood	I-Symptom
flow	I-Symptom
in	O
patients	O
with	O
dural	B-Disease
-	I-Disease
cavernous	I-Disease
fistulae	I-Disease
.	O
	
Diabetic	B-Disease
retinopathy	I-Disease
,	O
present	O
and	O
future	O
.	O
	
Conclusion	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
symposium	O
.	O
	
The	O
preceding	O
reports	O
of	O
the	O
Diabetic	B-Disease
Retinopathy	I-Disease
Symposium	O
are	O
reviewed	O
.	O
	
Diabetic	B-Disease
retinopathy	I-Disease
progresses	O
with	O
the	O
duration	O
of	O
disease	O
and	O
often	O
results	O
in	O
proliferative	B-Disease
retinopathy	I-Disease
in	O
the	O
juvenile	B-Characteristic
onset	I-Characteristic
patient	O
and	O
macular	B-Disease
edema	I-Disease
in	O
the	O
older	B-Characteristic
onset	I-Characteristic
patient	O
.	O
	
Periodic	B-Diagnostic_tool
ophthalmoscopic	I-Diagnostic_tool
examinations	I-Diagnostic_tool
are	O
essential	O
in	O
detecting	O
the	O
progression	O
of	O
retinopathy	B-Disease
and	O
development	O
of	O
disease	O
characteristics	O
which	O
indicate	O
a	O
need	O
for	O
treatment	O
.	O
	
Laboratory	O
and	O
clinical	O
experience	O
stress	O
the	O
importance	O
of	O
rigid	O
glucose	O
control	O
in	O
preventing	O
diabetic	B-Disease
retinopathy	I-Disease
.	O
	
Ischemia	B-Symptom
of	I-Symptom
the	I-Symptom
midperipheral	I-Symptom
retina	I-Symptom
stimulates	O
the	O
development	O
of	O
high	O
risk	O
factors	O
for	O
which	O
panretinal	O
photocoagulation	O
is	O
indicated	O
despite	O
side	O
effects	O
such	O
as	O
decreased	B-Symptom
dark	I-Symptom
adaptation	I-Symptom
.	O
	
Pars	O
plana	O
vitrectomy	O
results	O
in	O
substantial	O
visual	O
improvement	O
in	O
eyes	B-Anatomy
with	O
nonclearing	B-Symptom
vitreous	I-Symptom
hemorrhage	I-Symptom
and	O
/	O
or	O
traction	B-Symptom
retinal	I-Symptom
detachments	I-Symptom
involving	I-Symptom
the	I-Symptom
macula	I-Symptom
.	O
	
Future	O
advances	O
in	O
our	O
knowledge	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
should	O
come	O
from	O
the	O
National	O
Eye	B-Anatomy
Institute	O
'	O
s	O
Collaborative	O
Diabetic	B-Disease
Retinopathy	I-Disease
Vitrectomy	O
Study	O
and	O
Early	O
Treatment	O
Diabetic	B-Disease
Retinopathy	I-Disease
Study	O
,	O
and	O
the	O
analysis	O
of	O
vasoformative	B-Symptom
factors	I-Symptom
.	O
	
The	O
natural	O
history	O
of	O
retinopathy	B-Disease
in	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
juvenile	I-Disease
-	I-Disease
onset	I-Disease
diabetes	I-Disease
.	O
	
We	O
determined	O
the	O
cross	O
-	O
sectional	O
natural	O
history	O
of	O
retinopathy	B-Disease
by	O
prospective	O
study	O
of	O
461	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
juvenile	I-Disease
-	I-Disease
onset	I-Disease
diabetics	I-Disease
.	O
	
In	O
so	O
doing	O
,	O
we	O
compared	O
the	O
sensitivity	O
of	O
ophthalmoscopy	B-Diagnostic_tool
,	O
photography	B-Diagnostic_tool
,	O
and	O
fluorescein	B-Diagnostic_tool
angiography	I-Diagnostic_tool
in	O
detecting	O
retinopathy	B-Disease
.	O
	
Photography	B-Diagnostic_tool
was	O
far	O
more	O
reliable	O
than	O
ophthalmoscopy	B-Diagnostic_tool
in	O
detecting	O
early	B-Disease
retinopathy	I-Disease
and	O
equivalent	O
to	O
angiography	B-Diagnostic_tool
.	O
	
Retinopathy	B-Disease
was	O
not	O
present	O
at	O
diagnosis	O
of	O
diabetes	B-Disease
.	O
	
After	O
a	O
lag	O
period	O
,	O
the	O
prevalence	O
of	O
retinopathy	B-Disease
rose	O
in	O
sigmoidal	O
fashion	O
,	O
reaching	O
50	O
%	O
at	O
just	O
over	O
seven	O
years	O
duration	O
,	O
and	O
asymptotically	O
approaching	O
90	O
%	O
at	O
17	O
-	O
-	O
50	O
years	O
.	O
	
Proliferative	B-Disease
retinopathy	I-Disease
was	O
first	O
seen	O
at	O
13	O
years	O
duration	O
,	O
and	O
its	O
prevalence	O
rose	O
to	O
26	O
%	O
at	O
26	O
-	O
-	O
50	O
years	O
.	O
	
From	O
the	O
natural	O
history	O
we	O
computed	O
the	O
dimensions	O
of	O
a	O
proposed	O
clinical	O
trial	O
to	O
test	O
the	O
effect	O
of	O
tight	O
metabolic	O
control	O
in	O
prevention	O
of	O
retinopathy	B-Disease
.	O
	
Computer	O
-	O
enhanced	O
studies	O
of	O
diabetic	B-Disease
retinopathy	I-Disease
:	O
I	O
.	O
	
A	O
computer	O
program	O
designed	O
according	O
to	O
the	O
needs	O
of	O
clinical	O
investigators	O
has	O
recently	O
been	O
implemented	O
.	O
	
This	O
ambitious	O
undertaking	O
allows	O
the	O
ophthalmologist	O
direct	O
interfacing	O
and	O
control	O
over	O
all	O
his	O
data	O
,	O
presently	O
3	O
,	O
252	O
diabetic	B-Disease
patient	O
records	O
,	O
and	O
thus	O
harnesses	O
his	O
hypothesis	O
-	O
testing	O
intuitions	O
with	O
the	O
memory	O
,	O
speed	O
,	O
and	O
flexibility	O
of	O
modern	O
-	O
day	O
computers	O
.	O
	
There	O
are	O
three	O
program	O
modes	O
:	O
QUERY	O
,	O
a	O
disease	O
-	O
independent	O
language	O
by	O
which	O
the	O
clinician	O
selects	O
his	O
population	O
;	O
SELECT	O
,	O
the	O
actual	O
computer	O
selection	O
,	O
and	O
DISPLAY	O
:	O
where	O
general	O
statistical	O
maneuvers	O
,	O
relationships	O
among	O
disease	O
parameters	O
,	O
ancillary	O
data	O
compilations	O
,	O
and	O
printouts	O
are	O
performed	O
.	O
	
Being	O
computer	O
-	O
independent	O
and	O
disease	O
-	O
independent	O
,	O
and	O
adaptable	O
to	O
most	O
needs	O
of	O
clinical	O
investigators	O
,	O
this	O
computer	O
program	O
brings	O
a	O
refreshingly	O
new	O
approach	O
to	O
the	O
study	O
of	O
disease	O
.	O
	
Viewing	O
through	O
the	O
asteroids	B-Symptom
.	O
	
Thirty	O
to	O
seventy	O
percent	O
of	O
patients	O
with	O
asteroid	B-Disease
hyalosis	I-Disease
will	O
also	O
have	O
diabetes	B-Disease
.	O
	
In	O
this	O
group	O
of	O
patients	O
where	O
view	O
of	O
the	O
fundus	B-Anatomy
is	O
essential	O
,	O
it	O
is	O
often	O
difficult	O
or	O
impossible	O
by	O
conventional	B-Diagnostic_tool
ophthalmoscopy	I-Diagnostic_tool
.	O
	
We	O
have	O
noted	O
the	O
excellent	O
visualization	O
of	O
fundus	B-Anatomy
detail	O
in	O
asteroid	B-Disease
hyalosis	I-Disease
on	O
routine	O
fundus	B-Diagnostic_tool
fluorescein	I-Diagnostic_tool
angiography	I-Diagnostic_tool
.	O
	
The	O
asteroid	B-Symptom
bodies	I-Symptom
are	O
"	O
optically	O
removed	O
"	O
from	O
the	O
vitreous	B-Anatomy
with	O
this	O
technique	O
,	O
thus	O
affording	O
a	O
view	O
for	O
diagnosis	O
previously	O
thought	O
impossible	O
without	O
actual	O
vitrectomy	O
.	O
	
A	O
series	O
of	O
patients	O
,	O
optimal	O
camera	O
filter	O
combination	O
,	O
and	O
a	O
theory	O
for	O
this	O
effect	O
are	O
presented	O
.	O
	
Long	O
-	O
term	O
evaluation	O
of	O
patients	O
with	O
Best	B-Disease
'	I-Disease
s	I-Disease
vitelliform	I-Disease
dystrophy	I-Disease
.	O
	
We	O
examined	O
91	O
patients	O
with	O
Best	B-Disease
'	I-Disease
s	I-Disease
dystrophy	I-Disease
and	O
followed	O
54	O
affected	O
individuals	O
for	O
five	O
years	O
.	O
	
Most	O
eyes	B-Anatomy
with	O
normal	B-Symptom
maculas	I-Symptom
,	O
minimal	B-Symptom
pigment	I-Symptom
epithelial	I-Symptom
changes	I-Symptom
,	O
atrophic	B-Symptom
maculae	I-Symptom
,	O
or	O
fibrous	B-Symptom
macular	I-Symptom
scars	I-Symptom
did	O
not	O
change	O
stage	O
.	O
	
Eyes	B-Anatomy
with	O
vitelliform	B-Symptom
or	I-Symptom
pseudohypopyon	I-Symptom
lesions	I-Symptom
progressed	O
to	O
later	B-Disease
atrophic	I-Disease
macular	I-Disease
stages	I-Disease
.	O
	
Visual	B-Symptom
acuity	I-Symptom
decreased	I-Symptom
after	B-Characteristic
age	I-Characteristic
40	I-Characteristic
and	O
was	O
worse	O
for	O
patients	O
with	O
atrophic	B-Symptom
maculas	I-Symptom
and	O
fibrous	B-Symptom
scars	I-Symptom
.	O
	
Nineteen	O
percent	O
of	O
patients	O
with	O
atrophic	B-Symptom
maculas	I-Symptom
or	O
fibrous	B-Symptom
scars	I-Symptom
who	O
were	O
followed	O
for	O
8	O
to	O
10	O
years	O
were	O
the	O
only	O
patients	O
to	O
lose	B-Symptom
vision	I-Symptom
.	O
	
Lid	B-Disease
imbrication	I-Disease
syndrome	I-Disease
.	O
	
Diagnosis	O
with	O
rose	B-Diagnostic_tool
bengal	I-Diagnostic_tool
staining	I-Diagnostic_tool
.	O
	
Lid	B-Disease
imbrication	I-Disease
syndrome	I-Disease
is	O
an	O
abnormality	B-Symptom
of	I-Symptom
lid	I-Symptom
apposition	I-Symptom
in	I-Symptom
which	I-Symptom
the	I-Symptom
upper	I-Symptom
lid	I-Symptom
overlies	I-Symptom
the	I-Symptom
lower	I-Symptom
lid	I-Symptom
.	O
	
Patients	O
often	O
complain	O
of	O
irritation	B-Symptom
,	O
tearing	B-Symptom
,	O
and	O
foreign	B-Symptom
body	I-Symptom
sensation	I-Symptom
.	O
	
The	O
condition	O
may	O
be	O
difficult	O
to	O
diagnose	O
.	O
	
Twenty	O
-	O
one	O
patients	O
with	O
suspected	O
lid	B-Disease
imbrication	I-Disease
syndrome	I-Disease
were	O
compared	O
with	O
21	O
age	B-Characteristic
-	I-Characteristic
matched	I-Characteristic
controls	O
.	O
	
All	O
patients	O
were	O
given	O
0	O
.	O
5	O
%	O
topical	B-Diagnostic_tool
rose	I-Diagnostic_tool
bengal	I-Diagnostic_tool
.	O
	
The	O
diagnosis	O
of	O
lid	B-Disease
imbrication	I-Disease
syndrome	I-Disease
was	O
confirmed	O
by	O
the	O
presence	O
of	O
rose	B-Diagnostic_tool
bengal	I-Diagnostic_tool
staining	I-Diagnostic_tool
of	O
the	O
tarsal	B-Anatomy
conjunctiva	I-Anatomy
of	I-Anatomy
the	I-Anatomy
upper	I-Anatomy
lid	I-Anatomy
margin	I-Anatomy
.	O
	
The	O
amount	O
of	O
rose	B-Diagnostic_tool
bengal	I-Diagnostic_tool
staining	I-Diagnostic_tool
correlated	O
with	O
the	O
severity	O
of	O
lid	B-Disease
imbrication	I-Disease
.	O
	
Eighteen	O
of	O
21	O
patients	O
had	O
received	O
a	O
diagnosis	O
previously	O
of	O
dry	B-Disease
eye	I-Disease
syndrome	I-Disease
.	O
	
Four	O
patients	O
had	O
persistent	B-Symptom
epithelial	I-Symptom
defects	I-Symptom
.	O
	
Rose	B-Diagnostic_tool
bengal	I-Diagnostic_tool
staining	I-Diagnostic_tool
of	O
the	O
superior	B-Anatomy
lid	I-Anatomy
margin	I-Anatomy
tarsal	I-Anatomy
conjunctiva	I-Anatomy
offers	O
an	O
extremely	O
reliable	O
aid	O
for	O
diagnosing	O
lid	B-Disease
imbrication	I-Disease
syndrome	I-Disease
.	O
	
The	O
condition	O
commonly	O
presents	O
as	O
a	O
dry	B-Disease
eye	I-Disease
or	O
persistent	B-Symptom
epithelial	I-Symptom
defect	I-Symptom
.	O
	
Treatment	O
ranges	O
from	O
viscous	O
tear	O
substitutes	O
to	O
horizontal	O
lid	O
shortening	O
of	O
the	O
upper	B-Anatomy
lid	I-Anatomy
.	O
	
An	O
international	O
classification	O
and	O
grading	O
system	O
for	O
age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
and	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
.	O
	
The	O
International	O
ARM	B-Disease
Epidemiological	O
Study	O
Group	O
	
A	O
common	O
detection	O
and	O
classification	O
system	O
is	O
needed	O
for	O
epidemiologic	O
studies	O
of	O
age	B-Disease
-	I-Disease
related	I-Disease
maculopathy	I-Disease
(	O
ARM	B-Disease
)	O
.	O
	
Such	O
a	O
grading	O
scheme	O
for	O
ARM	B-Disease
is	O
described	O
in	O
this	O
paper	O
.	O
	
ARM	B-Disease
is	O
defined	O
as	O
a	O
degenerative	B-Disease
disorder	I-Disease
in	O
persons	O
>	B-Characteristic
or	I-Characteristic
=	I-Characteristic
50	I-Characteristic
years	I-Characteristic
of	I-Characteristic
age	I-Characteristic
characterized	O
on	O
grading	O
of	O
color	B-Diagnostic_tool
fundus	I-Diagnostic_tool
transparencies	I-Diagnostic_tool
by	O
the	O
presence	O
of	O
the	O
following	O
abnormalities	B-Symptom
in	I-Symptom
the	I-Symptom
macular	I-Symptom
area	I-Symptom
:	O
soft	B-Symptom
drusen	I-Symptom
>	B-Dimension
or	I-Dimension
=	I-Dimension
63	I-Dimension
microns	I-Dimension
,	O
hyperpigmentation	B-Symptom
and	O
/	O
or	O
hypopigmentation	B-Symptom
of	I-Symptom
the	I-Symptom
retinal	I-Symptom
pigment	I-Symptom
epithelium	I-Symptom
(	O
RPE	B-Anatomy
)	O
,	O
RPE	B-Symptom
and	I-Symptom
associated	I-Symptom
neurosensory	I-Symptom
detachment	I-Symptom
,	O
(	B-Symptom
peri	I-Symptom
)	I-Symptom
retinal	I-Symptom
hemorrhages	I-Symptom
,	O
geographic	B-Symptom
atrophy	I-Symptom
of	I-Symptom
the	I-Symptom
RPE	I-Symptom
,	O
or	O
(	B-Symptom
peri	I-Symptom
)	I-Symptom
retinal	I-Symptom
fibrous	I-Symptom
scarring	I-Symptom
in	I-Symptom
the	I-Symptom
absence	I-Symptom
of	I-Symptom
other	I-Symptom
retinal	I-Symptom
(	I-Symptom
vascular	I-Symptom
)	I-Symptom
disorders	I-Symptom
.	O
	
Visual	B-Diagnostic_tool
acuity	I-Diagnostic_tool
is	O
not	O
used	O
to	O
define	O
the	O
presence	O
of	O
ARM	B-Disease
.	O
	
Early	B-Disease
ARM	I-Disease
is	O
defined	O
as	O
the	O
presence	O
of	O
drusen	B-Symptom
and	O
RPE	B-Symptom
pigmentary	I-Symptom
abnormalities	I-Symptom
described	O
above	O
;	O
late	B-Disease
ARM	I-Disease
is	O
similar	O
to	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
and	O
includes	O
dry	B-Disease
AMD	I-Disease
(	O
geographic	B-Symptom
atrophy	I-Symptom
of	I-Symptom
the	I-Symptom
RPE	I-Symptom
in	I-Symptom
the	I-Symptom
absence	I-Symptom
of	I-Symptom
neovascular	I-Symptom
AMD	I-Symptom
)	O
or	O
neovascular	B-Disease
AMD	I-Disease
(	O
RPE	B-Symptom
detachment	I-Symptom
,	O
hemorrhages	B-Symptom
,	O
and	O
/	O
or	O
scars	B-Symptom
as	O
described	O
above	O
)	O
.	O
	
Methods	O
to	O
take	O
and	O
grade	O
fundus	B-Diagnostic_tool
transparencies	I-Diagnostic_tool
are	O
described	O
.	O
	
Ultrasound	B-Diagnostic_tool
biomicroscopy	I-Diagnostic_tool
in	O
pigment	B-Disease
dispersion	I-Disease
syndrome	I-Disease
.	O
	
To	O
examine	O
the	O
positional	B-Characteristic
relations	I-Characteristic
of	I-Characteristic
the	I-Characteristic
iris	I-Characteristic
,	I-Characteristic
lens	I-Characteristic
,	I-Characteristic
ciliary	I-Characteristic
processes	I-Characteristic
,	I-Characteristic
and	I-Characteristic
zonules	I-Characteristic
in	I-Characteristic
eyes	I-Characteristic
with	O
the	O
pigment	B-Disease
dispersion	I-Disease
syndrome	I-Disease
(	O
PDS	B-Disease
)	O
.	O
	
High	B-Diagnostic_tool
-	I-Diagnostic_tool
resolution	I-Diagnostic_tool
,	I-Diagnostic_tool
anterior	I-Diagnostic_tool
segment	I-Diagnostic_tool
ultrasound	I-Diagnostic_tool
biomicroscopy	I-Diagnostic_tool
was	O
performed	O
on	O
16	O
untreated	O
eyes	B-Anatomy
of	O
11	O
patients	O
with	O
PDS	B-Disease
.	O
	
Scanning	O
was	O
repeated	O
on	O
four	O
eyes	B-Anatomy
after	O
miotic	B-Disease
treatment	O
and	O
four	O
eyes	B-Anatomy
after	O
laser	O
iridotomy	O
.	O
	
Mid	B-Characteristic
-	I-Characteristic
peripheral	I-Characteristic
iris	I-Characteristic
concavity	I-Characteristic
could	O
be	O
demonstrated	O
in	O
56	O
%	O
,	O
irido	B-Characteristic
-	I-Characteristic
zonular	I-Characteristic
contact	I-Characteristic
in	O
25	O
%	O
,	O
and	O
irido	B-Characteristic
-	I-Characteristic
ciliary	I-Characteristic
process	I-Characteristic
contact	I-Characteristic
in	O
75	O
%	O
of	O
untreated	O
eyes	B-Anatomy
with	O
PDS	B-Disease
.	O
	
Repeat	O
scanning	O
after	O
laser	O
iridotomy	O
or	O
pilocarpine	O
therapy	O
showed	O
resolution	O
of	O
the	O
iris	B-Characteristic
concavity	I-Characteristic
and	O
irido	B-Characteristic
-	I-Characteristic
zonular	I-Characteristic
contact	I-Characteristic
in	O
all	O
eyes	B-Anatomy
receiving	O
these	O
therapies	O
.	O
	
Irido	B-Characteristic
-	I-Characteristic
ciliary	I-Characteristic
process	I-Characteristic
contact	I-Characteristic
persisted	O
in	O
some	O
eyes	B-Anatomy
.	O
	
The	O
authors	O
'	O
findings	O
demonstrate	O
the	O
structural	B-Characteristic
relations	I-Characteristic
among	I-Characteristic
the	I-Characteristic
iris	I-Characteristic
,	I-Characteristic
lens	I-Characteristic
,	I-Characteristic
zonules	I-Characteristic
,	I-Characteristic
and	I-Characteristic
ciliary	I-Characteristic
processes	I-Characteristic
in	I-Characteristic
vivo	I-Characteristic
that	O
characterize	O
the	O
PDS	B-Disease
.	O
	
Miotic	B-Disease
therapy	O
and	O
laser	O
iridotomy	O
eliminate	O
the	O
iris	B-Characteristic
concavity	I-Characteristic
in	O
all	O
patients	O
with	O
this	O
finding	O
,	O
supporting	O
the	O
hypothesis	O
of	O
reverse	B-Symptom
pupillary	I-Symptom
block	I-Symptom
.	O
	
Irido	B-Characteristic
-	I-Characteristic
ciliary	I-Characteristic
process	I-Characteristic
contact	I-Characteristic
may	O
be	O
another	O
mechanism	O
causing	O
release	O
of	O
pigment	O
.	O
	
This	O
issue	O
merits	O
further	O
clinical	O
and	O
histologic	O
study	O
.	O
	
Standardized	O
color	B-Diagnostic_tool
-	I-Diagnostic_tool
coded	I-Diagnostic_tool
maps	I-Diagnostic_tool
for	O
corneal	B-Anatomy
topography	O
.	O
	
Modern	O
videokeratoscopy	B-Diagnostic_tool
is	O
useful	O
in	O
assessing	O
corneal	B-Characteristic
shape	I-Characteristic
.	O
	
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
compare	O
color	B-Diagnostic_tool
-	I-Diagnostic_tool
coded	I-Diagnostic_tool
topographic	I-Diagnostic_tool
maps	I-Diagnostic_tool
using	O
standardized	O
scales	O
with	O
1	O
.	O
0	O
-	O
and	O
1	O
.	O
5	O
-	O
diopter	O
(	O
D	O
)	O
intervals	O
.	O
	
The	O
authors	O
assessed	O
the	O
use	O
of	O
the	O
two	O
scales	O
for	O
detecting	O
clinically	O
relevant	O
features	O
of	O
corneal	B-Characteristic
topography	I-Characteristic
such	O
as	O
regular	B-Symptom
astigmatism	I-Symptom
,	O
irregular	B-Symptom
astigmatism	I-Symptom
,	O
early	B-Symptom
keratoconus	I-Symptom
,	O
and	O
contact	B-Symptom
lens	I-Symptom
-	I-Symptom
induced	I-Symptom
corneal	I-Symptom
warpage	I-Symptom
.	O
	
A	O
total	O
of	O
50	O
normal	O
corneas	B-Anatomy
,	O
50	O
corneas	B-Anatomy
with	O
contact	O
lenses	O
,	O
50	O
that	O
had	O
keratoconus	B-Disease
(	O
25	O
early	O
to	O
moderate	B-Disease
and	O
25	O
advanced	B-Disease
)	O
,	O
50	O
that	O
had	O
penetrating	O
keratoplasty	O
,	O
20	O
that	O
had	O
extracapsular	B-Disease
cataract	I-Disease
surgery	O
,	O
17	O
that	O
had	O
excimer	O
laser	O
photorefractive	O
keratectomy	O
for	O
myopia	B-Disease
,	O
10	O
that	O
had	O
radial	O
keratotomy	O
,	O
3	O
that	O
had	O
aphakic	O
epikeratophakia	O
,	O
and	O
2	O
that	O
had	O
myopic	O
epikeratophakia	O
were	O
analyzed	O
with	O
a	O
corneal	B-Diagnostic_tool
topographic	I-Diagnostic_tool
analysis	O
system	O
.	O
	
Color	B-Diagnostic_tool
-	I-Diagnostic_tool
coded	I-Diagnostic_tool
maps	I-Diagnostic_tool
with	O
1	O
.	O
0	O
-	O
D	O
intervals	O
(	O
Maguire	O
/	O
Waring	O
scale	O
)	O
and	O
1	O
.	O
5	O
-	O
D	O
intervals	O
(	O
Klyce	O
/	O
Wilson	O
scale	O
)	O
were	O
compared	O
.	O
	
There	O
were	O
no	O
topographic	O
characteristics	O
that	O
were	O
not	O
appreciated	O
with	O
either	O
scale	O
for	O
corneas	B-Anatomy
with	O
dioptric	O
powers	O
that	O
fell	O
within	O
their	O
ranges	O
.	O
	
Conversely	O
,	O
for	O
corneas	B-Anatomy
that	O
had	O
powers	O
outside	O
the	O
range	O
of	O
the	O
1	O
.	O
0	O
-	O
diopter	O
scale	O
,	O
but	O
within	O
the	O
range	O
of	O
the	O
1	O
.	O
5	O
-	O
diopter	O
scale	O
,	O
the	O
former	O
produced	O
a	O
map	O
in	O
which	O
the	O
flattest	O
or	O
steepest	O
areas	O
were	O
artifactually	O
smoothed	O
.	O
	
This	O
study	O
suggests	O
that	O
the	O
Klyce	O
/	O
Wilson	O
scale	O
(	O
constant	O
,	O
1	O
.	O
5	O
-	O
D	O
intervals	O
)	O
provides	O
the	O
best	O
combination	O
of	O
sensitivity	O
for	O
detection	O
of	O
clinically	O
significant	O
topographic	O
features	O
and	O
the	O
widest	O
range	O
of	O
coverage	O
of	O
powers	O
that	O
are	O
found	O
on	O
a	O
variety	O
of	O
normal	O
,	O
pathologic	O
,	O
and	O
surgically	O
altered	O
corneas	B-Anatomy
.	O
	
The	O
adoption	O
of	O
the	O
Klyce	O
/	O
Wilson	O
scale	O
by	O
all	O
manufacturers	O
of	O
corneal	B-Diagnostic_tool
topographic	I-Diagnostic_tool
instruments	O
as	O
a	O
primary	O
standard	O
will	O
facilitate	O
communication	O
and	O
will	O
make	O
the	O
interpretation	O
of	O
corneal	B-Characteristic
topography	I-Characteristic
easier	O
for	O
both	O
the	O
expert	O
and	O
the	O
novice	O
.	O
	
Detection	O
of	O
Epstein	B-Characteristic
-	I-Characteristic
Barr	I-Characteristic
virus	I-Characteristic
genome	I-Characteristic
in	O
ocular	B-Anatomy
tissues	I-Anatomy
.	O
	
Epstein	B-Characteristic
-	I-Characteristic
Barr	I-Characteristic
virus	I-Characteristic
(	O
EBV	B-Characteristic
)	O
is	O
a	O
ubiquitous	O
mucosal	O
pathogen	O
with	O
a	O
propensity	O
for	O
lifelong	O
,	O
asymptomatic	O
persistence	O
.	O
	
Because	O
of	O
reported	O
association	O
between	O
EBV	B-Characteristic
and	O
ocular	B-Disease
inflammatory	I-Disease
disorders	I-Disease
,	O
we	O
tested	O
ocular	O
tissues	O
from	O
normal	O
eyes	B-Anatomy
for	O
presence	O
of	O
the	O
EBV	B-Characteristic
genome	I-Characteristic
.	O
	
Ten	O
freshly	O
harvested	O
cadaveric	O
human	O
eyes	B-Anatomy
were	O
dissected	O
into	O
limbal	B-Anatomy
cornea	I-Anatomy
,	O
central	B-Anatomy
cornea	I-Anatomy
,	O
aqueous	B-Anatomy
humor	I-Anatomy
,	O
iris	B-Anatomy
,	O
vitreous	B-Anatomy
humor	I-Anatomy
,	O
and	O
optic	B-Anatomy
nerve	I-Anatomy
.	O
	
Total	O
cellular	O
DNA	O
preparations	O
were	O
screened	O
for	O
DNA	O
sequences	O
specific	O
to	O
EBV	B-Characteristic
'	I-Characteristic
s	I-Characteristic
large	O
internal	O
repeat	O
region	O
.	O
	
After	O
Southern	O
transfer	O
,	O
polymerase	O
chain	O
reaction	O
products	O
were	O
detected	O
by	O
a	O
32P	O
-	O
labeled	O
oligonucleotide	O
probe	O
specific	O
to	O
amplified	O
sequences	O
internal	O
to	O
the	O
polymerase	O
chain	O
reaction	O
primers	O
.	O
	
Seven	O
of	O
ten	O
eyes	B-Anatomy
from	O
deceased	O
donors	O
yielded	O
a	O
polymerase	O
chain	O
reaction	O
product	O
,	O
indicating	O
presence	O
of	O
EBV	B-Characteristic
genome	I-Characteristic
.	O
	
In	O
all	O
,	O
12	O
(	O
20	O
%	O
)	O
of	O
60	O
cadaveric	O
ocular	B-Anatomy
samples	O
contained	O
EBV	B-Characteristic
DNA	I-Characteristic
.	O
	
Only	O
the	O
optic	B-Anatomy
nerve	I-Anatomy
was	O
consistently	O
negative	O
for	O
EBV	B-Characteristic
DNA	I-Characteristic
.	O
	
Detection	O
of	O
EBV	B-Characteristic
DNA	I-Characteristic
in	O
cadaveric	O
ocular	B-Anatomy
tissues	I-Anatomy
indicates	O
a	O
broad	O
anatomic	O
distribution	O
of	O
this	O
persistent	O
mucosal	O
pathogen	O
.	O
	
The	O
frequency	O
with	O
which	O
EBV	B-Characteristic
was	O
found	O
at	O
apparently	O
normal	O
ocular	B-Anatomy
sites	O
raises	O
the	O
possibility	O
for	O
viral	O
involvement	O
in	O
disease	O
states	O
,	O
but	O
emphasizes	O
the	O
need	O
for	O
specific	O
criteria	O
to	O
implicate	O
EBV	B-Characteristic
in	O
ocular	B-Anatomy
pathology	O
.	O
	
Value	O
of	O
logistic	B-Diagnostic_tool
discriminant	I-Diagnostic_tool
analysis	I-Diagnostic_tool
for	O
interpreting	O
initial	O
visual	B-Symptom
field	I-Symptom
defects	I-Symptom
.	O
	
The	O
authors	O
evaluate	O
logistic	B-Diagnostic_tool
discriminant	I-Diagnostic_tool
analysis	I-Diagnostic_tool
as	O
a	O
method	O
for	O
interpreting	O
visual	B-Characteristic
field	I-Characteristic
results	O
in	O
initial	O
stages	O
of	O
several	O
ophthalmic	B-Disease
diseases	I-Disease
.	O
	
The	O
authors	O
retrospectively	O
studied	O
the	O
visual	B-Symptom
field	I-Symptom
defects	I-Symptom
of	O
96	O
patients	O
with	O
early	B-Symptom
glaucomatous	I-Symptom
damage	I-Symptom
and	O
prospectively	O
studied	O
84	O
subjects	O
with	O
normal	O
eyes	B-Anatomy
(	O
n	O
=	O
28	O
)	O
,	O
cataracts	B-Disease
(	O
n	O
=	O
27	O
)	O
,	O
diabetic	B-Disease
retinopathy	I-Disease
(	O
n	O
=	O
14	O
)	O
,	O
or	O
hypertensive	B-Disease
retinopathy	I-Disease
(	O
n	O
=	O
15	O
)	O
.	O
	
The	O
visual	B-Characteristic
fields	I-Characteristic
were	O
examined	O
at	O
least	O
twice	O
with	O
program	B-Diagnostic_tool
G1	I-Diagnostic_tool
of	I-Diagnostic_tool
Octopus	I-Diagnostic_tool
500	I-Diagnostic_tool
(	O
Interzeag	O
AG	O
,	O
Schlieren	O
,	O
Switzerland	O
)	O
.	O
	
Only	O
one	O
eye	B-Anatomy
per	O
patient	O
was	O
randomly	O
selected	O
and	O
included	O
in	O
the	O
study	O
.	O
	
The	O
authors	O
created	O
a	O
database	O
with	O
all	O
visual	B-Characteristic
field	I-Characteristic
information	O
provided	O
by	O
Octopus	B-Diagnostic_tool
and	O
applied	O
logistic	B-Diagnostic_tool
discriminant	I-Diagnostic_tool
analysis	I-Diagnostic_tool
(	O
SAS	O
Logistic	O
Procedures	O
,	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
)	O
to	O
obtain	O
classification	O
rules	O
capable	O
of	O
qualifying	O
visual	B-Symptom
field	I-Symptom
defects	I-Symptom
as	O
glaucomatous	B-Disease
or	O
nonglaucomatous	O
.	O
	
The	O
rules	O
were	O
tested	O
with	O
an	O
independent	O
sample	O
.	O
	
There	O
were	O
significant	O
differences	O
between	O
the	O
groups	O
in	O
the	O
distribution	O
of	O
visual	B-Symptom
field	I-Symptom
defects	I-Symptom
tested	O
by	O
program	B-Diagnostic_tool
G1	I-Diagnostic_tool
.	O
	
Logistic	B-Diagnostic_tool
discriminant	I-Diagnostic_tool
analysis	I-Diagnostic_tool
correctly	O
identified	O
the	O
glaucomatous	B-Disease
or	O
nonglaucomatous	O
origin	O
of	O
the	O
defects	O
with	O
a	O
sensitivity	O
of	O
65	O
%	O
to	O
85	O
%	O
and	O
a	O
specificity	O
of	O
60	O
%	O
to	O
92	O
%	O
.	O
	
Logistic	B-Diagnostic_tool
discriminant	I-Diagnostic_tool
analysis	I-Diagnostic_tool
is	O
a	O
useful	O
tool	O
to	O
aid	O
in	O
the	O
interpretation	O
of	O
early	B-Disease
glaucomatous	I-Disease
and	O
nonglaucomatous	B-Symptom
visual	I-Symptom
field	I-Symptom
defects	I-Symptom
.	O
	
Evaluation	O
of	O
coexisting	O
optic	B-Symptom
nerve	I-Symptom
head	I-Symptom
drusen	I-Symptom
and	O
glaucoma	B-Disease
with	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
.	O
	
Optic	B-Symptom
nerve	I-Symptom
head	I-Symptom
drusen	I-Symptom
often	O
make	O
evaluation	O
of	O
the	O
nerve	B-Anatomy
head	I-Anatomy
difficult	O
to	O
interpret	O
.	O
	
In	O
addition	O
,	O
visual	B-Symptom
field	I-Symptom
defects	I-Symptom
are	O
known	O
to	O
occur	O
in	O
patients	O
with	O
optic	B-Symptom
disk	I-Symptom
drusen	I-Symptom
,	O
resembling	O
glaucomatous	B-Symptom
damage	I-Symptom
.	O
	
The	O
authors	O
report	O
two	O
cases	O
of	O
coincident	O
optic	B-Symptom
nerve	I-Symptom
head	I-Symptom
drusen	I-Symptom
and	O
glaucoma	B-Disease
,	O
in	O
which	O
the	O
use	O
of	O
optical	B-Diagnostic_tool
coherence	I-Diagnostic_tool
tomography	I-Diagnostic_tool
(	O
OCT	B-Diagnostic_tool
)	O
in	O
evaluating	O
the	O
nerve	B-Anatomy
fiber	I-Anatomy
layer	I-Anatomy
was	O
beneficial	O
.	O
	
Two	O
patients	O
with	O
both	O
optic	B-Symptom
nerve	I-Symptom
head	I-Symptom
drusen	I-Symptom
and	O
glaucoma	B-Disease
,	O
one	O
with	O
primary	B-Disease
open	I-Disease
angle	I-Disease
glaucoma	I-Disease
,	O
the	O
other	O
with	O
pseudoexfoliation	B-Disease
glaucoma	I-Disease
were	O
evaluated	O
.	O
	
Both	O
patients	O
had	O
asymmetric	B-Symptom
optic	I-Symptom
disk	I-Symptom
drusen	I-Symptom
,	O
with	O
clinically	O
visible	O
drusen	B-Symptom
only	O
in	O
one	O
eye	B-Anatomy
.	O
	
Ophthalmologic	B-Diagnostic_tool
examination	I-Diagnostic_tool
,	O
color	B-Diagnostic_tool
and	I-Diagnostic_tool
red	I-Diagnostic_tool
-	I-Diagnostic_tool
free	I-Diagnostic_tool
photography	I-Diagnostic_tool
,	O
automated	B-Diagnostic_tool
Humphrey	I-Diagnostic_tool
visual	I-Diagnostic_tool
field	I-Diagnostic_tool
testing	I-Diagnostic_tool
and	O
OCT	B-Diagnostic_tool
were	O
performed	O
.	O
	
Nerve	B-Symptom
fiber	I-Symptom
layer	I-Symptom
loss	I-Symptom
as	O
measured	O
by	O
OCT	B-Diagnostic_tool
was	O
found	O
to	O
be	O
greater	O
than	O
expected	O
by	O
the	O
appearance	O
of	O
the	O
optic	B-Anatomy
nerve	I-Anatomy
head	I-Anatomy
and	O
red	B-Diagnostic_tool
-	I-Diagnostic_tool
free	I-Diagnostic_tool
photography	I-Diagnostic_tool
,	O
with	O
visual	B-Characteristic
fields	I-Characteristic
consistent	O
with	O
findings	O
in	O
case	O
1	O
.	O
	
In	O
case	O
2	O
,	O
visual	B-Characteristic
fields	I-Characteristic
were	O
full	O
,	O
despite	O
nerve	B-Symptom
fiber	I-Symptom
layer	I-Symptom
thinning	I-Symptom
seen	O
by	O
OCT	B-Diagnostic_tool
and	O
red	B-Diagnostic_tool
-	I-Diagnostic_tool
free	I-Diagnostic_tool
photography	I-Diagnostic_tool
.	O
	
There	O
can	O
be	O
significant	O
nerve	B-Symptom
fiber	I-Symptom
layer	I-Symptom
thinning	I-Symptom
in	O
patients	O
with	O
both	O
glaucoma	B-Disease
and	O
optic	B-Symptom
disk	I-Symptom
drusen	I-Symptom
,	O
despite	O
the	O
appearance	O
of	O
the	O
optic	B-Anatomy
nerve	I-Anatomy
head	I-Anatomy
in	O
these	O
patients	O
.	O
	
The	O
cup	O
margin	O
may	O
be	O
obscured	O
by	O
the	O
drusen	B-Symptom
,	O
giving	O
rise	O
to	O
a	O
falsely	O
full	O
-	O
appearing	O
disk	O
.	O
	
In	O
such	O
cases	O
,	O
OCT	B-Diagnostic_tool
may	O
provide	O
a	O
useful	O
means	O
to	O
quantitatively	O
measure	O
the	O
nerve	B-Characteristic
fiber	I-Characteristic
layer	I-Characteristic
thickness	I-Characteristic
and	O
to	O
aid	O
in	O
the	O
management	O
of	O
these	O
patients	O
by	O
detecting	O
nerve	B-Symptom
fiber	I-Symptom
layer	I-Symptom
thinning	I-Symptom
earlier	O
than	O
would	O
otherwise	O
be	O
possible	O
.	O
	
Quantitative	O
detection	O
of	O
glaucomatous	B-Symptom
damage	I-Symptom
at	I-Symptom
the	I-Symptom
posterior	I-Symptom
pole	I-Symptom
by	O
retinal	B-Diagnostic_tool
thickness	I-Diagnostic_tool
mapping	I-Diagnostic_tool
.	O
	
A	O
pilot	O
study	O
.	O
	
The	O
posterior	B-Anatomy
pole	I-Anatomy
ganglion	I-Anatomy
cell	I-Anatomy
bodies	I-Anatomy
form	O
a	O
substantial	O
fraction	O
of	O
the	O
retinal	B-Characteristic
thickness	I-Characteristic
,	O
prompting	O
the	O
authors	O
to	O
study	O
the	O
feasibility	O
of	O
detecting	O
,	O
by	O
scanning	O
retinal	B-Characteristic
thickness	I-Characteristic
analysis	O
,	O
retinal	B-Symptom
changes	I-Symptom
at	I-Symptom
the	I-Symptom
posterior	I-Symptom
pole	I-Symptom
due	I-Symptom
to	I-Symptom
glaucomatous	I-Symptom
damage	I-Symptom
.	O
	
Nonconsecutive	O
case	O
series	O
.	O
	
One	O
or	O
both	O
eyes	B-Anatomy
of	O
patients	O
with	O
chronic	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
who	O
presented	O
with	O
either	O
a	O
superoinferior	B-Symptom
asymmetry	I-Symptom
in	I-Symptom
visual	I-Symptom
fields	I-Symptom
or	O
a	O
localized	B-Symptom
field	I-Symptom
loss	I-Symptom
or	O
a	O
nerve	B-Symptom
fiber	I-Symptom
layer	I-Symptom
defect	I-Symptom
visible	O
on	O
photography	B-Diagnostic_tool
were	O
recruited	O
.	O
	
Twenty	O
-	O
nine	O
eyes	O
of	O
18	O
patients	O
were	O
studied	O
.	O
	
A	O
laser	O
slit	O
was	O
projected	O
on	O
the	O
retina	B-Anatomy
and	O
scanned	O
,	O
in	O
400	O
msec	O
,	O
across	O
a	O
2	O
-	O
x	O
2	O
-	O
mm	O
area	O
of	O
the	O
fundus	B-Anatomy
,	O
yielding	O
optical	O
cross	O
-	O
sections	O
that	O
were	O
digitally	O
recorded	O
.	O
	
Nine	O
such	O
scans	O
covered	O
the	O
central	O
20	O
degrees	O
of	O
the	O
fundus	B-Anatomy
.	O
	
The	O
optical	O
cross	O
-	O
sections	O
were	O
analyzed	O
by	O
an	O
operator	O
-	O
free	O
algorithm	O
to	O
yield	O
a	O
three	O
-	O
or	O
two	O
-	O
dimensional	O
color	O
map	O
.	O
	
The	O
asymmetry	O
(	O
difference	O
)	O
between	O
the	O
visual	O
sensitivity	O
of	O
the	O
upper	B-Anatomy
and	I-Anatomy
lower	I-Anatomy
hemifields	I-Anatomy
was	O
compared	O
with	O
the	O
asymmetry	O
in	O
retinal	B-Characteristic
thickness	I-Characteristic
deviation	O
from	O
normal	O
.	O
	
Large	B-Symptom
losses	I-Symptom
(	I-Symptom
up	I-Symptom
to	I-Symptom
34	I-Symptom
%	I-Symptom
)	I-Symptom
in	I-Symptom
retinal	I-Symptom
thickness	I-Symptom
were	I-Symptom
detected	I-Symptom
at	I-Symptom
the	I-Symptom
posterior	I-Symptom
pole	I-Symptom
of	O
patients	O
with	O
glaucoma	B-Disease
due	O
to	O
the	O
loss	B-Symptom
of	I-Symptom
ganglion	I-Symptom
cells	I-Symptom
and	I-Symptom
nerve	I-Symptom
fibers	I-Symptom
.	O
	
A	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
the	O
asymmetry	O
in	O
visual	B-Symptom
sensitivity	I-Symptom
loss	I-Symptom
and	O
the	O
asymmetry	O
in	O
deviation	O
from	O
normal	O
thickness	O
(	O
r	O
=	O
0	O
.	O
72	O
;	O
P	O
<	O
0	O
.	O
0005	O
)	O
.	O
	
Mapping	O
of	O
the	O
retinal	B-Characteristic
thickness	I-Characteristic
may	O
provide	O
a	O
sensitive	O
method	O
for	O
the	O
detection	O
and	O
monitoring	O
of	O
early	B-Symptom
glaucomatous	I-Symptom
tissue	I-Symptom
loss	I-Symptom
in	I-Symptom
the	I-Symptom
posterior	I-Symptom
pole	I-Symptom
,	O
which	O
is	O
unique	O
due	O
to	O
the	O
combination	O
of	O
(	O
1	O
)	O
the	O
direct	O
measurement	O
of	O
neuroretinal	B-Symptom
loss	I-Symptom
in	I-Symptom
the	I-Symptom
central	I-Symptom
field	I-Symptom
of	I-Symptom
vision	I-Symptom
;	O
(	O
2	O
)	O
the	O
mapping	O
capability	O
;	O
and	O
(	O
3	O
)	O
the	O
rapid	O
image	O
acquisition	O
.	O
	
Topographic	O
detection	O
of	O
photorefractive	O
keratectomy	O
.	O
	
This	O
study	O
aimed	O
to	O
evaluate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
subjective	O
review	O
of	O
corneal	B-Characteristic
topography	I-Characteristic
to	O
detect	O
patients	O
who	O
have	O
undergone	O
photorefractive	O
keratectomy	O
(	O
PRK	O
)	O
.	O
	
Topographic	B-Diagnostic_tool
maps	I-Diagnostic_tool
from	O
3	O
different	O
devices	O
were	O
obtained	O
from	O
19	O
patients	O
with	O
postoperative	O
PRK	O
and	O
9	O
control	O
subjects	O
with	O
emmetropia	B-Disease
and	O
10	O
control	O
subjects	O
with	O
myopia	B-Disease
.	O
	
Each	O
image	O
was	O
printed	O
in	O
an	O
absolute	O
and	O
relative	O
scale	O
(	O
total	O
of	O
228	O
maps	O
)	O
and	O
graded	O
for	O
overall	O
shape	O
and	O
pattern	O
.	O
	
Fifteen	O
masked	O
reviewers	O
independently	O
rated	O
each	O
map	O
as	O
either	O
postoperative	O
PRK	O
or	O
not	O
.	O
	
The	O
overall	O
sensitivity	O
(	O
ability	O
to	O
detect	O
PRK	O
)	O
and	O
specificity	O
rates	O
(	O
ability	O
to	O
exclude	O
control	O
subjects	O
)	O
by	O
reviewers	O
were	O
65	O
%	O
and	O
93	O
%	O
,	O
respectively	O
.	O
	
Sensitivity	O
was	O
influenced	O
independently	O
by	O
the	O
scale	O
(	O
relative	O
,	O
68	O
%	O
;	O
absolute	O
,	O
62	O
%	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
experience	O
of	O
reviewer	O
(	O
experienced	O
,	O
77	O
%	O
;	O
inexperienced	O
,	O
53	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
device	O
(	O
Alcon	O
,	O
67	O
+	O
/	O
-	O
29	O
.	O
9	O
;	O
Eyesys	O
,	O
75	O
+	O
/	O
-	O
29	O
.	O
4	O
%	O
;	O
and	O
Tomey	O
,	O
54	O
+	O
/	O
-	O
31	O
.	O
7	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
	
Low	O
levels	O
of	O
preoperative	O
myopia	B-Disease
were	O
consistently	O
more	O
difficult	O
to	O
detect	O
than	O
higher	O
levels	O
(	O
low	O
myopia	B-Disease
-	O
1	O
.	O
50	O
to	O
-	O
2	O
.	O
99	O
diopters	O
[	O
D	O
]	O
sensitivity	O
:	O
53	O
+	O
/	O
-	O
34	O
.	O
5	O
%	O
;	O
medium	O
level	O
-	O
3	O
.	O
00	O
to	O
-	O
4	O
.	O
49	O
D	O
:	O
67	O
+	O
/	O
-	O
28	O
.	O
9	O
%	O
;	O
and	O
high	O
level	O
-	O
4	O
.	O
50	O
to	O
-	O
6	O
.	O
00	O
D	O
:	O
77	O
+	O
/	O
-	O
21	O
.	O
1	O
%	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
	
Differences	O
in	O
specificity	O
between	O
experienced	O
and	O
inexperienced	O
reviewers	O
were	O
obtained	O
when	O
maps	O
had	O
a	O
homogeneous	O
topographic	O
pattern	O
(	O
97	O
+	O
/	O
-	O
5	O
.	O
6	O
%	O
and	O
85	O
+	O
/	O
-	O
13	O
.	O
7	O
%	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
	
Several	O
control	O
topography	O
patterns	O
(	O
e	O
.	O
g	O
.	O
,	O
homogeneous	O
,	O
focal	O
,	O
and	O
keyhole	O
)	O
were	O
disproportionately	O
more	O
difficult	O
to	O
correctly	O
identify	O
on	O
the	O
Eyesys	O
device	O
.	O
	
Topographic	O
experience	O
is	O
a	O
significant	O
factor	O
influencing	O
the	O
correct	O
identification	O
of	O
PRK	O
.	O
	
Techniques	O
also	O
can	O
be	O
used	O
to	O
enhance	O
detection	O
,	O
such	O
as	O
the	O
use	O
of	O
different	O
devices	O
and	O
scales	O
.	O
	
However	O
,	O
if	O
subjective	O
review	O
of	O
topography	O
is	O
used	O
as	O
the	O
only	O
method	O
of	O
detection	O
,	O
many	O
patients	O
with	O
PRK	O
will	O
not	O
be	O
identified	O
properly	O
.	O
	
In	O
addition	O
,	O
the	O
most	O
prevalent	O
preoperative	O
myopic	B-Disease
category	O
in	O
the	O
general	O
population	O
(	O
myopia	B-Disease
<	O
-	O
3	O
.	O
00	O
D	O
)	O
also	O
is	O
the	O
most	O
difficult	O
to	O
detect	O
after	O
treatment	O
.	O
	
This	O
reduces	O
the	O
usefulness	O
of	O
topography	B-Diagnostic_tool
as	O
a	O
screening	O
tool	O
.	O
	
Other	O
techniques	O
are	O
needed	O
to	O
improve	O
the	O
detection	O
of	O
patients	O
with	O
postoperative	O
PRK	O
.	O
	
